1	"The <e1>child</e1> was carefully wrapped and bound into the <e2>cradle</e2> by means of a cord."
Other
Comment:

2	"A misty <e1>ridge</e1> uprises from the <e2>surge</e2>."
Other
Comment:

3	"This is the sprawling <e1>complex</e1> that is Peru's largest <e2>producer</e2> of silver."
Other
Comment:

4	"The current view is that the chronic <e1>inflammation</e1> in the distal part of the stomach caused by Helicobacter pylori <e2>infection</e2> results in an increased acid production from the non-infected upper corpus region of the stomach."
Cause-Effect(e2,e1)
Comment:

5	"Their <e1>composer</e1> has sunk into <e2>oblivion</e2>."
Other
Comment: violates b.1 and c.3

6	"The <e1>burst</e1> has been caused by water hammer <e2>pressure</e2>."
Cause-Effect(e2,e1)
Comment:

7	"The <e1>singer</e1>, who performed three of the nominated songs, also caused a <e2>commotion</e2> on the red carpet."
Cause-Effect(e1,e2)
Comment:

8	"His intellectually engaging books and <e1>essays</e1> remain pertinent to illuminating contemporary <e2>history</e2>."
Other
Comment: "pertinent to" is not necessarily about

9	"This sweet <e1>dress</e1> is made with a <e2>blend</e2> of cotton and silk, and the crochet flower necklace is the perfect accessory."
Other
Comment: the blend is the material out of which the dress is made; can't be Entity-Origin because the material is still present in the dress

10	"<e1>Suicide</e1> is one of the leading causes of <e2>death</e2> among pre-adolescents and teens, and victims of bullying are at an increased risk for committing suicide."
Cause-Effect(e1,e2)
Comment:

11	"He had chest pains and <e1>headaches</e1> from <e2>mold</e2> in the bedrooms."
Cause-Effect(e2,e1)
Comment:

12	"The Medicare buy-in <e1>plan</e1> ran into Senate <e2>resistance</e2>."
Other
Comment: violates c.3

13	"Financial <e1>stress</e1> is one of the main causes of <e2>divorce</e2>."
Cause-Effect(e1,e2)
Comment:

14	"The <e1>women</e1> that caused the <e2>accident</e2> was on the cell phone and ran thru the intersection without pausing on the median."
Cause-Effect(e1,e2)
Comment:

15	"<e1>Calluses</e1> are caused by improperly fitting shoes or by a <e2>skin abnormality</e2>."
Cause-Effect(e2,e1)
Comment:

16	"As in the popular movie "Deep Impact", the action of the Perseid <e1>meteor shower</e1> is caused by a <e2>comet</e2>, in this case periodic comet Swift-Tuttle."
Cause-Effect(e2,e1)
Comment:

17	"The following information appeared in the <e1>notes</e1> to consolidated financial <e2>statements</e2> of some corporate annual reports."
Other
Comment: We do not know what the notes are talking about; we only know that the notes are somehow connected to the statement.

18	"HipHop appropriates the symbols of a consumer society: oversized <e1>diamond</e1> <e2>colliers</e2> are worn."
Other
Comment:

19	"The <e1>radiation</e1> from the atomic <e2>bomb explosion</e2> is a typical acute radiation."
Cause-Effect(e2,e1)
Comment:

20	"A neoplastic <e1>recurrence</e1> arose from an extensive <e2>radiation</e2> induced ulceration."
Cause-Effect(e2,e1)
Comment:

21	"He has a tattoo on his right arm and <e1>scars</e1> from <e2>stitches</e2> on his right elbow."
Cause-Effect(e2,e1)
Comment:

22	"Kelvin bought a <e1>silver</e1> <e2>ring</e2> which he was so happy with and he keeps wearing it now even though its abit too big haha."
Other
Comment:

23	"My major <e1>disagreement</e1> with Lyons concerns the <e2>causal part</e2> of his theory."
Other
Comment:

24	"The infectious bacterial disease <e1>brucellosis</e1> has been found in a beef <e2>cow</e2> in eastern Idaho."
Other
Comment: diseases are not parts.

25	"As the Anglo-Norman force sustained but little loss in this battle, their archers at the onset showered a hail of arrows upon the Irish host who were not protected with mail armour, and shot them down in hundreds before they could get to close quarters; and then the charge of the heavy Anglo-Norman cavalry of mail-clad knights, completed the havoc and <e1>rout</e1> of the undisciplined Gaelic <e2>hosts</e2>."
Other
Comment: The pattern is at fault -- "rout" is not the name of a grouping; negation is outside

26	"The continuing Nigerian <e1>outbreak</e1> is the biggest ever caused by the <e2>vaccine</e2>."
Cause-Effect(e2,e1)
Comment:

27	"The <e1>fire</e1> inside WTC was caused by exploding <e2>fuel</e2>."
Cause-Effect(e2,e1)
Comment:

28	"The <e1>suffering</e1> caused by the <e2>terrorists</e2> is the real torture."
Cause-Effect(e2,e1)
Comment:

29	"In a poetic twist, the <e1>tsunami</e1> triggered by the rock <e2>band</e2> forced many American jazz and blues singers to seek work in the United Kingdom, which is where Anderson found a receptive audience in 1965."
Cause-Effect(e2,e1)
Comment:

30	"<e1>Leakage</e1> and fire caused due to <e2>corrosion</e2> of bypass piping for recirculation gas at a fuel oil desulphurization unit."
Cause-Effect(e2,e1)
Comment:

31	"The metal <e1>ball</e1> makes a ding ding ding <e2>noise</e2> when it swings back and hits the metal body of the lamp."
Cause-Effect(e1,e2)
Comment:

32	"Unlike other fish, grunion come out of the water completely to lay their eggs in the wet <e1>sand</e1> of the <e2>beach</e2>."
Other
Comment:

33	"Historical view of the <e1>damage</e1> caused by the 1693 Catania <e2>earthquake</e2> and the reconstruction activities."
Cause-Effect(e2,e1)
Comment:

34	"AI requested that the perpetrators be prosecuted to the fullest extent of the law, that adequate compensation be provided to the victims and that senior government and police officials offer apologies for the <e1>suffering</e1> caused by the responsible police <e2>officers</e2>."
Cause-Effect(e2,e1)
Comment:

35	"The <e1>findings</e1> have been published in a special <e2>section</e2> of the academic journal Archives of Sexual Behavior."
Other
Comment: Location. It cannot be Content-Container since the Content should be removable. It also cannot be Component-Whole since it violates (d).

36	"The Marshall Plan also provided a way of gaining public acceptance in Europe for the New Deal format that the United States had successfully used before the war to end the <e1>recession</e1> triggered by the 1929 Wall Street <e2>crash</e2>."
Cause-Effect(e2,e1)
Comment:

37	"Once they grow there, the <e1>swelling</e1> and inflammation caused by the <e2>infection</e2> closes off the sac, causing it not to "shed" bacteria, and protecting the bacteria inside from antibiotics and your body's own immune cells."
Cause-Effect(e2,e1)
Comment:

38	"Guitars are played acoustically; the <e1>tone</e1> is produced by the <e2>vibration</e2> of the strings which is amplified by the body of the guitar, which acts as a large hollow resonating chamber, or they may rely on an amplifier that can electronically manipulate tone."
Cause-Effect(e2,e1)
Comment:

39	"Flowers are reborn from the soil and the climate begins to warm, all set to a <e1>score</e1> improvised by an <e2>orchestra</e2> of birds."
Other
Comment: score is not a product

40	"Arcane Subtlety reduced the threat caused by Polymorph by 40% at max rank, though the <e1>threat</e1> caused by the <e2>spell</e2> is minimal."
Cause-Effect(e2,e1)
Comment:

41	"The beautiful hydrothermal features in the park (geysers, hot springs, mud pots, etc.), the uplift and subsidence, and many of the <e1>earthquakes</e1> are caused by the <e2>movements</e2> of hydrothermal and/or magmatic fluids."
Cause-Effect(e2,e1)
Comment:

42	"My parents bought her a <e1>silver</e1> <e2>necklace</e2> almost identical to the one pictured."
Other
Comment:

43	"Forward <e1>motion</e1> of the vehicle through the air caused a <e2>suction</e2> on the road draft tube."
Cause-Effect(e1,e2)
Comment:

44	"Paul Friedrich guides us through a <e1>babel</e1> of <e2>words</e2>, and worlds of the imagination ranging from his translations from five languages(notably the Russian of his literary studies) to the poetry of the Indian Mexico of his anthropological field work to America writ large -- super highways, a Vermont farm, father and child."
Other
Comment: Webster says: babel: 2 often not capitalized a: a confusion of sounds or voices b: a scene of noise or confusion --- so not a set.

45	"That <e1>decision</e1> was also the subject of an unsuccessful <e2>legal challenge</e2>."
Other
Comment: "legal challenge" is not a Message

46	"The <e1>malfunctions</e1> on Monday caused <e2>delays</e2> for patrons waiting to check out or renew books at the branches, and impeded access to personal accounts that allow users to renew or hold books online."
Cause-Effect(e1,e2)
Comment:

47	"The <e1>train ride</e1> from <e2>station</e2> to station is approximate 30 minutes."
Other
Comment:

48	"A <e1>maze</e1> of interlocking <e2>jurisdictions</e2> and levels of government confronts average citizens in trying to solve even the simplest of problems."
Other
Comment:This definitely is not a set: it is a pattern, an arrangement.

49	"Water <e1>damage</e1> from roof leaks, plumbing leaks or flooding lead to the <e2>growth</e2> of molds."
Cause-Effect(e1,e2)
Comment:

50	"Warm weather is here, and with it comes the <e1>scourge</e1> of <e2>mosquitoes</e2>."
Other
Comment: Like infestation, it is not a set.

51	"The <e1>formation</e1> of struvite <e2>stones</e2> is associated with the presence of urea-splitting bacteria, most commonly Proteus mirabilis (but also Klebsiella, Serratia, Providencia species)."
Other
Comment: A process.

52	"Our army was successfully engaged during the day with strong rearguards of all arms on the Petit Morin River, thereby materially assisting the progress of the French armies on our right and left, against whom the <e1>enemy</e1> was making his greatest <e2>efforts</e2>."
Other
Comment: Effort is not a concrete object.

53	"The <e1>discomfort</e1> from the <e2>injury</e2> was now precluding him from his occupation which involved prolonged procedures in the standing position."
Cause-Effect(e2,e1)
Comment:

54	"We always try to maintain the best <e1>environment</e1> for <e2>programmers</e2>, starting with good salary and conducive working environment."
Other
Comment: We cannot say the programmers actually/directly use the environment.

55	"The <e1>water</e1> pushed to the coast resulted in <e2>tides</e2> as much as three feet above normal, with waves of 5-10 feet atop these tides."
Cause-Effect(e1,e2)
Comment:

56	"The <e1>charge</e1> is the source of an electric <e2>field</e2>, which carries energy-the electrostatic self-energy."
Cause-Effect(e1,e2)
Comment:

57	"The <e1>tardiness</e1> however has been caused by the <e2>arrival</e2> of my old man; who in true Bloodworth fashion has had me walking everywhere."
Cause-Effect(e2,e1)
Comment:

58	"The river had now turned into full <e1>flood</e1> after the <e2>deluge</e2> of rain a few days ago."
Cause-Effect(e2,e1)
Comment:

59	"The <e1>cultivation</e1> consisted of plowing the crop with a double-shovel <e2>plow</e2>."
Other
Comment: Purpose-Tool

60	"She mentioned the <e1>scandal</e1> caused by a BBC <e2>documentary</e2> on the treatment of children in a special-needs home and asked how the state had responded to these."
Cause-Effect(e2,e1)
Comment:

61	"We have placed the <e1>candidates</e1> into <e2>roles</e2>."
Other
Comment: violates b.1

62	"Frequent agitations throw academic <e1>life</e1> into <e2>disarray</e2>."
Other
Comment: violates c.3

63	"Thus, in simple words, a <e1>tendon</e1> attaches a <e2>muscle</e2> to a bone."
Other
Comment:

64	"<e1>Positions</e1> were denoted by <e2>black dots</e2> along the tracks, the adjacent numbers indicating the day of the month."
Other
Comment:

65	"The World Health Organization(WHO) found that the <e1>radiation</e1> release from the Chernobyl <e2>accident</e2> was 200 times that of the Hiroshima and Nagasaki."
Cause-Effect(e2,e1)
Comment:

66	"Also, in the midst of the <e1>confusion</e1> caused by the <e2>coup</e2>, the issuing of militant posters was a way for artists and organizations to declare their active engagement against the rebellion."
Cause-Effect(e2,e1)
Comment:

67	"The <e1>accident</e1> caused a major traffic <e2>snarl</e2> on the arterial road."
Cause-Effect(e1,e2)
Comment:

68	"Two plane crash survivors have paid a special visit to the Hutt Hospital <e1>surgeon</e1> whose <e2>team</e2> helped to re-build their shattered faces eight years ago."
Other
Comment:The team is not a collection of surgeons.

69	"The various forms of idealistic, materialistic and agnostic philosophies are subject to the <e1>tension</e1> caused by the indicated <e2>situation</e2>."
Cause-Effect(e2,e1)
Comment:

70	"Tissue damage and <e1>electrode</e1> <e2>corrosion</e2> are both associatcd with high charge density stimulation."
Other
Comment:

71	"<e1>Contractions</e1> of the diaphragm are caused by stimulation of the vagus nerve either by the brain or by <e2>irritation</e2> anywhere along the length of the nerve."
Cause-Effect(e2,e1)
Comment:

72	"For Christmas, Daniel gave Kelly a Tiffany bracelet, and for Valentine's Day he bought a <e1>diamond</e1> <e2>necklace</e2>."
Other
Comment:

73	"Plantar <e1>warts</e1> are caused by a <e2>virus</e2> that infects the outer layer of skin on the soles of the feet."
Cause-Effect(e2,e1)
Comment:

74	"The <e1>sensor</e1> was manufactured in a cost effective thin film <e2>process</e2>."
Other
Comment:

75	"The putative left, we see, is just as eager as the nominal right to brand crime and violence with any hint of political motivation as terrorism, and therefore to remove it from the ordinary processes of criminal law and sanction, which are already quite draconian in these United States, and to animate parallel systems of harsher surveillance and punishment for the political <e1>compeers</e1> of such <e2>criminals</e2>."
Other
Comment: Compeer = peer (more or less). Not a set.

76	"This process passes on a health <e1>gene</e1> to the next <e2>generation</e2>."
Other
Comment: violates c.3

77	"The map to the left shows a snapshot of <e1>weather</e1> <e2>conditions</e2> in selected towns across Italy."
Other
Comment:

78	"The retailers poured <e1>resources</e1> into promoting low-alcohol <e2>wine</e2>."
Other
Comment: resources go to promoting, not to wine=

79	"The final <e1>part</e1> of the court is completed by the <e2>chapel</e2>, begun by Mary I in 1554 in memory of her father."
Other
Comment: part is not a producer

80	"The <e1>hotel</e1> arose from the <e2>reconstruction</e2> of historical building."
Other
Comment:

81	"This "all around immature nice guy" is, above all, a <e1>choreographer</e1>, having devised the <e2>moves</e2> to the film adaptation of Hairspray."
Other
Comment:

82	"The <e1>state</e1> has assembled a $230 million incentive <e2>package</e2> to lure the project, which could mean as many as 9000 jobs."
Other
Comment: this is not a product-producer, the package is not a concrete object.

83	"The stong <e1>earthquake</e1> caused a <e2>blackout</e2> on the sound stage and short-circuited some of the neon-tubed violins."
Cause-Effect(e1,e2)
Comment:

84	"The <e1>solution</e1> comprises the <e2>creation</e2> of a decentralized Internet host name resolution system with flat hierarchy on the basis of Metrized Small World data structure."
Other
Comment:

85	"Tension Release by Mega Food contains Sensoril, a clinically studied extract of a Ashwagandha that helps to inhibit fatigue and physical <e1>tension</e1> from everyday <e2>stress</e2>."
Cause-Effect(e2,e1)
Comment:

86	"With an innate desire to know and to do, mankind has progressed past placing a dead fish in every <e1>hill</e1> of <e2>corn</e2>, beans and squash."
Other
Comment: figurative speech; possibly a location.

87	"A special <e1>meeting</e1> of the <e2>shareholders</e2> of Lydia Diamond was held on December 23rd, 2009 and the Sale was approved by the shareholders."
Other
Comment: Participation, not belonging.

88	"The aim of this study, therefore, was to examine the embryo <e1>quality</e1> obtained from vitrified, warmed <e2>oocytes</e2> in a standard infertility population."
Other
Comment:

89	"<e1>Cardiovascular disease</e1> is one of the leading causes of <e2>morbidity</e2> and mortality in the UK, as well as in the developed and the developing world."
Cause-Effect(e1,e2)
Comment:

90	"The level surface closest to the MSS, known as the <e1>geoid</e1>, departs from an <e2>ellipsoid</e2> by about 100 m in each direction."
Other
Comment:

91	"<e1>Dizziness</e1> from nasal and <e2>sinus pressure</e2> usually can be seen on a good nasal examination and a CT of the sinuses."
Cause-Effect(e2,e1)
Comment:

92	"In the 2006 campaign, the <e1>governor</e1> won the Hispanic vote with <e2>appearances</e2> such as one at Casa de Maryland."
Other
Comment:

93	"The <e1>chair</e1> of the <e2>corporation</e2>, at the time of election, shall be either a former President, the retiring President, or a member (not emeritus) of the Corporation."
Other
Comment:

94	"The <e1>hole</e1> was found in a <e2>piece</e2> of the package that was ripped off near its edge."
Other
Comment: There is no functional connection; the hole probably appeared by accident.

95	"This <e1>meeting</e1> establishes the <e2>laws</e2> which govern the church and the priorities for the coming year."
Cause-Effect(e1,e2)
Comment: "laws" is a metonymy for "rule of law", which is a state

96	"He also pointed out that on the Sabbath the <e1>priests</e1> broke the commandment with priestly <e2>work</e2>."
Other
Comment:

97	"Phobia like <e1>fear</e1> from <e2>crowd</e2>, fear from insects, fear from height etc all contribute in developing the anxiety disorder."
Cause-Effect(e2,e1)
Comment:

98	"In a cloudless, new moon sky, a billion <e1>stars</e1> lit the <e2>heavens</e2>."
Other
Comment: heavens are not producer

99	"The hidden preamble or timing signal is employed to mark the time of commencement of the <e1>transmission</e1> of information pulses from a <e2>transmitter</e2>."
Cause-Effect(e2,e1)
Comment:

100	"Doe's <e1>confrontation</e1> with the flight attendant caused a <e2>commotion</e2> on the plane, prolonged the flight's delay, and added to the aggravation already being felt by the passengers and crew."
Cause-Effect(e1,e2)
Comment:

101	"The chronic myelogenous leukemia-specific P210 <e1>protein</e1> is the product of the bcr/abl hybrid <e2>gene</e2>."
Other
Comment:

102	"The purpose of the <e1>audit</e1> was to report on the <e2>financial statements</e2>."
Other
Comment: Audit here is a process, not a message.

103	"The increase of the signal might correspond to formation of the high-density excitons, while the <e1>reduction</e1> of the signal originates from the <e2>relaxation</e2>."
Cause-Effect(e2,e1)
Comment:

104	"We estimate a wind speed associated with the <e1>devastation</e1> caused by the <e2>tornado</e2>."
Cause-Effect(e2,e1)
Comment:

105	"The basic <e1>indicator</e1> of the health <e2>condition</e2> of trees, stands and forests is tree defoliation."
Cause-Effect(e2,e1)
Comment:

106	"The <e1>deficits</e1> are caused by <e2>people</e2> saving too much of their money."
Cause-Effect(e2,e1)
Comment:

107	"Unfortunately, my <e1>friend</e1> falls in <e2>love</e2> easily and breaks her heart all the time."
Other
Comment: violates b.1 and c.3

108	"Heat, <e1>wind</e1> and smoke cause flight <e2>delays</e2>."
Cause-Effect(e1,e2)
Comment:

109	"In developing countries four-fifths of all the <e1>illnesses</e1> are caused by water-borne <e2>diseases</e2>, with diarrhoea being the leading cause of childhood death."
Cause-Effect(e2,e1)
Comment:

110	"After completing the <e1>resetting</e1> through the reset <e2>signal</e2>, the bit period transmitted by the master module 30 is received."
Other
Comment: Purpose-Tool

111	"The <e1>destruction</e1> caused by the <e2>bombing</e2> of Attorney General Palmer's home."
Cause-Effect(e2,e1)
Comment:

112	"The second biggest factor affecting the <e1>sound</e1> produced by a <e2>drum</e2> is the tension at which the drum head is held against the shell of the drum."
Cause-Effect(e2,e1)
Comment:

113	"The largest <e1>landslide</e1> triggered by the <e2>earthquake</e2> is located approximately 32 kilometers southeast of Muzafarrabad in a tributary valley of the Jhelum River."
Cause-Effect(e2,e1)
Comment:

114	"The <e1>debris</e1> caused a <e2>crash</e2> on the Schuylkill, and it has been closed for hours because of the mishap."
Cause-Effect(e1,e2)
Comment:

115	"A <e1>fire</e1> triggered by the <e2>blasts</e2> damaged eight buildings at the plant, including one that was burned down."
Cause-Effect(e2,e1)
Comment:

116	"In his <e1>poem</e1>, written by the <e2>riverside</e2> near the battle-ground, Mr. Emerson alluded to "Yon stem headstone"."
Other
Comment:

117	"Mechanical <e1>faults</e1> caused delays and <e2>cancellations</e2> on Wellington's suburban train services this morning."
Cause-Effect(e1,e2)
Comment:

118	"<e1>Asparagus</e1> is a natural cure for <e2>cancer</e2>."
Other
Comment:

119	"Relieve spinal stenosis by enlarging the spinal canal to relieve <e1>pressure</e1> on the spinal cord that has been caused by a herniated or bulging <e2>disc</e2>."
Cause-Effect(e2,e1)
Comment:

120	"The <e1>beer</e1> acts as a great hair of the <e2>dog</e2>."
Other
Comment:

121	"The <e1>company</e1> has run into a financial <e2>problem</e2> over the last few years."
Other
Comment: violates b.1

122	"A <e1>girl</e1> plays her violin on a pogo <e2>stick</e2>."
Other
Comment: Locative relation.

123	"Mado manages to escape and kidnaps the <e1>scientist</e1>'s <e2>niece</e2>."
Other
Comment: the niece is not a product of the scientist

124	"Passengers have rights in the event of a delay or <e1>cancellation</e1> that has been caused by the <e2>airline</e2>."
Cause-Effect(e2,e1)
Comment:

125	"The screenplay by Patterson McNutt and Arthur J. Beckhard focuses on the adoption of a young <e1>orphan</e1> (Shirley Temple) by a wealthy <e2>bachelor</e2> (John Boles)."
Other
Comment: the orphan is not produced by the bachelor

126	"However Susanoo was in <e1>sorrow</e1> after the <e2>loss</e2> of his mother and he was raging in his kingdom."
Cause-Effect(e2,e1)
Comment:

127	"But the <e1>earthquake</e1> triggered by the <e2>eruption</e2> of Thera struck first."
Cause-Effect(e2,e1)
Comment:

128	"Our objective is to review <e1>advances</e1> in the molecular <e2>biology</e2> and pharmacogenomics of lung cancer and how they apply to personalizing medicine."
Other
Comment:

129	"<e1>Diabetes mellitus</e1> is one of the leading causes of irreversible <e2>blindness</e2> worldwide, and, in the United States."
Cause-Effect(e1,e2)
Comment:

130	"The <e1>crew</e1> assisted with the <e2>investigation</e2> and was in service for around an hour."
Other
Comment: Purpose-Tool

131	"This <e1>data</e1> has been concerning primarily assembly <e2>operations</e2>."
Other
Comment:

132	"Interior chief adds <e1>hurdles</e1> for <e2>drilling</e2> on public lands."
Other
Comment: Purpose-Tool

133	"It is the most efficient and compact form of <e1>insulation</e1> in a <e2>carafe</e2>, and it's unbreakable."
Other
Comment:

134	"Getting help has reduced the time to reverse all the <e1>irritation</e1> that had been caused by the <e2>fungus</e2>."
Cause-Effect(e2,e1)
Comment:

135	"On the other hand, the higher the <e1>satisfaction</e1> from the <e2>purchase</e2>, the greater the benefit of word-of-mouth referrals and repeat purchasing."
Cause-Effect(e2,e1)
Comment:

136	"Although big city marathons offer great crowd support and a large <e1>camaraderie</e1> of <e2>runners</e2>, running in a big city marathon is not for everyone."
Other
Comment: Camaraderie is the spirit of community. Not a set.

137	"In 48% of the divorces, the <e1>kinship systems</e1> of <e2>grandparents</e2> expanded with divorce through one or more of the following four processes."
Other
Comment:

138	"District Judge without a jury and judgment was entered for the defendants on the ground that the <e1>accident</e1> was caused by the plaintiff's own <e2>negligence</e2>."
Cause-Effect(e2,e1)
Comment:

139	"The world is experiencing an unprecedented <e1>glut</e1> of <e2>savings</e2>, driving down real interest rates."
Other
Comment: Glut means many, a lot --- not a set.

140	"The <e1>case</e1> centers on a <e2>tree</e2> at a high school that was a meeting place for white students."
Other
Comment:

141	"Still filled with <e1>rage</e1> after the <e2>fight</e2> with the Darkside, I rush at Ansem, light and dark energy overflowing from me."
Other
Comment:

142	"The children descend the ladder after hearing the fire <e1>alarm</e1> which has been triggered by the wood work workshop catching <e2>fire</e2>."
Cause-Effect(e2,e1)
Comment:

143	"Sometimes the best <e1>blogging</e1> is going on well away from the most visible <e2>places</e2>."
Other
Comment:

144	"The <e1>incident</e1> caused a brief <e2>sensation</e2> on the Web among people suspicious that it was a political commentary."
Cause-Effect(e1,e2)
Comment:

145	"The <e1>navy</e1> searched the vessel with the <e2>crew</e2> on board."
Other
Comment:

146	"He sealed the cut after making a <e1>cut</e1> of the stem with a clean, sharp <e2>blade</e2>."
Other
Comment: Purpose-Tool

147	"The workers locked themselves in the upstairs office and left the shocked <e1>managers</e1> downstairs in the <e2>shop</e2>."
Other
Comment:

148	"And this is frequently cited as "proof" that saturated fats and <e1>cholesterol</e1> cause heart <e2>disease</e2>."
Cause-Effect(e1,e2)
Comment:

149	"The Water Information Program is a public information <e1>program</e1> sponsored by the water <e2>districts</e2>, organizations and agencies in the San Juan and Dolores watersheds of Southwestern Colorado."
Other
Comment: district is not a producer

150	"Scientists recently succeeded in wiping out a nasty <e1>memory</e1> from the mind of a genetically-engineered <e2>mouse</e2>."
Other
Comment: the mouse does not produce the memory

151	"Many commercial soap, shower gel or cleanser products contain <e1>preservatives</e1>, colorants and chemicals that cause dryness, rashes, <e2>itchiness</e2> and roughness on the skin."
Cause-Effect(e1,e2)
Comment:

152	"Birchwood and Stockton Heath were called to the scene after <e1>pyrotechnics</e1> used during one of the performances caused a <e2>fire</e2> on the main stage."
Cause-Effect(e1,e2)
Comment:

153	"Like a catch-22 the worst part is that acne causes stress and <e1>stress</e1> triggers acne <e2>breakouts</e2>."
Cause-Effect(e1,e2)
Comment:

154	"The US patent system is in a <e1>crisis</e1> that has been caused by the <e2>flood</e2> of patent applications being filed at the USPTO every year."
Cause-Effect(e2,e1)
Comment:

155	"While many farmers did their <e1>plowing</e1> the land with a single furrow <e2>plow</e2>, some large-scale farmers began to use a multiple share or bukker plow."
Other
Comment: Purpose-Tool

156	"Letters were be submitted by 5 p.m. on the Wednesday before <e1>publication</e1> by <e2>mail</e2>."
Other
Comment: "by mail" modifies the submission, not the publication.

157	"Viral gastroenteritis is a highly contagious <e1>infection</e1> of the intestines caused by one of several <e2>viruses</e2>."
Cause-Effect(e2,e1)
Comment:

158	"The outer <e1>segment</e1> is comprised of a <e2>membrane</e2> which is folded into several layers of disks."
Other
Comment: It sounds like the membrane is the whole segment, not just part of it.

159	"Diet fizzy <e1>drinks</e1> and meat cause heart disease and <e2>diabetes</e2>."
Cause-Effect(e1,e2)
Comment:

160	"We explore the experience of <e1>grief</e1> after the <e2>loss</e2> of a parent and offers support; we also make simple suggestions, and we provide a place for sharing memories."
Cause-Effect(e2,e1)
Comment:

161	"The war <e1>mentality</e1> was generated by the Iraq <e2>war</e2> in combination with the constant drum beat of fear at home."
Cause-Effect(e2,e1)
Comment:

162	"<e1>Preeclampsia</e1> is still one of the leading causes of maternal <e2>mortality</e2>."
Cause-Effect(e1,e2)
Comment:

163	"Since no computers were then available to him, he hand-simulated the Boxes algorithm, using a <e1>device</e1> made from an assembly of <e2>matchboxes</e2>."
Other
Comment: matchboxes make the device

164	"Compared to running barefoot, <e1>running</e1> in conventional running <e2>shoes</e2> increases stress on the knee joints up to 38%."
Other
Comment: Purpose-Tool

165	"The <e1>demolition</e1> was the cause of <e2>terror</e2> and communal divide is just a way of not letting truth prevail."
Cause-Effect(e1,e2)
Comment:

166	"The <e1>outbreak</e1> resulted in 256 deaths and 3,402 <e2>injuries</e2>."
Cause-Effect(e1,e2)
Comment:

167	"The postcard took the <e1>reader</e1> into the author's <e2>past</e2>."
Other
Comment: violates b.1

168	"These emotionally wrenching experiences encouraged the volunteers to seek the <e1>comradeship</e1> of fellow <e2>veterans</e2>."
Other
Comment: What's sought is company.

169	"Clay County, a small but thriving colony grows in the seepage <e1>spring</e1> which is the source of the <e2>creek</e2>."
Other
Comment:

170	"New portable electronic <e1>devices</e1> are running into temperature sensitivity <e2>issues</e2>."
Other
Comment: violates b.1

171	"While melting butter on the <e1>stove</e1> is the preferred <e2>method</e2>, because it gives you more control over the process, you can also melt butter in a microwave."
Other
Comment: Modality is outside

172	"Sip the tea slowly to reduce stomach <e1>pain</e1> from <e2>indigestion</e2>, bloating and feeling of fullness."
Cause-Effect(e2,e1)
Comment:

173	"<e1>Alcohol</e1>, substance abuse and poverty all lead to <e2>child abuse</e2>."
Cause-Effect(e1,e2)
Comment:

174	"The ATM <e1>malfunction</e1> caused a <e2>rush</e2> on the ATM machine until the police sealed off the area."
Cause-Effect(e1,e2)
Comment:

175	"<e1>Physiotherapy</e1> was focused on <e2>admission avoidance</e2>, prevention of deterioration after admission and facilitating early discharge."
Other
Comment:

176	"Moreover, the knightly ethic was based on a sense of honour and reflected the ideal of a <e1>comradeship</e1> of <e2>arms</e2>."
Other
Comment: Ethics, not a set.

177	"Some <e1>sections</e1> have been denoted with an <e2>asterisk</e2>."
Other
Comment:

178	"The <e1>corpse</e1> of a murderer was dangling from the <e2>noose</e2>, twisting in the wind."
Other
Comment:

179	"<e1>Sodium</e1> causes fluid <e2>retention</e2>, which can lead to edema (swelling), increased blood pressure, and in those susceptible patients, congestive heart failure."
Cause-Effect(e1,e2)
Comment:

180	"He takes <e1>words</e1> into <e2>action</e2>."
Other
Comment: violates c.3

181	"In businesses generally the third party claims for the <e1>damages</e1> that has been caused by the company <e2>vehicle</e2>."
Cause-Effect(e2,e1)
Comment:

182	"The <e1>martyrs</e1> conquered the fears associated with <e2>persecution</e2> and always remained loyal to the Lord."
Other
Comment:

183	"Secretary Tim Geithner came along with a <e1>fistful</e1> of taxpayer <e2>dollars</e2>."
Other
Comment: Too metaphorical. Plus, a fistful is a quantity.

184	"The <e1>law</e1> established a major <e2>redistribution</e2> of territorial sovereignty within the Empire."
Cause-Effect(e1,e2)
Comment: redistribution caused by law

185	"Infectious mononucleosis due to the Epstein-Barr <e1>virus</e1> causes exudative <e2>tonsillitis</e2> or pharyngitis in about one-half of cases."
Cause-Effect(e1,e2)
Comment:

186	"During the trial, the prosecution presented "pictures of burning bodies and human remains as well as images of the <e1>explosion</e1> triggered by the Pentagon <e2>crash</e2>.""
Cause-Effect(e2,e1)
Comment:

187	"Extensive <e1>damage</e1> at the mine has been caused by the <e2>strikers</e2>."
Cause-Effect(e2,e1)
Comment:

188	"This is the <e1>site</e1> deep inside the <e2>earth</e2> where fault movement begin."
Other
Comment: the site is not an entity of its own.

189	"Thus, we have set-up, early on, a familiar literary dynamic --- two <e1>compeers</e1> of different <e2>ages</e2> thrown together: Huck Finn and Nigger Jim, Holden Caufield and sister Phoebe, hell --- maybe even Dmitri Karamazov and Alyosha (or, if we stretch it far enough, Falstaff and Prince Hal)."
Other
Comment:

190	"I too, get a <e1>headache</e1> from <e2>wine</e2>, and was always told that it was the sulfites."
Cause-Effect(e2,e1)
Comment: modality is outside

191	"The most significant is a well-preserved black and white mosaic for which the <e1>authority</e1> has given a provisional <e2>translation</e2>."
Other
Comment:

192	"Clinicians entered the <e1>patients</e1> into randomised controlled <e2>trials</e2>."
Other
Comment: violates b.1 and c.3

193	"The <e1>interrogation</e1> covers von Neurath's <e2>activities</e2> during the years 1932 to 1938 and Hitler's policy of aggression during the late 1930s."
Other
Comment: Not a message -- a process or a procedure.

194	"Describing all of the <e1>harm</e1> caused by the <e2>hurricane</e2> has filled entire books so this Web page summarizes the total damage and focuses on the damage incurred on Long Island, New York."
Cause-Effect(e2,e1)
Comment:

195	"Information is included on the <e1>disease</e1> caused by the <e2>organism</e2>, its transmission, geographical distribution, and hosts."
Cause-Effect(e2,e1)
Comment:

196	"The <e1>star</e1> is landing into <e2>controversies</e2> because of thoughtless statements."
Other
Comment: violates b.1 and c.3

197	"Our political <e1>prisoner</e1> is falling into <e2>oblivion</e2>."
Other
Comment: violates b.1 and c.3

198	"<e1>Infection</e1> is one of the commonest causes of <e2>death</e2> in burn patients, particularly."
Cause-Effect(e1,e2)
Comment:

199	"The Vikings had become assimilated into a peaceable society, and <e1>monasteries</e1> at Chertsey and Abingdon were founded by the <e2>river</e2>."
Other
Comment: location, the river is not making monasterties

200	"I was diagnosed with bipolar disorder following a <e1>breakdown</e1> triggered by the sudden <e2>death</e2> of my brother six years ago."
Cause-Effect(e2,e1)
Comment:

201	"For years now my <e1>daughter</e1> has put up with verbal <e2>harssement</e2> from a girl."
Other
Comment: harssement is not a product of the daughter but of a girl

202	"The longest serving <e1>spacecraft</e1> goes into <e2>retirement</e2>."
Other
Comment: violates b.1 and c.3

203	"The <e1>baby</e1> is falling into a <e2>sleep</e2>."
Other
Comment: violates b.1 and c.3

204	"The reactor <e1>meltdown</e1> caused a chain <e2>reaction</e2> that destroyed all the towers in the network."
Cause-Effect(e1,e2)
Comment:

205	"<e1>Convulsions</e1> that occur after DTaP are caused by a <e2>fever</e2>."
Cause-Effect(e2,e1)
Comment:

206	"Although a commercial Enigma, modified by Polish cryptanalysts to match a military Enigma, used phone plugs, the <e1>plugs</e1> in the <e2>plugboard</e2> of the actual Enigma had two prongs, but they still functioned electrically in the same way as phone plugs."
Other
Comment: The plugboard and plugs are separate parts of the machine.

207	"It is marked by a <e1>sign</e1> indicating the <e2>length</e2> of the pause."
Other
Comment: Purpose.

208	"As the vehicles caught <e1>fire</e1> after the <e2>collision</e2>, the transformers began to explode one after the other."
Cause-Effect(e2,e1)
Comment:

209	"<e1>Fog</e1> or smoke cause <e2>irritation</e2> to those with respiratory sensitivity."
Cause-Effect(e1,e2)
Comment:

210	"A <e1>professor</e1> portrays his students' term <e2>paper</e2> as his own."
Other
Comment: professor is not a producer

211	"The <e1>team</e1>, has carefully devised an amended research <e2>methodology</e2>; it has also since found that further compromises will have to be made."
Other
Comment: the team is not producing the methodology; modality is outside

212	"The <e1>sinking</e1> resulted in the <e2>loss</e2> of 112 lives, including those of 28 Americans."
Cause-Effect(e1,e2)
Comment:

213	"The <e1>team</e1> drafted a great <e2>player</e2> in 2002 when they chose Julius Peppers second overall."
Other
Comment: player is not a product

214	"Chronic daily headaches are tension headaches or <e1>headaches</e1> which are caused by taking too many <e2>pain killers</e2>."
Cause-Effect(e2,e1)
Comment:

215	"But over time, indigenous <e1>students</e1> have been moving into more specialised and skill-intensive <e2>components</e2> within disciplines."
Other
Comment: violates b.1

216	"A <e1>month</e1> of snowy <e2>sundays</e2> in January had an adverse impact on Prospect's finances."
Other
Comment:

217	"At necropsy a heavy <e1>infestation</e1> of Haematopinus <e2>lice</e2> was present, along with a polyserositis affecting the right hock, left elbow and peritoneum."
Other
Comment:

218	"Pneumococcal <e1>meningitis</e1> is caused by pneumococcus <e2>bacteria</e2>, which also cause several diseases of the respiratory system, including pneumonia."
Cause-Effect(e2,e1)
Comment:

219	"Three shark attacks in 24 hours threw local <e1>people</e1> into <e2>panic</e2>."
Other
Comment: violates b.1 and c.3

220	"We share a <e1>kinship</e1> of <e2>ideals</e2> with every man and woman on earth who struggles for their God-given rights."
Other
Comment:

221	"Also (on a proportional basis) the <e1>rainbow</e1> caused by the <e2>spray</e2> appeared smaller than that of the other rainbow."
Cause-Effect(e2,e1)
Comment:

222	"The <e1>changes</e1> now seen in the endometrium are caused by a <e2>hormone</e2> called progesterone."
Cause-Effect(e2,e1)
Comment:

223	"The <e1>waste</e1>, a mixture of gasoline, water and caustic soda, gave off toxic <e2>fumes</e2>."
Cause-Effect(e1,e2)
Comment:

224	"Case <e1>studies</e1>, some of them book long, have made a notable contribution to scientific <e2>medicine</e2>."
Other
Comment: the studies are published - (d) is satisfied. However, medicine is NOT their Topic

225	"<e1>Weak ligaments</e1> are caused by <e2>problems</e2> with collagen (protein fibres in the ligaments)."
Cause-Effect(e2,e1)
Comment:

226	"He puts <e1>creativity</e1> into <e2>use</e2>."
Other
Comment: violates c.3

227	"This article discusses the ethics of the Soldier of Fortune's guns-for-hire <e1>advertisements</e1> that resulted in several <e2>murders</e2> across the United States."
Cause-Effect(e1,e2)
Comment:

228	"In 1905 the <e1>press</e1> reported extensively and vividly on the <e2>disorders</e2> in the cities and countryside, the clamor for basic reform, the political discussions."
Other
Comment: Press is an agent here.

229	"<e1>Quotation</e1> is used to indicate the <e2>words</e2> of another speaker or writer."
Other
Comment: Purpose.

230	"The size of the thumbnails is changed with a sliding <e1>bar</e1> on the upper right <e2>corner</e2> of the window."
Other
Comment:

231	"They evaluated maximum number of breached assemblies and exposed fuel area for a proposed <e1>shipment</e1> in a <e2>cask</e2> with a test leakage rate."
Other
Comment:

232	"The <e1>battle</e1> caused a <e2>panic</e2> on the frontier, and settlers in the surrounding counties fled."
Cause-Effect(e1,e2)
Comment:

233	"For decades, most of the nation's renewable <e1>power</e1> has come from <e2>dams</e2>, which supplied cheap electricity without requiring fossil fuels."
Cause-Effect(e2,e1)
Comment: Cause-Effect (satisfies c - Objects emitting radiation/heat/light... are regarded as Causers of such emissions)

234	"The optical <e1>signal</e1> is generated by an externally modulated tunable <e2>laser</e2>, and introduced to the chip through a tapered fiber."
Cause-Effect(e2,e1)
Comment:

235	"The <e1>byelection</e1> was caused by the <e2>resignation</e2> of Boris Johnson following his election as mayor of London in May."
Cause-Effect(e2,e1)
Comment:

236	"Swissair was a victim of the clandestine wealth-transfer plaguing the productive sector as a result of the falling interest-rate <e1>structure</e1> caused by bond <e2>speculation</e2>."
Cause-Effect(e2,e1)
Comment:

237	"Dee's end caps make <e1>pier</e1> piling sidewall <e2>forms</e2> function more efficiently by locking the forms together so they stay in place."
Other
Comment: I really don't understand this sentence.

238	"He received reports from the residence hall presidents regarding <e1>evacuation</e1> after the fire <e2>drill</e2>."
Cause-Effect(e2,e1)
Comment:

239	"The frog is the environmental <e1>indicator</e1> of the <e2>land</e2>, but University of Queensland researchers reckon when it comes to the sea, we should look to the turtle."
Other
Comment:

240	"The <e1>tsunamis</e1> triggered by the massive <e2>earthquakes</e2> plunged those provinces into crisis: the number of people dead and missing has reached to 245,782 people."
Cause-Effect(e2,e1)
Comment:

241	"We have to take into account the reality of the <e1>damage</e1> that has been caused by the <e2>deregulation</e2> of nutritional supplements."
Cause-Effect(e2,e1)
Comment:

242	"The <e1>catastrophe</e1> is narrated through <e2>metaphor</e2>."
Other
Comment: Manner.

243	"Lesser Black-backed Gulls were capable of producing, on average, almost three times the normal <e1>clutch</e1> of three <e2>eggs</e2>."
Other
Comment: Quantification excludes the Member-Collection interpretation.

244	"A Channel 4 <e1>drama</e1> set in a psychiatric unit has been criticised by a TV <e2>watchdog</e2> for its "offensive" title and for reinforcing prejudice against people with mental health problems."
Other
Comment:

245	"<e1>Estrogen dominance</e1> is one of the main causes of <e2>osteoporosis</e2>, cancer, ovarian cysts, fibroids and a host of other female problems in the U.S."
Cause-Effect(e1,e2)
Comment:

246	"iTunes, however, is a different <e1>kettle</e1> of <e2>drums</e2>."
Other
Comment: It's an idiom. Non-compositional reading makes no sense.

247	"Wealth is nominally a <e1>superfluity</e1> of <e2>goods</e2> required for subsistence, but the character of these goods varies with the use of wealth."
Other
Comment:

248	"His <e1>wife</e1> is a participant in the <e2>blogosphere</e2>, and he doesn't want to ruin the surprise for her."
Other
Comment: modality and negation are outside

249	"The <e1>scan</e1> started at the rest <e2>potential</e2> toward the positive direction."
Other
Comment:

250	"The great news is that <e1>germs</e1> causing recreational water <e2>illnesses</e2> are killed by chlorine."
Cause-Effect(e1,e2)
Comment:

251	"The EU inserted <e1>experts</e1> into the national <e2>defence</e2>."
Other
Comment: violates b.1

252	"The <e1>shop</e1> machined the part with a 1.25 inch <e2>diameter</e2>."
Other
Comment: diameter is not a tool, instead a property of the part.

253	"By chance, Toe discovers a rainbow-coloured <e1>rock</e1> with hidden <e2>power</e2> to grant wishes."
Other
Comment: power is a property, cannot be Instrument.

254	"The turbines are making an electricity <e1>system</e1> with low <e2>carbon</e2> emissions even greener - already, in Seattle, more than 90 percent of the power comes from renewable sources."
Other
Comment: carbon is not a product of the system

255	"The <e1>disruption</e1> has been caused by a sensitivity reaction in the brain to an ingested <e2>substance</e2>."
Cause-Effect(e2,e1)
Comment:

256	"The enormous <e1>landslide</e1>, which was triggered by an exceptionally heavy <e2>rainfall</e2> event (500 mm in 24 h) on 30 October 1998."
Cause-Effect(e2,e1)
Comment:

257	"In the framework of a holistic approach to student development and support, Student Services are also the contact point for other functions such as student out-of-class involvement, <e1>student</e1> participation in the university <e2>governance</e2> as well as in the Student Union."
Other
Comment: Participation again -- not one of our relations.

258	"The <e1>market</e1> is rooted in the <e2>structure</e2> of Zanzibar household economies, and therefore proides an indispensible function in daily life."
Other
Comment:

259	"The complete <e1>examination process</e1> has been carried out according to the pertinent <e2>directives</e2>."
Other
Comment: "pertinent to" is not necessarily about

260	"The heated <e1>gas</e1> caused a <e2>pyrolysis</e2> on the lower part of oil shale and produced shale oil and oil shale gas are escaped from the retort through exhaust pipe."
Cause-Effect(e1,e2)
Comment:

261	"The signoff <e1>queue</e1> is used for <e2>reports</e2> that the user has not seen before."
Other
Comment: we have some Purpose-Tool relation here (the queue is used for reports); negation is outside

262	"Parties have inherited <e1>entitlements</e1> to <e2>property</e2>."
Other
Comment:

263	"The libel <e1>claimant</e1> has proved that the <e2>statement</e2> was defamatory."
Other
Comment: the claimant is not the producer of the statement

264	"The low oil <e1>prices</e1> caused the <e2>collapse</e2> of the wall and the Russian empire."
Cause-Effect(e1,e2)
Comment:

265	"By charging odd amounts like 49 or 99 cents, the <e1>cashier</e1> very probably opened the <e2>till</e2>."
Other
Comment: The till is the object of the opening instead of the Instrument.

266	"The <e1>pain</e1> was caused by the <e2>parasite</e2> entering the body through the skin during bathing or drinking of infested water."
Cause-Effect(e2,e1)
Comment:

267	"The <e1>reaction</e1> starts at a rather low <e2>temperature</e2> ( + 5C), and the calorimeter is run from 40 to 130C."
Cause-Effect(e2,e1)
Comment:

268	"Next to Moll lived the celebrated actress Nancy Dawson, a former <e1>harlot</e1> made famous by her lascivious <e2>hornpipe</e2> in Gay's phenomenally popular The Beggar'ss Opera."
Other
Comment: no evidence that the pipe was made by the harlot

269	"But we are not at all complacent and we are well aware of the <e1>challenges</e1> around <e2>recruitment</e2>."
Other
Comment: the negation is in the other clause, so we could keep the

270	"The influential <e1>towns</e1> of Brownville and Fontanelle were founded that <e2>year</e2> as well."
Other
Comment: year is not a producer

271	"A chance <e1>discovery</e1> made by a road <e2>worker</e2> in 1956 uncovered a rich find of 360 million year old fish fossils."
Other
Comment: (a) is satisfied

272	"Towne Bank, which has only one retail location, was one of those opportunistic upstarts, a <e1>bank</e1> built on a <e2>bubble</e2>."
Other
Comment: bubble is not a producer

273	"The <e1>helix</e1> runs away from the <e2>nucleotide</e2>."
Other
Comment:

274	"I derive a tremendous amount of <e1>joy</e1> from <e2>teaching</e2> students in the research laboratory."
Cause-Effect(e2,e1)
Comment:

275	"The study found that people who took the <e1>combination</e1> of cholinesterase <e2>inhibitors</e2> (Aricept, Razadyne, or Exelon) and Memantine, showed a significantly slower rate of cognitve decline than those who took only a cholinesterase inhibitor or no drug."
Other
Comment: Combination here is a mix, the elements are not independent of each other.

276	"Antelope <e1>horns</e1> grows from the Southern California desert <e2>mountains</e2> across to Arkansas and up into Kansas."
Other
Comment:

277	"A very serious <e1>problem</e1> ensued from the <e2>events</e2> of the day."
Cause-Effect(e2,e1)
Comment:

278	"He sent the <e1>revellers</e1> into <e2>party mode</e2>."
Other
Comment: violates c.3

279	"A first <e1>revolution</e1> was triggered by the growing use of reading and <e2>writing</e2>."
Cause-Effect(e2,e1)
Comment:

280	"The US regulatory <e1>agency</e1> was investigating <e2>allegations</e2> that at least one plane was considered unsafe to fly."
Other
Comment:

281	"The resulting <e1>biofilm</e1> grows from the <e2>inside</e2> out rather than planktonic organisms attaching and promoting the growth from the outside."
Other
Comment:

282	"The <e1>vibration</e1> caused by a heavy goods <e2>train</e2> on the Metropolitan Railway, which runs under the Exhibition premises, had shaken the figure off its balance."
Cause-Effect(e2,e1)
Comment:

283	"It also gives some of the history behind the <e1>formation</e1> of Wolf's <e2>dragoons</e2> and some of the battles and campaigns the mercenary regiment has fought."
Other
Comment: An arrangement, not a set; or maybe the process of forming.

284	"Voltage <e1>surges</e1> or spikes are caused by <e2>lightning</e2>, short circuits, power company equipment problems, and inductive spikes, among many other causes."
Cause-Effect(e2,e1)
Comment:

285	"The recovery is weak and fragile, and the economic and social <e1>damage</e1> caused by the <e2>crisis</e2> is long-lasting."
Cause-Effect(e2,e1)
Comment:

286	"The cutaneous <e1>mycoses</e1> are caused by a homogeneous group of keratinophilic <e2>fungi</e2> termed the dermatophytes."
Cause-Effect(e2,e1)
Comment:

287	"Recovery from the global economic <e1>crisis</e1> triggered by the <e2>collapse</e2> of Lehman Brothers was achieved with cooperation from Brazil, Russia, India and China."
Cause-Effect(e2,e1)
Comment:

288	"The <e1>microphone</e1> converts sound into an electrical <e2>signal</e2>."
Cause-Effect(e1,e2)
Comment:

289	"The trapped <e1>mass</e1> takes part in the <e2>movement</e2> and therefore contributes to the inertia of the system."
Other
Comment: Participation in an event. We do not see it as a form of membership. It rather is a kind of agency or co-agency.

290	"I've been a <e1>closet</e1> <e2>writer</e2> for a long time."
Other
Comment: closet is not a product

291	"<e1>Swelling</e1> of the resin is caused by the <e2>expansion</e2> of the structure as a result of water (or other liquid) molecules penetrating the matrix."
Cause-Effect(e2,e1)
Comment:

292	"There were <e1>setbacks</e1> and technical problems that ensued from the location <e2>design</e2>, flooding, and moisture that plagued the winery and bumped up the investment cost beyond the initial budgetary estimates."
Cause-Effect(e2,e1)
Comment:

293	"We find evidence that Ernst suffered a thrombotic cardiovascular event, i.e., a myocardial <e1>infraction</e1> triggered by a blood <e2>clot</e2>."
Cause-Effect(e2,e1)
Comment:

294	"<e1>Fire</e1> was venting from the first floor of a multi-storeyed <e2>building</e2> in South Mumbai's Nariman point area on Monday."
Other
Comment:

295	"The charcuterie was well portioned offering lots of variety, well textured, with a nice <e1>accompaniment</e1> of <e2>condiments</e2> and composed salads."
Other
Comment: As the words suggest, it is accompaniment, not belonging.

296	"The <e1>protesters</e1> carefully chose a private <e2>road</e2> in order not to cause inconvenience to the public."
Other
Comment: the road is the location

297	"The breakdown of the linear relation of J,1 D at peakeffect region indicates that the <e1>peakeffect</e1> originates from an addition pinning <e2>effect</e2>."
Cause-Effect(e2,e1)
Comment:

298	"The gist of <e1>trespass</e1> is direct physical <e2>interference</e2> with another's exclusive possession of land."
Other
Comment:

299	"However, a <e1>headache</e1> from <e2>wine</e2> is often stronger and last longer due to several compounds."
Cause-Effect(e2,e1)
Comment:

300	"Specialists from various <e1>fields</e1> pertinent to the <e2>theme</e2> took part and presented specific aspects of the topic."
Other
Comment:

301	"The <e1>container</e1> encloses a one-cup <e2>capacity</e2>, plus with the bonus lid it provides convenient storage of chopped foods."
Other
Comment: capacity is not a content

302	"The Maze procedure crates new pathways for the electrical <e1>impulses</e1> that trigger the <e2>heartbeat</e2>."
Cause-Effect(e1,e2)
Comment:

303	"Early in the <e1>song</e1>, the background <e2>singers</e2> repeat the Christian and Jewish word of praise, "Hallelujah"."
Other
Comment: the singer is not creating the song it is just singing it

304	"We discovered that my chronic <e1>migraines</e1> and neck pain were caused by the <e2>injuries</e2> I had sustained in my first car accident two and a half years ago."
Cause-Effect(e2,e1)
Comment:

305	"The 180 cm thick concrete <e1>shield</e1> starts at the <e2>radius</e2> of 600 cm."
Other
Comment:

306	"The continuous <e1>rains</e1> had caused the <e2>overflow</e2> of Sulangaling River, a creek of the Muara Batang."
Cause-Effect(e1,e2)
Comment:

307	"<e1>Sun</e1> and wind cause <e2>evaporation</e2> of water, causing rains, and this energy can be caught using hydroelectric power."
Cause-Effect(e1,e2)
Comment:

308	"It has changed the way I think about the <e1>formation</e1> of <e2>parties</e2> and party systems."
Other
Comment: It's the forming of.

309	"He schose the better approach: to be honest and understanding and to acknowledge the <e1>distress</e1> caused by the hallucinations or <e2>delusions</e2>."
Cause-Effect(e2,e1)
Comment:

310	"<e1>Fatigue</e1> <e2>corrosion</e2> and stress corrosion are similar, as both are caused by external stresses applied to the pipe and occur inside of the pipe."
Cause-Effect(e1,e2)
Comment:

311	"The <e1>fire</e1> started at the <e2>southeastern end</e2> of the Circus Maximus in shops selling flammable goods."
Other
Comment:

312	"We assessed the efficacy of a recombinant <e1>vaccine</e1> consisting of <e2>outer-surface protein A</e2> (OspA) without adjuvant in subjects at risk for Lyme disease."
Other
Comment: outer-surface protein A is a substance

313	"The best kept secret for avoiding abdominal <e1>weight gain</e1> due to <e2>stress</e2> is the use of adaptogens."
Cause-Effect(e2,e1)
Comment:

314	"Other <e1>items</e1> advertised on TV simply melt the chocolate on the <e2>stovetop</e2>."
Other
Comment: Locative

315	"The <e1>sense</e1> was extended from the <e2>language</e2> to the people who spoke it."
Other
Comment:

316	"The <e1>farmer</e1> produced a <e2>surplus</e2> despite the country's worst drought in 30 years by using conservation farming techniques."
Other
Comment: surplus is not a direct product

317	"It is an Eden invented by the <e1>poet</e1>'s <e2>imagination</e2> into which external values are not disregarded, but have been absorbed and re-invented."
Other
Comment: Violation of "(f) Properties, capabilities, aptitutes, skills, attitutes etc. are not acceptable as Instruments."

318	"Treasure Island is a gripping pirate <e1>story</e1>, fast-paced by the <e2>standards</e2> of its time and full of action."
Other
Comment: standard is not a producer

319	"Vietnam's response on the <e1>toll</e1> caused by the <e2>earthquake</e2> in Sichuan, China."
Cause-Effect(e2,e1)
Comment:

320	"A University of Colorado <e1>student</e1> died due to a <e2>jump</e2> from an overpass onto US 36."
Other
Comment: Other, because student cannot be effect.

321	"After mile 17 the <e1>course</e1> went away from the <e2>water</e2> and onto streets with trees."
Other
Comment:

322	"As the <e1>earth</e1> revolves around the <e2>sun</e2>, the place where light shines the brightest changes."
Other
Comment: That's location/orientation

323	"Their analysis demonstrates beyond any doubt that the <e1>problem</e1> of unemployment has been caused by the <e2>state</e2>, not by any inherent flaws or failures in a free market."
Cause-Effect(e2,e1)
Comment:

324	"The <e1>inequality</e1> and poverty caused the <e2>riots</e2> in 2001."
Cause-Effect(e1,e2)
Comment:

325	"The <e1>marshes</e1> have been drained into the <e2>farms</e2>."
Other
Comment: marches are wetlands; they do not move into the farms, only the water in them does

326	"<e1>Mitochondria</e1> were passed on to subsequent <e2>generations</e2> only through egg cells."
Other
Comment: violates b.1

327	"Cost-benefit <e1>analysis</e1> is used mainly to assess the monetary <e2>value</e2> of very large private and public sector projects."
Other
Comment: This is Purpose, which is not in our inventory.

328	"The three <e1>companions</e1> reached the city by <e2>way</e2> of the river Selintan."
Other
Comment: e2 is a location rather than an Instrument.

329	"It seems like the fever <e1>heat</e1> got pushed out from the <e2>body</e2> as rashes."
Cause-Effect(e2,e1)
Comment:

330	"This <e1>series</e1> made a contribution to the <e2>development</e2> of museological thought."
Other
Comment:

331	"Hence, the left regular <e1>grammars</e1> generate exactly all regular <e2>languages</e2>."
Other
Comment: grammar is not actively involved

332	"This feared <e1>ruler</e1> founded the largest land <e2>empire</e2> in history."
Other
Comment: the empire is not a real concrete object.

333	"To connect the microcontroller to the Internet, one must implement a <e1>protocol</e1> <e2>stack</e2> on the device."
Other
Comment:

334	"A <e1>technician</e1> assists the <e2>fishermen</e2> with this."
Other
Comment: Assistance, collaborative work.

335	"We are therefore invited software engineering researchers to apply for research <e1>awards</e1> in all <e2>areas</e2> of software engineering."
Other
Comment: The sentence violates: "(a) The Message X has descriptive, significative or propositional content and has been produced to communicate this content."

336	"The yellow <e1>discolouration</e1> has been caused by the damaging acidic <e2>properties</e2> of the low-grade mount used in the original frame."
Cause-Effect(e2,e1)
Comment:

337	"British <e1>troops</e1> made their deepest <e2>incursion</e2> into Basra yesterday, "poking a toe" within four miles of the centre."
Other
Comment:

338	"The <e1>damage</e1> caused by the <e2>tsunami</e2> - at least the physical damage - is barely visible in some places."
Cause-Effect(e2,e1)
Comment:

339	"For Jung, the <e1>individual</e1> is a participant in a '<e2>collective unconscious</e2>'."
Other
Comment:

340	"The <e1>gaps</e1> in the rings are caused by <e2>resonance</e2> between the particles in the rings and the moons orbiting nearby."
Cause-Effect(e2,e1)
Comment:

341	"He followed a specific procedure for obtaining the <e1>engineer</e1>'s <e2>permit</e2> in Quebec and met certain requirements to receive an engineer's permit."
Other
Comment: This would be a permit that allows the engineer to do his/her work, probably produced by some bureaucrat. See for example http://www.oiq.qc.ca/practice/permits/eng-permit.html

342	"The <e1>party</e1> starts in an <e2>hour</e2>."
Other
Comment:

343	"The resulting <e1>conflict</e1> caused the <e2>destruction</e2> of the town, and The Conqueror, Wisecrack, Jackdaw and most of the citizens of the town were transported to a demon-dimension."
Cause-Effect(e1,e2)
Comment:

344	"They discovered a good bit of published literature about <e1>modification</e1> of yeast with resveratrol-related <e2>genes</e2>."
Other
Comment: Purpose-Tool

345	"As the right front wheel of Senna's car hit the wall, the violent <e1>impact</e1> caused a <e2>torsion</e2> on the steering column, causing it to break."
Cause-Effect(e1,e2)
Comment:

346	"The above exceptions fully resolved the evaluation of a <e1>photograph</e1> by a <e2>court</e2> as a result of the claim."
Other
Comment:

347	"Scientists have successfully tested a <e1>system</e1> that translates brain waves into <e2>speech</e2>."
Other
Comment: speech is not a concrete object

348	"The <e1>company</e1> has assembled five independent food safety <e2>experts</e2> to serve on its newly formed Food Safety Advisory Council."
Other
Comment: the company is not the producer of experts

349	"The <e1>weather</e1> resulted in several deaths and hundreds of <e2>accidents</e2>."
Cause-Effect(e1,e2)
Comment:

350	"The <e1>fun run</e1> starts at <e2>noon</e2>."
Other
Comment:

351	"The site welcomed to the premier industrial <e1>grinding</e1> <e2>wheels</e2> resource."
Other
Comment: Purpose-Tool

352	"Sixty five million years ago an <e1>asteroid</e1> caused the <e2>extinction</e2> of the dinosaurs."
Cause-Effect(e1,e2)
Comment:

353	"Since this afternoon the <e1>models</e1> have come into somewhat better <e2>agreement</e2>."
Other
Comment: violates c.3

354	"Amtrak expects a normal rush hour after a fatal <e1>accident</e1> near Baltimore caused <e2>delays</e2> along the Northeast corridor."
Cause-Effect(e1,e2)
Comment:

355	"As we saw earlier, <e1>helicobacter</e1> is responsible for causing stomach <e2>ulcer</e2>."
Cause-Effect(e1,e2)
Comment:

356	"Over 90% of the cases of <e1>ringworm</e1> of the scalp are caused by Trichophyton tonsurans, a <e2>fungus</e2> that infects the hairs and causes them to break."
Cause-Effect(e2,e1)
Comment:

357	"So, while naked, he stole a <e1>car</e1> with <e2>children</e2> inside, dropped one out of the window, and drove it through a fence."
Other
Comment: (d) is not satisfied, vehicles are not containers

358	"Many <e1>shoulder problems</e1> are caused by the <e2>breakdown</e2> of soft tissues in the shoulder region."
Cause-Effect(e2,e1)
Comment:

359	"Tulip <e1>mania</e1>, in the 1600s, was caused by the massive <e2>influx</e2> of newly discovered Gold into Amsterdam from the new world: in particular the capture of the Spanish Treasury fleet."
Cause-Effect(e2,e1)
Comment:

360	"Currently, there is no known cure for asbestos cancer but several mesothelioma treatment regimens have proven to be successful in helping the patient avoid <e1>pain</e1> and discomfort caused by the <e2>disease</e2>."
Cause-Effect(e2,e1)
Comment:

361	"<e1>Percentages</e1> denote the interest <e2>rate</e2>."
Other
Comment:

362	"The <e1>president</e1> increased the fleet by the <e2>construction</e2> of one high-class cruiser."
Other
Comment: Here e2 is more of a single event than a method

363	"The patient experiences displaced emotional and financial <e1>deprivation</e1> as well as anger after the <e2>divorce</e2>."
Cause-Effect(e2,e1)
Comment:

364	"Now we are beginning to understand how the <e1>brain</e1> works using brain-machine interface <e2>technology</e2>."
Other
Comment: The brain is the target object of the study that uses technology.

365	"Regulations limit the use of RFID <e1>technology</e1> for human <e2>tracking</e2>."
Other
Comment: Purpose-Tool

366	"I was a little worried about making an <e1>ascent</e1> of the crux with a <e2>backpack</e2>."
Other
Comment:

367	"<e1>Implementation</e1> of this proposal is being discussed at the state <e2>level</e2>."
Other
Comment:

368	"This is based on the notion that a human is basically a <e1>purpose</e1> driven <e2>animal</e2>."
Other
Comment: Purpose is a property.

369	"<e1>Smoke</e1> is one of the leading causes of <e2>kidney failures</e2>."
Cause-Effect(e1,e2)
Comment:

370	"<e1>Germs</e1> are microscopic organisms that cause sickness or <e2>disease</e2>."
Cause-Effect(e1,e2)
Comment:

371	"I have just bought a <e1>silver</e1> <e2>necklace</e2> from a lady who makes her own jewellery with the fingerprints of my children on it."
Other
Comment:

372	"The Earth's thin, rocky <e1>crust</e1> is composed of <e2>silicon</e2>, aluminum, calcium, sodium and potassium."
Other
Comment: Material

373	"Yellow <e1>fever</e1> is caused by infection with yellow fever <e2>virus</e2>, which is transmitted by the bite of infected mosquitoes."
Cause-Effect(e2,e1)
Comment:

374	"While making <e1>observations</e1> of the microfossil through the binocular <e2>microscope</e2> or on a computer monitor, the investigator needed to manually move the specimen."
Other
Comment: Purpose-Tool

375	"Biddle has done a thorough job of cutting through the <e1>thicket</e1> of <e2>contradictions</e2> and fantasies that surround the strategic bombing debate from 1914 to 1945."
Other
Comment: A thicket is a pattern, not a set.

376	"Even though his 16-month old suffered from severe <e1>burns</e1> on her body caused by <e2>boiling water</e2> spilled on her, father refuses to allow ambulance to take his daughter to Hadassah because 'rabbi advised otherwise'."
Cause-Effect(e2,e1)
Comment:

377	"This study presents a comprehensive methodology for calculating the cost to <e1>society</e1> of various criminal <e2>acts</e2>."
Other
Comment:

378	"The fad started when a certain <e1>brand</e1> of socks manufactured by an American <e2>company</e2> became popular among Japanese schoolgirls."
Other
Comment: brand is not a tangible object

379	"After 5 minutes or so, the <e1>problem</e1> went away from an operational <e2>perspective</e2>."
Other
Comment:

380	"Frazerian theory of <e1>corn</e1> <e2>spirits</e2> and fertility and have thus needed to enquire no further, so their distribution and function remains unclear."
Other
Comment:

381	"The <e1>author</e1> cites the <e2>case</e2> of an American citizen during the general war."
Other
Comment: the author is the communicator, not the message.

382	"The army of Israel was utterly defeated and its camp ransacked, which terribly augmented the horrors and disasters of the <e1>rout</e1> of Saul's <e2>army</e2>."
Other
Comment: Here e1 is a subset of e2, not an individual item.

383	"Atopic <e1>dermatitis</e1>, the most common type of eczema, causes <e2>itchiness</e2> that's worse in the colder months."
Cause-Effect(e1,e2)
Comment:

384	"My eyes have seen the defeat of my adversaries; my ears have heard the <e1>rout</e1> of my wicked <e2>foes</e2>."
Other
Comment: The pattern is at fault -- "rout" is not the name of a grouping.

385	"Botulism is a rare but serious paralytic <e1>illness</e1> caused by a nerve <e2>toxin</e2> that is produced by the bacterium Clostridium botulinum."
Cause-Effect(e2,e1)
Comment:

386	"The <e1>benefits</e1> from <e2>inflation</e2> which Professor Mulligan cites (e.g., bailing out underwater mortgagers) are better understood as a government sponsored transfer of wealth from savers to speculators."
Cause-Effect(e2,e1)
Comment:

387	"The <e1>concerto</e1> comes from the <e2>pop</e2> of gas bubbles escaping the joints, snapping tendons and ligaments, and rickety arthritic joints."
Cause-Effect(e2,e1)
Comment:

388	"Another misconception I see often is a fuzzy idea of the difference between the copy constructor and the <e1>assignment</e1> <e2>operator</e2>."
Other
Comment:

389	"A urinary tract <e1>infection</e1> (UTI) is the most common cause of bladder <e2>irritation</e2>."
Cause-Effect(e1,e2)
Comment:

390	"The <e1>protest</e1> resulted in hours of traffic <e2>jams</e2> on Guangzhou's major roads, such as Guangyuanxi Lu, Huangshidong Lu and Dongfeng Lu."
Cause-Effect(e1,e2)
Comment:

391	"Evacuees with disabilities had a difficult time conveying the <e1>trauma</e1> caused by the unexpected <e2>arrival</e2> of uniformed officers who ordered them out of their homes and sometimes forcibly removed them."
Cause-Effect(e2,e1)
Comment:

392	"The <e1>discharge</e1> started from the burst pulse <e2>corona</e2>."
Other
Comment:

393	"Highly viscous <e1>lavas</e1> lead to a violent <e2>eruption</e2>."
Cause-Effect(e1,e2)
Comment:

394	"A US <e1>aircraft</e1> was dropped into a difficult <e2>landing</e2> in Mali."
Other
Comment: violates b.1 and c.3

395	"The <e1>cysts</e1> are caused by chronic <e2>inflammation</e2> of the perichondrium with production of serous fluid between the perichondrium and cartilage."
Cause-Effect(e2,e1)
Comment:

396	"Some posters (e.g. number 18) encouraged the population of areas near the front to evacuate, thus avoiding the overcrowding and ensuing problems of food distribution and <e1>disease</e1> caused by the incoming <e2>refugees</e2>."
Cause-Effect(e2,e1)
Comment:

397	"If a participant <e1>complaint</e1> is the source of an investigative <e2>lead</e2>, interim contact with the participant should be made by the investigator."
Cause-Effect(e1,e2)
Comment:

398	"The <e1>violence</e1> has been caused by the Hutu <e2>militia</e2> who fled Rwanda after the genocide in that country and who have been in hiding in the forest in Congo."
Cause-Effect(e2,e1)
Comment:

399	"The <e1>clock</e1> struck twelve with a loud <e2>chime</e2> that made me jump."
Cause-Effect(e1,e2)
Comment:

400	"<e1>Antacids</e1> work by using a <e2>base</e2> to neutralize the acid."
Other
Comment: e2 is a substance contained in e1.

401	"Ross noted that the <e1>landscapes</e1> he painted - typically <e2>mountains</e2>, lakes, snow, and log cabin scenes - were strongly influenced by his years living in Alaska, where he was stationed for the majority of his Air Force career."
Other
Comment:

402	"<e1>Signs</e1> placed at the flagpole island at the village square caused a <e2>stir</e2> on the Linglestown forum on PennLive.com."
Cause-Effect(e1,e2)
Comment:

403	"The valuable <e1>book</e1> has arrived into my <e2>care</e2>."
Other
Comment: violates b.1 and c.3

404	"Lena Basilone, a cook at Camp Pendleton, was in the hospital recovering from a severe kitchen <e1>burn</e1> after the <e2>spilling</e2> of scalding liquid on her feet."
Cause-Effect(e2,e1)
Comment:

405	"Gross <e1>revenues</e1> from the <e2>selling</e2> of crude oil in 2003 reached US$11.508 billion or some 112.85 percent of the amount targeted in the 2003 state budget."
Cause-Effect(e2,e1)
Comment:

406	"Whooping cough is another name for the pertussis, an <e1>infection</e1> of the airways caused by the <e2>bacteria</e2> bordetella pertussis."
Cause-Effect(e2,e1)
Comment:

407	"We are a <e1>petroleum</e1> and petrochemical <e2>company</e2>."
Other
Comment: petroleum is raw material

408	"The <e1>users</e1> are running into <e2>problems</e2> with the installer."
Other
Comment: violates b.1

409	"Eventually the <e1>path</e1> went away from the <e2>lake</e2> into some gorse."
Other
Comment:

410	"And it is why we are even prouder to announce that the appeal - thanks to the generosity of our readers - has raised 26,000 pounds, despite the <e1>hardship</e1> that has been caused by the <e2>recession</e2>."
Cause-Effect(e2,e1)
Comment:

411	"The <e1>problems</e1> are caused by buffer <e2>overflows</e2> when parsing an overly long parameter."
Cause-Effect(e2,e1)
Comment:

412	"The rock 'n' roll <e1>business</e1> is falling into <e2>self-parody</e2>."
Other
Comment: violates c.3

413	"A <e1>handful</e1> of <e2>countries</e2> blocked a legally binding deal on climate change in Copenhagen and the talks process needs urgent reform to prevent something similar happening again."
Other
Comment: This is a quantity.

414	"All <e1>aspects</e1> are indicated with colour light <e2>signals</e2>."
Other
Comment:

415	"He underlined the tiny <e1>sacrifices</e1> made by Western <e2>armies</e2> in comparison with those of the Red Army."
Other
Comment:

416	"One of the <e1>types</e1> of tissue that makes up <e2>bone</e2> is the mineralized osseous tissue, also called bone tissue, that gives it rigidity and a honeycomb-like three-dimensional internal structure."
Other
Comment: type is not a producer

417	"<e1>Discussion</e1> ensued from the Florida <e2>contingent</e2> on the fact that very stringent landowner protection laws in Florida make it imperative that the highest supportable appraised vallue be offered first."
Cause-Effect(e2,e1)
Comment:

418	"About 1830, the New York Mirror described the area as a "loathsome <e1>den</e1> of <e2>murderers</e2>, thieves, abandoned women, ruined children, filth, drunkenness, and broils.""
Other
Comment: Location.

419	"I sold a <e1>gold</e1> <e2>ring</e2> to another company online and they sent me a lousy check for $14.00."
Other
Comment:

420	"The dome of the museum rotunda is made from an actual brewing kettle, and walking into it gives <e1>visitors</e1> the sense of being in a <e2>kettle</e2>."
Other
Comment: the kettle is not a container

421	"Erikson(1976) found that <e1>people</e1> from among a community who escaped an horrific <e2>accident</e2> had made little progress after two years."
Other
Comment:

422	"The camp is more rugged than a hotel but comes with a great lake view and the <e1>comradeship</e1> of fellow chemistry <e2>teachers</e2>."
Other
Comment:

423	"It utilized a critical eye and free <e1>inquiry</e1> into the <e2>conditions</e2> of life and issues of morality."
Other
Comment: a process

424	"The old <e1>man</e1> went into diabetic <e2>coma</e2>."
Other
Comment: violates b.1 and c.3

425	"We find the <e1>candle</e1> <e2>light</e2> creates a special atmosphere not only for food, but ambiance for a relaxing convivial meal as well."
Cause-Effect(e1,e2)
Comment:

426	"Symptoms vary according to the degree of <e1>inflammation</e1> caused by the <e2>bacteria</e2>, ranging from slightly loose stools to bloody diarrhea, abdominal pain, and fever."
Cause-Effect(e2,e1)
Comment:

427	"High <e1>winds</e1> caused delays and <e2>cancellations</e2> of some state ferries."
Cause-Effect(e1,e2)
Comment:

428	"The front <e1>wheels</e1> are making a <e2>grinding noise</e2>."
Cause-Effect(e1,e2)
Comment:

429	"Williams syndrome: a genetic <e1>disorder</e1> that results in selective cognitive <e2>impairment</e2>."
Cause-Effect(e1,e2)
Comment:

430	"A Chowchilla man is behind bars, after a pipe <e1>bomb</e1> was discovered inside a mobile <e2>home</e2>."
Other
Comment:

431	"The <e1>symbol</e1> denotes <e2>concatenation</e2>."
Other
Comment:

432	"In the open air of the Sanz hotel, amid the music of the fountain and the <e1>glint</e1> of the <e2>goldfish</e2>, I almost forgot my nationality and imagined myself a great Spanish grandee, residing in an ancient Spanish mansion, and, no doubt, unconsciously adopted something of the stately walk and conversation suited to the part."
Other
Comment: It's to do with light reflected, not fish collected.

433	"I was lucky enough to see with my own eyes the recent stock-market crash, where they lost several million dollars, a <e1>rabble</e1> of dead <e2>money</e2> that went sliding off into the sea."
Other
Comment: Too abstract: money can't be a member of anything...

434	"And the economic <e1>crisis</e1> was generated due to the sub-prime mortgage <e2>mess</e2> brought about through government intervention in the market to promote progressive ideals (ie extending loans to low-income borrowers)."
Cause-Effect(e2,e1)
Comment:

435	"A specific <e1>legacy</e1> has relation to the <e2>time</e2> of making the will."
Other
Comment:

436	"By the late 1980s, however, the Bank was caught up in the debt <e1>crisis</e1> in the developing world caused by the <e2>recession</e2> and the dramatic rise in interest rates."
Cause-Effect(e2,e1)
Comment:

437	"The aim of this <e1>study</e1> was the <e2>measurement</e2> of the intensity and circumstances of drug use."
Other
Comment: here study is an activity - violates (d)

438	"The risks to housing and general corporate <e1>profits</e1> from <e2>inflation</e2> were quite clear and the defensive strategy over the long term has paid dividends."
Cause-Effect(e2,e1)
Comment:

439	"There is relatively little <e1>discomfort</e1> from this <e2>surgery</e2> and most individuals rarely take more than Tylenol for their discomfort."
Cause-Effect(e2,e1)
Comment:

440	"<e1>Fats</e1> from meat and dairy cause heart <e2>disease</e2>, the leading killer of people with diabetes."
Cause-Effect(e1,e2)
Comment:

441	"After <e1>runners</e1> carried the torch through the <e2>streets</e2> of North Platte, the torch was again handed off to a Pony Express rider, who continued down the trail."
Other
Comment:

442	"The <e1>contortions</e1> are caused by gravitational <e2>interactions</e2> with the small satellites Prometheus and Pandora."
Cause-Effect(e2,e1)
Comment:

443	"In future Britain, charismatic delinquent Alex DeLarge is jailed and later volunteers for an experimental aversion <e1>therapy</e1> developed by the <e2>government</e2> in an effort to solve society's crime problem."
Other
Comment:

444	"This <e1>smile</e1>, a true reflection of God's tenderness, is the source of an invincible <e2>hope</e2>."
Cause-Effect(e1,e2)
Comment:

445	"The <e1>earthquake</e1> caused a bulrush <e2>marsh</e2> at West Point, on the Puget Sound shore in Seattle, to drop and the tsunami deposited sand on top of the marsh."
Cause-Effect(e1,e2)
Comment:

446	"The greatest <e1>amazement</e1> was caused by the <e2>floats</e2>."
Cause-Effect(e2,e1)
Comment:

447	"The <e1>input</e1> <e2>queue</e2> is used for processing events from an MFG/PRO application to a WebSphere-connected application."
Other
Comment: Type.

448	"Treatment of cardiovascular <e1>collapse</e1> from caffeine <e2>overdose</e2> with lidocaine, phenylephrine, and hemodialysis."
Cause-Effect(e2,e1)
Comment:

449	"US forces fared so well that MacArthur gained Truman's permission to attempt a total <e1>rout</e1> of communist <e2>forces</e2>."
Other
Comment: The pattern is at fault -- "rout" is not the name of a grouping.

450	"The <e1>strategy</e1> covers the period to 2016, with a strong <e2>focus</e2> on 2010."
Other
Comment:

451	"To date, all <e1>outbreaks</e1> of the highly pathogenic form of avian influenza have been caused by <e2>viruses</e2> of the H5 and H7 subtypes."
Cause-Effect(e2,e1)
Comment:

452	"Wes Anderson has made one classic comedy(The Royal Tenenbaums) fueled by the <e1>tension</e1> from the characters' <e2>longings</e2> to burst out of the trappings in which they are framed."
Cause-Effect(e2,e1)
Comment:

453	"It is found that the <e1>polysilicon</e1> grows from an initial <e2>step</e2> of the deposition."
Other
Comment:

454	"In general, the greatest hypocalcemic effect was achieved by those liposomal <e1>preparations</e1> that resulted in the most sustained <e2>increase</e2> of L-hCT and F-hCT in plasma."
Cause-Effect(e1,e2)
Comment:

455	"The <e1>applet</e1> requires a <e2>browser</e2> that supports JDK 1.1.5 or above."
Other
Comment:

456	"<e1>Poverty</e1> is caused by <e2>overpopulation</e2>."
Cause-Effect(e2,e1)
Comment:

457	"This new, improved active piezoelectric <e1>hydrophone</e1> is made with shielded clear waterproof <e2>cable</e2> and a copper acoustic chamber coated in non-toxic, durable black rubber."
Other
Comment: Cable is mentioned as a material, not a part.

458	"The economic <e1>setbacks</e1> of 1893 had created <e2>unemployment</e2> and poverty which caused migration in search of new opportunities."
Cause-Effect(e1,e2)
Comment:

459	"At this time the <e1>farm</e1> had three <e2>horses</e2> and a small tractor."
Other
Comment:

460	"We are determined to pursue the <e1>conquest</e1> of evil with the <e2>good</e2>."
Other
Comment: Purpose-Tool

461	"Authentic <e1>people</e1>, knowing their place in the world, fulfill it with <e2>joy</e2> and attention."
Other
Comment:

462	"<e1>Unificationists</e1> sees Kingdom coming with the help of the new <e2>president</e2>."
Other
Comment:

463	"The <e1>software</e1> caused a pretty good <e2>drain</e2> on the CPU for some reason."
Cause-Effect(e1,e2)
Comment:

464	"The <e1>harm</e1> has been caused by the invitation <e2>system</e2>."
Cause-Effect(e2,e1)
Comment:

465	"While most of the experimental literature focuses on individual contributions, many real-world problems involve the <e1>formation</e1> of <e2>coalitions</e2>."
Other
Comment: Ditto.

466	"Alfred Nobel created his <e1>fortune</e1> from the <e2>selling</e2> of explosives that utilized nitroglycerin."
Cause-Effect(e2,e1)
Comment:

467	"Proper washing and skin care can help to remove <e1>bacteria</e1> and oils which cause <e2>acne</e2>."
Cause-Effect(e1,e2)
Comment:

468	"The coalition sprang up after the Tories released an economic <e1>statement</e1> lambasted by the opposition <e2>parties</e2>."
Other
Comment:

469	"The <e1>system</e1> combined the hierarchical <e2>structure</e2> of decision trees with a clean probabilistic semantics."
Other
Comment: structure is a property

470	"The <e1>lack</e1> of stability caused a strong <e2>reliance</e2> on the colonizers."
Cause-Effect(e1,e2)
Comment:

471	"A <e1>child</e1> has been placed into foster <e2>care</e2>."
Other
Comment: violates b.1

472	"Since then, millions of <e1>dollars</e1> have gone into <e2>reconstructions</e2> for victims of tsunami in 2004."
Other
Comment: violates b.1

473	"Its <e1>progenitor</e1> made his <e2>name</e2> with a wonderful non-fiction account of policing in Baltimore called Homicide."
Other
Comment: name is not a product

474	"The <e1>eruptions</e1> are caused by <e2>tectonic forces</e2> or by the compaction of sediments at the deltas of large rivers, such as the Mississippi."
Cause-Effect(e2,e1)
Comment:

475	"Lenin and the other leaders of the Soviet Union set about repairing the <e1>damage</e1> caused by the revolution and the civil <e2>war</e2>."
Cause-Effect(e2,e1)
Comment:

476	"The <e1>reaction</e1> from the international <e2>press</e2>, which I am sure you here in Tokyo have noticed, has been very wide and detailed."
Cause-Effect(e2,e1)
Comment:

477	"All <e1>houses</e1> are now built this <e2>way</e2>."
Other
Comment: manner; way is not a producer

478	"When the first model sank in August 1991, the <e1>crash</e1> caused a <e2>seismic event</e2> registering 3.0 on the Richter scale, and left nothing but a pile of debris at 220m of depth."
Cause-Effect(e1,e2)
Comment:

479	"The purpose of this <e1>test</e1> was to report to the American public on the academic <e2>achievement</e2> of individual students, schools, districts, and states."
Other
Comment: Purpose

480	"For example, driving recklessly and causing an auto <e1>accident</e1> that result in the <e2>death</e2> of another driver or passenger could be qualified as manslaughter."
Cause-Effect(e1,e2)
Comment:

481	"That coupled with the <e1>death</e1> and destruction caused by the <e2>storm</e2> was a very traumatic experience for these residents."
Cause-Effect(e2,e1)
Comment:

482	"I've been asking for a fizzy <e1>milk</e1> <e2>drink</e2> for a while."
Other
Comment:

483	"<e1>Manufacturers</e1> have traditionally been more concerned about <e2>factors</e2> like price, quality, or cycle time, and not as concerned over how much energy their manufacturing processes use."
Other
Comment: factors is not a product

484	"The <e1>infection</e1> came from a <e2>wound</e2>."
Cause-Effect(e2,e1)
Comment:

485	"The emission of electromagnetic <e1>radiation</e1> from <e2>cell phones</e2> continues to become a growing concern."
Cause-Effect(e2,e1)
Comment:

486	"We derive a pair of optimal weights on the <e1>dollar</e1> in a currency <e2>basket</e2> to stabilize their trade balances for both of the countries."
Other
Comment:

487	"Sumatera (Yagasu) made a <e1>profit</e1> from the <e2>selling</e2> of women groups' handicrafts activities."
Cause-Effect(e2,e1)
Comment:

488	"The ultimate D.C.-related work on this topic, in recent decades, anyway, may be Jerzy Kosinski's satirical Being There, the inspiration for a Peter Sellers <e1>film</e1> by the same <e2>name</e2>."
Other
Comment: the name does not produce the film

489	"<e1>Frustrations</e1>, threats, and conflicts cause <e2>stress</e2>."
Cause-Effect(e1,e2)
Comment:

490	"Kegs of Guinness rolled off and then were grabbed and stacked up against the <e1>wall</e1> by the pub <e2>owner</e2>."
Other
Comment: no evidence that the wall was build by the owner

491	"In this section are <e1>horses</e1> born in Tori <e2>stud</e2> that have made Tori breed famous and maintained that fame."
Other
Comment: Here stud is the location of the breeding

492	"Cyber squatter- A person who buys domain names, and holds them with the intent of making a <e1>profit</e1> from the <e2>selling</e2> of the domain name."
Cause-Effect(e2,e1)
Comment:

493	"The muscular <e1>dystrophies</e1> are caused by genetic <e2>defects</e2>, which means they are inherited at birth."
Cause-Effect(e2,e1)
Comment:

494	"In a two-mirror telescope equipped with an active optics system usually M2 is used to correct the <e1>aberrations</e1> originated by optical <e2>reasons</e2>, i.e. defocus and coma."
Cause-Effect(e2,e1)
Comment:

495	"The <e1>addition</e1> of water to the tank caused a runaway chemical <e2>reaction</e2>, resulting in a rapid rise in pressure and temperature."
Cause-Effect(e1,e2)
Comment:

496	"A new insulated pizza <e1>bag</e1> is delivered to the <e2>market</e2>."
Other
Comment: violates b.1

497	"Snails and <e1>slugs</e1> cause <e2>damage</e2> to seedlings, flowers, vegetables and shrubs."
Cause-Effect(e1,e2)
Comment:

498	"Even in World War II, American <e1>soldiers</e1> targeted the men with the <e2>katanas</e2> first because their killing power was feared and respected."
Other
Comment: Agency is missing.

499	"Having delivered her charge, she had silently returned to her <e1>tree</e1> deep in the <e2>woods</e2>."
Other
Comment: A specific tree, somehow special, is _located_ deep in the woods.

500	"The <e1>snowstorm</e1> caused a major <e2>catastrophe</e2> on the West Virginia Turnpike."
Cause-Effect(e1,e2)
Comment:

501	"<e1>Glaucoma</e1> is one of the leading causes for <e2>blindness</e2> and currently about 90 million patients worldwide are affected by the disease."
Cause-Effect(e1,e2)
Comment:

502	"Brittany Murphy's <e1>bedroom</e1> was filled with prescription <e2>drugs</e2>."
Other
Comment:

503	"There are everyday actions that can help prevent the spread of <e1>germs</e1> that cause respiratory illnesses like <e2>influenza</e2>."
Cause-Effect(e1,e2)
Comment:

504	"The <e1>outbreak</e1> was caused by the live polio <e2>virus</e2> that is used in vaccines given orally the preferred method in developing countries because it is cheaper and doesn't require medical training to dispense."
Cause-Effect(e2,e1)
Comment:

505	"The vagina was sutured behind the neourethra; the <e1>vagina</e1> accommodated a size 12 <e2>dilator</e2>."
Other
Comment: the example violates (c)

506	"September normally marks the arrival of the earliest <e1>run</e1> of <e2>fish</e2> into lake tributaries, and peak runs occur in October."
Other
Comment: It is what fish do. An activity, not a set.

507	"All-terrain <e1>vehicle sales</e1> sink into <e2>muck</e2>."
Other
Comment: violates b.1 and c.3

508	"<e1>Rice</e1> <e2>spirits</e2> in Asia are almost always female and regarded as a kind of mother figure (thus, the connection to fertility and tossing it at the bride)."
Other
Comment:

509	"And there's you, floating a couple of thousand feet up in the <e1>sky</e1> in a tiny little <e2>basket</e2>."
Other
Comment: it is not the sky that is contained in the basket

510	"Trade Union Side reiterated its <e1>concerns</e1> that the <e2>public sector</e2> was effectively subsidising these events and requested that this practice cease."
Other
Comment: Mental state: violates restriction (b).

511	"These <e1>drugs</e1> also cause headaches and <e2>nausea</e2>, affect your internal organs and raise your bad cholesterol."
Cause-Effect(e1,e2)
Comment:

512	"Well I know quite a few people who get <e1>dissatisfaction</e1> from <e2>laughing</e2> at retards."
Cause-Effect(e2,e1)
Comment:

513	"<e1>Adenosine deaminase</e1> converts purine riboside into an <e2>analog</e2> of a reactive intermediate."
Other
Comment: deaminase is a process

514	"As time passed, <e1>aluminum</e1> formed itself into a <e2>can</e2>, a lid, and a tab."
Other
Comment:

515	"<e1>Immigrants</e1> accounted for more than half of Britain's <e2>population</e2> growth in recent years."
Cause-Effect(e1,e2)
Comment: growth is an event.

516	"Iraqi soldiers inspect the <e1>damage</e1> after the <e2>explosion</e2> in a school in Baghdad."
Cause-Effect(e2,e1)
Comment:

517	"The <e1>rule</e1> is the subject of a <e2>legal challenge</e2> brought by ABC and its coalition partners."
Other
Comment: "legal challenge" is not a Message

518	"It is a literary <e1>style</e1> which portrays <e2>crime</e2> and violence in an unsentimental way."
Other
Comment: A style is not a message.

519	"In other words such people accept a <e1>form</e1> of mathematical <e2>platonists</e2>, whether or not they label themselves that way."
Other
Comment:

520	"The Nepalese government sets up a <e1>committee</e1> to inquire into the alleged <e2>misuse</e2> of diplomatic passports."
Other
Comment:

521	"The <e1>investigation</e1> was concerning a <e2>series</e2> of letters received at the House containing non-noxious white powder."
Other
Comment: A process (investigation) is not a message - violates (d)

522	"The <e1>plasma</e1> was generated by an RF <e2>discharge</e2> between two parallel electrodes whose diameter was 100 mm and separation was 40 mm using pure silane gas."
Other
Comment:

523	"With these two tools, the <e1>dataset</e1> was reduced from its original <e2>size</e2> of over 200 features into 17%."
Other
Comment:

524	"Old nests are used year after year by the <e1>carpenter</e1> <e2>bee</e2>."
Other
Comment: carpenter is not a product or producer

525	"The <e1>world</e1> is governed by mathematical <e2>laws</e2>."
Other
Comment: No communication here.

526	"The broker is entitled to <e1>commission</e1> from the <e2>selling</e2> of your property."
Cause-Effect(e2,e1)
Comment:

527	"<e1>Glaucoma</e1> is a group of neurodegenerative <e2>disorders</e2> characterized by the death of retinal ganglion cells and by a specific deformation of the optic nerve."
Other
Comment: Glaucoma is-a disorder.

528	"Parental pressures of <e1>unemployment</e1> and poverty lead to drug abuse and <e2>alcoholism</e2> or stress and depression which have a profound effect on children."
Cause-Effect(e1,e2)
Comment:

529	"Inside the car, <e1>keys</e1> were found in the <e2>ignition</e2> and Codario-Ferrino's license was discovered inside a purse on the passenger's seat."
Other
Comment: car is not a container according to (d)

530	"The <e1>magnetic field</e1> is generated by an electric <e2>current</e2> circulating in the star's interior."
Cause-Effect(e2,e1)
Comment:

531	"The <e1>species</e1> makes a squelching <e2>noise</e2>."
Cause-Effect(e1,e2)
Comment: the species are involved in the making of noise

532	"<e1>Tax cuts</e1> for rich are thrown into <e2>doubt</e2>."
Other
Comment: violates c.3

533	"It is part of a furniture <e1>line</e1> conceived for Anthropologie by British interior <e2>designers</e2>."
Other
Comment:

534	"The political <e1>unity</e1> of the Iroquois was the source of their <e2>power</e2>, but it was by no means perfect."
Cause-Effect(e1,e2)
Comment:

535	"South Bade <e1>residents</e1> have been blown back into primitive <e2>lifestyle</e2>."
Other
Comment: violates c.3

536	"Here are the news reports and photographs of the <e1>devastations</e1> caused by the <e2>storm</e2>."
Cause-Effect(e2,e1)
Comment:

537	"Today's curious <e1>thinkers</e1> are keeping Ben's traditions alive by inventing new and improved <e2>ways</e2> to make things work."
Other
Comment: way is not a product

538	"The <e1>movement</e1> of the flag on the surface of the moon was caused by the <e2>vaccum</e2>."
Cause-Effect(e2,e1)
Comment:

539	"The hollow <e1>bar</e1> mounting the cameras encloses a wiring <e2>harness</e2> between the cameras."
Other
Comment: no evidence for content-container

540	"Propionibacteria acnes, or P. acnes, are the <e1>bacteria</e1> responsible for acne <e2>breakouts</e2>."
Cause-Effect(e1,e2)
Comment:

541	"In the <e1>poem</e1>, an <e2>albatross</e2> starts to follow a ship - being followed by an albatross was generally considered an omen of good luck."
Other
Comment: the albatross is not the producer of the poem

542	"Oil <e1>extraction</e1> in the Amazon has already caused the <e2>extinction</e2> of the Tetete and Zaparo nationalities and continues to threaten indigenous peoples."
Cause-Effect(e1,e2)
Comment:

543	"The 100 MHz RF <e1>signal</e1> for the amplitude modulator was derived from a pulse pattern <e2>generator</e2> (PPG)."
Cause-Effect(e2,e1)
Comment:

544	"The temperature <e1>distributions</e1> in a <e2>vial</e2> during freeze-drying of a skim milk solution were determined experimentally."
Other
Comment: no evidence for content-container, distributions is not a content

545	"The first <e1>seismic arrival</e1> from an <e2>earthquake</e2> is the P wave, which is usually relatively low-amplitude."
Cause-Effect(e2,e1)
Comment:

546	"These centres, along with appropriate educational and psychosocial interventions, helped children overcome the <e1>trauma</e1> and stress caused by the <e2>earthquake</e2>."
Cause-Effect(e2,e1)
Comment:

547	"American skiier Lindsey Vonn denied downhill treble as <e1>fog</e1> caused <e2>cancellation</e2> in Val d'Isere."
Cause-Effect(e1,e2)
Comment:

548	"The opposing <e1>party</e1> hid the anvil with a <e2>view</e2> to important consequences."
Other
Comment: opinion.

549	"Mark also spoke about post-September 11 civil rights and civil liberties <e1>issues</e1> facing <e2>immigrants</e2>."
Other
Comment:

550	"The judge directed the <e1>court</e1> to decide the preliminary issue raised by the <e2>petitioner</e2>."
Other
Comment:

551	"It has been assumed that the <e1>quench</e1> starts at the middle <e2>cross-section</e2> of the magnet."
Other
Comment:

552	"Ice <e1>cream</e1> was made by <e2>hand</e2> in a large bowl placed inside a tub filled with ice and salt."
Other
Comment: manner

553	"The <e1>user</e1> is cooling a processor with a power <e2>usage</e2> of 35W, using a conventional heatsink."
Other
Comment:

554	"The <e1>tsunami</e1> resulted in significant property <e2>damage</e2> but only two fatalities in RS."
Cause-Effect(e1,e2)
Comment:

555	"The <e1>president</e1> has made <e2>taxes</e2> and spending the big issues again."
Other
Comment:

556	"By the end of the work day, the <e1>anger</e1> was radiating from the <e2>city</e2>."
Cause-Effect(e2,e1)
Comment:

557	"The Big Barn Farm friends discover a <e1>pile</e1> of <e2>junk</e2>."
Other
Comment: Quantity.

558	"In view of the terrible <e1>destruction</e1> that was caused by the flood <e2>waves</e2>, we have to fear that a number of Germans, clearly in the three-digit numbers, will be among the dead."
Cause-Effect(e2,e1)
Comment:

559	"This is wishful <e1>thinking</e1> by a <e2>scribe</e2> who is more blind to the reality than those he accuses of blindness."
Other
Comment: (a) is satisfied

560	"Public education systems have carried <e1>nations</e1> into <e2>prosperity</e2>."
Other
Comment: violates c.3

561	"Making and fitting <e1>horseshoes</e1> was only part of the life of a <e2>blacksmith</e2>."
Other
Comment: no evidence that blachsmith is the producer of the horseshoes

562	"It's hell in the hospitals where the amputees's <e1>screaming</e1> after the <e2>lapse</e2> of morphine is heard all the time."
Cause-Effect(e2,e1)
Comment:

563	"Scientists discovered that these <e1>drugs</e1> were related to heart valve <e2>disease</e2>."
Cause-Effect(e1,e2)
Comment:

564	"Beeswax is a natural wax produced in the bee <e1>hive</e1> of honey <e2>bees</e2> of the genus Apis."
Other
Comment: Location.

565	"Typically, <e1>varieties</e1> of this sort were grown on flat land by <e2>peasants</e2>."
Other
Comment: varieties is not a product

566	"The <e1>criminals</e1> that caused the <e2>fire</e2> illegally entered our country."
Cause-Effect(e1,e2)
Comment:

567	"These <e1>views</e1> were reflected in his building <e2>designs</e2>."
Other
Comment:

568	"Then, certain texts do talk about English <e1>society</e1> of various <e2>ages</e2>."
Other
Comment: That is, at various times.

569	"To create a good seal, manufacturers put a foam- or gel-filled seal between the <e1>ear</e1> <e2>cup</e2> and your head."
Other
Comment: The cup is part of the headphones, not part of the ear.

570	"A file photo shows a microlight <e1>pilot</e1> flying with <e2>geese</e2>."
Other
Comment:

571	"Their <e1>deed</e1> of agreement was drawn up in the temple by a notary <e2>public</e2> and confirmed with an oath "by god and the king.""
Other
Comment: deed is not a product

572	"A jack-knifed <e1>lorry</e1> caused <e2>delays</e2> on the A27 eastbound between Havant, Hampshire, and Chichester, West Sussex."
Cause-Effect(e1,e2)
Comment:

573	"<e1>Viruses</e1> that cause respiratory <e2>illness</e2> typically are capable of causing a range of clinical manifestations, and asymptomatic infections are possible."
Cause-Effect(e1,e2)
Comment:

574	"Their whole <e1>future</e1> is being thrown into <e2>disarray</e2>."
Other
Comment: violates c.3

575	"The inherent RNA silencing <e1>mechanism</e1> in plants has been effectively manipulated as a tool for the targeted <e2>down-regulation</e2> of genes."
Other
Comment: Purpose-Tool

576	"His <e1>wife</e1>, a successful corporate lawyer, has given up <e2>work</e2>."
Other
Comment:

577	"In this method, <e1>multiword concepts</e1> are treated as <e2>single words</e2>."
Other
Comment:

578	"Franken's <e1>uncle</e1>, who was in the Russian army, liberated Auschwitz with Barry's <e2>uncle</e2>."
Other
Comment:

579	"92% of the CO2 <e1>emissions</e1> are caused by the <e2>lorries</e2>, but this is not fair so a different distribution method is needed."
Cause-Effect(e2,e1)
Comment: modality and negation are outside

580	"Widely previously interpreted as precursory activity to the 1906 earthquake, they have been found to have a strong seasonal pattern and have been postulated to be due to large seasonal sediment loads in coastal bays that overlie faults as a result of the <e1>erosion</e1> caused by <e2>hydraulic mining</e2> in the later years of the California Gold Rush."
Cause-Effect(e2,e1)
Comment:

581	"The exception is the <e1>player</e1> who drew the <e2>ace</e2>, who may stop whenever they want."
Other
Comment: ace is not a product; modality is outside

582	"The <e1>infant</e1> was born in a <e2>condition</e2> of shock and died in ten minutes."
Other
Comment:

583	"A <e1>shortage</e1> of folate cause megaloblastic <e2>anemia</e2>, where red blood cells are large and pale."
Cause-Effect(e1,e2)
Comment:

584	"There are drain openings on both sides of the street in the <e1>curbs</e1> of the <e2>sidewalks</e2>."
Other
Comment:

585	"Rains and melting <e1>snow</e1> lead to Genesee County's biggest sewage <e2>spill</e2> of the year."
Cause-Effect(e1,e2)
Comment:

586	"A stereo <e1>buss</e1> outputs the stereo buss <e2>signal</e2>; a record buss outputs the record buss signal."
Cause-Effect(e1,e2)
Comment: (a) is satisfied

587	"Marital breakdown is often attributed to unresolved <e1>grief</e1> from infertility, <e2>miscarriage</e2>, and the loss of a child."
Cause-Effect(e2,e1)
Comment:

588	"A highway shield is a <e1>sign</e1> denoting the <e2>route number</e2> of a highway, usually in the form of a symbolic shape with the route number."
Other
Comment: to denote is not to be a message.

589	"In addition, a brief <e1>biography</e1> establishing her <e2>credentials</e2> was included at the end of the report."
Cause-Effect(e1,e2)
Comment:

590	"The <e1>defendants</e1> took advantage of Astor's diminished mental <e2>capacity</e2> to carry them out."
Other
Comment:

591	"The <e1>man</e1> has journeyed into deeper level <e2>studies</e2> with sound masters."
Other
Comment: violates b.1

592	"In addition, soil and river systems have been contaminated by the harsh chemicals used in cocaine production and the air has been polluted by the <e1>smoke</e1> caused by the <e2>burning</e2> of jungle and forest for coca bush cultivation."
Cause-Effect(e2,e1)
Comment:

593	"He bought a <e1>gold</e1> <e2>bracelet</e2> for $200."
Other
Comment:

594	"Most people buy pre-made <e1>candle</e1> <e2>wicks</e2> when making homemade candles."
Other
Comment: The wicks haven't been made into candles yet.

595	"The <e1>removal</e1> duplicate songs is done with the user-friendly start-up <e2>wizard</e2>."
Other
Comment: Purpose-Tool

596	"The <e1>recession</e1> caused by the <e2>stock bubble</e2> was relatively mild, but so was the recovery."
Cause-Effect(e2,e1)
Comment:

597	"I thought sometimes I saw the flash of distant spires, the sunny gleam of upland pastures, the soft <e1>undulation</e1> of purple <e2>hills</e2>."
Other
Comment: A kind of movement, not set membership.

598	"In the Senate, the <e1>sizzle</e1> comes from an issue ad <e2>bill</e2> from Dem Sen. Jon Erpenbach."
Cause-Effect(e2,e1)
Comment:

599	"Cali, Colombia, for their series of articles on the <e1>emergency</e1> caused by a <e2>landslide</e2> on the highway leading to the coast."
Cause-Effect(e2,e1)
Comment:

600	"The financial <e1>losses</e1> caused by the <e2>earthquake</e2> were estimated at $7 million."
Cause-Effect(e2,e1)
Comment:

601	"The December 26th <e1>tsunami</e1> <e2>disaster</e2> is an example of a tsunami which was triggered by an earthquake."
Cause-Effect(e1,e2)
Comment:

602	"The <e1>violence</e1> resulted in the <e2>death</e2> of police "capo" Filippo Raciti, which caused widespread soul-searching and a week-long suspension of Italian football."
Cause-Effect(e1,e2)
Comment:

603	"<e1>Discomfort</e1> from <e2>braces</e2> is similar to that of working out at the gym - the first few days you know you' done something different, but then the body adapts and the discomfort disappears."
Cause-Effect(e2,e1)
Comment: modality is outside

604	"Because the <e1>fire</e1> was caused by <e2>fireworks</e2>, costs associated with suppressing the fire were also applied."
Cause-Effect(e2,e1)
Comment:

605	"The Titan heats the dermis to cause collagen contraction while ensuring <e1>preservation</e1> the epidermis through continuous <e2>cooling</e2>."
Cause-Effect(e2,e1)
Comment:

606	"The spiral <e1>light</e1> was caused by the <e2>missile</e2>."
Cause-Effect(e2,e1)
Comment:

607	"One of these papers which was published in the journal Climate Research turned out to be so badly flawed that the <e1>scandal</e1> resulted in the <e2>resignation</e2> of the editor-in-chief."
Cause-Effect(e1,e2)
Comment:

608	"<e1>Bed sores</e1> (also known as: pressure sores, decubitus ulcers or pressure ulcers) are caused by <e2>pressure</e2>, which cuts off blood flow to parts of the body."
Cause-Effect(e2,e1)
Comment:

609	"The <e1>presentation</e1> generated <e2>debate</e2> and there was general discussion on how journalists can better equip themselves to handle the challenges."
Cause-Effect(e1,e2)
Comment: the presentation is causing a debate

610	"On my backpacking trip, the <e1>insoles</e1> caused a hot <e2>spot</e2> on the left side of my right heel and a blister on the right side of my left heel."
Cause-Effect(e1,e2)
Comment:

611	"The Code applies to all <e1>sponsorship</e1> related to <e2>corporate image</e2>, brands, products, services activities or events of any kind."
Other
Comment: The sponsorship is not a message.

612	"<e1>Cities</e1> produce surprisingly low carbon <e2>emissions</e2> per capita."
Cause-Effect(e1,e2)
Comment: (a) is satisfied

613	"A tiny Serbian <e1>village</e1> has put up a <e2>statue</e2> in honour of its adopted patron - Sylvester Stallone's Rocky."
Other
Comment: not clear whether the statue was made by them

614	"Cayenne <e1>pepper</e1> is a miracle cure for <e2>ulcers</e2> and so many other conditions, plus aids assimilation of nutrients and vitamins."
Other
Comment:

615	"Excluding the current <e1>outbreaks</e1> caused by the H5N1 <e2>virus</e2>, only 24 outbreaks of highly pathogenic avian influenza have been recorded worldwide since 1959."
Cause-Effect(e2,e1)
Comment:

616	"Tom Reynold's brought his first barrel of flour from DeTour on a <e1>jumper</e1> drawn by an <e2>ox</e2>."
Other
Comment: the ox is not a producer

617	"<e1>Alternators</e1> generate <e2>electricity</e2> by the same principle as DC generators."
Cause-Effect(e2,e1)
Comment:

618	"French-style pate is in fact easier to make than my <e1>grandmother</e1>'s chopped <e2>liver</e2>, which called for rendering chicken fat."
Other
Comment: grandmother is not a producer

619	"Many of the 550 <e1>deaths</e1> are directly and intentionally caused by the <e2>physician</e2> but not reported as euthanasia because they lacked consent."
Cause-Effect(e2,e1)
Comment: negation is outside

620	"John Chaney is found home on the range herding <e1>cattle</e1> on his Clarksburg <e2>farm</e2>."
Other
Comment:

621	"New <e1>plans</e1> are outlined for another wind <e2>farm</e2> in north Devon of no more than four turbines."
Other
Comment: just outlined, so not announced yet - violation of (d)

622	"Two <e1>universities</e1> entered in <e2>collaboration</e2> focusing on development of plant biotechnology."
Other
Comment: violates c.3

623	"A cafe <e1>owner</e1> thought up an unlikely beverage that has created a 'miracle' <e2>cure</e2>."
Other
Comment: the bevearge is the producer not the owner

624	"The <e1>actress</e1> went into <e2>cardiac arrest</e2>."
Other
Comment: violates b.1 and c.3

625	"The boat <e1>rides</e1> leave from the <e2>harbour</e2> at Avoch, chugging out into the firth in search of bottle nose dolphins."
Other
Comment:

626	"This readable <e1>book</e1> is the product of Darwin's amazing <e2>journey</e2> aboard the Beagle."
Other
Comment: Cannot be Cause-Effect or Product-Producer because of restrictions in those relations.

627	"He puts a driver bit that fits the <e1>screw</e1> in the drill press <e2>chuck</e2>."
Other
Comment:

628	"The <e1>defendant</e1> was acting from his own <e2>computer</e2> in London."
Other
Comment:

629	"<e1>Smoke</e1> from wood <e2>fires</e2> in Tutbury Castle in Nottingham was considered unendurable by Eleanor of Aquitaine, wife of Henry II, causing her to move out in 1157."
Cause-Effect(e2,e1)
Comment:

630	"The <e1>increase</e1> is caused by the <e2>absorption</e2> of UV radiation by the oxygen and ozone."
Cause-Effect(e2,e1)
Comment:

631	"The court sent the <e1>drug addict</e1> into <e2>hibernation</e2>."
Other
Comment: violates b.1 and c.3

632	"Take medicine to reduce sneezing and <e1>coughing</e1> from <e2>allergies</e2>."
Cause-Effect(e2,e1)
Comment:

633	"Showing interest in something is a large step towards <e1>happiness</e1> after <e2>depression</e2>."
Other
Comment:

634	"By now, my <e1>friends</e1> are familiar with my almost english <e2>obsession</e2> with toast."
Other
Comment:

635	"The <e1>charges</e1> originated in an attempted <e2>blackmail</e2> against Moti, a constitutional lawyer and Australian citizen, in Vanuatu in 1997-98."
Other
Comment:

636	"Generally it appears that most of the <e1>damage</e1> was caused by the winds and the rough <e2>seas</e2>."
Cause-Effect(e2,e1)
Comment:

637	"<e1>Radiology</e1> is the branch or specialty of medicine that deals with the study and application of <e2>imaging technology</e2>."
Other
Comment:

638	"World practices have shown that often local authorities are quicker to respond to the natural <e1>disasters</e1> caused by the climate <e2>change</e2>."
Cause-Effect(e2,e1)
Comment:

639	"There are four locations of this restaurant, owned by the Buckley <e1>company</e1> of Dublin <e2>butchers</e2>."
Other
Comment: Company is here used in the sense of 'firm'.

640	"The funds raised through this appeal have a direct impact on the people affected by the severe <e1>devastations</e1> caused by the <e2>storms</e2>."
Cause-Effect(e2,e1)
Comment:

641	"The <e1>harness</e1> was in a <e2>chest</e2>."
Other
Comment:

642	"As the group ventures deeper into the forest, the eerie <e1>realm</e1> unleashes its <e2>spirits</e2> unto the intruders, killing them one by one."
Other
Comment: it cannot be E-O because e1 is actively involved, cannot be P-P because e2 is not a concrete object, and spirits are not part of the realm, they live there.

643	"Preventing <e1>stream</e1> and riverbank <e2>erosion</e2> is one of the main focuses in riparian protection and restoration."
Other
Comment:

644	"<e1>Outbreaks</e1> caused by the oral vaccine's live <e2>virus</e2> have happened before."
Cause-Effect(e2,e1)
Comment:

645	"The <e1>compromise</e1> resolved the crisis through a series of secret <e2>negotiations</e2> involving Republican and Democratic politicians and various interest groups."
Cause-Effect(e2,e1)
Comment:

646	"<e1>Men</e1> work inside a <e2>caisson</e2> while excavating for bridge foundations."
Other
Comment: people cannot be content

647	"Frequently the <e1>author</e1> departs from an <e2>explanation</e2> of what has transpired and the facts and forces pertaining to the action."
Other
Comment:

648	"The <e1>band</e1> performs with a high level of <e2>musicality</e2>, energy and spirit while combining sensitive group interplay with dynamic solo improvisations."
Other
Comment: Musicality is a property, so can't be an Instrument.

649	"The <e1>process</e1> builds many <e2>features</e2> into the product that translate into benefits for you."
Other
Comment:

650	"Where a worker works in a <e1>factory</e1> for more than nine <e2>hours</e2> in any day or for more than forty-eight hours in any week, he shall be entitled to wages at the rate of twice his ordinary rate of wages."
Other
Comment: factory does not produce time

651	"The <e1>work</e1> is rooted in an <e2>effort</e2> to demonstrate commonality between the arts by focusing on classical rhetoric as the main discursive agency."
Other
Comment:

652	"Thermocerin is a powerful fat <e1>burner</e1> that works with a combination of natural <e2>herbs</e2> such as White and Green Tea, Capsaicin, and Caffeine."
Other
Comment: The herbs etc. are ingredients of thermocerin; as they are no longer perceptibly distinguishable Component-Whole cannot hold, and as they are present in thermocerin Entity-Origin cannot hold.

653	"Peter Wayner, a <e1>technology</e1> <e2>writer</e2>, struggles with how to respond to the widespread piracy of his books online."
Other
Comment: writer is not a producer

654	"So solar thermal power generation works essentially the same as generation from fossil fuels except that instead of using steam produced from the combustion of fossil fuels, the <e1>steam</e1> is produced by the <e2>heat</e2> collected from sunlight."
Cause-Effect(e2,e1)
Comment:

655	"But the <e1>problem</e1> requires a broader <e2>solution</e2> - one that is consistent with the new U.S. commitment to cross-border cooperation."
Other
Comment:

656	"The size of the <e1>assemblies</e1> grows from the byssus substrate <e2>interface</e2> to the transition layer."
Other
Comment:

657	"<e1>Autonomic imbalance</e1> is one of the multifactorial causes of essential <e2>hypertension</e2> currently."
Cause-Effect(e1,e2)
Comment:

658	"Narrative <e1>identity</e1> takes part in the story's <e2>movement</e2>, in the dialectic between order and disorder."
Other
Comment:

659	"As I move closer to the kitchen, the steady <e1>hum</e1> of the <e2>refrigerator</e2> grows stronger."
Cause-Effect(e2,e1)
Comment:

660	"The real <e1>output</e1> per capita is running into inherent <e2>barriers</e2>."
Other
Comment: violates b.1

661	"Fatty <e1>acid</e1> and phospholipid chlorohydrins cause cell stress and endothelial <e2>adhesion</e2>."
Cause-Effect(e1,e2)
Comment:

662	"The Earth was the center of the universe, and the <e1>sky</e1> was enclosed in a <e2>dome</e2>."
Other
Comment:

663	"The new <e1>cigarettes</e1> cause headaches and <e2>nausea</e2> and contain dangerous chemicals."
Cause-Effect(e1,e2)
Comment:

664	"Bangladesh has urged India to do away with <e1>visas</e1> for <e2>travel</e2> between the two neighbours to boost trade."
Other
Comment: Purpose-Tool

665	"I made sure that the end could still slide freely over the <e1>dowel</e1> <e2>rod</e2>."
Other
Comment: "A dowel is a solid cylindrical rod, usually made of wood, plastic or metal. In its original manufactured form, dowel is called dowel rod." (http://en.wikipedia.org/wiki/Dowel)

666	"On the hour, the <e1>clock</e1> plays a <e2>melody</e2> with motion."
Cause-Effect(e1,e2)
Comment:

667	"For example, a <e1>technology</e1> <e2>manufacturer</e2> undertook a seven-year, $200 million human resources outsourcing effort."
Other
Comment: technology is not a product

668	"Nurses' <e1>militancy</e1> stemmed from two different kinds of <e2>experiences</e2>."
Cause-Effect(e2,e1)
Comment:

669	"This <e1>publication</e1> is supported by a <e2>grant</e2> from Merck."
Other
Comment: Relation is more like Instrument-Product

670	"The <e1>pollution</e1> from animal <e2>factories</e2> is also destroying parts of the world's oceans."
Cause-Effect(e2,e1)
Comment:

671	"But O'Brien was proud of how his <e1>team</e1> finished a difficult <e2>season</e2>."
Other
Comment: season is not a product

672	"The <e1>achievements</e1> of Michael Phelps in the pool proved to be a major <e2>talking point</e2> for the riders."
Other
Comment:

673	"A remarkable <e1>combination</e1> of favourable <e2>circumstances</e2> saw the technology progress from the innovation phase - its trial in prototype form - through to adoption and widespread use, in only a few years."
Other
Comment: Combination here is a mix, the elements are not independent of each other.

674	"The NNT and NNH are useful indices to describe the trade-off between the benefit and the <e1>harm</e1> produced by a new <e2>treatment</e2>."
Cause-Effect(e2,e1)
Comment:

675	"<e1>Acne</e1> is caused by <e2>clogging</e2> of sebaceous (oil producing) glands on the skin."
Cause-Effect(e2,e1)
Comment:

676	"This ordinance was a result of the <e1>bond</e1> of profit <e2>agents</e2> getting angry over the recent expansion of the Broward County Pretrial program."
Other
Comment: The bond here means a tight connection (between agents who share a feeling). Not a set.

677	"No water enters the inside of the dishwasher, and the <e1>motor</e1> makes a <e2>sound</e2> as if under strain."
Cause-Effect(e1,e2)
Comment: negation and modality are outside

678	"The vessel went down in a typhoon and the <e1>man</e1> was discovered inside a cork <e2>buffer</e2> used to prevent damage to the ship during docking."
Other
Comment:

679	"Walking trails, fire pit and a tree <e1>fort</e1> in the <e2>woods</e2> have encouraged him to spend time outside."
Other
Comment: The fort is located in the woods.

680	"A cutting tool of the <e1>sort</e1> used for deep hole <e2>drilling</e2> has a cutting head mounted on a shank."
Other
Comment: Purpose-Tool

681	"The <e1>fluctuations</e1> are caused by state and federal <e2>taxes</e2>, distance from refineries to filling stations and environmental laws."
Cause-Effect(e2,e1)
Comment:

682	"<e1>Rabies</e1> is caused by a <e2>virus</e2> that is usually contracted through the saliva of an infected animal."
Cause-Effect(e2,e1)
Comment:

683	"An <e1>accident</e1> has been caused by the <e2>fog</e2>."
Cause-Effect(e2,e1)
Comment:

684	"The <e1>injury</e1> resulted in numerous <e2>operations</e2> to save his eyesight."
Cause-Effect(e1,e2)
Comment:

685	"This time the <e1>lobster</e1> was full of its superb <e2>flavor</e2>, which suffused even into the buttered corn."
Other
Comment:

686	"The <e1>mistress</e1> fries the <e2>rashers</e2> in a small china fryingpan over the lamp, passing to each person the hot slices as they are done."
Other
Comment: e2 is the Patient, not the Instrument of the frying event.

687	"In Luxembourg, the <e1>majority</e1> of migrant <e2>workers</e2> are cross-border workers who maintain their residence in neighbouring countries such as Belgium, France and Germany; as a result, employers and public authorities recognise their diplomas rather easily."
Other
Comment: Measure.

688	"Various <e1>studies</e1> have been conducted with regard to the above <e2>phenomena</e2>."
Other
Comment: here we have a process; violates (d)

689	"We address the longer-term budget <e1>imbalance</e1> that has been caused by the <e2>tax cuts</e2>."
Cause-Effect(e2,e1)
Comment:

690	"In North America, about 58 percent of the <e1>wildfires</e1> are caused by <e2>humans</e2>."
Cause-Effect(e2,e1)
Comment:

691	"We put <e1>fairness</e1> into <e2>copyright use</e2>."
Other
Comment: violates c.3

692	"Data shows that public <e1>concern</e1> about the <e2>economy</e2> has moved into the top five issues facing the country."
Other
Comment: This is a mental state, and nothing suggests its verbalisation. Restriction (b).

693	"The <e1>quota</e1> was extended from six <e2>weeks</e2> to 10 weeks in 2009."
Other
Comment:

694	"My cousins have some fun sliding down the <e1>steps</e1> in a laundry <e2>basket</e2>."
Other
Comment: the steps are not in the basket

695	"Volvo stores the <e1>information</e1> in a secure and protected <e2>environment</e2> for as long as they believe it will help the company understand how to serve its clients better."
Other
Comment: not a container; modality is outside

696	"Details about how Catholic Church <e1>dioceses</e1> dealt with <e2>allegations</e2> of child abuse are to emerge within the coming weeks."
Other
Comment:

697	"Make sure the child takes lots of fluids in spite of the oral discomfort to prevent high <e1>fever</e1> from <e2>dehydration</e2>."
Cause-Effect(e2,e1)
Comment:

698	"The Tafawa Balewa Square (TBS) in Lagos hosted a <e1>galaxy</e1> of <e2>events</e2> with tourism and culture activities as center of attraction."
Other
Comment:

699	"A rare and incurable congenital <e1>disease</e1> which causes <e2>blindness</e2> has been successfully treated for the first time using gene therapy."
Cause-Effect(e1,e2)
Comment:

700	"As I pulled unit apart the small fan on top of light was caked with dust, the <e1>heat</e1> caused a little <e2>discoloration</e2> on the difusing lense."
Cause-Effect(e1,e2)
Comment:

701	"His work has led to new treatments for addicts, tests for drug intoxication and understanding of how <e1>heroin</e1>, other opiates and cocaine cause dependence and <e2>withdrawal</e2>."
Cause-Effect(e1,e2)
Comment:

702	"Serious troubles have dragged the infamous <e1>actress</e1> into <e2>chaos</e2>."
Other
Comment: violates b.1 and c.3

703	"The Shakespeare Authorship Studies Conference is the world's largest <e1>convocation</e1> of <e2>academicians</e2> and scholars to gather annually for the purpose of sharing new research on the life and works of the Elizabethan era's premier poet, playwright and wordsmith."
Other
Comment: Participation.

704	"<e1>Shrinkage</e1> from <e2>washing</e2> has always been considered a serious problem for cotton knitted fabrics."
Cause-Effect(e2,e1)
Comment:

705	"This article goes some wat towards, identifying some of the <e1>conflicts</e1> arose from the previous and present agricultural <e2>development</e2>."
Cause-Effect(e2,e1)
Comment:

706	"The <e1>disruption</e1> caused by the latest Christmas <e2>terrorist</e2> has added too much to the weary trip home."
Cause-Effect(e2,e1)
Comment:

707	"Senior figures in the sport expect the Brawn cars to be the subject of a technical protest over the design of their <e1>diffusers</e1> by rival <e2>teams</e2>."
Other
Comment: no evidence for product-producer

708	"Such <e1>exemption</e1> also applies to <e2>goods</e2> supplied for use on ships and aircraft."
Other
Comment:

709	"The <e1>nun</e1> fulfills his fantasy with a <e2>kiss</e2> that would make a hooker blush."
Other
Comment: Here e2 denotes an event rather than a technique; the situation is paraphrasable by "the nun kissed him" without loss of information. Modality is outside.

710	"The <e1>company</e1> has landed into great <e2>controversies</e2>."
Other
Comment: violates b.1 and c.3

711	"The Barbarian <e1>invasions</e1> of the fifth century were triggered by the <e2>destruction</e2> of the Gothic kingdoms by the Huns in 372-375."
Cause-Effect(e2,e1)
Comment:

712	"The form was printed and filled out before <e1>return</e1> by <e2>mail</e2>."
Other
Comment: Purpose-Tool

713	"Both in Malta and Jamaica, the <e1>couple</e1> made many <e2>friends</e2> by immersing themselves in the local culture."
Other
Comment: friends is not a product

714	"However, the increased demand logically calls for expansion and modification of intake processes to reach the goal of pairing each potential member with a <e1>sorority</e1> of their <e2>choice</e2>."
Other
Comment:

715	"Ho Chi Minh City and Hanoi are in <e1>floods</e1> after the <e2>rain</e2>."
Cause-Effect(e2,e1)
Comment:

716	"Eighty percent of the mortgage <e1>fraud</e1> has been caused by the banks and the lending <e2>institutions</e2>."
Cause-Effect(e2,e1)
Comment:

717	"Using solar electricity instead of conventional electricity sources helps to reduce <e1>pollution</e1> that causes <e2>smog</e2>, acid rain, respiratory illness and global warming."
Cause-Effect(e1,e2)
Comment:

718	"State and local implementation of the $787 billion package has degenerated into a <e1>scrimmage</e1> of competing <e2>agendas</e2> among governors and legislatures, state capitals and city halls, and even between neighboring municipalities."
Other
Comment: Scrimmage is a game of a scuffle, not a set.

719	"It gets a little bit "chicken first or egg first" on examination but the primary truth is that the <e1>attacks</e1> are caused by the <e2>fear</e2> of the attacks themselve."
Cause-Effect(e2,e1)
Comment:

720	"Third year student David Beer is one of those affected by the <e1>pay</e1> <e2>dispute</e2>."
Other
Comment: Argument -- not message.

721	"These <e1>studies</e1> supplied exploratory <e2>details</e2> on some of the determinant attributes and provided a basis for the current research."
Other
Comment: a process - violates (d)

722	"The big <e1>bang</e1> was caused by the <e2>collision</e2> of two parallel universes."
Cause-Effect(e2,e1)
Comment:

723	"The <e1>increase</e1> in customers, though, caused a <e2>strain</e2> on the company servers."
Cause-Effect(e1,e2)
Comment:

724	"My <e1>credit card bill</e1> is approaching its <e2>limits</e2>."
Other
Comment: violates (a)

725	"The <e1>lymphomas</e1> are caused by neoplastic <e2>proliferation</e2> of cells in the lymphoid system."
Cause-Effect(e2,e1)
Comment:

726	"<e1>Acne</e1> is caused by <e2>infections</e2> that occur when pores in the skin are filled with oil, dirt, or other substances."
Cause-Effect(e2,e1)
Comment:

727	"A girl with a mitochondrial disorder who developed a neurodegenerative disorder with "features of autism" after getting a <e1>fever</e1> from <e2>vaccines</e2>."
Cause-Effect(e2,e1)
Comment:

728	"Swype -- founded by the Cliff Kushler, the <e1>inventor</e1> of the T9 text input <e2>technology</e2> -- raised $1.3 million earlier this year."
Other
Comment:

729	"It is no accident that the title of the exhibition is a homage to one of the classic figures of contemporaneity, Antoni Tapies, whose work breached all the boundaries imposed on artistic <e1>creation</e1> by the <e2>critics</e2>."
Other
Comment:

730	"The <e1>storm</e1> caused a tremendous amount of <e2>damage</e2> on the landing beaches, and for the time completely isolated the troops at Anzac."
Cause-Effect(e1,e2)
Comment:

731	"And on other stormy days the boy learned to whittle out a straight <e1>shaft</e1> for the long <e2>bow</e2>, and tip it with gray goose feathers."
Other
Comment: The shaft is part of an arrow, not of the bow. It's not being used in the scenario described.

732	"But in 1993, Montalban had a 10-hour surgery to try to alleviate the pain and <e1>discomfort</e1> from this <e2>injury</e2>."
Cause-Effect(e2,e1)
Comment:

733	"We have inherited <e1>predispositions</e1> to <e2>anxiety</e2>."
Other
Comment:

734	"This notifies the commencement of the <e1>exclusion</e1> of hospitals from the <e2>definition</e2>."
Other
Comment:

735	"An <e1>examination</e1> has been made of all <e2>articles</e2> published in the review from 1944 through 1953."
Other
Comment:

736	"Celiac <e1>disease</e1> (CD) is an inflammatory disorder of the upper small intestine triggered by the <e2>ingestion</e2> of wheat, rye, barley, and possibly oat products."
Cause-Effect(e2,e1)
Comment:

737	"Swine Flu - Popular name for the <e1>illness</e1> caused by the H1N1 <e2>virus</e2>."
Cause-Effect(e2,e1)
Comment:

738	"It is an eye which never blanched at danger, and it is the <e1>boast</e1> of his <e2>soldiers</e2> that he never looked unpityingly upon the sufferings of his followers."
Other
Comment: The boast is the soldiers' state of being proud. negation does not concern the relation

739	"The Jungle Book, because of its moral tone, came to be used as a motivational <e1>book</e1> by the <e2>movement</e2>."
Other
Comment: the movement does not make the book it is using it

740	"The <e1>shape</e1> of the vessel is seen in a <e2>ewer</e2> that has been in the Metropolitan Museum for many years."
Other
Comment:

741	"Both ships caught <e1>fire</e1> after the <e2>collision</e2> but the blazes were brought under control."
Cause-Effect(e2,e1)
Comment:

742	"<e1>Sadness</e1> leads to <e2>inspiration</e2>, so in this story of love and hate, respect and betrayal, learn about the history of the Mexican Wrestling Wars."
Cause-Effect(e1,e2)
Comment:

743	"The <e1>cyclotron</e1> started from the <e2>beginning</e2> of January 2000."
Other
Comment:

744	"Consequently, <e1>play</e1> of a game starts in an initial <e2>state</e2>, at which players collect payoffs only if they remain in that state so that it becomes the final."
Other
Comment:

745	"In 1965, a <e1>farmer</e1> dug up the lower <e2>jawbone</e2> of a mammoth while in the process of expanding his cellar."
Other
Comment: jawbone is not a product of the farmer

746	"One immediate challenge posed by this method was that only a <e1>handful</e1> of <e2>images</e2> were viewable on a computer screen at the same time."
Other
Comment: This is a quantity.

747	"In this paper, we introduce dynamic analysis and model transformations of longitudinal <e1>flight</e1> of hypersonic <e2>aircrafts</e2>."
Other
Comment: It's what planes do.

748	"Since the bar sold alcohol to a person that was already obviously intoxicated, it became liable for the subsequent <e1>harm</e1> that was caused by the drunk <e2>driver</e2>."
Cause-Effect(e2,e1)
Comment:

749	"<e1>Sharpening</e1> <e2>stones</e2>, water stones or whetstones are used to grind and hone the edges of steel tools and implements."
Other
Comment: Purpose-Tool

750	"Asia feels the <e1>pain</e1> caused by the <e2>crisis</e2> but could be poised for rapid recovery."
Cause-Effect(e2,e1)
Comment:

751	"The <e1>boom</e1> and shaking was caused by the <e2>asteroid</e2> that passed Earth yesterday."
Cause-Effect(e2,e1)
Comment:

752	"On the morning of May 25, many schools in northeast China were evacuated because of the <e1>earthquake</e1> caused by the North Korea <e2>nuclear test</e2>."
Cause-Effect(e2,e1)
Comment:

753	"The<e1>staff</e1> in the <e2>shop</e2> are all left-handed themselves and are happy to demonstrate products, explain why they are left-handed and give helpful advice to left-handers of all ages."
Other
Comment:

754	"Seborrheic <e1>dermatitis</e1> is one of the causes for <e2>dandruff</e2>."
Cause-Effect(e1,e2)
Comment:

755	"Sierra Leone in the wake of the <e1>devastation</e1> caused by the decade old civil <e2>conflict</e2> in every sector of our society, the education sector, being key."
Cause-Effect(e2,e1)
Comment:

756	"The theory in possession about leather-making shows that penetration and <e1>bond</e1> of tanning <e2>agents</e2> are supplement each other during the tanning process."
Other
Comment: Bond refers to the process of binding.

757	"Hepatitis B is a potentially life-threatening liver <e1>infection</e1> caused by the hepatitis B <e2>virus</e2>."
Cause-Effect(e2,e1)
Comment:

758	"The <e1>unions</e1> are moving into <e2>politics</e2>."
Other
Comment: violates b.1

759	"On investigation, however, it was found that all the <e1>noise</e1> was caused by the <e2>arrival</e2> of Fred Riemer with an ox-team load of flour."
Cause-Effect(e2,e1)
Comment:

760	"I especially enjoyed Matthew Wells' bare arms waving his hockey stick at the <e1>umpire</e1> in the Australia-Canada <e2>match</e2> to dispute a decision."
Other
Comment:

761	"The <e1>manor</e1> had <e2>lands</e2> in Old Thame, Moreton and North Weston and property in New Thame."
Other
Comment: Here it seems to be ownership rather than a part-whole relationship, though it's not 100% clear.

762	"This meeting was called in response to a request of Eastern labor papers, but happened to fall amid the <e1>excitement</e1> caused by the Pittsburgh <e2>riot</e2>."
Cause-Effect(e2,e1)
Comment:

763	"Many commercial soap, shower gel or cleanser products contain preservatives, colorants and <e1>chemicals</e1> that cause dryness, rashes, itchiness and <e2>roughness</e2> on the skin."
Cause-Effect(e1,e2)
Comment:

764	"In what's become a drug legend, he got woozy, dreamy and saw a <e1>kaleidoscope</e1> of dancing <e2>colours</e2>."
Other
Comment: This is not really a set. It's a pattern.

765	"All <e1>infrastructure</e1> is falling into <e2>disrepair</e2>."
Other
Comment: violates c.3

766	"Priority must be given to efforts to combat <e1>insecurity</e1> and thus poverty, major cause of <e2>violence</e2> most often experienced by poorest."
Cause-Effect(e1,e2)
Comment:

767	"The situation called for peanut butter <e1>cookies</e1> baked from the simplest <e2>recipe</e2> imaginable."
Other
Comment:

768	"The angry <e1>driver</e1> then demonstrated his displeasure by speeding around the other <e2>vehicle</e2>, cutting the other driver off."
Other
Comment:

769	"The <e1>compromises</e1> contained in the agreement caused the civil <e2>war</e2> in the 26 counties in June 1922-April 1923, in which the pro-Treaty Provisional Government defeated the anti-Treaty Republican forces."
Cause-Effect(e1,e2)
Comment:

770	"The <e1>disruption</e1> has been caused by <e2>work</e2> being carried out by track operator Network Rail."
Cause-Effect(e2,e1)
Comment:

771	"A person with an intrinsic motivation to run gains <e1>satisfaction</e1> from a very long <e2>running</e2> around their favourite course on a calm, sunny day."
Cause-Effect(e2,e1)
Comment:

772	"The real possibility of total engulfment by flame or <e1>suffocation</e1> from <e2>smoke</e2> was a constant threat."
Cause-Effect(e2,e1)
Comment:

773	"The <e1>committee</e1> is approaching the final <e2>decision</e2>."
Other
Comment: violates c.2

774	"<e1>Details</e1> include pertinent <e2>people</e2> involved as well as interesting facts and production statistics."
Other
Comment:

775	"The <e1>abuse</e1> is rooted in the perpetrator's mental <e2>illness</e2>."
Cause-Effect(e2,e1)
Comment:

776	"It was a <e1>factory</e1> for destroying perfectly good <e2>pants</e2>."
Other
Comment: the factory destroys the plants it does not produce them

777	"The <e1>birthmarks</e1> are caused by <e2>expansions</e2> (dilations) in tiny blood vessels called capillaries."
Cause-Effect(e2,e1)
Comment:

778	"Every household needs a <e1>nest</e1> of <e2>tables</e2> - functional and economic with space."
Other
Comment: An arrangement, not a collection.

779	"Meanwhile, the <e1>builder</e1> is shifting the <e2>mud</e2> to some other place in closed vehicles."
Other
Comment:

780	"Traditional techniques are encouraged in all the work and volunteers benefit by getting away from the stress of modern day life and enjoying the spirit and <e1>fellowship</e1> of the skilled <e2>craftsmen</e2> of the past."
Other
Comment: This means a feeling of comradeship.

781	"The <e1>dispute</e1> has resulted in major regional <e2>wars</e2> and two Palestinian Intifadas with tragedies on both sides."
Cause-Effect(e1,e2)
Comment:

782	"This photograph shows the <e1>vortices</e1> created by the water strider's <e2>legs</e2> as it moves across the water."
Cause-Effect(e2,e1)
Comment:

783	"The common <e1>cold</e1> and the flu are caused by different <e2>viruses</e2>, with symptoms of the flu presenting more quickly and with more severity than those of a cold."
Cause-Effect(e2,e1)
Comment:

784	"Brazilian campaign laws include several <e1>restrictions</e1> on political <e2>speech</e2> that can seem arcane to outsiders, and even to some Brazilians."
Other
Comment: The modality is outside e1-e2. This is not a speech as a message. This is speech as a category of political activities.

785	"Her <e1>mother</e1> copes with that using <e2>humor</e2> as a shield."
Other
Comment: Violation of "(f) Properties, capabilities, aptitutes, skills, attitutes etc. are not acceptable as Instruments."

786	"I stand here above the twisting gorge the <e1>winds</e1> have carved out of the <e2>sand</e2>."
Other
Comment: sand is not the product of winds

787	"The <e1>author</e1> makes reference to all <e2>sciences</e2>, to many classical works in both psychology and biology."
Other
Comment: e1 is not the message, he is the communicator/creator.

788	"The two <e1>countries</e1> finally entered into a code share <e2>agreement</e2>."
Other
Comment: violates c.3

789	"P6 stimulation for PONV is a convincing case for the efficacy of acupuncture; to that were later added <e1>nausea</e1> from <e2>chemotherapy</e2> or pregnancy, and dental pain."
Cause-Effect(e2,e1)
Comment:

790	"The <e1>geology</e1> comprises <e2>granite</e2> of the Mesozoic era as the bedrock."
Other
Comment: Geology is a property

791	"Mixed in equal parts with peppermint, Elder flowers help reduce the <e1>fevers</e1> and aches caused by <e2>colds</e2> and the flu."
Cause-Effect(e2,e1)
Comment:

792	"The following pages are organized by subject, and investigate the root causes of <e1>damage</e1> caused by the <e2>quake</e2>."
Cause-Effect(e2,e1)
Comment:

793	"In the <e1>chaos</e1> and urgency caused by the <e2>hurricanes</e2>, it was difficult to keep track of people with psychiatric disabilities."
Cause-Effect(e2,e1)
Comment:

794	"Pulmonary Arterial Hypertension clinical <e1>community</e1> builds order from <e2>chaos</e2>."
Other
Comment:

795	"These two <e1>ports</e1> were specialized in the <e2>manufacture</e2> of luxury goods."
Other
Comment: Manufacture was located there.

796	"Construction progress is steady and the <e1>builder</e1> has now established the <e2>location</e2> of offices on the future car park area along Forest Road."
Other
Comment: the location is not a product

797	"As the years passed, some of the <e1>invaders</e1> graduated from <e2>pity</e2> to an emotion resembling guilt."
Other
Comment:

798	"The <e1>editors</e1> assembled many of the leading medical specialists, <e2>researchers</e2> and allied health professionals who have extensive clinical experience with polio survivors."
Other
Comment: researchers is not a product

799	"Old <e1>scars</e1> from <e2>stitches</e2> that were successfully put in but ripped out by the individual are also common."
Cause-Effect(e2,e1)
Comment:

800	"The <e1>fighting</e1> resulted in hundreds of <e2>deaths</e2> and in the deployment of peace keepers into East Timor."
Cause-Effect(e1,e2)
Comment:

801	"Most of the <e1>streaks</e1> are caused by <e2>meteoroids</e2> about the size of a grain of sand, although meteoroids are porous and much less dense than sand."
Cause-Effect(e2,e1)
Comment:

802	"Three <e1>methods</e1> approaching the <e2>analysis</e2> of cells are described, with applications."
Other
Comment: Purpose-Tool, and thus Other.

803	"The <e1>strategy</e1> departs from an overriding <e2>goal</e2>."
Other
Comment:

804	"Side-pull brakes are secured by a <e1>cable</e1> clamp <e2>nut</e2>."
Other
Comment:

805	"The expressive colour, contrasting with the blackness of an apocalyptic sky, the chiaroscuro that accentuates the insubstantial limbs, and the desert landscape and <e1>pile</e1> of <e2>excrement</e2> dominating the scene express Miro's profound pessimism."
Other
Comment: Quantity.

806	"The large anti-neutrino <e1>component</e1> is the source of an irreducible <e2>background</e2>."
Cause-Effect(e1,e2)
Comment:

807	"The <e1>mortality</e1> caused by the <e2>war</e2> is also high."
Cause-Effect(e2,e1)
Comment:

808	"Until now, this corner of the <e1>painter</e1>'s rambling private <e2>collection</e2> has been all but forgotten."
Other
Comment: Ownership and thus Other

809	"Before he leaves Ephesus, however, a <e1>riot</e1> breaks out, instigated by the <e2>silversmiths</e2> who manufacture idols of the goddess Artemis; they are afraid that Paul's evangelistic success will ruin their business."
Cause-Effect(e2,e1)
Comment: modality is outside

810	"The <e1>eruption</e1> resulted in massive lahar <e2>flows</e2> (a mixture of ash, lava, rock and water), primarily in the Rio Montana and Marker watersheds."
Cause-Effect(e1,e2)
Comment:

811	"A seemingly orthodox <e1>person</e1> has departed into serious <e2>error</e2>."
Other
Comment: violates b.1 and c.3

812	"A Philippine Airforce aerial shot shows residents standing on a rooftop to escape the <e1>floodwaters</e1> caused by continuous <e2>rains</e2> brought on by Typhoon Ketsana in Marikina city, metro Manila September 27, 2009."
Cause-Effect(e2,e1)
Comment:

813	"The <e1>pressure</e1> was caused by the rapid power <e2>acceleration</e2> at the start."
Cause-Effect(e2,e1)
Comment:

814	"The real <e1>man</e1> departs from <e2>holiness</e2>."
Other
Comment:

815	"Some of these <e1>data</e1> were presented in a <e2>paper</e2> read at the annual meeting."
Other
Comment: The problem in this sentence that only part of the data is presented in the paper.

816	"The item is engraved with the English <e1>author</e1>'s <e2>initials</e2>."
Other
Comment: The initials are a property of the author. Other.

817	"In addition to the Sudanese rebels, the <e1>bombing</e1> resulted in the <e2>deaths</e2> of several Chadian civilians and livestock."
Cause-Effect(e1,e2)
Comment:

818	"Three distinct <e1>formulations</e1> of valproic acid have been investigated in clinical <e2>trials</e2>."
Other
Comment: Here "clinical trials" refers to experiments, not to a public event. Violates (d).

819	"There were <e1>stacks</e1> of Verizon's directories piled up by <e2>entrances</e2> of buldings."
Other
Comment: the entrance is not a product of the stacks

820	"Here I show that Adh-psi is actually a new, functional <e1>gene</e1> recently descended from an Adh <e2>duplication</e2>."
Other
Comment:

821	"The <e1>governor</e1> is assisted by a vice <e2>governor</e2>."
Other
Comment: Assistance, collaborative work.

822	"The noise <e1>signal</e1> was generated by a noise <e2>diode</e2> (ENR = 27 dB) and gated with a high-speed electronic switch."
Cause-Effect(e2,e1)
Comment:

823	"Ordinary <e1>warts</e1> on the hands and feet are caused by <e2>viruses</e2>, which only affect humans."
Cause-Effect(e2,e1)
Comment:

824	"The <e1>focus</e1> has largely been on the subject of <e2>ethics</e2>."
Other
Comment: The focus is not a message.

825	"<e1>Unemployment</e1> has been caused by <e2>people</e2> who either knowingly or unknowingly have priced people out of jobs."
Cause-Effect(e2,e1)
Comment:

826	"The <e1>noise</e1> and vibration caused by the <e2>passage</e2> of trains resulted in unacceptable conditions within the convention center as standard construction techniques had been used."
Cause-Effect(e2,e1)
Comment:

827	"Because of the ethics <e1>scandal</e1> that resulted in the <e2>impeachment</e2> of the state's Governor, there was real hope for real ethics reform in Illinois this year."
Cause-Effect(e1,e2)
Comment:

828	"The <e1>origin</e1> of <e2>berserkers</e2> is unknown, although Tacitus mentions groups of Germanic warriors with berserk-like fury."
Other
Comment:

829	"The storm ended up causing about a fraction of the <e1>damage</e1> caused by the Chesapeake Bay <e2>storm</e2>."
Cause-Effect(e2,e1)
Comment:

830	"Primary wholesale markets are held in a fixed place and transact daily a large volume of <e1>business</e1> emanated from the village <e2>markets</e2>."
Cause-Effect(e2,e1)
Comment:

831	"In the episode "My Future Self 'n' Me" the boys discover a joint and rolling papers on a tree <e1>stump</e1> in the <e2>woods</e2>."
Other
Comment: Location.

832	"It opens with a group of diplomats having a <e1>discussion</e1> around a rectangular <e2>table</e2> covered with a green cloth."
Other
Comment: This is location.

833	"The <e1>principles</e1> on which <e2>homoeopathy</e2> is based are very different to conventional medical beliefs."
Other
Comment:

834	"The <e1>bears</e1> have gone into <e2>hibernation</e2>."
Other
Comment: violates b.1 and c.3

835	"The Bishop was also happy to talk about some of the contentious <e1>issues</e1> affecting the <e2>church</e2> at the moment."
Other
Comment:

836	"High blood <e1>pressure</e1> is caused by a <e2>narrowing</e2> of the arteries, which means the heart has to work harder in order to push the blood through."
Cause-Effect(e2,e1)
Comment:

837	"The genreal <e1>anesthetic</e1> cause unconsciousness and <e2>insensibility</e2> to paid and are used for major surgical procedures."
Cause-Effect(e1,e2)
Comment:

838	"<e1>Acne</e1> or pimples are caused by <e2>hormonal changes</e2>, wrong food habits and improper skin care."
Cause-Effect(e2,e1)
Comment:

839	"In July he was sent north to quell a <e1>rebellion</e1> instigated by the discontented <e2>people</e2> of Warwick."
Cause-Effect(e2,e1)
Comment:

840	"These trends have thrown <e1>women</e1> into totally inhibiting <e2>situations</e2>."
Other
Comment: violates c.3

841	"Ironically, the <e1>damage</e1> caused by the <e2>floods</e2>, and the subsequent insurance payout, were what prompted the restoration of the station building."
Cause-Effect(e2,e1)
Comment:

842	"The wooden <e1>rod</e1> is attached to the <e2>arm</e2> of the chair, which on my chair has an L-shaped opening (corner) under the armrest."
Other
Comment:

843	"Like Shibnath, our <e1>protagonist</e1> too takes part in the freedom <e2>movement</e2> of India, faces the pangs of foreign rule, and is inspired by Sarojini Naidu and other notable figures like veteran communist leader Ravi Narayan Reddy."
Other
Comment: Participation in an event. We do not see it as a form of membership. It rather is a kind of agency or co-agency.

844	"The <e1>process</e1> is assisted by benign <e2>intervention</e2> or neglect."
Other
Comment:

845	"The court found proof that the fatal <e1>fire</e1> was caused by the <e2>dryer</e2>."
Cause-Effect(e2,e1)
Comment:

846	"13, students were evacuated from Conrad Residence for approximately 15 minutes after <e1>burnt food</e1> in one of the kitchens set off the fire <e2>alarm</e2>."
Cause-Effect(e1,e2)
Comment:

847	"Lavender is excellent in the reatment of <e1>headaches</e1> from fatigue and <e2>exhaustion</e2>."
Cause-Effect(e2,e1)
Comment:

848	"The Archbishop of York, Dr John Sentamu, visited the stoneyard to survey the <e1>damage</e1> caused by the <e2>fire</e2>."
Cause-Effect(e2,e1)
Comment:

849	"One of the most vivid portraits is that of Brookie Simmons, a white woman who fought to abolish child labor in a <e1>town</e1> <e2>factory</e2>."
Other
Comment: more like location, the town does not produce the factory

850	"My first encounter in my luxurious hotels casino was the sound of a woman behind the roulette wheels screaming for <e1>joy</e1> after <e2>hitting</e2> the 12225.00 jackpot."
Cause-Effect(e2,e1)
Comment:

851	"It is a branch of <e1>philosophy</e1> dealing with the <e2>nature</e2> of beauty, art, and taste, and with the creation and appreciation of beauty."
Other
Comment:

852	"Our future leaders are learning about <e1>economics</e1> and politics from the real <e2>world</e2>."
Other
Comment: violation of (a).

853	"This <e1>style</e1> of music reflected <e2>feelings</e2> and situations experienced in daily life."
Other
Comment:

854	"Looked at from one side, the <e1>wall</e1> enclosed a barren sixty-acre <e2>field</e2> called the Port of Anarres."
Other
Comment: the field is not contained by the wall

855	"Each <e1>antler</e1> grows from an <e2>attachment point</e2> on the skull called a pedicle."
Other
Comment:

856	"There was a serious <e1>increase</e1> in the acidity of the seas caused by the acid <e2>rains</e2>."
Cause-Effect(e2,e1)
Comment:

857	"<e1>Bounding pulses</e1> are caused by the relatively low systemic <e2>arterial blood pressure</e2> due to the continuous runoff of blood from the aorta into the pulmonary artery."
Cause-Effect(e2,e1)
Comment:

858	"<e1>Enrichment</e1> of the soil with liquid seaweed <e2>extract</e2> has just enough of an alkaline effect that slugs hate."
Other
Comment: Purpose-Tool

859	"The <e1>deficits</e1> caused by the fiscal stimulus <e2>package</e2> end in 2011 and will help to sustain a fragile recovery in 2010, the deficits projected for the longer term are a threat to our economic future."
Cause-Effect(e2,e1)
Comment: modality is outside

860	"The <e1>suffering</e1> caused by the <e2>bleeding</e2> depends on where the arteriovenous malformation is located."
Cause-Effect(e2,e1)
Comment:

861	"The banks, in order to employ the government deposits, gave unusual accommodation to their customers, until, moving in a <e1>circle</e1> of <e2>fallacies</e2>, the whole colony dreamed of growing rich by selling to each other land which produced nothing."
Other
Comment: Highly abstract and equally highly metaphorical.

862	"Major car manufacturers are launching more and more cars to attain the top position in this <e1>jungle</e1> of <e2>automotives</e2>."
Other
Comment:

863	"They have taken this from my trousseau when something rustles beyond the staggering <e1>gambol</e1> of the shadow <e2>dancers</e2>."
Other
Comment: Not a collection! Gambolling = dancing.

864	"Instead of placing the <e1>seeds</e1> in a strainer <e2>basket</e2>, they were placed in a wet muslin or cheesecloth and hung up."
Other
Comment:

865	"Our <e1>company</e1> has entered into the exclusive <e2>retail business</e2> and plans to open 60 retail stores in the country in the next 5 years."
Other
Comment: violates b.1

866	"The overall <e1>damage</e1> caused by the <e2>destruction</e2> of land and property for the Wall's construction has taken many years to recover further."
Cause-Effect(e2,e1)
Comment:

867	"The <e1>pain</e1> he felt was caused by the plant <e2>rubbing</e2> against his capillaries."
Cause-Effect(e2,e1)
Comment:

868	"These <e1>loans</e1> are travelling into <e2>foreclosure</e2> significantly slower than conventional loans."
Other
Comment: violates c.3

869	"Several blocks of flats caught <e1>fire</e1> after the <e2>blaze</e2> spread from a building site in Sumner Road."
Cause-Effect(e2,e1)
Comment:

870	"The Hawke's Bay Herald building was completely destroyed by the <e1>fire</e1> after the <e2>earthquake</e2>."
Cause-Effect(e2,e1)
Comment:

871	"We seek to actually reverse the <e1>injury</e1> that has been caused by the <e2>heart attack</e2>."
Cause-Effect(e2,e1)
Comment:

872	"The <e1>echoing</e1> you see is from an expect <e2>command</e2> running after send has run."
Cause-Effect(e2,e1)
Comment:

873	"They were your <e1>run-of-the-mill</e1> poultry <e2>workers</e2> and janitors, people whose chief crime was to cross a border, an arbitrarily line that determines who is rich and who is poor, who has rights and who doesn't."
Other
Comment:

874	"In the spring of 1950, the FCC issued a warning to the Hollywood motion picture studios against withholding product and <e1>talent</e1> from broadcast <e2>television</e2>, in what motion picture exhibitors denounced as "a bullying statement"."
Other
Comment:

875	"The undernourished kittens were 'rehabilitated' with ad libitum access to <e1>food</e1> from six <e2>weeks</e2> of age onwards, and eventually achieved normal body size."
Other
Comment:

876	"<e1>Lymphedema</e1> is an abnormal build-up of fluid that causes <e2>swelling</e2>, most often in the arms or legs."
Cause-Effect(e1,e2)
Comment:

877	"<e1>Religion</e1> has become the hottest <e2>topic</e2> of study for United States historians."
Other
Comment: here study is an activity - violates (d)

878	"Since the PN <e1>signal</e1> is generated by an <e2>algorithm</e2>, knowledge of the algorithm reveals the entire sequence."
Cause-Effect(e2,e1)
Comment:

879	"This government views <e1>science</e1> simply as a tool for profit <e2>generation</e2>."
Other
Comment: Purpose-Tool

880	"Argentina was the <e1>destruction</e1> of the natural grasslands caused by the <e2>expansion</e2> of the cropping frontiers starting in 1875."
Cause-Effect(e2,e1)
Comment:

881	"This dissertation examines four <e1>romances</e1> copied by the <e2>scribe</e2> himself."
Other
Comment: scribe is not a producer

882	"Nepala cabinet held a chilly outdoor <e1>meeting</e1> on a Mount Everest <e2>plateau</e2> today."
Other
Comment: This looks like location.

883	"The Java <e1>developer</e1> has moved into Weblogic <e2>administration</e2>."
Other
Comment: violates b.1

884	"The <e1>death</e1> of the rat caused the <e2>relocation</e2> of the flea, and if its next host just happened to be a human, then contagion was the result."
Cause-Effect(e1,e2)
Comment:

885	"<e1>Producers</e1> planted the frozen <e2>scallops</e2> that led to Spike's elimination from Top Chef."
Other
Comment: scallops is not a product of the producers

886	"The <e1>firm</e1> assembled a project <e2>team</e2> consisting of the authors of this paper to develop its OnStar telematics business."
Other
Comment: team is not a product

887	"The <e1>injury</e1> or death was caused by the <e2>intoxication</e2> and the employee shall be barred from receiving workers' compensation."
Cause-Effect(e2,e1)
Comment:

888	"I suffer from <e1>headaches</e1> from <e2>perfume</e2> and any other toxic thing I get to smell."
Cause-Effect(e2,e1)
Comment:

889	"The <e1>book</e1> departs from the <e2>movie</e2> in several respects, but Eggers does an excellent job taking us inside Max's head and motivations."
Other
Comment:

890	"When opened to its tote bag form, it looks like a unsubstantial <e1>tote</e1> <e2>bag</e2> with a compartment for the umbrella."
Other
Comment: "The term tote, meaning "to carry" can be traced back to the 17th century but was not used to describe bags until 1900" (http://en.wikipedia.org/wiki/Tote_bag)

891	"These changes can be caused by the tumor itself, by <e1>increased pressure</e1> within the skull caused by the presence of the <e2>tumor</e2>."
Cause-Effect(e2,e1)
Comment:

892	"Instead, the doctor had administered a <e1>drug</e1> which had caused the eventual <e2>death</e2> of the child."
Cause-Effect(e1,e2)
Comment:

893	"The <e1>crashes</e1> resulted in the <e2>collapse</e2> of much of the World Trade Center complex, the destruction of part of the southwest side of the Pentagon."
Cause-Effect(e1,e2)
Comment:

894	"The fact that you actually caused an <e1>accident</e1> that resulted in <e2>injury</e2> or death gives them the justification they need to prosecute you to the fullest extent of the law, and seek the toughest penalties possible."
Cause-Effect(e1,e2)
Comment:

895	"With Bummer gone for the night the groms decide to surf at night with the help of floodlights, but the <e1>floodlights</e1> cause a <e2>power outage</e2> for the entire hotel."
Cause-Effect(e1,e2)
Comment:

896	"An <e1>inflammation</e1> of the liver caused by the hepatitis A <e2>virus</e2> (HAV)."
Cause-Effect(e2,e1)
Comment:

897	"The conclusion of the investigation was that the <e1>loss</e1> was caused by a <e2>failure</e2> in a cell wall, resulting in a serious crack and a leakage that the pumps were not able to cope with."
Cause-Effect(e2,e1)
Comment:

898	"The <e1>tsunami</e1> was generated by an unusual type of <e2>earthquake</e2> that occurs near oceanic trenches."
Cause-Effect(e2,e1)
Comment:

899	"Each <e1>student</e1> is a participant in a web conferencing <e2>session</e2>."
Other
Comment: The session is not a collection of students.

900	"Around the globe, unique and fascinating species face <e1>extinction</e1> from <e2>hunting</e2> and habitat destruction, which affects vulnerable animals in every kind of environment."
Cause-Effect(e2,e1)
Comment:

901	"Most <e1>people</e1> are familiar with <e2>feelings</e2> of anxiety."
Other
Comment: Here feelings are not used by people, instead people feel them and are used to them.

902	"Capacity is the <e1>combination</e1> of human <e2>resources</e2> and institutions that permits countries to achieve their development goals."
Other
Comment: Combination here is a mix, the elements are not independent of each other.

903	"The <e1>team</e1> finishes the <e2>season</e2> with a 9-11 record, just short of tournament contention."
Other
Comment: season is not a product

904	"It became an obsession but, frustrated at every turn, he eventually made do with a <e1>copy</e1> made by a family <e2>firm</e2> in Nottingham."
Other
Comment:

905	"But the most <e1>damage</e1> has been caused by the corrosive <e2>effects</e2> of wind and water."
Cause-Effect(e2,e1)
Comment:

906	"These <e1>city dwellers</e1> have sunk into <e2>abominations</e2>."
Other
Comment: violates b.1 and c.3

907	"The model describes the relationship between a government and the <e1>manager</e1> of a <e2>firm</e2> which produces a pure public good, under private or public ownership."
Other
Comment:

908	"<e1>Brutality</e1> was an intrinsic part of <e2>plantation life</e2> and no child, however privileged or protected, could escape its ugliness or it savagery."
Other
Comment:

909	"The <e1>police</e1> told an open government <e2>surveyor</e2> it "doesn't give out the records"."
Other
Comment: surveyor is not a product; negation is outside

910	"The <e1>movement</e1> developed from the <e2>rediscovery</e2> by European scholars of many Greek and Roman texts."
Cause-Effect(e1,e2)
Comment:

911	"The vascular <e1>dilatation</e1> was caused by the sympathetic and the course of vaso-motor <e2>nerves</e2>."
Cause-Effect(e2,e1)
Comment:

912	"Sheet and <e1>rill</e1> <e2>erosion</e2> is considered to be the most harmful of all soil erosion forms since it may be unnoticed or ignored by the peasant."
Cause-Effect(e2,e1)
Comment:

913	"The female constructs a <e1>nest</e1> of <e2>grass</e2> in a hollow on the ground."
Other
Comment: e2 is a material, not a component

914	"The <e1>problem</e1> comes from the <e2>widgets</e2> resembling HTC's own Sense UI widgets."
Cause-Effect(e2,e1)
Comment:

915	"The <e1>kids</e1> get to hop around in a <e2>sack</e2> or pillowcase."
Other
Comment: in this example, the sack is not a container

916	"More important <e1>advantages</e1> are related to the <e2>position</e2> of a left-handed first baseman with respect to the base."
Other
Comment:

917	"The <e1>fire</e1> is caused by <e2>overheating</e2> of connections, which is cause by its turn by poor ohmic contact."
Cause-Effect(e2,e1)
Comment:

918	"Figure 9 shows the average <e1>delays</e1> obtained with this <e2>policy</e2> as compared with those of the previous subsection."
Cause-Effect(e2,e1)
Comment:

919	"The <e1>trip</e1> of two mountain <e2>goats</e2> to was also a subject for discussion."
Other
Comment: does trip here refer to 'journey' or group?

920	"Space shuttle science shows how 1908 Tunguska <e1>explosion</e1> was caused by a <e2>comet</e2>."
Cause-Effect(e2,e1)
Comment:

921	"Cobalt metal <e1>fume</e1> and dust cause upper respiratory tract irritation, chronic interstitial pneumonitis, and skin <e2>sensitization</e2>."
Cause-Effect(e1,e2)
Comment:

922	"Every child and young person seen at Starship with <e1>intoxication</e1> from alcohol or illicit <e2>drug use</e2> had a social work assessment before leaving the hospital."
Cause-Effect(e2,e1)
Comment:

923	"The original <e1>santur</e1> was made with tree <e2>bark</e2>, stones and stringed with goat intestines."
Other
Comment: tree bark is a substance not a part.

924	"His <e1>place</e1> was in the <e2>desk</e2> in front of me."
Other
Comment: desk is not a container (a) is not satisfied

925	"Some time in 2002, the <e1>chief executive</e1> of this <e2>corporation</e2> sought and received board approval to construct a modern training school for its staff."
Other
Comment:

926	"Over much of the past decade, the <e1>leader</e1> has methodically fashioned the party into a re-election <e2>machine</e2>."
Other
Comment: the machine is not a real product

927	"With the <e1>pollution</e1> caused by the <e2>buring</e2> of coal, the light-colored tree trunks became darker due to soot."
Cause-Effect(e2,e1)
Comment:

928	"He stirred the oil, garlic and cumin seeds together in a <e1>dish</e1> large enough to hold the <e2>sardines</e2> in a single layer."
Other
Comment:

929	"Continued <e1>exposure</e1> to higher concentrations of the gas cause disorientation, <e2>convulsions</e2>, unconsciousness and death."
Cause-Effect(e1,e2)
Comment:

930	"These chemical <e1>studies</e1> were directed toward <e2>proof</e2> of structure of the indole components of the seeds."
Cause-Effect(e1,e2)
Comment:

931	"The <e1>riot</e1> was instigated by the <e2>clergy</e2> of the Church of England with the active support and collaboration of the magistrates."
Cause-Effect(e2,e1)
Comment:

932	"The <e1>farm</e1> is participant in <e2>forestry</e2> and there have already been planted around eight thousand plants."
Other
Comment: Participation is a relation generally different from all our Nine. Component-Whole may be close sometimes.

933	"But the <e1>discomfort</e1> caused by the <e2>ointment</e2> and the duration of treatment often result in non-compliance."
Cause-Effect(e2,e1)
Comment:

934	"<e1>Menopause</e1> and PMS cause stress and <e2>anxiety</e2> even without imbalanced hormones."
Cause-Effect(e1,e2)
Comment:

935	"The <e1>arrest</e1> completes a dismal past five <e2>weeks</e2> for the 25-year-old."
Other
Comment: weeks is not a product

936	"The <e1>killings</e1> resulted in indiscriminate <e2>firing</e2> by unknown people in Garden area of the city."
Cause-Effect(e1,e2)
Comment:

937	"The <e1>cow</e1> makes a <e2>sound</e2> called lowing, also known as mooing."
Cause-Effect(e2,e1)
Comment:

938	"<e1>Flashes</e1> are caused by the vitreous gel <e2>tugging</e2> on the retina."
Cause-Effect(e2,e1)
Comment:

939	"Information about Salmonellosis, an <e1>illness</e1> caused by a <e2>bacteria</e2> found in raw food, soil, or water."
Cause-Effect(e2,e1)
Comment:

940	"In the <e1>book</e1>, a distinguished country <e2>gentleman</e2> becomes a knight after reading too many chivalric novels."
Other
Comment: gentleman is not a producer

941	"Natural Liver Cirrhosis Treatment Liver cirrhosis is a degenerative inflammatory <e1>disease</e1> that results in <e2>hardening</e2> and scarring of liver cells."
Cause-Effect(e1,e2)
Comment:

942	"The day-old <e1>baby</e1> was taken into <e2>intensive care</e2>."
Other
Comment: violates b.1

943	"And these <e1>gases</e1> cause <e2>evaporation</e2> of water from sea and soil."
Cause-Effect(e1,e2)
Comment:

944	"Congregational <e1>clergy</e1> of various <e2>denominations</e2> were surveyed to assess their understanding and experience of trauma."
Other
Comment: Ditto.

945	"I am currently taking a <e1>medication</e1> which causes <e2>tingling</e2> in my hands and feet, but I also have vitamin d deficiency r/t hyperparathyroidism and my calcium is up and down."
Cause-Effect(e1,e2)
Comment:

946	"But by far the most frequent tsunami-maker is the <e1>buckling</e1> of the seafloor caused by an undersea <e2>earthquake</e2>."
Cause-Effect(e2,e1)
Comment:

947	"A magnetic bracelet helps the <e1>pain</e1> from <e2>stroke</e2> in your arm."
Cause-Effect(e2,e1)
Comment:

948	"Dalindyebo R900-million and the tribe a further R80-billion in compensation for the <e1>humiliation</e1> caused by the monarch's criminal <e2>trial</e2>."
Cause-Effect(e2,e1)
Comment:

949	"The sales <e1>cycle</e1> has shortened from several <e2>months</e2> to weeks."
Other
Comment:

950	"The <e1>study</e1> on which this <e2>paper</e2> is based was prompted by concerns about marking standards."
Other
Comment: The study is the content of the paper, not the topic --- topic would be biology, history, standards etc.

951	"Also, every <e1>employee</e1> who is a participant in the <e2>trust</e2> automatically has a beneficial interest in the ownership of the agency."
Other
Comment: Here 'trust' is not a collection of employees.

952	"Part of the task which the authors set themselves is the delineation and validation of the idea that a <e1>subculture</e1> of <e2>violence</e2> exists."
Other
Comment: A type of subculture.

953	"The <e1>author</e1>'s <e2>name</e2> gives her work a brand image that informs consumers' choices of literary and artistic works."
Other
Comment: name is not a product

954	"In the healthy heart, the left <e1>ventricle</e1> performs a systolic wringing motion, with a counterclockwise <e2>rotation</e2> at the apex."
Other
Comment: manner

955	"<e1>Water</e1> <e2>erosion</e2> is the detachment and removal of soil material by water."
Cause-Effect(e1,e2)
Comment:

956	"<e1>Lesions</e1> involving the medial part of the premotor cortex, the supplementary motor area (SMA) and the rear portion of the medial part of the precentral gyrus caused a contralateral, severe leg-predominant <e2>hemiplegia</e2>, distally predominant and a less severe proximal weakness of the arm."
Cause-Effect(e1,e2)
Comment:

957	"Examining the <e1>disruption</e1> caused by pupil <e2>mobility</e2>."
Cause-Effect(e2,e1)
Comment:

958	"The second <e1>injury</e1> also started from the aforementioned <e2>collision</e2>, but has only recently re-surfaced."
Cause-Effect(e2,e1)
Comment:

959	"<e1>Production</e1> and investigation of such a detector arose from an inadequate <e2>sensitivity</e2> of a commercial p-type Si detector."
Cause-Effect(e2,e1)
Comment:

960	"The <e1>director</e1>, Robert Connolly, who co-wrote the script with David Williamson, assembles the pieces with great methodical <e2>logic</e2>."
Other
Comment: Violation of "(f) Properties, capabilities, aptitutes, skills, attitutes etc. are not acceptable as Instruments."

961	"However, apart from visual design elements, one also gets creative with the <e1>layout</e1> of the <e2>site</e2>."
Other
Comment: layout is a property

962	"<e1>Discovery</e1> consists of <e2>seeing</e2> what everybody else has seen and thinking what nobody else has thought."
Other
Comment: It could have been Component-Whole, but e1 does not comply with restriction (a); negation is outside

963	"The <e1>inflammation</e1> is caused by the <e2>growth</e2> of unusual bacteria, which usually results from antibiotic use."
Cause-Effect(e2,e1)
Comment:

964	"The <e1>exhibition</e1> The Art of the Motorcycle caused a <e2>revolution</e2> on the museum scene with its presentation of the motorcycle as a metaphor of the 20th century."
Cause-Effect(e1,e2)
Comment:

965	"Pressures occur throughout life and those <e1>pressures</e1> cause <e2>stress</e2>."
Cause-Effect(e1,e2)
Comment:

966	"One of the best vantage <e1>points</e1> of the Boston skyline is from the <e2>water</e2>, in a boat heading toward the Boston Harbor Islands."
Other
Comment:

967	"With iterpipes, python is ready to replace the bash <e1>shell</e1> for <e2>scripting</e2>."
Other
Comment: Purpose-Tool

968	"The <e1>drugs</e1> cause <e2>unconsciousness</e2> and cardiac arrest separately."
Cause-Effect(e1,e2)
Comment:

969	"This is an absorbing <e1>book</e1>, diminished by the choppy <e2>way</e2> Ackerman balances Antonina's account with the larger story of the Warsaw Holocaust."
Other
Comment: way is not a product or producer

970	"<e1>Electrolysis</e1> of the resulting mixture caused the <e2>reduction</e2> of the aluminum ions in the Al2O3."
Cause-Effect(e1,e2)
Comment:

971	"The <e1>president</e1> of the <e2>bank</e2> has told us that most of the State banks exist by its forbearance."
Other
Comment: modality is outside

972	"Last month, <e1>scientists</e1> sliced the <e2>brain</e2> into 2401 paper-thin sections, part of a project to create an open-access digital atlas."
Other
Comment:

973	"Chin creates his <e1>work</e1> based on his <e2>life experiences</e2> and observations."
Other
Comment: based on -- not directly the topic

974	"These include the tapping of the package, the way one holds their cigarette, the oral gratification, and the easy social <e1>camaraderie</e1> of <e2>smokers</e2> on a break."
Other
Comment:... or fellow smokers.

975	"This <e1>meeting</e1> of devoted <e2>friends</e2> and lovers served as the foundation of the NAMES Project AIDS Memorial Quilt."
Other
Comment:

976	"Self-organization become apparent in evolution as <e1>self-assemblage</e1> of the gene <e2>networks</e2> and cascades."
Other
Comment:

977	"Many different bacteria, <e1>protozoa</e1> and viruses cause food <e2>poisoning</e2>, but most cases are the result of just a few species of bacteria."
Cause-Effect(e1,e2)
Comment:

978	"The boy learned how to protect the socket for making a picture <e1>light switch</e1> <e2>cover</e2> in this free home decorating video."
Other
Comment:

979	"The concepts of <e1>psychoanalysis</e1> have been applied to <e2>films</e2> in various ways."
Other
Comment:

980	"One sad (excuse the pun) consequence is that a winter of suffering from SAD adds to the <e1>weight gain</e1> caused by the <e2>antidepressants</e2>."
Cause-Effect(e2,e1)
Comment:

981	"The poor management pushed the <e1>workers</e1> into <e2>depression</e2>."
Other
Comment: violates c.3

982	"<e1>Pilgrimage</e1> to Mecca is a basic <e2>tenet</e2> of Islam."
Other
Comment:

983	"The structural <e1>deficit</e1> has been caused by the series of <e2>tax cuts</e2>, not the recession or defense needs."
Cause-Effect(e2,e1)
Comment:

984	"The <e1>hypermenorrhea</e1> was made worse by <e2>treatment</e2>."
Other
Comment: treatment is not a producer

985	"After facing the hopelessness of the future, the <e1>poet</e1> sank into <e2>despair</e2>."
Other
Comment: violates b.1 and c.3

986	"The final <e1>rules</e1> are under <e2>consideration</e2> and are expected by June 30."
Other
Comment:

987	"The <e1>manager</e1> saw a black <e2>male</e2> fire two shots while beside his car in the parking lot."
Other
Comment: male is not a product

988	"However, the <e1>emperor</e1> took advantage of the <e2>gathering</e2> to determine the order and organization of the church."
Other
Comment: e2 is the temporal location.

989	"It took a long time to undo the <e1>damage</e1> that has been caused by the <e2>crisis</e2> of confidence, damage whose effects are just now beginning to make themselves felt in a slow, glacial collapse."
Cause-Effect(e2,e1)
Comment:

990	"The immediate origin of the <e1>pigment</e1> in circulation is from the <e2>breakdown</e2> of endodermal tissue."
Other
Comment:

991	"This <e1>car</e1> definitely has snob <e2>appeal</e2> with its good looks and saloon functionality."
Other
Comment:

992	"<e1>Electromagnets</e1> have come into <e2>use</e2>."
Other
Comment: violates b.1 and c.3

993	"The Lisbon <e1>treaty</e1> has come into <e2>force</e2>."
Other
Comment: violates c.3

994	"The rescue teams found 17 of the 25 crew thrown into the sea when the tanker caught <e1>fire</e1> after the <e2>collision</e2>."
Cause-Effect(e2,e1)
Comment:

995	"The <e1>kids</e1> liberate the ponies with the <e2>help</e2> of a sympathetic groom."
Other
Comment:

996	"Approximately 1,000 <e1>farm</e1> <e2>animals</e2> receive health and medical care each year in our Farm Animal Hospital."
Other
Comment:

997	"<e1>Trauma</e1> to the face and nasal area causes <e2>nosebleeds</e2>, such as getting punched or violently slapped."
Cause-Effect(e1,e2)
Comment:

998	"Some comments from readers highlight the <e1>frustration</e1> and inconvenience caused by the 3-pin <e2>system</e2>."
Cause-Effect(e2,e1)
Comment:

999	"Visual <e1>observations</e1> from <e2>space</e2> reveal a number of fascinating natural phenomena of interest to meteorologists and aeronomists, such as aurorae, airglow, aerosol layers, lightning, and atmospheric refraction effects."
Other
Comment:

1000	"The <e1>speech</e1> was delivered from the <e2>steps</e2> of Lincoln Memorial on August 28, 1963 as part of his famous March on Washington."
Other
Comment:

1001	"The city accuses Wells Fargo of engaging in illegal "reverse redlining" - targeting black neighborhoods for bad <e1>loans</e1> that resulted in mass <e2>foreclosures</e2>."
Other
Comment:

1002	"She once took a tin of her delicious <e1>cookies</e1> made from the following old <e2>recipe</e2>."
Other
Comment:

1003	"Our <e1>newsroom</e1> contains the latest <e2>developments</e2> in UK foreign policy and news on the work of the British Embassy and Consulates around the US."
Other
Comment: Location

1004	"Pneumonia is an <e1>inflammation</e1> of the lungs caused by bacteria, viruses, or chemical <e2>irritants</e2>."
Cause-Effect(e2,e1)
Comment:

1005	"The <e1>blockages</e1> are caused by a build-up of <e2>fatty plaque</e2> along the artery walls."
Cause-Effect(e2,e1)
Comment:

1006	"Considerable <e1>attention</e1> has been directed toward the <e2>study</e2> of the motility of the stomach and its regulation by the extrinsic nerves."
Other
Comment: The sentence violates restriction (b).

1007	"The <e1>demise</e1> of the bees has been caused by the globalization of <e2>commerce</e2>."
Cause-Effect(e2,e1)
Comment:

1008	"Staphylococcal <e1>food poisoning</e1> is caused by <e2>eating</e2> food contaminated with Staphylococcus aureus."
Cause-Effect(e2,e1)
Comment:

1009	"Doc's former lover, the erstwhile hippie Shasta, has become entangled with a married, <e1>billionaire</e1> <e2>developer</e2>, Marty Wolfmann."
Other
Comment:

1010	"British, were engaged, at great odds, with the swarming <e1>rabble</e1> of the <e2>alleys</e2>."
Other
Comment: Metaphorical sentence, 'alleys' is not suitable as a member.

1011	"<e1>Properties</e1> of the soils developed from the <e2>amphibolites</e2> of Santiago-Ponte Ulla, Spain."
Cause-Effect(e1,e2)
Comment:

1012	"The Declaration urged that such <e1>strategies</e1> address the root <e2>causes</e2> and risk factors of crime and victimization."
Other
Comment: a strategy is a method of (prescription for) doing something

1013	"Solar disturbances such as flares, prominences, and sunspots increase the amount of <e1>radiation</e1> from the <e2>sun</e2>."
Cause-Effect(e2,e1)
Comment:

1014	"The results support the theoretical model conceptualizing alcohol use and misuse as being the product of <e1>stress</e1> caused by constraints and <e2>resources</e2> brought to bear simultaneously by agent personality, structures of daily life, and macro social structures."
Cause-Effect(e2,e1)
Comment:

1015	"When the great <e1>union</e1> of the popular <e2>masses</e2> of France opposed the great union of the adherents of the monarchy and the victory of 'political reform' had been attained, many countries followed the French example and undertook all sorts of 'political reforms'."
Other
Comment: A union cannot possibly be an element of masses.

1016	"A significant portion of head and neck <e1>cancers</e1>, anal cancers, and cancer of the larynx are caused by the human <e2>papillomavirus</e2>."
Cause-Effect(e2,e1)
Comment:

1017	"<e1>Overpopulation</e1> and poverty cause <e2>tension</e2> not only within communities and countries, but throughout the world."
Cause-Effect(e1,e2)
Comment:

1018	"A great <e1>resume</e1> is the best tool for a successful career <e2>transition</e2>."
Other
Comment: Purpose-Tool

1019	"The only <e1>light</e1> in the house was radiating from the TV <e2>screen</e2>."
Cause-Effect(e2,e1)
Comment:

1020	"In economic terms, the ecological <e1>catastrophe</e1> caused by the Prestige oil <e2>spill</e2> is comparable with that caused by the Exxon Valdez."
Cause-Effect(e2,e1)
Comment:

1021	"Tense is a temporal linguistic <e1>quality</e1> expressing the <e2>time</e2>."
Other
Comment:

1022	"The beautiful <e1>outside</e1> of the <e2>store</e2> is complementary to the local surroundings and is designed to be a store of the community."
Other
Comment:

1023	"An important aim concerning <e1>enamel</e1> and dentin <e2>erosion</e2> is to identify agents that might protect the tooth surface from demineralization."
Other
Comment:

1024	"A representative is a technical guarantor, a partner or an <e1>officer</e1> of an enterprise who is a member of the <e2>corporation</e2> and who is designated as a representative for the enterprise in accordance with sections 79 and 80 of the Regulation respecting the internal management of the Corporation of Master Electricians of Quebec."
Other
Comment: Indirect membership: enterprise, not officer.

1025	"Biomagnetic Research, in Arizona, makes a range of devices for neutralizing <e1>radiation</e1> from <e2>computers</e2> and other sources."
Cause-Effect(e2,e1)
Comment:

1026	"The family members also get great <e1>joy</e1> from <e2>dogs</e2> doing tricks and great for family activities."
Cause-Effect(e2,e1)
Comment:

1027	"<e1>Natron</e1> is an ingredient for making a distinct <e2>color</e2> called Egyptian blue."
Other
Comment:

1028	"The US forces have withdrawn due to the <e1>damage</e1> caused by the eruption and the <e2>typhoon</e2>."
Cause-Effect(e2,e1)
Comment:

1029	"The <e1>riot</e1> resulted in the <e2>deaths</e2> of 196 people, and led to a major reform in the country's economic policy favouring the Malays."
Cause-Effect(e1,e2)
Comment:

1030	"Canine <e1>flea</e1> <e2>infestation</e2> is caused by fleas, which are small, wingless blood-sucking insects."
Cause-Effect(e1,e2)
Comment:

1031	"In this case report we describe a young female with BCS, which was the result of a <e1>combination</e1> of risk <e2>factors</e2>, including the recently discovered G20210A."
Other
Comment: Combination here is a mix, the elements are not independent of each other.

1032	"He went up to Oxford during the war to read English and, after war service in India, codirected The Tempest with Neville Coghill in an outdoor <e1>production</e1> by the Worcester College <e2>lake</e2>."
Other
Comment: lake is not a product

1033	"He founded the Emmaus Program, an annual <e1>convocation</e1> of diocesan <e2>clergy</e2> for their continuing education and spiritual formation, in 1983."
Other
Comment: Participation.

1034	"Stella Liebeck is the woman who sued McDonalds after she suffered a serious <e1>burn</e1> after the <e2>spilling</e2> of a cup of coffee on her lap."
Cause-Effect(e2,e1)
Comment:

1035	"The <e1>bending</e1> caused a <e2>fracture</e2> on the tension side of the test specimen, but the UHMP fiber ribbon held the fractured parts together."
Cause-Effect(e1,e2)
Comment:

1036	"Following a decision made by the Typhoon Committee in cooperation with United Nations agencies and the League of Red Crescent Societies, ESCAP compiles every year region-wide statistics and reports on the <e1>harm</e1> caused by tropical cyclones, <e2>floods</e2>, droughts and other severe weather events."
Cause-Effect(e2,e1)
Comment:

1037	"<e1>Panic</e1> <e2>attacks</e2> linked to heart disease and heart attacks."
Other
Comment:

1038	"However in addition to Maori, other population <e1>groups</e1> need specific recognition in the Bill, including <e2>people</e2> with disabilities."
Other
Comment: People with disabilities are a KIND of group.

1039	"The <e1>influx</e1> caused a further <e2>drain</e2> on the country's already scanty resources."
Cause-Effect(e1,e2)
Comment:

1040	"Today most of the world's unreached people live in the <e1>jungle</e1> of big <e2>cities</e2> and no longer in the real jungle."
Other
Comment: "Jungle" here is a quality (something is like a jungle), not a set of like things.

1041	"This ingredient also repairs the <e1>damage</e1> that has been caused by the <e2>sun</e2>."
Cause-Effect(e2,e1)
Comment:

1042	"Mark Patterson discusses the <e1>issues</e1> affecting daily <e2>life</e2> in the north-west."
Other
Comment:

1043	"I picked up the latest issue of Woman's World magazine a few days ago because it had a head line about the effect of <e1>safflower</e1> on <e2>belly fat</e2>."
Other
Comment:

1044	"Apparently, beyond the <e1>damage</e1> caused by the smoke and the <e2>water</e2>, the structure of the store itself it was not overly damaged."
Cause-Effect(e2,e1)
Comment:

1045	"Individuals with this change, or with similar mutations in the USH2A gene, develop moderate to severe hearing loss and retinitis pigmentosa, a <e1>disorder</e1> that results in <e2>loss</e2> of vision."
Cause-Effect(e1,e2)
Comment:

1046	"Barber's Olympic bobsleigh <e1>plans</e1> go into <e2>meltdown</e2>."
Other
Comment: violates c.3

1047	"Whitaker had what it took to play the terrifying Ugandan dictator - but the other <e1>man</e1> convinced him with his <e2>passion</e2> for the part."
Other
Comment:

1048	"The <e1>burglar</e1> forgot to log out before leaving the home with two diamond <e2>rings</e2>."
Other
Comment:

1049	"The Germanic <e1>migrations</e1> of the fifth century were triggered by the <e2>destruction</e2> of the Gothic kingdoms by the Huns in 372-375."
Cause-Effect(e2,e1)
Comment:

1050	"The <e1>country</e1> is sinking into <e2>turmoil</e2>."
Other
Comment: violates b.1 and c.3

1051	"In the run-up to this match, a new <e1>war</e1> of words has erupted on the <e2>internet</e2> in yet another twist to the long-simmering saga."
Other
Comment: A collocation: "war of words". The Internet is the place of that war.

1052	"The purpose of this <e1>thesis research</e1> was to examine <e2>social structure</e2>, culture, and gender as potential sources of variation in the seriousness of punishment recommended for everyday acts of wrongdoing."
Other
Comment: Research is a process, not a message - violation of (d). The modality is outside e1-e2.

1053	"The reference <e1>signal</e1> was generated from an auxiliary <e2>photomultiplier</e2> (RCA 1P28) with a quantum counter."
Cause-Effect(e2,e1)
Comment:

1054	"Rodrigues, who is also the governor of Punjab has been accused by the <e1>congress</e1> of various murky <e2>deals</e2> worth billions of rupees."
Other
Comment: Not the right syntax.

1055	"The electromagnetic (EM) <e1>radiation</e1> from the <e2>sun</e2> arrives mostly in the form of visible and infrared wavelengths."
Cause-Effect(e2,e1)
Comment:

1056	"The <e1>pseudolesion</e1> was caused by <e2>drainage</e2> of the paraumbilical vein."
Cause-Effect(e2,e1)
Comment:

1057	"User-edited article about Salmonellosis, the <e1>infection</e1> caused by Salmonella <e2>bacteria</e2>, leading to diarrhea, fever, vomiting, and abdominal cramps."
Cause-Effect(e2,e1)
Comment:

1058	"This paper presents the results of a survey of the building <e1>damage</e1> caused by the ash fall from the cataclysmic <e2>eruption</e2> of Mount Pinatubo."
Cause-Effect(e2,e1)
Comment:

1059	"Streema is an online <e1>radio</e1> <e2>tuner</e2> to listen, discover and share radios with your friends."
Other
Comment:

1060	"The <e1>companies</e1> have gone into <e2>liquidation</e2>."
Other
Comment: violates b.1 and c.3

1061	"Investigations had indicated the <e1>fire</e1> started from the <e2>airconditioners</e2> because on arrival that was the area engulfed."
Other
Comment:

1062	"The <e1>earthquake</e1> caused the <e2>failures</e2> of the electric power system, the water supply system, the sewer system, the telephone and telegraph systems."
Cause-Effect(e1,e2)
Comment:

1063	"The <e1>guy</e1> put up a <e2>fight</e2>, so the mugger takes out a gun and shoots him, point blank."
Cause-Effect(e1,e2)
Comment:

1064	"They are hedging bets on hosting the terror <e1>scum</e1> of different <e2>tripes</e2>."
Other
Comment: Tripes??!

1065	"It is the oil that allows the <e1>radicalisation</e1> <e2>machine</e2>'s many cogs to turn."
Other
Comment: no evidence for product-producer

1066	"A third <e1>book</e1> was requested by the <e2>editor</e2>, E.L. Doctorow but he changed jobs before the manuscript was completed."
Other
Comment: the editor does not produce the book

1067	"<e1>Boils</e1> or furuncles are caused by staphylococcal bacterial <e2>infections</e2> of the hair follicles."
Cause-Effect(e2,e1)
Comment:

1068	"Other <e1>stations</e1> (and cable channels) have spawned imitation <e2>shows</e2>."
Other
Comment: stations are not producers in this case

1069	"I'm the coin-operated machine supplier a.k.a. the <e1>coin</e1> <e2>operator</e2>."
Other
Comment: the operator supplies machines that are coin-operated, so there's no direct link between the operator and the coins.

1070	"Cervical <e1>cancer</e1> is caused by <e2>infection</e2> with the human papillomavirus (HPV) and is one of the most common cancers in women in developing countries."
Cause-Effect(e2,e1)
Comment:

1071	"Notwithstanding problems associated with screening, many of those <e1>cancers</e1> were caused by <e2>radiation exposures</e2> shortly after the accident."
Cause-Effect(e2,e1)
Comment:

1072	"These corporate leaders have inherited Woodrow Wilson's <e1>commitment</e1> to <e2>scholarship</e2>."
Other
Comment:

1073	"This year's Nobel Laureates in Physiology or Medicine made the remarkable and unexpected discovery that inflammation in the stomach (gastritis) as well as ulceration of the stomach or duodenum (peptic ulcer disease) is the result of an <e1>infection</e1> of the stomach caused by the <e2>bacterium</e2> Helicobacter pylori."
Cause-Effect(e2,e1)
Comment:

1074	"The siding <e1>installer</e1> erroneously installed the siding with a 6" <e2>reveal</e2>, rather than a 7" reveal as required."
Other
Comment: The reveal is not a material but a measurement of the amount of raw material that is exposed.

1075	"As usual, an <e1>asterisk</e1> denotes a censored <e2>observation</e2>."
Other
Comment:

1076	"A thorough oral examination, which includes dental X-rays, determines that the <e1>toothache</e1> is coming from a <e2>jaw problem</e2>."
Cause-Effect(e2,e1)
Comment:

1077	"Also, we note the <e1>convergence</e1> over the lakes caused by the land breeze <e2>circulation</e2>."
Cause-Effect(e2,e1)
Comment:

1078	"Pam Court added to the <e1>debate</e1> pointing out the <e2>need</e2> for investment in primary care as part of the long term strategy."
Other
Comment: The addition makes it a negative example.

1079	"Ji-Sung finds Jae-Young, but the <e1>striker</e1> blasts over the bar with only the <e2>keeper</e2> to beat."
Other
Comment:

1080	"The severe <e1>recession</e1> triggered by the global <e2>crisis</e2> has bottomed out, thanks in part to a rebound in exports, although production remains the same."
Cause-Effect(e2,e1)
Comment:

1081	"In the 1998 crisis, capital <e1>flight</e1> caused a <e2>crisis</e2> on the currency markets, as the removal of funds from Russia necessarily entailed the conversion of rubles to dollars."
Cause-Effect(e1,e2)
Comment:

1082	"I used to get terrible <e1>headaches</e1> from sinus and <e2>infections</e2> that resulted in taking antibiotics a few times a year."
Cause-Effect(e2,e1)
Comment:

1083	"Specially designed lampposts are spaced along the <e1>curbs</e1> of the <e2>roadway</e2>."
Other
Comment:

1084	"The <e1>grief</e1> from <e2>infertility</e2> is at times so overwhelming that no one person can provide all the comfort and support that his or her partner needs."
Cause-Effect(e2,e1)
Comment:

1085	"Becker & Castillo (1990) compared the root systems of three species of shrub or treelet with saplings of three tree <e1>species</e1> in the <e2>forest</e2> on Barro Colorado."
Other
Comment: A species is a taxonomic concept, so: a class of trees. A forest is not a collection of abstract classes of trees.

1086	"Monilia, candida or yeast <e1>infections</e1> are caused by various species of <e2>candida</e2>, especially Candida albicans, and are very common in babies and young children."
Cause-Effect(e2,e1)
Comment:

1087	"The elderly found it hard to cope with the high heat-humidity, which often causes nausea and <e1>dizziness</e1> from exhaustion and <e2>dehydration</e2>."
Cause-Effect(e2,e1)
Comment:

1088	"The government and some private companies hold stakes in this <e1>export</e1> <e2>company</e2>."
Other
Comment: export is not a product

1089	"The <e1>cowboy</e1> swiftly adjusted the halter with a <e2>turn</e2> of chain between the jaws."
Other
Comment:

1090	"When they stood, he held out to them an endless scroll, filled with a <e1>maze</e1> of <e2>letters</e2>, words, the very stories they had been listening to."
Other
Comment: Mazes are configurations, not sets.

1091	"The <e1>curvature</e1> of the piece was originally from a small <e2>bowl</e2> or cup."
Other
Comment:

1092	"<e1>Solutions</e1> involving <e2>legislation</e2>, technical innovation and international cooperation have been examined."
Other
Comment:

1093	"The <e1>earthquake</e1> caused a massive <e2>avalanche</e2> on the northern slope of Mount Huascar."
Cause-Effect(e1,e2)
Comment:

1094	"They calculated the exit positions of the backscattered <e1>electrons</e1> from a single-scattering <e2>approach</e2>."
Other
Comment:

1095	"There are several scripts to shut down Windows, hibernate or put the <e1>computer</e1> to <e2>sleep</e2>."
Other
Comment: violates b.1 and c.3

1096	"The <e1>president</e1> of the <e2>university</e2> of the Philippines is elected for a single six-year term by the University's twelve-member Board of Regents."
Other
Comment:

1097	"The JFK baggage system <e1>malfunction</e1> caused <e2>delays</e2> for some flights and caused some passengers to simply travel without their things."
Cause-Effect(e1,e2)
Comment:

1098	"Small <e1>particles</e1>, grime and dirt cause friction and microscopic <e2>scratches</e2> that over time destroy the performance of equipment."
Cause-Effect(e1,e2)
Comment:

1099	"When a <e1>tsunami</e1> is generated by a strong offshore <e2>earthquake</e2>, its first waves would reach the outer coast minutes after the ground stops shaking."
Cause-Effect(e2,e1)
Comment: modality is outside

1100	"Molten <e1>globules</e1> have moved into <e2>action</e2>."
Other
Comment: violates b.1 and c.3

1101	"A deposit ages, soil formation, <e1>weathering</e1>, diagenetic processes, and earthquake shaking lead to consolidation and <e2>cementation</e2> of the sediment."
Cause-Effect(e1,e2)
Comment:

1102	"There were two smiling and waving individuals hanging under the <e1>bun</e1> in a wicker <e2>basket</e2> equipped with the big Bunsen burner."
Other
Comment:

1103	"When the <e1>hobo</e1> leaves the next <e2>morning</e2>, Dick notices that on the gate is a picture of a knife."
Other
Comment:

1104	"Another good salad calls for a <e1>cupful</e1> of <e2>shrimps</e2>, cut in small pieces; half a cupful of celery hearts diced small, and seasoning of pepper and salt."
Other
Comment: Cupful is a measurement.

1105	"The cheering and <e1>screaming</e1> after the <e2>victory</e2> had hardly died down when Marilyn Kelly proclaimed "Party at my house!"."
Cause-Effect(e2,e1)
Comment:

1106	"You counted almost thirty-three honorable punches and kicks thrown in this clip of little kid <e1>screaming</e1> after the terrible <e2>fight</e2>."
Cause-Effect(e2,e1)
Comment:

1107	"The blind <e1>woman</e1> took the <e2>taxi</e2> driver to the Equality Tribunal."
Other
Comment:

1108	"Poor umpiring pushed the <e1>test</e1> into <e2>controversy</e2>."
Other
Comment: violates b.1 and c.3

1109	"There is several bulk sms software and the popular ones can be purchased online after making the <e1>payment</e1> through secured payment <e2>gateway</e2>."
Other
Comment:

1110	"Other <e1>countries</e1> are also sinking into <e2>recession</e2>."
Other
Comment: violates b.1 and c.3

1111	"<e1>Lesions</e1> restricted to the rear portion of the medial part of the precentral gyrus caused a contralateral predominantly distal <e2>leg weakness</e2>."
Cause-Effect(e1,e2)
Comment:

1112	"One of the largest Internet piracy rings in the world has been shut down in a police <e1>operation</e1> that resulted in the <e2>arrest</e2> of 181 people."
Cause-Effect(e1,e2)
Comment:

1113	"These <e1>conditions</e1> have relation to such matters as the <e2>magnitude</e2> and importance of the company."
Other
Comment:

1114	"DOD/USAF/AFRCC initiated Federal SAR response activities for <e1>incidents</e1> that result in aeronautical <e2>distress</e2>."
Cause-Effect(e1,e2)
Comment:

1115	"Pavlov-like, looking at the picture aids "let-down," the <e1>release</e1> of milk normally triggered by the <e2>presence</e2> of the baby, its touch, its cry."
Cause-Effect(e2,e1)
Comment:

1116	"A declarative sentence or <e1>declaration</e1>, the most common type, commonly makes a <e2>statement</e2>."
Other
Comment: statement is not a producer

1117	"Workers at a Devon hospital are due to strike on 5 January for two days in a <e1>dispute</e1> over sick <e2>pay</e2>."
Other
Comment: violates (b)

1118	"<e1>Readers</e1> focus on the <e2>content</e2> rather than struggling to see the words."
Other
Comment: Here we have Interpreter-Content relation.

1119	"The <e1>inspiration</e1> for the multi-touch technology came from a decidedly non-digital <e2>event</e2>."
Cause-Effect(e2,e1)
Comment:

1120	"The victim slipped off the gangway while attempting to close the <e1>lid</e1> of the <e2>tank</e2> trailer."
Other
Comment: Lid is part of the trailer, not the tank

1121	"Now that recovery and <e1>reconstruction</e1> after the <e2>tsunami</e2> are getting under way, we want to see people move into their new homes, communities resume their livelihoods and children back into their rebuilt schools."
Other
Comment: modality is outside

1122	"The bond-insurance <e1>unit</e1> was placed into <e2>receivership</e2>."
Other
Comment: violates c.3

1123	"The European Ombudsman, P. Nikiforos Diamandouros, has asked the European Commission to correct an administrative <e1>error</e1> concerning fishing <e2>quotas</e2> in the West of Scotland."
Other
Comment:

1124	"Raj driven to <e1>rage</e1> after <e2>reading</e2> about yet another weirdly spelled Web 2.0 company is struggling on TechCrunch."
Cause-Effect(e2,e1)
Comment:

1125	"CENT's hotly anticipated new <e1>album</e1> has been leaked on to the <e2>public</e2>."
Other
Comment: violates b.1

1126	"Foreign <e1>minister</e1> participated in a high level UN <e2>conference</e2> on financing for development."
Other
Comment: Participation in an event. We do not see it as a form of membership. It rather is a kind of agency or co-agency.

1127	"<e1>Studies</e1> described in this article investigated two <e2>questions</e2> about forgiveness."
Other
Comment: study here is activity - violation of (d)

1128	"The team prepared GIS precipitation and contour maps of the area (approximately 777 square miles) depicting the landforms and identifying the <e1>flooding</e1> and landslides caused by the <e2>rainfall</e2>."
Cause-Effect(e2,e1)
Comment:

1129	"The 1906 San Francisco <e1>earthquake</e1> was caused by a <e2>rupture</e2> on the San Andreas Fault, a continental transform fault that forms part of the boundary between the Pacific Plate and the North American Plate."
Cause-Effect(e2,e1)
Comment:

1130	"The <e1>relationship</e1> between funding source and study outcome was investigated in several other <e2>studies</e2>."
Other
Comment: here study is a process - violation of (d)

1131	"The <e1>grief</e1> from sudden <e2>death</e2> is completely different from expected death, when families have time to prepare and say goodbye."
Cause-Effect(e2,e1)
Comment:

1132	"The <e1>book</e1>, compiled by the <e2>poet</e2>'s daughter, includes memoirs by writers, poets, translators, critics, actors, and theater directors."
Other
Comment: daughter is not a producer

1133	"Schoniger's technique for <e1>combustion</e1> of organic compounds in a <e2>flask</e2> filled with oxygen is well known."
Other
Comment: does not express content-container relation

1134	"The <e1>wounds</e1> caused by the scourging and the <e2>thorns</e2> are almost invisible."
Cause-Effect(e2,e1)
Comment:

1135	"A series of steps takes you to the top of the falls where you get a wide and spectacular view of the stone bowl that the <e1>creek</e1> has carved over the <e2>ages</e2>."
Other
Comment: ages is not a producer

1136	"The <e1>war</e1> was caused by the expansionist <e2>desires</e2> of Hitler, Mussolini and the Japanese imperialists."
Cause-Effect(e2,e1)
Comment:

1137	"The <e1>narcs</e1> planted a <e2>rock</e2> of cocaine on me when they arrested my buddy with his stash."
Other
Comment: the rock is not made by the narcs

1138	"<e1>Osteoporosis</e1> is caused by a sharp <e2>decrease</e2> in estrogen levels that leads to an increased rate of bone remodeling."
Cause-Effect(e2,e1)
Comment:

1139	"A beautiful young <e1>girl</e1> is going into blissful <e2>trance</e2>."
Other
Comment: violates b.1 and c.3

1140	"In the <e1>background</e1> is a depiction of a <e2>city</e2> with angels that along a path that leads towards it."
Other
Comment: Background may be part of a medium, but it's a long shot.

1141	"The economic <e1>collapse</e1> was caused by <e2>consumers</e2> buying mortgages they couldn't afford and the housing collapse."
Cause-Effect(e2,e1)
Comment:

1142	"Convulsions that occur after DTaP are usually not caused directly by the vaccine, but by a <e1>fever</e1>, which in turn was triggered by the <e2>vaccine</e2>."
Cause-Effect(e2,e1)
Comment:

1143	"To determine, once and for all, how the <e1>manakin</e1> was making its bizarre <e2>sounds</e2>, Bostwick and colleagues decided to take feather samples."
Cause-Effect(e2,e1)
Comment:

1144	"The opening <e1>angle</e1> of the Cherenkov cone measures the velocity with a <e2>resolution</e2> of 0.2%."
Other
Comment: manner

1145	"It damaged some components of espresso machines and the <e1>plastics</e1> inside the <e2>machine</e2> absorbed it and started to pass on odour and taste to the espresso."
Other
Comment: the plastics are substances

1146	"These <e1>implants</e1> were placed into <e2>function</e2>."
Other
Comment: violates b.1 and c.3

1147	"We have three of the finest Hanoverian <e1>stallions</e1> in England standing at <e2>stud</e2>."
Other
Comment: Stud is the location of the breeding Location and thus Other

1148	"<e1>Criminal procedure</e1> refers to the <e2>legal process</e2> for adjudicating claims that someone has violated criminal law."
Other
Comment: procedure is a process here - violation of (d)

1149	"The present invention relates to a method for producing battery electrodes, <e1>electrodes</e1> produced by this <e2>method</e2>, and batteries containing such electrodes."
Other
Comment: method is not a producer

1150	"Licenses and Permits are <e1>revenues</e1> from the <e2>selling</e2> of vendor and dog licenses and other items."
Cause-Effect(e2,e1)
Comment:

1151	"But none of this was really necessary, because you just head for the largest <e1>building</e1> ever created by <e2>man</e2>."
Other
Comment: (a) is satisfied, however 'man' is not a concrete object here.

1152	"The following <e1>activity</e1> involves surveying the child health <e2>resources</e2> available in your group's community."
Other
Comment:

1153	"Much of the work on continuous <e1>culture</e1> of <e2>bacteria</e2> has been carried out with aerobic bacteria, though little has been done with strict anaerobes."
Other
Comment: We interpret culture as 'growing'.

1154	"As you age, the bones and <e1>cartilage</e1> that make up your <e2>backbone</e2> and neck gradually deteriorate, sometimes forming irregular bony outgrowths called bone spurs."
Other
Comment: cartilage is a substance

1155	"A <e1>choice</e1> takes you forward by a more or less fixed number of pages at any given position in the <e2>book</e2>."
Other
Comment: choice is not a producer

1156	"Only a few <e1>congressmen</e1> attended that first <e2>party</e2> in 1977."
Other
Comment: In this context party refers to a festivity instead of the political party.

1157	"A British prison <e1>escapee</e1> who taunted police over the internet has established a <e2>following</e2> of more than 32000 fans on Facebook."
Other
Comment:

1158	"The purpose of the <e1>focus groups</e1> was to determine user <e2>needs</e2>, wants, and concerns early and progressively throughout the development of the prototype."
Other
Comment: People could not be messages.

1159	"The port <e1>side</e1> of a vessel is indicated with a red navigation <e2>light</e2> at night."
Other
Comment:

1160	"More than 4500 tons of nitrogen oxides annually -- a <e1>pollutant</e1> that causes smog, acid <e2>rain</e2>, and contributes to asthma attacks and other breathing problems."
Cause-Effect(e1,e2)
Comment:

1161	"<e1>Addiction</e1> and poverty lead to <e2>neglect</e2> and abuse."
Cause-Effect(e1,e2)
Comment:

1162	"I had three of the eights against a <e1>flush</e1> of <e2>clubs</e2>."
Other
Comment: This is a five-card hand, not a set.

1163	"He has inherited <e1>susceptibility</e1> to certain <e2>cancers</e2>."
Other
Comment:

1164	"The <e1>swelling</e1> of the vocal fold mucosa is caused by <e2>smoking</e2>."
Cause-Effect(e2,e1)
Comment:

1165	"In conclusion, <e1>incubation</e1> of the aorta produces a specific <e2>reduction</e2> in agonist-evoked contraction."
Cause-Effect(e1,e2)
Comment: (a) is satisfied

1166	"The <e1>celebrity</e1> arrived to crash the <e2>party</e2>."
Other
Comment: Purpose

1167	"His <e1>stories</e1> range from near <e2>future</e2> predictions to far future, far space improvisations."
Other
Comment:

1168	"We owe it to ourselves to separate the riffraff from <e1>riffraff</e1> of less unsavory <e2>characteristics</e2>."
Other
Comment: This is the characteristics of riffraf members.

1169	"The <e1>tourism sector</e1> is sinking into deeper <e2>poverty</e2>."
Other
Comment: violates b.1 and c.3

1170	"In recent years, the <e1>issue</e1> of experimentation upon nonhuman animals has become the subject of media <e2>attention</e2>."
Other
Comment:

1171	"On the last day, in a small shop in the Plaka, the oldest quarter in Athens, I bought a <e1>silver</e1> <e2>ring</e2> with Athena's image carved on it."
Other
Comment:

1172	"Rama Revealed (1993) is a <e1>science fiction</e1> <e2>novel</e2> by Arthur C. Clarke and Gentry Lee."
Other
Comment: A type of novel.

1173	"The <e1>high humidity</e1> caused by the <e2>rainfall</e2> damaged the seed of PU already mature while the good soil moisture allowed the seed of SO, TO and OO to fill better."
Cause-Effect(e2,e1)
Comment:

1174	"Additionally, the <e1>president</e1> won the Democratic nomination with the <e2>help</e2> of the super delegates."
Other
Comment:

1175	"The superb <e1>location</e1> of this <e2>fortress</e2> allows us a great view over the surrounding mountains."
Other
Comment: changed e1 from "superb" to "location"

1176	"The <e1>defendant</e1>, in order to prove his plea of justification, produced a <e2>witness</e2> named Mary Dillon."
Other
Comment: the witness is not a product

1177	"First, the H5N1 <e1>virus</e1> has caused by far the greatest number of human cases of very severe <e2>disease</e2> and the greatest number of deaths."
Cause-Effect(e1,e2)
Comment:

1178	"Many <e1>symptoms</e1> of fight or flight are caused by <e2>chemical changes</e2> in the body, but these two symptoms of are caused by chronic, rapid, shallow breathing."
Cause-Effect(e2,e1)
Comment:

1179	"I took this <e1>photo</e1> out of an airplane <e2>window</e2>."
Other
Comment:

1180	"Homeless <e1>teenagers</e1> return home with the help of family <e2>ties</e2>."
Other
Comment:

1181	"The <e1>assassination</e1> resulted in extensive <e2>arrests</e2> of governmental, security, and criminal figures."
Cause-Effect(e1,e2)
Comment:

1182	"The <e1>storm</e1> resulted in 31 deaths and 2.5 million dollars <e2>damage</e2>."
Cause-Effect(e1,e2)
Comment:

1183	"I bought a <e1>silver</e1> <e2>ring</e2> from a Bass Pro Shops, a hunting/fishing chain store, for $53."
Other
Comment:

1184	"Obama's economic <e1>policies</e1> are turning into a global <e2>disaster</e2>."
Cause-Effect(e1,e2)
Comment:

1185	"<e1>Environmentalists</e1>, utilities, and green businesses are turning to behavioral <e2>economics</e2>."
Other
Comment:

1186	"The original <e1>play</e1> was inspired by a <e2>trip</e2> to Europe made by Murray Burnett in 1938."
Other
Comment: the trip itself is not actively involved in the production of the play

1187	"The <e1>supreme court</e1> has applied the protections of this amendment to the <e2>states</e2> through the Due Process Clause of the Fourteenth Amendment."
Other
Comment:

1188	"In the end what was left of the city was <e1>miles</e1> from the <e2>sea</e2>, and many of the inhabitants left swampy lowland to live in the surrounding hills."
Other
Comment:

1189	"Thus, evaluating capital punishment as a form of retribution is reduced by Sellin to merely estimating the proportion of capital <e1>murders</e1> that result in <e2>execution</e2>."
Cause-Effect(e1,e2)
Comment:

1190	"In recent years there have been many advances in the use of <e1>opioids</e1> for cancer <e2>pain</e2>."
Other
Comment: Purpose-Tool

1191	"The authors propose galaxy <e1>clusters</e1> as a tool for <e2>cosmology</e2>."
Other
Comment:Purpose-Tool

1192	"<e1>Dizziness</e1> was caused by whiplash and head <e2>injury</e2>."
Cause-Effect(e2,e1)
Comment:

1193	"Five neighbors used snow blowers to clear the road ahead while the other <e1>neighbors</e1> dug out the <e2>snow</e2> around the ambulance with snow shovels."
Other
Comment: snow is not a product

1194	"The <e1>hull</e1> caused a <e2>scratch</e2> on the eye and that is why it's not healing all the way."
Cause-Effect(e1,e2)
Comment:

1195	"The <e1>massacre</e1> resulted in a local and international <e2>onslaught</e2>."
Cause-Effect(e1,e2)
Comment:

1196	"Our ancestors have passed on <e1>knowledge</e1> to <e2>descendants</e2>."
Other
Comment: violates b.1

1197	"Hell already offers a <e1>cornucopia</e1> of employment <e2>opportunities</e2> for anyone coming from a myriad of backgrounds, but they lack name recognition."
Other
Comment: This is a kind of measure. Not a whole. Not a container either. See "the horn of plenty". Highly metaphorical.

1198	"The <e1>church</e1> is sinking into indolent <e2>obscurity</e2>."
Other
Comment: violates b.1 and c.3

1199	"Both <e1>colds</e1> and flu cause <e2>inflammation</e2> of the mucous membranes (found in the nose, throat and mouth)."
Cause-Effect(e1,e2)
Comment:

1200	"Texas prepares for <e1>crush</e1> of <e2>executions</e2>."
Other
Comment: Executions are events. Events have a specific time point, seems odd to use them in the member-collection relation.

1201	"<e1>Constipation</e1> is the most common cause of <e2>abdominal pain</e2> in the pediatric population."
Cause-Effect(e1,e2)
Comment:

1202	"Our country is resolving the war and <e1>poverty</e1> caused by the previous <e2>administration</e2>."
Cause-Effect(e2,e1)
Comment:

1203	"22 traditional dancing <e1>ensembles</e1> participated in the <e2>festival</e2> of Razlog."
Other
Comment: Participation in an event. We do not see it as a form of membership. It rather is a kind of agency or co-agency.

1204	"For registration purposes, the <e1>property</e1> in a <e2>vessel</e2> is divided into 64 indivisible shares."
Other
Comment: (d) is violated as vehicles cannot be containers

1205	"The Buffs once again lacked playmakers, the wide receivers couldn't get open, the <e1>offense</e1> went away from the running <e2>game</e2> early."
Other
Comment:

1206	"The <e1>pain</e1> was radiating from the <e2>contraction</e2> out to my hips and back and then down both my legs all the way to my toes."
Cause-Effect(e2,e1)
Comment:

1207	"The citizens remained in their houses, and only vagabonds, the <e1>scum</e1> of various <e2>nationalities</e2>, and spies were about; women were not to be seen, or only such as belonged to the dregs of society."
Other
Comment:'various nationalities' is a property of the scum

1208	"Hardcore country cats are happy to live in the shed or the chicken house, or a nest deep inside a <e1>straw</e1> <e2>stack</e2>."
Other
Comment: Material.

1209	"The fresh Muslim <e1>anger</e1> has been caused by the opening <e2>speech</e2> delivered by Pope Benedict XVI on September 12, 2006."
Cause-Effect(e2,e1)
Comment:

1210	"I milked their <e1>evening</e1> <e2>drink</e2> for them and then found them asleep."
Other
Comment:

1211	"<e1>Cold sores</e1> or fever blisters are caused by the herpes simplex <e2>virus</e2> and are usually relatively easy to identify."
Cause-Effect(e2,e1)
Comment:

1212	"His <e1>parents</e1> have been dragged into his alleged life insurance <e2>fraud</e2>."
Other
Comment: violates b.1

1213	"Biology is the <e1>natural science</e1> concerned with the <e2>study</e2> of life and living organisms."
Other
Comment: study is an activity - violates (d)

1214	"Some of them breed in the rice-field, while other <e1>fish</e1> enter the field through <e2>tidal action</e2>."
Other
Comment:

1215	"A <e1>gunman</e1> pumped a bullet into his right <e2>leg</e2> and fled his Northwest Side convenience store with several hundred dollars."
Other
Comment: the leg is not a product

1216	"The <e1>quarrel</e1> during the night of the crime was caused by <e2>money</e2>."
Cause-Effect(e2,e1)
Comment:

1217	"The <e1>manuscript</e1> has been the object of intense <e2>study</e2> by many professional and amateur cryptographers."
Other
Comment: here study is an activity - violates (d)

1218	"<e1>Sinusitis</e1> is the inflammation of the sinuses caused by a bacterial <e2>infection</e2>."
Cause-Effect(e2,e1)
Comment:

1219	"Enigmatic discoveries of dark matter a few decades ago and of dark energy a few years ago have thrown <e1>physics</e1> into <e2>turmoil</e2>."
Other
Comment: violates c.3

1220	"The current study demonstrates that angiogenesis occurs early following transplantation, resulting in a <e1>hookup</e1> of donor and recipient <e2>vessels</e2>."
Other
Comment:

1221	"As the face of each card is displayed, the <e1>subject</e1> identifies the name associated with the <e2>card</e2>."
Other
Comment:

1222	"During the great <e1>fire</e1> of the <e2>aftershock</e2> in Tokyo in 1923 many Ginkgo trees survived while other trees died."
Cause-Effect(e2,e1)
Comment:

1223	"The major <e1>product</e1> arose from an <e2>attack</e2> of aromatic compound."
Cause-Effect(e2,e1)
Comment:

1224	"<e1>Interpolation</e1> of the missing samples repairs the waveform with a minimum of <e2>distortion</e2>."
Cause-Effect(e1,e2)
Comment:

1225	"The DC-DC <e1>converter</e1> was manufactured in a 130nm bulk CMOS <e2>process</e2>."
Other
Comment:

1226	"The <e1>house</e1> is going into <e2>foreclosure</e2>."
Other
Comment: violates b.1 and c.3

1227	"The <e1>editor cum scientist</e1> approached the pod with <e2>reverence</e2>, and a remote control device."
Other
Comment: manner

1228	"The worst <e1>devastation</e1> around us has been caused by the abject failure of religious <e2>education</e2>."
Cause-Effect(e2,e1)
Comment:

1229	"A judge has ordered a woman to hand over her daughter's pet sheep to a rescue centre after a legal <e1>wrangle</e1> over <e2>ownership</e2> of the animal."
Other
Comment:

1230	"A rasher of bacon was found in a returned <e1>book</e1> by a Worthing <e2>librarian</e2>."
Other
Comment: the librarian is not the producer

1231	"In order to gather experimental data, researchers explicitly defined a <e1>model</e1> describing the <e2>process</e2>."
Other
Comment: The process is a subject, but the model is not a message.

1232	"The dotted <e1>line</e1> refers to experimental and simulated <e2>data</e2>."
Other
Comment:

1233	"Man gets life sentence in kidnap, ransom case of <e1>woman</e1> he kept in makeshift <e2>casket</e2>."
Other
Comment:

1234	"But among the heroin addicts especially, there is frequently a very severe depression, and <e1>depression</e1> is one of the main causes of <e2>suicide</e2>."
Cause-Effect(e1,e2)
Comment:

1235	"His deeds have thrown thousands of <e1>people</e1> into eternal financial <e2>damnation</e2>."
Other
Comment: violates c.3

1236	"Pear and Ginger Marmalade was made from a <e1>glut</e1> of corella <e2>pears</e2>."
Other
Comment: I interpret glut as amount.

1237	"The loan <e1>program</e1> is running into insurmountable <e2>difficulties</e2>."
Other
Comment: violates b.1

1238	"What we saw was a promising <e1>idea</e1> sabotaged by a muddled and undernourished <e2>script</e2>."
Other
Comment: script is not a producer

1239	"We minimized excessive <e1>flows</e1> that cause flooding, bank <e2>erosion</e2>, and habitat loss."
Cause-Effect(e1,e2)
Comment:

1240	"The final character was the brilliant <e1>scientist</e1> <e2>inventor</e2> and technology geek."
Other
Comment: scientist is not a product or producer

1241	"For example, <e1>measles</e1> and chickenpox cause <e2>rashes</e2> along with other symptoms."
Cause-Effect(e1,e2)
Comment:

1242	"However, the planning <e1>proposal</e1> has generated <e2>opposition</e2> from locals who have voiced fears over health issues."
Cause-Effect(e1,e2)
Comment: (a) is satisfied

1243	"Allaah decreed joy and sadness, because <e1>joy</e1> results in <e2>laughter</e2> and sadness leads to crying."
Cause-Effect(e1,e2)
Comment:

1244	"The <e1>arbiter</e1> of the <e2>game</e2> begins the game and requests a move from the first player."
Other
Comment:

1245	"In the beginning, a <e1>fire</e1> started from the ring <e2>area</e2> of a crude oil storage tank(33000kl)."
Other
Comment:

1246	"<e1>Malaria</e1> is caused by infection with a <e2>parasite</e2> called Plasmodium that is transmitted by mosquitos."
Cause-Effect(e2,e1)
Comment:

1247	"The <e1>arrows</e1> act as avatars of the <e2>students</e2>."
Other
Comment: This cannot be Message-Topic since it violates (h)

1248	"The banded <e1>racer</e1> needs <e2>advice</e2> on accommodation."
Other
Comment: violates c.2

1249	"We catch <e1>happiness</e1> from friends and family <e2>members</e2> like an emotional virus."
Other
Comment:

1250	"Two years passed before I saw the ibex again, despite regular field trips to the area and the services of an NCWCD ranger who knew every bend in the <e1>maze</e1> of <e2>canyons</e2>."
Other
Comment: It's an arrangement, not a set. Elements are not interchangeable.

1251	"The <e1>warmth</e1> was radiating from the <e2>fireplace</e2> to all corners of the room."
Cause-Effect(e2,e1)
Comment:

1252	"The <e1>bakeries</e1> in the supermarket <e2>area</e2> also reduce the prices on their goods as closing time approaches."
Other
Comment:

1253	"The reports regarding the casualties has been announced and the <e1>loss</e1> that has been caused by the <e2>quake</e2> is being estimated."
Cause-Effect(e2,e1)
Comment:

1254	"I bought a whole <e1>cartload</e1> of <e2>groceries</e2>, and spent a fraction of what I would at any regular grocery store."
Other
Comment: A measure of quantity: as much as a cart will hold. Modality is outside

1255	"Air <e1>pollution</e1> from coal-fired power <e2>plants</e2> is large and varied and contributes to a significant number of negative environmental and health problems."
Cause-Effect(e2,e1)
Comment:

1256	"Former Safety-Service Director Rex Katterheinrich estimated the city collecting $2.16 million in 2009, who took into account for the economic <e1>slowdown</e1> caused by the national <e2>recession</e2>."
Cause-Effect(e2,e1)
Comment:

1257	"Dr. Marshall is the discoverer of Helicobacter (H. pylori), the <e1>germ</e1> that causes peptic <e2>ulcer</e2>."
Cause-Effect(e1,e2)
Comment:

1258	"The recipes are culled from various restaurant chefs, magazines and Brother Victor-Antoine d'Avila-Latourrette, a <e1>monk</e1> and cookbook <e2>author</e2>."
Other
Comment: monk is not a producer.

1259	"The dates for when the coral reefs had been living(125,000, 105,000, and 82,000 years ago) closely matched <e1>dates</e1> from Milankovitch <e2>cycles</e2> for times when the ice sheets should have been melted and the seas at their highest(127,000, 106,000, and 82,000 years ago)."
Other
Comment:

1260	"<e1>Suspects</e1> were brought into <e2>custody</e2> for questions."
Other
Comment: violates b.1

1261	"The <e1>sadness</e1> from <e2>divorce</e2> meant more if you were aware she was married very briefly to choreographer/director Michael Bennett, who shaped her career, then created the "Chorus Line" character around her in 1975."
Cause-Effect(e2,e1)
Comment:

1262	"NGU (NonGonococcal Urethritis) is an <e1>infection</e1> of the urethra caused by <e2>pathogens</e2> ( germs ) other than gonorrhea."
Cause-Effect(e2,e1)
Comment:

1263	"<e1>Mom</e1> of 5 succeeded with can-do <e2>attitude</e2>."
Other
Comment: attitudes, properties etc cannot be considered Instruments.

1264	"The <e1>crash</e1> caused a <e2>gash</e2> on the west side of the Pentagon measuring 30 yards wide and 10 yards deep."
Cause-Effect(e1,e2)
Comment:

1265	"The scientists injected <e1>fluids</e1> into the <e2>animals</e2>."
Other
Comment:

1266	"A stimulant, <e1>nicotine</e1> causes a temporary <e2>increase</e2> in alertness and a calm feeling."
Cause-Effect(e1,e2)
Comment:

1267	"He treated the <e1>pain</e1> from <e2>shingles</e2> as it persisted for long periods of time."
Cause-Effect(e2,e1)
Comment:

1268	"The addition of a <e1>velocity</e1> <e2>stack</e2> on the carb inlet helps stop some fuel spray coming out the carb when the engine is running."
Other
Comment:

1269	"His new research shows that the tree <e1>trunks</e1> in the <e2>forest</e2> act like hot water bottles."
Other
Comment: A forest is a collection of trees, not a collection of tree trunks.

1270	"This <e1>matter</e1> became the subject of protracted <e2>legal action</e2>, from which the employer emerged victorious."
Other
Comment:

1271	"Recent <e1>researches</e1> are making a valuable contribution to the <e2>history</e2> of logic in a period little known in the West."
Other
Comment:

1272	"There are many types and causes of headaches, from <e1>tension</e1> <e2>headaches</e2> due to stress to migraines triggered by certain foods."
Cause-Effect(e1,e2)
Comment:

1273	"<e1>Males</e1> had their urethra and urachus ligated with a fine silastic <e2>tubing</e2>."
Other
Comment: e1 is not the Agent

1274	"Patients with adenomyosis experience <e1>pain</e1> from this <e2>disease</e2> in the early 30's."
Cause-Effect(e2,e1)
Comment:

1275	"Including <e1>amenities</e1> such as <e2>kiosks</e2> create pedestrian-friendly spaces."
Other
Comment: A kiosk is a type of amenity.

1276	"Shin <e1>splints</e1> are caused by the <e2>muscles</e2> on the front and sides of the leg."
Other
Comment:

1277	"The chief safety <e1>officer</e1> announced the Gwinnett-Barrow-Jackson enforcement wave with the <e2>unveiling</e2> of a replica of new traffic warning signs that have been posted along I-85."
Other
Comment:

1278	"Automatic diagnosis has replaced <e1>simulation</e1> for the <e2>correction</e2> of simple design errors."
Other
Comment: Purpose-Tool

1279	"He moves <e1>people</e1> into <e2>climate action</e2>."
Other
Comment: violates c.3

1280	"The mobile <e1>meth</e1> was inside a <e2>van</e2> parked inside a storage unit at 4095 West Kearns."
Other
Comment:

1281	"These <e1>tests</e1> establish baseline <e2>information</e2> on employees and help insure that they are appropriately matched to the physical demands of their jobs."
Cause-Effect(e1,e2)
Comment: information is an occurrence

1282	"Because the <e1>disorders</e1> are caused by defective lysosomal <e2>enzymes</e2>, with the result being lysosomal accumulation of pathway intermediates, these are often referred to as lysosomal storage diseases."
Cause-Effect(e2,e1)
Comment:

1283	"The UK <e1>economy</e1> has come out of <e2>recession</e2>, after figures showed it had grown by a weaker-than-expected 0.1% in the last three months of 2009."
Other
Comment:

1284	"The current <e1>crisis</e1> was caused by the <e2>housing bubble</e2>, and the primary cause of the housing bubble was the Federal Reserve keeping interest rates at 1 percent."
Cause-Effect(e2,e1)
Comment:

1285	"I read that interview you did with the <e1>guy</e1> who came up with flash <e2>mobs</e2>."
Other
Comment: no evidence for product-producer

1286	"Winners of four straight games, the <e1>side</e1> has constructed the program's best <e2>start</e2> since 1979-80 and the third-best opening in school history."
Other
Comment: no evidence for Product-Producer

1287	"The Tour of California raced through West Marin on Monday in a <e1>blur</e1> of speeding <e2>bicyclists</e2> and their caravan of support vehicles, once again sparking charges that it puts spectators in harm's way."
Other
Comment: A blur is an event.

1288	"That song immediately segues into the maniacal "Red & Purple", a bewilderingly worded love <e1>song</e1> accompanied by a toy <e2>piano</e2> and fuzzy bass."
Other
Comment: the piano is not responsible for the production of the song

1289	"Both over-the-counter pain <e1>pills</e1> and prescription drugs cause medication-overuse <e2>headaches</e2>."
Cause-Effect(e1,e2)
Comment:

1290	"The protein <e1>products</e1> encoded by this <e2>class</e2> of resistance gene are located within the plant cell cytoplasm."
Other
Comment: class is not a producer

1291	"Most <e1>deaths</e1> from the accident were caused by radiation <e2>poisoning</e2>."
Cause-Effect(e2,e1)
Comment:

1292	"The <e1>prisoner</e1> was taken into preventive <e2>custody</e2> this morning."
Other
Comment: violates b.1

1293	"Bankers were assessing the <e1>loss</e1> caused by the poor <e2>performance</e2> of Gartmore's 340m pounds IPO this week after it needed to be scaled down and its price slashed."
Cause-Effect(e2,e1)
Comment:

1294	"The <e1>phrase</e1> was related in a <e2>preface</e2> of a 1904 collection of Drury's stories."
Other
Comment: The relation is unclear.

1295	"The <e1>company</e1> has been dragged into a <e2>lawsuit</e2>."
Other
Comment: violates b.1

1296	"State abandoned national socio-cultural imperatives and rushed in to join the scandalous community and the <e1>camaraderie</e1> of the <e2>tyrants</e2>."
Other
Comment: That's how they feel -- as fellow tyrants.

1297	"The <e1>pronouns</e1> are indicated with <e2>parentheses</e2> and are given for example purposes."
Other
Comment:

1298	"The aim of <e1>ecophilosophy</e1> is a total or comprehensive <e2>view</e2> of our human and individual situation."
Other
Comment: Scientific disciplines are not messages.

1299	"U.S. <e1>embassy</e1> participated in <e2>opening</e2> of the unique exhibition about general Pika."
Other
Comment: Participation in an event. We do not see it as a form of membership. It rather is a kind of agency or co-agency.

1300	"The origin of the superficial <e1>extensors</e1> is from a flattened common extensor <e2>tendon</e2>."
Other
Comment:

1301	"A first prototype of the new <e1>system</e1> is constructed from the preliminary <e2>design</e2>."
Other
Comment:

1302	"GIS revealed a relationship between <e1>cracks</e1> caused by <e2>earthquakes</e2> and paddy fields."
Cause-Effect(e2,e1)
Comment:

1303	"A reasonable <e1>approach</e1> was distilled from the initial <e2>shock</e2> at the conflicting data."
Other
Comment:

1304	"The <e1>researcher</e1> approached the subjects and their experiences with an open <e2>mind</e2>."
Other
Comment:

1305	"They presented very extensive and detailed report on greenhouse <e1>heating</e1> with <e2>compost</e2>."
Other
Comment: Purpose-Tool

1306	"Both <e1>bacteria</e1> cause <e2>mortality</e2> in target species via a lethal septicaemia as a result of spore germination."
Cause-Effect(e1,e2)
Comment:

1307	"Pancreatitis is an <e1>inflammation</e1> of the pancreas caused by a <e2>malfunction</e2> involving the digestive enzymes that the pancreas makes."
Cause-Effect(e2,e1)
Comment:

1308	"The direct <e1>catastrophe</e1> caused by the <e2>earthquake</e2> was estimated at 10.2 billion euro, clearly justifying European intervention."
Cause-Effect(e2,e1)
Comment:

1309	"The <e1>damages</e1> caused by the <e2>fires</e2> that immediately broke out and raged for three days, were by far worse than those caused by the earthquake itself."
Cause-Effect(e2,e1)
Comment:

1310	"Gavin wears a <e1>kilt</e1> for the <e2>outing</e2>."
Other
Comment: Purpose-Tool

1311	"As longtime publishers in the healthcare industry, we, too, are skeptical about the <e1>glut</e1> of <e2>startups</e2> in this area."
Other
Comment: Glut means many, a lot --- not a set.

1312	"The <e1>citizenship</e1> and connection to Britain and Italy is shown in <e2>parentheses</e2>."
Other
Comment:

1313	"He testified that cause of <e1>death</e1> was massive bleeding into the blood sac of the heart caused by a stab <e2>wound</e2> on the left chest."
Cause-Effect(e2,e1)
Comment:

1314	"The scale of such landslides on natural slopes can be large enough to devastate entire villages or towns, such as the Huascaran Avalanche triggered by the Peru earthquake (1970, Mw = 7.8), or the complex <e1>slides</e1> caused by the Alaska <e2>earthquake</e2> in 1964 (Ms = 8.4)."
Cause-Effect(e2,e1)
Comment:

1315	"A remote <e1>slope</e1> of Nevado Mismi, a 5316 m peak, is the ultimate source of the <e2>river</e2>."
Other
Comment:

1316	"The <e1>composition</e1> forming the subject of the present <e2>invention</e2> included one or more fillers as defined above."
Other
Comment: Invention is much too little like a message.

1317	"Chronic daily headaches are <e1>tension</e1> <e2>headaches</e2> or headaches which are caused by taking too many pain killers."
Cause-Effect(e1,e2)
Comment:

1318	"The immediate, down-to-earth <e1>impact</e1> of the poem is established in the first two <e2>lines</e2>."
Other
Comment: This is a form of effect, though maybe not exactly Cause-Effect.

1319	"As soon as the <e1>lumberjack</e1> saw the <e2>thief</e2>, the lumberjack thought that "If I kill him and bring his head to the authorities, I will get a reward.""
Other
Comment:

1320	"A <e1>trend</e1> has been caused by the growing absolute numbers of young people on the planet, and by the <e2>rising unemployment rate</e2>."
Cause-Effect(e2,e1)
Comment:

1321	"For some reason, the <e1>star</e1> was blinded from his own <e2>insight</e2> about the incommensurability of time."
Other
Comment:

1322	"<e1>Birth defects</e1> are caused by <e2>drugs</e2> that the persons have been exposed to before birth."
Cause-Effect(e2,e1)
Comment:

1323	"The precautionary <e1>principle</e1> insists on <e2>certainty</e2> that a technology is not harmful before it can be used."
Other
Comment: The modality is outside e1-e2.

1324	"The <e1>soils</e1> used for the <e2>growing</e2> of irrigated cotton in the Macquarie Valley of N.S.W. are variable and each soil type has its own characteristics and problems."
Other
Comment: Purpose-Tool

1325	"<e1>Rainwater</e1> falls into special <e2>use</e2>."
Other
Comment: violates b.1 and c.3

1326	"In these cases of <e1>fever</e1> from <e2>constipation</e2> there are no local signs except, perhaps, a varying amount of tenderness over the sigmoid flexure of the colon, but only appreciable where the distension of gut is extreme."
Cause-Effect(e2,e1)
Comment:

1327	"When the <e1>cleaner</e1> was down in a <e2>cistern</e2>, the children enjoyed looking down into the cistern to see him work."
Other
Comment:

1328	"The <e1>cell line</e1> was derived from a macrophage-enriched <e2>cell culture</e2>."
Other
Comment:

1329	"<e1>Toxoplasmosis</e1> is caused by infection with Toxoplasma gondii, an obligate intracellular <e2>parasite</e2>."
Cause-Effect(e2,e1)
Comment:

1330	"Most importantly, the <e1>shock</e1> and anger caused by the surprise <e2>attack</e2> on Pearl Harbor united a divided nation and was translated into a wholehearted commitment to victory in World War II."
Cause-Effect(e2,e1)
Comment:

1331	"Morton's <e1>neuroma</e1> is the most common cause of localized <e2>pain</e2> in the third interspace and these diagnostic tests produce good indications of the condition."
Cause-Effect(e1,e2)
Comment:

1332	"The government of Iraq has established a <e1>committee</e1> to consider a proposed <e2>amendment</e2> to the Constitution of Iraq."
Other
Comment: Here we have Purpose-Tool relation - committee for amendment.

1333	"New experiences throw <e1>neurons</e1> into <e2>reverse</e2>."
Other
Comment: violates c.3

1334	"I've never seen anything like it in my life: they have a whole <e1>town</e1> of prarie <e2>dogs</e2>."
Other
Comment: A place, not a set; modality and negation are outside

1335	"Furthermore, the substrate doping density at which impact <e1>ionization</e1> causes <e2>avalanche</e2> breakdown at the trench capacitor junction has been estimated."
Cause-Effect(e1,e2)
Comment:

1336	"The <e1>man</e1> is falling into a drug <e2>addiction</e2> and needs help."
Other
Comment: violates b.1 and c.3

1337	"Major disasters like <e1>cyclone</e1>, floods and the storm surges, drought are caused by <e2>climate change</e2>."
Cause-Effect(e2,e1)
Comment:

1338	"I really got into using baking <e1>soda</e1> for <e2>cleaning</e2>, so I buy it in bulk."
Other
Comment: Purpose-Tool

1339	"Knee <e1>injuries</e1> from <e2>running</e2> are treated and prevented by following tips and performing stretches from Runner's World.com."
Cause-Effect(e2,e1)
Comment:

1340	"Each <e1>zone</e1> is denoted with an <e2>icon</e2> indicating how difficult the zone is expected to be to conquer."
Other
Comment: violates (h)

1341	"Ita s hard for me to fathom the <e1>craziness</e1> that has been caused by the H1N1 <e2>virus</e2>."
Cause-Effect(e2,e1)
Comment:

1342	"The <e1>fit</e1> of this <e2>jacket</e2> is perfect, it is not bulky."
Other
Comment: fit is a property.

1343	"The <e1>displacement</e1> comes from low <e2>atmospheric pressure</e2> within the centre of the depression."
Cause-Effect(e2,e1)
Comment:

1344	"Blast fishing or <e1>dynamite</e1> <e2>fishing</e2> is the practice of using explosives to stun or kill fish."
Other
Comment: Purpose-Tool

1345	"In 1993, international <e1>news agencies</e1> reported the <e2>murder</e2> of a four-year- old English boy, James Bulger."
Other
Comment: The agencies are the communicators not the message.

1346	"<e1>Dacryoadenitis</e1> is caused by local <e2>infection</e2> of the lacrimal gland by bacteria or viruses."
Cause-Effect(e2,e1)
Comment:

1347	"First of all, it is a source of specialist <e1>cadre</e1> of various <e2>specialties</e2>, such as monument and art renovation, foreign language teachers, economists, chemists, lawyers and IT specialists, just to name a few, who often stay in the city after graduating."
Other
Comment: Kinds of cadre.

1348	"Shortly after takeoff, an apparent systems <e1>malfunction</e1> has caused the inadvertent <e2>launch</e2> of an AIM-9 Sidewinder missile."
Cause-Effect(e1,e2)
Comment:

1349	"After the war, as the Midway was preparing for retirement, she was called upon one last time to the Philippines to help with an <e1>evacuation</e1> after the <e2>eruption</e2> of Mt. Pinatubo."
Cause-Effect(e2,e1)
Comment:

1350	"The <e1>palace</e1> was built by the <e2>lake</e2> during the reign of the Umayyad caliph al-Walid I (705-715 CE)."
Other
Comment: the lake is not a producer

1351	"The <e1>vibrations</e1> caused a violent twisting <e2>motion</e2> on the bridge."
Cause-Effect(e1,e2)
Comment:

1352	"The final <e1>round</e1> lets the last 2 <e2>contestants</e2> answer the question from a hint of a given qualification to find the last man standing."
Other
Comment:

1353	"To help doctors to know and cure <e1>headaches</e1> from <e2>medication overuse</e2> a revised criteria was published by the International Headache Society."
Cause-Effect(e2,e1)
Comment:

1354	"The debates <e1>proposal</e1> is still under <e2>consideration</e2>, although there are potential problems."
Other
Comment:

1355	"Less <e1>obedience</e1> was extracted from <e2>subjects</e2> in this case."
Other
Comment:

1356	"Head <e1>injuries</e1> are a common cause of <e2>unconsciousness</e2> and they occur in many sports like rugby and boxing."
Cause-Effect(e1,e2)
Comment:

1357	"Modern <e1>pioneer</e1> builds home from <e2>scratch</e2>."
Other
Comment:

1358	"His <e1>girlfriend</e1> was in a <e2>trunk</e2> and they drove over a bridge."
Other
Comment: restriction (d) is violated

1359	"The <e1>tabernacle</e1> was inside a rectangular <e2>court</e2> whose entrance faced the East."
Other
Comment:

1360	"The <e1>colouration</e1> has been caused by a blue <e2>dye</e2>."
Cause-Effect(e2,e1)
Comment:

1361	"From the <e1>anger</e1>, <e2>sky</e2> was evolved, from the sky air was evolved, from the air fire was evolved and from the fire water was evolved."
Other
Comment:

1362	"Occasionally, a dream proffers no solution but portrays only the <e1>anxiety</e1> which is generated by the <e2>conflict</e2>."
Cause-Effect(e2,e1)
Comment:

1363	"When the merchant was ready to come home, he had bought a <e1>diamond</e1> <e2>necklace</e2> for his first daughter."
Other
Comment:

1364	"Your Republican tax cut fetish has drained government <e1>surpluses</e1> into unprecedented <e2>deficits</e2>."
Other
Comment: violates c.3

1365	"They ordered <e1>vaccine</e1> made with a 50-year-old egg <e2>technology</e2> rather than experimental methods."
Other
Comment: the technology is not actively involved in the making of the vaccione

1366	"This was meant to represent the resting of the <e1>maize</e1> <e2>spirits</e2> until the next harvesting period came around."
Other
Comment:

1367	"Robert Pattinson wears a <e1>suit</e1> for a cemetery <e2>scene</e2> on location."
Other
Comment: Purpose-Tool

1368	"Using the product around the house killed <e1>germs</e1> that were causing flu, colds or <e2>sore throat</e2>."
Cause-Effect(e1,e2)
Comment:

1369	"Police charge a Carlisle man with eight <e1>offences</e1> in relation to the illegal <e2>trade</e2> of endangered tortoises."
Other
Comment:

1370	"An Iraqi <e1>unit</e1> is sent to battle the <e2>cult</e2>."
Other
Comment:

1371	"In Australia, fifty cent <e1>coins</e1> have been put into <e2>circulation</e2>."
Other
Comment: violates b.1 and c.3

1372	"This consensus paper describes the essential skills that clinicians need to help persons who are experiencing <e1>grief</e1> after the <e2>death</e2> of a loved one."
Cause-Effect(e2,e1)
Comment:

1373	"Perhaps even more compelling, the <e1>design</e1> is rooted in an optimistic <e2>worldview</e2>."
Other
Comment:

1374	"After making an <e1>impression</e1> the crowd with an a capella <e2>rendition</e2> of their national anthem, the South African were immediately under pressure."
Cause-Effect(e2,e1)
Comment:

1375	"As delegates gather in Copenhagen for the UN climate summit, a new poll shows growing <e1>concern</e1> for <e2>climate change</e2>."
Other
Comment: It's a mental state, and nothing suggests its verbalisation. Restriction (b).

1376	"The Washington <e1>sniper</e1> is put to <e2>death</e2>."
Other
Comment: violates b.1 and c.3

1377	"On 16th Avenue, throngs of cars crowded the street forming a huge traffic <e1>jam</e1> of honking <e2>horns</e2> with people hanging out of windows and sunroofs, slapping high-fives to all who passed."
Other
Comment: Sounds are not suited as elements of a collection.

1378	"After massive <e1>companies</e1> were bailed out of the <e2>recession</e2> earlier this year, an advantage to cardholders started to be there."
Other
Comment:

1379	"The <e1>orchestra</e1> was in a <e2>box</e2> above the stage."
Other
Comment:

1380	"He put the <e1>posts</e1> in <e2>chronological order</e2>."
Other
Comment: violates b.1

1381	"Recently, <e1>marketing spending</e1> translated into <e2>revenue</e2>."
Cause-Effect(e1,e2)
Comment:

1382	"A simple <e1>intervention</e1> in relation to local small-scale gold <e2>production</e2> was undertaken in the late 1980s."
Other
Comment:

1383	"In reality, however, the <e1>drama</e1> has been caused by the erupting <e2>ash</e2> and smoke colliding with a lightning storm."
Cause-Effect(e2,e1)
Comment:

1384	"Yet on the whole, given the constraints of sticking so closely to the original book, the <e1>developer</e1> has crafted a thoroughly pleasing puzzle <e2>adventure</e2>."
Cause-Effect(e1,e2)
Comment:

1385	"The <e1>story</e1> is narrated in <e2>flashback</e2>."
Other
Comment: Manner.

1386	"The <e1>subject</e1> was taken into <e2>custody</e2> for trespassing."
Other
Comment: violates b.1

1387	"After <e1>receipt</e1> of the invoice through the <e2>air-mail</e2> or the email, we send it the accounting department for payment procedures."
Other
Comment:

1388	"In a decade, <e1>neighborhoods</e1> are sinking into <e2>disrepair</e2>."
Other
Comment: violates c.3

1389	"The plasma <e1>membrane</e1> is composed of a double layer (bilayer) of <e2>lipids</e2>, oily substances found in all cells (see Figure 1)."
Other
Comment: Material

1390	"<e1>Corruption</e1> is one of the main causes of a global <e2>crisis</e2> that deprives more than a billion people of access to safe drinking water and more than 2.6 billion of access to sanitation systems."
Cause-Effect(e1,e2)
Comment:

1391	"When Frances was 13, she read an article about a <e1>woman</e1> who escaped an unhappy <e2>marriage</e2> and went to Kenya."
Other
Comment:

1392	"Many commercial soap, shower gel or cleanser products contain preservatives, <e1>colorants</e1> and chemicals that cause dryness, <e2>rashes</e2>, itchiness and roughness on the skin."
Cause-Effect(e1,e2)
Comment:

1393	"The <e1>presentation</e1> of the data is rooted in an <e2>identity</e2> in which a nation's saving is equal to domestic investment plus net foreign investment."
Other
Comment:

1394	"Both her <e1>parents</e1> wind up accompanying her to the <e2>factory</e2>, though her mother disapproves of Violet's gum-chewing habit."
Other
Comment: factory and parents are not product-producer

1395	"For all the <e1>pain</e1> caused by the great <e2>recession</e2>, the job market still was not in as bad shape as it had been during the depths of the early 1980s recession, until now."
Cause-Effect(e2,e1)
Comment:

1396	"Landrieu where he saw firsthand the <e1>destruction</e1> caused by the <e2>hurricanes</e2> and the failure of the storm protection system."
Cause-Effect(e2,e1)
Comment:

1397	"Sea <e1>breezes</e1> are caused by cool and more dense <e2>air</e2> moving inland off the water."
Cause-Effect(e2,e1)
Comment:

1398	"These <e1>germs</e1> cause several kinds of illnesses, such as <e2>diarrhea</e2>, meningitis or a cold."
Cause-Effect(e1,e2)
Comment:

1399	"Waves and <e1>coastal</e1> <e2>erosion</e2> is a good general discussion of these subjects."
Other
Comment:

1400	"Baking <e1>soda</e1> safely tackles kitchen <e2>jobs</e2> above and beyond the legendary box at the back of the refrigerator."
Other
Comment: Purpose-Tool

1401	"But the <e1>role</e1> is also under <e2>scrutiny</e2> in this affair."
Other
Comment:

1402	"At the end of a long day, the <e1>teacher</e1> relaxed with a short <e2>nap</e2> on her sofa."
Other
Comment: e2 is a simple event and can't be an instrument.

1403	"The <e1>road</e1> starts at an <e2>intersection</e2> with Melrose Avenue, East 165th Street, Brook Avenue and Park Avenue in Melrose."
Other
Comment:

1404	"The <e1>artist</e1> hid the convulsion with a forced <e2>laugh</e2> and finished the performance, but went immediately to bed."
Other
Comment: simple event.

1405	"The <e1>organisation</e1> campaigns against such things as <e2>child labour</e2>."
Other
Comment: this is against child labour

1406	"The <e1>brown areas</e1> are caused by <e2>drought</e2>, brown patch, take-all-patch, chinch bugs or grubs."
Cause-Effect(e2,e1)
Comment:

1407	"But in 2004 the <e1>rupture</e1> started at the <e2>southeast end</e2> of the segment and ran northwestward, the opposite direction from those that struck in '34 and '66."
Other
Comment:

1408	"The other countries passed their own <e1>laws</e1> to establish local slave <e2>registries</e2>."
Other
Comment:

1409	"Many adults retain <e1>scars</e1> from <e2>acne breakouts</e2> during their teen years and feel marked for life."
Cause-Effect(e2,e1)
Comment:

1410	"Northern Michigan towns hosts an <e1>array</e1> of Yuletide <e2>events</e2>."
Other
Comment: Events cannot be elements of a collection.

1411	"The slow <e1>suffocation</e1> of the cells swiftly cause unconsciousness and <e2>shock</e2>, soon followed by death."
Cause-Effect(e1,e2)
Comment:

1412	"The <e1>granules</e1> and the pebbles are caused by a <e2>magnetic force</e2> to collide with one another, thereby resulting in liberation of the oxygen molecules contained in the granules and the pebbles."
Other
Comment:

1413	"Description StyleSearch is a <e1>competition</e1> to establish the UK's most ethical <e2>dressers</e2>."
Other
Comment: To establish is a form of purposeful activity. No message here.

1414	"In these cases, the <e1>disappointment</e1> from the <e2>purchase</e2> is not forgotten over time, but rather accumulates."
Cause-Effect(e2,e1)
Comment:

1415	"In 1805 merchants of the city formed a <e1>troop</e1> of <e2>cavalry</e2> in Montreal."
Other
Comment: It would be too big a stretch to assume that cavalry means individual riders. This describes really a kind of troop.

1416	"The <e1>streaking</e1> was from the <e2>penguins</e2> doing what all animals do in the forests and woods, etc."
Other
Comment:

1417	"The term "dung beetle" or Mistkaefer is in fact used in the <e1>novella</e1> by the cleaning <e2>lady</e2> near the end of the story, but it is not used in the narration."
Other
Comment: lady is not a producer

1418	"Other standards can apply to <e1>products</e1> covered by this <e2>document</e2>."
Other
Comment: the document is not a producer

1419	"Unemployment, <e1>debt</e1> and poverty cause enormous <e2>stress</e2>."
Cause-Effect(e1,e2)
Comment:

1420	"The <e1>earthquake</e1> was caused by the Anatolian plate and the Eurasian <e2>plate</e2> moving past each other."
Cause-Effect(e2,e1)
Comment:

1421	"While it took only minutes for the Pacific <e1>tsunami</e1> and earthquake to cause <e2>havoc</e2> to the south coast of Samoa, the rebuilding and reconstruction efforts will take years."
Cause-Effect(e1,e2)
Comment: modality is outside

1422	"Many more resources are required in order to stem the <e1>devastation</e1> that has been caused by the <e2>epidemic</e2> throughout sub-Saharan Africa."
Cause-Effect(e2,e1)
Comment:

1423	"The responsibility of the <e1>carrier</e1> commences from the moment he receives the merchandise, personally or through a <e2>person</e2> charged for the purpose."
Other
Comment: e2 is employing e1.

1424	"In one case, the <e1>waterjet</e1> caused a large <e2>gouge</e2> on the bottom side of a a copper/ wood/copper piece."
Cause-Effect(e1,e2)
Comment:

1425	"Frustrations, <e1>threats</e1>, and conflicts cause <e2>stress</e2>."
Cause-Effect(e1,e2)
Comment:

1426	"This is an atlas of <e1>maps</e1> and graphic <e2>representations</e2> of the geographies of the new electronic territories of the Internet, the World-Wide Web and other emerging Cyberspaces."
Other
Comment:

1427	"The <e1>damages</e1> caused by mudslides, <e2>tremors</e2>, subsidence, superficial or underground water were verified, as well as swelling clay soils."
Cause-Effect(e2,e1)
Comment:

1428	"The sound <e1>machine</e1> contained 10 <e2>sounds</e2> that his dog loved."
Cause-Effect(e1,e2)
Comment:

1429	"Coast <e1>guard</e1> participates in Veterans Day observance <e2>ceremony</e2> in Juneau."
Other
Comment: Participation in an event. We do not see it as a form of membership. It rather is a kind of agency or co-agency.

1430	"The <e1>steam</e1> caused a <e2>backpressure</e2> on the VTD, resulting in the rupture disc opening."
Cause-Effect(e1,e2)
Comment:

1431	"The campaign coincides with a government <e1>initiative</e1> to promote <e2>safer drinking</e2>."
Other
Comment: I cannot see initiative as a Message.

1432	"There was the <e1>glitter</e1> of <e2>admirals</e2> and generals before the high altar, and the brighter colors of the representatives of powers and potentates."
Other
Comment: not sure

1433	"Furthermore, the present invention includes a composition for <e1>treatment</e1> of disorders associated with or enhanced by an <e2>eosinophilia</e2>."
Other
Comment:

1434	"His <e1>death</e1> during one of the Portuguese raids caused the <e2>abandonment</e2> of the settlement."
Cause-Effect(e1,e2)
Comment:

1435	"By choosing to hold the <e1>ceremony</e1> in a public <e2>building</e2> and inviting guests you are recognizing both that your new life affects the lives of many other people."
Other
Comment: the ceremony itself is not contained in the building, the buildings more like a location

1436	"Ku's sculpture-like <e1>knitwear</e1> was inspired by the <e2>concept</e2> of 'Sculpture.'"
Other
Comment: concept is not a producer

1437	"The <e1>eight-year-old boy</e1> was locked in a <e2>safe</e2> for a prank but had to be rescued when his air ran short."
Other
Comment:

1438	"Finally, this entire assembly is covered by a <e1>lid</e1> attached to the rear of the <e2>coffeemaker</e2> and latches in front."
Other
Comment: It doesn't sound like the lid is part of the coffeemaker, it's just attached to it

1439	"<e1>Exposure</e1> to vapor causes intense <e2>watering</e2> and irritation to eyes."
Cause-Effect(e1,e2)
Comment:

1440	"Biting into the grill-charred, bronze-fleshed Copper River salmon fillet perched on a <e1>hill</e1> of crisp-tender green <e2>beans</e2> and roasted fingerling potatoes -- a dribble of mustard vinaigrette around the plate rim the only sauce it wanted -- I was back in San Francisco again."
Other
Comment: A hill is a spatial structure; modality is outside

1441	"<e1>Democrats</e1> are running into one <e2>problem</e2> after another trying to pass the health care bill in the Senate."
Other
Comment: violates b.1

1442	"The <e1>scandals</e1> are caused by the young female <e2>celebs</e2> who 'inadvertently' reveal glimpses of their naked faces as they get out of limousines."
Cause-Effect(e2,e1)
Comment:

1443	"The <e1>infection</e1> was caused by the contaminated <e2>chopsticks</e2> used by the parent to feed her child."
Cause-Effect(e2,e1)
Comment:

1444	""Any time," he told her before turning to the <e1>boy</e1> who was in the <e2>desk</e2> next to him."
Other
Comment: the desk does not contain the boy; reported speech is OK here

1445	"The <e1>convention</e1> took into account <e2>discharges</e2> of harmful substances from ships."
Other
Comment:

1446	"Grint shows he's becoming a delightful comic <e1>actor</e1> with a highly flexible <e2>voice</e2>."
Other
Comment: Personal properties. qualities, skills cannot be Instruments.

1447	"An unknown source brought an <e1>alien frog</e1> into our <e2>eco-system</e2>."
Other
Comment: violates b.1

1448	"They achieved the maximum possible <e1>flexibility</e1> in a crockery <e2>basket</e2> for receiving a plurality of different items of crockery."
Other
Comment: flexibility is not a content

1449	"Internal <e1>emails</e1> have been leaked to the public <e2>broadcasting</e2>."
Other
Comment: violates b.1

1450	"These latter <e1>reports</e1> were subjected to intensive <e2>examination</e2>."
Other
Comment:

1451	"The <e1>aircraft</e1> accommodated a <e2>pilot</e2> and copilot sitting side-by-side in a framed canopy."
Other
Comment:

1452	"A University of Michigan study of 756 recently unemployed job seekers has found that medical and emotional <e1>fallout</e1>, including depression, from <e2>unemployment</e2> continued even after two years, when 71 percent were re-employed."
Cause-Effect(e2,e1)
Comment:

1453	"Before leaving Peter bought a <e1>silver</e1> star <e2>necklace</e2> for Tina."
Other
Comment:

1454	"The <e1>accolade</e1> was decided upon after an intense <e2>discussion</e2> between about 200 members."
Cause-Effect(e2,e1)
Comment: This cannot be Message-Topic since (1) Cause-Effect is a stronger relation, according to the Guidelines, and (2) discussions, quarrels, etc. are accepted as Messages only when the information is spread outside the participants. Here we have "between".

1455	"The infamous <e1>teacher</e1> has been dragged into another child abuse <e2>case</e2>."
Other
Comment: violates b.1

1456	"Food <e1>poisoning</e1> is perhaps the commonest cause of <e2>abdominal pain</e2>, especially in the young dog or the scavenger type."
Cause-Effect(e1,e2)
Comment:

1457	"The first days were frustrating as the winds were blowing for large sails, but the <e1>direction</e1> was from the <e2>north</e2>, and the bay was at low tide."
Other
Comment:

1458	"The model was approved by as the top <e1>design</e1> by a professional <e2>panel</e2>; however, it was later exhibited for the public."
Other
Comment:

1459	"Instead, the <e1>success</e1> of the revolution is the reason for the <e2>celebration</e2>."
Cause-Effect(e1,e2)
Comment:

1460	"I got a <e1>fever</e1> from <e2>exhaustion</e2> and it seems like I'm better but basically my body is suffering from major exhaustion so I'm always tired."
Cause-Effect(e2,e1)
Comment:

1461	"This is one of the most abundant tree <e1>species</e1> in the whole <e2>forest</e2>, and with a maximum height of 14 m. the dominant tree species of the first canopy layer."
Other
Comment: A species is a taxonomic concept, so: a class of trees. A forest is not a collection of abstract classes of trees.

1462	"The trio, the penguins, and a <e1>cartload</e1> of <e2>chimpanzees</e2> use the newly-fixed plane (which looks more like a helicopter) to come to the rescue."
Other
Comment: A measure of quantity: as much as a cart will hold.

1463	"The author examines some <e1>issues</e1> connected to religious <e2>freedom</e2>."
Other
Comment: "connected to" is not necessarily about

1464	"The <e1>hinge</e1> caused a <e2>crack</e2> on the left side of my kindle, and Amazon has been horrible about helping with this issue."
Cause-Effect(e1,e2)
Comment:

1465	"<e1>Injury</e1> of patients of the Bikini accident has been caused by the <e2>radiation</e2> of the fallout in contrast to the atomic bomb injury at Hiroshima and Nagasaki."
Cause-Effect(e2,e1)
Comment:

1466	"The abdominal <e1>distention</e1> caused by the <e2>worms</e2> was slightly asymmetrical when compared with the normal fright-induced swelling."
Cause-Effect(e2,e1)
Comment:

1467	"More than thirty people lost their lives in June, in the <e1>disaster</e1> caused by torrential <e2>rains</e2> in Hiroshima Prefecture, and in September more than thirty people lost their lives in the damage caused by the typhoon that swept through various regions, centering on Kumamoto Prefecture."
Cause-Effect(e2,e1)
Comment:

1468	"I've sold a <e1>diamond</e1> <e2>ring</e2> that I bought at Zales for about $500 for $200 on craigslist."
Other
Comment:

1469	"This introductory <e1>text</e1> makes a threefold contribution to the undergraduate <e2>literature</e2>."
Other
Comment: The document is about something, but that something is not named.

1470	"Term <e1>limits</e1> apply to many <e2>offices</e2> at both the federal and state level in the United States."
Other
Comment:

1471	"Liberal <e1>ideas</e1> insist on large <e2>gambles</e2> and conservatives rely on incremental small changes."
Other
Comment:

1472	"Learning about the dynamics of addiction starts from repairing the <e1>damage</e1> that has been caused by the <e2>addiction</e2>."
Cause-Effect(e2,e1)
Comment:

1473	"The first is that the <e1>ossicles</e1> are caused by an avulsion <e2>fracture</e2> 1,5 and the second is that the ossicles occur as a result of accessory ossification."
Other
Comment:

1474	"American scientists have discovered a way of creating new <e1>brain cells</e1> in a <e2>dish</e2>."
Other
Comment: no evidence for Content-Container

1475	"<e1>Farmers</e1> till now have negotiated with the <e2>market</e2> as individuals."
Other
Comment:

1476	"The corporate <e1>regulator</e1> has been dragged into undertaker's <e2>inquiry</e2>."
Other
Comment: violates b.1

1477	"A febrile seizure is a <e1>convulsion</e1> in a child triggered by a <e2>fever</e2>."
Cause-Effect(e2,e1)
Comment:

1478	"The merchant facilitates attacks using fake or modified terminals, towards tapping both the financial data stored on the <e1>cards</e1> as well as the <e2>pin</e2> of the cardsholders."
Other
Comment:

1479	"The disruption of electricity and telecommunication lines have thrown the <e1>city</e1> into <e2>darkness</e2>."
Other
Comment: violates c.3

1480	"Recently, there is a <e1>movement</e1> afoot, instigated by the heterodox section of the <e2>community</e2>, as well as by the followers of the Gatha Alone Cultists to proselytise others to become "Zarthushtis"."
Cause-Effect(e2,e1)
Comment:

1481	"The <e1>experiments</e1> reported in this article investigated two specific <e2>properties</e2> of the location probability effect."
Other
Comment: The Message is the article, not the experiments.

1482	"Yet a recent tour of the handful of year-round farmers' markets in town turned up a <e1>cornucopia</e1> of fresh <e2>foods</e2>, from staples to rarities, sweets to meats."
Other
Comment: This is a kind of measure.

1483	"Regardless I got my life back, <e1>sadness</e1> from <e2>divorce</e2> is GONE I am thrilled I am not bleeding, dont need red shorts to walk my daughter to the park."
Cause-Effect(e2,e1)
Comment:

1484	"After some time, the <e1>acids</e1> caused a white <e2>spot</e2> on the tooth where they dissolved some of the enamel."
Other
Comment:

1485	"He is personally responsible for the <e1>carnage</e1> that has been caused by the <e2>fight</e2>."
Cause-Effect(e2,e1)
Comment:

1486	"He has highlighted some important <e1>issues</e1> with regard to the <e2>abilities</e2> of firefighters."
Other
Comment:

1487	"He has been used to promote many <e1>issues</e1> to do with <e2>animal welfare</e2> and has also helped raise funds for many of the service charities."
Other
Comment: Issues are not messages.

1488	"Hundreds of years ago the <e1>island</e1> was almost discovered by an <e2>explorer</e2> called Marco Polo."
Other
Comment: island is not a product

1489	"The <e1>decline</e1> of the old ideologies has made many of the old Left-Right <e2>arguments</e2> redundant."
Other
Comment: the arguments are not products of the decline

1490	"The <e1>size</e1> of the issue was increased from its initial <e2>amount</e2> of US$750 million following strong market interest."
Other
Comment:

1491	"Peters's <e1>pain</e1> and symptoms were caused by the automobile <e2>accident</e2>."
Cause-Effect(e2,e1)
Comment:

1492	"ProVention has supported the development of a series of IFRC studies on rebuilding and <e1>reconstruction</e1> after the <e2>tsunami</e2> to identify lessons learned in promoting and strengthening community roles in the rebuilding process."
Other
Comment:

1493	"Last week the <e1>city</e1> had patched up the offending <e2>section</e2> of roadway."
Other
Comment: city is not a producer of the section

1494	"It is the oldest and largest international research consortium aimed at understanding the <e1>challenges</e1> facing the global automotive <e2>industry</e2>."
Other
Comment:

1495	"The goal of the <e1>project</e1> was to introduce environmentally efficient production <e2>technologies</e2>."
Other
Comment: Goal or purpose.

1496	"Sensitive pets experience <e1>rashes</e1> and discomfort from ticks and <e2>fleas</e2>."
Cause-Effect(e2,e1)
Comment:

1497	""Morning Sickness" is a bit of a misnomer, as <e1>nausea</e1> from <e2>pregnancy</e2>; it can happen at any time of the day."
Cause-Effect(e2,e1)
Comment: modality is outside

1498	"Some people took this as an indication that the <e1>increase</e1> was caused by the MMR <e2>vaccine</e2>."
Cause-Effect(e2,e1)
Comment:

1499	"The <e1>prisoner</e1> has departed into <e2>captivity</e2>."
Other
Comment: violates b.1 and c.3

1500	"Moreover, it is beyond the power of the State to compel the Syme family to retain their shares or, more importantly, to oblige Mr Macdonald to remain the <e1>chief executive</e1> of this <e2>company</e2>."
Other
Comment:

1501	"The <e1>wind</e1> caused a neat effect on the smoke clouds though, causing a <e2>corkscrew</e2> in the otherwise straight line."
Cause-Effect(e1,e2)
Comment:

1502	"A women <e1>fear</e1> from darkness, insects, <e2>cockroaches</e2>, mice, lizards, spiders and more and more."
Cause-Effect(e2,e1)
Comment:

1503	"The <e1>house</e1> was packed from that <e2>moment</e2> to past midnight."
Other
Comment:

1504	"<e1>Prospectors</e1> have arrived in midland <e2>cars</e2>."
Other
Comment: Manner

1505	"Bacteria and comedonal <e1>debris</e1> cause acne pimples or <e2>pustules</e2> (inflammatory lesions)."
Cause-Effect(e1,e2)
Comment:

1506	"The <e1>chimps</e1> had tasted cooked <e2>food</e2> before, which may have influenced the outcome."
Other
Comment: food is not product of chimps

1507	"Autologous <e1>blood</e1> <e2>clot</e2> is useful to occlude and repair perforations in small side branches of the coronary artery without myocardial damage."
Other
Comment:

1508	"The <e1>slope</e1> on a distance-time graph represents the <e2>speed</e2> of an object."
Other
Comment:

1509	"The illustrators <e1>section</e1> has been brought into the new web <e2>format</e2>."
Other
Comment: violates c.3

1510	"<e1>Families</e1> are being thrown into <e2>poverty</e2> by our corrupt health care system."
Other
Comment: violates c.3

1511	"Since the earliest period of its history, the <e1>church</e1> made use of <e2>messengers</e2>, called "cursores," in order to communicate with the entire world."
Other
Comment: People are not usually classified as Instruments, unless they are clearly non-agentive in the situation, this is similar to employment.

1512	"An oil <e1>spill</e1> caused by a <e2>collision</e2> between a ship and a barge closed the ship channel servicing the nation's second largest port."
Cause-Effect(e2,e1)
Comment:

1513	"In America, one of <e1>dynamite</e1>'s first use was in the <e2>creation</e2> of trenches for irrigation systems."
Other
Comment: Purpose-Tool

1514	"Excessive anxiety, worry or <e1>fear</e1> are among the causes of <e2>heart attack</e2>."
Cause-Effect(e1,e2)
Comment:

1515	"The <e1>builder</e1> who has mortgaged the <e2>land</e2> to raise money will have to spell this out in all advertisements and brochures."
Other
Comment: land is not a product; modality is outside

1516	"Medical <e1>bills</e1> make up half of <e2>bankruptcies</e2>."
Cause-Effect(e1,e2)
Comment:

1517	"Stuart's <e1>cavalry</e1> observed the passing through the <e2>town</e2>."
Other
Comment:

1518	"In reality, <e1>acne</e1> is caused by <e2>bacteria</e2> and oil on the skin."
Cause-Effect(e2,e1)
Comment:

1519	"While he was freeing himself from the <e1>clutches</e1> of the <e2>dishwasher</e2>, he ripped off some of his skin, revealing his bionic arm."
Other
Comment:

1520	"A locksmith copies and repairs car <e1>keys</e1> for modern <e2>vehicles</e2> at a lower cost."
Other
Comment:

1521	"When the <e1>traveller</e1> drew up the <e2>blind</e2> the next morning, the sea opened before him joyously under the broad August sunlight."
Other
Comment: the blind is not produced by the traveller

1522	"The 77-year-old is <e1>suffering</e1> from <e2>exhaustion</e2> and he will undergo medical tests."
Cause-Effect(e2,e1)
Comment: modality is outside

1523	"A substrate treating apparatus for <e1>treatment</e1> of substrates with a treating <e2>liquid</e2> includes a treating tank having an inner tank for storing the treating liquid."
Other
Comment: Purpose-Tool

1524	"They are <e1>symbols</e1> that indicate the <e2>structure</e2> and organization of written language."
Other
Comment:

1525	"The <e1>company</e1> has moved into <e2>mobile software applications</e2>, which connect to enterprise databases."
Other
Comment:

1526	"Many <e1>students</e1> participated in the tutoring <e2>programs</e2> funded by the legislation, but the controversial element was not the options for public schools or the tutoring program (both of which where never challenged)."
Other
Comment: negation is outside

1527	"The <e1>orders</e1> are shipped to foreign <e2>countries</e2> using US postal service delivery."
Other
Comment:

1528	"We began to reverse the <e1>damage</e1> to one of the greatest rivers in the state caused by the <e2>construction</e2> of a dam nearly 70 years ago."
Cause-Effect(e2,e1)
Comment:

1529	"A <e1>loop</e1> emiting short flashes of <e2>light</e2> is projected onto volunteer members of the audience."
Cause-Effect(e1,e2)
Comment:

1530	"<e1>Earthquakes</e1> are caused by <e2>movement</e2> of the earth's crust along this fault."
Cause-Effect(e2,e1)
Comment:

1531	"We see that the <e1>universe</e1> starts at an initial <e2>epoch</e2> t0."
Other
Comment:

1532	"Rice University and Houston-based MI SWACO, the world's largest producer of <e1>drilling</e1> <e2>fluids</e2> for the petrochemical industry, aim to develop a graphene additive."
Other
Comment: Purpose-Tool

1533	"The tsunami was generated by an undersea <e1>landslide</e1>, which was triggered by the <e2>earthquake</e2>."
Cause-Effect(e2,e1)
Comment:

1534	"The greatest <e1>plenitude</e1> of <e2>graces</e2> was conferred on him as man, and from him, as he was our head, derived to all the members of his Church."
Other
Comment: Measure.

1535	"In the presence of Cuba's favorite son, Estrada Palma, who is to enjoy the honor of being the first <e1>chief executive</e1> of this <e2>republic</e2>."
Other
Comment:

1536	"Welch shows how <e1>laws</e1> composed to incorporate rural <e2>workers</e2> in a controlled way became platforms for unexpected protest and political mobilization culminating in the 1963 Rural Laborer Statute (ETR)."
Other
Comment: the workers did not make the laws

1537	"The decision to take the <e1>meeting</e1> on the <e2>road</e2> gave groups around the world the opportunity to host future Keele Meetings."
Other
Comment:

1538	"Dr. K.P. Kumar is the <e1>chairman</e1> of the <e2>college</e2> that strives to impart value education to students and guide them for excellent prospects in career making."
Other
Comment:

1539	"The dancing <e1>duo</e1> caused a <e2>stir</e2> on the 2008 series of the show with their infusion of classic Michael Jackson songs and dance moves mixed with bangra."
Cause-Effect(e1,e2)
Comment:

1540	"This Pacific Chorus <e1>frog</e1> was found in a Christmas <e2>tree</e2> being sold in Anchorage, Alaska."
Other
Comment: the tree is not a container

1541	"The spreading riots threw the <e1>country</e1> into <e2>turmoil</e2>."
Other
Comment: violates c.3

1542	"Dutch National Ballet's new <e1>production</e1>, by the creative <e2>partnership</e2> of Rachel Beaujean and Ricardo Bustamante, is based on the original ballet by Jean Coralli and Jules Perrot."
Other
Comment: partnership is not a producer

1543	"This was performed by <e1>illumination</e1> of the urethra with a <e2>candle</e2>."
Other
Comment:

1544	"Our <e1>companions</e1> have departed into <e2>eternity</e2>."
Other
Comment: violates b.1 and c.3

1545	"This is the second Italian championship won by Woody with <e1>horses</e1> bred in his <e2>stud</e2>."
Other
Comment: Here stud is the location of the breeding - Other.

1546	"The deeper <e1>currents</e1> are caused by <e2>heat</e2> from the sun."
Cause-Effect(e2,e1)
Comment:

1547	"But this is a very dark <e1>novel</e1>, driven by an unsparing <e2>view</e2> of human nature and a clear-eyed analysis of the idea of human perfectibility."
Other
Comment: view is not a producer

1548	"Since arriving in Cairns, co-workers have thrown the new <e1>employee</e1> into local <e2>issues</e2>."
Other
Comment: violates b.1

1549	"An alert victim with a broken neck or severely torn ligament has enough <e1>discomfort</e1> from the <e2>injury</e2> and muscle spasm to force him to hold his neck still."
Cause-Effect(e2,e1)
Comment:

1550	"The Affiliate Classroom promotes the direct sales and gets <e1>commission</e1> from the <e2>selling</e2> of products."
Cause-Effect(e2,e1)
Comment:

1551	"The act of repeated hand washing is the compulsive behavior performed in an attempt to remove the <e1>anxiety</e1> caused by the obsessive <e2>thought</e2>."
Cause-Effect(e2,e1)
Comment:

1552	"It's basically just a shack with a fridge and some fosters <e1>beers</e1> stacked up the back <e2>wall</e2>."
Other
Comment: wall is not a product

1553	"That's right boys and girls you read that correctly, you just shared a <e1>printer</e1> over the <e2>internet</e2>."
Other
Comment:

1554	"She bought a <e1>gold</e1> <e2>bracelet</e2> for her sister."
Other
Comment:

1555	"People have inherited a <e1>tendency</e1> to <e2>obesity</e2>."
Other
Comment:

1556	"I stood at the great central window, which was wide open, and watched the <e1>whiteness</e1> of the <e2>swans</e2> moving vaguely over the surface of the canal in the oncoming twilight."
Other
Comment: Colour.

1557	"In relation to the <e1>catastrophe</e1> caused by the <e2>rains</e2> of recent days in the Sierra and Coastal zones of Chiapas."
Cause-Effect(e2,e1)
Comment:

1558	"The second primer <e1>set</e1> was derived from a specific variant surface glycoprotein(VSG) expression <e2>site</e2> where the SRA gene is expressed(R-ES)."
Other
Comment:

1559	"When the police raid the catacombs, Shannyn's character hits her head while fleeing only to wake up alone in the <e1>maze</e1> of <e2>skulls</e2> and bones."
Other
Comment:This definitely is not a set: it is a pattern, an arrangement.

1560	"The magnetic <e1>island</e1> grows from the resonant <e2>radius</e2> until the so-called mixing radius rmix and full reconnection are reached."
Other
Comment:

1561	"I have blocked out the PIN <e1>code</e1> of the <e2>phone</e2> (Please do not give this code to the customer)."
Other
Comment:

1562	"The <e1>research</e1>, performed at the Kyoto Prefectural University of Medicine, has been presented at a medical <e2>meeting</e2> in Japan."
Other
Comment: Meeting.

1563	"The <e1>housing</e1> encloses a double sealed ball <e2>bearing</e2>, with a lower lip seal for additional protection."
Other
Comment:

1564	"The new <e1>law</e1> has been brought into <e2>force</e2>."
Other
Comment: violates c.3

1565	"The <e1>restaurant</e1> was filled with <e2>customers</e2>, most of them children and mothers."
Other
Comment:

1566	"The <e1>development</e1> of oil palm plantations is one of the biggest causes of rainforest <e2>clearance</e2>."
Cause-Effect(e1,e2)
Comment:

1567	"A <e1>terrorist</e1> has planted a <e2>bomb</e2> in a city centre and it is due to go off in one or two hours' time."
Other
Comment: not enough evidence to decide whetehr the bomb is a product of the terrorist

1568	"<e1>Asthma</e1> causes <e2>swelling</e2> and narrowing of the airways."
Cause-Effect(e1,e2)
Comment:

1569	"The weekend <e1>snowstorm</e1> caused <e2>delays</e2> that had some passengers still stuck in Washington, DC on Monday night."
Cause-Effect(e1,e2)
Comment:

1570	"The heaviest <e1>rain</e1> fell from an <e2>area</e2> from Roane and Clay Counties northeastward across Braxton, Gilmer and Lewis Counties and into Southern Harrison county."
Other
Comment:

1571	"We hold the <e1>magnesium ribbon</e1> in <e2>tongs</e2>, and place one end in a Bunsen burner flame."
Other
Comment:

1572	"The <e1>walk</e1> starts at an <e2>entry</e2> to Mealmore Forest."
Other
Comment:

1573	"The71-year-old <e1>man</e1> has already converted a room in the basement into an <e2>office</e2>."
Other
Comment:

1574	"Global warming <e1>pollution</e1> from <e2>cars</e2>, light trucks and SUV's is the single largest source of global warming pollution generated in Maine."
Cause-Effect(e2,e1)
Comment:

1575	"The <e1>insert</e1> starts in the left <e2>column</e2> and only spans the left column."
Other
Comment:

1576	"Cervical strain results from the physical stresses of everyday life, including poor posture, muscle <e1>tension</e1> from psychologic stress or <e2>poor sleeping</e2>."
Cause-Effect(e2,e1)
Comment:

1577	"The reference clock <e1>signal</e1> originates from an internal clock <e2>source</e2>."
Cause-Effect(e2,e1)
Comment:

1578	"The morning session of the <e1>symposium</e1> ends with a reunion lunch for the <e2>attendees</e2>."
Other
Comment:

1579	"The chemical <e1>reaction</e1> in the water caused a bubbling <e2>affect</e2> on the surface."
Cause-Effect(e1,e2)
Comment:

1580	"The <e1>research</e1> has been published in a <e2>paper</e2> by the Scottish Records Association."
Other
Comment: Location. It cannot be Content-Container since the Content should be removable. It also cannot be Component-Whole since it violates (d).

1581	"The <e1>conflict</e1> is rooted in an ongoing <e2>refusal</e2> by the Palestinians and the Arab world to recognize the right of the Jewish people."
Cause-Effect(e2,e1)
Comment:

1582	"A spot <e1>fire</e1> is caused by burning <e2>embers</e2> being blown away by high winds that occur during bushfires."
Cause-Effect(e2,e1)
Comment:

1583	"Stack gummy savers with a little frosting in between to make a <e1>smoke</e1> <e2>stack</e2> on the engine."
Other
Comment: Type of stack, and the same three times below.

1584	"A <e1>rock</e1> in the road caused an <e2>accident</e2> by breaking the rear wheel on the wagon."
Cause-Effect(e1,e2)
Comment:

1585	"Ditto for his funny turn as a <e1>man</e1> who instigates the <e2>kidnapping</e2> of his own wife in E Niwas's Love Ke Liye Kuch Bhi Karega."
Cause-Effect(e1,e2)
Comment:

1586	"The <e1>explosion</e1> caused a <e2>gas leak</e2> on the pipeline near the village of Pouce Coupe, south of Dawson Creek."
Cause-Effect(e1,e2)
Comment:

1587	"A spaghetti <e1>pie</e1> served at a church dinner had caused the <e2>poisoning</e2> of one hundred people."
Cause-Effect(e1,e2)
Comment:

1588	"<e1>Prospectors</e1> seeking their fortune in the Colorado gold fields traveled to Denver on the Smoky Hill <e2>trail</e2> from Kansas and points east."
Other
Comment: locations cannot be instruments in this case.

1589	"Most commercial <e1>pasta</e1> is made by this <e2>method</e2>."
Other
Comment: it is more like manner, the method is not a producer

1590	"Many marriages do not recover from affairs at all, but at least one-third do find some way to rebuild trust and <e1>happiness</e1> after an <e2>affair</e2>."
Other
Comment:

1591	"My dog has a <e1>fever</e1> from <e2>allergies</e2> he was given clavamox and a shot."
Cause-Effect(e2,e1)
Comment:

1592	"We sold a <e1>diamond</e1> <e2>ring</e2> on consignment through a jeweller who also dealt in second hand jewellery."
Other
Comment:

1593	"It is also when a <e1>parent</e1> manipulates a <e2>child</e2>."
Other
Comment:

1594	"The <e1>shooting</e1> stemmed from an <e2>argument</e2> the two students had "in the community" over the weekend."
Cause-Effect(e2,e1)
Comment:

1595	"The <e1>chemicals</e1> used for screen <e2>reclamation</e2> are some of the most hazardous products in a screen printing facility."
Other
Comment: Purpose-Tool

1596	"The four <e1>men</e1> are being dragged into the criminal <e2>underworld</e2>."
Other
Comment: violates b.1

1597	"While the curved shape resembles the gentle <e1>undulation</e1> of sand <e2>dunes</e2>, two raised starfish accent the border."
Other
Comment:

1598	"Part of the <e1>problem</e1> is rooted in an ill-conceived state <e2>law</e2>."
Cause-Effect(e2,e1)
Comment:

1599	"An important challenge for the new administration was to address the <e1>insecurity</e1> and poverty caused by civil <e2>war</e2>."
Cause-Effect(e2,e1)
Comment:

1600	"The old <e1>man</e1> fixed the children with a firm <e2>stare</e2>."
Other
Comment:

1601	"An Afghan handed over innocent <e1>people</e1> into <e2>torture</e2>."
Other
Comment: violates b.1 and c.3

1602	"His good taste for good cheese leads to the <e1>factory</e1>'s commercial <e2>success</e2>."
Other
Comment: success is not a product

1603	"Phone <e1>masts</e1> for the high-tech third generation mobile phones cause headaches and <e2>nausea</e2>."
Cause-Effect(e1,e2)
Comment:

1604	"Claiming to have better FM reception than the previous model, this <e1>radio</e1> <e2>tuner</e2> works with both Windows and Mac systems."
Other
Comment: modality is outside

1605	"A <e1>diapir</e1> uprises from the upward-convex silicone <e2>dome</e2>, intruding within the sand."
Other
Comment:

1606	"This acoustic <e1>instrumental</e1> (which has always been one of my favorites), makes an abrupt departure from the band's <e2>signature</e2> and dark-sounding metal riffs."
Other
Comment:

1607	"The <e1>laptop</e1> was in the <e2>desk</e2>."
Other
Comment: it is not inside the desk

1608	"The <e1>findings</e1> were from two years of DNA <e2>testing</e2> and CT scans on 16 mummies, including those of Tutankhamun and his family, the team that carried out the study said in an article to be published Wednesday in the Journal of the American Medical Association."
Other
Comment:

1609	"The immediate post-war years were a <e1>hive</e1> of <e2>ideas</e2> at Glyndebourne, some worked and others did not."
Other
Comment: Here hive refers to location or place.

1610	"Various hormonal, bacterial and inflammatory <e1>disturbances</e1> cause <e2>acne</e2>."
Cause-Effect(e1,e2)
Comment:

1611	"The Gateway DX-4822-01 <e1>computer</e1> makes a convincing pitch with the performance <e2>numbers</e2> and features to earn its place in your home."
Other
Comment:

1612	"<e1>Paralysis</e1> or convulsions are caused by hormone deficiencies and <e2>imbalances</e2>."
Cause-Effect(e2,e1)
Comment:

1613	""Suzy" probably refers to the <e1>artist</e1>'s <e2>assistant</e2>, Suzanne Miller."
Other
Comment: People are not usually classified as Instruments, unless they are clearly non-agentive in the situation. This is a collaborative work.

1614	"A sharp marginal <e1>rim</e1> starts at the anterior <e2>dorsal angle</e2> and continues around the anterior and ventral margins to the posterior-ventral angle."
Other
Comment:

1615	"Real <e1>estate</e1> builds itself out of <e2>downturn</e2>."
Other
Comment:

1616	"A detailed estimate is built up of many <e1>component</e1> <e2>parts</e2> which may result in cumulative errors."
Other
Comment: Kind of parts.

1617	"<e1>Conflict</e1> had caused the <e2>collapse</e2> of the Somali Republic."
Cause-Effect(e1,e2)
Comment:

1618	"A concise, comprehensive style is- a great ornament in narration; and a <e1>superfluity</e1> of unnecessary <e2>words</e2>, altogether improper."
Other
Comment: A kind of measurement.

1619	"The <e1>vowel length</e1> was denoted by the <e2>acute accent</e2>."
Other
Comment:

1620	"The fatal <e1>mistake</e1> caused a <e2>quarrel</e2> between different companies."
Cause-Effect(e1,e2)
Comment:

1621	"Many <e1>disorders</e1> of the stomach and intestines cause nausea and <e2>vomiting</e2>."
Cause-Effect(e1,e2)
Comment:

1622	"These are all symptoms of the muscle <e1>paralysis</e1> caused by the bacterial <e2>toxin</e2>."
Cause-Effect(e2,e1)
Comment:

1623	"A makeup <e1>artist</e1> applies the finishing <e2>touches</e2> to Marquesa Lawrence before the taping of a segment of "The Scholar.""
Other
Comment: We decided that e2 is an event rather than an entity.

1624	"Gaza <e1>families</e1> recover from three <e2>weeks</e2> of war."
Other
Comment:

1625	"We detect defect sites by chemical <e1>modification</e1> of the sites with <e2>polymers</e2>."
Other
Comment:

1626	"It was drizzling lightly in late October when the midnight <e1>shift</e1> started at the Owls Head Water pollution control <e2>plant</e2>."
Other
Comment:

1627	"It was the <e1>destruction</e1> of the gold standard by the government that caused the unprecedented <e2>collapse</e2> in the world economy."
Cause-Effect(e1,e2)
Comment:

1628	"<e1>Coughing</e1> from <e2>asthma</e2> is worse at night or early in the morning, making it hard to sleep."
Cause-Effect(e2,e1)
Comment:

1629	"5 lbs of <e1>clay</e1> made into a <e2>canister</e2> hold a 5 lb bag of flour."
Other
Comment: clay is the material out of which the canister is made.

1630	"The Obama administration supports ending the use of <e1>antibiotics</e1> for <e2>growth</e2> and feed efficiency in food animals."
Cause-Effect(e1,e2)
Comment:

1631	"The <e1>concerns</e1> were related to property <e2>taxes</e2>, sewage systems, property values, and control of school districts."
Other
Comment: Violation of (b).

1632	"The <e1>machine</e1> needs user <e2>confirmation</e2> EACH time the camera is turned on."
Other
Comment: confirmation is not a product

1633	"The primary electron <e1>beam</e1> was generated by an electrostatically focused electron <e2>gun</e2>, with a rhenium strip cathode."
Cause-Effect(e2,e1)
Comment:

1634	"CACHE designs <e1>qualifications</e1> in the <e2>care</e2> and education of children and young people."
Other
Comment:

1635	"Higher doses of <e1>cocaine</e1> cause convulsions, severe maternal weight loss and increased maternal <e2>mortality</e2>."
Cause-Effect(e1,e2)
Comment:

1636	"A <e1>dog</e1> loose on the carriageway caused a five-vehicle <e2>crash</e2> on the M25 on Wednesday morning."
Cause-Effect(e1,e2)
Comment:

1637	"The <e1>microprocessor cluster</e1> has been migrated into high-end embedded <e2>applications</e2>."
Other
Comment: violates b.1

1638	"In economic terms, <e1>pollution</e1> from fossil <e2>fuels</e2> is regarded as a negative externality and should be taxed."
Cause-Effect(e2,e1)
Comment:

1639	"Third, air and water <e1>pollution</e1> from fossil <e2>fuels</e2> are a huge problem in China."
Cause-Effect(e2,e1)
Comment:

1640	"Murmur of Water, Kuttimuratov's other piece I photographed for you, shows the Zoroastrian <e1>goddess</e1> of water with a <e2>fish</e2>."
Other
Comment:

1641	"In 1880, there was a strong <e1>typhoon</e1> and an earthquake that lead to the <e2>destruction</e2> of the instrument."
Cause-Effect(e1,e2)
Comment:

1642	"Two extra-time goals sent the <e1>team</e1> into the Carling <e2>final</e2>."
Other
Comment: violates b.1

1643	"The foreign <e1>company</e1> has entered into the insurance <e2>market</e2> in China."
Other
Comment: violates b.1

1644	"Also included is our Commission Authorization form, which collects the <e1>author</e1>'s contact <e2>information</e2> and authorizes us to retain our standard 5% commission."
Other
Comment: information is not product if the author

1645	"<e1>Speeding</e1> is one of the more obvious causes of pedestrian <e2>accidents</e2>."
Cause-Effect(e1,e2)
Comment:

1646	"The <e1>high temperature</e1> caused a <e2>decomposition reaction</e2>, increased the inner pressure of the reactor, and resulted in a rupture."
Cause-Effect(e1,e2)
Comment:

1647	"<e1>Access</e1> to Two Gateway Center is gained from a <e2>doorway</e2> just inside the Liberty Avenue vehicle entrance."
Other
Comment:

1648	"The <e1>deterioration</e1> has been caused by an apparently endless <e2>recession</e2>."
Cause-Effect(e2,e1)
Comment:

1649	"The scientific, yet understandable reasons of why the L*Bo Aid is so effective in eliminating and preventing <e1>elbow pain</e1> due to epicondylitis commonly referred to as "Tennis Elbow" and <e2>tendinitis</e2>."
Cause-Effect(e2,e1)
Comment:

1650	"The principal hazard facing the publisher with respect to reviews is getting panned by an honest <e1>book</e1> <e2>reviewer</e2> or scammed by a phony book reviewer."
Other
Comment: the reviewer is not a producer

1651	"The <e1>process</e1> departs from an <e2>inspiration</e2> and idea generation phase based on challenges the company faces in the coming years."
Cause-Effect(e2,e1)
Comment:

1652	"The <e1>decline</e1> has been caused by the <e2>immigration</e2> of lower ability immigrants."
Cause-Effect(e2,e1)
Comment:

1653	"Instead, <e1>criminal law</e1> is set out in a diverse <e2>range</e2> of statutes and court decisions."
Cause-Effect(e2,e1)
Comment: The statutes and court decisions cause law (which means "the rule of law" - a state).

1654	"Here, the <e1>coast</e1> comprises coastal <e2>lowlands</e2> that receive the many small rivers flowing from the lake-studded plains of the island's western half."
Other
Comment:

1655	"Infectious <e1>conjunctivitis</e1> is the most common cause of <e2>pinkeye</e2> around the world."
Cause-Effect(e1,e2)
Comment:

1656	"The <e1>singing</e1> comes from the substantial <e2>figure</e2> of Mole - Paul Smith in the normal world - who crams into his days a full-time job."
Cause-Effect(e2,e1)
Comment:

1657	"The <e1>bacon</e1> is home cured by our local <e2>butcher</e2> who also supplies the award winning sausages."
Other
Comment: butcher is not a producer, bacon is raw material

1658	"The damage in Washington was so much less than the <e1>damage</e1> caused by the 1994 Northridge <e2>earthquake</e2>, despite that their magnitudes were so similar-- 6.8 vs. 6.7."
Cause-Effect(e2,e1)
Comment:

1659	"Here, we analysed changes in heterozygosity over time in an insular mouflon (Ovis aries) <e1>population</e1> founded by two <e2>individuals</e2> in 1957."
Other
Comment: indirect relation: the individuals started the population but they were others involved in the act of increasing the population

1660	"In early 2007 renewed a coal mining <e1>activity</e1> in the region triggered the <e2>earthquake</e2>, although earthquake activity has been present in the area at least since white settlement first occurred."
Cause-Effect(e1,e2)
Comment:

1661	"Since last year, many <e1>people</e1> are sinking into <e2>debt</e2>."
Other
Comment: violates b.1 and c.3

1662	"This <e1>bacteria</e1> causes skin infections, colds, or <e2>diarrhea</e2>."
Cause-Effect(e1,e2)
Comment:

1663	"Brushing the air with both hands and <e1>coughing</e1> from the <e2>dust</e2>, it settled on both vehicles."
Cause-Effect(e2,e1)
Comment:

1664	"<e1>Experts</e1> said that the creation of such <e2>facilities</e2> contributes to strengthening the city's position as one of eastern Cuba's major tourist destinations."
Other
Comment: experts are not producers

1665	"<e1>Anger</e1> leads to <e2>aggressions</e2> towards colleagues."
Cause-Effect(e1,e2)
Comment:

1666	"The former <e1>emission</e1> arose from the primary collisional <e2>excitation</e2>."
Cause-Effect(e2,e1)
Comment:

1667	"A solar calendar is a calendar whose <e1>dates</e1> indicate the <e2>position</e2> of the earth on its revolution around the sun."
Other
Comment:

1668	"This sweet satisfaction was only troubled by the <e1>sorrow</e1> caused by the horrible <e2>attack</e2> on the person of a representative of the nation."
Cause-Effect(e2,e1)
Comment:

1669	"I love the sweet and salty <e1>combo</e1> of the watermelon <e2>salads</e2> that have been all over the food world lately."
Other
Comment: This is not a set: we are talking about a complex taste.

1670	"It is exciting to see the <e1>windsurfers</e1> conquer the water body with their impressive <e2>control</e2> and skills."
Other
Comment:

1671	"It's the <e1>quality</e1> inside a fertilizer <e2>bag</e2>."
Other
Comment: quality is not a content

1672	"Many depression sufferers and their physicians revealed that <e1>insomnia</e1> was caused by <e2>depression</e2>."
Cause-Effect(e2,e1)
Comment:

1673	"She wears a <e1>brace</e1> for her left <e2>ankle</e2>, has restricted use of her left hand, still has vision problems and continues with therapy."
Other
Comment: we interpret here that she is using the brace not the ankle.

1674	"The increased <e1>spending</e1> caused a <e2>strain</e2> on the state treasury as the Sultan was spending increasing amounts of time in the harem rather than leading the people."
Cause-Effect(e1,e2)
Comment:

1675	"My earliest research <e1>interest</e1> stemmed from an <e2>internship</e2> at Tall Timbers."
Cause-Effect(e2,e1)
Comment:

1676	"Here are some ways to avoid mindless eating and boost your weight <e1>loss</e1> from <e2>running</e2>."
Cause-Effect(e2,e1)
Comment:

1677	"Latest <e1>figures</e1> show <e2>unemployment</e2> in Wales is rising again despite falls in the previous two months."
Other
Comment:

1678	"The <e1>tides</e1> caused by the <e2>sun</e2> follow the exact same methods as those by the moon."
Cause-Effect(e2,e1)
Comment:

1679	"The <e1>organizers</e1> of the retreat near Lake Placid threw together a <e2>group</e2> of people on a hunch."
Other
Comment: group is not a product

1680	"This <e1>study</e1> aimed at assessing the <e2>processing time</e2> of a natural scene in a fast categorization task of its context or 'gist'."
Other
Comment: Here the study is a process; it is NOT written work. Violates (d).

1681	"Athens, in his time, was strictly a portion of feudal Europe, and the <e1>chivalry</e1> of Athenian <e2>dukes</e2> was familiar to those for whom he wrote, and wherever chivalry was in esteem; and when he described a fatal battle in the plain of Thebes, the slaughter of knights, the despair of their ladies, he recalled a great catastrophe recent in men's memories."
Other
Comment: It's a character trait, a code -- not a set.

1682	"Lionsgate has announced that they have pulled the <e1>film</e1> from its release <e2>date</e2>, but as of yet have not announced when we can expect to dee the movie in theaters."
Other
Comment: the negation is outside

1683	"I forgot to shut the bathroom door before showering and the <e1>steam</e1> set off the smoke <e2>alarm</e2> on the wall between the bathroom and my bedroom."
Cause-Effect(e1,e2)
Comment:

1684	"Characteristics of a vacuum <e1>spark</e1> triggered by the transient hollowcathode discharge electron <e2>beam</e2>."
Cause-Effect(e2,e1)
Comment:

1685	"The sliding bar <e1>assembly</e1> is attached to the removable <e2>panel</e2> and the bush is mounted to the panel's stationary support."
Other
Comment:

1686	"The <e1>electrician</e1> carries out audibility <e2>checks</e2> throughout the building during the drill."
Other
Comment:

1687	"A <e1>dehydrator</e1> is best for the <e2>drying</e2> of high moisture herbs."
Other
Comment: Purpose-Tool

1688	"Each year, many infants and toddlers die due to <e1>suffocation</e1> from <e2>breathing</e2> small objects into their breathing passages and lungs."
Cause-Effect(e2,e1)
Comment:

1689	"Aware of the <e1>suffering</e1> caused by the <e2>destruction</e2> of life, I am committed to cultivating compassion and learning ways to protect the lives of people, animals, plants, and minerals."
Cause-Effect(e2,e1)
Comment:

1690	"Even way back in the San Francisco earthquake, most of the damage was caused by <e1>fire</e1> after the <e2>earthquake</e2>."
Cause-Effect(e2,e1)
Comment:

1691	"The <e1>company</e1> has entered into a reseller <e2>agreement</e2>."
Other
Comment: violates c.3

1692	"More <e1>people</e1> are falling into <e2>poverty</e2>, especially those already struggling to make ends meet."
Other
Comment: violates b.1 and c.3

1693	"The <e1>decade</e1> produced a bumper <e2>crop</e2> of great movies."
Other
Comment: decade is not a producer

1694	"The <e1>trail</e1> starts at an <e2>elevation</e2> of 5600' and steadily climbs to the top of a 6850' promontory overlooking Pine and Juniper Canyons."
Other
Comment:

1695	"The <e1>smile</e1> runs away from the kid's <e2>face</e2>."
Other
Comment:

1696	"They are navigational <e1>maps</e1> based on realistic <e2>descriptions</e2> of harbours and coasts."
Other
Comment: Descriptions are the source of/for maps.

1697	"The <e1>bottom</e1> is welded into each monoseal <e2>casket</e2> using a continuous weld aldong the entire seam."
Other
Comment: no indication for Content-Container relation

1698	"He's stuffed <e1>pork</e1> into <e2>defense</e2> and homeland security."
Other
Comment: This CANNOT be Entity-Destination; it violates E-D's b.1.

1699	"Liver <e1>cancer</e1> caused by HBV <e2>virus</e2> is among the first three causes of death from cancer in men, and a major cause of cancer in women."
Cause-Effect(e2,e1)
Comment:

1700	"A common side effect of strict elimination after extended periods of use is <e1>headaches</e1> from <e2>caffeine withdrawal</e2>, which is also a clear sign of the addiction."
Cause-Effect(e2,e1)
Comment:

1701	"The <e1>war</e1> resulted in other collateral imperial <e2>conquests</e2> as well."
Cause-Effect(e1,e2)
Comment:

1702	"I hear it, too, in the lovely expansiveness of his work as a <e1>chamber</e1> <e2>musician</e2>."
Other
Comment: chamber is not a product

1703	"The teenager fell seriously ill after receiving the <e1>injection</e1>, along with thousands of other <e2>pupils</e2> across Northern Ireland last Friday."
Other
Comment:

1704	"The <e1>light</e1> that is currently reaching the Earth was generated in the <e2>sun</e2> approximately 100000 years ago."
Cause-Effect(e2,e1)
Comment:

1705	"The bounded <e1>applicability</e1> of the Perceptron arose from the <e2>linearity</e2> of its modifiable decision rule."
Cause-Effect(e2,e1)
Comment:

1706	"The shock <e1>wave</e1> was generated by an <e2>explosive</e2> made from RDX."
Cause-Effect(e2,e1)
Comment:

1707	"At that time there was also a Renaissance <e1>building</e1> founded by the <e2>wall</e2>."
Other
Comment: wall is not a producer

1708	"Lycophytes are vascular plants in the class Lycopodiopsida, a division of vascular plants known as Pteridophytes (the <e1>ferns</e1> and their <e2>allies</e2>)."
Other
Comment: This relation is symmetric in a way that Instrument-Agency isn't.

1709	"The <e1>department</e1> achieved the goal with a 75% <e2>reduction</e2> in accidents."
Other
Comment:

1710	"In a literature review of 875 cases of Merkel cell carcinoma, the <e1>tumor</e1> was the cause of <e2>death</e2> in 34% of these patients."
Cause-Effect(e1,e2)
Comment:

1711	"The <e1>instability</e1> grows from an <e2>perturbation</e2> whose initial amplitude is small."
Cause-Effect(e2,e1)
Comment:

1712	"Both <e1>praise</e1> and blame cause <e2>concern</e2>, for they bring people hope and fear."
Cause-Effect(e1,e2)
Comment:

1713	"This article is about pre-existing <e1>conditions</e1> with respect to <e2>health insurance</e2>."
Other
Comment: If the sentence was annotated: This <e1>article<e2> is about pre-existing <e2>conditions</e2> with respect to health insurance., then we would have had have Message-Topic.

1714	"The dreary tenement scene is architecturally reminiscent of the neighbourhood of Fagin's <e1>den</e1> of <e2>child-thieves</e2> in Oliver Twist."
Other
Comment: Location, as per Dickens (but there is sense ambiguity here; see Webster: 4: a subdivision of a Cub Scout pack made up of two or more boys).

1715	"A method of mitigating the effect of a market <e1>spike</e1> caused by the triggering and the <e2>election</e2> of a conditional order includes monitoring conditional orders."
Cause-Effect(e2,e1)
Comment:

1716	"My <e1>friend</e1> has entered into a new <e2>relationship</e2>."
Other
Comment: violates c.3

1717	"The <e1>deaths</e1> of Israelis caused by <e2>terror</e2> are permanent and irreversible whereas the hardships faced by the Palestinians are temporary and reversible."
Cause-Effect(e2,e1)
Comment:

1718	"<e1>Job dissatisfaction</e1> is one of the main causes of <e2>stress</e2> and stress is one of the main causes of illness."
Cause-Effect(e1,e2)
Comment:

1719	"The <e1>stroke</e1>, which was triggered by a <e2>bout</e2> of chicken pox, also weakened her arteries so much that doctors said she had the brain 'of an 80-year-old'."
Cause-Effect(e2,e1)
Comment:

1720	"Commuters and holiday <e1>travellers</e1> are running into heavy <e2>delays</e2> on Route 128 in Weston this morning."
Other
Comment: violates b.1 and c.3

1721	"The <e1>aerosol</e1> was generated from an oxalic <e2>acid solution</e2> containing only the tracer."
Other
Comment:

1722	"The <e1>delay</e1> in the progression of these applications has been caused by the original <e2>applicants</e2>."
Cause-Effect(e2,e1)
Comment:

1723	"About two hours later, officers got an anonymous tip that the <e1>gunman</e1> was inside a nearby <e2>apartment building</e2>."
Other
Comment: this example states the location of the gunman

1724	"The executioners have carried the <e1>scholar</e1> into <e2>exile</e2>."
Other
Comment: violates c.3

1725	"Boslough and colleagues achieved fame more than a decade ago by accurately predicting that that the <e1>fireball</e1> caused by the <e2>intersection</e2> of the comet Shoemaker-Levy 9 with Jupiter is observable from Earth."
Cause-Effect(e2,e1)
Comment:

1726	"Declining oil revenues have dragged this poor <e1>country</e1> into even deeper <e2>recession</e2>."
Other
Comment: violates c.3

1727	"Here are reside meningococcal bacilli in the vaccine and it is accessible to bolt the ache or become a carrier of the <e1>ache</e1> from the <e2>vaccine</e2>."
Cause-Effect(e2,e1)
Comment:

1728	"The <e1>student</e1> demonstrates his/her understanding through active <e2>participation</e2> in the learning process."
Other
Comment: The feeling here is that e2 is not a method, just an event. It's a bit wooly.

1729	"HC <e1>lawyers</e1> entered into a <e2>scuffle</e2> over the division of AP."
Other
Comment: violates b.1 and c.3

1730	"The <e1>slope</e1> is going away from the <e2>house</e2>."
Other
Comment:

1731	"There are <e1>charts</e1> for all <e2>land masses</e2> on Earth, and long-distance charts for trans-oceanic travel."
Other
Comment: This is Purpose-Tool and thus Other; note "for". Charts communicate structure, if at all, not land masses.

1732	"The <e1>initiative</e1>, called The Big Switch Off, aims to reduce <e2>energy consumption</e2> by turning off lights and unused appliances."
Other
Comment: initiative are not Messages.

1733	"Good <e1>breeding</e1> consists of <e2>concealing</e2> how much we think of ourselves and how little we think of the other person."
Cause-Effect(e1,e2)
Comment: Good breeding causes certain behaviour. (It is an iffy diagnosis.)

1734	"The <e1>bruises</e1> are caused by the attacker's <e2>fingertips</e2> pressing into the skin."
Cause-Effect(e2,e1)
Comment:

1735	"<e1>Fog</e1>, rain, darkness, and or blowing snow lead to <e2>disorientation</e2>."
Cause-Effect(e1,e2)
Comment:

1736	"Fungal growth and aflatoxin <e1>contamination</e1> are caused by the following factors: warm temperature, high <e2>humidity</e2> and poor soil condition."
Cause-Effect(e2,e1)
Comment:

1737	"The <e1>tides</e1> are caused by the <e2>gravitational force</e2> of the Moon."
Cause-Effect(e2,e1)
Comment:

1738	"By now an SEO-minded <e1>attendee</e1> has journeyed deep into advanced SEO <e2>concepts</e2>."
Other
Comment: violates b.1

1739	"Reducing the <e1>harm</e1> caused by the <e2>War</e2> on Drugs is a big task."
Cause-Effect(e2,e1)
Comment:

1740	"I recently decided to work a bit outside of Visual Studio and configure a plain text <e1>editor</e1> to work with the C# <e2>compiler</e2>."
Other
Comment: e1 and e2 are interacting, but neither is really using the other

1741	"Five ancient <e1>temples</e1> have fallen into <e2>disrepair</e2>."
Other
Comment: violates b.1 and c.3

1742	"The request to alter the voice to a great extent has resulted in exaggerated deviations from the "normally" accepted opera <e1>singer</e1>'s <e2>timbre</e2>."
Other
Comment: e2 is a property of e1.

1743	"The <e1>reindeer</e1> made his television <e2>debut</e2> on NBC in 1964, when Rankin/Bass produced a stop-motion animated TV special."
Other
Comment:

1744	"Sotheby's yesterday in Hong Kong sold a <e1>diamond</e1> <e2>ring</e2> containing a 8.74 carat blue diamond for 3.5m pounds."
Other
Comment:

1745	"When these fuels are burned, they create air <e1>pollution</e1> that contributes to global warming and causes smog, acid rain and respiratory <e2>disease</e2>."
Cause-Effect(e1,e2)
Comment:

1746	"The Financial Regulator today amended the code of conduct of mortgage arrears by increasing the <e1>moratorium</e1> from six <e2>months</e2> to 12 months."
Other
Comment:

1747	"In psychology, Eysenck Personality Questionnaire (EPQ) is a <e1>questionnaire</e1> to assess the personality <e2>traits</e2> of a person."
Other
Comment: Purpose.

1748	"My friend got a <e1>rash</e1> from a mosquito <e2>bite</e2> and Westcort helped her but it left a scar so she also put on Mederma after the rash went away."
Cause-Effect(e2,e1)
Comment:

1749	"It really underscores everything in the pro-life movement, that <e1>abortion</e1> is part of a very sad <e2>story</e2> for women."
Other
Comment:

1750	"The floating zenith <e1>telescope</e1> has come into formal observatory <e2>routine</e2> since September."
Other
Comment: violates b.1 and c.3

1751	"These <e1>germs</e1> cause illnesses ranging from common ailments, like the cold and <e2>flu</e2>, to disabling."
Cause-Effect(e1,e2)
Comment:

1752	"The greatest impact of the tsunami was generally in an east-west direction, so the <e1>havoc</e1> caused by the <e2>tsunami</e2> along the southwestern shores of Sri Lanka was not as severe as along the eastern coast."
Cause-Effect(e2,e1)
Comment:

1753	"The <e1>blisters</e1> are caused by <e2>moisture</e2> that was actually trapped in between the layers of paint."
Other
Comment:

1754	"Orientation is towards the future, and <e1>satisfaction</e1> is gained from <e2>feelings</e2> of progress."
Other
Comment:

1755	"<e1>Scleroderma</e1> is a disease of the body's connective tissue that causes thickening and <e2>hardening</e2> of the skin."
Cause-Effect(e1,e2)
Comment:

1756	"The developmental <e1>bureaucracy</e1> has come into <e2>being</e2>."
Other
Comment: violates c.3

1757	"The <e1>cramps</e1> are caused by the <e2>anxiety reaction</e2> but because the sufferer has high anxiety, they can be interpreted in other ways; fears grow and the anxiety worsens."
Cause-Effect(e2,e1)
Comment:

1758	"All 18 of the <e1>men</e1> assist that <e2>season</e2>."
Other
Comment:

1759	"The <e1>website</e1> is concerned with the <e2>dissemination</e2> and exchange of information about the EnCoRe project."
Other
Comment: Purpose.

1760	"Germany produced many of the bottle stopper <e1>marbles</e1> made by this <e2>method</e2>."
Other
Comment: method is not a producer and it is not actively involved in the production

1761	"A <e1>fuel leak</e1> in one of the C-17s caused a <e2>delay</e2> on the morning of Nov. 7 as the crew was preparing for departure for Cairo, Egypt."
Cause-Effect(e1,e2)
Comment:

1762	"<e1>Pinworm</e1> <e2>infestation</e2> is very rarely fatal; death and morbidity are from secondary infection."
Cause-Effect(e1,e2)
Comment:

1763	"The <e1>lava</e1> has been blown into great <e2>bubbles</e2>."
Other
Comment: violates c.1

1764	"Some accounts detail the routine and perfunctory nature of arrest and proceedings against the <e1>riffraff</e1> of the "criminal <e2>classes</e2>" (Friedman and Percival)."
Other
Comment:

1765	"An advance <e1>visit</e1> was made by <e2>staff</e2> to arrange the visits."
Other
Comment:

1766	"The <e1>drugs</e1> he sold had caused the overdose <e2>death</e2> of Matthew Lessard, 19, of Lowell."
Cause-Effect(e1,e2)
Comment:

1767	"The <e1>jar</e1> from the fall had caused a subdural <e2>hematoma</e2> on the right front side of my brain that shows up in the CT."
Cause-Effect(e1,e2)
Comment:

1768	"The Hip Hop National <e1>interschool</e1> is rescheduled to the 1st <e2>week</e2> of July."
Other
Comment:

1769	"Davies, the <e1>writer</e1> behind award-winning BBC <e2>adaptations</e2> of Bleak House, Little Dorrit and Pride and Prejudice, blamed what he called a "new breed" of BBC executives."
Other
Comment:

1770	"In February of 1885 the <e1>news</e1> reached the city by <e2>telegraph</e2> that Indians and half breeds had massacred a number of white people at Duck Lake."
Other
Comment: e1 is not an Agent.

1771	"At his inauguration in November, he pledged a fresh start after an election marred by fraud and violence, but disappointed many by presenting a <e1>cabinet</e1> of familiar <e2>names</e2>."
Other
Comment: Double metonymy, a bit much. People are members of a government, but names are not members of a cabinet of ministers.

1772	"<e1>Earthquakes</e1> are caused by the <e2>discharge</e2> of accumulated along geologic faults."
Cause-Effect(e2,e1)
Comment:

1773	"The <e1>outdoor unit</e1> is going into <e2>defrost</e2>."
Other
Comment: violates c.3

1774	"<e1>Oscillation</e1> of the lever caused by the <e2>swinging</e2> of the pendulum."
Cause-Effect(e2,e1)
Comment:

1775	"Method according to claim 1, characterized in that the time duration of the quality reduction is limited at least to the duration of the <e1>interference</e1> triggered by the switching <e2>process</e2>."
Cause-Effect(e2,e1)
Comment:

1776	"Student <e1>protests</e1> are turning into a Twitter <e2>revolution</e2> in Moldova."
Cause-Effect(e1,e2)
Comment:

1777	"Glacial <e1>landscapes</e1> are parts of the <e2>earth</e2> that were covered by glaciers during the last Ice Age."
Other
Comment:

1778	"While Twitter is a powerful social <e1>medium</e1> for spreading <e2>news</e2> and information, some government agencies fear it could also be used by terrorists as a tool for communication."
Other
Comment: Purpose-Tool, so - Other; the modality is outside e1-e2

1779	"Nasal <e1>dryness</e1> causes nosebleeds, <e2>coughing</e2>, wheezing, and other short-term respiratory problems."
Cause-Effect(e1,e2)
Comment:

1780	"The <e1>building</e1> was surrounded by <e2>police</e2> who arrested three people as they tried to gain access."
Other
Comment: the police is not the producer of the building

1781	"Colds and <e1>flu</e1> cause <e2>inflammation</e2> of the mucous membranes of the nose, throat and mouth."
Cause-Effect(e1,e2)
Comment:

1782	"The internal <e1>payoff</e1> is rooted in the psychological <e2>cost</e2> of preference falsification."
Other
Comment:

1783	"The government has spended the following 18 months before the elections in a similar vein - shooting a whole <e1>lead</e1> of Conservative <e2>foxes</e2>, to extend the metaphor - namely Heathrow and Royal Mail privatisation."
Other
Comment: Too metaphorical.

1784	"Defra identified the different <e1>noises</e1> made by <e2>dogs</e2> and the meanings behind them."
Cause-Effect(e1,e2)
Comment:

1785	"Annulment is a <e1>legal procedure</e1> for declaring a <e2>marriage</e2> null and void."
Other
Comment: It's a procedure, not a message - violates (d)

1786	"They stored the <e1>wine</e1> in a cool <e2>temperature</e2>."
Other
Comment: temperature is not a container for wine and vice versa; nor is it Destination

1787	"The <e1>company</e1> moved into the music <e2>business</e2>."
Other
Comment: violates b.1

1788	"The Maryland Department of the Environment has already worked to reduce the amount of <e1>pollution</e1> from sources like cars and <e2>factories</e2>."
Cause-Effect(e2,e1)
Comment:

1789	"<e1>Soya farming</e1> is one of the main causes of tropical <e2>deforestation</e2>, which currently produces a fifth of global climate change."
Cause-Effect(e1,e2)
Comment:

1790	"The encroaching <e1>darkness</e1> has been caused by the twin horrors of war and a mysterious <e2>plague</e2>."
Cause-Effect(e2,e1)
Comment:

1791	"Since the <e1>complex</e1> was built in <e2>stages</e2>, discrepancies exist in completion dates due to differing opinions on "completion"."
Other
Comment:

1792	"A <e1>mason</e1> has removed the original left and right <e2>edges</e2> and in their place has prepared a simple moulding on each side."
Other
Comment: edges is not a product

1793	"Alzheimer's disease is a degenerative brain <e1>disorder</e1> that results in <e2>memory loss</e2>, impaired thinking, difficulty finding the right word when speaking, and personality changes (see "Warning signs of Alzheimer's disease," below)."
Cause-Effect(e1,e2)
Comment:

1794	"The clock <e1>signal</e1> was generated from an external cavity semiconductor <e2>laser</e2>."
Cause-Effect(e2,e1)
Comment:

1795	"Only a <e1>minority</e1> of Armenian <e2>physicians</e2> felt well prepared to counsel patients to quit smoking."
Other
Comment: Measure.

1796	"The <e1>team</e1> captured the provincial title with a convincing 6-1 <e2>victory</e2> over their adversaries, the Pas Huskies."
Other
Comment: victory is an event and can't be an Instrument.

1797	"A University of Washington system named Hubble looks for these black holes and maps them on a Web site, providing an ever-changing <e1>constellation</e1> of the Internet's weak <e2>points</e2>."
Other
Comment: A constellation is a spatial arrangement.

1798	"The <e1>landslides</e1> caused by these earthquakes and <e2>aftershocks</e2> were concentrated along the mudstone and sandstone surfaces."
Cause-Effect(e2,e1)
Comment:

1799	"The desperate <e1>man</e1> who had clung to the stump had battered the rocks with a shuddering <e2>thump</e2>."
Cause-Effect(e1,e2)
Comment: the man action has caused the thump (noise).

1800	"This <e1>document</e1> makes a significant contribution into further <e2>clarification</e2> of the access to drinking water as a human right."
Other
Comment: There is a contribution to clarification, but not clarification itself. The document is about "access to drinking water". But given the e2, Other is right.

1801	"Systemically, dust and <e1>fume</e1> cause irritation of the upper respiratory tract, metallic taste and <e2>nausea</e2>."
Cause-Effect(e1,e2)
Comment:

1802	"The <e1>dust</e1>, noise, and sleep deprivation produced by the <e2>construction</e2> are intolerable."
Cause-Effect(e2,e1)
Comment:

1803	"The NRMA's president, Wendy Machin, and the chief executive, Tony Stuart, were among members of the <e1>party</e1> which viewed the concert in a private <e2>box</e2>."
Other
Comment:

1804	"The picture at the top shows a <e1>farmer</e1> with a genetically engineered cotton <e2>plant</e2> in South Africa in 2003."
Other
Comment: Product-Producer might be implicit, but there's no direct evidence.

1805	"Integrated <e1>production schemes</e1> are spreading into various <e2>crops</e2> and may have relevance for sectors such as dairy production."
Other
Comment: the crops are not the destination of the schemes - rather their object; modality is outside

1806	"The <e1>transmitter</e1> sends a radio <e2>signal</e2> to the doorbell radio receiver inside the building."
Cause-Effect(e1,e2)
Comment:

1807	"They are all in on it and the same <e1>people</e1> who caused the <e2>destruction</e2> of the economy are still running the show so they can keep us down and buy up the country cheap."
Cause-Effect(e1,e2)
Comment:

1808	"In two of the cases reported in the media, an older woman's baby was stillborn because of an abnormal placeta, and one of the <e1>miscarriages</e1> was caused by the umbilical <e2>chord</e2> encircling the fetus."
Cause-Effect(e2,e1)
Comment:

1809	"When it was closer she saw the <e1>light</e1> was coming from a <e2>flashlight</e2> being carried in the mouth of a large black Scottie dog, its muzzle gray with age."
Cause-Effect(e2,e1)
Comment:

1810	"The <e1>building</e1> leaked from every conceivable <e2>place</e2>."
Other
Comment:

1811	"Both goals were addressed, but the primary goal of the <e1>street</e1> <e2>furniture</e2> was to enhance the quality of life for people in Phildaelphia and the secondary goal was to increase revenue for the City of Philadelphia."
Other
Comment: Seems more "located in" than "part of"

1812	"The jury's <e1>deliberations</e1> were reported weekly on <e2>air</e2>."
Other
Comment: Air is a medium.

1813	"<e1>Vulvodynia</e1> is the cause of chronic <e2>vulval pain</e2> in the absence of skin disease and infection."
Cause-Effect(e1,e2)
Comment:

1814	"This movie has thrown <e1>viewers</e1> into <e2>confusion</e2>."
Other
Comment: violates b.1 and c.3

1815	"Olympic chiefs are worried about the environmental <e1>damage</e1> caused by the Olympic <e2>flame</e2>."
Cause-Effect(e2,e1)
Comment:

1816	"The log truck caught <e1>fire</e1> after the <e2>collision</e2>, but the 35-year-old driver escaped before the cab became engulfed in flames."
Cause-Effect(e2,e1)
Comment:

1817	"The <e1>aeroplane</e1> was withdrawn from that <e2>duty</e2> and confined to low-level flying, where it became a success."
Other
Comment:

1818	"I have an additional concern about body exposure to any electromagnetic <e1>radiation</e1>, from <e2>computers</e2> and cell phones held next to the body."
Cause-Effect(e2,e1)
Comment:

1819	"The <e1>spill</e1> was caused by a <e2>leak</e2> in a Kuwaiti tanker carrying 160,000 tonnes of crude, after it collided with a dredger further south on December 14."
Cause-Effect(e2,e1)
Comment:

1820	"Josie Cormier, succumbed to peer pressure and now hangs out with the popular <e1>crowd</e1> that often instigates the <e2>harassment</e2>."
Cause-Effect(e1,e2)
Comment:

1821	"He had visited Myer's during the afternoon and bought a <e1>gold</e1> <e2>bracelet</e2> for $300."
Other
Comment:

1822	"The saving from the introduction of a single <e1>machine</e1> for flange hole <e2>drilling</e2> was 15500 rubles."
Other
Comment: Purpose-Tool

1823	"Her unexpected <e1>elimination</e1> caused a <e2>riot</e2> on the Internet, and one blog site (SOHH.com) referred to her elimination episode as the one where the show lost all credibility."
Cause-Effect(e1,e2)
Comment:

1824	"Their standard variable <e1>rates</e1> are still under <e2>review</e2>."
Other
Comment: a process

1825	"I changed the balance of the flavours through my selection of bread, and got an <e1>increase</e1> in the sweetness with a choice of <e2>raisin bread</e2>."
Cause-Effect(e2,e1)
Comment: Why not Cause-Effect?

1826	"<e1>Children</e1> in rural Southern areas fell into <e2>poverty</e2> faster than those in cities in 2008."
Other
Comment: violates b.1 and c.3

1827	"Our <e1>inquiry</e1> into the city's job creation funding came from a reader's <e2>tip</e2>."
Cause-Effect(e2,e1)
Comment:

1828	"It is very natural and normal to feel grief and <e1>sorrow</e1> after the <e2>loss</e2> of a pet."
Cause-Effect(e2,e1)
Comment:

1829	"The dog, owned by Steve Abbott, the singer's manager, is stranger to music and has reacted to the <e1>sounds</e1> made by any other of Universal's top <e2>names</e2>."
Other
Comment: the names are not actively involved in the production. "... performance of previously-existing works are not considered to be creative acts."

1830	"The <e1>irritation</e1> from the <e2>chemicals</e2> in the tobacco is considered to be the number one contributing factor."
Cause-Effect(e2,e1)
Comment:

1831	"The exit portion of the <e1>runway</e1> is cantilevered from the support <e2>stanchion</e2>."
Other
Comment:

1832	"The <e1>smell</e1> was radiating from all directions, from every <e2>tree</e2> and branch."
Cause-Effect(e2,e1)
Comment:

1833	"The town's population is approximately four, the school closed years ago and <e1>birds</e1> have turned the church into a poop-caked <e2>aviary</e2>."
Other
Comment: aviary is not a product

1834	"The <e1>party</e1> has made the <e2>crazies</e2> into mainstream Republicans."
Other
Comment: crazies is not a product

1835	"The <e1>lymphomas</e1> are divided into two major categories: Hodgkin lymphoma and all other <e2>lymphomas</e2>, called non-Hodgkin lymphomas."
Other
Comment: The Member-Collection definition calls this "Class-Member"

1836	"The children sent their <e1>marriage</e1> into a <e2>downward spiral</e2>."
Other
Comment: violates c.3

1837	"Thousands of women suffer <e1>headaches</e1> from <e2>caffeine withdrawal</e2> as a result of this study."
Cause-Effect(e2,e1)
Comment:

1838	"Once again, the infamous <e1>politician</e1> has landed into a nepotism <e2>controversy</e2>."
Other
Comment: violates b.1 and c.3

1839	"Up to 85% of <e1>viruses</e1> that cause respiratory <e2>illness</e2> are identified by the technology."
Cause-Effect(e1,e2)
Comment:

1840	"In recent years, considerable <e1>attention</e1> has been focused on regenerative <e2>medicine</e2> because of its applicability to a wide range of medical fields."
Other
Comment: violation of (a)

1841	"The <e1>study</e1> is making a valuable contribution to determining the <e2>levels</e2> of sustainable tourism in this country."
Other
Comment: The study is about something, but that something is not named.

1842	"The recovery plan was the commencement of a captive breeding <e1>program</e1> from a small wild <e2>population</e2>."
Other
Comment:

1843	"The <e1>disruption</e1> has been caused by the freak storms and flash <e2>floods</e2> overnight."
Cause-Effect(e2,e1)
Comment:

1844	"An organization with the mission of allowing a safe haven for parents to share their <e1>grief</e1> after the <e2>death</e2> of a child."
Cause-Effect(e2,e1)
Comment:

1845	"I have been talking extensively here about the <e1>disruption</e1> that has been caused by the Brazilian Air Traffic Controllers white <e2>strike</e2>."
Cause-Effect(e2,e1)
Comment:

1846	"The <e1>detectives</e1> have been dragged into a mysterious <e2>case</e2>."
Other
Comment: violates b.1

1847	"Legislators are considering new <e1>limits</e1> on <e2>stem cell research</e2>."
Other
Comment:

1848	"Air <e1>pollution</e1> from <e2>coal</e2> fired sources is so serious we can not afford a policy that backslides in any way."
Cause-Effect(e2,e1)
Comment:

1849	"The <e1>satellite</e1> has been placed into <e2>service</e2>."
Other
Comment: violates b.1 and c.3

1850	"In these cases, marriages performed in the <e1>temple</e1> by a duly authorized temple <e2>sealer</e2> are recognized by the government."
Other
Comment: the sealer is not a producer of the temple

1851	"Many viral <e1>infections</e1> that cause <e2>rash</e2> resolve within several days and require no medication."
Cause-Effect(e1,e2)
Comment:

1852	"The kind of treatments necessary to kill the <e1>bacteria</e1> which cause acne <e2>breakouts</e2> must be prescribed or administered by a medical professional."
Cause-Effect(e1,e2)
Comment:

1853	"The <e1>opposition leader</e1> has gone into <e2>hiding</e2>."
Other
Comment: violates b.1 and c.3

1854	"I had another <e1>idea</e1> to do with <e2>child care</e2> that was stroller related."
Other
Comment: violation of (b).

1855	"I've just sold a <e1>gold</e1> <e2>ring</e2>, which was my last asset and now we have nothing left for a better life."
Other
Comment:

1856	"<e1>Blinking</e1> is caused by the <e2>eyelids</e2> sliding down over the positively charged cornea, whereas saccade potentials are caused by changes in the orientation of the corneoretinal dipole."
Cause-Effect(e2,e1)
Comment:

1857	"The surprise <e1>visit</e1> caused a <e2>frenzy</e2> on the already chaotic trading floor."
Cause-Effect(e1,e2)
Comment:

1858	"But I am trying to get a week <e1>number</e1> from a given <e2>date</e2>."
Other
Comment:

1859	"An agenda of deeper reforms can boost public confidence even as it undoes a lot of the <e1>distress</e1> caused by the financiers and <e2>bankers</e2>."
Cause-Effect(e2,e1)
Comment:

1860	"Be sure to drink plenty of water to prevent running a <e1>fever</e1> from <e2>dehydration</e2>."
Cause-Effect(e2,e1)
Comment:

1861	"Our first <e1>sighting</e1> of the mighty Mount Kinabalu was from quite a <e2>distance</e2> and it was still extremely impressive."
Other
Comment:

1862	"The consequences of the <e1>injuries</e1> caused by the <e2>bike-accident</e2> in February, fractures in the area of head and neck, unfortunately have turned out to be still too severe."
Cause-Effect(e2,e1)
Comment:

1863	"The <e1>agency</e1> also provides a third of the region's power <e2>supply</e2>, drawn mostly from generators inside big dams."
Other
Comment: agency is not a producer

1864	"More people know and understand their <e1>rights</e1> on issues such as <e2>benefits</e2>, housing and employment."
Other
Comment: A kind of.

1865	"The passenger set off the <e1>devices</e1> at Detroit Metropolitan Airport, causing a <e2>commotion</e2> and some injuries."
Other
Comment:

1866	"The <e1>association</e1> keeps teachers informed about current <e2>developments</e2>."
Other
Comment:

1867	"The amide-linked local <e1>anesthetics</e1>, bupivacaine and ropivacaine, cause <e2>depression</e2> of cardiac contractility and dysrhythmias."
Cause-Effect(e1,e2)
Comment:

1868	"From the transistor radio you listened to under the <e1>pillow</e1> of your <e2>bed</e2> to streamcasts on the Net, Fisher covers it all, and extremely well."
Other
Comment:

1869	"The functionalist <e1>approach</e1> tries to explain the <e2>convergence</e2> of modern welfare states."
Other
Comment: Internalized -- see restriction (b).

1870	"Aware of the <e1>suffering</e1> caused by unmindful <e2>drinking</e2>, I am committed to cultivate good health, both physical and mental, for myself, my family, and my society."
Cause-Effect(e2,e1)
Comment:

1871	"This <e1>configuration</e1> of <e2>dominoes</e2> is called the layout, string, or line of play."
Other
Comment:

1872	"Milinkovich, executive director for life of the Eclipse Foundation (just kidding Mike) broke the <e1>news</e1> today in his <e2>blog</e2>."
Other
Comment: A blog is a communication channel.

1873	"Oak root and chamomile provide a gentle astringent that helps reduce inflammation and calms skin <e1>irritation</e1> from the <e2>sun</e2> and environmental pollutants."
Cause-Effect(e2,e1)
Comment:

1874	"The <e1>colitis</e1> usually is caused by taking <e2>antibiotics</e2>."
Cause-Effect(e2,e1)
Comment:

1875	"This lowly structure is preserved and protected from decay by having built over it an outer <e1>structure</e1> surmounted by a great <e2>dome</e2> of glass."
Other
Comment: dome is not a producer

1876	"The <e1>protein molecule</e1> has come into <e2>existence</e2> by natural processes."
Other
Comment: violates c.3

1877	"The halting of easy <e1>profits</e1> from <e2>inflation</e2> brought on a banking crisis, which resulted in a complete restructuring of the industry during the late 1990s."
Cause-Effect(e2,e1)
Comment:

1878	"Overall, the <e1>fire</e1> after the <e2>earthquake</e2> burned out 7456 houses in over 530 localities."
Cause-Effect(e2,e1)
Comment:

1879	"The <e1>hero</e1> initially attempts to stop the train with his own <e2>strength</e2>, but fails miserably and doesn't slow the train down."
Other
Comment:

1880	"Remaining under the same influence, it was in the natural <e1>order</e1> of <e2>events</e2> that John, a little later, recorded his awakening into the new life at a religious meeting at a quarter before nine o'clock on the evening of May 24th 1738."
Other
Comment:

1881	"The northwest <e1>swell</e1> was generated by a powerful <e2>storm</e2> off Japan on Jan. 5 and gained strength last week."
Cause-Effect(e2,e1)
Comment:

1882	"In the same way that diet and <e1>stress</e1> effect facial <e2>acne</e2> they also effect body acne therefore the basic "clear skin rules" of cutting out greasy, fatty foods, and sugary foods as well as trying to reduce everyday stress apply to body acne as well."
Cause-Effect(e1,e2)
Comment:

1883	"This latest <e1>adventure</e1> from the animation <e2>wizards</e2> at Pixar is beautiful, masterly, inspired - and delivers a powerful ecological message."
Other
Comment: no product-producer is involved

1884	"<e1>Hairdressing</e1> with <e2>color</e2> has become a common trend these days."
Other
Comment:Purpose-Tool

1885	"The height-time profiles revealed that the <e1>downflow</e1> started at <e2>times</e2> of the deceleration phase of the CME core."
Other
Comment:

1886	"The <e1>team</e1> won the Association's championship with some <e2>regularity</e2>."
Other
Comment:

1887	"The <e1>wire</e1> had caused a slight <e2>injury</e2> on the ventral side of the neck and at the base of horns."
Cause-Effect(e1,e2)
Comment:

1888	"The industrial chemical <e1>melamine</e1> was found in a <e2>sample</e2> of infant formula made in the USA."
Other
Comment: not a container (so cannot be C-C), and substances can't be components (so cannot be C-W)

1889	"Who buys all these glittering <e1>diamond</e1> <e2>colliers</e2>, rings, pendants, etc., eto., is. a mystery."
Other
Comment:

1890	"Better&Partners Communications is an advertising <e1>agency</e1> specialized in TV <e2>ads</e2>, outdoors, media, marketing, consulting, press, etc..."
Other
Comment:

1891	"The spread is mainly airborne, via the virus-laden <e1>droplets</e1> produced by coughing and <e2>sneezing</e2>."
Other
Comment: sneezing is a process

1892	"Special articles specifically on gas corrosion and <e1>stress</e1> <e2>corrosion</e2> are also available in the literature."
Cause-Effect(e1,e2)
Comment:

1893	"Recent traffic studies by the department show that a majority of the <e1>accidents</e1> are caused by <e2>drivers</e2>."
Cause-Effect(e2,e1)
Comment:

1894	"Chest <e1>pain</e1> from <e2>indigestion</e2> feels like an intense burning and is usually accompanied by regurgitation and gas."
Cause-Effect(e2,e1)
Comment:

1895	"It was intermittently wet and dry, and almost always followed with a whine and often a few <e1>tears</e1> from the terrible <e2>pain</e2>."
Cause-Effect(e2,e1)
Comment:

1896	"The mite's <e1>burrows</e1>, fecal matter, proteins and eggs cause itching, <e2>rashes</e2> and sensitivity."
Cause-Effect(e1,e2)
Comment:

1897	"It also uses the <e1>intranet</e1> to inform staff about <e2>training opportunities</e2> or forthcoming staff events."
Other
Comment: Here we have a channel rather than a message.

1898	"The kiosk was placed at a statewide <e1>convention</e1> of science <e2>teachers</e2> and in a high school science classroom."
Other
Comment: Participants -- not members: participants as agents or co-agents in an event.

1899	"Thus previous scientific estimates had overstated the <e1>devastation</e1> caused by the <e2>asteroid</e2>, since topographic and ecologic factors contributing to the result had not been taken into account."
Cause-Effect(e2,e1)
Comment:

1900	"The analysis <e1>device</e1> instigates the <e2>termination</e2> of the connection."
Cause-Effect(e1,e2)
Comment:

1901	"Kids built forts and tree <e1>houses</e1> in the <e2>woods</e2> out of materials swiped from the construction sites that would eventually render those woods someone's back yard."
Other
Comment: Houses are located in the woods. modality is outside

1902	"Either we saw our mothers show <e1>fear</e1> from <e2>bugs</e2> /spiders/cockroaches and learned to fear them irrationally."
Cause-Effect(e2,e1)
Comment:

1903	"A <e1>woman</e1> was recovering from a bullet <e2>wound</e2> after she was caught in the cross-fire of a shootout."
Other
Comment:

1904	"I was digging up the <e1>earth</e1> to throw into the <e2>cradle</e2>, when I turned up a lump of ore about the size of a small walnut, which I knew at once was a piece of gold."
Other
Comment: modality is outside

1905	"So Mary found a pocketknife in the compartment and a straw from her <e1>soda</e1> <e2>drink</e2> now spilled everywhere."
Other
Comment:

1906	"These four superb performers - and at the end it's almost impossible to believe there have been so few of them - present a wordless show that is like a <e1>circus</e1> of human <e2>dreams</e2> and nightmares."
Other
Comment: Dreams are events and cannot be regarded as part of a collection; modality and negation are outside

1907	"It's common to get a slight <e1>fever</e1> from <e2>immunizations</e2>, which can make them uncomfortable."
Cause-Effect(e2,e1)
Comment:

1908	"They are intentionally sewn larger than the pillow to accommodate for <e1>shrinkage</e1> from <e2>washing</e2>."
Cause-Effect(e2,e1)
Comment:

1909	"A <e1>trawl</e1> through ancient copies of the Herts Advertiser threw up a treasure <e2>trove</e2> of information about the early days of the city's first ever cinema."
Other
Comment:

1910	"This unwillingness to fund on a secured basis placed stress on the <e1>liquidity</e1> of the <e2>firm</e2>."
Other
Comment: Liquidity is a state or property.

1911	"Heavy <e1>thunderstorms</e1> caused <e2>cancellation</e2> of races later in the afternoon preventing the Masters Mens fours and Masters Womens and Womens eights from racing."
Cause-Effect(e1,e2)
Comment:

1912	"She sold a <e1>gold</e1> <e2>ring</e2> she received as a gift from her company and her old '80s style chains."
Other
Comment:

1913	"Actually, the earthquake is largely from a global company that had interests insured in China, whereas the <e1>snowstorm</e1> <e2>losses</e2> are exclusively from a variety of Chinese companies that we had relationships with for some year."
Cause-Effect(e1,e2)
Comment:

1914	"By avoiding or limiting contact with trash the chance of contracting <e1>germs</e1> that lead to <e2>sickness</e2> or disease is decreased."
Cause-Effect(e1,e2)
Comment:

1915	"The <e1>dialect</e1> spoken in the South Karelian Region of Finland is part of the South Eastern dialects of the Finnish <e2>language</e2>."
Other
Comment:

1916	"<e1>Climate change</e1> is the topic of the <e2>day</e2>."
Other
Comment: This is time, or period -- not a message.

1917	"His promised bride was already in great <e1>peril</e1> from the twisted love of an insane <e2>suitor</e2>."
Other
Comment:

1918	"In the years since the ADM scandal of the 1990s, the <e1>calamities</e1> caused by the <e2>subversion</e2> of the food resources of masses of people to the private profit interests of a few has reached new heights."
Cause-Effect(e2,e1)
Comment:

1919	"Worker <e1>bees</e1> eating ordinary <e2>honey</e2> live only four to six weeks."
Other
Comment: honey is not being produced

1920	"The living <e1>vaccine</e1>, caused a sharp <e2>temperature elevation</e2> on the day following the second injection."
Cause-Effect(e1,e2)
Comment:

1921	"In a person who already has some neck <e1>tension</e1> from <e2>stress</e2>, such an event can lead to a long-term increase of neck tension."
Cause-Effect(e2,e1)
Comment:

1922	"The first order of business when a patient complains of palpitations is to check whether the <e1>palpitations</e1> are caused by a <e2>heart rhythm</e2>."
Cause-Effect(e2,e1)
Comment:

1923	"We report the second case of ureteropelvic junction <e1>obstruction</e1> after radiofrequency <e2>ablation</e2> that resulted in nephrectomy."
Other
Comment:

1924	"The <e1>miscarriages</e1> are caused by one time, non-repeating <e2>genetic problems</e2>."
Cause-Effect(e2,e1)
Comment:

1925	"It found the net aggregate economic benefit to native-born Americans from the enormous <e1>influx</e1> accidentally triggered by the 1965 <e2>immigration</e2> is nugatory-less than $10 billion a year, in an economy of $10 trillion."
Cause-Effect(e2,e1)
Comment:

1926	"The <e1>lighting</e1> in the <e2>shop</e2> was dim and the walls were covered with shelves which were covered with shoes."
Other
Comment:

1927	"This statement threw <e1>people</e1> into <e2>chaos</e2>."
Other
Comment: violates c.3

1928	"The concert closes with the young <e1>composer</e1>'s take on another <e2>aria</e2> from Guilio Cesare, the notoriously tricky Al lampo dell'armi."
Other
Comment: aria is not a product of the composer

1929	"McGee's <e1>talent</e1> stemmed from mother's <e2>teaching</e2>."
Cause-Effect(e2,e1)
Comment:

1930	"Harbor Beach man pleads in <e1>case</e1> that stemmed from dog <e2>attack</e2> on tot."
Cause-Effect(e2,e1)
Comment:

1931	"The younger <e1>female</e1> got out rather easily from the <e2>cuffs</e2> and massaged her wrists."
Other
Comment:

1932	"<e1>Sinusitis</e1> and tinnitus cause stress or <e2>anxiety</e2>."
Cause-Effect(e1,e2)
Comment:

1933	"The hand-cranked <e1>churn</e1> produced smoother <e2>ice cream</e2> than the pot freezer and did it quicker."
Other
Comment: the churn itself is not actively involved in the making of ice cream

1934	"It is the way of <e1>deliverance</e1> from vicious <e2>cycles</e2> of anger and insult."
Other
Comment:

1935	"The cool <e1>fog</e1> of the summer morning had inundated the fabric of the blimp's coverings with excess <e2>moisture</e2>, adding additional weight to the aircraft."
Cause-Effect(e1,e2)
Comment:

1936	"The <e1>kids</e1> dug into the Baked Ziti with <e2>gusto</e2>."
Other
Comment: manner.

1937	"The <e1>perturbations</e1> caused by the substorm related field-aligned <e2>currents</e2> are most notable in the east-west deflections of the geosynchronous magnetic field."
Cause-Effect(e2,e1)
Comment:

1938	"Xanax works by changing brain <e1>chemicals</e1> that cause stress and <e2>anxiety</e2>."
Cause-Effect(e1,e2)
Comment:

1939	"However several species of <e1>fungi</e1>, insect, and bacteria cause <e2>mortality</e2> or reduced growth of the tree."
Cause-Effect(e1,e2)
Comment:

1940	"The <e1>cockpit</e1> accommodated a <e2>crew</e2> of three, including pilot, radar operator, and sensor operator."
Other
Comment: no evidence for content-container

1941	"The author clearly got a great deal of <e1>pleasure</e1> from the <e2>work</e2> and did not allow his vast amount of material to force him into shallow generalizations."
Cause-Effect(e2,e1)
Comment:

1942	"General information about the <e1>infection</e1> caused by the <e2>bacteria</e2> called Salmonella, when food is eaten raw or undercooked."
Cause-Effect(e2,e1)
Comment:

1943	"All the <e1>profits</e1> from the <e2>books</e2> listed below are donated to the Norman Historic Preservation Program, Inc. (NHPP) to be used toward the renovation of the old Norman High School as a children's educational center and museum."
Cause-Effect(e2,e1)
Comment:

1944	"<e1>Physical geography</e1> examines the <e2>natural environment</e2> and how the climate, vegetation & life, soil, water, and landforms are produced and interact."
Other
Comment: Sciences are not messages.

1945	"Recently the <e1>man</e1> was put into an Interpol red flag <e2>list</e2>."
Other
Comment: This cannot be Entity-Destination since it violates E-D's b.1

1946	"Gaza following the widespread <e1>destruction</e1> caused by the Israeli <e2>invasion</e2>."
Cause-Effect(e2,e1)
Comment:

1947	"The <e1>continent</e1> has sunk into deep economic <e2>abyss</e2>."
Other
Comment: violates b.1 and c.3

1948	"<e1>Investigations</e1> are under way to establish the <e2>identity</e2> of human remains found by police in woodland in Surrey."
Other
Comment: here "investigation" is an activity/process - violation of (d)

1949	"The <e1>hole</e1> has been caused by the <e2>accumulation</e2> of dust into planets like Earth."
Cause-Effect(e2,e1)
Comment:

1950	"I managed to squeeze decent <e1>photos</e1> out of an <e2>iPhone</e2>."
Other
Comment:

1951	"Sigmoid colon <e1>diverticulitis</e1> is the most common cause of acute <e2>pain</e2> in the left lower abdomen in older adults."
Cause-Effect(e1,e2)
Comment:

1952	"The relative <e1>calm</e1> produced by the Shia <e2>ceasefire</e2> has coincided with what the CIA is now calling the "near strategic defeat" of al-Qaeda in Iraq."
Cause-Effect(e1,e2)
Comment: calm is state

1953	"The <e1>auction</e1> started at the ungodly <e2>hour</e2> of 10 am, which I'm guessing ensures no one will show up after hitting the bars and bid drunk."
Other
Comment: modality and negatio are outside

1954	"We are aware that <e1>acne</e1> or pimples are caused by <e2>hormonal imbalance</e2>, improper skin care or bad eating habits."
Cause-Effect(e2,e1)
Comment:

1955	"My grandmother is beautiful too but she has a lot of <e1>wrinkles</e1> from the <e2>sun</e2>."
Cause-Effect(e2,e1)
Comment:

1956	"Originally, the <e1>buttonhole</e1> accommodated a <e2>button</e2> sewn to the underside of the opposite lapel, thus allowing a man to button all the way up in brisk weather."
Other
Comment: modality is outside

1957	"He established a new administrative system, sent a regiment of regular troops which quelled the lroquois, and then invested vast sums in economicdevelopment, establishing new industries such as lumbering and shipbuilding and subsidizing the immigration of skilled and unskilled labor, and marriageable girls for the <e1>superfluity</e1> of <e2>bachelors</e2>."
Other
Comment:

1958	"You store the <e1>information</e1> in the <e2>variable</e2> in your source code."
Other
Comment:

1959	"The confrontation between Martyn and Liz earlier ended with a <e1>struggle</e1> that resulted in Martyn's <e2>drowning</e2>."
Cause-Effect(e1,e2)
Comment:

1960	"His <e1>scepticism</e1> in regard to the <e2>liberal reforms</e2> of the sixties made him very unpopular among the more progressive writers of that time."
Other
Comment: attitude, not communication

1961	"The Lancet study already demonstrated that, as of July 2006, the <e1>deaths</e1> caused by the U.S. <e2>invasion</e2> of Iraq rivaled the death toll of the 1994 Rwandan genocide."
Cause-Effect(e2,e1)
Comment:

1962	"A 3-year-old boy sustains a chemical <e1>burn</e1> after the <e2>spilling</e2> of bleach onto his lower extremities."
Cause-Effect(e2,e1)
Comment:

1963	"In the Fifties, they developed a <e1>technique</e1> for treating blood with <e2>ozone</e2> called 'major autohemotherapy'."
Other
Comment: Purpose-Tool

1964	"I get severe headaches and <e1>dizziness</e1> from colas and <e2>drinks</e2> with nutrasweet (aspartame) and splenda (sucralose)."
Cause-Effect(e2,e1)
Comment:

1965	"They have thrown <e1>mankind</e1> into deeper <e2>bondage</e2> than ever."
Other
Comment: violates c.3

1966	"Before attacking the Walthers <e1>kit</e1> with a razor <e2>saw</e2>, however, let's take care of some other important layout details."
Other
Comment:

1967	"AT LEAST 140000 <e1>homeowners</e1> have fallen into negative <e2>equity</e2>."
Other
Comment: violates b.1 and c.3

1968	"All <e1>parties</e1> were taken into <e2>confidence</e2> over Swat offensive."
Other
Comment: violates c.3

1969	"The CCCB is an institution that organizes contemporary cultural <e1>events</e1> and exhibitions with regard to <e2>music</e2>, dance, debates and readings."
Other
Comment: To be in relation to, or have a relation with, does not mean to be a topic of

1970	"Since then, numerous independent feature <e1>directors</e1> have journeyed into <e2>series television</e2>."
Other
Comment: violates b.1

1971	"For a few more years the <e1>surplus</e1> is generated by the <e2>excess</e2> of Social Security tax revenue over benefits paid to today's elderly and disabled."
Cause-Effect(e2,e1)
Comment:

1972	"The <e1>decline</e1> in populations has been caused by the <e2>influx</e2> of industrial and resident waste water, sludge sedimentation, and land reclamation."
Cause-Effect(e2,e1)
Comment:

1973	"A <e1>lamp</e1> emiting a strong white <e2>light</e2> is placed on an mobile block makes it possible to the scanner to sweep all the document."
Cause-Effect(e1,e2)
Comment:

1974	"Relena's head was bowed, though the <e1>heat</e1> was radiating from the young <e2>princess</e2> in waves."
Cause-Effect(e2,e1)
Comment:

1975	"In many patients, the <e1>disease</e1> caused by the H5N1 <e2>virus</e2> follows an unusually aggressive clinical course, with rapid deterioration and high fatality."
Cause-Effect(e2,e1)
Comment:

1976	"The <e1>automaton</e1> starts in the initial <e2>state</e2>, reads input character by character and changes state according to the program"
Other
Comment:

1977	"Agriculture has again become a <e1>producer</e1> of renewable domestic <e2>energy</e2> to offset supply disruption and stabilize fuel prices."
Cause-Effect(e1,e2)
Comment:

1978	"The <e1>lawnmower</e1> cuts a <e2>swath</e2> of grass as it moves across the lawn."
Other
Comment:

1979	"The centre and right images show progressive <e1>shrinkage</e1> after two and four <e2>years</e2>."
Other
Comment:

1980	"Although Harry noticed it during exercise, the change that was identified was the difference in muscular <e1>discomfort</e1> from the <e2>beginning</e2> of his training program (riding five miles per day) to his current status two months later."
Other
Comment:

1981	"A <e1>moat</e1> keeps the <e2>enemy</e2> at bay."
Other
Comment:

1982	"His lung function remained stable after complete <e1>removal</e1> from <e2>exposure</e2> to metalworking fluids."
Other
Comment:

1983	"Losing land to new white settlers, non-payment, past broken treaties, plus food shortages and <e1>famine</e1> following crop <e2>failure</e2> led to great discontent among the Dakota people."
Cause-Effect(e2,e1)
Comment:

1984	"The <e1>patient</e1> is kept in the <e2>hospital</e2> one night for observation."
Other
Comment: Content-Container in e1 --> e2 is excluded because of the restriction that people cannot be contents. An entity-location relation is more appropriate.

1985	"Some people voluntarily get involved with politicisation, while others become victims of <e1>circumstances</e1> created by the <e2>politicisation</e2>."
Cause-Effect(e2,e1)
Comment:

1986	"They're bringing in applications such as catalog management and order <e1>fulfillment</e1> from <e2>vendors</e2>, then laboriously developing and integrating those applications themselves."
Other
Comment:

1987	"Polar bears and hippos have joined the ranks of species threatened with <e1>extinction</e1> from <e2>climate change</e2>, unregulated hunting and other dangers created by humans."
Cause-Effect(e2,e1)
Comment:

1988	"Most of the <e1>excitement</e1> came from the <e2>anticipation</e2> of winning a nice prize, all for the sum of one dollar."
Cause-Effect(e2,e1)
Comment:

1989	"Their retreat was disorderly and confused and much like a flight, the Pallantines hanging on their flanks and rear and doing great <e1>damage</e1> from early <e2>dawn</e2> till evening."
Other
Comment:

1990	"These Hebrew histories tell the story of a people's upward <e1>growth</e1> from <e2>savagery</e2>."
Other
Comment:

1991	"<e1>Progress</e1> comes from constructive <e2>competition</e2>, and churches and religions can benefit greatly from it."
Cause-Effect(e2,e1)
Comment:

1992	"The concrete <e1>sidewalk</e1> radiated <e2>heat</e2> like a furnace, and there was no relief in the shade of a large crepe myrtle tree as they walked under it."
Cause-Effect(e1,e2)
Comment:

1993	"In a preliminary investigation, Cheddar <e1>cheese</e1> was made with a lactococcal <e2>starter</e2> overproducing different peptidases."
Other
Comment: It also cannot be Entity-Origin because the lactococcal starter is not the main source material of cheese (milk is), so violation of (b). This cannot be Component-Whole because it violates "(d) X has a clear boundary and could, in principle, be separated from Y" - the case is like 'alcohol-wine'.

1994	"The <e1>fire</e1> started with an <e2>explosion</e2> in the cargo hold and spread across the ship within 10 minutes."
Cause-Effect(e2,e1)
Comment:

1995	"Until last year, Afghanistan was an <e1>opium</e1> <e2>exporter</e2>, not a major heroin producer."
Other
Comment: Export does not entail production; negation is outside

1996	"The <e1>logs</e1> sawed smoothly and accurately using either saw <e2>design</e2>."
Other
Comment:

1997	"Villagers live in constant <e1>terror</e1> of indiscriminate <e2>gunfire</e2> which fills the nights throughout Chechnya."
Cause-Effect(e2,e1)
Comment:

1998	"But the contents of the <e1>audit</e1> were a closely held <e2>secret</e2>, and attempts to obtain other records were denied repeatedly."
Other
Comment: None of the nine relations seems to hold; "secret" seems to be a state of the audit.

1999	"The <e1>tenant</e1> has farmed for this <e2>owner</e2> for several years and doesn't want to lose the ground, but also does not want to pay the large increase in rent."
Other
Comment: modality and negation are outside

2000	"There was an the <e1>outrage</e1> from the sexism <e2>crusaders</e2>."
Cause-Effect(e2,e1)
Comment:

2001	"His highly original and topical act reaches from the top of the corporate ladder into blokes' sheds, leaving his audiences <e1>aching</e1> from <e2>laughter</e2>."
Cause-Effect(e2,e1)
Comment:

2002	"The <e1>toolkits</e1> provide a secure <e2>framework</e2> where sensitive information remains private."
Other
Comment: "Provision" here doesn't mean creation.

2003	"In a nutshell, <e1>orienteering</e1> combines a physical <e2>skill</e2> with a more cerebral element."
Other
Comment:

2004	"The <e1>food</e1> is kept in the <e2>kitchen</e2> and guests help themselves as it is a self service."
Other
Comment: food is located in the kitchen.

2005	"Videotape is a fragile medium subject to damage and <e1>deterioration</e1> from <e2>exposure</e2> to poor environmental conditions and inadequate handling practices."
Cause-Effect(e2,e1)
Comment:

2006	"The <e1>challenges</e1> are being addressed from a manufacturing <e2>standpoint</e2> rather than ICT solutions that could answer them."
Other
Comment:

2007	"Most of the <e1>steam</e1> comes from a volcano's <e2>magma</e2>."
Cause-Effect(e2,e1)
Comment:

2008	"When I start the engine the <e1>car</e1> makes a screaching <e2>sound</e2>."
Cause-Effect(e1,e2)
Comment:

2009	"Touch sliding <e1>keyboard</e1> offers keyless <e2>typing</e2>."
Other
Comment: Purpose-Tool

2010	"The enclosed <e1>community</e1> produced the enclosed <e2>personality</e2>, and vice versa."
Cause-Effect(e1,e2)
Comment: Personality is a state

2011	"<e1>Batteries</e1> kept in <e2>good condition</e2> have a 5 to 6 year service life."
Other
Comment: "good condition" is a possible state for batteries.

2012	"In a clock, the '<e1>tick</e1>' is produced by the <e2>action</e2> of the escapement."
Cause-Effect(e2,e1)
Comment:

2013	"Non-UK <e1>students</e1> benefit from the bursary <e2>scheme</e2>."
Other
Comment:

2014	"The risks of this procedure include anesthesia complications, post-operative difficulty breathing, and <e1>sore throat</e1> from <e2>intubation</e2>."
Cause-Effect(e2,e1)
Comment:

2015	"The <e1>bulldozer</e1> is kept in the <e2>area</e2> and is suspected of being used to create makeshift paths across the river."
Other
Comment: "area" cannot be considered a container; this seems an entity-location example.

2016	"A <e1>marinade</e1> that contains <e2>acid</e2>, alcohol or salt has been used for a short time."
Other
Comment: acid in this case is an ingredient, it stands for an acid ingredient such as lemon or vinegar that do not have clear boundaries (stuff-object relation).

2017	"To say that <e1>rowing</e1> is just pulling an <e2>oar</e2> is like saying golf is just swinging a club."
Other
Comment: Purpose-Tool

2018	"The main cell types are fibroblasts, macrophages and adipocytes (the <e1>hypodermis</e1> contains 50% of <e2>body fat</e2>)."
Other
Comment: body fat is part of hypodermis cells but does not have clear boundaries (stuff-object relation).

2019	"Whilst audio sampled at 8kHz is sufficient for communication, such narrow-band speech does not sound natural, leading to user <e1>frustration</e1> after prolonged <e2>exposure</e2>, and making language learning difficult."
Cause-Effect(e2,e1)
Comment:

2020	"With these axioms, the <e1>judges</e1> cultivated the <e2>principles</e2> of judgment, and those principles could be used in gauging the restrictions on freedom that were justified or unjustified, in any domain of the law."
Other
Comment:Cultivation is not creation. The principles already existed.

2021	"Some inactivated influenza vaccine contains thimerosal, a <e1>preservative</e1> that contains <e2>mercury</e2>."
Other
Comment: mercury is part of the preservative, and it does not have clear boundaries (stuff-object relation).

2022	"Initiated during the early 1990's National Mineral Resource Assessment, this project received a major <e1>boost</e1> from <e2>funding</e2> provided through the 'Data-at-Risk' add-on funding received by the USGS through the 2004 fiscal year."
Cause-Effect(e2,e1)
Comment:

2023	"A pop-up roll cage and active headrests aim to protect occupants during a rollover, and the <e1>floorboard</e1> is made from <e2>bamboo</e2> and aluminum."
Other
Comment:

2024	"The <e1>energy</e1> of emission produces the <e2>separation field</e2>."
Cause-Effect(e1,e2)
Comment: Neither the energy nor the separation field are concrete objects.

2025	"<e1>Batteries</e1> stored in a <e2>discharged state</e2> are susceptible to freezing, sulfation and an increased rate of discharge."
Other
Comment: discharge state is a state of the entity batteries. None of the nine relations holds.

2026	"I derive tremendous pleasure and <e1>fulfillment</e1> from <e2>teaching</e2>, particularly when I am able to help students understand a previously foreign concept or idea, aid them in seeing a familiar object or event from a new and unusual perspective, guide them with projects they are working on, or encourage the interests they have."
Cause-Effect(e2,e1)
Comment:

2027	"Sometimes the <e1>blockage</e1> comes from <e2>fear</e2>, as for a CEO who hates public speaking but must give frequent speeches."
Cause-Effect(e2,e1)
Comment:

2028	"It makes the drive more comfortable by intelligently seeking out what the <e1>passengers</e1> inside the <e2>car</e2> prefer in terms of temperature, music, lighting etc."
Other
Comment: Content-Container is excluded because people should not be considered contents. Instead it could be entity-location.

2029	"It is a family luxury villa with breeze-kissed balconies from which the <e1>sounds</e1> of the sea provide a sensuous nightly <e2>serenade</e2>."
Other
Comment: The sounds are a property of the serenade.

2030	"When they took the floor against a team favored to win the national championship, the <e1>patriots</e1> radiated carefree <e2>confidence</e2>."
Cause-Effect(e1,e2)
Comment:

2031	"The discharge <e1>valve</e1> is kept in the <e2>closed position</e2> at all times unless the dike is deliberately being drained."
Other
Comment: closed position describe the state of the valve. None of the nine relations holds.

2032	"The 3 km long <e1>beach</e1> extends from the <e2>mouth</e2> of the Oro River in the west, to the cliffs of Point Caramonal to the southeast."
Other
Comment:

2033	"The <e1>tests</e1> are generated randomly from a <e2>bank</e2> of questions developed for each module."
Other
Comment:

2034	"Suddenly a <e1>nurse</e1> takes off her familiar loose-fitting <e2>clothes</e2>, and dresses her in clothes, which fit her more closely."
Other
Comment:

2035	"The outer <e1>shell</e1> is made from anodized <e2>aluminum</e2>."
Other
Comment:

2036	"The <e1>servant</e1> brought forth <e2>jewels</e2> of silver, and jewels of gold, and clothing, and gave them to Rebekah."
Other
Comment:

2037	"Colorful, almost fat-free salad <e1>dressings</e1> start with fresh <e2>fruit</e2>."
Other
Comment:

2038	"Until 1729 the <e1>building</e1> contained only the <e2>grammar school</e2>."
Other
Comment: Buildings shouldn't be considered as containers. Instead the grammar school is located in the building.

2039	"The <e1>move</e1> makes a <e2>mockery</e2> of China's long-standing opposition to such capabilities in the hands of other powers."
Other
Comment:

2040	"He went on to examine the <e1>theory</e1> from a risk assessment <e2>perspective</e2>."
Other
Comment:

2041	"Kids love watching the stages of <e1>growth</e1> from <e2>caterpillar</e2> to cocoon to butterfly in this easy reliable kit."
Other
Comment:

2042	"The <e1>mood</e1> inside the <e2>car</e2> was very quiet as the couple continued home and went to bed."
Other
Comment: Here mood stands for the "people in a given/quiet mood" but people shouldn't be contents. None of the nine relations holds.

2043	"Television cooking shows and more advertising have put <e1>wine</e1> in the <e2>limelight</e2>."
Other
Comment: None of the nine relations holds; it cannot be Entity-Destination because of b.1 in E-D's definition

2044	"<e1>Zinc</e1> is essential for <e2>growth</e2> and cell division."
Cause-Effect(e1,e2)
Comment:

2045	"With its non-slip, ambidextrous grip, the <e1>peeler</e1> glides effortlessly through <e2>foods</e2>."
Other
Comment:

2046	"The backup <e1>vocals</e1> are from a rather talented <e2>female</e2>, Stephanie Eitel."
Cause-Effect(e1,e2)
Comment:

2047	"Two years ago, President George W. Bush ordered the <e1>activation</e1> by the <e2>end</e2> of 2004 of a system capable of defending the United States against a missile attack by a terrorist group or an unfriendly rogue state such as North Korea."
Other
Comment:

2048	"The soft brown and beige <e1>tones</e1> in the decoration provide a tranquil <e2>mood</e2>."
Cause-Effect(e1,e2)
Comment:

2049	"The <e1>tram</e1> makes the <e2>trip</e2> from the main university campus in less than 5 minutes, while driving can take 15 minutes or longer."
Other
Comment: Trip is an event.

2050	"A <e1>lodge</e1> combines a <e2>colonial atmosphere</e2> with the rustic beauty and history of Africa."
Other
Comment:

2051	"You proved that a <e1>gas</e1> takes up <e2>space</e2>."
Other
Comment:

2052	"Their <e1>success</e1> comes from their <e2>ability</e2> to quickly answer a growing surge of mid-size customer demands -- demands that *always* focus around ease of implementation and ease of administration/use."
Cause-Effect(e2,e1)
Comment:

2053	"The <e1>filament</e1> emits a yellowish-white <e2>light</e2>, and the walls have a strong yellow tint."
Cause-Effect(e1,e2)
Comment:

2054	"This program is an effective step to mitigate <e1>damage</e1> from <e2>hurricanes</e2>, but let us not forget this is a retroactive measure."
Cause-Effect(e2,e1)
Comment: modality and negation are outside

2055	"It's not unlike an archeological dig through an attic, <e1>choking</e1> from <e2>laughter</e2> rather than dust, as familiar and forgotten memories are refreshed and taken for a satirical synaptic spin by a master humorist."
Cause-Effect(e2,e1)
Comment:

2056	"These are memorable words written on a piece of <e1>paper</e1> kept in a <e2>museum</e2>."
Other
Comment: Location.

2057	"Quality forged pinking <e1>scissors</e1> cut with exceptional <e2>ease</e2> and efficiency."
Other
Comment:

2058	"Six glowing disks await <e1>activation</e1> by the <e2>footsteps</e2> of desert wanderers."
Cause-Effect(e2,e1)
Comment:

2059	"Significant reductions of these levels produce pastries with poor lift in the oven and with unacceptable <e1>shrinkage</e1> after <e2>cooling</e2>."
Cause-Effect(e2,e1)
Comment:

2060	"The <e1>transmitter</e1> generates the electromagnetic <e2>wave</e2>, some of which will be incident on the receiver."
Cause-Effect(e1,e2)
Comment: the modality is outside

2061	"It is set in the most beautiful surroundings and the <e1>land</e1> has been biodynamically farmed for many <e2>years</e2>."
Other
Comment: E2 is a temporal expression.

2062	"Some plants and animals are facing <e1>extinction</e1> from Alberta's <e2>lakes</e2>, rivers, mountains and prairies."
Other
Comment:

2063	"True <e1>progress</e1> comes from <e2>science</e2>, debate, inference, logic and reasoning."
Cause-Effect(e2,e1)
Comment:

2064	"Preliminary experiments seemed to support this idea in that the <e1>quenches</e1> produced the predicted high <e2>vortex-densities</e2>."
Cause-Effect(e1,e2)
Comment: Wikipedia - A quench refers to a rapid cooling, i.e. an event. The relation is outside the scope of the hedge "seemed".

2065	"A tear or a crease changes the character of the surface more drastically than a mere <e1>deformation</e1> from <e2>roundness</e2>."
Cause-Effect(e2,e1)
Comment:

2066	"Continuous <e1>improvement</e1> starts with <e2>measuring</e2> process performance, and instigating a robust process for reviewing further changes logically and quickly."
Cause-Effect(e2,e1)
Comment:

2067	"The period of tumor <e1>shrinkage</e1> after radiation <e2>therapy</e2> is often long and varied (mean 29 months)."
Cause-Effect(e2,e1)
Comment:

2068	"Arthur and Franz are thieves, or they're trying to be thieves, and somehow learn that Odile lives in a <e1>house</e1> that contains a large sum of <e2>money</e2>."
Other
Comment: The money seems not to be stored in the house, it is simply located there.

2069	"First, the <e1>sound</e1> radiated from a <e2>surface</e2> simulating a two-dimensional monopole is calculated using an unstructured mesh."
Cause-Effect(e2,e1)
Comment:

2070	"I have always drawn <e1>satisfaction</e1> from <e2>exertion</e2>, straining my muscles to their limits."
Cause-Effect(e2,e1)
Comment:

2071	"That happens when the <e1>media</e1> makes a <e2>mistake</e2>."
Cause-Effect(e1,e2)
Comment:

2072	"Sudden <e1>death</e1> from <e2>inhalation</e2> of petroleum distillates is well recognised in misuses of volatile substances."
Cause-Effect(e2,e1)
Comment:

2073	"The <e1>architect</e1> carefully designed the 15 <e2>rowhouses</e2>, reflecting the suburban ideal of the late 1800s."
Other
Comment:: The architect is not really the one bringing the house into existence.

2074	"The piglet's incisor <e1>teeth</e1> are cut off with <e2>pliers</e2>."
Other
Comment:

2075	"InterSense, Inc., a market leader in precision motion technology, today announced that Hydro, a leading offshore <e1>producer</e1> of <e2>oil</e2> and gas, has installed its tenth InterSense IS-900 Precision Motion Tracking System as part of Hydro's large scale immersive visualization rooms."
Other
Comment: An oil producer doesn't actually create oil. The oil already exists in the ground, the producer just exports it.

2076	"The <e1>move</e1> from binary <e2>access</e2> (yes or no) to fine-grained authorization betrays a shift in mindset: from a defensible perimeter to a qualifier that identifies who can access what room."
Other
Comment:

2077	"On the courtyard there is a <e1>room</e1> that contains a <e2>billiard table</e2>, a big cinema screen with a Sony DVC/CD Player with over 300 titles and several sofas."
Other
Comment: We prefer considering the room as a location and the billiard table is located in the room.

2078	"She opened a fridge in the side of the door and got out a <e1>blueberry</e1> <e2>vodka</e2>."
Other
Comment:

2079	"The <e1>kitchen</e1> holds little <e2>clues</e2> about how we tried to reinvent the past."
Other
Comment: None of the nine relations seems to hold. It could be a property of the abstract concept "cuisine".

2080	"We continue to see progress toward a world free of the daily <e1>terror</e1> of antipersonnel <e2>landmines</e2>."
Cause-Effect(e2,e1)
Comment:

2081	"The <e1>micropump</e1> is fabricated by the <e2>anisotropic etching</e2>, the boron diffusion and the metal evaporation."
Other
Comment: The etching is an event or process, restriction (f) applies, events cannot be Producers.

2082	"Dr. Aimee Rose, a member of the <e1>team</e1> who made the <e2>discovery</e2>, predicts it will save many lives, both military and civilian."
Other
Comment: The word discovery has two senses "the act of discovering" and "what was discovered" and in this sentence both senses are evenly probable. In this context we cannot determine with the discovery is an abstract or physical object. the modality is outside.

2083	"Furthermore, <e1>control</e1> over agricultural <e2>research</e2>, production, distribution and practice is shifting from public institutions to private corporations, which are profit driven and are not motivated by humanitarian concerns."
Other
Comment:

2084	"In a conventional, steam turbine-only power plant, the <e1>heat</e1> required to produce the steam comes from a <e2>boiler</e2>."
Cause-Effect(e2,e1)
Comment:

2085	"In converting a tree into thick planks, the <e1>saw</e1> causes a <e2>waste</e2> of a very small fractional part."
Other
Comment:

2086	"Until recently patient record was represented by <e1>documents</e1> in paper kept in a variety of <e2>formats</e2>, different contents, and places."
Other
Comment: The format is a sort of surface property for paper document.

2087	"The <e1>display table</e1> contained <e2>books</e2> and posters for visitors to browse."
Other
Comment: Location (books are not enclosed).

2088	"After several years of self-observation, Alexander began to teach his method of conscious <e1>inhibition</e1> through manual facilitated <e2>movement</e2>."
Cause-Effect(e2,e1)
Comment:

2089	"As the molten metal cools, it hardens and assumes the <e1>shape</e1> created by the mold's <e2>cavity</e2>."
Cause-Effect(e2,e1)
Comment: Assume that shape is a state. How agentive is the cavity in the shaping process? Borderline.

2090	"In particular, we work on devices that take the <e1>signal</e1> that is carried in a <e2>beam</e2> of light going through an optical fiber and transfer that signal to another beam of light going through the same fiber."
Other
Comment: Signal-beam is like information-wave (064).

2091	"A knitting needle or <e1>knitting pin</e1> is a long stick or rod used as a tool in the <e2>manufacture</e2> of hand knitted fabric."
Other
Comment: Purpose-Tool

2092	"<e1>Driving</e1> with sleep <e2>deprivation</e2> has similar effects as driving under the influence."
Other
Comment:

2093	"We planetary citizens have a unique capacity for <e1>ecstasy</e1> from <e2>repetition</e2> - especially when it comes from drumming."
Cause-Effect(e2,e1)
Comment:

2094	"As many as 18 products in your home come from this <e1>guy</e1>'s <e2>company</e2>."
Other
Comment: The guy owns the company.

2095	"The <e1>scintillator material</e1> produces <e2>visible light</e2> when transversed by the particle's radiated energy."
Cause-Effect(e1,e2)
Comment:

2096	"The acoustic test is where we put the <e1>spacecraft</e1> in a <e2>sound chamber</e2> and blast it with over 140 decibels of noise for at least a full minute to simulate what it is going to experience during the launch."
Other
Comment: e1 --> e2 is entity-location.

2097	"The <e1>evacuation</e1> after the Chernobyl <e2>accident</e2> was poorly planned and chaotic."
Cause-Effect(e2,e1)
Comment:

2098	"The typical flu <e1>infection</e1> starts with <e2>fever</e2>, muscular pains, headache and general fatigue."
Other
Comment:

2099	"I had told this <e1>headhunter</e1>'s <e2>company</e2> repeatedly that I was only interested in working in the Philadelphia area."
Other
Comment:

2100	"A single <e1>blow</e1> made with the <e2>chisel</e2> angled incorrectly cracks a block or break a delicate protrusion."
Other
Comment:

2101	"A second aspect of the invention provides apparatuses for indicating the position of an <e1>oar</e1> during <e2>rowing</e2>."
Other
Comment: Purpose-Tool

2102	"Such airships are essentially motorized free balloons and the <e1>engines</e1> are carried in a <e2>car</e2> attached to the lower side or bottom of the bag."
Other
Comment: The car here is a means of transportation.

2103	"Their chemical <e1>activation</e1> by <e2>light</e2> (halogen, plasma, lasers, etc.) enhances their efficiency by reducing exposure time and number of appointments."
Cause-Effect(e2,e1)
Comment:

2104	"The moisturizers' primary function is to keep skin moist, minimize <e1>wrinkles</e1> from <e2>dryness</e2>, smoothe and soften skin, and to deliver other ingredients, like sunscreen, that benefit the skin."
Cause-Effect(e2,e1)
Comment:

2105	"The <e1>ancients</e1> cultivated the <e2>species</e2> Heracleum Sphondylium which is the parsnip a similar plant to carrots."
Other
Comment: Cultivation is not creation. The species already existed.

2106	"This lamp causes serious skin burn and eye <e1>inflammation</e1> from shortwave ultraviolet <e2>radiation</e2> when outer envelope of the lamp is broken or punctured."
Cause-Effect(e2,e1)
Comment:

2107	"In contrast, clay-textured soils are more difficult to prepare a <e1>canola</e1> <e2>seedbed</e2> because the clods can be too large when worked wet, and they tend to crust once worked to a fine seedbed."
Other
Comment:

2108	"We recommend rinsing your <e1>grater</e1> in warm <e2>water</e2> immediately after each use."
Other
Comment:

2109	"Genuine <e1>joy</e1> comes from profound spiritual <e2>awareness</e2> on life and an absolute clarity of direction, living for a purpose."
Cause-Effect(e2,e1)
Comment:

2110	"The <e1>detainee</e1> is kept in the <e2>cell</e2> 23.5 hours a day."
Other
Comment: People should not be considered contents. Might be entity-location.

2111	"Research shows that 30% to 40% of law students experience <e1>depression</e1> after their first <e2>semester</e2> and this depression persists throughout law school."
Other
Comment:

2112	"The findings clearly show a high level of <e1>satisfaction</e1> from <e2>customers</e2> using new cutting-edge retail technology that has led to higher sales."
Other
Comment:

2113	"The <e1>experimenters</e1> designed the <e2>shape</e2> and size of the enlarged fiber ends so they don't experience the stresses that usually snap fibers and limit a short-fiber composite's performance."
Other
Comment: A shape is not a physical object but a state or property of a physical object.

2114	"The <e1>light</e1> in the background is from the <e2>sunrise</e2>."
Cause-Effect(e2,e1)
Comment:

2115	"The milled powder is then heated converting it into a <e1>vapour</e1> which is then carried in a <e2>stream</e2> of argon to be deposited on the wafer."
Other
Comment: A stream is not clearly delineated in space. Content-Container is excluded. See 064, 067.

2116	"Because winter has been mild in much of the country, <e1>oil</e1> <e2>prices</e2> have been low for the past few months."
Other
Comment:

2117	"The <e1>introduction</e1> of the gas stove, the electric mixer and the food processor made the <e2>process</e2> easier, faster and more reliable."
Other
Comment: The introduction does not cause the process.

2118	"Our powered <e1>scissors</e1> effortlessly cut <e2>fabrics</e2>, gift wrap, vinyl and much more."
Other
Comment:

2119	"The volunteers enjoy a sense of satisfaction and personal <e1>fulfillment</e1> from <e2>helping</e2> others, and recent findings suggest that this feeling may well be a major reason why many people choose to volunteer."
Cause-Effect(e2,e1)
Comment: modality is outside

2120	"The simulation <e1>study</e1> produces voluminous <e2>results</e2>, since there are two types of models, each with four different specifications and with two sample sizes involved."
Other
Comment: The study is an event, "result" is used here in the sense of information rather than event.

2121	"It is best to use bold flavors in <e1>herb</e1> <e2>butter</e2>."
Other
Comment:

2122	"Ribozymes, also known as catalytic RNA and molecular scissors, break down <e1>nucleic acid</e1> inside a <e2>cell</e2>, cut out bad genetic information and splice in good material."
Other
Comment: nucleic acid is part of the cell, but it does not have clear boundaries (stuff-object relation).

2123	"This prescription drug alleviates <e1>panic</e1> from <e2>claustrophobia</e2> and is also very handy for airplane rides and in case of broken-down subway cars or elevators."
Cause-Effect(e2,e1)
Comment:

2124	"We do know this <e1>telecommunications</e1> <e2>company</e2>."
Other
Comment: telecommunications is not a concrete object nor is it an mental activity.

2125	"In my Vancouver home there is small portion of our <e1>kitchen</e1> that contains my <e2>desk</e2>."
Other
Comment: The desk is located in the kitchen, it is not stored or carried inside it.

2126	"While public <e1>drinking</e1> <e2>regulations</e2> varied, some form of the beer parlour became the norm across the country."
Other
Comment:

2127	"The decedent was a licensed commercial truck driver and had been employed by this <e1>trucking</e1> <e2>company</e2> for five years."
Other
Comment:

2128	"It has helped to revive a city whose primary natural resource -- its charm -- is constantly threatened with <e1>extinction</e1> from <e2>overdevelopment</e2>."
Cause-Effect(e2,e1)
Comment:

2129	"The remarkably comprehensive 32-page 2004 Memorandum of Understanding prohibited the <e1>candidates</e1> from asking each other <e2>questions</e2>, limited rebuttals to a mere 30 seconds, barred direct follow-up questions and entirely prohibited surrebuttals."
Other
Comment:

2130	"Francis Hauksbee proves that sound needs air to travel, by experiments with a <e1>clock</e1> inside a <e2>vacuum</e2>."
Other
Comment: location; the purpose is not storing or carrying.

2131	"The <e1>ghosts</e1> in my <e2>house</e2> are mischievous, like little children."
Other
Comment: As for people, we could not want to consider "ghosts" as contents; entity-location fits better.

2132	"Diabetes drug shows promise for preventing brain <e1>injury</e1> from radiation <e2>therapy</e2>."
Cause-Effect(e2,e1)
Comment:

2133	"The date for final payment is shown on the <e1>confirmation</e1> <e2>invoice</e2>."
Other
Comment:

2134	"It also includes an automatic purge valve for quick <e1>equalization</e1> after <e2>changes</e2> in atmospheric pressure."
Other
Comment:

2135	"Taxi <e1>driver</e1> spotted stolen <e2>car</e2> shortly after police sent out an alert."
Other
Comment:

2136	"Elecom's gear drive <e1>keyboard</e1> prevents typing <e2>errors</e2>."
Other
Comment:

2137	"In prolific suspense novelist Johansen's energetic new Eve Duncan thriller (Countdown, 2005, etc.), the forensics <e1>sculptor</e1> makes a dangerous <e2>deal</e2> with a Colombian weapons dealer."
Other
Comment:

2138	"This <e1>view</e1> from the inside is from the <e2>bridge</e2> that spans Atherton Street."
Other
Comment:

2139	"Unlike most of the annual showers the <e1>antihelion radiant</e1> is produced by <e2>debris</e2> from unknown sources orbiting in a direct motion like the earth."
Other
Comment: The antihelion radiant is an area of the sky from which sporadic meteors can originate. Debris are concrete.

2140	"The <e1>kitchen</e1> holds many <e2>opportunities</e2> for teaching kids as well as having fun."
Other
Comment: Pure metaphor.

2141	"Apparantly you think two wrongs can make a right, but that doesn't help the starving people of Zimbabwe, who were previously not starving due to the <e1>land</e1> being farmed for <e2>profit</e2> instead of used as political gifts."
Other
Comment: The modality and negation are outside of the relation.

2142	"A White House <e1>usher</e1> prepares the blue <e2>room</e2> for a luncheon for the European Commission."
Other
Comment: The usher did not create the blue room.

2143	"The Wal-Mart Supercenter plans to employ as many as 455 associates, including 180 planned new <e1>jobs</e1> created by the <e2>relocation</e2>."
Other
Comment: Relocation is an event, jobs are organisational entities.

2144	"In the case of aerodynamic lift, the <e1>aircraft</e1> is kept in the <e2>air</e2> by wings or rotors (see aerodynamics)."
Other
Comment: It is a sort of located in relation. None of the nine relations holds. (Weakly possible: location.)

2145	"The <e1>rain</e1> begets the <e2>food</e2> we eat."
Other
Comment: Borderline, how active is the contribution of the rain? It can't be Cause-Effect because food is a concrete substance.

2146	"The local <e1>citizens</e1> farmed for a <e2>living</e2>, raising a variety of crops including peanuts, cotton, hay, sorghum, and a variety of truck crops."
Other
Comment: Living is an abstract object.

2147	"Scientific <e1>progress</e1> comes from <e2>breakthroughs</e2> and breakthroughs by their very nature are unpredictable and surprising in their impact."
Cause-Effect(e2,e1)
Comment:

2148	"Entering the <e1>fissure</e1> created by the meteor's <e2>impact</e2>, Sephiroth merged with all the energy of the planet, granting him god-like power over it."
Other
Comment: Impact is an event, a fissure is a concrete entity.

2149	"The good friar was insistent on both celibacy and <e1>abstinence</e1> from <e2>laughter</e2>."
Other
Comment:

2150	"On the other hand, the <e1>information</e1> being carried in a high frequency quasi-sinusoidal <e2>wave</e2> invites comparisons with the auditory system of vertebrates."
Other
Comment: not Component-Whole, not Content-Container.

2151	"A <e1>midwife</e1> assists the <e2>birth</e2>, and women usually rely on their mothers or other women for support during labour."
Other
Comment: (e) People are not usually classified as Instruments, unless they are clearly non-agentive in the situation.

2152	"The <e1>afterglow</e1> is produced by <e2>shock waves</e2> in the jets of tenuous gas that shoot from the blast at almost the speed of light."
Cause-Effect(e2,e1)
Comment:

2153	"Like normal 'Simon' games, it starts with a one digit sequence, and then increases indefinitely until the <e1>caller</e1> makes a <e2>mistake</e2>."
Cause-Effect(e1,e2)
Comment:

2154	"<e1>Profit</e1> from <e2>sale</e2> of investments is tax-free for general insurers."
Cause-Effect(e2,e1)
Comment:

2155	"The conference center has at least one dedicated main conference <e1>room</e1> that contains a minimum of 1,000 <e2>square feet</e2>."
Other
Comment: Measure.

2156	"The design of the shape of the can ends moreover has a marked effect on their ability to resist <e1>deformation</e1> from internal <e2>pressure</e2>."
Cause-Effect(e2,e1)
Comment:

2157	"The white fatty <e1>substance</e1> obtained from the head of the sperm whale was used in <e2>pharmaceuticals</e2> and candles."
Other
Comment: The fatty substance is an ingredient of the pharmaceuticals.

2158	"The <e1>dose</e1> makes the <e2>poison</e2>."
Other
Comment: Dose is a measurement.

2159	"The margarine is <e1>imitation</e1> <e2>butter</e2> was without the superior flavor and pleasant mouthfeel."
Other
Comment:

2160	"The <e1>tools</e1> made the <e2>job</e2> easy when it could have been a nightmare."
Other
Comment: The tools help to produce something, the job refers to the process not the product.

2161	"Companies face big <e1>risk</e1> from <e2>loss</e2> of key employees."
Cause-Effect(e2,e1)
Comment:

2162	"The story put <e1>wine</e1> in a <e2>positive health light</e2> and pointed out that it was superior to other foods in that particular regard."
Other
Comment: None of the nine relations seems to hold; it cannot be Entity-Destination because of b.1 in E-D's definition

2163	"Heating oil is similar to <e1>diesel</e1> <e2>oil</e2>, and the process of refining it is very similar."
Other
Comment:

2164	"That's because nostalgia serves a useful defensive and reparative function; it took the <e1>sting</e1> from a <e2>painful episode</e2> in his life by shading the script."
Other
Comment: an idiom, none of the nine relations holds. (In a highly metaphorical sense, this might be Component-Whole.)

2165	"The <e1>plane</e1> makes a parabolic <e2>maneuver</e2>, much like a roller coaster with steep climbs and descents, that simulates zero gravity conditions."
Other
Comment:

2166	"Some people experience <e1>tremors</e1> after <e2>drinking</e2> coffee and tea."
Cause-Effect(e2,e1)
Comment:

2167	"I'm running a <e1>charity</e1> that helps the poorest school <e2>libraries</e2> in the U.S."
Other
Comment:

2168	"<e1>Hitting</e1> out of <e2>anger</e2> is absolutely wrong."
Cause-Effect(e2,e1)
Comment:

2169	"These characteristics are inconsistent with <e1>observations</e1> from <e2>earthquakes</e2> of comparable distance and magnitude to those that dominate the hazard at Yucca Mountain."
Other
Comment:

2170	"He derives great joy and <e1>happiness</e1> from <e2>cycling</e2>."
Cause-Effect(e2,e1)
Comment:

2171	"The man cannot be too old - in his middle thirties - but his face exhibits more <e1>wrinkles</e1> from <e2>smiling</e2> than I've seen upon the mug of the happiest of grandparents."
Cause-Effect(e2,e1)
Comment:

2172	"The randomized hypertensive ABCD study demonstrated a decrease in myocardial infarction with ACE inhibitors and a <e1>decrease</e1> in overall mortality with aggressive blood pressure <e2>control</e2>."
Cause-Effect(e2,e1)
Comment:

2173	"The resulting <e1>shockwaves</e1> produced the metal-forming <e2>conditions</e2> for periods of 100-200 ns."
Cause-Effect(e1,e2)
Comment: Shockwaves and conditions are events.

2174	"Myles and Simpson also identify defensive <e1>behaviour</e1> from <e2>learners</e2> like lashing out verbally or physically or threatening the educators or other learners and withdrawing from others emotionally or physically."
Other
Comment:

2175	"Another <e1>drinking</e1> <e2>accident</e2> happened in the Gallup area the other day, which is plagued by drinking and driving accidents."
Cause-Effect(e1,e2)
Comment:

2176	"The <e1>programmer</e1> made a <e2>mistake</e2> with respect to quoting, but it appeared as over-quoting instead of lurking as a security problem."
Cause-Effect(e1,e2)
Comment:

2177	"The <e1>temperature</e1> inside the <e2>car</e2> was 79 degrees."
Other
Comment: temperature is a property (or state) of the car's interior.

2178	"<e1>Entrepreneurship</e1> out of <e2>necessity</e2> is quite common in Europe where 60% of female headed businesses in Northern Europe and 70% in Southern Europe are established for this reason."
Cause-Effect(e2,e1)
Comment:

2179	"The <e1>actor</e1> played a psychopathic preacher with a restrained <e2>malice</e2>."
Other
Comment:

2180	"A <e1>nurse</e1> helps the <e2>caregiver</e2>."
Other
Comment: It violates (e) "People are not usually classified as Instruments, unless they are clearly non-agentive in the situation." The nurse "helps", so she is co-operative.

2181	"Anthony finds inspiration in a beautiful, enigmatic older woman who teaches him to follow his heart and find <e1>happiness</e1> through swing <e2>dancing</e2>."
Cause-Effect(e2,e1)
Comment:

2182	"St John's wort reduced the severity of <e1>depression</e1> after six <e2>weeks</e2>."
Other
Comment:

2183	"Statistical <e1>analysis</e1> was made using the PCSM <e2>program</e2>."
Other
Comment: Purpose-Tool

2184	"Habitat <e1>degradation</e1> from within stream <e2>channels</e2>, loss of riparian vegetation, and reductions in water quality degrade and also limit the population."
Other
Comment:

2185	"They often have a <e1>pump</e1> over the drainage <e2>hole</e2> to draw the waste water towards it."
Other
Comment:

2186	"Surgery is reserved for treating residual disease six to eight <e1>weeks</e1> after radiation <e2>therapy</e2> or for recurrence."
Other
Comment:

2187	"I'm finding the most <e1>joy</e1> comes from Asian <e2>flavours</e2>; beautiful fresh fish; things that have been marinated; roasted vegetables; meats that intensify in flavour during the cooking process; and dishes made from the most brilliant, fresh, in-season food."
Cause-Effect(e2,e1)
Comment:

2188	"A cancer survivor writes about the relatively rare occurrence of <e1>calcification</e1> of the breast after radiation <e2>therapy</e2>."
Cause-Effect(e2,e1)
Comment:

2189	"<e1>Batteries</e1> stored in <e2>contact</e2> with one another generate heat and hydrogen gas."
Other
Comment: "in contact with" describes the way in which batteries are stored. None of the nine relations holds.

2190	"Of the situation in the fifteenth century, Parkes remarks: 'The <e1>mass</e1> of the people cultivated the <e2>land</e2>'."
Other
Comment: The land was not brought into existence by the people, it already existed.

2191	"His tendency to experience pathological <e1>anxiety</e1> from his early <e2>years</e2> and his tendency to respond to novelty, change, and challenges with an exaggerated anxiety response were noted."
Other
Comment:

2192	"The entire site was actively farmed during the 2004 growing season and aerial photography indicates the <e1>site</e1> has been farmed for multiple <e2>years</e2>."
Other
Comment: E2 is a temporal expression.

2193	"The <e1>neutrons</e1> were produced by <e2>bombarding</e2> a tritium target with deuterium."
Cause-Effect(e2,e1)
Comment:

2194	"Before doing for his hair <e1>reduction</e1> by laser <e2>treatment</e2>, he first consulted with a dermatologist."
Cause-Effect(e2,e1)
Comment: modal "should" doesn't affect the relation?

2195	"The <e1>rings</e1> are preferably made from a <e2>copolymer polypropylene</e2>."
Other
Comment:

2196	"Ancient pagan traditions used <e1>famine</e1> following <e2>feast</e2> as a way of revealing truth."
Other
Comment:

2197	"The <e1>students</e1> designed the home's living <e2>areas</e2> with an eye toward making a small house feel spacious."
Other
Comment:

2198	"The <e1>company</e1> developed the <e2>negatives</e2> and returned the camera with a fresh roll of film."
Other
Comment: Developing negatives doesn't mean making them.

2199	"The <e1>measurement</e1> was made using a gonio-photometric color measurement <e2>system</e2>."
Other
Comment: Purpose-Tool

2200	"Any <e1>deformation</e1> from the circular <e2>form</e2> have a significant effect on the ability of the hose to sustain internal pressure."
Other
Comment:

2201	"The check given by Charles V to the advance of the Ottoman power along the African coast made him appear to the world as the liberator of the Christians and the <e1>terror</e1> of the <e2>infidels</e2>, and gave him such prestige that Francis felt obliged to get all the advantage possible out of his alliance."
Other
Comment:

2202	"Craig expressed his <e1>frustration</e1> after Monday's <e2>meeting</e2>."
Other
Comment:

2203	"It supports the personal information and interaction environment thus liberating the <e1>person</e1> from tedious <e2>chores</e2> and enriching their life and interaction with others in social or business contexts it enlarges the personal contribution."
Other
Comment:

2204	"The <e1>clutter</e1> in my <e2>house</e2> was destroying me."
Other
Comment: A state.

2205	"It is a motorized spherical mechanism that simulates the <e1>rowing motion</e1> of an <e2>oar</e2>."
Other
Comment:

2206	"The site was encircled by a high fence and one could see a <e1>crane</e1> lifting some heavy <e2>construction material</e2>."
Other
Comment:

2207	"With lyrical descriptions of landscape and terse, unpunctuated dialogue, a distinctive <e1>voice</e1> powered a gripping <e2>story</e2>."
Other
Comment: The voice might be interpreted as an Instrument, but Agency is missing. No one of the nine relations applies.

2208	"During his travel to Russia you managed to buy vodka in a <e1>plastic</e1> <e2>bag</e2>."
Other
Comment:

2209	"Among them, 24% is related to <e1>microarrays</e1> fabricated by the microspotting <e2>approach</e2>."
Other
Comment:

2210	"Chinese liquor is a kind of <e1>wine</e1> produced by solidified <e2>fermentation</e2> of grain."
Other
Comment: Fermentation is an event, wine is a concrete substance.

2211	"The <e1>saw</e1> cut a large <e2>hole</e2> in a huge concrete wall at the plant."
Other
Comment: e1 is an Instrument, so Cause-Effect and Product-Producer are ruled out. But e2 is not an Agent.

2212	"A <e1>raindrop</e1> keeps the same <e2>shape</e2> to a reasonable approximation all the time it is falling."
Other
Comment:

2213	"The <e1>scientists</e1> made the surprising <e2>observation</e2> that SMN binds efficiently -- and carry out its functions -- when the proteins to which it needs to bind are first "tagged" by specific enzymes."
Other
Comment: Observation is ambiguous, it could be an event or a speech act. The former seems more probable.

2214	"Short-term side effects are uncommon, but include <e1>headache</e1> from <e2>eyestrain</e2>, nausea, agitation or nervousness."
Cause-Effect(e2,e1)
Comment:

2215	"The reaction <e1>mixture</e1> is kept in the <e2>dark</e2> at room temperature for 1 1/2 hours."
Other
Comment: "Dark" is a state.

2216	"Thatch is caused by excessive <e1>growth</e1> from <e2>overfertilizing</e2>, by allowing the grass to get too high before mowing, or by incorrect watering."
Cause-Effect(e2,e1)
Comment:

2217	"Alabama has since enacted legislation, allowing <e1>death</e1> by lethal <e2>injection</e2> as an alternative choice to death in the electric chair."
Cause-Effect(e2,e1)
Comment:

2218	"As the officer shone his flashlight on the lock he was working on, he spotted a <e1>marijuana pipe</e1> laying on the floor inside the <e2>car</e2>."
Other
Comment: Vehicles should not be considered containers. The marijuana pipe was located in the car.

2219	"The <e1>organization</e1> helps educate practitioner <e2>dentists</e2> through clinical meetings."
Other
Comment: This is collaboration rather than use.

2220	"One newly formed Iraqi battalion is on duty, with 27 scheduled for <e1>activation</e1> by <e2>summer</e2> 2004."
Other
Comment:

2221	"The <e1>bacon</e1> <e2>manufacture</e2> is the 74th greatest export of Denmark."
Other
Comment: Manufacture is an event.

2222	"The <e1>trench</e1> was inside the <e2>fenced back yard</e2>."
Other
Comment: The fenced back yard is more a location than a container.

2223	"Strikingly large in scale, this <e1>grater</e1> shaves a perfect <e2>portion</e2> in a single stroke."
Other
Comment:

2224	"<e1>Heating</e1> <e2>oil</e2> is a refined oil made from petroleum, used in furnaces to heat buildings."
Other
Comment:

2225	"Original <e1>sculptures</e1> were carved with a <e2>chainsaw</e2>."
Other
Comment:

2226	"It's very rewarding and I get a great deal of enjoyment and <e1>satisfaction</e1> from <e2>mentoring</e2>."
Cause-Effect(e2,e1)
Comment:

2227	"Other non-native species used in aquaculture are brook trout (Salvelinus fontinalis) and lake trout (Salvelinus namaycush), <e1>fishes</e1> that mainly has been farmed for stocking <e2>purposes</e2>."
Other
Comment:

2228	"The <e1>bombing</e1> produced the worst <e2>carnage</e2> since a Nov. 23 attack in the Shi'ite slum of Sadr City that killed more than 200 people."
Cause-Effect(e1,e2)
Comment: Bombing and carnage are events.

2229	"My problem is that the <e1>advertisement</e1> gives the <e2>impression</e2> that women in rural Bangladesh have 6 children."
Cause-Effect(e1,e2)
Comment:

2230	"The southern <e1>supercell</e1> produced the longest <e2>tornado track</e2> of the outbreak (tornado #4)."
Cause-Effect(e1,e2)
Comment: A super cell storm is an occurrence.

2231	"The newer lesser-known attraction that the kibbutz offers is a reconstructed <e1>oil</e1> <e2>press</e2> whose beginnings can be traced to the early 20th century in Jaffa."
Other
Comment: This is something like Instrument-Product.

2232	"That year, summer students at the VLA made the first discovery of radio <e1>emission</e1> from a brown <e2>dwarf</e2>."
Cause-Effect(e2,e1)
Comment:

2233	"The tongue has taste buds, but a cat's <e1>appetite</e1> comes from the <e2>smell</e2> of the food and doesn't come from the taste of it."
Cause-Effect(e2,e1)
Comment:

2234	"They understand the <e1>stakes</e1> from a personal <e2>perspective</e2>, as well, since the extremists have tried to assassinate them."
Other
Comment:

2235	"The <e1>dryer</e1> emits <e2>air</e2> that is regulated close to your body temperature."
Cause-Effect(e2,e1)
Comment:

2236	"Sparky Anderson is making progress in his <e1>recovery</e1> from <e2>exhaustion</e2> and could return to managing the Detroit Tigers within a week."
Other
Comment:

2237	"Flight <e1>disruption</e1> after the <e2>attacks</e2> in the US delayed him there for three days."
Cause-Effect(e2,e1)
Comment:

2238	"Ray Parlour shows his <e1>frustration</e1> after Middlesbrough's <e2>defeat</e2>."
Cause-Effect(e2,e1)
Comment:

2239	"To repair, he used duct tape and caulk to seal <e1>gaps</e1> in the <e2>metal box</e2> and between joints and seams in the duct."
Other
Comment: Here gaps are a status or defect, not a functional part of the box.

2240	"Hundreds of thousands in central China are sleeping outdoors for fear of more <e1>tremors</e1> after Saturday's <e2>earthquake</e2>."
Cause-Effect(e2,e1)
Comment:

2241	"The <e1>carbohydrase</e1> is produced by a <e2>process</e2> which completely removes the organism Rhizopus oryzae from the carbohydrase product."
Other
Comment: A process cannot be a Producer.

2242	"We saved the <e1>planet</e1> from the imperialist <e2>threat</e2>."
Other
Comment:

2243	"The contents of the <e1>satchel</e1> were a <e2>revelation</e2>."
Other
Comment: it seems more a property of the satchel.

2244	"InterSense, Inc., a market leader in precision motion technology, today announced that Hydro, a leading <e1>offshore</e1> <e2>producer</e2> of oil and gas, has installed its tenth InterSense IS-900 Precision Motion Tracking System as part of Hydro's large scale immersive visualization rooms."
Other
Comment:

2245	"She got rid of the <e1>ants</e1> in the <e2>kitchen</e2> without using dangerous pesticides."
Other
Comment: The kitchen is not a container, ants are located in the kitchen.

2246	"The <e1>taste</e1> is from the <e2>ginseng</e2>, not alcohol."
Cause-Effect(e2,e1)
Comment:

2247	"In each <e1>house</e1> lives a <e2>person</e2> with a different nationality."
Other
Comment: People should not be considered content and buildings should not be considered containers.

2248	"Maybe the most significant difference is that we have changed from <e1>emigration</e1> out of <e2>necessity</e2> to emigration in search of new opportunities."
Cause-Effect(e2,e1)
Comment:

2249	"An <e1>office</e1> that contains <e2>plants</e2> creates an agreeable environment for yourself and others."
Other
Comment: office is more a location than a container.

2250	"This daily assault of inflammation in their digestive system, plus the <e1>inflammation</e1> from your <e2>joints</e2> and an overworked immune system and excess weight easily exceed the amount of inflammation your body can effectively handle."
Other
Comment:

2251	"'The Incredible Shrinking Man' follows Matheson's novel and effectively captures the <e1>terror</e1> of the <e2>protagonist</e2> as he shrinks to oblivion."
Other
Comment:

2252	"Nausea is the sensation of unease and <e1>discomfort</e1> from the <e2>stomach</e2>, with the sufferers feeling that they may vomit."
Other
Comment:

2253	"On both of my systems, the <e1>reboot</e1> produced the ominous <e2>message</e2> 'Missing operating system'."
Cause-Effect(e1,e2)
Comment:

2254	"The <e1>person</e1> providing the <e2>alibi</e2> is the culprit and would be providing a fabricated alibi."
Cause-Effect(e1,e2)
Comment: modality is outside

2255	"Once the <e1>photon</e1> was inside the <e2>cloud</e2>, the control beam was switched off, allowing the photon to come to a halt inside the dense ensemble of atoms."
Other
Comment: A container must be clearly delineated in space. This looks like location.

2256	"The effect of pain <e1>relief</e1> by <e2>acupuncture</e2> lasts for an extended period of time, sometimes months after the needle was removed."
Cause-Effect(e2,e1)
Comment:

2257	"About 30 ducks were found dead in Klamath County in the past two days, and officials are investigating whether the <e1>deaths</e1> are from a cholera <e2>outbreak</e2>."
Cause-Effect(e2,e1)
Comment:

2258	"Principals respond to a <e1>decrease</e1> in uncertainty with more aggressive <e2>strategies</e2>."
Cause-Effect(e1,e2)
Comment:

2259	"Most of the <e1>taste</e1> of strong onions comes from the <e2>smell</e2>."
Cause-Effect(e2,e1)
Comment:

2260	"A city nightclub has had an ambitious expansion plan blocked over concerns about unruly <e1>behaviour</e1> from drunken <e2>revellers</e2>."
Cause-Effect(e2,e1)
Comment:

2261	"The studies revealed that skin <e1>irritation</e1> from <e2>soaps</e2>, inaccessibility to supplies or sinks, and insufficient time to wash hands between every patient care contact were the main reasons given by healthcare workers for lack of handwashing compliance."
Cause-Effect(e2,e1)
Comment:

2262	"The <e1>hardcopy</e1> <e2>book</e2> (at an even higher price) and this one purchase ensures you are up to date with all future releases of the electronic book."
Other
Comment:

2263	"But not every run of the <e1>experiment</e1> produced the desired <e2>state</e2> - a very large number of failed tries accompanied each successful creation."
Cause-Effect(e1,e2)
Comment:

2264	"Monica Mullikin ('00) is working for Willis of Minneapolis as a catastrophe risk analyst for this <e1>reinsurance</e1> <e2>company</e2>."
Other
Comment:

2265	"The brachioradialis <e1>reflex</e1> is observed by striking the brachioradialis tendon directly with the <e2>hammer</e2> when the patient's arm is resting."
Other
Comment: e2 is an Instrument

2266	"The <e1>movie</e1> gives the inaccurate <e2>impression</e2> that the Apaches all surrendered."
Cause-Effect(e1,e2)
Comment:

2267	"Saunders felt a resurgence of the <e1>panic</e1> from this <e2>morning</e2> when he'd regained consciousness in the minefield."
Other
Comment:

2268	"Learning to change your vehicle's <e1>engine</e1> <e2>oil</e2> saves you time and money."
Other
Comment:

2269	"The <e1>soy milk</e1> makes a great coffee <e2>creamer</e2> (and with whatever else you can cook it)."
Other
Comment: "makes" is synonymous with "is" here.

2270	"Thailand has been bracing itself for a <e1>downturn</e1> in the wake of the <e2>bombs</e2>, especially in the tourist sector."
Cause-Effect(e2,e1)
Comment:

2271	"Literary criticism is the study of literature by means of a microscopic knowledge of the language in which a book is written, of its <e1>growth</e1> from various <e2>roots</e2>, of its stages of development and the factors influencing them, of its condition in the period of this particular composition, of the writer's idiosyncrasies of thought and style in his ripening periods, of the general history and literature of his race, and of the special characteristics of his age and of his contemporary writers."
Other
Comment:

2272	"The <e1>ringtone</e1> makes the <e2>telecommunicator</e2>."
Other
Comment:

2273	"The <e1>spiciness</e1> comes from small capsaicin <e2>glands</e2> located between the pepper's outside skin and the white ribs inside."
Cause-Effect(e2,e1)
Comment:

2274	"In one day, the Red Crescent treated more than 50 injuries - mainly broken bones caused by <e1>panic</e1> from <e2>aftershocks</e2>."
Cause-Effect(e2,e1)
Comment:

2275	"American <e1>sports</e1> are played with the <e2>hands</e2>."
Other
Comment: Hands are parts of the players involved in sports, so they cannot be Instruments.

2276	"Japanese commuters look at a <e1>clock</e1> inside a Tokyo <e2>train station</e2>."
Other
Comment: Location. A station is not even remotely as container-like as rooms and caves can be.

2277	"He mounts the photo on a <e1>material</e1> that contains <e2>acid</e2>, so that the paper absorbs the acid which in turn attacks the photo itself."
Other
Comment: The material is made of acid, and acid does not have clear boundaries (stuff-object relation).

2278	"In the most common form of such an attack, called ischemic stroke, the <e1>blockage</e1> comes from a blood <e2>clot</e2> that develops in one of the brain's blood vessels."
Cause-Effect(e2,e1)
Comment:

2279	"The report links conditions in some of the worst affected localities and the likelihood that dire poverty - combined with despair and <e1>outrage</e1> over rampant <e2>corruption</e2>, repressive policies, and governments' failure to address local needs - could lead to outbreaks of localised unrest with the potential to spread into a wider regional conflict."
Cause-Effect(e2,e1)
Comment: modality is outside

2280	"Everybody in the region experienced the <e1>tremors</e1> after <e2>midnight</e2>."
Other
Comment:

2281	"A <e1>thermostat</e1> keeps the <e2>water</e2> at the requested temperature."
Other
Comment:

2282	"The troubled company is still feeling <e1>aftershocks</e1> after its devastating <e2>withdrawal</e2> of the pain medication Vioxx six months ago."
Cause-Effect(e2,e1)
Comment:

2283	"Energy <e1>expenditure</e1> through physical <e2>activity</e2> is a key component in the prevention and treatment of overweight and obesity."
Cause-Effect(e2,e1)
Comment:

2284	"The <e1>artist</e1> who originally made the <e2>song</e2> popular is listed for reference only."
Other
Comment: Making a song popular is not the same as making it.

2285	"The quartz sample <e1>tube</e1> with polyradical residue was cut with diamond <e2>knife</e2> to the size that fit into the Teflon digestion vessel."
Other
Comment: Again Instrument-Product.

2286	"Clinton Portis, who missed last week's game against Dallas because of a shoulder <e1>injury</e1> from the <e2>preseason</e2>, rushed for 86 yards on 16 attempts to become the fifth-fastest player to reach the 6,000-yard mark in his career."
Other
Comment:

2287	"The <e1>cathode</e1> emits <e2>electrons</e2>."
Cause-Effect(e1,e2)
Comment: electrons have no mass.

2288	"The <e1>product</e1> emits <e2>radiation</e2>."
Cause-Effect(e1,e2)
Comment:

2289	"They put <e1>wine</e1> in the exact <e2>context</e2> it needs to be kept in - not so bloody serious."
Other
Comment: None of the nine relations hold.

2290	"<e1>Infection</e1> starts with manual <e2>execution</e2> of the binary."
Cause-Effect(e2,e1)
Comment:

2291	"The <e1>construction</e1> gives a <e2>refinement</e2> of Nori's argument in the case of a self-product of a curve."
Cause-Effect(e1,e2)
Comment:

2292	"<e1>Picric acid</e1> is kept in an <e2>aqueous solution</e2>, which makes it suitable and safe to handle."
Other
Comment: Picric acid is part of the aqueous solution but does not have clear boundaries (stuff-object relation).

2293	"The big <e1>savings</e1> is coming from the <e2>hardware side</e2>."
Other
Comment:

2294	"Examples include the <e1>exclusion</e1> of certain benefits from funding <e2>standards</e2> and the exclusion of entire plans from certain funding requirements."
Other
Comment:

2295	"When he was back he noticed that he had locked the <e1>keys</e1> inside the <e2>car</e2>."
Other
Comment: Vehicles should not be considered containers: keys are located, not stored, in the car.

2296	"The <e1>collaboration</e1> produced the PUMP(Pittsburg urban mathematics program) <e2>curriculum</e2>, which focuses on mathematical analyses of real-world situations, the use of computational tools, and on making algebra accessible to all students."
Other
Comment: The collaboration is an event and cannot be a Producer; the curriculum is a creative work.

2297	"The only <e1>change</e1> is from the energy company's <e2>end</e2>, where their section of the gas or electricity infrastructure is now supplying an extra home."
Other
Comment:

2298	"A <e1>potato</e1> <e2>peeler</e2> is a metal blade attached to a metal, plastic or wooden handle that is used for peeling vegetables, usually potatoes."
Other
Comment:

2299	"A pool with a sand <e1>beach</e1> is located inside the <e2>cave</e2>."
Other
Comment: The cave is more a location than a container and the beach is not stored there (entity-location relation).

2300	"The third <e1>observation</e1> was made with the Echellette <e2>spectrograph</e2>."
Other
Comment: Purpose-Tool

2301	"For projects submitted at national level, the <e1>volunteer</e1> is sent by a <e2>organization</e2> legally established in his/her country of residence."
Other
Comment:

2302	"In zen, there is a strong relationship between <e1>work</e1> and <e2>food</e2>, for the former begets the latter."
Other
Comment: The relation is a causal one, but food is a concrete substance and cannot be an Effect, while work is an event and cannot be a Producer.

2303	"There were the years of constant fatigue and shortness of breath, the heart attack at age 11, the <e1>collapse</e1> from <e2>exhaustion</e2> on her high school graduation night."
Cause-Effect(e2,e1)
Comment:

2304	"The commission merely implements the contracts, shielding the major party <e1>candidates</e1> from public <e2>criticism</e2>."
Other
Comment:

2305	"And because of a last minute <e1>collapse</e1> from <e2>top</e2> to bottom - what would be and should be a perfect season to this point is just another year."
Other
Comment: modality is outside

2306	"The surrounding <e1>region</e1> is farmed for its <e2>fertility</e2>."
Other
Comment:

2307	"Peterson worked as a <e1>fertilizer</e1> <e2>salesman</e2> before his arrest."
Other
Comment:

2308	"<e1>Surgery</e1> after radiation <e2>chemotherapy</e2> is an effective local treatment, which is able to significantly increase local tumor control compared to radiation chemotherapy only."
Other
Comment:

2309	"The pipeline had to face the following main concerns from opposition: disturbance of animal migration patterns, environmental <e1>damage</e1> from <e2>spills</e2>, geological concerns and the Alaskan permafrost."
Cause-Effect(e2,e1)
Comment:

2310	"A <e1>therapist</e1> helps the <e2>patient</e2> to understand himself or herself better."
Other
Comment: (e) People are not usually classified as Instruments, unless they are clearly non-agentive in the situation.

2311	"<e1>Dehydration</e1> from fluid <e2>loss</e2> is the only major problem the virus causes, most often in the elderly."
Cause-Effect(e2,e1)
Comment:

2312	"<e1>Yoga</e1> is fantastic for increased <e2>flexibility</e2>, which is great for cross-training with all the other programs we offer."
Cause-Effect(e1,e2)
Comment:

2313	"The <e1>electricity</e1> is produced by 440 nuclear <e2>reactors</e2> in 31 countries."
Cause-Effect(e2,e1)
Comment:

2314	"A <e1>mediator</e1> assists the <e2>parties</e2> in finding their own answers for the problems before them by encouraging constructive communications, keeping the parties focused on settlement alternatives, offering information and suggestions as needed, and building the foundation for improved relations between the parties."
Other
Comment: (e) People are not usually classified as Instruments, unless they are clearly non-agentive in the situation.

2315	"This year's newest attractions include a dedicated music zone which takes you on a musical journey around the world and gives you a chance to experience musical <e1>ecstasy</e1> from different <e2>cultures</e2>."
Other
Comment:

2316	"He was a <e1>trouble</e1> <e2>maker</e2> then, a leader in SDS, and a trouble maker he remains."
Cause-Effect(e1,e2)
Comment:

2317	"The <e1>driver</e1> was trapped inside the <e2>car</e2>, which landed upside down, and died while emergency crews were preparing to transport him to a local hospital."
Other
Comment: We excluded Content-Container because people should not be considered contents and vehicles should not be considered containers.

2318	"Since the <e1>evacuation</e1> was after normal <e2>business hours</e2>, the on-duty Security Officer and maintenance personnel were responsible for the notification and evacuation of occupants of all buildings."
Other
Comment: modality is outside

2319	"The controlled environment <e1>facility</e1> is for <e2>growth</e2> of experimental material only."
Other
Comment:

2320	"The <e1>materials</e1> were produced by <e2>mixing</e2> the constituents and processing them through a press/sinter cycle to produce a consolidated material."
Other
Comment:

2321	"The hotel is in the style of a <e1>country</e1> <e2>lodge</e2> and only has 18 rooms."
Other
Comment:

2322	"In summer 2000, an Adventist church in Polotsk, Vitebsk Region, was damaged by a <e1>fire</e1> started with <e2>flammable liquids</e2>."
Cause-Effect(e2,e1)
Comment:

2323	"The film also features documentary like segments about fishing and about the <e1>evacuation</e1> after the <e2>eruption</e2> of the volcano."
Cause-Effect(e2,e1)
Comment:

2324	"The voltage swing obtainable across the load is greater than the output voltage <e1>swing</e1> obtainable from the <e2>amplifier</e2> alone, thus the efficiency of the amplifier system and power handling capacity of the system are improved."
Cause-Effect(e2,e1)
Comment:

2325	"This was the signal for dozens of others to do the same and the <e1>noise</e1> inside the <e2>car</e2> was quite something."
Other
Comment: None of the nine relations seems to hold. The car is not the origin/producer of the noise.

2326	"In 1871, nearly 60 percent of the Italian <e1>population</e1> farmed for a <e2>living</e2>, attempting to eke out an existence from arid land that often was not their own."
Other
Comment: Living is an abstract object.

2327	"<e1>Cooperation</e1> through physical <e2>activity</e2> promotes important life skills."
Other
Comment:

2328	"We examined mood <e1>alterations</e1> through physical <e2>activity</e2> and other interventions."
Cause-Effect(e2,e1)
Comment:

2329	"In addition, scientists maye have a number of potentially useful targets to prevent and treat this lethal tumour because of the findings that NOX5 mediated <e1>overproduction</e1> of hydrogen peroxide is responsible for increased <e2>growth</e2> and decreased death of cancer cells."
Cause-Effect(e1,e2)
Comment:

2330	"In a little time the numbers increased from forty-five to eighty, and soon after to a greater number; which, with the majority of the clergy, and the whole of the national representatives, put the <e1>malcontents</e1> in a very <e2>diminutive condition</e2>."
Other
Comment: None of the nine relations holds. (Maybe state.); cannot be Entity-Destination since E-D's c.3 does not allow states as destinations

2331	"Paul the <e1>novelist</e1> has a <e2>computer</e2> but uses his old Smith Corona manual."
Other
Comment:

2332	"It was also felt necessary at this time to draw up a similar document, dealing not with the prevention of marine <e1>pollution</e1> by <e2>dumping</e2>, but instead with the prevention of marine pollution by discharges of dangerous substances from land-based sources, watercourses or pipelines."
Cause-Effect(e2,e1)
Comment:

2333	"Short-term disability and long-term <e1>disability</e1> <e2>benefits</e2> are available at no cost to USTelecom employees."
Cause-Effect(e1,e2)
Comment:

2334	"There are three set changes and two intervals which help the <e1>recovery</e1> from <e2>laughter</e2>, but the entertainment is maintained despite the well expected ending."
Other
Comment:

2335	"This proves that the <e1>generator</e1> actually produced the renewable <e2>energy</e2> purchased and acts as the operative instrument of the transaction."
Cause-Effect(e1,e2)
Comment:

2336	"Because it's a strong, lint-free synthetic material with tiny absorbent fibers, <e1>microfiber</e1> allows a <e2>mop</e2> to hold sufficient water without dripping."
Other
Comment: Not Component-Whole because microfiber is a material not a part.

2337	"The <e1>shroud</e1> is kept in the <e2>cathedral</e2> of St. John the Baptist in Turin, Italy."
Other
Comment: Location

2338	"The said <e1>whistle</e1> produced the 2600 Hz <e2>tone</e2> necessary to authorize calls."
Cause-Effect(e1,e2)
Comment:

2339	"While that operation was a success, the <e1>contents</e1> of the satchel were a tiny <e2>loss</e2> for the traffickers."
Other
Comment: None of the nine relation holds between "loss" and "satchel".

2340	"There exists a widespread <e1>controversy</e1> over stem cell <e2>research</e2> that emanates from the techniques used in the creation and usage of stem cells."
Cause-Effect(e2,e1)
Comment: The controversy is widespread and about the research, moreover the research causes the controversy. According to our guidelines Cause-Effect is however more informative.

2341	"In the months leading up to trade negotiations, estimates of the economic <e1>gains</e1> from trade <e2>liberalization</e2> suddenly become newsworthy."
Cause-Effect(e2,e1)
Comment:

2342	"The resulting anti-social <e1>behaviour</e1> from alcohol <e2>consumption</e2> is an on-going matter that the town and the police continue to address, particularly in the summer months."
Cause-Effect(e2,e1)
Comment:

2343	"The <e1>revolution</e1> brought forth impassioned <e2>pleas</e2> condemning the common law for not respecting the interests of the people and calling for law reform."
Cause-Effect(e2,e1)
Comment:

2344	"And John was able to talk to some people in the U.S. government and verify that the substantive contents of the <e1>memo</e1> were a reasonably accurate <e2>transcription</e2> of what had transpired."
Other
Comment: Mis-tagged again... It's a form of "equivalence", in that the memo is a transcription (not part of it); modality is outside

2345	"He combines strawberries and <e1>powder</e1> <e2>sugar</e2> and mixes well."
Other
Comment:

2346	"The health <e1>benefits</e1> of alcoholic <e2>beverages</e2> are the subject of this investigation."
Cause-Effect(e2,e1)
Comment:

2347	"And we do recommend excersise, as the <e1>kitchen</e1> holds <e2>culinary temptations</e2> in store for you that are bound to prolong your evening and lift your spirit."
Other
Comment: None of the nine relations seems to hold; modality is outside

2348	"I struggle for my dream of painless perfection but a <e1>snowdrift</e1> keeps the <e2>door</e2> from opening."
Other
Comment:

2349	"We conducted a usability test on the enterprise-wide navigation system for this <e1>heathcare</e1> <e2>company</e2>'s proposed intranet redesign."
Other
Comment: Healthcare is not a concrete object nor is it an mental activity.

2350	"<e1>Inhibition</e1> through synaptic <e2>depression</e2> is unlike the previous forms of inhibition in that it turns on more slowly and thus acts as delayed negative feedback."
Cause-Effect(e2,e1)
Comment:

2351	"The <e1>joy</e1> comes from Cather's <e2>writing</e2>: precise observation and wording, the lilting cadence of her phrasing, the beautiful and clear pictures she evokes of scenery and characters, and the unfamiliar, old fashioned words and expressions she uses."
Cause-Effect(e2,e1)
Comment:

2352	"The <e1>robber</e1> was inside the <e2>office</e2> when the manager decided to take action and escape out the side door."
Other
Comment: People should not be contents, instead the robber was located in the office.

2353	"<e1>Famine</e1> following <e2>drought</e2> has hit the West African savannahs, where there have been other bad droughts, notably the great one of 1972-74."
Cause-Effect(e2,e1)
Comment:

2354	"But for the family that shares the cooking and clean up duties, the <e1>kitchen</e1> holds a special <e2>nuturing role</e2> beyond supplying nutrition for the physical body."
Other
Comment: This might be purpose.

2355	"The small knife <e1>assemblies</e1> are widely used for cutting various <e2>strips</e2> of flexible materials."
Other
Comment:

2356	"<e1>People</e1> harvest the <e2>seeds</e2>, macerate them, and roll them into thick sticks of dry, hardened paste which can then be stored or exported from the region."
Other
Comment: Harvesting is not creation

2357	"Grubs tend to cause significant <e1>damage</e1> from <e2>autumn</e2> to spring by which time the larvae are becoming fully grown."
Other
Comment:

2358	"<e1>Adults</e1> with <e2>sleep deprivation</e2> who listened to soft classical music at bedtime reported a 35 percent improvement in their quality of sleep."
Other
Comment:

2359	"It was this moist <e1>ground</e1> that during construction engulfed a <e2>crane</e2> which remains under the stadium today."
Other
Comment:

2360	"Tom plans to continue to live the <e1>country</e1> <e2>life</e2> as he grows older."
Other
Comment:

2361	"Near Adelaide the <e1>land</e1> is intensively farmed for <e2>dairying</e2>, fruit, and vegetables."
Other
Comment: Dairying is an event, not an entity.

2362	"Ride Metrorail and then pick up a car just <e1>steps</e1> from the <e2>train</e2> to run errands, shop or reach any other business or social event not easily accessible via transit."
Other
Comment:

2363	"Providence had sent the old <e1>man</e1> into the world with a <e2>chisel</e2> in his hand."
Other
Comment: The man isn't using the chisel for anything.

2364	"And, of course, everyone wants to prove the truth of their beliefs through experience, but the <e1>belief</e1> begets the <e2>experience</e2>."
Cause-Effect(e1,e2)
Comment: Both elements are occurrences; modality is outside

2365	"The mesopause separates the <e1>mesosphere</e1> from the <e2>thermosphere</e2>."
Other
Comment:

2366	"The <e1>man</e1> radiated <e2>jolliness</e2>."
Cause-Effect(e1,e2)
Comment:

2367	"Earplugs relieve the <e1>discomfort</e1> from <e2>traveling</e2> with a cold allergy or sinus condition."
Cause-Effect(e2,e1)
Comment:

2368	"There is a rise in erratic <e1>behaviour</e1> from substance <e2>abuse</e2> and frustration caused by long waits for hospital treatment."
Cause-Effect(e2,e1)
Comment:

2369	"The residents and <e1>scientists</e1> learned from the Krakatau <e2>explosion</e2>."
Other
Comment:

2370	"This is an overview of the viewer from a <e1>developer</e1>'s <e2>perspective</e2>."
Other
Comment:

2371	"Months later, the <e1>birds</e1> composed the <e2>syllables</e2> into complete songs, whether the songs matched natural patterns or not."
Other
Comment: The sentence describes the creation of songs from pre-existing syllables.

2372	"The spring <e1>molt</e1> produces mottled brown <e2>feathers</e2>, making the female almost invisible as she sits on her nest."
Cause-Effect(e1,e2)
Comment: The molt is the process or the cause, not the producer.

2373	"Beauty had scarcely uttered these words when the <e1>castle</e1> radiated with <e2>light</e2>."
Cause-Effect(e1,e2)
Comment:

2374	"Muscles, tendons, and ligaments surround the ankle providing the <e1>stability</e1> the <e2>ankle joint</e2> needs for walking and running."
Other
Comment:

2375	"This durable short sleeve crew neck tee shirt is made of preshrunk cotton to minimize <e1>shrinkage</e1> after <e2>washing</e2>."
Cause-Effect(e2,e1)
Comment:

2376	"The <e1>institution</e1> provides a <e2>deposit</e2>, as set in the Commission dues and fees schedule, towards the fee when it submits its appeal document."
Other
Comment:

2377	"We take <e1>multivitamin</e1> that contains <e2>vitamins</e2> D, E, K, and beta-carotene."
Other
Comment: vitamins are part of the multivitamin with no clear boundaries (stuff-object relation).

2378	"Many <e1>students</e1> deviate from the ideal <e2>curricula</e2> presented in a later section of this bulletin."
Other
Comment:

2379	"Givers gain moral strength and <e1>happiness</e1> from <e2>giving</e2>."
Cause-Effect(e2,e1)
Comment:

2380	"Effective <e1>canola</e1> <e2>production</e2> requires hands-on involvement with the crop."
Other
Comment:

2381	"Auto EQ is a powerful sound tuning feature which uses a microphone to monitor and analyse the <e1>acoustics</e1> inside the <e2>car</e2>."
Other
Comment: Acoustics is a property of the interior of the car.

2382	"A very robust metal hydride discovery <e1>approach</e1> was made with a demonstrated HTS <e2>methodology</e2>."
Other
Comment: Purpose-Tool

2383	"The Norwalk <e1>juicer</e1> grinds and presses any <e2>fruit</e2> or vegetable."
Other
Comment:

2384	"Citing the <e1>conflict</e1> of interest created by the ethics <e2>charges</e2>, Nifong asked the state attorney general's office to take over the lacrosse case."
Cause-Effect(e2,e1)
Comment:

2385	"Sometimes <e1>joy</e1> comes from unexpected <e2>places</e2>."
Other
Comment:

2386	"Located inside the <e1>cave</e1> was an old, broken-down army field <e2>telephone</e2>."
Other
Comment: The "cave" is more a location than a container.

2387	"Apartment residents in Delaware were awarded $1 million for health problems due to mold <e1>growth</e1> from unrepaired <e2>leaks</e2>."
Cause-Effect(e2,e1)
Comment:

2388	"The rap star was apprehended at John Wayne Airport late last month and his <e1>truncheon</e1> was confiscated by <e2>police</e2>."
Other
Comment:

2389	"The severe <e1>famine</e1> following the <e2>good years</e2> required a political and economic reorganization in the country."
Other
Comment:

2390	"Retailers have done their bit to put <e1>wine</e1> in the <e2>hands</e2> of the masses, to make it more accessible to the wider UK public."
Other
Comment: None of the nine relations holds. It's a metaphorical location, perhaps.

2391	"The <e1>kitchen</e1> contained primarily <e2>drug paraphernalia</e2>."
Other
Comment: drug paraphernalia were located in the kitchen.

2392	"A lamp's lumen output expresses the total amount of <e1>light</e1> the <e2>lamp</e2> emits in all directions per unit time."
Cause-Effect(e2,e1)
Comment:

2393	"The <e1>tutors</e1> provide a consistent, reliable <e2>intervention</e2> that allows students who are falling behind an opportunity to reach proficiency."
Other
Comment:

2394	"<e1>Brushing</e1> after <e2>meals</e2> became part of your daily schedule."
Other
Comment:

2395	"A <e1>bus</e1> <e2>company</e2> has pledged a week-long roadside survey after a group of workers complained about its Bradford to Morley service."
Other
Comment: In this sentence the bus company does not produce the buses but it uses them.

2396	"When deliberations began, the <e1>crowd</e1> of people jamming the hallways radiated <e2>optimism</e2>."
Cause-Effect(e1,e2)
Comment:

2397	"The snooker <e1>player</e1> played the game with a <e2>smile</e2> on his face."
Other
Comment: The player isn't using his smile for anything. Could be Cause-Effect?

2398	"But Hong Kong was able to recover from that and is now experiencing strong economic <e1>growth</e1> from <e2>exports</e2>."
Cause-Effect(e2,e1)
Comment:

2399	"The <e1>sun</e1> emits <e2>light</e2> or radiation at a large range of energies or frequencies."
Cause-Effect(e1,e2)
Comment:

2400	"However, the fact that the guinea pigs appeared to function in a normal physiological manner indicates that the <e1>diets</e1> contained the necessary <e2>energy density</e2>."
Other
Comment: energy density seems to be a property of the diets.

2401	"Mr C notes <e1>worsening</e1> of seizures and cognition with sleep <e2>deprivation</e2> and stress."
Cause-Effect(e2,e1)
Comment:

2402	"The punk <e1>explosion</e1> cultivated the underground/indie rock <e2>scene</e2> that would one day be called 'alternative music'."
Other
Comment: modality is outside

2403	"The <e1>carpet</e1> is made from recycled <e2>materials</e2>."
Other
Comment:

2404	"This is incorrect, and when a <e1>minicab</e1> <e2>company</e2> uses the word taxi on their livery it can lead to prosecution by the local government body."
Other
Comment: In this sentence the mincab company does not produce the minicabs but it uses them.

2405	"A <e1>facilitator</e1> keeps the <e2>discussion</e2> focused and limited to the allotted time, while the recorder keeps a written record of the panel's recommendations."
Other
Comment:

2406	"Hand creams counteract <e1>dryness</e1> from <e2>exposure</e2> to wind, sun, and detergents."
Cause-Effect(e2,e1)
Comment:

2407	"Eye <e1>discomfort</e1> from this <e2>staring effect</e2> is exacerbated by low humidity."
Cause-Effect(e2,e1)
Comment:

2408	"The <e1>transmitter</e1> emits a constant radio <e2>signal</e2> to crea."
Cause-Effect(e1,e2)
Comment:

2409	"Parents also experience <e1>anxiety</e1> from <e2>fear</e2> of the suffering of their child and worry about an uncertain outcome."
Cause-Effect(e2,e1)
Comment:

2410	"In chemical lasers the <e1>inversion</e1> is produced by a chemical <e2>reaction</e2>."
Cause-Effect(e2,e1)
Comment:

2411	"A V8 <e1>engine</e1> mated with a manual transmission powers the convertible <e2>concept</e2>."
Other
Comment: The engine is an integral and functional part of the concept (car). Agencies cannot use their parts as Intruments.

2412	"When the <e1>notice</e1> is sent by <e2>fax</e2>, the notice is not deemed received until 3 days after faxing it."
Other
Comment:

2413	"The farmers and city officials in the region have tried to get state money to move the <e1>farmers</e1> <e2>market</e2> into a first-class operation and tourist attraction."
Other
Comment:

2414	"Intravenous <e1>azithromycin</e1> -induced <e2>ototoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2415	"Immobilization, while Paget's bone disease was present, and perhaps enhanced activation of <e1>dihydrotachysterol</e1> by rifampicin, could have led to <e2>increased calcium-release</e2> into the circulation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2416	"Unaccountable severe <e1>hypercalcemia</e1> in a patient treated for hypoparathyroidism with <e2>dihydrotachysterol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2417	"METHODS: We report two cases of <e1>pseudoporphyria</e1> caused by <e2>naproxen</e2> and oxaprozin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2418	"METHODS: We report two cases of <e1>pseudoporphyria</e1> caused by naproxen and <e2>oxaprozin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2419	"<e1>Naproxen</e1>, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating <e2>erythropoietic protoporphyria</e2> in the pediatric population."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2420	"RESULTS: A 44-year-old man taking <e1>naproxen</e1> for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and <e2>cutaneous fragility</e2> on the face and the back of the hands."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2421	"RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on <e1>oxaprozin</e1> for rheumatoid arthritis presented with tense bullae and <e2>cutaneous fragility</e2> on the face and the back of the hands."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2422	"RESULTS: A 44-year-old man taking <e1>naproxen</e1> for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with <e2>tense bullae</e2> and cutaneous fragility on the face and the back of the hands."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2423	"RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on <e1>oxaprozin</e1> for rheumatoid arthritis presented with <e2>tense bullae</e2> and cutaneous fragility on the face and the back of the hands."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2424	"BACKGROUND: How to best treat psychotic patients who have had past <e1>clozapine</e1> -induced agranulocytosis or <e2>granulocytopenia</e2> remains a problem."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2425	"CONCLUSION: The results suggest that olanzapine may be useful in treating patients with <e1>clozapine</e1> -induced <e2>granulocytopenia</e2> without the risk of recurrence of hematologic side effects."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2426	"Prolonged severe <e1>5-fluorouracil</e1> -associated <e2>neurotoxicity</e2> in a patient with dihydropyrimidine dehydrogenase deficiency."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2427	"We describe the side effects of <e1>5-FU</e1> in a colon cancer patient who suffered severe mucositis, desquamating dermatitis, prolonged myelosuppression, and <e2>neurologic toxicity</e2> that required admission to the intensive care unit."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2428	"We describe the side effects of <e1>5-FU</e1> in a colon cancer patient who suffered severe mucositis, desquamating dermatitis, <e2>prolonged myelosuppression</e2>, and neurologic toxicity that required admission to the intensive care unit."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2429	"We describe the side effects of <e1>5-FU</e1> in a colon cancer patient who suffered <e2>severe mucositis</e2>, desquamating dermatitis, prolonged myelosuppression, and neurologic toxicity that required admission to the intensive care unit."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2430	"This case suggests that <e1>BH-AC</e1>, a derivative of cytosine arabinoside (1-beta-D-arabinofuranosylcytosine) could be a cause of reversible <e2>encephalopathy syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2431	"We report a case of reversible <e1>encephalopathy syndrome</e1> in a 16-year-old girl with acute myelogenous leukemia (AML), who is undergoing during consolidation chemotherapy composed of <e2>BH-AC</e2> (N4-behenoyl-1-beta-D-arabinofuranosyl cytosine) and idarubicin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2432	"We report a case of reversible <e1>encephalopathy syndrome</e1> in a 16-year-old girl with acute myelogenous leukemia (AML), who is undergoing during consolidation chemotherapy composed of BH-AC (N4-behenoyl-1-beta-D-arabinofuranosyl cytosine) and <e2>idarubicin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2433	"In one case, the readministration of <e1>riluzole</e1> was followed by the relapse of <e2>hepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2434	"We report the cases of two patients who developed acute <e1>hepatitis</e1> after taking <e2>riluzole</e2> at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2435	"<e1>Lupus-like syndrome</e1> caused by <e2>5-aminosalicylic acid</e2> in patients with inflammatory bowel disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2436	"Although the two local anesthetics usually do not cause <e1>methemoglobinemia</e1>, we suspect that the displacement of <e2>lidocaine</e2> from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants, was the reason for the development of <e1>methemoglobinemia</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2437	"<e1>Methemoglobinemia</e1> after axillary block with <e2>bupivacaine</e2> and additional injection of lidocaine in the operative field."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2438	"<e1>Methemoglobinemia</e1> after axillary block with bupivacaine and additional injection of <e2>lidocaine</e2> in the operative field."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2439	"We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant <e1>methemoglobinemia</e1> after an axillary block with <e2>bupivacaine</e2> and additional injection of lidocaine in the operative field."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2440	"We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant <e1>methemoglobinemia</e1> after an axillary block with bupivacaine and additional injection of <e2>lidocaine</e2> in the operative field."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2441	"Detection of activated eosinophils in nasal polyps of an <e1>aspirin</e1> -induced <e2>asthma</e2> patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2442	"An episode of subacute <e1>encephalopathy</e1> after the infusion of a moderate dose of <e2>methotrexate</e2> (1500 mg/m2) (MTX) is reported in a young adult with metastastic gastric cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2443	"We believe that this represents an unusual case of moderate-dose <e1>MTX</e1> -induced <e2>neurotoxicity</e2> in a patient with gastric cancer, which has not previously been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2444	"We describe a life threatening side effect of acute <e1>epoprostenol</e1> infusion (<e2>pulmonary edema</e2>) in a patient with pulmonary hypertension associated with limited scleroderma and discuss its management and potential etiology."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2445	"A 14-year-old girl with newly diagnosed SLE developed a <e1>pruritic bullous eruption</e1> while on <e2>prednisone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2446	"<e1>Hydroxyurea</e1> -induced <e2>acute interstitial pneumonitis</e2> in a patient with essential thrombocythemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2447	"The clinical course suggests that the <e1>interstitial pneumonitis</e1> was induced by <e2>hydroxyurea</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2448	"This is the first case of <e1>hydroxyurea</e1> -induced <e2>acute interstitial pneumonitis</e2> reported in the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2449	"Allergic and <e1>irritant contact dermatitis</e1> to <e2>calcipotriol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2450	"<e1>Calcipotriol</e1> (Daivonex R; Leo Pharmaceuticals, Zurich, Switzerland) may cause irritation of the skin, whereas <e2>allergic reactions</e2> are less common."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2451	"<e1>Calcipotriol</e1> (Daivonex R; Leo Pharmaceuticals, Zurich, Switzerland) may cause <e2>irritation of the skin</e2>, whereas allergic reactions are less common."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2452	"The present observation suggests, that a batch of different testing doses, including lower testing doses may help to differentiate between an allergic type of contact dermatitis and an <e1>irritant type of reaction</e1> after treatment with <e2>calcipotriol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2453	"<e1>Myotonia</e1> associated with sarcoidosis: marked exacerbation with <e2>pravastatin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2454	"<e1>Pravastatin</e1> is associated with <e2>myotonia</e2> in animals."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2455	"This case suggests that sarcoidosis and <e1>pravastatin</e1>, two entities not frequently associated with <e2>myotonia</e2>, may interact in a synergistic manner to produce severe clinical <e2>myotonia</e2> in humans."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2456	"Hypersensitivity to <e1>aspirin</e1> can be manifested as acute asthma, urticaria and/or <e2>angioedema</e2>, or a systemic anaphylactoid reaction."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2457	"Hypersensitivity to <e1>aspirin</e1> can be manifested as acute asthma, urticaria and/or angioedema, or a <e2>systemic anaphylactoid reaction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2458	"Hypersensitivity to <e1>aspirin</e1> can be manifested as acute asthma, <e2>urticaria</e2> and/or angioedema, or a systemic anaphylactoid reaction."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2459	"CONCLUSION: Fixed drug <e1>eruption</e1> is associated with many drugs but this is the first such report with <e2>omeprazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2460	"Fixed drug <e1>eruption</e1> in hands caused by <e2>omeprazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2461	"The objective of this report is to describe a case of fixed drug <e1>eruption</e1> that occurred during <e2>omeprazole</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2462	"A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with <e1>diffuse erythema</e1> and pustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of <e2>salazosulfapyridine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2463	"A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, malaise, and <e1>fever up to 39 degrees C</e1> one day after the administration of <e2>salazosulfapyridine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2464	"A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, <e1>malaise</e1>, and fever up to 39 degrees C one day after the administration of <e2>salazosulfapyridine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2465	"A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and <e1>pustules</e1> on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of <e2>salazosulfapyridine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2466	"<e1>Acute generalized exanthematous pustulosis</e1> induced by <e2>salazosulfapyridine</e2> in a patient with ulcerative colitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2467	"We report a case of <e1>acute generalized exanthematous pustulosis</e1> (AGEP) induced by <e2>salazosulfapyridine</e2> in a patient with ulcerative colitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2468	"CASE SUMMARY: A 39-year-old white Jewish schizophrenic man treated with <e1>olanzapine</e1> developed an <e2>elevated serum CK concentration</e2> with a peak concentration of 4000 IU/L (normal < 230)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2469	"DISCUSSION: <e1>Olanzapine</e1>, like other atypical antipsychotic drugs, may cause <e2>muscle injury with concomitant elevations of serum CK</e2> of muscle origin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2470	"Marked <e1>elevation of serum creatine kinase</e1> associated with <e2>olanzapine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2471	"OBJECTIVE: To report a case of marked <e1>elevation of serum creatine kinase</e1> (CK) associated with <e2>olanzapine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2472	"<e1>Diclofenac</e1> -associated <e2>hepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2473	"This patient, who had a history of osteoarthritis, had severe <e1>hepatitis</e1> 5 weeks after being started on <e2>diclofenac</e2> for increasing pain in the joints."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2474	"<e1>2-CdA</e1> induces <e2>lymphocytopenia</e2>, which may explain the improvement in this patient's psoriasis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2475	"One case of <e1>priapism</e1> occurred during <e2>heparin</e2> therapy for a previous surgical operation to the knee is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2476	"<e1>Priapism</e1> as a complication of <e2>heparin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2477	"The association between <e1>heparin</e1> and priapism is often recognized; <e2>abnormal platelet aggregation</e2> could play a role in the pathogenesis of this side effect."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2478	"The association between <e1>heparin</e1> and <e2>priapism</e2> is often recognized; abnormal platelet aggregation could play a role in the pathogenesis of this side effect."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2479	"It carries a well-known risk of neutropenia and <e1>agranulocytosis</e1>, which necessitates the immediate discontinuation of <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2480	"It carries a well-known risk of <e1>neutropenia</e1> and agranulocytosis, which necessitates the immediate discontinuation of <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2481	"OBJECTIVE: We report a patient who developed neutropenia on <e1>clozapine</e1>, but behind the cell count decrease showed to be a <e2>diurnal variation of the white blood cells</e2> (WBC)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2482	"<e1>Acute neutrophilic dermatosis</e1> induced by <e2>all-trans-retinoic acid</e2> treatment for acute promyelocytic leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2483	"Findings on discontinuation and rechallenge supported the assumption that the <e1>hair loss</e1> was a side effect of the <e2>paroxetine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2484	"<e1>Hair loss</e1> associated with <e2>paroxetine</e2> treatment: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2485	"We report on a 37-year-old female who complained of moderate <e1>hair loss</e1> during <e2>paroxetine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2486	"CONCLUSION: Patients with <e1>insulin</e1> allergy may not have complete resolution of their symptoms after standard desensitization, particularly those patients with concomitant <e2>protamine allergy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2487	"METHODS: The patient required <e1>insulin</e1> desensitization for severe urticaria, <e2>angioedema</e2>, and occasional wheezing resulting from her <e1>insulin</e1> dose."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2488	"METHODS: The patient required <e1>insulin</e1> desensitization for severe urticaria, <e2>angioedema</e2>, and occasional wheezing resulting from her <e1>insulin</e1> dose."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2489	"METHODS: The patient required <e1>insulin</e1> desensitization for <e2>severe urticaria</e2>, angioedema, and occasional wheezing resulting from her <e1>insulin</e1> dose."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2490	"METHODS: The patient required <e1>insulin</e1> desensitization for <e2>severe urticaria</e2>, angioedema, and occasional wheezing resulting from her <e1>insulin</e1> dose."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2491	"METHODS: The patient required <e1>insulin</e1> desensitization for severe urticaria, angioedema, and occasional <e2>wheezing</e2> resulting from her <e1>insulin</e1> dose."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2492	"METHODS: The patient required <e1>insulin</e1> desensitization for severe urticaria, angioedema, and occasional <e2>wheezing</e2> resulting from her <e1>insulin</e1> dose."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2493	"OBJECTIVE: The purpose of this study was to determine whether desensitization to NPH <e1>insulin</e1>, as well as standard <e1>insulin</e1> desensitization, could control <e2>allergic symptoms</e2> in a patient allergic to both NPH and regular <e1>insulin</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2494	"OBJECTIVE: The purpose of this study was to determine whether desensitization to <e1>NPH insulin</e1>, as well as standard insulin desensitization, could control <e2>allergic symptoms</e2> in a patient allergic to both NPH and regular insulin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2495	"Patients receiving <e1>neutral protamine Hagedorn (NPH) insulin</e1> are at increased risk for the development of <e2>protamine hypersensitivity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2496	"<e1>Protamine allergy</e1> as a complication of <e2>insulin</e2> hypersensitivity: A case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2497	"She continued to receive regular <e1>insulin</e1> 4 times per day over the following 3 years with only occasional <e2>hives</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2498	"The patient had recurrence of urticaria and <e1>angioedema</e1> a year and a half later, at which point the NPH was stopped and she was desensitized to regular <e2>insulin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2499	"The patient had recurrence of urticaria and <e1>angioedema</e1> a year and a half later, at which point the <e2>NPH</e2> was stopped and she was desensitized to regular insulin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2500	"The patient had recurrence of <e1>urticaria</e1> and angioedema a year and a half later, at which point the NPH was stopped and she was desensitized to regular <e2>insulin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2501	"The patient had recurrence of <e1>urticaria</e1> and angioedema a year and a half later, at which point the <e2>NPH</e2> was stopped and she was desensitized to regular insulin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2502	"A 5-month-old infant became <e1>lethargic</e1> and poorly responsive after receiving 1 drop of <e2>brimonidine</e2> in each eye."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2503	"A 5-month-old infant became lethargic and <e1>poorly responsive</e1> after receiving 1 drop of <e2>brimonidine</e2> in each eye."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2504	"An 11-day-old infant became lethargic and <e1>apneic</e1> after a single drop of <e2>brimonidine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2505	"An 11-day-old infant became <e1>lethargic</e1> and apneic after a single drop of <e2>brimonidine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2506	"Apparent <e1>central nervous system depression</e1> in infants after the use of topical <e2>brimonidine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2507	"CONCLUSIONS: Topical <e1>brimonidine</e1> may be associated with <e2>central nervous system depression</e2> in infants."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2508	"PURPOSE: To report two cases in which topical <e1>brimonidine</e1> resulted in apparent <e2>central nervous system depression</e2> and unresponsiveness in an infant."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2509	"Ceftriaxone was approved in 1997 for the treatment of otitis media despite previous studies that documented an association of <e1>ceftriaxone</e1> with <e2>elevated hepato-biliary enzymes</e2> and transient biliary stasis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2510	"Ceftriaxone was approved in 1997 for the treatment of otitis media despite previous studies that documented an association of <e1>ceftriaxone</e1> with elevated hepato-biliary enzymes and <e2>transient biliary stasis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2511	"<e1>Hepato-biliary abnormalities</e1> secondary to <e2>ceftriaxone</e2> use: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2512	"<e1>Anterior lumbosacral radiculopathy</e1> after intrathecal <e2>methotrexate</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2513	"Reported are three children who developed <e1>progressive paraparesis</e1> after intrathecal <e2>methotrexate</e2> administration followed by complete or partial recovery."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2514	"During the first days of <e1>arsenic trioxide</e1> treatment a rapid <e2>decrease in the D-dimers</e2> was seen (normal values reached until day 7), together with a slight decrease in peripheral blood leukocytes."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2515	"During the first days of <e1>arsenic trioxide</e1> treatment a rapid decrease in the D-dimers was seen (normal values reached until day 7), together with a <e2>slight decrease in peripheral blood leukocytes</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2516	"A 22-year-old black man developed fever, <e1>chills</e1>, fatigue, night sweats, tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting <e2>minocycline</e2> therapy for acne."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2517	"A 22-year-old black man developed fever, chills, <e1>fatigue</e1>, night sweats, tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting <e2>minocycline</e2> therapy for acne."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2518	"A 22-year-old black man developed <e1>fever</e1>, chills, fatigue, night sweats, tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting <e2>minocycline</e2> therapy for acne."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2519	"A 22-year-old black man developed fever, chills, fatigue, night sweats, tender lymphadenopathy, and a <e1>generalized, pruritic, macular eruption</e1> 3 weeks after starting <e2>minocycline</e2> therapy for acne."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2520	"A 22-year-old black man developed fever, chills, fatigue, <e1>night sweats</e1>, tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting <e2>minocycline</e2> therapy for acne."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2521	"With the negative viral serologies, the clinical picture was most consistent with an infectious <e1>mononucleosis-like syndrome</e1> produced by the<e2> minocycline</e2> ingestion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2522	"We conclude that the presence of this metabolic defect combined with topical <e1>5-FU</e1> (a drug demonstrating a narrow therapeutic index) results in the unusual presentation of <e2>life-threatening toxicity</e2> after treatment with a topical drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2523	"We now report the first known cancer patient who developed <e1>life-threatening complications</e1> after treatment with topical <e2>5-FU</e2> and was shown subsequently to have profound DPD deficiency."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2524	"An <e1>acute ischaemic event</e1> associated with the use of <e2>venlafaxine</e2>: a case report and proposed pathophysiological mechanisms."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2525	"The association of <e1>venlafaxine</e1> treatment with <e2>ischaemic events</e2> could be explained by its unique pharmacological and haemodynamic properties."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2526	"This is the first report of a possible association between an <e1>acute cardiovascular event</e1> and <e2>venlafaxine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2527	"We present a case of an elderly woman with a pre-existing history of ischaemic heart disease, who was treated with <e1>venlafaxine</e1>, and developed <e2>acute myocardial ischaemia</e2> within the first week of treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2528	"Apparent <e1>cyclophosphamide</e1> (cytoxan) <e2>embryopathy</e2>: a distinct phenotype?"
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2529	"The purpose of this report is to document a new case of in utero <e1>CP</e1> exposure with multiple congenital anomalies and to establish an apparent <e1>CP</e1> <e2>embryopathy</e2> phenotype."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2530	"The purpose of this report is to document a new case of in utero <e1>CP</e1> exposure with <e2>multiple congenital anomalies</e2> and to establish an apparent <e1>CP</e1> embryopathy phenotype."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2531	"The reported cases of in utero exposure to <e1>cyclosposphamide</e1> shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, <e2>blepharophimosis</e2>, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2532	"The reported cases of in utero exposure to <e1>cyclosposphamide</e1> shared the following manifestations with our patient: growth deficiency, developmental delay, <e2>craniosynostosis</e2>, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2533	"The reported cases of in utero exposure to <e1>cyclosposphamide</e1> shared the following manifestations with our patient: growth deficiency, <e2>developmental delay</e2>, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2534	"The reported cases of in utero exposure to <e1>cyclosposphamide</e1> shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and <e2>distal limb defects</e2> including hypoplastic thumbs and oligodactyly."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2535	"The reported cases of in utero exposure to <e1>cyclosposphamide</e1> shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, blepharophimosis, <e2>flat nasal bridge</e2>, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2536	"The reported cases of in utero exposure to <e1>cyclosposphamide</e1> shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including <e2>hypoplastic thumbs</e2> and oligodactyly."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2537	"The reported cases of in utero exposure to <e1>cyclosposphamide</e1> shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and <e2>oligodactyly</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2538	"We conclude that (a) <e1>cyclophosphamide</e1> is a <e2>human teratogen</e2>, (b) a distinct phenotype exists, and (c) the safety of CP in pregnancy is in serious question."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2539	"In all cases, <e1>seizures</e1> were controlled by withdrawal of <e2>phenytoin</e2> and reduction of drug levels."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2540	"Paradoxical <e1>seizures</e1> in <e2>phenytoin</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2541	"We present three patients with paradoxical <e1>seizures</e1>; their serum <e2>phenytoin</e2> levels were 43.5 mcg/mL, 46.5 mcg/mL and 38.3 mcg/mL."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2542	"CONCLUSIONS: This case suggests that <e1>losartan</e1> can induce late-onset <e2>angioedema</e2> in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2543	"<e1>Losartan</e1> -induced <e2>angioedema</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2544	"OBJECTIVE: To report a case of <e1>angioedema</e1> associated with <e2>losartan</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2545	"The incidence of <e1>angioedema</e1> secondary to <e2>losartan</e2>, an angiotensin II receptor antagonist, is unknown."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2546	"We report the case of a female acromegalic patient in whom multiple <e1>hepatic adenomas</e1> appeared soon after <e2>danazol</e2> treatment for uterine fibromatosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2547	"<e1>Heparin</e1> -induced <e2>thrombocytopenia</e2> is a rare and serious complication of anticoagulation therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2548	"Pediatric <e1>heparin</e1> -induced <e2>thrombocytopenia</e2>: management with Danaparoid (orgaran)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2549	"There remains a paucity of information pertaining to alternative anticoagulation strategies for use during cardiopulmonary bypass concomitant with <e1>heparin</e1> -induced <e2>thrombocytopenia</e2>, especially in children."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2550	"We report the successful treatment of <e1>heparin</e1> -induced thrombocytopenia and subsequent <e2>hemorrhagic complications</e2> postoperatively in a 2-year-old child with Danaparoid (orgaran)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2551	"We report the successful treatment of <e1>heparin</e1> -induced <e2>thrombocytopenia</e2> and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2552	"<e1>Taxane</e1> -induced <e2>glaucoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2553	"We report a case of <e1>glaucoma</e1> induced by <e2>doxetaxel</e2> therapy for metastatic breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2554	"Acute <e1>hyperphosphatemia</e1> caused by <e2>sodium phosphate</e2> enema in a patient with liver dysfunction and chronic renal failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2555	"We report a case of acute <e1>hyperphosphatemia</e1> secondary to rectal administration of sodium phosphate and <e2>sodium biphosphate</e2> (Fleet enema)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2556	"We report a case of acute <e1>hyperphosphatemia</e1> secondary to rectal administration of <e2>sodium phosphate</e2> and sodium biphosphate (Fleet enema)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2557	"<e1>Prolongation of the QT interval</e1> and ventricular tachyarrhymias have been described in patients on <e2>amiodarone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2558	"Prolongation of the QT interval and <e1>ventricular tachyarrhymias</e1> have been described in patients on <e2>amiodarone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2559	"We report a case of recurrent <e1>torsades de pointes</e1> following treatment with pentavalent antimonial drugs and <e2>amiodarone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2560	"Emphasis is given to the differentiation of <e1>diphenylhydantoin</e1> induced <e2>gingival hyperplasia</e2> from the angiomatous enlargement of the gingiva before any treatment is planned."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2561	"A 66-year-old Japanese woman with severe scleroderma developed <e1>anemia</e1> and thrombocytopenia due to D-penicillamine (<e2>D-Pen</e2>) treatment, although the leukopenia was not markedly severe."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2562	"A 66-year-old Japanese woman with severe scleroderma developed <e1>anemia</e1> and thrombocytopenia due to <e2>D-penicillamine</e2> (D-Pen) treatment, although the leukopenia was not markedly severe."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2563	"A 66-year-old Japanese woman with severe scleroderma developed anemia and <e1>thrombocytopenia</e1> due to D-penicillamine (<e2>D-Pen</e2>) treatment, although the leukopenia was not markedly severe."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2564	"A 66-year-old Japanese woman with severe scleroderma developed anemia and <e1>thrombocytopenia</e1> due to <e2>D-penicillamine</e2> (D-Pen) treatment, although the leukopenia was not markedly severe."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2565	"Cessation of <e1>D-Pen</e1> and the start of corticosteroid therapy were followed by recovery from <e2>bicytopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2566	"In vitro <e1>inhibition of hematopoiesis</e1> in a patient with systemic sclerosis treated with <e2>D-penicillamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2567	"These findings suggest that <e1>bicytopenia</e1> in this patient was caused by <e2>D-Pen</e2> and may be due to different sensitivities in the hematopoietic lineage."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2568	"A 48-year-old woman who was treated for thyrotoxicosis with <e1>methimazole</e1> developed <e2>agranulocytosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2569	"Postoperative <e1>hypocalcemic tetany</e1> caused by fleet phospho-soda preparation in a patient taking <e2>alendronate sodium</e2>: report of a case."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2570	"Postoperative <e1>hypocalcemic tetany</e1> caused by <e2>fleet phospho-soda</e2> preparation in a patient taking alendronate sodium: report of a case."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2571	"This case report describes a patient who was previously prescribed <e1>alendronate</e1> (Fosamax) and presented with postoperative hypophosphatemia and <e2>hypocalcemic tetany</e2> after bowel preparation with Fleet Phospho-Soda."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2572	"This case report describes a patient who was previously prescribed alendronate (Fosamax) and presented with postoperative hypophosphatemia and <e1>hypocalcemic tetany</e1> after bowel preparation with <e2>Fleet Phospho-Soda</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2573	"This case report describes a patient who was previously prescribed alendronate (<e1>Fosamax</e1>) and presented with postoperative hypophosphatemia and <e2>hypocalcemic tetany</e2> after bowel preparation with Fleet Phospho-Soda."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2574	"This case report describes a patient who was previously prescribed <e1>alendronate</e1> (Fosamax) and presented with postoperative <e2>hypophosphatemia</e2> and hypocalcemic tetany after bowel preparation with Fleet Phospho-Soda."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2575	"This case report describes a patient who was previously prescribed alendronate (Fosamax) and presented with postoperative <e1>hypophosphatemia</e1> and hypocalcemic tetany after bowel preparation with <e2>Fleet Phospho-Soda</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2576	"This case report describes a patient who was previously prescribed alendronate (<e1>Fosamax</e1>) and presented with postoperative <e2>hypophosphatemia</e2> and hypocalcemic tetany after bowel preparation with Fleet Phospho-Soda."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2577	"Described here are 2 patients who developed <e1>thrombotic microangiopathy</e1> of the kidneys after receiving high cumulative doses of the new anticancer drug <e2>gemcitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2578	"Thrombotic microangiopathy with <e1>renal failure</e1> in two patients undergoing <e2>gemcitabine</e2> chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2579	"<e1>Thrombotic microangiopathy</e1> with renal failure in two patients undergoing <e2>gemcitabine</e2> chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2580	"The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom <e1>B-cell non-Hodgkin's lymphoma</e1> was diagnosed 9 months after treatment with <e2>infliximab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2581	"The relationship between <e1>infliximab</e1> treatment and <e2>lymphoma</e2> in Crohn's disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2582	"The second is a 29-year-old man with CD in whom <e1>nodular sclerosing Hodgkin's lymphoma</e1> was diagnosed 3 weeks after infusion with <e2>infliximab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2583	"We describe the clinical course of 2 patients with Crohn's disease (CD) in whom <e1>lymphoma</e1> was diagnosed after treatment with <e2>infliximab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2584	"<e2>Codeine</e2> intoxication in the neonate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2585	"We report a case of <e2>codeine</e2> intoxication in the neonate, in which the drug was prescribed for cough control during an emergency department visit."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2586	"<e1>Hydroxyurea</e1> (HU) and sodium phenylbutyrate (SPB) have been shown to <e2>increase fetal hemoglobin</e2> (Hb F) levels in patients with thalassemia intermedia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2587	"Hydroxyurea (HU) and <e1>sodium phenylbutyrate</e1> (SPB) have been shown to <e2>increase fetal hemoglobin</e2> (Hb F) levels in patients with thalassemia intermedia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2588	"Of the four patients who responded to <e1>HU</e1> with an <e2>increase in total Hb</e2>, all reported symptomatic improvement and three have not required further transfusions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2589	"Prolonged responses were achieved with low doses of <e1>HU</e1> (3-10 mg/kg/day) and higher doses were associated with mild reversible hematologic or <e2>hepatic toxicity</e2> and no further increases in Hb."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2590	"Prolonged responses were achieved with low doses of <e1>HU</e1> (3-10 mg/kg/day) and higher doses were associated with <e2>mild reversible hematologic</e2> or hepatic toxicity and no further increases in Hb."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2591	"Sodium phenylbutyrate was added to treatment with <e1>HU</e1> in two patients, but failed to produce an increase in total Hb despite <e2>increasing Hb F</e2> levels."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2592	"<e1>Sodium phenylbutyrate</e1> was added to treatment with HU in two patients, but failed to produce an increase in total Hb despite <e2>increasing Hb F</e2> levels."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2593	"We conclude that low-dose <e1>HU</e1> therapy in patients with thalassemia intermedia may <e2>increase total Hb</e2> levels sufficiently to eliminate the need for transfusions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2594	"We describe the clinical response, as determined by <e1>increases in total Hb</e1> and decreased transfusion needs, in five patients with thalassemia intermedia treated with <e2>HU</e2> alone or in combination with SPB."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2595	"We describe the clinical response, as determined by <e1>increases in total Hb</e1> and decreased transfusion needs, in five patients with thalassemia intermedia treated with HU alone or in combination with <e2>SPB</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2596	"A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of <e1>oolong tea</e1> that eventually reached 15 L each day, became <e2>delirious</e2> and was admitted to a psychiatric hospital."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2597	"After abstinence from <e1>oolong tea</e1> his <e2>delirium</e2> resolved."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2598	"Severe rhabdomyolysis following massive ingestion of oolong tea: <e2>caffeine</e2> intoxication with coexisting hyponatremia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2599	"Severe rhabdomyolysis following massive ingestion of <e1>oolong tea</e1>: <e2>caffeine intoxication</e2> with coexisting hyponatremia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2600	"Severe <e1>rhabdomyolysis</e1> following massive ingestion of oolong tea: <e2>caffeine</e2> intoxication with coexisting hyponatremia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2601	"Severe <e1>rhabdomyolysis</e1> following massive ingestion of <e2>oolong tea</e2>: caffeine intoxication with coexisting hyponatremia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2602	"The clinical course suggests that <e1>caffeine</e1>, which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the <e2>delirium</e2>, although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2603	"The clinical course suggests that <e1>caffeine</e1>, which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although severe <e2>hyponatremia</e2> has been reported to cause rhabdomyolysis on rare occasions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2604	"The clinical course suggests that <e1>caffeine</e1>, which is present in oolong tea, was mainly responsible for the <e2>rhabdomyolysis</e2> as well as the delirium, although severe hyponatremia has been reported to cause <e2>rhabdomyolysis</e2> on rare occasions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2605	"The clinical course suggests that <e1>caffeine</e1>, which is present in oolong tea, was mainly responsible for the <e2>rhabdomyolysis</e2> as well as the delirium, although severe hyponatremia has been reported to cause <e2>rhabdomyolysis</e2> on rare occasions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2606	"The possibility of severe <e1>rhabdomyolysis</e1> should be considered in a patient with water intoxication due to massive ingestion of <e2>caffeine</e2> -containing beverages."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2607	"The possibility of severe rhabdomyolysis should be considered in a patient with <e1>water intoxication</e1> due to massive ingestion of <e2>caffeine</e2> -containing beverages."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2608	"We hypothesize that <e2>caffeine</e2> toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2609	"We hypothesize that <e1>caffeine</e1> toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the <e2>coexisting hyponatremia</e2>, to result in unusually severe rhabdomyolysis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2610	"We hypothesize that <e1>caffeine</e1> toxicity <e2>injured the muscle cells</e2>, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2611	"We hypothesize that <e1>caffeine</e1> toxicity injured the muscle cells, which were fragile due to the <e2>potassium depletion</e2> induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2612	"We hypothesize that <e1>caffeine</e1> toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe <e2>rhabdomyolysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2613	"After the addition of <e1>citalopram</e1>, a desmethylclomipramine plasma level increase and an <e2>8-hydroacy-desmethylclomipramine plasma level decrease</e2> were observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2614	"After the addition of <e1>citalopram</e1>, a <e2>desmethylclomipramine plasma level increase</e2> and an 8-hydroacy-desmethylclomipramine plasma level decrease were observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2615	"We report 3 cases of HIV-1 infected patients who experienced symptomatic <e1>angiolipomas</e1> shortly after starting antiretroviral therapy including the protease inhibitor <e2>indinavir</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2616	"<e1>Elevated serum triglycerides</e1> with <e2>clozapine</e2> resolved with risperidone in four patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2617	"In two patients <e1>clozapine</e1> was reinstated after risperidone was discontinued; <e2>serum triglyceride levels increased</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2618	"This increase when <e1>clozapine</e1> was switched to risperidone and vice versa is consistent with our previous report of <e2>elevated serum triglyceride levels</e2> in <e1>clozapine</e1> -treated patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2619	"Intravenous <e1>valproate</e1> associated with significant <e2>hypotension</e2> in the treatment of status epilepticus."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2620	"To our knowledge, this is the first report of significant <e1>hypotension</e1> associated with intravenous <e2>valproate</e2> in the treatment of status epilepticus in the pediatric population."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2621	"We report a case of severe <e1>hypotension</e1> associated with intravenous <e2>valproate</e2> used to treat status epilepticus in an 11-year-old girl."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2622	"In both patients the <e1>rippling phenomena worsened</e1> with <e2>pyridostigmine</e2> treatment but markedly improved after immunosuppression with azathioprine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2623	"A diagnosis of masked <e2>theophylline</e2> poisoning should be considered in similar situations involving a rapid decrease of insulin requirements."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2624	"Salicylate <e1>intoxication</e1> was excluded, and <e2>theophylline</e2> was finally incriminated."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2625	"<e2>Theophylline</e2> intoxication mimicking diabetic ketoacidosis in a child."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2626	"This compound, used by adults in the child's home, had caused accidental <e2>theophylline</e2> poisoning, mimicking diabetic ketoacidosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2627	"Methylene blue in the treatment and prevention of <e2>ifosfamide</e2> -induced encephalopathy: report of 12 cases and a review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2628	"Ten to 15% of patients treated with <e1>ifosfamide</e1> develop an <e2>encephalopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2629	"We conclude that MB is an effective treatment for <e2>ifosfamide</e2> -induced encephalopathy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2630	"<e1>Portal vein thrombosis</e1> in a patient with severe haemophilia A and F V G1691A mutation during continuous infusion of <e2>F VIII</e2> after intramural jejunal bleeding--successful thrombolysis under heparin therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2631	"We report on a 14-year-old boy with severe haemophilia A who developed a <e1>portal vein thrombosis</e1> during continuous infusion of <e2>F VIII</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2632	"A 60-year-old woman with diabetes mellitus (type 2) developed an <e1>acute icteric hepatitis-like illness</e1> 6 weeks after the initiation of <e2>gliclazide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2633	"<e1>Gliclazide</e1> -induced <e2>acute hepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2634	"In conclusion, this case strongly suggests that <e1>gliclazide</e1> can induce <e2>acute icteric liver necro-inflammation</e2> which may be misdiagnosed clinically as acute viral hepatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2635	"We believe that this is the first description of <e1>acute hepatitis</e1> caused by an idiosyncratic adverse reaction to <e2>gliclazide</e2> or to one of its metabolites."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2636	"We describe the case of <e1>acute hepatitis</e1> induced by <e2>gliclazide</e2>, a second generation sulfonylurea."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2637	"Caution is, therefore, needed to prevent undesired accumulation of <e1>TCA</e1> that may lead to protracted <e2>Cushing's syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2638	"<e1>Cushing's syndrome</e1> persisted more than 6 months while <e2>TCA</e2> concentrations remained detectable for at least 80 days."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2639	"The presented patient was treated with 200 mg <e1>TCA</e1> and developed <e2>Cushing's syndrome</e2> 6 weeks later (cortisol and ACTH concentrations were below limits of detection, <e1>TCA</e1> concentrations were > 3 micrograms/l)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2640	"Both had impaired lung function and <e1>abnormal computed tomographic scans</e1>, and their condition improved when <e2>nitrofurantoin</e2> was withdrawn and corticosteroid treatment commenced."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2641	"Both had <e1>impaired lung function</e1> and abnormal computed tomographic scans, and their condition improved when <e2>nitrofurantoin</e2> was withdrawn and corticosteroid treatment commenced."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2642	"<e1>Bronchiolitis obliterans organising pneumonia</e1> associated with the use of <e2>nitrofurantoin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2643	"The case histories are presented of two patients who developed lung disease associated with the use of <e1>nitrofurantoin</e1> with histological features of bronchiolitis obliterans organising pneumonia (<e2>BOOP</e2>), a rare but recognised form of drug induced injury."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2644	"The case histories are presented of two patients who developed lung disease associated with the use of <e1>nitrofurantoin</e1> with histological features of <e2>bronchiolitis obliterans organising pneumonia</e2> (BOOP), a rare but recognised form of drug induced injury."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2645	"The case histories are presented of two patients who developed <e1>lung disease</e1> associated with the use of <e2>nitrofurantoin</e2> with histological features of bronchiolitis obliterans organising pneumonia (BOOP), a rare but recognised form of drug induced injury."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2646	"The favourable outcome in these two patients contrasts with the <e1>fatal outcome</e1> of the two other reported cases of <e2>nitrofurantoin</e2> induced BOOP."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2647	"The favourable outcome in these two patients contrasts with the fatal outcome of the two other reported cases of <e2>nitrofurantoin</e2> induced BOOP."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2648	"The spectrum of <e1>nitrofurantoin</e1> <e2>lung injury</e2> continues to widen."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2649	"The two middle aged women presented with <e1>respiratory symptoms</e1> after prolonged treatment with <e2>nitrofurantoin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2650	"We suggest that the previous classification of <e2>nitrofurantoin</e2> induced lung injury into "acute" and "chronic" injury is an oversimplification in view of the wide variety of pathological entities that have subsequently emerged."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2651	"Intravenous administration of levodopa ameliorated a refractory <e1>akathisia</e1> case induced by <e2>interferon-alpha</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2652	"The present report illustrates a rare case of refractory <e1>akathisia</e1> after <e2>interferon-alpha</e2> treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with <e2>interferon-alpha</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2653	"The present report illustrates a rare case of refractory akathisia after <e1>interferon-alpha</e1> treatment and also that levodopa treatment would be theoretically and practically useful in reducing the <e2>neurotoxicity</e2> associated with <e1>interferon-alpha</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2654	"<e1>Acute erythroid leukemia</e1> after <e2>cyclophosphamide</e2> therapy for multiple myeloma: report of two cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2655	"The development of erythroid leukemia plus <e1>carcinoma</e1> in these two men suggests mutagenic change secondary to <e2>cyclophosphamide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2656	"<e1>Scleroderma-like reaction</e1> induced by uracil-tegafur (<e2>UFT</e2>), a second-generation anticancer agent."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2657	"<e1>Scleroderma-like reaction</e1> induced by <e2>uracil-tegafur</e2> (UFT), a second-generation anticancer agent."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2658	"This is the first report of <e2>UFT</e2> -induced scleroderma-like reaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2659	"We report a case of a <e1>scleroderma-like reaction</e1> induced by long-term administration of <e2>UFT</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2660	"<e1>Central nervous system manifestations</e1> of an <e2>ibuprofen</e2> overdose reversed by naloxone."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2661	"<e1>Ibuprofen</e1> overdose is usually characterized by GI upset, <e2>dizziness</e2>, and mild sedation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2662	"<e1>Ibuprofen</e1> overdose is usually characterized by <e2>GI upset</e2>, dizziness, and mild sedation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2663	"<e1>Ibuprofen</e1> overdose is usually characterized by GI upset, dizziness, and <e2>mild sedation</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2664	"Presently, treatment of acute <e2>ibuprofen</e2> intoxication with complications requires supportive therapy until the symptoms resolve over 24 to 48 hours."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2665	"We report the case of an 11-month-old female infant with a <e1>depressed level of consciousness</e1> after ingestion of <e2>ibuprofen</e2> whose mental status markedly improved with administration of naloxone."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2666	"<e1>Flecainide</e1> -associated pneumonitis with <e2>acute respiratory failure</e2> in a patient with the LEOPARD syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2667	"<e1>Flecainide</e1> -associated <e2>pneumonitis</e2> with acute respiratory failure in a patient with the LEOPARD syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2668	"<e1>Flecainide</e1> is a rare cause of <e2>hypersensitivity pneumonitis</e2>, and few cases have been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2669	"We describe a case of <e1>interstitial hypoxaemiant pneumonitis</e1> probably related to <e2>flecainide</e2> in a patient with the LEOPARD syndrome, a rare congenital disorder."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2670	"<e1>Sagittal sinus thrombosis</e1> associated with transient free protein S deficiency after <e2>L-asparaginase</e2> treatment: case report and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2671	"Sagittal sinus thrombosis associated with <e1>transient free protein S deficiency</e1> after <e2>L-asparaginase</e2> treatment: case report and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2672	"We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a <e1>seizure</e1> during consolidation treatment with <e2>L-asparaginase</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2673	"We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated <e1>transient ischemic attacks</e1> followed by a seizure during consolidation treatment with <e2>L-asparaginase</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2674	"We report on a young adolescent with <e1>benign intracranial hypertension</e1> which we attribute to the use of <e2>minocycline</e2> for acne."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2675	"We report 2 patients who developed <e1>polyarteritis nodosa</e1> following <e2>vaccination against hepatitis B</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2676	"In this case, it was suspected that a combination of cigarette smoking, pulmonary fibrosis, and low-dose <e1>methotrexate</e1> therapy might have promoted the development of <e2>lung cancer</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2677	"This case report illustrates the use of continuous high-dose intracoronary nitroglycerin infusion through a 6 French coronary guiding catheter in the treatment of a patient with <e1>cocaine</e1> -induced <e2>refractory coronary vasospasm</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2678	"However, as illustrated by these and other cases reported to date, the onset of <e1>troglitazone</e1> -induced <e2>liver injury</e2> is insidious and temporally variable."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2679	"It remains to be seen whether the <e1>hepatotoxicity</e1> associated with <e2>troglitazone</e2> is a drug-class effect or specific to <e2>troglitazone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2680	"It remains to be seen whether the <e1>hepatotoxicity</e1> associated with <e2>troglitazone</e2> is a drug-class effect or specific to <e2>troglitazone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2681	"Other thiazolidinediones currently in clinical trials may be able to provide the therapeutic benefits of <e1>troglitazone</e1> without significant <e2>hepatotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2682	"The three reported cases demonstrate that <e1>troglitazone</e1> is an idiosyncratic hepatotoxin that can lead to <e2>irreversible liver injury</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2683	"<e1>Troglitazone</e1> -induced <e2>fulminant hepatic failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2684	"<e1>Nitrofurantoin</e1> -induced <e2>lung disease</e2>: two cases demonstrating resolution of apparently irreversible CT abnormalities."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2685	"We present two cases of <e1>nitrofurantoin</e1> -induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated <e2>distortion of the lung parenchyma</e2>, thought to represent established fibrosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2686	"We present two cases of <e1>nitrofurantoin</e1> -induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established <e2>fibrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2687	"We present two cases of <e1>nitrofurantoin</e1> -induced <e2>pulmonary toxicity</e2> in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2688	"We present two cases of <e1>nitrofurantoin</e1> -induced pulmonary toxicity in which the initial HRCT showed a <e2>widespread reticular pattern</e2> and associated distortion of the lung parenchyma, thought to represent established fibrosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2689	"<e1>Fluoxetine</e1> -related <e2>death</e2> in a child with cytochrome P-450 2D6 genetic deficiency."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2690	"The medical examiner's report indicated <e1>death</e1> caused by <e2>fluoxetine</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2691	"The medical examiner's report indicated death caused by <e2>fluoxetine</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2692	"This is the first report of a <e1>fluoxetine</e1> -related <e2>death</e2> in a child with a confirmed genetic polymorphism of the CYP2D6 gene that results in impaired drug metabolism."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2693	"A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a <e1>spinal cord lesion</e1> following the use of <e2>zolmitriptan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2694	"<e1>Spinal cord infarction</e1> during use of <e2>zolmitriptan</e2>: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2695	"The temporal relationship suggests that the <e1>spinal cord infarction</e1> may be related to the use of <e2>zolmitriptan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2696	"CASE SUMMARY: A 10-year-old white girl with bilateral optic glioma developed a <e1>hypersensitivity</e1> reaction to <e2>carboplatin</e2> after nine courses."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2697	"This regimen could prove useful for other patients who develop <e1>hypersensitivity</e1> reactions to <e2>carboplatin</e2> and allow therapy to continue."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2698	"Perinatal vasoconstrictive <e1>renal insufficiency</e1> associated with maternal <e2>nimesulide</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2699	"This is the first report of an <e1>adverse effect of fetal renal circulation</e1> by maternal ingestion of <e2>nimesulide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2700	"Although the <e1>t-AML</e1> developed following oral <e2>etoposide</e2> therapy, the child had previously received high-dose, multiagent chemotherapy, and rearrangement of the MLL gene was not demonstrated."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2701	"<e1>Secondary leukemia</e1> in a child with neuroblastoma while on oral <e2>etoposide</e2>: what is the cause?"
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2702	"The authors present a case of <e1>t-AML</e1> that developed in a child with metastatic neuroblastoma 18 months after he received oral <e2>etoposide</e2>, given for palliation purpose."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2703	"BACKGROUND: <e1>Cyanamide</e1>, an aversive agent widely used in Japan, is known to induce various degrees of <e2>hepatic lesion with ground-glass inclusion bodies</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2704	"Case 2: A 43-year-old male alcoholic remained completely abstinent with <e1>cyanamide</e1> treatment for 5 years and complained of <e2>general fatigue</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2705	"Case 3: A 29-year-old female alcoholic complained of general <e1>fatigue</e1> and a slight fever after 1.5 years of abstinence with <e2>cyanamide</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2706	"Case 3: A 29-year-old female alcoholic complained of general fatigue and a slight <e1>fever</e1> after 1.5 years of abstinence with <e2>cyanamide</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2707	"Case 4: A 61-year-old male alcoholic who remained completely abstinent while taking <e1>cyanamide</e1> for 3 years showed slight <e2>elevation of serum transaminases</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2708	"CONCLUSION: In some abstainers who take <e1>cyanamide</e1> for several years, thin septum-like liver fibrosis progresses along with the emergence of <e2>ground-glass hepatocytes</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2709	"CONCLUSION: In some abstainers who take <e1>cyanamide</e1> for several years, thin <e2>septum-like liver fibrosis</e2> progresses along with the emergence of ground-glass hepatocytes."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2710	"<e1>Cyanamide</e1> -induced <e2>liver dysfunction</e2> after abstinence in alcoholics: a long-term follow-up study on four cases."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2711	"When <e1>cyanamide</e1> -treated alcoholics relapse into drinking, more severe <e2>inflammation</e2> develops in the liver."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2712	"A patient with an allergy to a macrolide antibiotic was given <e1>tacrolimus</e1> and developed a <e2>sudden cutaneous reaction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2713	"A 77-year-old woman with no history of epilepsy presented a probable <e1>nonconvulsive status epilepticus</e1> while receiving continuous intravenous <e2>morphine</e2> for back pain relating to vertebral metastasis of a malignant lymphoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2714	"A <e1>generalized tonic-clonic seizure</e1> occurred a few minutes after injection of the morphine antagonist <e2>naloxone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2715	"<e1>Nonconvulsive status epilepticus</e1>: the role of <e2>morphine</e2> and its antagonist."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2716	"Spontaneous <e1>bacterial peritonitis</e1> induced by intraarterial <e2>vasopressin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2717	"Although the literature on the use of <e1>risperidone</e1> in elderly patients with dementia consists largely of uncontrolled trials, case reports, and chart reviews, it appears that this agent is effective for managing agitation in this population and does so with a low frequency of extrapyramidal symptoms (<e2>EPS</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2718	"Although the literature on the use of <e1>risperidone</e1> in elderly patients with dementia consists largely of uncontrolled trials, case reports, and chart reviews, it appears that this agent is effective for managing agitation in this population and does so with a low frequency of <e2>extrapyramidal symptoms</e2> (EPS)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2719	"Three months following splenectomy, <e1>multiple abscesses</e1> occurred in the muscles of both thighs while the patient was receiving the third course of the <e2>CHOP</e2> regimen."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2720	"After seven months' continuous treatment for suspected tuberculosis with rifampicin and <e1>ethambutol</e1> a nine-year-old boy developed polyarthritis, rash and hepatitis in association with <e2>anti-native DNA antibodies</e2> and positive antinuclear factor."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2721	"After seven months' continuous treatment for suspected tuberculosis with rifampicin and <e1>ethambutol</e1> a nine-year-old boy developed polyarthritis, rash and <e2>hepatitis</e2> in association with anti-native DNA antibodies and positive antinuclear factor."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2722	"After seven months' continuous treatment for suspected tuberculosis with rifampicin and <e1>ethambutol</e1> a nine-year-old boy developed <e2>polyarthritis</e2>, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2723	"After seven months' continuous treatment for suspected tuberculosis with rifampicin and <e1>ethambutol</e1> a nine-year-old boy developed polyarthritis, <e2>rash</e2> and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2724	"Polyarthritis, hepatitis and <e1>anti-native DNA antibodies</e1> after treatment with <e2>ethambutol</e2> and rifampicin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2725	"Polyarthritis, hepatitis and <e1>anti-native DNA antibodies</e1> after treatment with ethambutol and <e2>rifampicin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2726	"Polyarthritis, <e1>hepatitis</e1> and anti-native DNA antibodies after treatment with <e2>ethambutol</e2> and rifampicin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2727	"Polyarthritis, <e1>hepatitis</e1> and anti-native DNA antibodies after treatment with ethambutol and <e2>rifampicin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2728	"<e1>Polyarthritis</e1>, hepatitis and anti-native DNA antibodies after treatment with <e2>ethambutol</e2> and rifampicin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2729	"<e1>Polyarthritis</e1>, hepatitis and anti-native DNA antibodies after treatment with ethambutol and <e2>rifampicin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2730	"A case of <e1>normotensive scleroderma renal crisis</e1> after high-dose <e2>methylprednisolone</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2731	"<e1>HUS</e1> has been reported after several anticancer chemotherapies and most often after <e2>mitomycin C</e2> -based chemotherapy regimens."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2732	"<e1>Severe hemolytic uremic syndrome</e1> in an advanced ovarian cancer patient treated with <e2>carboplatin</e2> and gemcitabine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2733	"<e1>Severe hemolytic uremic syndrome</e1> in an advanced ovarian cancer patient treated with carboplatin and <e2>gemcitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2734	"We present a case of <e1>HUS</e1> in an advanced ovarian cancer patient treated with <e2>carboplatin</e2> and gemcitabine, and described its favorable outcome after chemotherapy interruption and supportive care with a 1 year follow-up."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2735	"We present a case of <e1>HUS</e1> in an advanced ovarian cancer patient treated with carboplatin and <e2>gemcitabine</e2>, and described its favorable outcome after chemotherapy interruption and supportive care with a 1 year follow-up."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2736	"An evaluation of ovarian structure and function should be considered in women of reproductive age being treated with <e1>valproate</e1> for epilepsy, especially if they develop <e2>menstrual cycle disturbances</e2> during treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2737	"BACKGROUND: Reproductive endocrine disorders characterized by menstrual disorders, polycystic ovaries, and <e1>hyperandrogenism</e1> seem to be common among women treated with <e2>sodium valproate</e2> for epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2738	"BACKGROUND: Reproductive endocrine disorders characterized by <e1>menstrual disorders</e1>, polycystic ovaries, and hyperandrogenism seem to be common among women treated with <e2>sodium valproate</e2> for epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2739	"BACKGROUND: Reproductive endocrine disorders characterized by menstrual disorders, <e1>polycystic ovaries</e1>, and hyperandrogenism seem to be common among women treated with <e2>sodium valproate</e2> for epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2740	"BACKGROUND: <e1>Reproductive endocrine disorders</e1> characterized by menstrual disorders, polycystic ovaries, and hyperandrogenism seem to be common among women treated with <e2>sodium valproate</e2> for epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2741	"CONCLUSIONS: The 3 cases presented here illustrate the development of <e1>reproductive endocrine disorders</e1> after the initiation of <e2>valproate</e2> therapy in women with epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2742	"OBJECTIVE: To describe the development of <e1>valproate</e1> -related <e2>reproductive endocrine disorders</e2> in women with epilepsy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2743	"PATIENTS: Three patients developed a <e1>reproductive endocrine disorder</e1> during treatment with <e2>valproate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2744	"RESULTS: Replacing <e1>valproate</e1> with lamotrigine resulted in a decrease in <e2>serum testosterone</e2> concentrations in all 3 women."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2745	"The polycystic changes disappeared from the ovaries in 2 of the women after <e1>valproate</e1> therapy was discontinued, and the 2 women who had gained weight and developed <e2>amenorrhea</e2> while being treated with <e1>valproate</e1> lost weight and resumed menstruating after the change in medication."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2746	"The polycystic changes disappeared from the ovaries in 2 of the women after <e1>valproate</e1> therapy was discontinued, and the 2 women who had <e2>gained weight</e2> and developed amenorrhea while being treated with <e1>valproate</e1> lost weight and resumed menstruating after the change in medication."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2747	"The <e1>polycystic changes</e1> disappeared from the ovaries in 2 of the women after <e2>valproate</e2> therapy was discontinued, and the 2 women who had gained weight and developed amenorrhea while being treated with <e2>valproate</e2> lost weight and resumed menstruating after the change in medication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2748	"However, recurrent <e1>staphylococcus aureus sepsis</e1> developed during <e2>CyA</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2749	"Recurrent septicemia with <e1>lethal</e1> outcome during and after <e2>cyclosporine</e2> therapy in severe ulcerative colitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2750	"Recurrent <e1>septicemia</e1> with lethal outcome during and after <e2>cyclosporine</e2> therapy in severe ulcerative colitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2751	"A 60 year-old woman with chronic renal failure developed acute <e1>proximal muscle weakness</e1> after receiving a regular dosage of <e2>colchicine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2752	"<e1>Colchicine</e1> -induced <e2>myopathy</e2> in renal failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2753	"Muscle biopsy revealed variation in muscle fiber size and few vacuolated fibers which were features of <e1>colchicine</e1> -induced <e2>myopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2754	"Muscle biopsy revealed variation in muscle fiber size and few <e1>vacuolated fibers</e1> which were features of <e2>colchicine</e2> -induced myopathy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2755	"Muscle biopsy revealed <e1>variation in muscle fiber size</e1> and few vacuolated fibers which were features of <e2>colchicine</e2> -induced myopathy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2756	"A third patient experienced <e1>disabling neurotoxicity</e1> in the extremity of a prior ulnar nerve and tendon transposition after receiving <e2>paclitaxel</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2757	"Phantom limb pain as a manifestation of <e1>paclitaxel</e1> <e2>neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2758	"<e1>Phantom limb pain</e1> as a manifestation of <e2>paclitaxel</e2> neurotoxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2759	"Physicians should be aware that <e1>PLP</e1> can occur after initiation of <e2>paclitaxel</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2760	"We describe 2 patients with prior amputation who experienced <e1>phantom limb pain</e1> (PLP) after receiving <e2>paclitaxel</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2761	"We describe 2 patients with prior amputation who experienced phantom limb pain (<e1>PLP</e1>) after receiving <e2>paclitaxel</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2762	"Skin manifestations of a case of <e1>phenylbutazone</e1> -induced <e2>serum sickness-like reactions</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2763	"<e1>Skin manifestations</e1> of a case of <e2>phenylbutazone</e2> -induced serum sickness-like reactions."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2764	"Our experience supports hemodialysis for ESRF patients with <e2>atenolol</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2765	"Allergic reaction to <e1>gemfibrozil</e1> manifesting as <e2>eosinophilic gastroenteritis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2766	"We describe a case of <e1>EGE</e1> manifested as an allergy to <e2>gemfibrozil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2767	"This is the second report of <e1>lactic acidosis</e1> in a patient on stavudine and <e2>lamivudine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2768	"This is the second report of <e1>lactic acidosis</e1> in a patient on <e2>stavudine</e2> and lamivudine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2769	"We present an AIDS patient with severe and prolonged <e1>lactic acidosis</e1> on stavudine and <e2>lamivudine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2770	"We present an AIDS patient with severe and prolonged <e1>lactic acidosis</e1> on <e2>stavudine</e2> and lamivudine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2771	"<e1>Ataxia</e1> caused by <e2>propafenone</e2> has been reported to the pharmaceutical companies and drug monitoring agencies, but has not been well described or emphasized in the medical literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2772	"A wide variety of <e1>adverse central nervous system effects</e1> have been reported in association with <e2>propafenone</e2>; dizziness is the most common."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2773	"A wide variety of adverse central nervous system effects have been reported in association with <e1>propafenone</e1>; <e2>dizziness</e2> is the most common."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2774	"<e1>Propafenone</e1> -induced <e2>ataxia</e2>: report of three cases."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2775	"We describe 3 elderly patients with moderate to severe <e1>ataxia</e1> that occurred while they were taking <e2>propafenone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2776	"A 74-year-old man received oral administration of <e1>pilsicainide</e1>, a pure sodium channel blocker with slow recovery kinetics, to convert paroxysmal atrial fibrillation to sinus rhythm and developed <e2>loss of consciousness</e2> two days later."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2777	"When <e1>pilsicainide</e1> is prescribed in patients with coronary artery disease or renal dysfunction, close attention must be paid to avoid <e2>life-threatening arrhythmias</e2> due to high plasma concentrations of the drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2778	"The cases are important in documenting that drug-induced <e1>dystonia</e1>s do occur in patients with dementia, that <e2>risperidone</e2> appears to have contributed to <e1>dystonia</e1> among elderly patients, and that the categorization of dystonic reactions needs further clarification."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2779	"Provocation of <e1>non-convulsive status epilepticus</e1> by <e2>tiagabine</e2> in three adolescent patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2780	"The events of <e1>non-convulsive status epilepticus</e1> subsided following reduction in <e2>tiagabine</e2> dosages."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2781	"This is the first report of <e1>non-convulsive status epilepticus</e1> provoked by <e2>tiagabine</e2> in adolescent patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2782	"There have been many reports of probable <e1>lithium</e1> -induced <e2>organic brain syndromes</e2> occurring when serum <e1>lithium</e1> levels are within or close to the therapeutic range."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2783	"When the acute manic state is characterized by marked psychotic symptoms and <e1>intense anxiety</e1>, it may be associated with increased vulnerability to the development of severe <e2>lithium</e2> neurotoxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2784	"When the acute manic state is characterized by marked psychotic symptoms and intense anxiety, it may be associated with increased vulnerability to the development of severe <e1>lithium</e1> <e2>neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2785	"When the acute manic state is characterized by marked <e1>psychotic symptoms</e1> and intense anxiety, it may be associated with increased vulnerability to the development of severe <e2>lithium</e2> neurotoxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2786	"Protease inhibitor-induced <e2>carbamazepine</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2787	"Protease inhibitors (ritonavir and saquinavir) were added to the treatment and the patient developed progressive ataxia related to <e2>carbamazepine</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2788	"Protease inhibitors (<e1>ritonavir</e1> and saquinavir) were added to the treatment and the patient developed progressive ataxia related to <e2>carbamazepine toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2789	"Protease inhibitors (ritonavir and <e1>saquinavir</e1>) were added to the treatment and the patient developed progressive ataxia related to <e2>carbamazepine toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2790	"Protease inhibitors (ritonavir and saquinavir) were added to the treatment and the patient developed <e1>progressive ataxia</e1> related to <e2>carbamazepine</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2791	"Protease inhibitors (<e1>ritonavir</e1> and saquinavir) were added to the treatment and the patient developed <e2>progressive ataxia</e2> related to carbamazepine toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2792	"Protease inhibitors (ritonavir and <e1>saquinavir</e1>) were added to the treatment and the patient developed <e2>progressive ataxia</e2> related to carbamazepine toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2793	"<e1>Ritonavir</e1> acted as a CYP3A4 inhibitor, diminishing carbamazepine metabolism and provoking an increase in serum levels and <e2>clinical toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2794	"<e1>Ritonavir</e1> acted as a CYP3A4 inhibitor, <e2>diminishing carbamazepine metabolism</e2> and provoking an increase in serum levels and clinical toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2795	"<e1>Ritonavir</e1> acted as a CYP3A4 inhibitor, diminishing carbamazepine metabolism and provoking an <e2>increase in serum levels</e2> and clinical toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2796	"The patient was diagnosed with <e2>carbamazepine</e2> toxicity related to the introduction of ritonavir."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2797	"The patient was diagnosed with <e1>carbamazepine toxicity</e1> related to the introduction of <e2>ritonavir</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2798	"<e1>Anaphylaxis</e1> to <e2>calcitonin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2799	"CONCLUSION: We have introduced a case of <e1>anaphylaxis </e1>by <e2>calcitonin</e2> that suggest an IgE mediated hypersensitivity reaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2800	"The intramuscular challenge test with 25 UI of <e1>Miacalcic</e1> was positive with an immediate <e2>anaphylactic reaction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2801	"We introduce a case of a sixty years old woman with several previous episodes of rhinitis, <e1>conjunctivitis</e1> and perspiration immediately after the administration of salmon <e2>calcitonin</e2> with nasal spray or intramuscular administration (Calsynar)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2802	"We introduce a case of a sixty years old woman with several previous episodes of rhinitis, <e1>conjunctivitis</e1> and perspiration immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration (<e2>Calsynar</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2803	"We introduce a case of a sixty years old woman with several previous episodes of rhinitis, conjunctivitis and <e1>perspiration</e1> immediately after the administration of salmon <e2>calcitonin</e2> with nasal spray or intramuscular administration (Calsynar)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2804	"We introduce a case of a sixty years old woman with several previous episodes of rhinitis, conjunctivitis and <e1>perspiration</e1> immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration (<e2>Calsynar</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2805	"We introduce a case of a sixty years old woman with several previous episodes of <e1>rhinitis</e1>, conjunctivitis and perspiration immediately after the administration of salmon <e2>calcitonin</e2> with nasal spray or intramuscular administration (Calsynar)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2806	"We introduce a case of a sixty years old woman with several previous episodes of <e1>rhinitis</e1>, conjunctivitis and perspiration immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration (<e2>Calsynar</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2807	"<e1>Minocycline</e1> as a cause of drug-induced <e2>autoimmune hepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2808	"<e1>Minocycline</e1> -induced <e2>autoimmune hepatitis</e2> is usually identical to sporadic <e2>autoimmune hepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2809	"We describe the clinical and liver biopsy morphologic features for 4 patients with <e1>minocycline</e1> -induced <e2>autoimmune hepatitis</e2> (group 1)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2810	"<e1>L-asparaginase</e1> -provoked seizures as singular expression of <e2>central nervous toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2811	"<e1>L-asparaginase</e1> -provoked <e2>seizures</e2> as singular expression of central nervous toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2812	"Patients treated with <e1>L-asparaginase</e1> may present with <e2>hemorrhagic</e2> and thrombotic cerebrovascular events."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2813	"Patients treated with <e1>L-asparaginase</e1> may present with hemorrhagic and <e2>thrombotic cerebrovascular events</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2814	"We report a case of <e1>seizure</e1> associated with <e2>L-asparaginase</e2> therapy but no evidence of hemorrhagic or thrombotic cerebrovascular events."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2815	"Eighty-two patients with various malignancies who received imipenem/<e1>cilastatin</e1> 143 times for <e2>neutropenic fever</e2> between March 1994 and October 1999 in Department of Pediatric Oncology, Gazi University, were identified."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2816	"Eighty-two patients with various malignancies who received <e1>imipenem</e1>/cilastatin 143 times for <e2>neutropenic fever</e2> between March 1994 and October 1999 in Department of Pediatric Oncology, Gazi University, were identified."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2817	"Incidence of <e1>seizures</e1> in pediatric cancer patients treated with imipenem/<e2>cilastatin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2818	"Incidence of <e1>seizures</e1> in pediatric cancer patients treated with <e2>imipenem</e2>/cilastatin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2819	"<e1>Proconvulsive</e1> tendency of imipenem/<e2>cilastatin</e2> is one of its well-known side effects."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2820	"<e1>Proconvulsive</e1> tendency of <e2>imipenem</e2>/cilastatin is one of its well-known side effects."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2821	"Three of these patients had <e1>convulsions</e1> attributed to imipenem/<e2>cilastatin</e2>; 3.6% of the patients had seizure, or 2% of imipenem/<e2>cilastatin</e2> administrations was followed by a seizure attack."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2822	"Three of these patients had <e1>convulsions</e1> attributed to <e2>imipenem</e2>/cilastatin; 3.6% of the patients had seizure, or 2% of <e2>imipenem</e2>/cilastatin administrations was followed by a seizure attack."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2823	"Three of these patients had convulsions attributed to imipenem/<e1>cilastatin</e1>; 3.6% of the patients had <e2>seizure</e2>, or 2% of imipenem/<e1>cilastatin</e1> administrations was followed by a <e2>seizure</e2> attack."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2824	"Three of these patients had convulsions attributed to <e1>imipenem</e1>/cilastatin; 3.6% of the patients had <e2>seizure</e2>, or 2% of <e1>imipenem</e1>/cilastatin administrations was followed by a <e2>seizure</e2> attack."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2825	"Three of these patients had convulsions attributed to imipenem/<e1>cilastatin</e1>; 3.6% of the patients had <e2>seizure</e2>, or 2% of imipenem/<e1>cilastatin</e1> administrations was followed by a <e2>seizure</e2> attack."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2826	"Three of these patients had convulsions attributed to <e1>imipenem</e1>/cilastatin; 3.6% of the patients had <e2>seizure</e2>, or 2% of <e1>imipenem</e1>/cilastatin administrations was followed by a <e2>seizure</e2> attack."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2827	"<e1>Gabapentin</e1> -induced mood changes with <e2>hypomanic</e2> features in adults."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2828	"<e1>Gabapentin</e1> -induced <e2>mood changes</e2> with hypomanic features in adults."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2829	"We report two adults who received <e1>gabapentin</e1> (GBP) and subsequently developed <e2>behavioural side effects</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2830	"We report two adults who received gabapentin (<e1>GBP</e1>) and subsequently developed <e2>behavioural side effects</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2831	"<e1>Acute pancreatitis</e1> in a child with idiopathic ulcerative colitis on long-term <e2>5-aminosalicylic acid</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2832	"We describe a 10-year-old boy with ulcerative colitis who developed <e1>acute pancreatitis</e1> while on long-term treatment with <e2>5-aminosalicylic acid</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2833	"CONCLUSION: Marked <e1>visual field constriction</e1> appears to be associated with <e2>vigabatrin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2834	"Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with <e1>vigabatrin</e1> -attributed <e2>visual field constriction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2835	"PURPOSE: Symptomatic <e1>visual field constriction</e1> thought to be associated with <e2>vigabatrin</e2> has been reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2836	"The current study investigated the visual fields and visual electrophysiology of eight patients with known <e1>vigabatrin</e1> -attributed <e2>visual field loss</e2>, three of whom were reported previously."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2837	"The <e1>field defects</e1> and some electrophysiological abnormalities persist when <e2>vigabatrin</e2> therapy is withdrawn."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2838	"<e1>Depressive symptoms</e1> disappeared after <e2>interferon</e2> therapy was stopped."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2839	"Treatment of chronic hepatitis C with interferon alpha (<e1>IFN-alpha</e1>) is relatively contraindicated in patients with psychiatric disorders because of possible severe <e2>psychiatric side effects</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2840	"Treatment of chronic hepatitis C with <e1>interferon alpha</e1> (IFN-alpha) is relatively contraindicated in patients with psychiatric disorders because of possible severe <e2>psychiatric side effects</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2841	"While for ribavirin antidepressant effects are not known, we suppose that antidepressants may prevent <e1>changes in serotonergic or noradrenergic neurotransmission</e1> caused by <e2>IFN-alpha</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2842	"Intensive high-flux hemodiafiltration is often used in the management of <e2>vancomycin</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2843	"Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of <e2>vancomycin</e2> toxicity: intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2844	"We describe 2 children with cerebral palsy who suffered significant <e1>morbidity</e1> immediately after treatment with <e2>hyperbaric oxygen</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2845	"A 33-year-old male presented with <e1>brown discolouration of the fingernails</e1> following the application of 4% hydroquinone in sorbolene cream and <e2>0.1% tretinoin cream</e2> to the face intermittently for 9 months."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2846	"A 33-year-old male presented with <e1>brown discolouration of the fingernails</e1> following the application of <e2>4% hydroquinone in sorbolene cream</e2> and 0.1% tretinoin cream to the face intermittently for 9 months."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2847	"<e1>Nail staining</e1> from <e2>hydroquinone</e2> cream."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2848	"<e1>Gangrene</e1> of the fingertips after <e2>bleomycin</e2> and methotrexate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2849	"<e1>Gangrene</e1> of the fingertips after bleomycin and <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2850	"This supports the well-reported potential of <e1>bleomycin</e1> to trigger <e2>acral vascular toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2851	"We describe a 57-year-old man with acral erythrocyanosis progressing to <e1>acute digital ischemia</e1> and gangrene that developed after combined chemotherapy (<e2>bleomycin</e2> and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2852	"We describe a 57-year-old man with acral erythrocyanosis progressing to <e1>acute digital ischemia</e1> and gangrene that developed after combined chemotherapy (bleomycin and <e2>methotrexate</e2>) used to treat a metastatic squamous cell carcinoma of the hypopharynx."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2853	"We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and <e1>gangrene</e1> that developed after combined chemotherapy (<e2>bleomycin</e2> and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2854	"We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and <e1>gangrene</e1> that developed after combined chemotherapy (bleomycin and <e2>methotrexate</e2>) used to treat a metastatic squamous cell carcinoma of the hypopharynx."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2855	"<e1>Diarrhea-associated over-anticoagulation</e1> in a patient taking <e2>warfarin</e2>: therapeutic role of cholestyramine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2856	"We present a case of significant over-anticoagulation temporally associated with a bout of protracted <e1>diarrhea</e1> in a patient on <e2>warfarin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2857	"We present a case of significant <e1>over-anticoagulation</e1> temporally associated with a bout of protracted diarrhea in a patient on <e2>warfarin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2858	"<e1>MI</e1> related to the use of activated and non-activated <e2>PCCs</e2> predominantly affects young patients who often have no preceding history of, or risk factors for, <e1>MI</e1> and tends to be associated with large cumulative doses of concentrate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2859	"Recombinant VIIa concentrate in the management of bleeding following <e1>prothrombin complex concentrate</e1> -related <e2>myocardial infarction</e2> in patients with haemophilia and inhibitors."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2860	"We have safely used recombinant factor VIIa to treat bleeding in the immediate and long-term period following <e1>PCC</e1> -related <e2>MI</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2861	"Even after a strict warning, he took another <e1>quinine</e1> tablet that evening, which triggered his fifth episode of severe <e2>thrombocytopenia</e2>, and confirmed the etiology of <e1>quinine</e1> -induced <e2>thrombocytopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2862	"Even after a strict warning, he took another <e1>quinine</e1> tablet that evening, which triggered his fifth episode of severe <e2>thrombocytopenia</e2>, and confirmed the etiology of <e1>quinine</e1> -induced <e2>thrombocytopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2863	"Even after a strict warning, he took another <e1>quinine</e1> tablet that evening, which triggered his fifth episode of severe <e2>thrombocytopenia</e2>, and confirmed the etiology of <e1>quinine</e1> -induced <e2>thrombocytopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2864	"Occult <e1>quinine</e1> -induced <e2>thrombocytopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2865	"Only after three subsequent episodes of severe, symptomatic <e1>thrombocytopenia</e1> over the next four weeks did he say, upon repeat questioning, that he had continued to take <e2>quinine</e2> for night leg cramps."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2866	"An 8-year-old child with familial Mediterranean fever exhibited signs of <e2>colchicine</e2> intoxication while receiving prophylactic doses of the drug."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2867	"CONCLUSION: To the best of our knowledge, this is the first time <e2>colchicine</e2> intoxication in this age group has been described in the English literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2868	"Near fatal acute <e2>colchicine</e2> intoxication in a child."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2869	"<e1>Near fatal</e1> acute <e2>colchicine</e2> intoxication in a child."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2870	"<e1>Acute myeloid leukemia</e1> and lung cancer occurring in a chronic lymphocytic leukemia patient treated with <e2>fludarabine</e2> and autologous peripheral blood stem-cell transplantation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2871	"Acute myeloid leukemia and <e1>lung cancer</e1> occurring in a chronic lymphocytic leukemia patient treated with <e2>fludarabine</e2> and autologous peripheral blood stem-cell transplantation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2872	"We describe the exceptional development of <e1>AML</e1> and lung cancer in a patient with previously diagnosed CLL in minimal residual disease status after <e2>fludarabine</e2> treatment followed by autologous peripheral blood stem-cell transplantation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2873	"We describe the exceptional development of AML and <e1>lung cancer</e1> in a patient with previously diagnosed CLL in minimal residual disease status after <e2>fludarabine</e2> treatment followed by autologous peripheral blood stem-cell transplantation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2874	"In 2 of the 3 cases the patients were also taking <e1>lithium carbonate</e1> and beta-blockers, both of which could have contributed to the <e2>incontinence</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2875	"In the present paper the authors describe 2 female patients who developed <e1>incontinence</e1> secondary to the selective serotonin reuptake inhibitors <e2>paroxetine</e2> and sertraline, as well as a third who developed this side effect on venlafaxine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2876	"In the present paper the authors describe 2 female patients who developed <e1>incontinence</e1> secondary to the selective serotonin reuptake inhibitors paroxetine and <e2>sertraline</e2>, as well as a third who developed this side effect on venlafaxine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2877	"In the present paper the authors describe 2 female patients who developed <e1>incontinence</e1> secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on <e2>venlafaxine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2878	"This concerns 2 male patients who experienced <e1>incontinence</e1> while taking <e2>venlafaxine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2879	"Case studies in <e1>heparin</e1> -induced <e2>thrombocytopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2880	"Major points illustrated are, (1) occurrence of <e1>HIT</e1> with any dose or form of <e2>heparin</e2>; (2) misperceptions on the diagnostic criteria; (3) correct (thrombin inhibitors) and incorrect (platelet transfusions and warfarin) management; (4) influence of management strategy on clinical outcomes; (5) severity of the syndrome; and (6) potential for both anamnestic response to <e2>heparin</e2> and disappearance of <e1>HIT</e1> antibodies over time."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2881	"Type II <e1>heparin</e1> -induced <e2>thrombocytopenia</e2> (HIT) is an immunological disorder characterized by antibodies to <e1>heparin</e1> -platelet factor 4 complexes and a high risk of thrombotic complications."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2882	"After several unrevealing medical work-ups, he was found to have a high blood <e2>lead</e2> level (122 microg/dL); he has a history of scraping and sanding <e2>lead</e2> paint without adequate protective measures."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2883	"It also highlights a current major etiologic question, that is, whether and to what degree <e1>lead</e1> exposure contributes to the development of <e2>hypertension</e2>, and raises the issue of whether <e1>lead</e1> -induced <e2>hypertension</e2> constitutes a subset of <e2>hypertension</e2> that is especially amenable to therapy with dietary calcium."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2884	"It also highlights a current major etiologic question, that is, whether and to what degree <e1>lead</e1> exposure contributes to the development of hypertension, and raises the issue of whether <e1>lead</e1> -induced hypertension constitutes a subset of hypertension that is especially amenable to therapy with dietary calcium."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2885	"Poorly controlled hypertension in a painter with chronic <e2>lead</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2886	"This case demonstrates an occupational activity (construction) that has now become the dominant source of <e1>lead</e1> exposure for U.S. adults, the importance of a good occupational history to suspecting and making a diagnosis, the possible outcomes of chronic <e1>lead</e1> toxicity, and the importance of preventing further exposure and using proper methods to treat acute toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2887	"<e1>Severe rash</e1>, including the Stevens-Johnson syndrome (SJS), is the major toxicity of <e2>nevirapine</e2> and is described in the package labeling with a prominent, boxed warning."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2888	"Severe rash, including the Stevens-Johnson syndrome (<e1>SJS</e1>), is the major toxicity of <e2>nevirapine</e2> and is described in the package labeling with a prominent, boxed warning."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2889	"Severe rash, including the <e1>Stevens-Johnson syndrome</e1> (SJS), is the major toxicity of <e2>nevirapine</e2> and is described in the package labeling with a prominent, boxed warning."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2890	"<e1>Stevens-Johnson syndrome</e1> caused by the antiretroviral drug <e2>nevirapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2891	"Though physicians treating large populations of patients with HIV are well aware of this complication, only one other report of <e1>nevirapine</e1> -associated <e2>SJS</e2> has been documented in the dermatology literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2892	"We describe 2 cases of <e1>SJS</e1> related to <e2>nevirapine</e2> use and review the literature on this newly recognized association."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2893	"Oral intake and <e1>acarbose</e1> were withheld and the <e2>ileus</e2> spontaneously resolved after 2 days."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2894	"There is evidence that the angiotensin II receptor antagonist, <e1>losartan</e1>, <e2>increases urate excretion</e2> by reducing reabsorption of urate in the renal proximal tubule."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2895	"<e1>Atrial fibrillation</e1> occurring in a patient taking <e2>etanercept</e2> plus methotrexate for rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2896	"<e1>Atrial fibrillation</e1> occurring in a patient taking etanercept plus <e2>methotrexate</e2> for rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2897	"A review of the literature revealed two other cases of <e1>hepatic angiosarcoma</e1> in patients after long-term <e2>cyclophosphamide</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2898	"<e1>Hepatic angiosarcoma</e1> occurring after <e2>cyclophosphamide</e2> therapy: case report and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2899	"We propose that <e1>cyclophosphamide</e1> be added to the list of exposures potentially associated with <e2>hepatic angiosarcoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2900	"<e1>ARA-C</e1> is frequently associated with <e2>dermatologic toxicity</e2>, but this is only the second case of toxic epidermal necrolysis described in connection with this drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2901	"<e1>ARA-C</e1> is frequently associated with dermatologic toxicity, but this is only the second case of <e2>toxic epidermal necrolysis</e2> described in connection with this drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2902	"On the fifth day after administration of a high dose of <e1>ARA-C</e1> (2 g/m2 intravenously every 12 hours), she developed <e2>bullous lesions on the hands and soles that disseminated, evolving to necrosis</e2>, sepsis, and death on the 22nd day."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2903	"On the fifth day after administration of a high dose of <e1>ARA-C</e1> (2 g/m2 intravenously every 12 hours), she developed bullous lesions on the hands and soles that disseminated, evolving to necrosis, sepsis, and <e2>death</e2> on the 22nd day."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2904	"On the fifth day after administration of a high dose of <e1>ARA-C</e1> (2 g/m2 intravenously every 12 hours), she developed bullous lesions on the hands and soles that disseminated, evolving to necrosis, <e2>sepsis</e2>, and death on the 22nd day."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2905	"<e1>Toxic epidermal necrolysis</e1> after the use of high-dose <e2>cytosine arabinoside</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2906	"We report a fatal case of toxic epidermal necrolysis (<e1>TEN</e1>) resulting from a high dose of cytosine arabinoside (<e2>ARA-C</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2907	"We report a fatal case of toxic epidermal necrolysis (<e1>TEN</e1>) resulting from a high dose of <e2>cytosine arabinoside</e2> (ARA-C)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2908	"We report a fatal case of <e1>toxic epidermal necrolysis</e1> (TEN) resulting from a high dose of cytosine arabinoside (<e2>ARA-C</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2909	"We report a fatal case of <e1>toxic epidermal necrolysis</e1> (TEN) resulting from a high dose of <e2>cytosine arabinoside</e2> (ARA-C)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2910	"<e1>Quetiapine</e1> and <e2>obsessive-compulsive symptoms</e2> (OCS): case report and review of atypical antipsychotic-induced OCS."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2911	"<e1>Quetiapine</e1> and obsessive-compulsive symptoms (<e2>OCS</e2>): case report and review of atypical antipsychotic-induced <e2>OCS</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2912	"<e1>Quetiapine</e1> and obsessive-compulsive symptoms (<e2>OCS</e2>): case report and review of atypical antipsychotic-induced <e2>OCS</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2913	"The first known report of <e1>quetiapine</e1> <e2>exacerbating OCS</e2> in a 43-year-old man with obsessive-compulsive disorder (OCD), trichotillomania, delusional disorder and bipolar II disorder is presented."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2914	"He was diagnosed with possible <e1>serotonin syndrome</e1>; his symptoms resolved after <e2>clomipramine</e2> was stopped but before clozapine was restarted eight days later."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2915	"OBJECTIVE: To report on the possible development of <e1>serotonin syndrome</e1> in a patient receiving <e2>clomipramine</e2> after clozapine was withdrawn from the treatment regimen."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2916	"OBJECTIVE: To report on the possible development of <e1>serotonin syndrome</e1> in a patient receiving clomipramine after <e2>clozapine</e2> was withdrawn from the treatment regimen."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2917	"Possible <e1>serotonin syndrome</e1> associated with <e2>clomipramine</e2> after withdrawal of clozapine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2918	"Possible <e1>serotonin syndrome</e1> associated with clomipramine after withdrawal of <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2919	"The day after clozapine was stopped, while he was still receiving <e1>clomipramine</e1> 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, <e2>agitated</e2>, and confused."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2920	"The day after <e1>clozapine</e1> was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, <e2>agitated</e2>, and confused."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2921	"The day after clozapine was stopped, while he was still receiving <e1>clomipramine</e1> 150 mg/d, he began <e2>behaving oddly</e2>, started sweating profusely, shivering, and became tremulous, agitated, and confused."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2922	"The day after <e1>clozapine</e1> was stopped, while he was still receiving clomipramine 150 mg/d, he began <e2>behaving oddly</e2>, started sweating profusely, shivering, and became tremulous, agitated, and confused."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2923	"The day after clozapine was stopped, while he was still receiving <e1>clomipramine</e1> 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and <e2>confused</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2924	"The day after <e1>clozapine</e1> was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and <e2>confused</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2925	"The day after clozapine was stopped, while he was still receiving <e1>clomipramine</e1> 150 mg/d, he began behaving oddly, started sweating profusely, <e2>shivering</e2>, and became tremulous, agitated, and confused."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2926	"The day after <e1>clozapine</e1> was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, <e2>shivering</e2>, and became tremulous, agitated, and confused."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2927	"The day after clozapine was stopped, while he was still receiving <e1>clomipramine</e1> 150 mg/d, he began behaving oddly, started <e2>sweating profusely</e2>, shivering, and became tremulous, agitated, and confused."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2928	"The day after <e1>clozapine</e1> was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started <e2>sweating profusely</e2>, shivering, and became tremulous, agitated, and confused."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2929	"The day after clozapine was stopped, while he was still receiving <e1>clomipramine</e1> 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became <e2>tremulous</e2>, agitated, and confused."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2930	"The day after <e1>clozapine</e1> was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became <e2>tremulous</e2>, agitated, and confused."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2931	"<e1>Quinine</e1> induced <e2>coagulopathy</e2> --a near fatal experience."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2932	"The cause of his bleeding was a <e1>severe thrombocytopoaenia</e1>, induced by chronic ingestion of <e2>quinine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2933	"Dose-dependent <e1>olanzapine</e1> -associated <e2>leukopenia</e2>: three case reports."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2934	"These cases suggest the possibility that, in some patients, leukopenia or <e1>agranulocytosis</e1> during <e2>olanzapine</e2> treatment might be dose-related."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2935	"These cases suggest the possibility that, in some patients, <e1>leukopenia</e1> or agranulocytosis during <e2>olanzapine</e2> treatment might be dose-related."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2936	"We report three cases of patients who developed <e1>leukopenia</e1> during <e2>olanzapine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2937	"CONCLUSION: This case illustrates a potential link between dermatologic and ocular <e2>5-FU</e2> toxicities."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2938	"Differential diagnoses included ocular rosacea with cicatrizing conjunctivitis and <e1>5-FU</e1> -induced <e2>ectropion</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2939	"DISCUSSION: Patients with <e1>5-FU</e1> -induced <e2>ectropion</e2> experience tender, red, scaled lids, making contact lens wear difficult."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2940	"DISCUSSION: Patients with <e1>5-FU</e1> -induced ectropion experience <e2>tender, red, scaled lids</e2>, making contact lens wear difficult."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2941	"<e1>Ectropion</e1> secondary to bolus injection of <e2>5-fluorouracil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2942	"Exacerbation of <e1>5-FU</e1> <e2>dermatologic toxicities</e2> in patients with preexisting conditions suggests the importance of aggressive ocular prophylaxis, using frequent ocular lubrication and topical steroid preparations with concurrent medical management of pre-existing dermatologic conditions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2943	"Presented is a case of <e1>acute renal failure</e1> induced by <e2>acetazolamide</e2> therapy for glaucoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2944	"<e1>Renal failure</e1> associated with <e2>acetazolamide</e2> therapy for glaucoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2945	"This sulfonamide like nephropathy should be differentiated from <e1>acetazolamide</e1> -related <e2>calcium phosphate nephrolithiasis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2946	"<e1>Ischaemic colitis</e1> in a patient taking <e2>meloxicam</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2947	"Symptoms and <e1>endoscopic lesions</e1> quickly regressed within 1 week of <e2>meloxicam</e2> withdrawal."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2948	"We describe a patient who presented with <e1>bloody diarrhoea</e1> after 15 mg <e2>meloxicam</e2> daily for 10 days for osteoarthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2949	"We suggest that <e1>meloxicam</e1> might have <e2>intestinal toxic effects</e2> when taken in high doses, because of reduced COX-2 selectivity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2950	"As these cases revealed, close monitoring of blood chemistry is mandatory after starting <e1>spironolactone</e1>, and patients should be advised to stop <e1>spironolactone</e1> immediately if <e2>diarrhoea</e2> develops."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2951	"In patients with chronic heart failure, <e1>spironolactone</e1> added to conventional treatment may lead to <e2>serious and, occasionally, fatal hyperkalaemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2952	"In some cases this seems to happen because <e1>spironolactone</e1> causes <e2>diarrhoea</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2953	"<e1>Serious adverse events</e1> experienced by patients with chronic heart failure taking <e2>spironolactone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2954	"We report a patient with advanced colonic carcinoma who was treated with concomitant chemoirradiation with <e1>oxaliplatin</e1> and developed a peculiar <e2>dermnatitis</e2> in the irradiated field after being exposed to subsequent chemotherapy with <e1>oxaliplatin</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2955	"An 11-year-old boy developed a <e1>severe enteropathy</e1> 2 years after initiation of <e2>clofazimine</e2> treatment for graft-versus-host disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2956	"<e1>Clofazimine</e1> <e2>enteropathy</e2> caused by crystal deposition can be life-threatening."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2957	"<e1>Clofazimine</e1> enteropathy caused by crystal deposition can be <e2>life-threatening</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2958	"<e1>Clofazimine</e1> <e2>enteropathy</e2> in a pediatric bone marrow transplant recipient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2959	"She developed a <e1>severe urticarial rash</e1> 3 weeks following initiation of therapy with <e2>Enoxaparin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2960	"We cared for a patient with progressive renal impairment who presented with <e1>blurred vision</e1>, QRS broadening and cardiac failure due to chronic <e2>cibenzoline</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2961	"We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and <e1>cardiac failure</e1> due to chronic <e2>cibenzoline</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2962	"We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure due to chronic <e2>cibenzoline</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2963	"We cared for a patient with progressive renal impairment who presented with blurred vision, <e1>QRS broadening</e1> and cardiac failure due to chronic <e2>cibenzoline</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2964	"Indolent <e1>aspergillus arthritis</e1> complicating <e2>fludarabine</e2> -based non-myeloablative stem cell transplantation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2965	"We describe two patients with <e1>aspergillus arthritis of the knee joint</e1> following <e2>fludarabine</e2> -based non-myeloablative stem cell transplantation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2966	"CONCLUSION: The present findings suggest that <e1>fluvoxamine</e1> can cause <e2>increased libido</e2> in some patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2967	"<e1>Increased libido</e1> in a woman treated with <e2>fluvoxamine</e2>: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2968	"OBJECTIVE: The aim of this paper is to describe a case of <e1>increased libido</e1> during <e2>fluvoxamine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2969	"RESULTS: The patient, a 27-year-old married Japanese woman with borderline personality disorder, developed an <e1>increased libido</e1> with the administration of <e2>fluvoxamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2970	"The <e1>increased libido</e1> disappeared after <e2>fluvoxamine</e2> was discontinued."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2971	"An infant who developed <e1>pancreatitis</e1> during <e2>meglumine antimoniate</e2> treatment for visceral leishmaniasis and who was successfully treated with a combination of allopurinol and ketoconazole is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2972	"Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in an infant who developed <e1>pancreatitis</e1> caused by <e2>meglumine antimoniate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2973	"CONCLUSIONS: This case report showed that the clinical appearance of <e1>Hashimoto's disease</e1> after <e2>IFN-alpha</e2> therapy for chronic C hepatitis in our patient was associated with a specific genetic predisposition (DR5) for this pathology."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2974	"Further studies are necessary to evaluate whether the study of HLA antigens may be a very useful tool to detect the patients with a predisposition to develop <e1>autoimmune thyroiditis</e1>, in order to make a early diagnosis of thyroid disorders during the <e2>IFN-alpha</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2975	"Further studies are necessary to evaluate whether the study of HLA antigens may be a very useful tool to detect the patients with a predisposition to develop autoimmune thyroiditis, in order to make a early diagnosis of <e1>thyroid disorders</e1> during the <e2>IFN-alpha</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2976	"<e1>Hashimoto's disease</e1> during <e2>interferon-alpha</e2> therapy in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2977	"OBJECTIVES: The authors described a case of <e1>Hashimoto's disease</e1> during interferon-alpha (<e2>IFN-alpha</e2>) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2978	"OBJECTIVES: The authors described a case of <e1>Hashimoto's disease</e1> during <e2>interferon-alpha</e2> (IFN-alpha) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2979	"During dose-finding studies for intravenous proton pump inhibitors <e1>omeprazole</e1> and pantoprazole, three of six young female volunteers receiving <e1>omeprazole</e1> and two young female volunteers receiving pantoprazole developed <e2>peripheral edema</e2> within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2980	"During dose-finding studies for intravenous proton pump inhibitors omeprazole and <e1>pantoprazole</e1>, three of six young female volunteers receiving omeprazole and two young female volunteers receiving <e1>pantoprazole</e1> developed <e2>peripheral edema</e2> within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2981	"<e1>Pheripheral edema</e1> was observed in five female patients after taking proton pump inhibitors omeprazole, <e2>lansoprazole</e2>, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2982	"<e1>Pheripheral edema</e1> was observed in five female patients after taking proton pump inhibitors <e2>omeprazole</e2>, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2983	"<e1>Pheripheral edema</e1> was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or <e2>pantoprazole</e2> for 7-15 days for peptic acid diseases in recommended standard doses."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2984	"<e1>Motor fluctuations</e1> appear after 2-3 years of <e2>levodopa</e2> treatment, and affect at least 50% of patients after five years."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2985	"CONCLUSION: Significant <e1>weight loss</e1> is a potential adverse event in patients with rheumatoid arthritis treated with <e2>leflunomide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2986	"<e1>Leflunomide</e1> -associated <e2>weight loss</e2> in rheumatoid arthritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2987	"METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if <e1>weight loss</e1> had occurred as an adverse event in patients treated with <e2>leflunomide</e2> between November 1998 and January 2000."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2988	"OBJECTIVE: To determine the frequency of <e1>weight loss</e1> in patients treated with <e2>leflunomide</e2> for rheumatoid arthritis at an arthritis referral center."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2989	"RESULTS: Five of 70 patients who had begun <e1>leflunomide</e1> therapy had significant <e2>weight loss</e2> that could not be linked to other identifiable etiologies."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2990	"It is increasingly recognized that dose adjustment of oral <e1>valacyclovir</e1> in renal failure is necessary to avoid <e2>neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2991	"<e1>Neurotoxicity</e1> of <e2>valacyclovir</e2> in peritoneal dialysis: a pharmacokinetic study."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2992	"She developed <e1>neurotoxicity</e1> with an adjustment dosage of <e2>valacyclovir</e2> for a cutaneous zoster infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2993	"<e1>Avascular necrosis of the femoral head</e1> in patients with prostate cancer treated with <e2>cyproterone acetate</e2> and radiotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2994	"We report the case histories of two patients with histologically confirmed adenocarcinoma of the prostate, both of whom had been treated with steroidal anti-androgen therapy in the form of <e1>cyproterone acetate</e1> prior to radical or palliative pelvic irradiation, and who subsequently developed <e2>femoral head avascular necrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2995	"<e1>Levofloxacin</e1> induced <e2>polymorphic ventricular tachycardia</e2> with normal QT interval."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2996	"We report the first case of <e1>polymorphic ventricular tachycardia</e1> with normal QT interval associated with the oral use of <e2>levofloxacin</e2> in the absence of other etiologies known to cause these arrhythmias."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2997	"So far, few cases of <e1>pulmonary side effects</e1> caused by <e2>ticlopidine</e2> have been reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2998	"Special care should be taken when <e1>pulmonary symptoms</e1> appear in association with <e2>ticlopidine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2999	"<e1>Ticlopidine</e1> -induced <e2>interstitial pulmonary disease</e2>: a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3000	"We report a case of <e1>interstitial pulmonary disease</e1> that occurred together with lymphocytic colitis during treatment with <e2>ticlopidine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3001	"We report a case of interstitial pulmonary disease that occurred together with <e1>lymphocytic colitis</e1> during treatment with <e2>ticlopidine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3002	"A patient that received <e1>methadone</e1> for cancer-associated pain developed <e2>myoclonus</e2> as a side effect."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3003	"<e1>Methadone</e1> -induced <e2>myoclonus</e2> in advanced cancer."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3004	"OBJECTIVE: To report a case of <e1>fatal hyperkalemia</e1> owing to <e2>succinylcholine</e2> administration in a patient with mucositis secondary to chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3005	"<e1>Succinylcholine</e1> -induced <e2>hyperkalemia</e2> in a patient with mucositis secondary to chemotherapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3006	"We believe that mucositis was a contributing factor to this case of <e1>fatal hyperkalemia</e1> after administration of <e2>succinylcholine</e2>, with a mechanism similar to that reported with thermal injury."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3007	"<e1>Cutaneous seeding</e1> after ultrasound-guided percutaneous <e2>ethanol injection</e2> for treatment of hepatocellular carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3008	"We describe a case of needle-track <e1>cutaneous seeding</e1> of hepatocellular carcinoma (HCC) after sonographically guided percutaneous <e2>ethanol injection</e2> (PEI)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3009	"<e1>Adenosine</e1> -induced <e2>ventricular fibrillation</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3010	"However, <e1>adenosine</e1> shortens the antegrade refractoriness of accessory atrioventricular connections and may cause <e2>acceleration of the ventricular rate</e2> during atrial fibrillation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3011	"We observed <e1>ventricular fibrillation</e1> in 2 patients who presented to the emergency department with pre-excited atrial fibrillation and were given 12 mg of <e2>adenosine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3012	"After the dose of <e1>methylprednisolone</e1> was reduced from 40 mg to 20 mg i.v. q6h and shifted to other anti-asthma treatment by procaterol metered dose inhaler via spacer, the <e2>psychotic reaction</e2> disappeared a few hours later."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3013	"Continuous EEG monitoring is helpful in managing <e1>seizures</e1> that occur as a complication of <e2>CBZ</e2> OD, after the course of recovery or worsening, and in providing assistance with prognosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3014	"Massive <e1>CBZ</e1> OD may produce a reversible encephalopathy that includes <e2>cortical hyperexcitability</e2>, a profound burst-suppression EEG pattern, and cranial nerve areflexia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3015	"Massive <e1>CBZ</e1> OD may produce a reversible encephalopathy that includes cortical hyperexcitability, a profound burst-suppression EEG pattern, and <e2>cranial nerve areflexia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3016	"Massive <e1>CBZ</e1> OD may produce a reversible encephalopathy that includes cortical hyperexcitability, a <e2>profound burst-suppression EEG pattern</e2>, and cranial nerve areflexia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3017	"Massive <e1>CBZ</e1> OD may produce a <e2>reversible encephalopathy</e2> that includes cortical hyperexcitability, a profound burst-suppression EEG pattern, and cranial nerve areflexia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3018	"Massive plasmocytosis due to <e1>methimazole</e1> -induced <e2>bone marrow toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3019	"<e1>Massive plasmocytosis</e1> due to <e2>methimazole</e2> -induced bone marrow toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3020	"To our knowledge this is the first report of pancytopenia due to <e1>MMI</e1>, where the usual hypoplasia found is replaced by <e2>massive plasmocytosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3021	"To our knowledge this is the first report of <e1>pancytopenia</e1> due to <e2>MMI</e2>, where the usual hypoplasia found is replaced by massive plasmocytosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3022	"We report a case of <e1>fulminant hepatic failure</e1> associated with <e2>didanosine</e2> and masquerading as a surgical abdomen and compare the clinical, biologic, histologic, and ultrastructural findings with reports described previously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3023	"This report details a case of <e1>bilateral avascular necrosis of the femoral heads</e1> in a patient receiving 'standard' doses of <e2>dexamethasone</e2> as part of the antiemetic regimen used in cisplatin-based combination chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3024	"Although no coagulation study was done and the Meckel's diverticulum is normally associated with bleeding, the particular intensity of the following <e1>hemorrhage</e1> may have been favored by <e2>metformin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3025	"An obese patient, not diabetic, treated with <e1>metformin</e1> for some weeks, was referred to us with <e2>severe inferior digestive hemorrhage</e2>, diagnosed with Meckel's diverticulum."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3026	"<e1>Digestive hemorrhage</e1> caused by a Meckel's diverticulum in a <e2>metformin</e2> -treated patient: is there any connection?"
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3027	"<e1>Ulcer became worse</e1> after tobramycin and <e2>gentamycin</e2> treatment for 2 days."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3028	"<e1>Ulcer became worse</e1> after <e2>tobramycin</e2> and gentamycin treatment for 2 days."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3029	"Possible linkage of <e1>amprenavir</e1> with <e2>intracranial bleeding</e2> in an HIV-infected hemophiliac."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3030	"The <e1>bleeding</e1> resolved on discontinuation of <e2>APV</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3031	"We report the occurrence of spontaneous <e1>intracranial bleeding</e1> in an human immunodeficiency virus (HIV)-infected adolescent with hemophilia A who was receiving <e2>amprenavir</e2> (APV)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3032	"According to the Naranjo probability scale, the relationship of <e1>gemcitabine</e1> treatment with <e2>cutaneous eruption</e2> in our patient is possible."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3033	"CONCLUSIONS: We report the first case of <e1>gemcitabine</e1> -induced <e2>LABD</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3034	"<e1>Linear immunoglobulin A bullous dermatosis</e1> induced by <e2>gemcitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3035	"OBJECTIVE: To report a case of linear immunoglobulin (Ig) A bullous dermatosis (<e1>LABD</e1>) induced by <e2>gemcitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3036	"OBJECTIVE: To report a case of <e1>linear immunoglobulin (Ig) A bullous dermatosis</e1> (LABD) induced by <e2>gemcitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3037	"Twenty-four hours after the administration of <e1>gemcitabine</e1>, a <e2>symmetric, bullous, herpetiform eruption</e2> appeared on his trunk and upper limbs."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3038	"<e1>Vancomycin</e1> is the most frequently implicated drug, but other agents have been reported to cause <e2>LABD</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3039	"Although <e1>taxol</e1> has shown significant activity in advanced ovarian cancer, <e2>peripheral neuropathy</e2> is likely to become the major dose-limiting toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3040	"A rare case of advanced ovarian carcinoma who developed <e1>difficulty walking</e1> 25 days after treatment with weekly <e2>paclitaxel</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3041	"We describe a case of advanced ovarian carcinoma who developed <e1>difficulty walking</e1> because of marked pain in the lower extremities and loss of proprioception 25 days after treatment with weekly <e2>taxol</e2> (80 mg/m(2)x3)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3042	"We describe a case of advanced ovarian carcinoma who developed difficulty walking because of marked pain in the lower extremities and <e1>loss of proprioception</e1> 25 days after treatment with weekly <e2>taxol</e2> (80 mg/m(2)x3)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3043	"We describe a case of advanced ovarian carcinoma who developed difficulty walking because of <e1>marked pain</e1> in the lower extremities and loss of proprioception 25 days after treatment with weekly <e2>taxol</e2> (80 mg/m(2)x3)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3044	"Relief by naloxone of <e1>morphine</e1> -induced <e2>spasm</e2> of the sphincter of Oddi in a post-cholecystectomy patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3045	"We present the case of a patient who had undergone cholecystectomy previously, but in whom <e1>morphine</e1> given in the Emergency Department precipitated pain consistent with <e2>biliary colic</e2>; the pain resolved promptly after administration of naloxone."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3046	"We present the case of a patient who had undergone cholecystectomy previously, but in whom <e1>morphine</e1> given in the Emergency Department precipitated <e2>pain</e2> consistent with biliary colic; the <e2>pain</e2> resolved promptly after administration of naloxone."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3047	"<e1>Myasthenia gravis</e1> during low-dose <e2>IFN-alpha</e2> therapy for chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3048	"A patient with rheumatoid arthritis developed an acute <e1>intrahepatic cholestasis</e1> after 100 mg of <e2>sodium aurothiomalate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3049	"<e1>Acute lung injury</e1> associated with <e2>5-fluorouracil</e2> and oxaliplatinum combined chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3050	"<e1>Acute lung injury</e1> associated with 5-fluorouracil and <e2>oxaliplatinum</e2> combined chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3051	"Diarrhoea, T-CD4+ lymphopenia and <e1>bilateral patchy pulmonary infiltrates</e1> developed in a male 60 yrs of age, who was treated with oxaliplatinum and <e2>5-fluorouracil</e2> for unresectable rectum carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3052	"Diarrhoea, T-CD4+ lymphopenia and <e1>bilateral patchy pulmonary infiltrates</e1> developed in a male 60 yrs of age, who was treated with <e2>oxaliplatinum</e2> and 5-fluorouracil for unresectable rectum carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3053	"<e1>Diarrhoea</e1>, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and <e2>5-fluorouracil</e2> for unresectable rectum carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3054	"<e1>Diarrhoea</e1>, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with <e2>oxaliplatinum</e2> and 5-fluorouracil for unresectable rectum carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3055	"Diarrhoea, <e1>T-CD4+ lymphopenia</e1> and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and <e2>5-fluorouracil</e2> for unresectable rectum carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3056	"Diarrhoea, <e1>T-CD4+ lymphopenia</e1> and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with <e2>oxaliplatinum</e2> and 5-fluorouracil for unresectable rectum carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3057	"It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a <e1>pulmonary adverse reaction</e1>, a feature never previously associated with oxaliplatinum and <e2>5-fluorouracil</e2> regimens."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3058	"It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a <e1>pulmonary adverse reaction</e1>, a feature never previously associated with <e2>oxaliplatinum</e2> and 5-fluorouracil regimens."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3059	"BACKGROUND: <e1>Accutane</e1> a <e2>teratogenic</e2> prescription drug licensed to treat severe, recalcitrant nodular acne."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3060	"RESULTS: The estimated number of <e1>Accutane</e1> prescriptions for reproductive-aged women has more than doubled in the past 10 years; it is the most widely used <e2>teratogenic</e2> drug in the United States, with approximately 2.5 per 1,000 reproductive-aged women exposed to <e1>Accutane</e1> in 1999."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3061	"A 62-year-old woman treated with <e1>pranlukast</e1> for 2 months developed interstitial pneumonitis with a <e2>high fever</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3062	"A 62-year-old woman treated with <e1>pranlukast</e1> for 2 months developed <e2>interstitial pneumonitis</e2> with a high fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3063	"Acute <e1>interstitial pneumonia</e1> induced by <e2>ONO-1078</e2> (pranlukast), a leukotriene receptor antagonist."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3064	"Acute <e1>interstitial pneumonia</e1> induced by ONO-1078 (<e2>pranlukast</e2>), a leukotriene receptor antagonist."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3065	"An asymptomatic HIV-infected woman experienced right-sided <e1>renal colicky pain</e1> during treatment with <e2>indinavir</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3066	"<e1>Indinavir</e1> -associated nephrolithiasis and chronic <e2>interstitial nephritis</e2> were the only possible causes identified in this patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3067	"<e1>Indinavir</e1> -associated <e2>nephrolithiasis</e2> and chronic interstitial nephritis were the only possible causes identified in this patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3068	"<e1>Papillary necrosis</e1> associated with the HIV protease inhibitor <e2>indinavir</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3069	"Physicians should be aware that <e1>indinavir</e1> <e2>nephrolithiasis</e2> may cause papillary necrosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3070	"Physicians should be aware that <e1>indinavir</e1> nephrolithiasis may cause <e2>papillary necrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3071	"The HIV protease inhibitor <e1>indinavir</e1> may cause nephrolithiasis and <e2>interstitial nephritis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3072	"The HIV protease inhibitor <e1>indinavir</e1> may cause <e2>nephrolithiasis</e2> and interstitial nephritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3073	"The renal consequences of <e1>indinavir</e1> -associated <e2>nephrotoxicity</e2> are uncertain."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3074	"We report a case of <e1>papillary necrosis</e1> in a patient treated with <e2>indinavir</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3075	"We describe 2 male patients, a 49-year-old with psoriatic arthritis and impaired renal function and a 43-year-old renal transplant recipient, who both sustained a marked <e1>decline in glomerular filtration rate</e1> in conjunction with a selective inhibitor of cyclooxygenase-2 (COX-2), <e2>rofecoxib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3076	"CONCLUSIONS: <e1>LTG</e1> overdose may result in a severe but reversible <e2>encephalopathy</e2>, a previously undescribed phenomenon."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3077	"Evaluation revealed elevated serum <e2>LTG</e2> levels and no other etiology for encephalopathy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3078	"METHODS: A 55-year-old woman became <e1>stuporous</e1> after overdose with <e2>lamotrigine</e2> (LTG) and valproic acid (VPA) tablets."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3079	"METHODS: A 55-year-old woman became <e1>stuporous</e1> after overdose with lamotrigine (<e2>LTG</e2>) and valproic acid (VPA) tablets."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3080	"METHODS: A 55-year-old woman became <e1>stuporous</e1> after overdose with lamotrigine (LTG) and <e2>valproic acid</e2> (VPA) tablets."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3081	"METHODS: A 55-year-old woman became <e1>stuporous</e1> after overdose with lamotrigine (LTG) and valproic acid (<e2>VPA</e2>) tablets."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3082	"PURPOSE: To report that acute <e1>lamotrigine</e1> poisoning may result in severe <e2>encephalopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3083	"<e1>Stupor</e1> from <e2>lamotrigine</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3084	"The cause of death was determined to be <e1>acute intoxication</e1> by <e2>olanzapine</e2>, and the manner of death was accidental."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3085	"This article describes the case of a 25-year-old man found <e1>dead</e1> at home who had been prescribed <e2>olanzapine</e2> for schizophrenia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3086	"<e1>Lichenoid drug eruption</e1> to <e2>salsalate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3087	"This <e1>eruption</e1> emerged after 1 month of therapy with <e2>salsalate</e2>, persisted for as long as <e2>salsalate</e2> was administered, and cleared within 3 weeks of discontinuing the medication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3088	"We describe a patient who experienced a <e1>lichenoid eruption</e1> after the initiation of <e2>salsalate</e2> for relief of arthritic pain."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3089	"<e1>Amphotericin B</e1> -induced <e2>seizures</e2> in a patient with AIDS."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3090	"CASE SUMMARY: A 46-year-old African-American man experienced recurrent <e1>grand mal seizures</e1> during intravenous infusion of <e2>amphotericin B</e2>, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3091	"CONCLUSIONS: <e1>Amphotericin B</e1> seems to be the probable cause of the <e2>seizures</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3092	"Despite administration of phenytoin and lorazepam, the <e1>seizures</e1> persisted and occurred only during <e2>amphotercin B</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3093	"<e1>Didanosine</e1> also has a potential for inducing <e2>seizures</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3094	"OBJECTIVE: To report a case of multiple episodes of <e1>seizure</e1> activity in an AIDS patent following <e2>amphotericin B</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3095	"The time course of events suggested that <e1>amphotericin B</e1> was the cause of the <e2>seizures</e2> in this AIDS patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3096	"To date, only three cases of <e1>seizures</e1> associated with <e2>amphotericin B</e2> have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3097	"<e1>Vocal cord paralysis</e1> as a consequence of peritonsillar infiltration with <e2>bupivacaine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3098	"We present the case of a 5-year-old girl who developed <e1>bilateral vocal cord paralysis</e1> following preoperative peritonsillar <e2>bupivacaine</e2> infiltration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3099	"A 53 year old Greenlandic male was admitted twice over a period of 4 years with a new complete <e1>right bundle branch block</e1> after ingestion of 10 g and 4 g of <e2>carbamazepine</e2> respectively."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3100	"<e1>Carbamazepine</e1> induced <e2>right bundle branch block</e2> in a Greenlandic patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3101	"<e1>Cicatricial entropion</e1> associated with chronic <e2>dipivefrin</e2> application."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3102	"CONCLUSIONS: Cicatrization in the substantia propria of the conjunctiva by excessive lymphocytic infiltration after topically administered antiglaucoma drugs including <e1>dipivefrin</e1> is a possible mechanism of action for <e2>entropion</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3103	"Nine eyes from 6 patients, 74 years to 90 years of age, referred by ophthalmologists for repair of <e1>cicatricial entropion</e1> after at least 2 years of twice-a-day application of <e2>dipivefrin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3104	"PURPOSE: To report patients who presented to the oculoplastics department for repair of <e1>cicatrical entropion</e1> after topical use of <e2>dipivefrin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3105	"A 34-year-old lady developed a <e1>constellation of dermatitis</e1>, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral <e2>sulphasalazine</e2> for sero-negative rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3106	"A 34-year-old lady developed a constellation of dermatitis, <e1>fever</e1>, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral <e2>sulphasalazine</e2> for sero-negative rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3107	"A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and <e1>hepatitis</e1>, beginning on the 17th day of a course of oral <e2>sulphasalazine</e2> for sero-negative rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3108	"A 34-year-old lady developed a constellation of dermatitis, fever, <e1>lymphadenopathy</e1> and hepatitis, beginning on the 17th day of a course of oral <e2>sulphasalazine</e2> for sero-negative rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3109	"It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called "3-week <e1>sulphasalazine</e1> syndrome", a rare, but often <e2>fatal</e2>, immunoallergic reaction to <e1>sulphasalazine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3110	"It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called "3-week <e1>sulphasalazine</e1> syndrome", a rare, but often <e2>fatal</e2>, immunoallergic reaction to <e1>sulphasalazine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3111	"It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called "3-week <e1>sulphasalazine</e1> syndrome", a rare, but often fatal, <e2>immunoallergic reaction</e2> to <e1>sulphasalazine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3112	"It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called "3-week <e1>sulphasalazine</e1> syndrome", a rare, but often fatal, <e2>immunoallergic reaction</e2> to <e1>sulphasalazine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3113	"It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called "3-week <e2>sulphasalazine</e2> syndrome", a rare, but often fatal, immunoallergic reaction to <e2>sulphasalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3114	"It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called "3-week <e2>sulphasalazine</e2> syndrome", a rare, but often fatal, immunoallergic reaction to <e2>sulphasalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3115	"The 3-week <e2>sulphasalazine</e2> syndrome strikes again."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3116	"Interestingly, the use of carboplatin (CBDCA) and VDS in the subsequent treatment course was well tolerated indicating that the <e1>SIADH</e1> was most likely to have been induced by administration of <e2>CDDP</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3117	"Syndrome of inappropriate secretion of ADH (<e1>SIADH</e1>) following <e2>cisplatin</e2> administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3118	"<e1>Syndrome of inappropriate secretion of ADH</e1> (SIADH) following <e2>cisplatin</e2> administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3119	"We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (<e1>SIADH</e1>) following systemic chemotherapy with cisplatin (<e2>CDDP</e2>) and vindesine (VDS)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3120	"We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (<e1>SIADH</e1>) following systemic chemotherapy with <e2>cisplatin</e2> (CDDP) and vindesine (VDS)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3121	"We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (<e1>SIADH</e1>) following systemic chemotherapy with cisplatin (CDDP) and vindesine (<e2>VDS</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3122	"We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (<e1>SIADH</e1>) following systemic chemotherapy with cisplatin (CDDP) and <e2>vindesine</e2> (VDS)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3123	"We report a patient with pulmonary adenocarcinoma complicated by the <e1>syndrome of inappropriate secretion of antidiuretic hormone</e1> (SIADH) following systemic chemotherapy with cisplatin (<e2>CDDP</e2>) and vindesine (VDS)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3124	"We report a patient with pulmonary adenocarcinoma complicated by the <e1>syndrome of inappropriate secretion of antidiuretic hormone</e1> (SIADH) following systemic chemotherapy with <e2>cisplatin</e2> (CDDP) and vindesine (VDS)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3125	"We report a patient with pulmonary adenocarcinoma complicated by the <e1>syndrome of inappropriate secretion of antidiuretic hormone</e1> (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (<e2>VDS</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3126	"We report a patient with pulmonary adenocarcinoma complicated by the <e1>syndrome of inappropriate secretion of antidiuretic hormone</e1> (SIADH) following systemic chemotherapy with cisplatin (CDDP) and <e2>vindesine</e2> (VDS)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3127	"After extensive neurological 'work up', we realized that the <e1>anisocoria</e1> was related to the transdermal <e2>scopolamine</e2> patch that we had prescribed for weaning off the opioid."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3128	"<e1>Anisocoria</e1> from transdermal <e2>scopolamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3129	"<e1>De novo absence status</e1> of late onset following withdrawal of <e2>lorazepam</e2>: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3130	"The aim of this report is to describe the clinical and electroencephalographic findings seen in an elderly woman without previous history of seizures who developed a <e1>nonconvulsive generalized status epilepticus</e1> following acute withdrawal of <e2>lorazepam</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3131	"Early recognition of hereditary motor and sensory neuropathy type 1 can avoid life-threatening <e2>vincristine</e2> neurotoxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3132	"Recognizing early signs of HMSN, such as areflexia and pes cavus deformity, can prevent <e1>severe neurotoxicity</e1> of polychemotherapy by avoiding <e2>vincristine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3133	"The disease predisposes to severe <e2>vincristine</e2> neurotoxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3134	"We report a 31-year-old women with recurrent Hodgkin's lymphoma and unrecognized HMSN-1 who developed <e1>severe motor neuropathy</e1> 3 weeks after the first cycle of treatment including 2 mg of <e2>vincristine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3135	"Acute <e1>asymptomatic hepatitis</e1> in a healthy normal volunteer exposed to 2 oral doses of <e2>amodiaquine</e2> and artesunate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3136	"Acute <e1>asymptomatic hepatitis</e1> in a healthy normal volunteer exposed to 2 oral doses of amodiaquine and <e2>artesunate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3137	"This report describes an unexpected drug-induced <e1>hepatitis</e1> in a previously healthy young woman exposed to 2 doses of <e2>amodiaquine</e2> and artesunate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3138	"This report describes an unexpected drug-induced <e1>hepatitis</e1> in a previously healthy young woman exposed to 2 doses of amodiaquine and <e2>artesunate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3139	"<e1>Systemic allergic contact dermatitis</e1> to <e2>8-methoxypsoralen</e2> (8-MOP)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3140	"<e1>Systemic allergic contact dermatitis</e1> to 8-methoxypsoralen (<e2>8-MOP</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3141	"We describe a patient who had a <e1>systemic allergic contact dermatitis</e1> to <e2>8-MOP</e2> develop during her second course of PUVA treatment for psoriasis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3142	"A 33-year-old man with a history of recreational <e1>benztropine</e1> abuse presented to the emergency department with confusion, <e2>abdominal pain</e2>, and distention."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3143	"A 33-year-old man with a history of recreational <e1>benztropine</e1> abuse presented to the emergency department with <e2>confusion</e2>, abdominal pain, and distention."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3144	"A 33-year-old man with a history of recreational <e1>benztropine</e1> abuse presented to the emergency department with confusion, abdominal pain, and <e2>distention</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3145	"<e1>Agranulocytosis</e1> and granulocytopenia associated with <e2>quetiapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3146	"Agranulocytosis and <e1>granulocytopenia</e1> associated with <e2>quetiapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3147	"CONCLUSION: Although a definite association has not been proven, clinicians should be aware of the possibility of <e1>agranulocytosis</e1> while using <e2>quetiapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3148	"METHOD: We describe three case-reports concerning <e1>haematological adverse effects</e1> of <e2>quetiapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3149	"RESULTS: <e1>Quetiapine</e1> was associated with leucopenia in two patients and clinically apparent <e2>agranulocytosis</e2> in one patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3150	"RESULTS: <e1>Quetiapine</e1> was associated with <e2>leucopenia</e2> in two patients and clinically apparent agranulocytosis in one patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3151	"CONCLUSIONS: There is very little published information regarding <e1>ofloxacin</e1> -induced <e2>toxic epidermal necrolysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3152	"However, a large case-control study included three cases of either <e1>Stevens-Johnson syndrome</e1> or toxic epidermal necrolysis associated with <e2>ofloxacin</e2> use, but no details of the cases were given."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3153	"However, a large case-control study included three cases of either Stevens-Johnson syndrome or <e1>toxic epidermal necrolysis</e1> associated with <e2>ofloxacin</e2> use, but no details of the cases were given."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3154	"It is hoped that this case report creates awareness that <e1>ofloxacin</e1> -induced <e2>toxic epidermal necrolysis</e2> is possible."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3155	"OBJECTIVE: To report a fatal case of <e1>toxic epidermal necrolysis</e1> in a man who was treated with oral <e2>ofloxacin</e2> for epididymitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3156	"<e1>Ofloxacin</e1>: a probable cause of <e2>toxic epidermal necrolysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3157	"This report rules out other causes of <e1>toxic epidermal necrolysis</e1> and implicates <e2>ofloxacin</e2> in what appears to be an atypical presentation of drug-induced <e1>toxic epidermal necrolysis</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3158	"This report rules out other causes of <e1>toxic epidermal necrolysis</e1> and implicates <e2>ofloxacin</e2> in what appears to be an atypical presentation of drug-induced <e1>toxic epidermal necrolysis</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3159	"A boy with chronic neutropenia and recurrent inflammatory skin lesions developed <e1>multiple erythematous nodules</e1> following administration of <e2>G-CSF</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3160	"A girl with cystic fibrosis and cyclic neutropenia developed an <e1>erythematous papular eruption</e1> without fever or neutrophilia 7 months after commencing therapy with <e2>G-CSF</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3161	"<e1>Neutrophilic dermatoses</e1> in two children with idiopathic neutropenia: association with granulocyte colony-stimulating factor (<e2>G-CSF</e2>) therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3162	"<e1>Neutrophilic dermatoses</e1> in two children with idiopathic neutropenia: association with <e2>granulocyte colony-stimulating factor</e2> (G-CSF) therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3163	"Painful <e1>neutrophilic skin lesions</e1> were observed in two children receiving granulocyte colony-stimulating factor (<e2>G-CSF</e2>) for treatment of idiopathic neutropenia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3164	"Painful <e1>neutrophilic skin lesions</e1> were observed in two children receiving <e2>granulocyte colony-stimulating factor</e2> (G-CSF) for treatment of idiopathic neutropenia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3165	"<e1>Painful</e1> neutrophilic skin lesions were observed in two children receiving granulocyte colony-stimulating factor (<e2>G-CSF</e2>) for treatment of idiopathic neutropenia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3166	"<e1>Painful</e1> neutrophilic skin lesions were observed in two children receiving <e2>granulocyte colony-stimulating factor</e2> (G-CSF) for treatment of idiopathic neutropenia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3167	"We believe that these skin eruptions belong to a spectrum of <e1>neutrophilic dermatoses</e1> that can be induced or aggravated by <e2>G-CSF</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3168	"We believe that these <e1>skin eruptions</e1> belong to a spectrum of neutrophilic dermatoses that can be induced or aggravated by <e2>G-CSF</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3169	"There is a putative role of <e1>liothyronine</e1> administration in precipitating or activating <e2>hyperthyroidism</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3170	"<e1>Triiodothyronine</e1> -induced <e2>thyrotoxicosis</e2> in ophthalmic Graves disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3171	"This case report describes the development of asymptomatic visual field defects (<e1>VFDs</e1>) in a psychiatric patient with bipolar disorder receiving adjunctive <e2>tiagabine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3172	"This case report describes the development of asymptomatic <e1>visual field defects</e1> (VFDs) in a psychiatric patient with bipolar disorder receiving adjunctive <e2>tiagabine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3173	"<e1>Pulmonary toxicity</e1> with <e2>mefloquine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3174	"This is the second report of <e1>acute lung injury</e1> and diffuse alveolar damage caused by <e2>mefloquine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3175	"This is the second report of acute lung injury and <e1>diffuse alveolar damage</e1> caused by <e2>mefloquine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3176	"This report presents a case of <e1>acute lung injury</e1> developing within hours after administration of <e2>mefloquine</e2> for a low-level Plasmodium falciparum malaria, which was persistent despite halofantrine therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3177	"An adult male presented with <e1>central blindness</e1> after ingesting <e2>methanol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3178	"Reversal of severe <e1>methanol</e1> -induced <e2>visual impairment</e2>: no evidence of retinal toxicity due to fomepizole."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3179	"Extra caution should be taken in using <e1>octreotide</e1> or its long-acting analog in patients otherwise predisposed to <e2>intrahepatic bile stasis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3180	"Gallstones and <e1>bile sludge</e1> are common side effects of <e2>octreotide</e2> therapy but rarely become symptomatic or require treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3181	"<e1>Gallstones</e1> and bile sludge are common side effects of <e2>octreotide</e2> therapy but rarely become symptomatic or require treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3182	"<e1>Hepatolithiasis</e1> (intrahepatic stone) during <e2>octreotide</e2> therapy for acromegaly: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3183	"In addition to its known effect on gallbladder stasis, <e1>octreotide</e1> <e2>alters bile acid composition</e2> and may thus hasten intrahepatic sludge and stone formation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3184	"In addition to its known effect on <e1>gallbladder stasis</e1>, <e2>octreotide</e2> alters bile acid composition and may thus hasten intrahepatic sludge and stone formation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3185	"In addition to its known effect on gallbladder stasis, <e1>octreotide</e1> alters bile acid composition and may thus <e2>hasten intrahepatic sludge</e2> and stone formation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3186	"In addition to its known effect on gallbladder stasis, <e1>octreotide</e1> alters bile acid composition and may thus hasten intrahepatic sludge and <e2>stone formation</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3187	"This is the first reported case of <e1>hepatolithiasis</e1> during <e2>octreotide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3188	"We report a case of <e1>hepatolithiasis</e1> (intrahepatic stone) complicated by gram-negative sepsis in a 37 year old male with acromegaly being treated with <e2>octreotide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3189	"However, in the mid-to-late 1980s, a series of letters to the editor and case reports announced an association between <e1>tamoxifen</e1> therapy in women with breast cancer and the development of <e2>endometrial carcinoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3190	"In this healthy population, the relative risk of developing <e1>endometrial carcinoma</e1> in the <e2>tamoxifen</e2> arm was 2.54, although when stratified by age, in women over 50, the risk grew to 4.01."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3191	"<e1>INH</e1>, which is a leading cause of <e2>drug eruptions</e2> in the above group of drugs was withdrawn."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3192	"<e1>Isonicotinic acid hydrazide</e1> induced <e2>anagen effluvium</e2> and associated lichenoid eruption."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3193	"<e1>Isonicotinic acid hydrazide</e1> induced anagen effluvium and associated <e2>lichenoid eruption</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3194	"Such <e1>anagen effluvium</e1> with lichenoid eruption following <e2>INH</e2> therapy has not been observed previously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3195	"Such anagen effluvium with <e1>lichenoid eruption</e1> following <e2>INH</e2> therapy has not been observed previously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3196	"<e1>Linear IgA bullous dermatosis</e1> occurring after <e2>carbamazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3197	"We report a patient who experienced <e1>LABD</e1> shortly after starting <e2>carbamazepine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3198	"After a second dose of <e1>metoclopramide</e1>, these symptoms recurred and were associated with confusion, <e2>agitation</e2>, fever, diaphoresis, tachypnea, tachycardia, and hypertension."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3199	"After a second dose of <e1>metoclopramide</e1>, these symptoms recurred and were associated with <e2>confusion</e2>, agitation, fever, diaphoresis, tachypnea, tachycardia, and hypertension."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3200	"After a second dose of <e1>metoclopramide</e1>, these symptoms recurred and were associated with confusion, agitation, fever, <e2>diaphoresis</e2>, tachypnea, tachycardia, and hypertension."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3201	"After a second dose of <e1>metoclopramide</e1>, these symptoms recurred and were associated with confusion, agitation, <e2>fever</e2>, diaphoresis, tachypnea, tachycardia, and hypertension."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3202	"After a second dose of <e1>metoclopramide</e1>, these symptoms recurred and were associated with confusion, agitation, fever, diaphoresis, tachypnea, tachycardia, and <e2>hypertension</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3203	"After a second dose of <e1>metoclopramide</e1>, these symptoms recurred and were associated with confusion, agitation, fever, diaphoresis, tachypnea, <e2>tachycardia</e2>, and hypertension."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3204	"After a second dose of <e1>metoclopramide</e1>, these symptoms recurred and were associated with confusion, agitation, fever, diaphoresis, <e2>tachypnea</e2>, tachycardia, and hypertension."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3205	"CONCLUSIONS: Clinicians should be aware of a risk of serotonin syndrome with serious <e1>extrapyramidal reactions</e1> in patients receiving sertraline or venlafaxine when <e2>metoclopramide</e2> is coadministered even in a single, conventional dose."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3206	"CONCLUSIONS: Clinicians should be aware of a risk of serotonin syndrome with serious <e1>extrapyramidal reactions</e1> in patients receiving <e2>sertraline</e2> or venlafaxine when metoclopramide is coadministered even in a single, conventional dose."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3207	"CONCLUSIONS: Clinicians should be aware of a risk of serotonin syndrome with serious <e1>extrapyramidal reactions</e1> in patients receiving sertraline or <e2>venlafaxine</e2> when metoclopramide is coadministered even in a single, conventional dose."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3208	"CONCLUSIONS: Clinicians should be aware of a risk of <e1>serotonin syndrome</e1> with serious extrapyramidal reactions in patients receiving sertraline or venlafaxine when <e2>metoclopramide</e2> is coadministered even in a single, conventional dose."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3209	"CONCLUSIONS: Clinicians should be aware of a risk of <e1>serotonin syndrome</e1> with serious extrapyramidal reactions in patients receiving <e2>sertraline</e2> or venlafaxine when metoclopramide is coadministered even in a single, conventional dose."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3210	"CONCLUSIONS: Clinicians should be aware of a risk of <e1>serotonin syndrome</e1> with serious extrapyramidal reactions in patients receiving sertraline or <e2>venlafaxine</e2> when metoclopramide is coadministered even in a single, conventional dose."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3211	"OBJECTIVE: To report 2 cases of serotonin syndrome with serious <e1>extrapyramidal movement disorders</e1> occurring when <e2>metoclopramide</e2> was coadministered with sertraline or venlafaxine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3212	"OBJECTIVE: To report 2 cases of serotonin syndrome with serious <e1>extrapyramidal movement disorders</e1> occurring when metoclopramide was coadministered with <e2>sertraline</e2> or venlafaxine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3213	"OBJECTIVE: To report 2 cases of serotonin syndrome with serious <e1>extrapyramidal movement disorders</e1> occurring when metoclopramide was coadministered with sertraline or <e2>venlafaxine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3214	"OBJECTIVE: To report 2 cases of <e1>serotonin syndrome</e1> with serious extrapyramidal movement disorders occurring when <e2>metoclopramide</e2> was coadministered with sertraline or venlafaxine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3215	"OBJECTIVE: To report 2 cases of <e1>serotonin syndrome</e1> with serious extrapyramidal movement disorders occurring when metoclopramide was coadministered with <e2>sertraline</e2> or venlafaxine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3216	"OBJECTIVE: To report 2 cases of <e1>serotonin syndrome</e1> with serious extrapyramidal movement disorders occurring when metoclopramide was coadministered with sertraline or <e2>venlafaxine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3217	"<e1>Serotonin syndrome</e1> caused by selective serotonin reuptake-inhibitors-<e2>metoclopramide</e2> interaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3218	"She was administered <e1>metoclopramide</e1> because of nausea and, within 2 hours, developed <e2>agitation</e2>, dysarthria, diaphoresis, and a movement disorder."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3219	"She was administered <e1>metoclopramide</e1> because of nausea and, within 2 hours, developed agitation, dysarthria, <e2>diaphoresis</e2>, and a movement disorder."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3220	"She was administered <e1>metoclopramide</e1> because of nausea and, within 2 hours, developed agitation, <e2>dysarthria</e2>, diaphoresis, and a movement disorder."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3221	"She was administered <e1>metoclopramide</e1> because of nausea and, within 2 hours, developed agitation, dysarthria, diaphoresis, and a <e2>movement disorder</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3222	"She was admitted following a fall and, after being given <e1>metoclopramide</e1>, developed <e2>movement disorder</e2> and a period of unresponsiveness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3223	"She was admitted following a fall and, after being given <e1>metoclopramide</e1>, developed movement disorder and a period of <e2>unresponsiveness</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3224	"A patient suffering from a rare enzyme deficiency developed a <e1>malignant neuroleptic syndrome</e1> after having been treated with one single dose of <e2>haloperidol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3225	"BACKGROUND: reports on <e1>delated cutaneous reactions</e1> to <e2>captopril</e2> have been seldom reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3226	"<e1>Captopril</e1> is an angiotensin-converting enzyme (ACE) inhibitor and their <e2>cutaneous side-effects</e2> are documented, but little has been published concerning the usefulness of patch test when they occur."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3227	"<e1>Dermatitis</e1> to <e2>captopril</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3228	"We presented the case of a patient who developed a <e1>cutaneous reaction</e1> induced by <e2>captopril</e2> with positive patch test."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3229	"A 62-year-old Caucasian man with atrial fibrillation who was taking <e1>warfarin</e1> reported an episode of <e2>hematochezia</e2>; his international normalized ratio (INR) was 1.74."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3230	"<e1>Warfarin</e1> -associated <e2>bleeding</e2> complication saved life."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3231	"<e1>Warfarin</e1> -associated <e2>bleeding</e2> generally is considered deleterious; however, in our patient it unmasked an early stage of colon cancer and thus may have saved the patient's life."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3232	"A case of polymyositis with <e1>dilated cardiomyopathy</e1> associated with <e2>interferon alpha</e2> treatment for hepatitis B."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3233	"A case of <e1>polymyositis</e1> with dilated cardiomyopathy associated with <e2>interferon alpha</e2> treatment for hepatitis B."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3234	"In this case, <e1>interferon alpha</e1> induced polymyositis and <e2>cardiomyopathy</e2> is diagnosed in a 33-yr-old male patient with history of chronic hepatitis B."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3235	"In this case, <e1>interferon alpha</e1> induced <e2>polymyositis</e2> and cardiomyopathy is diagnosed in a 33-yr-old male patient with history of chronic hepatitis B."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3236	"<e1>Polymyositis</e1> is a rare complication of <e2>interferon alpha</e2> treatment as a result of immune-modulating role of the drug itself."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3237	"To treat hepatitis B, <e1>interferon alpha</e1> was administered until the proximal <e2>muscle weakness</e2> developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3238	"Long-term follow-up after <e1>neoplastic seeding</e1> complicating percutaneous <e2>ethanol</e2> injection for treatment of hepatocellular carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3239	"We describe a case of <e1>subcutaneous metastasis</e1> along the needle track after percutaneous <e2>ethanol</e2> injection (PEI) for treatment of hepatocellular carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3240	"<e1>Aggressive endometrial carcinoma</e1> in a breast cancer patient treated with <e2>tamoxifen</e2> with normal transvaginal ultrasonography."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3241	"Since <e1>tamoxifen</e1> therapy can induce <e2>endometrial disorders</e2>, surveillance schemes of women taking <e1>tamoxifen</e1> have been recommended."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3242	"Since <e1>tamoxifen</e1> therapy can induce <e2>endometrial disorders</e2>, surveillance schemes of women taking <e1>tamoxifen</e1> have been recommended."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3243	"We described a very atypical case of a high stage, high grade <e1>endometrial cancer</e1> associated with <e2>tamoxifen</e2> in a 64-year-old woman with a past history of breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3244	"Beginning ductopenia was present in two, suggesting that <e1>itraconazole</e1> might be responsible for the occurrence of prolonged drug-induced <e2>cholangiopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3245	"Beginning <e1>ductopenia</e1> was present in two, suggesting that <e2>itraconazole</e2> might be responsible for the occurrence of prolonged drug-induced cholangiopathy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3246	"CONCLUSIONS: <e1>Itraconazole</e1> -induced liver injury presents with a <e2>cholestatic pattern of injury</e2> with damage to the interlobular bile ducts, possibly leading to ductopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3247	"CONCLUSIONS: <e1>Itraconazole</e1> -induced liver injury presents with a cholestatic pattern of injury with <e2>damage to the interlobular bile ducts</e2>, possibly leading to ductopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3248	"CONCLUSIONS: <e1>Itraconazole</e1> -induced liver injury presents with a cholestatic pattern of injury with damage to the interlobular bile ducts, possibly leading to <e2>ductopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3249	"CONCLUSIONS: <e1>Itraconazole</e1> -induced <e2>liver injury</e2> presents with a cholestatic pattern of injury with damage to the interlobular bile ducts, possibly leading to ductopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3250	"<e1>Hepatotoxicity</e1> related to <e2>itraconazole</e2>: report of three cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3251	"METHODS: Three patients with apparent <e1>itraconazole</e1> -induced <e2>liver injury</e2> were studied."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3252	"The occurrence of acute <e1>hepatitis</e1> is best known for <e2>ketoconazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3253	"We report on three patients who developed acute <e1>liver damage</e1> during therapy with <e2>itraconazole</e2>, and in whom liver biopsy specimens were obtained."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3254	"We suggest that <e1>itraconazole</e1> should be added to the list of drugs that may be responsible for a drug-induced <e2>vanishing bile duct syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3255	"With <e1>itraconazole</e1>, <e2>hepatotoxic</e2> reactions have only very rarely been reported, and histologic data are lacking."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3256	"<e1>Thrombotic stroke</e1> associated with the use of <e2>porcine factor VIII</e2> in a patient with acquired haemophilia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3257	"We have recently encountered a patient with acquired haemophilia who developed a <e1>thrombotic left middle cerebral artery distribution stroke</e1> while being treated with <e2>pFVIII</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3258	"We speculate that platelet activation induced by <e1>pFVIII</e1> may have contributed to <e2>thrombosis</e2> and suggest that <e1>pFVIII</e1> be used with caution in elderly patients with pre-existing cardiovascular risk factors."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3259	"<e1>Cutaneous sarcoidosis</e1> during <e2>interferon alfa</e2> and ribavirin treatment of hepatitis C virus infection: two cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3260	"<e1>Cutaneous sarcoidosis</e1> during interferon alfa and <e2>ribavirin</e2> treatment of hepatitis C virus infection: two cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3261	"There have been more than 20 observations of the appearance or aggravation of this <e1>granulomatosis</e1> with <e2>interferon alfa</e2> and more recently with the combination of <e2>interferon alfa</e2> plus ribavirin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3262	"There have been more than 20 observations of the appearance or aggravation of this <e1>granulomatosis</e1> with <e2>interferon alfa</e2> and more recently with the combination of <e2>interferon alfa</e2> plus ribavirin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3263	"There have been more than 20 observations of the appearance or aggravation of this <e1>granulomatosis</e1> with interferon alfa and more recently with the combination of interferon alfa plus <e2>ribavirin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3264	"We report two new cases of <e1>sarcoidosis</e1> in two patients with hepatitis C virus infection treated with <e2>interferon alfa</e2> and ribavirin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3265	"We report two new cases of <e1>sarcoidosis</e1> in two patients with hepatitis C virus infection treated with interferon alfa and <e2>ribavirin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3266	"CONCLUSIONS: Although <e1>mirtazapine</e1> offers clinicians a combination of strong efficacy and good safety, we suggest bearing <e2>SS</e2> in mind when prescribing this drug, especially in frail, elderly patients with underlying chronic conditions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3267	"DISCU<e1>SS</e1>ION: A review of the cases of <e1>SS</e1> with implication of <e2>mirtazapine</e2> as the cause was performed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3268	"OBJECTIVE: To document a case of <e1>serotonin syndrome</e1> (SS) associated with <e2>mirtazapine</e2> monotherapy, review the previously reported cases of SS associated with this tetracyclic antidepressant, and discuss the possible pathogenic mechanisms leading to this serious adverse drug reaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3269	"OBJECTIVE: To document a case of serotonin syndrome (<e1>SS</e1>) associated with <e2>mirtazapine</e2> monotherapy, review the previously reported cases of <e1>SS</e1> associated with this tetracyclic antidepressant, and discuss the possible pathogenic mechanisms leading to this serious adverse drug reaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3270	"Severe <e1>serotonin syndrome</e1> induced by <e2>mirtazapine</e2> monotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3271	"<e1>Pulmonary toxicity</e1> secondary to <e2>procarbazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3272	"A 64-year-old man presented with <e1>proteinuria</e1> during postoperative <e2>interferon (IFN)-beta</e2> therapy against malignant melanoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3273	"<e1>Minimal change nephrotic syndrome</e1> developing during postoperative <e2>interferon-beta</e2> therapy for malignant melanoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3274	"To our knowledge this is the first report that demonstrates <e1>histological abnormalities of the glomerulus</e1> associated with postoperative <e2>IFN-beta</e2> therapy for the malignant melanoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3275	"The authors report two cases of <e1>delayed elimination</e1> of methotrexate in patients receiving <e2>ciprofloxacin</e2>, with severe toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3276	"The authors report two cases of <e1>delayed elimination</e1> of <e2>methotrexate</e2> in patients receiving ciprofloxacin, with severe toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3277	"The authors report two cases of delayed elimination of methotrexate in patients receiving <e1>ciprofloxacin</e1>, with severe <e2>toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3278	"CONCLUSIONS: Clinicians should be aware of the possible association of <e1>thrombocytopenia</e1> with <e2>lansoprazole</e2> and discontinue the drug if <e1>thrombocytopenia</e1> becomes apparent."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3279	"DISCUSSION: After exclusion of other causes, the onset of <e1>thrombocytopenia</e1> after administration of <e2>lansoprazole</e2>, the resolution of the adverse reaction after discontinuation of the drug, and the fact that no other medicines were introduced during this time frame lead us to believe that this was most likely an idiosyncratic thrombocytopenic response to <e2>lansoprazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3280	"DISCUSSION: After exclusion of other causes, the onset of thrombocytopenia after administration of <e1>lansoprazole</e1>, the resolution of the adverse reaction after discontinuation of the drug, and the fact that no other medicines were introduced during this time frame lead us to believe that this was most likely an idiosyncratic <e2>thrombocytopenic</e2> response to <e1>lansoprazole</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3281	"He was started on oral <e1>lansoprazole</e1> 60 mg twice daily and, on hospital day 2, his <e2>platelet count decreased</e2> to 102 x 10(3)/mm(3); on hospital day 3, the platelet count was 36 x 10(3)/mm(3)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3282	"<e1>Lansoprazole</e1> -induced <e2>thrombocytopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3283	"OBJECTIVE: To describe a case of <e1>thrombocytopenia</e1> associated with the administration of <e2>lansoprazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3284	"To date, this is the first reported case of what appears to be isolated <e1>thrombocytopenia</e1> associated with <e2>lansoprazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3285	"Life-threatening <e1>anaphylactoid reaction</e1> to <e2>amifostine</e2> used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3286	"The most common side effects associated with <e1>amifostine</e1> are nausea, vomiting, hypotension, hypocalcemia and <e2>allergic reactions</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3287	"The most common side effects associated with <e1>amifostine</e1> are nausea, vomiting, hypotension, <e2>hypocalcemia</e2> and allergic reactions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3288	"The most common side effects associated with <e1>amifostine</e1> are nausea, vomiting, <e2>hypotension</e2>, hypocalcemia and allergic reactions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3289	"The most common side effects associated with <e1>amifostine</e1> are <e2>nausea</e2>, vomiting, hypotension, hypocalcemia and allergic reactions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3290	"The most common side effects associated with <e1>amifostine</e1> are nausea, <e2>vomiting</e2>, hypotension, hypocalcemia and allergic reactions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3291	"The patient suffered a <e1>life-threatening anaphylactoid reaction</e1> to <e2>amifostine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3292	"<e1>Agranulocytosis</e1> during <e2>clozapine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3293	"Granulocytopenia and <e1>agranulocytosis</e1> are considered among the most dangerous adverse effects of <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3294	"<e1>Granulocytopenia</e1> and agranulocytosis are considered among the most dangerous adverse effects of <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3295	"The female patient received <e1>clozapine</e1> in a daily dose of 400 mg, which induced <e2>agranulocytosis</e2> after 2 months."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3296	"The male patient was treated with 225-mg/day <e1>clozapine</e1> and the time to the diagnosis of <e2>agranulocytosis</e2> was 6 weeks."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3297	"A 53-year-old man developed <e1>NMS</e1> without rigidity while taking <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3298	"Atypical <e1>neuroleptic malignant syndrome</e1> associated with <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3299	"CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral <e1>zuclopenthixol</e1>, an antipsychotic from the thioxanthene family, who developed an acute, <e2>painful erection</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3300	"CONCLUSIONS: <e1>Priapism</e1> is an uncommon but potentially serious adverse effect of <e2>zuclopenthixol</e2> that practitioners, as with many other antipsychotics, should be aware of."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3301	"DISCUSSION: The occurrence of <e1>priapism</e1> in our patient was related to <e2>zuclopenthixol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3302	"OBJECTIVE: To present a single case of <e1>zuclopenthixol</e1> -induced <e2>priapism</e2> and a literature review."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3303	"<e1>Priapism</e1> associated with <e2>zuclopenthixol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3304	"The capacity of <e1>zuclopenthixol</e1> to induce <e2>priapism</e2> is thought to be due to its antagonist activity on alpha-adrenergic receptors."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3305	"After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming <e1>sepsis</e1> associated with <e2>metamizole</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3306	"<e1>Metamizole</e1>, a nonsteroidal antiinflammatory agent, is prohibited in the United States because of the risk of <e2>agranulocytosis</e2> but is widely used in Mexico and other countries."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3307	"Erythropoietin is beneficial in <e1>mitomycin</e1> -induced <e2>hemolytic-uremic syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3308	"We describe a patient who developed <e1>HUS</e1> after treatment with <e2>mitomycin C</e2> (total dose 144 mg/m2) due to a carcinoma of the ascending colon."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3309	"<e1>Levofloxacin</e1> -induced <e2>toxic epidermal necrolysis</e2> in an elderly patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3310	"To our knowledge, this case is the first published report of <e1>levofloxacin</e1> -induced <e2>TEN</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3311	"A 31-year-old female developed multiple episodes of <e1>grand mal seizures</e1> after combination chemotherapy with cisplatin, vinblastine and <e2>bleomycin</e2> for germ cell ovarian cancer stage Ic."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3312	"A 31-year-old female developed multiple episodes of <e1>grand mal seizures</e1> after combination chemotherapy with <e2>cisplatin</e2>, vinblastine and bleomycin for germ cell ovarian cancer stage Ic."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3313	"A 31-year-old female developed multiple episodes of <e1>grand mal seizures</e1> after combination chemotherapy with cisplatin, <e2>vinblastine</e2> and bleomycin for germ cell ovarian cancer stage Ic."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3314	"<e1>Posterior leukoencephalopathy</e1> following cisplatin, <e2>bleomycin</e2> and vinblastine therapy for germ cell tumor of the ovary."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3315	"<e1>Posterior leukoencephalopathy</e1> following <e2>cisplatin</e2>, bleomycin and vinblastine therapy for germ cell tumor of the ovary."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3316	"<e1>Posterior leukoencephalopathy</e1> following cisplatin, bleomycin and <e2>vinblastine</e2> therapy for germ cell tumor of the ovary."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3317	"After 5 days of treatment with <e1>IL-2</e1>, the patient developed a <e2>hemorrhagic lesion</e2> that progressed to toxic epidermal necrolysis, as well as grade 4 pancytopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3318	"After 5 days of treatment with <e1>IL-2</e1>, the patient developed a hemorrhagic lesion that progressed to toxic epidermal necrolysis, as well as grade 4 <e2>pancytopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3319	"After 5 days of treatment with <e1>IL-2</e1>, the patient developed a hemorrhagic lesion that progressed to <e2>toxic epidermal necrolysis</e2>, as well as grade 4 pancytopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3320	"OBJECTIVE: To report a case of <e1>cutaneous and hematologic toxicity</e1> in a patient treated with <e2>IL-2</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3321	"Subcutaneous <e1>IL-2</e1> is safe and well tolerated, with a <e2>mortality rate <3</e2>%."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3322	"<e1>Toxic epidermal necrolysis</e1> associated with <e2>interleukin-2</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3323	"A case of <e1>anaphylactoid reaction</e1> due solely to the use of <e2>Gelofusine</e2> in a patient with non-haemorrhagic hypovolaemia is presented, with a discussion on the management and the use of allergy identification jewellery."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3324	"<e2>Gelofusine</e2> allergy--the need for identification jewellery."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3325	"The authors describe <e1>valproate</e1> -induced <e2>hyperammonemia</e2> and mental status changes in an 88-year-old man, the first known reported case in an elderly patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3326	"The authors describe <e1>valproate</e1> -induced hyperammonemia and <e2>mental status changes</e2> in an 88-year-old man, the first known reported case in an elderly patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3327	"<e1>Valproate</e1> -induced hyperammonemia as a cause of <e2>altered mental status</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3328	"<e1>Valproate</e1> -induced <e2>hyperammonemia</e2> as a cause of altered mental status."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3329	"<e1>Leiomyosarcoma</e1> in urinary bladder after <e2>cyclophosphamide</e2> therapy for retinoblastoma and review of bladder sarcomas."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3330	"The epivodes of <e1>NMS</e1> occured under treatment with clozapine, risperidone, and <e2>amisulpride</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3331	"The epivodes of <e1>NMS</e1> occured under treatment with <e2>clozapine</e2>, risperidone, and amisulpride."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3332	"The epivodes of <e1>NMS</e1> occured under treatment with clozapine, <e2>risperidone</e2>, and amisulpride."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3333	"A 73-year-old woman presented with fever and <e1>cough</e1> 2 weeks after completing the third cycle of <e2>fludarabine</e2> for chronic lymphocytic leukemia (CLL)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3334	"A 73-year-old woman presented with <e1>fever</e1> and cough 2 weeks after completing the third cycle of <e2>fludarabine</e2> for chronic lymphocytic leukemia (CLL)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3335	"<e1>Fludarabine</e1> induced lung toxicity must be considered in all patients who develop unexplained <e2>lung disease</e2> while receiving fludarabine."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3336	"Fludarabine induced lung toxicity must be considered in all patients who develop unexplained <e1>lung disease</e1> while receiving <e2>fludarabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3337	"<e1>Fludarabine</e1> induced <e2>lung toxicity</e2> must be considered in all patients who develop unexplained lung disease while receiving fludarabine."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3338	"<e1>Multiple pulmonary nodules</e1>: an unusual presentation of <e2>fludarabine</e2> pulmonary toxicity: case report and review of literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3339	"Multiple pulmonary nodules: an unusual presentation of <e1>fludarabine</e1> <e2>pulmonary toxicity</e2>: case report and review of literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3340	"This case extends the spectrum of <e1>fludarabine</e1> pulmonary toxicity to include <e2>pulmonary nodules</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3341	"This case extends the spectrum of <e1>fludarabine</e1> <e2>pulmonary toxicity</e2> to include pulmonary nodules."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3342	"To our knowledge, four cases of <e1>interstitial pneumonitis</e1> associated with <e2>fludarabine</e2> have been reported in medical literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3343	"<e1>Epoprostenol</e1> may be associated rarely with severe <e2>erythroderma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3344	"Severe <e1>erythroderma</e1> as a complication of continuous <e2>epoprostenol</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3345	"We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with <e1>epoprostenol</e1>, presented with rapidly progressive erythema, scaling, nausea and vomiting, and <e2>fever</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3346	"We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with <e1>epoprostenol</e1>, presented with rapidly progressive erythema, scaling, <e2>nausea</e2> and vomiting, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3347	"We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with <e1>epoprostenol</e1>, presented with <e2>rapidly progressive erythema</e2>, scaling, nausea and vomiting, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3348	"We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with <e1>epoprostenol</e1>, presented with rapidly progressive erythema, <e2>scaling</e2>, nausea and vomiting, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3349	"We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with <e1>epoprostenol</e1>, presented with rapidly progressive erythema, scaling, nausea and <e2>vomiting</e2>, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3350	"A 50-year-old diabetic and hypertensive male patient is reported who had <e1>ticlopidine</e1> -induced <e2>marrow aplasia</e2> partially responsive to colony-stimulating factors and corticosteroids, but experienced complete recovery with cyclosporine."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3351	"There is no consensus on the treatment of <e1>ticlopidine</e1> -induced <e2>marrow aplasia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3352	"<e1>Ticlopidine</e1> -induced <e2>marrow aplasia</e2> treated with cyclosporine."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3353	"A 53-year-old man developed <e1>lower leg edema</e1> 4 weeks after <e2>rosiglitazone</e2> was increased from 4 mg once/day to 4 mg twice/day."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3354	"A 75-year-old man developed <e1>bilateral lower leg edema</e1> 6 months after switching from troglitazone to <e2>pioglitazone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3355	"A 77-year-old man developed <e1>ankle, hand, and facial swelling</e1> 2 weeks after starting <e2>rosiglitazone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3356	"Two cases of <e1>polymorphic ventricular tachycardia</e1> induced by the administration of <e2>verapamil</e2> against paroxysmal supraventricular tachycardia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3357	"<e1>Verapamil</e1> is widely used for the termination of paroxysmal supraventricular tachycardia (PSVT) with little <e2>proarrhythmic effect</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3358	"We describe two cases of PSVT that changed to <e1>non-sustained polymorphic ventricular tachycardia</e1> after administration of <e2>verapamil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3359	"<e1>Epsilon-aminocaproic acid</e1> and <e2>renal complications</e2>: case report and review of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3360	"Neonatal <e1>mydriasis</e1>: intravenous <e2>lidocaine</e2> adverse reaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3361	"We present a neonate with a seizure disorder who acutely developed <e1>pupillary mydriasis</e1> secondary to <e2>lidocaine</e2> overdose."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3362	"We suggest adding this side effect to the list of untoward effects of <e1>lidocaine</e1> and to the differential diagnosis of fixed <e2>dilated pupils</e2> in neonates treated with <e1>lidocaine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3363	"Myelodysplasia terminating in <e1>acute myeloid leukemia</e1> in a hairy cell leukemia patient treated with <e2>2-deoxycoformycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3364	"<e1>Myelodysplasia</e1> terminating in acute myeloid leukemia in a hairy cell leukemia patient treated with <e2>2-deoxycoformycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3365	"To the best of our knowledge only two previous cases of <e1>AML</e1> have been linked to treatment of HCL with purine analogs, both with <e2>2-chlorodeoxyadenosine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3366	"CONCLUSIONS: Peripheral administration of low-dose <e1>vasopressin</e1> for septic shock should be discouraged because of the risk of <e2>ischemic skin complications</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3367	"OBJECTIVE: To describe a case of severe <e1>skin necrosis</e1> resulting from peripheral intravenous administration of low-dose <e2>vasopressin</e2> in a patient with catecholamine-resistant septic shock."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3368	"<e1>Skin necrosis</e1> after extravasation of low-dose <e2>vasopressin</e2> administered for septic shock."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3369	"<e1>Mitomycin-C</e1> induced <e2>hemolytic uremic syndrome</e2>: a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3370	"<e1>Mitomycin-C</e1> is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of <e2>hemolytic uremic syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3371	"Although <e1>vasculitis</e1> has been reported in the course of hairy cell leukaemia, it has only rarely been reported as the consequence of <e2>cladribine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3372	"<e1>Systemic vasculitis</e1> complicating hairy cell leukaemia treatment with <e2>cladribine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3373	"We describe a 73-year-old woman who developed serious <e1>systemic vasculitis</e1> with associated thrombocytopenia in the course of treatment with <e2>cladribine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3374	"We describe a 73-year-old woman who developed serious systemic vasculitis with associated <e1>thrombocytopenia</e1> in the course of treatment with <e2>cladribine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3375	"Drug-induced <e1>mammary hyperplasias</e1> have been reported as rare complications of <e2>D-penicillamine</e2> and Neothetazone."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3376	"Drug-induced <e1>mammary hyperplasias</e1> have been reported as rare complications of D-penicillamine and <e2>Neothetazone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3377	"<e1>Gigantomastia</e1> induced by <e2>bucillamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3378	"Retrospectively, <e1>bucillamine</e1> was believed to be the cause of the <e2>giant hypertrophy</e2> because of its structural similarity to D-penicillamine, which was the subject of an abundance of reports of mammary hyperplasia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3379	"Retrospectively, bucillamine was believed to be the cause of the giant hypertrophy because of its structural similarity to <e1>D-penicillamine</e1>, which was the subject of an abundance of reports of <e2>mammary hyperplasia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3380	"The authors report the first case of <e1>bucillamine</e1> -induced <e2>giant mammary hyperplasia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3381	"The authors describe three families in whom the occurrence of <e1>FVS</e1> in all the siblings strongly suggests hereditary susceptibility to <e2>valproic acid</e2> -induced adverse outcome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3382	"The fetal <e1>valproate</e1> syndrome (FVS) is characterized by distinctive facial appearance, major and minor malformations, and <e2>developmental delay</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3383	"The fetal <e1>valproate</e1> syndrome (FVS) is characterized by <e2>distinctive facial appearance</e2>, major and minor malformations, and developmental delay."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3384	"The fetal <e2>valproate</e2> syndrome (FVS) is characterized by distinctive facial appearance, major and minor malformations, and developmental delay."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3385	"The fetal <e1>valproate</e1> syndrome (<e2>FVS</e2>) is characterized by distinctive facial appearance, major and minor malformations, and developmental delay."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3386	"The fetal <e1>valproate</e1> syndrome (FVS) is characterized by distinctive facial appearance, <e2>major and minor malformations</e2>, and developmental delay."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3387	"<e2>Valproate</e2> embryopathy in three sets of siblings: further proof of hereditary susceptibility."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3388	"<e1>Generalised pustular psoriasis</e1> induced by <e2>cyclosporin a</e2> withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3389	"We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of <e1>cyclosporin A</e1> induced a generalised pustular exacerbation and a <e2>aggravation of the joint condition</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3390	"We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of <e1>cyclosporin A</e1> induced a <e2>generalised pustular exacerbation</e2> and a aggravation of the joint condition."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3391	"The first case concerns a 70-year-old man who developed severe <e1>aplastic anemia</e1> 7 weeks after treatment with 500 mg of <e2>ticlopidine</e2> daily."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3392	"The second was an 82-year-old man receiving <e1>ticlopidine</e1> for 2 years when, during a febrile episode, he was found neutropenic with <e2>marrow aplasia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3393	"The second was an 82-year-old man receiving <e1>ticlopidine</e1> for 2 years when, during a febrile episode, he was found <e2>neutropenic</e2> with marrow aplasia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3394	"<e1>Ticlopidine</e1> -induced <e2>aplastic anemia</e2> (TIAA) is considered very uncommon."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3395	"<e1>Ticlopidine</e1> -induced aplastic anemia (<e2>TIAA</e2>) is considered very uncommon."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3396	"<e1>Ticlopidine</e1> -induced <e2>aplastic anemia</e2>: two new case reports, review, and meta-analysis of 55 additional cases."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3397	"When the data of the 57 patients are evaluated, a reversible direct <e1>cytotoxic effect</e1> of <e2>ticlopidine</e2> on the pluripotent/bipotent hematopoietic progenitor stem cell is proposed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3398	"<e1>Fixed drug eruption</e1> to <e2>rofecoxib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3399	"<e1>Rofecoxib</e1>, used for dysmenorrhea, caused a <e2>herpetiform fixed drug eruption</e2> predominantly involving the lips with classic clinical and histological findings in a red-brown lesion on the dorsal hand."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3400	"<e1>Rofecoxib</e1>, used for dysmenorrhea, caused a herpetiform fixed drug eruption predominantly involving the lips with classic clinical and histological findings in a <e2>red-brown lesion</e2> on the dorsal hand."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3401	"A patient who had been treated with large doses of <e1>thyroid hormone</e1> for several years developed features of secondary <e2>hypothyroidism</e2> after <e1>thyroid hormone</e1> withdrawal."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3402	"BACKGROUND: Gemcitabine has mild renal toxicity, but cases of <e1>gemcitabine</e1> -associated <e2>hemolytic-uremic syndrome</e2> (HUS) have been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3403	"BACKGROUND: <e1>Gemcitabine</e1> has mild renal toxicity, but cases of gemcitabine-associated <e2>hemolytic-uremic syndrome</e2> (HUS) have been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3404	"BACKGROUND: Gemcitabine has mild renal toxicity, but cases of <e1>gemcitabine</e1> -associated hemolytic-uremic syndrome (<e2>HUS</e2>) have been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3405	"BACKGROUND: <e1>Gemcitabine</e1> has mild renal toxicity, but cases of gemcitabine-associated hemolytic-uremic syndrome (<e2>HUS</e2>) have been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3406	"BACKGROUND: <e1>Gemcitabine</e1> has mild <e2>renal toxicity</e2>, but cases of gemcitabine-associated hemolytic-uremic syndrome (HUS) have been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3407	"CONCLUSION: There are only a few confirmed cases of <e1>gemcitabine</e1> -associated <e2>HUS</e2> despite the widespread use of the drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3408	"<e1>Gemcitabine</e1> -associated <e2>hemolytic-uremic syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3409	"Mean time between initiation of <e1>gemcitabine</e1> therapy and onset of <e2>HUS</e2> was 7.4 +/- 3.5 months, or 21.9 +/- 10.9 doses of <e1>gemcitabine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3410	"Mean time between initiation of <e1>gemcitabine</e1> therapy and onset of <e2>HUS</e2> was 7.4 +/- 3.5 months, or 21.9 +/- 10.9 doses of <e1>gemcitabine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3411	"METHODS: A case is presented of a 45-year-old woman on prolonged <e1>gemcitabine</e1> treatment for ovarian cancer who developed <e2>HUS</e2> and recovered after drug discontinuation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3412	"RESULTS: Including our own patient, a total of 26 cases of <e1>gemcitabine</e1> -associated <e2>HUS</e2> were identified."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3413	"An <e1>amiodarone</e1> <e2>optic neuropathy</e2> has been described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3414	"Biomicroscopy revealed <e1>amiodarone</e1> <e2>corneal deposits</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3415	"CASE REPORT: Soon after initiation of <e1>amiodarone HCl</e1> (200 mg/day), a 76-year-old man came to us with symptoms of visual "shining," glare, <e2>color vision anomalies</e2>, and gradually decreased vision."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3416	"CASE REPORT: Soon after initiation of <e1>amiodarone HCl</e1> (200 mg/day), a 76-year-old man came to us with symptoms of visual "shining," glare, color vision anomalies, and gradually <e2>decreased vision</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3417	"CASE REPORT: Soon after initiation of <e1>amiodarone HCl</e1> (200 mg/day), a 76-year-old man came to us with symptoms of visual "shining," <e2>glare</e2>, color vision anomalies, and gradually decreased vision."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3418	"CASE REPORT: Soon after initiation of <e1>amiodarone HCl</e1> (200 mg/day), a 76-year-old man came to us with symptoms of <e2>visual "shining</e2>," glare, color vision anomalies, and gradually decreased vision."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3419	"<e1>Visual changes</e1> secondary to initiation of <e2>amiodarone</e2>: a case report and review involving ocular management in cardiac polypharmacy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3420	"While both <e1>amiodarone</e1> and digoxin can cause permanent visual changes, the <e2>ocular effects</e2> are often reversible."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3421	"While both amiodarone and <e1>digoxin</e1> can cause permanent visual changes, the <e2>ocular effects</e2> are often reversible."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3422	"While both <e1>amiodarone</e1> and digoxin can cause permanent <e2>visual changes</e2>, the ocular effects are often reversible."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3423	"While both amiodarone and <e1>digoxin</e1> can cause permanent <e2>visual changes</e2>, the ocular effects are often reversible."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3424	"Infant twins sustained severe <e1>circumoral and pharyngeal burns</e1> from a concentrated solution of <e2>benzalkonium</e2> (Zephiran) chloride prescribed for treatment of candidiasis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3425	"Infant twins sustained severe <e1>circumoral and pharyngeal burns</e1> from a concentrated solution of benzalkonium (<e2>Zephiran</e2>) chloride prescribed for treatment of candidiasis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3426	"CONCLUSION: Long-term treatment with <e1>rifabutin</e1> may have a reversible and previously undescribed <e2>side-effect on retinal function</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3427	"PURPOSE: To describe the clinical and electrophysiological findings in a young boy with <e1>decreased vision</e1> possibly due to retinal damage by <e2>rifabutin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3428	"PURPOSE: To describe the clinical and electrophysiological findings in a young boy with decreased vision possibly due to <e1>retinal damage</e1> by <e2>rifabutin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3429	"Retinal dysfunction and <e1>anterior segment deposits</e1> in a patient treated with <e2>rifabutin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3430	"<e1>Retinal dysfunction</e1> and anterior segment deposits in a patient treated with <e2>rifabutin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3431	"We suggest that objective evaluation of retinal function with electrophysiological methods should be performed in patients with <e1>visual disturbance</e1> during treatment with <e2>rifabutin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3432	"A case is presented of a patient who experienced <e1>benzodiazepine withdrawal symptoms</e1> on discontinuation of <e2>nefazodone</e2>, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3433	"A case of <e1>SIADH</e1> induced by <e2>mizoribin</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3434	"<e1>ADH hypersecretion</e1> in relation to plasma osmolality was reversed by <e2>mizoribin</e2> withdrawal, suggesting that bredinin might adversely induce SIADH."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3435	"ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that <e1>bredinin</e1> might adversely induce <e2>SIADH</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3436	"In summary, we report herein the first case of <e1>SIADH</e1> believed to be an adverse effect of <e2>mizoribin</e2>, which may therefore needed to be added to the list of drugs which can induce <e1>SIADH</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3437	"In summary, we report herein the first case of <e1>SIADH</e1> believed to be an adverse effect of <e2>mizoribin</e2>, which may therefore needed to be added to the list of drugs which can induce <e1>SIADH</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3438	"We describe a 74-year-old man with rheumatoid arthritis (RA) who developed syndrome of inappropriate secretion of antidiuretic hormone (<e1>SIADH</e1>) 1.5 months after commencement of <e2>mizoribin</e2> prescription when his arthritis was improved."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3439	"We describe a 74-year-old man with rheumatoid arthritis (RA) who developed <e1>syndrome of inappropriate secretion of antidiuretic hormone</e1> (SIADH) 1.5 months after commencement of <e2>mizoribin</e2> prescription when his arthritis was improved."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3440	"The disease-modifying drugs he was taking, <e1>cyclosporin</e1> and methotrexate, were stopped, and the <e2>lymphoma</e2> resolved spontaneously without the use of chemotherapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3441	"The disease-modifying drugs he was taking, cyclosporin and <e1>methotrexate</e1>, were stopped, and the <e2>lymphoma</e2> resolved spontaneously without the use of chemotherapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3442	"Acute onset of <e1>nephrotic syndrome</e1> during <e2>interferon-alpha</e2> retreatment for chronic active hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3443	"We herein report this rare case of acute onset of <e1>nephrotic syndrome</e1> during <e2>interferon-alpha</e2> retreatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3444	"A 21-year-old man with Tourette's syndrome, pedophilia, Asperger's syndrome, and multiple sclerosis experienced <e1>seizures</e1> after receiving therapy with <e2>interferon beta-1a</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3445	"Seizures and <e1>extrapyramidal symptoms</e1> in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta-1a and <e2>clomipramine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3446	"Seizures and <e1>extrapyramidal symptoms</e1> in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with <e2>interferon beta-1a</e2> and clomipramine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3447	"<e1>Seizures</e1> and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta-1a and <e2>clomipramine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3448	"<e1>Seizures</e1> and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with <e2>interferon beta-1a</e2> and clomipramine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3449	"A 68-year-old female patient with advanced ovarian carcinoma <e1>collapsed</e1> whilst receiving a <e2>carboplatin</e2> and cyclophosphamide infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3450	"A 68-year-old female patient with advanced ovarian carcinoma <e1>collapsed</e1> whilst receiving a carboplatin and <e2>cyclophosphamide</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3451	"<e1>Carboplatin</e1> hypersensitivity presenting as <e2>coronary vasospasm</e2> - a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3452	"Hypersensitivity to <e1>carboplatin</e1> is a rare but real complication of therapy and should be considered in patients presenting with <e2>hyperacute changes on ECG</e2> whilst receiving <e1>carboplatin</e1> therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3453	"<e1>Hypersensitivity</e1> to <e2>carboplatin</e2> is a rare but real complication of therapy and should be considered in patients presenting with hyperacute changes on ECG whilst receiving <e2>carboplatin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3454	"A 60-year-old white man with chronic bronchitis was noted to develop <e1>acute respiratory failure</e1> and metabolic acidosis four days after being started on <e2>methazolamide</e2> (Neptazane) for an ophthalmologic problem."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3455	"A 60-year-old white man with chronic bronchitis was noted to develop <e1>acute respiratory failure</e1> and metabolic acidosis four days after being started on methazolamide (<e2>Neptazane</e2>) for an ophthalmologic problem."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3456	"A 60-year-old white man with chronic bronchitis was noted to develop acute respiratory failure and <e1>metabolic acidosis</e1> four days after being started on <e2>methazolamide</e2> (Neptazane) for an ophthalmologic problem."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3457	"A 60-year-old white man with chronic bronchitis was noted to develop acute respiratory failure and <e1>metabolic acidosis</e1> four days after being started on methazolamide (<e2>Neptazane</e2>) for an ophthalmologic problem."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3458	"<e1>Capecitabine</e1> was discontinued and the <e2>allergic reactions</e2> resolved after the woman took diphenhydramine for 1 week."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3459	"CONCLUSIONS: The use of fluorouracil treatment with careful monitoring can be considered in a patient with mild <e1>allergic reactions</e1> to <e2>capecitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3460	"Fluorouracil for <e1>allergic reactions</e1> to <e2>capecitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3461	"It was postulated that the <e1>allergic reaction</e1> was most likely caused by <e2>capecitabine</e2> or the intermediate metabolites based on the immediate reappearance of symptoms from the rechallenge, pharmacokinetic data, and well-tolerance of fluorouracil."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3462	"OBJECTIVE: To report the safe use of fluorouracil in a patient with breast cancer who had <e1>allergic reactions</e1> to <e2>capecitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3463	"She developed a generalized rash and itching, sore throat, and <e1>dizziness</e1> approximately 4 hours after the first dose of <e2>capecitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3464	"She developed a <e1>generalized rash</e1> and itching, sore throat, and dizziness approximately 4 hours after the first dose of <e2>capecitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3465	"She developed a generalized rash and <e1>itching</e1>, sore throat, and dizziness approximately 4 hours after the first dose of <e2>capecitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3466	"She developed a generalized rash and itching, <e1>sore throat</e1>, and dizziness approximately 4 hours after the first dose of <e2>capecitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3467	"After five and six weeks of continuous oral administration of <e1>methylprednisolone</e1>, the boys developed <e2>steroid diabetes</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3468	"Reduction of <e1>methylprednisolone</e1> dosage rather than insulin therapy resulted in better control of <e2>glycemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3469	"Contrary to previous recommendations, our experience cautions against the further use of high-dose <e1>cytarabine</e1> in patients who develop <e2>PPE</e2>, and is a timely reminder of the potential toxicity of this agent, which is now increasingly being used as first-line treatment in the management of haematologic malignancies."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3470	"It has been suggested that <e1>PPE</e1> caused by <e2>cytarabine</e2> does not recur with subsequent <e2>cytarabine</e2> re-challenge."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3471	"Recurrent <e1>palmar-plantar erythrodysaesthesia</e1> following high-dose <e2>cytarabine</e2> treatment for acute lymphoblastic leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3472	"We report a patient with recurrent, increasingly severe episodes of PPE, ultimately complicated by a severe <e1>bullous eruption</e1>, following successive cycles of high-dose <e2>cytarabine</e2> for the treatment of acute lymphoblastic leukaemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3473	"We report a patient with recurrent, increasingly severe episodes of <e1>PPE</e1>, ultimately complicated by a severe bullous eruption, following successive cycles of high-dose <e2>cytarabine</e2> for the treatment of acute lymphoblastic leukaemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3474	"Atypical endometriosis may act as a precancerous lesion in the process of <e1>tamoxifen</e1> -induced <e2>malignant transformation of endometriosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3475	"BACKGROUND: <e1>Ovarian cancer</e1> arising from an endometriotic cyst in a postmenopausal woman under <e2>tamoxifen</e2> therapy is rare."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3476	"CONCLUSION: <e1>Tamoxifen</e1> may cause <e2>malignant transformation of endometriosis</e2> through atypical endometriosis even in the postmenopausal state."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3477	"<e1>Ovarian endometrioid adenocarcinoma</e1> arising from an endometriotic cyst in a postmenopausal woman under <e2>tamoxifen</e2> therapy for breast cancer: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3478	"<e1>Clinical, spectroscopic, and imaging abnormalities</e1> resolved with discontinuation of <e2>metronidazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3479	"Proton MRS examination demonstrated a persistent <e1>lactate elevation</e1> during <e2>metronidazole</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3480	"<e1>Reversible MR imaging and MR spectroscopy abnormalities</e1> in association with <e2>metronidazole</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3481	"After nine previous uncomplicated cycles she developed severe <e1>anaphylaxis</e1> to <e2>cisplatin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3482	"<e1>Anaphylaxis</e1> to <e2>cisplatin</e2> following nine previous uncomplicated cycles."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3483	"<e1>Anaphylaxis</e1> to <e2>cisplatin</e2> is an infrequent life-threatening complication which may occur even in patients who have received prior treatment with <e2>cisplatin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3484	"Although <e1>isradipine</e1> has been associated with <e2>hepatocellular injury</e2>, there are no reports of fulminant liver failure with this agent, and our patient had been treated for >2 years without signs of toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3485	"A second possibility is an interaction between <e1>clarithromycin</e1> and isradipine, potentially <e2>increasing the hepatic toxicity</e2> of isradipine."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3486	"A second possibility is an interaction between clarithromycin and <e1>isradipine</e1>, potentially <e2>increasing the hepatic toxicity</e2> of <e1>isradipine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3487	"A second possibility is an interaction between clarithromycin and <e1>isradipine</e1>, potentially <e2>increasing the hepatic toxicity</e2> of <e1>isradipine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3488	"CASE SUMMARY: A 58-year-old white woman developed <e1>fulminant liver failure</e1> while being treated with the macrolide antibiotic <e2>clarithromycin</e2> for pneumonia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3489	"CONCLUSIONS: <e1>Clarithromycin</e1> may be a cause of <e2>fulminant liver failure</e2> either alone or by inhibiting the metabolism of other drugs."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3490	"<e1>Fulminant liver failure</e1> associated with <e2>clarithromycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3491	"OBJECTIVE: To report a patient developing <e1>fulminant liver failure</e1> while being treated with <e2>clarithromycin</e2> for pneumonia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3492	"The most likely cause of liver failure in this patient was, therefore, <e1>clarithromycin</e1>, which undergoes hepatic metabolism and has been reported to cause <e2>fulminant hepatic failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3493	"The most likely cause of <e1>liver failure</e1> in this patient was, therefore, <e2>clarithromycin</e2>, which undergoes hepatic metabolism and has been reported to cause fulminant hepatic failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3494	"A <e1>paradoxical ocular effect</e1> of <e2>brimonidine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3495	"CONCLUSION: Under certain circumstances topical <e1>brimonidine</e1> can cause <e2>paradoxical raised IOP</e2> necessitating vigilance in follow-up of patients on topical <e1>brimonidine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3496	"PURPOSE: We report an unusual <e1>paradoxical effect</e1> of <e2>brimonidine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3497	"RESULTS: <e1>Brimonidine</e1> was observed to cause <e2>IOP elevation</e2>, confirmed on rechallenge, scoring 8 (strong probability) on an adverse drug reaction probability score."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3498	"Although <e1>gabapentin</e1> withdrawal has been previously reported and usually consists of <e2>anxiety</e2>, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to <e1>gabapentin</e1> withdrawal."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3499	"Although <e1>gabapentin</e1> withdrawal has been previously reported and usually consists of anxiety, <e2>diaphoresis</e2>, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to <e1>gabapentin</e1> withdrawal."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3500	"Although <e1>gabapentin</e1> withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with <e2>generalized seizures</e2> and status epilepticus secondary to <e1>gabapentin</e1> withdrawal."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3501	"Although <e1>gabapentin</e1> withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with <e2>generalized seizures</e2> and status epilepticus secondary to <e1>gabapentin</e1> withdrawal."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3502	"Although <e1>gabapentin</e1> withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and <e2>palpitations</e2>, this is the first reported patient with generalized seizures and status epilepticus secondary to <e1>gabapentin</e1> withdrawal."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3503	"Although <e1>gabapentin</e1> withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and <e2>status epilepticus</e2> secondary to <e1>gabapentin</e1> withdrawal."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3504	"Although <e1>gabapentin</e1> withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and <e2>status epilepticus</e2> secondary to <e1>gabapentin</e1> withdrawal."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3505	"<e1>Gabapentin</e1> withdrawal presenting as <e2>status epilepticus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3506	"Although visual hallucinations have not been reported as an adverse effect of this agent, we describe three patients who experienced complex visual hallucinations and <e1>altered mental status</e1> after <e2>zonisamide</e2> treatment was begun or its dosage increased."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3507	"Although <e1>visual hallucinations</e1> have not been reported as an adverse effect of this agent, we describe three patients who experienced complex <e1>visual hallucinations</e1> and altered mental status after <e2>zonisamide</e2> treatment was begun or its dosage increased."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3508	"<e1>Visual hallucinations</e1> associated with <e2>zonisamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3509	"<e1>Doxycycline</e1> -induced <e2>hypoglycemia</e2> in a nondiabetic young man."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3510	"We report the first case of <e1>doxycycline</e1> -induced <e2>hypoglycemia</e2> in a young nondiabetic man."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3511	"For patients who suffer from osteogenic sarcoma and have <e1>anaphylactic reactions</e1> to <e2>MTX</e2>, this desensitization protocol will allow these patients to continue with needed therapeutic or palliative chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3512	"He had an immediate hypersensitivity reaction during the initiation of the <e1>MTX</e1> infusion with diffuse urticaria, facial swelling, cough, and <e2>chest tightness</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3513	"He had an immediate hypersensitivity reaction during the initiation of the <e1>MTX</e1> infusion with diffuse urticaria, facial swelling, <e2>cough</e2>, and chest tightness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3514	"He had an immediate hypersensitivity reaction during the initiation of the <e1>MTX</e1> infusion with <e2>diffuse urticaria</e2>, facial swelling, cough, and chest tightness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3515	"He had an immediate hypersensitivity reaction during the initiation of the <e1>MTX</e1> infusion with diffuse urticaria, <e2>facial swelling</e2>, cough, and chest tightness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3516	"He had an immediate <e1>hypersensitivity reaction</e1> during the initiation of the <e2>MTX</e2> infusion with diffuse urticaria, facial swelling, cough, and chest tightness."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3517	"He was later skin tested to confirm <e1>allergy</e1> to <e2>MTX</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3518	"Successful desensitization to high-dose <e1>methotrexate</e1> after <e2>systemic anaphylaxis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3519	"The successful development and implementation of this protocol will have impact on patients who have <e1>anaphylactic reactions</e1> to <e2>MTX</e2> but require this medication for specific diseases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3520	"The authors report a case of <e1>Balint syndrome</e1> with irreversible posterior leukoencephalopathy on MRI following intrathecal methotrexate and <e2>cytarabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3521	"The authors report a case of <e1>Balint syndrome</e1> with irreversible posterior leukoencephalopathy on MRI following intrathecal <e2>methotrexate</e2> and cytarabine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3522	"The authors report a case of Balint syndrome with irreversible <e1>posterior leukoencephalopathy</e1> on MRI following intrathecal methotrexate and <e2>cytarabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3523	"The authors report a case of Balint syndrome with irreversible <e1>posterior leukoencephalopathy</e1> on MRI following intrathecal <e2>methotrexate</e2> and cytarabine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3524	"We present a unique case of <e1>GTBM</e1> in a patient with myeloma following treatment with <e2>Melphalan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3525	"Patients with lymphoblastic lymphoma who had treatment with <e1>L-asparaginase</e1> and steroid are predisposed to the development of <e2>cortical venous thrombosis</e2> and may have this syndrome in addition to a dural puncture headache."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3526	"Patients with lymphoblastic lymphoma who had treatment with <e1>L-asparaginase</e1> and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a <e2>dural puncture headache</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3527	"<e1>Interstitial pneumonitis</e1> associated with <e2>sirolimus</e2>: a dilemma for lung transplantation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3528	"<e1>Rapamycin</e1>/sirolimus-induced <e2>pneumonitis</e2> has been described previously in renal transplant recipients, and this report describes a stable heart-lung transplant recipient who developed a pulmonary infiltrate that reversed after ceasing SR therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3529	"Rapamycin/<e1>sirolimus</e1> -induced <e2>pneumonitis</e2> has been described previously in renal transplant recipients, and this report describes a stable heart-lung transplant recipient who developed a pulmonary infiltrate that reversed after ceasing SR therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3530	"<e1>Rapamycin</e1>/sirolimus-induced pneumonitis has been described previously in renal transplant recipients, and this report describes a stable heart-lung transplant recipient who developed a <e2>pulmonary infiltrate</e2> that reversed after ceasing SR therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3531	"Rapamycin/<e1>sirolimus</e1> -induced pneumonitis has been described previously in renal transplant recipients, and this report describes a stable heart-lung transplant recipient who developed a <e2>pulmonary infiltrate</e2> that reversed after ceasing SR therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3532	"Rapamycin/sirolimus-induced pneumonitis has been described previously in renal transplant recipients, and this report describes a stable heart-lung transplant recipient who developed a <e1>pulmonary infiltrate</e1> that reversed after ceasing <e2>SR</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3533	"Rapamycin/sirolimus (SR), trade named <e1>Rapammune</e1> (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, <e2>hyperlipidemia</e2>, and infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3534	"<e1>Rapamycin</e1>/sirolimus (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, <e2>hyperlipidemia</e2>, and infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3535	"Rapamycin/<e1>sirolimus</e1> (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, <e2>hyperlipidemia</e2>, and infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3536	"Rapamycin/sirolimus (<e1>SR</e1>), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, <e2>hyperlipidemia</e2>, and infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3537	"Rapamycin/sirolimus (SR), trade named <e1>Rapammune</e1> (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, <e2>hypertension</e2>, hyperlipidemia, and infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3538	"<e1>Rapamycin</e1>/sirolimus (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, <e2>hypertension</e2>, hyperlipidemia, and infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3539	"Rapamycin/<e1>sirolimus</e1> (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, <e2>hypertension</e2>, hyperlipidemia, and infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3540	"Rapamycin/sirolimus (<e1>SR</e1>), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, <e2>hypertension</e2>, hyperlipidemia, and infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3541	"Rapamycin/sirolimus (SR), trade named <e1>Rapammune</e1> (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and <e2>infection</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3542	"<e1>Rapamycin</e1>/sirolimus (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and <e2>infection</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3543	"Rapamycin/<e1>sirolimus</e1> (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and <e2>infection</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3544	"Rapamycin/sirolimus (<e1>SR</e1>), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and <e2>infection</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3545	"Rapamycin/sirolimus (SR), trade named <e1>Rapammune</e1> (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with <e2>myelosuppression</e2>, hypertension, hyperlipidemia, and infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3546	"<e1>Rapamycin</e1>/sirolimus (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with <e2>myelosuppression</e2>, hypertension, hyperlipidemia, and infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3547	"Rapamycin/<e1>sirolimus</e1> (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with <e2>myelosuppression</e2>, hypertension, hyperlipidemia, and infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3548	"Rapamycin/sirolimus (<e1>SR</e1>), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with <e2>myelosuppression</e2>, hypertension, hyperlipidemia, and infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3549	"A 16-year-old boy developed <e1>fever</e1>, generalized rigidity, leukocytosis, and increased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and <e2>lithium</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3550	"A 16-year-old boy developed <e1>fever</e1>, generalized rigidity, leukocytosis, and increased serum transaminase and creatine kinase levels while receiving treatment with <e2>olanzapine</e2> and lithium."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3551	"A 16-year-old boy developed fever, <e1>generalized rigidity</e1>, leukocytosis, and increased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and <e2>lithium</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3552	"A 16-year-old boy developed fever, <e1>generalized rigidity</e1>, leukocytosis, and increased serum transaminase and creatine kinase levels while receiving treatment with <e2>olanzapine</e2> and lithium."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3553	"A 16-year-old boy developed fever, generalized rigidity, leukocytosis, and <e1>increased serum transaminase and creatine kinase</e1> levels while receiving treatment with olanzapine and <e2>lithium</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3554	"A 16-year-old boy developed fever, generalized rigidity, leukocytosis, and <e1>increased serum transaminase and creatine kinase</e1> levels while receiving treatment with <e2>olanzapine</e2> and lithium."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3555	"A 16-year-old boy developed fever, generalized rigidity, <e1>leukocytosis</e1>, and increased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and <e2>lithium</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3556	"A 16-year-old boy developed fever, generalized rigidity, <e1>leukocytosis</e1>, and increased serum transaminase and creatine kinase levels while receiving treatment with <e2>olanzapine</e2> and lithium."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3557	"Concomitant administration of <e1>lithium</e1> with olanzapine may place patients at risk for <e2>NMS</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3558	"Concomitant administration of lithium with <e1>olanzapine</e1> may place patients at risk for <e2>NMS</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3559	"<e1>Neuroleptic malignant syndrome</e1> in an adolescent receiving olanzapine-<e2>lithium</e2> combination therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3560	"<e1>Neuroleptic malignant syndrome</e1> in an adolescent receiving <e2>olanzapine</e2> -lithium combination therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3561	"Both <e1>6-MP</e1> and AZA are widely used and are known to cause <e2>hepatotoxicity</e2> in a proportion of patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3562	"Both 6-MP and <e1>AZA</e1> are widely used and are known to cause <e2>hepatotoxicity</e2> in a proportion of patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3563	"<e1>Hepatotoxicity</e1> associated with <e2>6-thioguanine</e2> therapy for Crohn's disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3564	"This case highlights the need to monitor liver enzymes in patients treated with 6-TG and identifies the need for additional research focused on the mechanism of <e1>thiopurine</e1> -induced <e2>hepatic injury</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3565	"We believe the temporal association of the <e1>abnormal liver enzymes</e1> in this patient, in the absence of other offending agents, argues strongly in favor of <e2>6-TG</e2> as a cause of liver enzyme abnormalities."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3566	"We believe the temporal association of the abnormal liver enzymes in this patient, in the absence of other offending agents, argues strongly in favor of <e1>6-TG</e1> as a cause of <e2>liver enzyme abnormalities</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3567	"We describe a case of significant <e1>elevation of serum transaminases</e1> in a patient treated with <e2>6-TG</e2> for a flare of Crohn's disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3568	"Early peritoneal dialysis has not previously been reported for <e1>lisinopril</e1> induced <e2>multiorgan failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3569	"We observed transient <e1>panhypogammaglobulinaemia</e1> in a patient with neuropsychiatric SLE after treatment with prednisolone and <e2>cyclophosphamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3570	"We observed transient <e1>panhypogammaglobulinaemia</e1> in a patient with neuropsychiatric SLE after treatment with <e2>prednisolone</e2> and cyclophosphamide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3571	"<e1>Fulminant hepatic failure</e1> developed in a 24-year-old black woman who had been treated with propylthiouracil and <e2>propranolol</e2> for hyperthyroidism."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3572	"<e1>Fulminant hepatic failure</e1> developed in a 24-year-old black woman who had been treated with <e2>propylthiouracil</e2> and propranolol for hyperthyroidism."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3573	"<e1>Fulminant hepatitis</e1> and lymphocyte sensitization due to <e2>propylthiouracil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3574	"These observations indicate that submassive hepatic necrosis may result from treatment with <e1>propylthiouracil</e1> and are consistent with the notion that sensitization mechanisms may be responsible for the <e2>hepatic injury</e2> induced by this drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3575	"These observations indicate that <e1>submassive hepatic necrosis</e1> may result from treatment with <e2>propylthiouracil</e2> and are consistent with the notion that sensitization mechanisms may be responsible for the hepatic injury induced by this drug."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3576	"The diagnosis of <e1>hypothermia</e1> was delayed until it was apparent for several days but resolved with the discontinuation of <e2>risperidone</e2> and continuation of clozapine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3577	"This is a case report of subtle, mild <e1>hypothermia</e1> in a 54-year old female patient receiving <e2>risperidone</e2> for schizophrenia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3578	"<e1>Akathisia</e1> is a relatively rare side effect with the newer atypical antipsychotic agents, particularly <e2>clozapine</e2>, and is easily misdiagnosed in children."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3579	"<e1>Clozapine</e1> -induced <e2>akathisia</e2> in children with schizophrenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3580	"Two cases of childhood-onset schizophrenia associated with <e1>clozapine</e1> -induced <e2>akathisia</e2> responsive to beta-blocker treatment are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3581	"After reviewing the literature we suggest the CPM was a complication of <e1>lithium</e1> toxicity which affected the lateral geniculate nucleus which produced <e2>blindness</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3582	"After reviewing the literature we suggest the <e1>CPM</e1> was a complication of <e2>lithium</e2> toxicity which affected the lateral geniculate nucleus which produced blindness."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3583	"<e1>Central pontine myelinolysis</e1> manifested by temporary blindness: a possible complication of <e2>lithium</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3584	"Central pontine myelinolysis manifested by <e1>temporary blindness</e1>: a possible complication of <e2>lithium</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3585	"Antithyroid treatment with <e1>propylthiouracil</e1> (PTU) resulted in <e2>elevated hepatic enzymes</e2> and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3586	"Antithyroid treatment with propylthiouracil (<e1>PTU</e1>) resulted in <e2>elevated hepatic enzymes</e2> and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3587	"Successful treatment with carbimazole of a hyperthyroid pregnancy with <e1>hepatic impairment</e1> after <e2>propylthiouracil</e2> administration: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3588	"Interferon-alpha (<e1>IFN-alpha</e1>) may precipitate or exacerbate the occurrence of <e2>MPGN</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3589	"<e1>Interferon-alpha</e1> (IFN-alpha) may precipitate or exacerbate the occurrence of <e2>MPGN</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3590	"<e1>Minimal change disease</e1> in a patient receiving <e2>IFN-alpha</e2> therapy for chronic hepatitis C virus infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3591	"A 58-yr-old male patient with essential thrombocythaemia (ET) developed <e1>chronic myeloid leukaemia</e1> (CML) after continuous uneventful treatment with <e2>hydroxyurea</e2> for 18 yr."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3592	"A 58-yr-old male patient with essential thrombocythaemia (ET) developed chronic myeloid leukaemia (<e1>CML</e1>) after continuous uneventful treatment with <e2>hydroxyurea</e2> for 18 yr."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3593	"Emergence of <e1>Philadelphia positive chronic myeloid leukaemia</e1> during treatment with <e2>hydroxyurea</e2> for Philadelphia negative essential thrombocythaemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3594	"There are no previous reports in the literature about the emergence of <e1>CML</e1> during treatment with <e2>hydroxyurea</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3595	"His fever resolved, but he developed symptoms consistent with those of <e2>chloroquine</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3596	"OBJECTIVE: To report a case of severe <e2>chloroquine</e2> toxicity in the presence of high-grade <e2>chloroquine</e2> -resistant Plasmodium vivax."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3597	"<e1>Toxicity</e1> related to <e2>chloroquine</e2> treatment of resistant vivax malaria."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3598	"A 72-year-old woman with a history of thyrotoxicosis presented with sore throat and <e1>fever</e1> two weeks after starting <e2>carbimazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3599	"A 72-year-old woman with a history of thyrotoxicosis presented with <e1>sore throat</e1> and fever two weeks after starting <e2>carbimazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3600	"Treatment of <e1>carbimazole</e1> -induced <e2>agranulocytosis</e2> and sepsis with granulocyte colony stimulating factor."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3601	"Treatment of <e1>carbimazole</e1> -induced agranulocytosis and <e2>sepsis</e2> with granulocyte colony stimulating factor."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3602	"We present the management of <e1>agranulocytosis</e1> and neutropenic sepsis secondary to <e2>carbimazole</e2> with recombinant human granulocyte colony stimulating factor (G-CSF)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3603	"We present the management of agranulocytosis and <e1>neutropenic sepsis</e1> secondary to <e2>carbimazole</e2> with recombinant human granulocyte colony stimulating factor (G-CSF)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3604	"<e1>Comeoscleral perforation</e1> after pterygium excision and intraoperative <e2>mitomycin C</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3605	"To the best of our knowledge, <e1>corneoscleral melting</e1> in the first postoperative week after a single intraoperative application of <e2>mitomycin C</e2> has not been reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3606	"A 71-year-old man, who had a history of a previous <e1>bullous drug reaction</e1> to a <e2>sulfonamide</e2>, began receiving an ophthalmic preparation that contained sulfacetamide sodium."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3607	"The patient received only the ophthalmic <e1>sulfonamide</e1>, and it was used for one day, but he developed <e2>Stevens-Johnson syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3608	"The <e1>sulfonamides</e1> are the best verified drug-trigger for <e2>erythema multiforme</e2> and Stevens-Johnson syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3609	"The <e1>sulfonamides</e1> are the best verified drug-trigger for erythema multiforme and <e2>Stevens-Johnson syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3610	"Based on these findings, the patient was diagnosed with <e1>diabetes insipidus</e1> secondary to <e2>lithium</e2> therapy and was treated successfully with amiloride."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3611	"Clinicians have been aware of <e2>lithium</e2> toxicity for many years and traditionally have administered thiazide diuretics for <e2>lithium</e2> -induced polyuria and nephrogenic diabetes insipidus."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3612	"Clinicians have been aware of <e1>lithium</e1> toxicity for many years and traditionally have administered thiazide diuretics for <e1>lithium</e1> -induced polyuria and <e2>nephrogenic diabetes insipidus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3613	"Clinicians have been aware of <e1>lithium</e1> toxicity for many years and traditionally have administered thiazide diuretics for <e1>lithium</e1> -induced polyuria and <e2>nephrogenic diabetes insipidus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3614	"Clinicians have been aware of <e1>lithium</e1> toxicity for many years and traditionally have administered thiazide diuretics for <e1>lithium</e1> -induced <e2>polyuria</e2> and nephrogenic diabetes insipidus."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3615	"Clinicians have been aware of <e1>lithium</e1> toxicity for many years and traditionally have administered thiazide diuretics for <e1>lithium</e1> -induced <e2>polyuria</e2> and nephrogenic diabetes insipidus."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3616	"Treatment of <e1>lithium</e1> -induced <e2>diabetes insipidus</e2> with amiloride."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3617	"<e1>Systemic capillary leak syndrome</e1> after granulocyte colony-stimulating factor (<e2>G-CSF</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3618	"<e1>Systemic capillary leak syndrome</e1> after <e2>granulocyte colony-stimulating factor</e2> (G-CSF)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3619	"We present two cases in which both patients suffered with <e1>CLS</e1>, which we believe was caused following administration of <e2>granulocyte colony-stimulating factor</e2>, to our knowledge not described in the intensive care patient previously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3620	"<e1>FK506</e1>, which began to be administered 12 days earlier, rose to a level of 44 ng/mL (normal range, 10-20 ng/mL) 1 day before <e2>neurologic abnormalities</e2> began."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3621	"Rapid identification of <e1>speech loss</e1> linked to <e2>FK506</e2> may be important because reduction or cessation of the drug may be associated with reverse of <e1>speech loss</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3622	"Tacrolimus (<e1>FK506</e1>), an immunosuppressant, has been associated with <e2>mutism</e2> in adults after liver transplant."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3623	"<e1>Tacrolimus</e1> (FK506), an immunosuppressant, has been associated with <e2>mutism</e2> in adults after liver transplant."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3624	"Tacrolimus (<e1>FK506</e1>)-induced <e2>mutism</e2> after liver transplant."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3625	"<e1>Tacrolimus</e1> (FK506)-induced <e2>mutism</e2> after liver transplant."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3626	"Does the use of <e1>insulin</e1> in a patient with liver dysfunction increase water retention in the body, i.e. cause <e1>insulin</e1> <e2>oedema</e2>?"
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3627	"Soon after introduction of <e1>insulin</e1> therapy, she developed severe anasarca, including marked peripheral oedema, <e2>ascites</e2> and pleural effusion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3628	"Soon after introduction of <e1>insulin</e1> therapy, she developed severe anasarca, including marked <e2>peripheral oedema</e2>, ascites and pleural effusion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3629	"Soon after introduction of <e1>insulin</e1> therapy, she developed severe anasarca, including marked peripheral oedema, ascites and <e2>pleural effusion</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3630	"Soon after introduction of <e1>insulin</e1> therapy, she developed <e2>severe anasarca</e2>, including marked peripheral oedema, ascites and pleural effusion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3631	"The induced hyperglycaemia could not be controlled sufficiently, despite a high dose of <e1>insulin</e1> (> 110 units/day), suggesting the existence of <e1>insulin</e1> insensitivity and hyper<e1>insulin</e1>aemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3632	"The induced hyperglycaemia could not be controlled sufficiently, despite a high dose of <e1>insulin</e1> (> 110 units/day), suggesting the existence of <e1>insulin</e1> insensitivity and hyper<e1>insulin</e1>aemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3633	"We conjectured that the side effects of <e1>insulin</e1>, such as <e2>anti-natriuresis</e2> and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies <e1>insulin</e1> insensitivity, hyper<e1>insulin</e1>aemia and hypoalbuminaemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3634	"We conjectured that the side effects of <e1>insulin</e1>, such as anti-natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies <e1>insulin</e1> insensitivity, hyper<e1>insulin</e1>aemia and hypoalbuminaemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3635	"We conjectured that the side effects of <e1>insulin</e1>, such as anti-natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies <e1>insulin</e1> insensitivity, hyper<e1>insulin</e1>aemia and <e2>hypoalbuminaemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3636	"We conjectured that the side effects of <e1>insulin</e1>, such as anti-natriuresis and <e2>increased vascular permeability</e2>, might be pronounced in the presence of the hepatic dysfunction that accompanies <e1>insulin</e1> insensitivity, hyper<e1>insulin</e1>aemia and hypoalbuminaemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3637	"We conjectured that the side effects of <e1>insulin</e1>, such as anti-natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies <e1>insulin</e1> insensitivity, hyper<e1>insulin</e1>aemia and hypoalbuminaemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3638	"While 40 mg/day of <e1>prednisolone</e1> improved hepatic dysfunction dramatically, her <e2>diabetic milieu deteriorated</e2> seriously."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3639	"Intrathecal <e1>methotrexate</e1> -induced <e2>acute cerebellar syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3640	"We describe a patient who developed <e1>acute cerebellar syndrome</e1> after prophylactic intrathecal <e2>methotrexate</e2> administration and recovered spontaneously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3641	"<e1>Angioimmunoblastic lymphadenopathy with dysproteinemia</e1> following <e2>doxycycline</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3642	"We report a case of <e1>AILD</e1> in an 80-year-old male who presented with a generalized pruritic maculopapular eruption and fever following <e2>doxycycline</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3643	"We report a case of AILD in an 80-year-old male who presented with a generalized pruritic maculopapular eruption and <e1>fever</e1> following <e2>doxycycline</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3644	"We report a case of AILD in an 80-year-old male who presented with a <e1>generalized pruritic maculopapular eruption</e1> and fever following <e2>doxycycline</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3645	"<e1>Anaphylaxis</e1> from <e2>isoniazid</e2> is a possible side effect to this commonly prescribed antibiotic."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3646	"<e1>Isoniazid</e1> -induced <e2>anaphylaxis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3647	"A case is reported in which severe hypocalcemia, with a <e1>low plasma parathyroid hormone</e1> (PTH) concentration, resulted from the therapeutic use of <e2>magnesium sulfate</e2> for toxemia of pregnancy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3648	"A case is reported in which severe hypocalcemia, with a low plasma parathyroid hormone (<e1>PTH</e1>) concentration, resulted from the therapeutic use of <e2>magnesium sulfate</e2> for toxemia of pregnancy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3649	"A case is reported in which <e1>severe hypocalcemia</e1>, with a low plasma parathyroid hormone (PTH) concentration, resulted from the therapeutic use of <e2>magnesium sulfate</e2> for toxemia of pregnancy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3650	"<e1>Carbamazepine</e1> -related <e2>hyponatremia</e2> following cardiopulmonary bypass."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3651	"We discuss the association between <e1>carbamazepine</e1> and <e2>hyponatremia</e2> and the causes of <e2>hyponatremia</e2> after cardiopulmonary bypass."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3652	"After <e1>5-ASA</e1> was discontinued, the <e2>polyneuropathy</e2> symptoms recovered gradually."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3653	"<e1>Sensorimotor polyneuropathy</e1> with <e2>5-aminosalicylic acid</e2>: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3654	"This clinical course suggests that the <e1>sensorimotor polyneuropathy</e1> may have been caused by <e2>5-ASA</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3655	"When SASP was changed to <e1>5-aminosalicylic acid</e1> (5-ASA), his skin eruptions were resolved, however, he developed weakness and <e2>atrophy</e2> in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3656	"When SASP was changed to 5-aminosalicylic acid (<e1>5-ASA</e1>), his skin eruptions were resolved, however, he developed weakness and <e2>atrophy</e2> in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3657	"When SASP was changed to <e1>5-aminosalicylic acid</e1> (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and <e2>gait disturbance</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3658	"When SASP was changed to 5-aminosalicylic acid (<e1>5-ASA</e1>), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and <e2>gait disturbance</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3659	"When SASP was changed to <e1>5-aminosalicylic acid</e1> (5-ASA), his skin eruptions were resolved, however, he developed <e2>weakness</e2> and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3660	"When SASP was changed to 5-aminosalicylic acid (<e1>5-ASA</e1>), his skin eruptions were resolved, however, he developed <e2>weakness</e2> and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3661	"When SASP was changed to <e1>5-aminosalicylic acid</e1> (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive <e2>worsening of the dysesthesia</e2> in his legs and gait disturbance."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3662	"When SASP was changed to 5-aminosalicylic acid (<e1>5-ASA</e1>), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive <e2>worsening of the dysesthesia</e2> in his legs and gait disturbance."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3663	"<e1>Disseminated cellulitic cryptococcosis</e1> in the setting of <e2>prednisone</e2> monotherapy for pemphigus vulgaris."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3664	"In both cases, high fever, skin rash, liver dysfunction and <e1>atypical lymphocytosis</e1> developed 3 weeks after initiating treatment with <e2>SASP</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3665	"In both cases, <e1>high fever</e1>, skin rash, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with <e2>SASP</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3666	"In both cases, high fever, skin rash, <e1>liver dysfunction</e1> and atypical lymphocytosis developed 3 weeks after initiating treatment with <e2>SASP</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3667	"In both cases, high fever, <e1>skin rash</e1>, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with <e2>SASP</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3668	"Slow acetylator genotypes as a possible risk factor for <e1>infectious mononucleosis-like syndrome</e1> induced by <e2>salazosulfapyridine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3669	"We report two patients with <e1>infectious mononucleosis-like syndrome</e1> induced by <e2>salazosulfapyridine</e2> (SASP)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3670	"We report two patients with <e1>infectious mononucleosis-like syndrome</e1> induced by salazosulfapyridine (<e2>SASP</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3671	"A 45-year-old woman with steroid-dependent Crohn's colitis, successfully managed with maintenance <e1>infliximab</e1> infusions and methotrexate, developed a <e2>lupus-like syndrome</e2> eight months after her initial infusion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3672	"A 45-year-old woman with steroid-dependent Crohn's colitis, successfully managed with maintenance infliximab infusions and <e1>methotrexate</e1>, developed a <e2>lupus-like syndrome</e2> eight months after her initial infusion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3673	"A <e1>lupus-like syndrome</e1> associated with <e2>infliximab</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3674	"<e1>Infliximab</e1> therapy may cause a <e2>lupus-like syndrome</e2> that is reversible upon discontinuing this agent."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3675	"We report in detail an unusual adverse reaction to <e1>infliximab</e1> therapy, a drug-induced <e2>lupus-like clinical syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3676	"Chronic myelogenous leukemia (CML), hepatitis C, and interferon alpha (<e1>IFNalpha</e1>) have all been associated with <e2>renal dysfunction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3677	"Chronic myelogenous leukemia (CML), hepatitis C, and <e1>interferon alpha</e1> (IFNalpha) have all been associated with <e2>renal dysfunction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3678	"Despite the underlying hepatitis C, this case represents <e1>renal abnormalities</e1> consistent with <e2>IFNalpha</e2> therapy for CML."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3679	"<e1>Interferon-alpha</e1> -induced <e2>focal segmental glomerulosclerosis</e2> in chronic myelogenous leukemia: a case report and review of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3680	"The renal biopsy showed <e1>focal segmental glomerulosclerosis</e1>, which has only been previously reported in two cases of CML treated with <e2>IFNalpha</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3681	"Severe <e1>autoimmune hemolytic anemia</e1> following <e2>rituximab</e2> therapy in a patient with a lymphoproliferative disorder."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3682	"The pathophysiological mechanisms remain unknown, although the drug could act through massive cytokines liberation after <e1>destruction of CD20 positive cells</e1> by <e2>rituximab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3683	"The pathophysiological mechanisms remain unknown, although the drug could act through <e1>massive cytokines liberation</e1> after destruction of CD20 positive cells by <e2>rituximab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3684	"We report the first case, to our knowledge, of <e1>rituximab</e1> -related <e2>autoimmune hemolytic anemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3685	"Early-onset <e1>acute transverse myelitis</e1> following <e2>hepatitis B vaccination</e2> and respiratory infection: case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3686	"In this paper, we report a case of 3 years-old boy who developed <e1>acute onset tetraparesia</e1> following a viral respiratory infecction and <e2>hepatitis B vaccination</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3687	"Although it would be expected that, like other type IA toxicities, <e1>diphenhydramine</e1> -induced <e2>cardiotoxicity</e2> could be responsive to hypertonic sodium bicarbonate, this finding is largely unappreciated."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3688	"<e1>Diphenhydramine</e1> -induced wide complex <e2>dysrhythmia</e2> responds to treatment with sodium bicarbonate."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3689	"However, because <e1>diphenhydramine</e1> also exhibits type IA sodium channel blockade, <e2>cardiac toxicity</e2> is also possible."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3690	"We describe 3 cases of <e1>diphenhydramine</e1> -induced <e2>cardiac toxicity</e2> that were responsive to bicarbonate."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3691	"We describe a patient with extranodal non-Hodgkin lymphoma who developed <e1>systemic candidiasis</e1> after treatment with a <e2>cyclophosphamide</e2> -based chemotherapy regimen."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3692	"<e1>Stevens-Johnson syndrome</e1> in a boy with nephrotic syndrome during <e2>prednisolone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3693	"We report a case of <e1>SJS</e1> in a 14-year-old male with nephrotic syndrome, who was treated with oral <e2>prednisolone</e2> for 6 weeks."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3694	"A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a <e1>reversal reaction</e1> after starting <e2>dapsone</e2> and rifampin therapy is presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3695	"A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a <e1>reversal reaction</e1> after starting dapsone and <e2>rifampin</e2> therapy is presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3696	"However, in order to avoid <e1>neuropathic side effects</e1>, patients under <e2>thalidomide</e2> therapy should be monitored every 6 months with nerve conduction studies while taking the drug."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3697	"After a two-month interruption of interferon administration, natural <e1>interferon alpha</e1> was given but followed by another episode of the same <e2>neurological manifestations</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3698	"Case 1, a 62-year-old woman, developed <e1>bilateral optic neuritis</e1> with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of <e2>recombinant interferon alpha-2a</e2> for chronic active hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3699	"Case 1, a 62-year-old woman, developed bilateral optic neuritis with <e1>decreased sensation of vibration</e1> and increased deep tendon reflex in the lower extremities after a seven-month use of <e2>recombinant interferon alpha-2a</e2> for chronic active hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3700	"Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and <e1>increased deep tendon reflex</e1> in the lower extremities after a seven-month use of <e2>recombinant interferon alpha-2a</e2> for chronic active hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3701	"Case 2, a 29-year-old woman, developed <e1>bilateral optic neuritis</e1> combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of <e2>recombinant interferon alpha-2b</e2> for chronic myelogenous leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3702	"Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as <e1>bowel and bladder dysfunction</e1> after a 22-month use of <e2>recombinant interferon alpha-2b</e2> for chronic myelogenous leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3703	"Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with <e1>numbness of the lower extremities</e1> as well as bowel and bladder dysfunction after a 22-month use of <e2>recombinant interferon alpha-2b</e2> for chronic myelogenous leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3704	"CONCLUSIONS: Optic neuritis in combination with other <e1>neurological signs</e1>, simulating multiple sclerosis, should be included in the list of adverse effects of recombinant and natural <e2>interferon alpha</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3705	"CONCLUSIONS: <e1>Optic neuritis</e1> in combination with other neurological signs, simulating multiple sclerosis, should be included in the list of adverse effects of recombinant and natural <e2>interferon alpha</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3706	"<e1>Multiple sclerosis-like disease</e1> secondary to <e2>alpha interferon</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3707	"PURPOSE: To describe <e1>bilateral optic neuritis</e1> that occurred as an adverse effect of recombinant and natural <e2>interferon alpha</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3708	"<e1>Acute abdomen</e1> due to endometriosis in a premenopausal woman taking <e2>tamoxifen</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3709	"Acute abdomen due to <e1>endometriosis</e1> in a premenopausal woman taking <e2>tamoxifen</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3710	"We describe a premenopausal woman who, while having <e1>tamoxifen</e1> due to a diagnosis of in situ ductal carcinoma, developed <e2>endometriosis</e2> requiring surgery."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3711	"A case report of fatal <e1>dapsone</e1> -induced <e2>agranulocytosis</e2> in an Indian mid-borderline leprosy patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3712	"<e1>Fatal agranulocytosis</e1> in an Indian male receiving 100mg of <e2>dapsone</e2> daily, hospitalized for mid-borderline leprosy in type I reaction with triple nerve paralysis is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3713	"Various case reports concerning <e1>dapsone</e1> -induced <e2>agranulocytosis</e2> are reviewed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3714	"<e1>Massive pulmonary embolism</e1> due to late-onset <e2>heparin</e2> -induced thrombocytopenia following coronary artery bypass graft surgery: successful treatment with lepirudin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3715	"Massive pulmonary embolism due to late-onset <e1>heparin</e1> -induced <e2>thrombocytopenia</e2> following coronary artery bypass graft surgery: successful treatment with lepirudin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3716	"Most cardiac surgical patients have had previous exposure to <e1>heparin</e1> for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing <e1>heparin</e1> -induced <e2>thrombocytopenia</e2> (HIT) postoperatively."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3717	"<e1>Acute psychosis</e1> associated with <e2>levetiracetam</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3718	"A twelve year-old-girl with idiopathic partial epilepsy with secondary generalization, developed <e1>acute psychosis</e1> 10 days after the administration of <e2>levetiracetam</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3719	"The <e1>psychotic behavior</e1> resolved completely soon after the discontinuation of <e2>levetiracetam</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3720	"CASES: "A" was an 8-year-old boy with attention deficit and chronic tic disorder who developed <e1>obsessive-compulsive symptoms</e1> within 2 weeks of starting <e2>risperidone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3721	"<e1>Obsessive-compulsive symptoms</e1> suddenly emerged 10 days after starting <e2>risperidone</e2> and resolved within 3 days of discontinuation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3722	"<e1>Risperidone</e1> -induced <e2>obsessive-compulsive symptoms</e2> in two children."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3723	"<e1>Proliferation of abnormal bone marrow histiocytes</e1>, an undesired effect of <e2>granulocyte macrophage-colony-stimulating factor</e2> therapy in a patient with Hurler's syndrome undergoing bone marrow transplantation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3724	"Possible <e1>heart failure exacerbation</e1> associated with <e2>rosiglitazone</e2>: case report and literature review."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3725	"<e1>Enoxaparin</e1> -induced <e2>generalized exanthem</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3726	"Only one case of a <e1>generalized maculopapular rash</e1> with <e2>enoxaparin</e2> has been reported in Europe."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3727	"To our knowledge, this is the first case reported in the English literature of a <e1>generalized exanthem</e1> due to subcutaneous injection of <e2>enoxaparin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3728	"Behavioral side effects associated with <e1>clonazepam</e1> may include agitation, <e2>aggression</e2>, hyperactivity, irritability, property destruction, and temper tantrums."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3729	"Behavioral side effects associated with <e1>clonazepam</e1> may include <e2>agitation</e2>, aggression, hyperactivity, irritability, property destruction, and temper tantrums."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3730	"Behavioral side effects associated with <e1>clonazepam</e1> may include agitation, aggression, <e2>hyperactivity</e2>, irritability, property destruction, and temper tantrums."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3731	"Behavioral side effects associated with <e1>clonazepam</e1> may include agitation, aggression, hyperactivity, <e2>irritability</e2>, property destruction, and temper tantrums."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3732	"Behavioral side effects associated with <e1>clonazepam</e1> may include agitation, aggression, hyperactivity, irritability, <e2>property destruction</e2>, and temper tantrums."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3733	"Behavioral side effects associated with <e1>clonazepam</e1> may include agitation, aggression, hyperactivity, irritability, property destruction, and <e2>temper tantrums</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3734	"This report describes an individual with mental retardation who experienced <e1>behavioral exacerbation</e1> associated with <e2>clonazepam</e2> prescribed at 2 mg/day (0.02 mg/kg/day) to treat aggression, self-injurious behavior, property destruction, and screaming, which was measured with a 15-minute partial interval recording measurement method."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3735	"<e1>Cefuroxime</e1> -induced <e2>immune hemolysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3736	"We report the first case of <e1>IHA</e1> associated with <e2>cefuroxime</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3737	"After 39 hours on <e1>argatroban</e1>, the infusion was stopped when minor <e2>bleeding</e2> was observed with a concurrent activated partial thromboplastin time (aPTT) of 100 seconds."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3738	"Argatroban for <e1>heparin</e1> -induced <e2>thrombocytopenia</e2> in hepato-renal failure and CVVHD."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3739	"<e1>Argatroban</e1> is hepatically cleared and may be the preferred direct thrombin inhibitor in the presence of significant renal impairment, but conversely has prolonged effects in <e2>hepatic failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3740	"OBJECTIVE: To report a case of significant <e1>hepatic and renal failure</e1> with the use of <e2>argatroban</e2> in a patient with heparin-induced thrombocytopenia (HIT) requiring continuous veno-veno hemodialysis (CVVHD)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3741	"OBJECTIVE: To report a case of significant hepatic and renal failure with the use of argatroban in a patient with <e1>heparin</e1> -induced <e2>thrombocytopenia</e2> (HIT) requiring continuous veno-veno hemodialysis (CVVHD)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3742	"<e1>Schneiderian first-rank symptoms</e1> associated with <e2>fluvoxamine</e2> treatment: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3743	"The patient, a 28-year-old man suffering from panic disorder, developed several <e1>first-rank symptoms</e1> during <e2>fluvoxamine</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3744	"This communication describes a patient who developed <e1>Schneiderian first-rank symptoms</e1> in the course of treatment with <e2>fluvoxamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3745	"This finding suggests that <e1>fluvoxamine</e1> can precipitate <e2>Schneiderian first-rank symptoms</e2> in some susceptible patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3746	"We present a surprising case of a woman schizophrenic patient treated with <e1>clozapine</e1> suffering from <e2>EPS</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3747	"<e1>Hyperpigmentation</e1> during <e2>interferon-alpha</e2> therapy for chronic hepatitis C virus infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3748	"These <e1>skin lesions</e1> may be induced or worsened during antiviral therapy with interferon-alpha (<e2>IFN</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3749	"These <e1>skin lesions</e1> may be induced or worsened during antiviral therapy with <e2>interferon-alpha</e2> (IFN)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3750	"We describe two dark-skinned patients who developed <e1>hyperpigmented skin</e1> and tongue lesions during combination therapy with <e2>IFN</e2> and ribavirin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3751	"We describe two dark-skinned patients who developed <e1>hyperpigmented skin</e1> and tongue lesions during combination therapy with IFN and <e2>ribavirin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3752	"We describe two dark-skinned patients who developed hyperpigmented skin and <e1>tongue lesions</e1> during combination therapy with <e2>IFN</e2> and ribavirin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3753	"We describe two dark-skinned patients who developed hyperpigmented skin and <e1>tongue lesions</e1> during combination therapy with IFN and <e2>ribavirin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3754	"It is concluded that simultaneous administration of <e1>ciprofloxacin</e1> and tazobactam/piperacillin may cause marked <e2>thrombocytosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3755	"It is concluded that simultaneous administration of ciprofloxacin and tazobactam/<e1>piperacillin</e1> may cause marked <e2>thrombocytosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3756	"It is concluded that simultaneous administration of ciprofloxacin and <e1>tazobactam</e1>/piperacillin may cause marked <e2>thrombocytosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3757	"Since the <e1>thrombocyte count started to increase</e1> immediately after initiation and dropped immediately after discontinuation of <e2>ciprofloxacin</e2> and tazobactam/piperacillin and all other drugs were discontinued already before or were started after the nadir of the thrombocyte count, these two antibiotics were regarded causative."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3758	"Since the <e1>thrombocyte count started to increase</e1> immediately after initiation and dropped immediately after discontinuation of ciprofloxacin and tazobactam/<e2>piperacillin</e2> and all other drugs were discontinued already before or were started after the nadir of the thrombocyte count, these two antibiotics were regarded causative."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3759	"Since the <e1>thrombocyte count started to increase</e1> immediately after initiation and dropped immediately after discontinuation of ciprofloxacin and <e2>tazobactam</e2>/piperacillin and all other drugs were discontinued already before or were started after the nadir of the thrombocyte count, these two antibiotics were regarded causative."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3760	"<e1>Thrombocytosis</e1> under <e2>ciprofloxacin</e2> and tazobactam/piperacillin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3761	"<e1>Thrombocytosis</e1> under ciprofloxacin and tazobactam/<e2>piperacillin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3762	"<e1>Thrombocytosis</e1> under ciprofloxacin and <e2>tazobactam</e2>/piperacillin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3763	"<e1>Anaphylaxis</e1> after the injection of <e2>chymopapain</e2> occurs in about 1% of such cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3764	"Both patients suddenly became <e1>hypotensive</e1> after injection of <e2>chymopapain</e2> into a disk."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3765	"<e1>Lethargy</e1> in a newborn: <e2>lithium</e2> toxicity or lab error?"
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3766	"Lethargy in a newborn: <e2>lithium</e2> toxicity or lab error?"
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3767	"The newborn manifested a four day course of <e1>lethargy</e1> with unexplained high <e2>lithium</e2> levels in the adult toxic range."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3768	"A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, <e1>fever</e1>, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of <e2>carbamazepine</e2> (CBZ; Tegretol) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3769	"A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, <e1>fever</e1>, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (<e2>CBZ</e2>; Tegretol) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3770	"A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, <e1>fever</e1>, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (CBZ; <e2>Tegretol</e2>) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3771	"A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, <e1>leukopenia</e1> and positive anti-nuclear antibody (ANA) two weeks after administration of <e2>carbamazepine</e2> (CBZ; Tegretol) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3772	"A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, <e1>leukopenia</e1> and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (<e2>CBZ</e2>; Tegretol) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3773	"A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, <e1>leukopenia</e1> and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (CBZ; <e2>Tegretol</e2>) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3774	"A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, leukopenia and <e1>positive anti-nuclear antibody</e1> (ANA) two weeks after administration of <e2>carbamazepine</e2> (CBZ; Tegretol) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3775	"A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, leukopenia and <e1>positive anti-nuclear antibody</e1> (ANA) two weeks after administration of carbamazepine (<e2>CBZ</e2>; Tegretol) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3776	"A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, leukopenia and <e1>positive anti-nuclear antibody</e1> (ANA) two weeks after administration of carbamazepine (CBZ; <e2>Tegretol</e2>) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3777	"A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, <e1>rash</e1>, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of <e2>carbamazepine</e2> (CBZ; Tegretol) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3778	"A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, <e1>rash</e1>, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (<e2>CBZ</e2>; Tegretol) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3779	"A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, <e1>rash</e1>, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (CBZ; <e2>Tegretol</e2>) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3780	"A 14-year-old female developed <e1>systemic lupus erythematosus (SLE)-like symptoms</e1>, rash, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of <e2>carbamazepine</e2> (CBZ; Tegretol) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3781	"A 14-year-old female developed <e1>systemic lupus erythematosus (SLE)-like symptoms</e1>, rash, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (<e2>CBZ</e2>; Tegretol) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3782	"A 14-year-old female developed <e1>systemic lupus erythematosus (SLE)-like symptoms</e1>, rash, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (CBZ; <e2>Tegretol</e2>) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3783	"<e1>Carbamazepine</e1> -induced <e2>systemic lupus erythematosus-like disease</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3784	"The cases of <e1>CBZ</e1> -induced <e2>SLE</e2> reported in the literature were reviewed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3785	"After four months, while receiving <e1>RH</e1>, he developed painful <e2>bilateral gynaecomastia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3786	"<e1>Gynaecomastia</e1> is a rarely reported adverse drug reaction due to <e2>isoniazid</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3787	"<e1>Isoniazid</e1> associated, painful, <e2>bilateral gynaecomastia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3788	"A patient suffering from <e1>heparin</e1> -associated thrombocytopenia (HAT), recurrent arteriothromboses, and <e2>acute renal failure</e2> after treatment with standard <e1>heparin</e1> is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3789	"A patient suffering from <e1>heparin</e1> -associated thrombocytopenia (HAT), recurrent arteriothromboses, and <e2>acute renal failure</e2> after treatment with standard <e1>heparin</e1> is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3790	"A patient suffering from <e1>heparin</e1> -associated thrombocytopenia (<e2>HAT</e2>), recurrent arteriothromboses, and acute renal failure after treatment with standard <e1>heparin</e1> is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3791	"A patient suffering from <e1>heparin</e1> -associated thrombocytopenia (<e2>HAT</e2>), recurrent arteriothromboses, and acute renal failure after treatment with standard <e1>heparin</e1> is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3792	"A patient suffering from <e1>heparin</e1> -associated thrombocytopenia (HAT), <e2>recurrent arteriothromboses</e2>, and acute renal failure after treatment with standard <e1>heparin</e1> is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3793	"A patient suffering from <e1>heparin</e1> -associated thrombocytopenia (HAT), <e2>recurrent arteriothromboses</e2>, and acute renal failure after treatment with standard <e1>heparin</e1> is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3794	"A patient suffering from <e1>heparin</e1> -associated <e2>thrombocytopenia</e2> (HAT), recurrent arteriothromboses, and acute renal failure after treatment with standard <e1>heparin</e1> is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3795	"A patient suffering from <e1>heparin</e1> -associated <e2>thrombocytopenia</e2> (HAT), recurrent arteriothromboses, and acute renal failure after treatment with standard <e1>heparin</e1> is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3796	"By means of the in vitro heparin-induced <e1>platelet activation</e1> (HIPA) assay it was shown that standard heparin and the LMW heparins Fragmin and Fraxiparin (Sanofi Labaz, Munich, FRG), as well as the enoxaparine <e2>Clexane</e2> (Nattermann, Cologne, FRG), all induced <e1>platelet activation</e1> with the patient's serum."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3797	"By means of the in vitro heparin-induced <e1>platelet activation</e1> (HIPA) assay it was shown that standard heparin and the LMW heparins <e2>Fragmin</e2> and Fraxiparin (Sanofi Labaz, Munich, FRG), as well as the enoxaparine Clexane (Nattermann, Cologne, FRG), all induced <e1>platelet activation</e1> with the patient's serum."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3798	"By means of the in vitro heparin-induced <e1>platelet activation</e1> (HIPA) assay it was shown that standard heparin and the LMW heparins Fragmin and <e2>Fraxiparin</e2> (Sanofi Labaz, Munich, FRG), as well as the enoxaparine Clexane (Nattermann, Cologne, FRG), all induced <e1>platelet activation</e1> with the patient's serum."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3799	"By means of the in vitro <e1>heparin</e1> -induced <e2>platelet activation</e2> (HIPA) assay it was shown that standard <e1>heparin</e1> and the LMW <e1>heparin</e1>s Fragmin and Fraxiparin (Sanofi Labaz, Munich, FRG), as well as the enoxaparine Clexane (Nattermann, Cologne, FRG), all induced <e2>platelet activation</e2> with the patient's serum."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3800	"<e1>Heparin</e1> -associated <e2>thrombocytopenia</e2>: successful therapy with the heparinoid Org 10172 in a patient showing cross-reaction to LMW heparins."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3801	"<e1>Hemodynamic collapse</e1> following <e2>labetalol</e2> administration in preeclampsia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3802	"A patient with Parkinson's disease, initially treated with <e1>bromocriptine</e1> and subsequently with cabergoline, developed progressive <e2>pleuropulmonary abnormalities</e2> during the latter therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3803	"A patient with Parkinson's disease, initially treated with bromocriptine and subsequently with <e1>cabergoline</e1>, developed progressive <e2>pleuropulmonary abnormalities</e2> during the latter therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3804	"<e1>Pleuropulmonary changes</e1> during treatment of Parkinson's disease with a long-acting ergot derivative, <e2>cabergoline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3805	"Thus cabergoline may cause similar <e1>pleuropulmonary abnormalities</e1> to <e2>bromocriptine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3806	"Thus <e1>cabergoline</e1> may cause similar <e2>pleuropulmonary abnormalities</e2> to bromocriptine."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3807	"<e1>Acute myopathy</e1> with selective degeneration of myosin filaments following status asthmaticus treated with <e2>methylprednisolone</e2> and vecuronium."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3808	"<e1>Acute myopathy</e1> with selective degeneration of myosin filaments following status asthmaticus treated with methylprednisolone and <e2>vecuronium</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3809	"Acute myopathy with selective <e1>degeneration of myosin filaments</e1> following status asthmaticus treated with <e2>methylprednisolone</e2> and vecuronium."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3810	"Acute myopathy with selective <e1>degeneration of myosin filaments</e1> following status asthmaticus treated with methylprednisolone and <e2>vecuronium</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3811	"<e1>Flaccid quadriparesis</e1> was noted after discontinuation of <e2>vecuronium</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3812	"This entity is probably related to a combination of high doses of corticosteroids, <e1>vecuronium</e1> administration and metabolic abnormalities associated with <e2>respiratory failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3813	"A patient with ulcerative colitis developed skin pigmentation and <e1>diffuse pulmonary shadowing</e1> without respiratory symptomatology, while taking <e2>sulfasalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3814	"A patient with ulcerative colitis developed <e1>skin pigmentation</e1> and diffuse pulmonary shadowing without respiratory symptomatology, while taking <e2>sulfasalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3815	"<e1>Pulmonary infiltrates</e1> and skin pigmentation associated with <e2>sulfasalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3816	"Pulmonary infiltrates and <e1>skin pigmentation</e1> associated with <e2>sulfasalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3817	"<e1>Sulfasalazine</e1> -induced <e2>lung disorder</e2> is an extremely rare entity which must be considered in all ulcerative colitis patients while on sulfasalazine therapy, despite the absence of pulmonary symptomatology."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3818	"<e1>Sulfasalazine</e1> -induced lung disorder is an extremely rare entity which must be considered in all <e2>ulcerative colitis</e2> patients while on sulfasalazine therapy, despite the absence of pulmonary symptomatology."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3819	"Sulfasalazine-induced lung disorder is an extremely rare entity which must be considered in all <e1>ulcerative colitis</e1> patients while on <e2>sulfasalazine</e2> therapy, despite the absence of pulmonary symptomatology."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3820	"Reversible <e1>sclerotic changes of lumbar spine and femur</e1> due to long-term oral <e2>isotretinoin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3821	"Although an association between exposure to <e1>bleomycin</e1> and the development of <e2>scleroderma</e2> has been suspected, few cases are reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3822	"Our series of 3 patients supports a causal connection between <e1>bleomycin</e1> and <e2>scleroderma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3823	"<e1>Scleroderma</e1> in association with the use of <e2>bleomycin</e2>: a report of 3 cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3824	"We describe the development of <e1>cutaneous scleroderma</e1> in 3 patients coincident with the use of <e2>bleomycin</e2> in low cumulative doses of less than 100 U."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3825	"A patient presented with <e1>dilated cardiomyopathy</e1> after many years of overusing an <e2>adrenaline</e2> inhaler."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3826	"<e1>Dilated cardiomyopathy</e1> associated with chronic overuse of an <e2>adrenaline</e2> inhaler."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3827	"A 21-year-old woman suffering from bipolar affective disorder developed systemic lupus erythematosus (<e1>SLE</e1>) with characteristic laboratory findings, 18 months after starting <e2>carbamazepine</e2> maintenance treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3828	"A 21-year-old woman suffering from bipolar affective disorder developed <e1>systemic lupus erythematosus</e1> (SLE) with characteristic laboratory findings, 18 months after starting <e2>carbamazepine</e2> maintenance treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3829	"Although both the spontaneous occurrence of <e1>SLE</e1> and the psychosis as a sign of CNS involvement of <e1>SLE</e1> cannot be excluded, <e1>SLE</e1> could be considered as an adverse effect of <e2>carbamazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3830	"Although both the spontaneous occurrence of <e1>SLE</e1> and the psychosis as a sign of CNS involvement of <e1>SLE</e1> cannot be excluded, <e1>SLE</e1> could be considered as an adverse effect of <e2>carbamazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3831	"Although both the spontaneous occurrence of <e1>SLE</e1> and the psychosis as a sign of CNS involvement of <e1>SLE</e1> cannot be excluded, <e1>SLE</e1> could be considered as an adverse effect of <e2>carbamazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3832	"<e1>Carbamazepine</e1> -induced <e2>systemic lupus erythematosus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3833	"<e1>SLE</e1> receded after withdrawal of <e2>carbamazepine</e2> and treatment with anti-inflammatory drugs."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3834	"We report a case of <e1>acne fulminans</e1> occurring during treatment with <e2>13-cis-retinoic acid</e2> for cystic acne."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3835	"Carbamyl phosphate synthetase-1 deficiency discovered after <e1>valproic acid</e1> -induced <e2>coma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3836	"<e1>Valproic acid</e1> induced <e2>coma</e2> is presented in an adult patient without a history of metabolic disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3837	"<e1>Asterixis</e1> induced by <e2>carbamazepine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3838	"In this report we present four patients treated with a combination of different psychotropic drugs, in whom <e1>asterixis</e1> was triggered either by adding <e2>carbamazepine</e2> (CBZ) to a treatment regimen, or by increasing its dosage."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3839	"In this report we present four patients treated with a combination of different psychotropic drugs, in whom <e1>asterixis</e1> was triggered either by adding carbamazepine (<e2>CBZ</e2>) to a treatment regimen, or by increasing its dosage."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3840	"We consider <e1>asterixis</e1> to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with <e2>CBZ</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3841	"We consider <e1>asterixis</e1> to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or <e2>clozapine</e2> are used in combination with CBZ."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3842	"We consider <e1>asterixis</e1> to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as <e2>lithium</e2> or clozapine are used in combination with CBZ."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3843	"We consider asterixis to be an easily overlooked sign of <e1>neurotoxicity</e1>, which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with <e2>CBZ</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3844	"We consider asterixis to be an easily overlooked sign of <e1>neurotoxicity</e1>, which may occur even at low or moderate dosage levels, if certain drugs as lithium or <e2>clozapine</e2> are used in combination with CBZ."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3845	"We consider asterixis to be an easily overlooked sign of <e1>neurotoxicity</e1>, which may occur even at low or moderate dosage levels, if certain drugs as <e2>lithium</e2> or clozapine are used in combination with CBZ."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3846	"<e1>Encephalopathy</e1> and seizures induced by intravesical <e2>alum</e2> irrigations."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3847	"Encephalopathy and <e1>seizures</e1> induced by intravesical <e2>alum</e2> irrigations."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3848	"<e1>Hemorrhagic cystitis</e1> is a significant toxic effect of <e2>cyclophosphamide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3849	"We report four cases of encephalopathy coincident with elevated <e2>alum</e2>inum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with <e2>alum</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3850	"We report four cases of <e1>encephalopathy</e1> coincident with elevated <e2>alum</e2>inum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with <e2>alum</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3851	"We report four cases of encephalopathy coincident with elevated <e1>alum</e1>inum levels as well as one patient who developed <e2>seizures</e2> while receiving continuous bladder irrigations with <e1>alum</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3852	"Seizure with <e1>hyponatremia</e1> in a child prescribed <e2>desmopressin</e2> for nocturnal enuresis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3853	"<e1>Seizure</e1> with hyponatremia in a child prescribed <e2>desmopressin</e2> for nocturnal enuresis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3854	"We report a case of hyponatremia associated with a <e1>grand mal seizure</e1> in a 28 month-old child after intra-nasal <e2>desmopressin</e2> administration for high fluid intake with nocturnal enuresis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3855	"We report a case of <e1>hyponatremia</e1> associated with a grand mal seizure in a 28 month-old child after intra-nasal <e2>desmopressin</e2> administration for high fluid intake with nocturnal enuresis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3856	"This case report describes a 38-year-old male in whom <e1>SIADH</e1> was strongly suspected secondary to <e2>Tegretol</e2> therapy to control a seizure disorder."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3857	"<e1>Gestational diabetes</e1> was no less severe (degree of hyperglycaemia, need for insulin therapy) when associated with <e2>norethisterone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3858	"However, follow-up revealed that gestational diabetes when associated with <e1>norethisterone</e1> had a lesser risk of emerging <e2>diabetes mellitus</e2> and impaired glucose tolerance."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3859	"However, follow-up revealed that <e1>gestational diabetes</e1> when associated with <e2>norethisterone</e2> had a lesser risk of emerging diabetes mellitus and impaired glucose tolerance."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3860	"However, follow-up revealed that gestational diabetes when associated with <e1>norethisterone</e1> had a lesser risk of emerging diabetes mellitus and <e2>impaired glucose tolerance</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3861	"In a single practice during the 21 years 1971-1991, the incidence of <e1>gestational diabetes</e1> in pregnancies in which <e2>norethisterone</e2> was prescribed was 32.4% (22 of 69) in comparison with 7.1% in pregnancies in which the women did not take <e2>norethisterone</e2> (137 of 1,684) (p < 0.001)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3862	"Masculinization of a female fetus occurred in 5 of 39 (12.8%) exposed to <e1>norethisterone</e1>; all were cases of <e2>clitoral hypertrophy</e2> not requiring surgical treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3863	"<e1>Masculinization of a female fetus</e1> occurred in 5 of 39 (12.8%) exposed to <e2>norethisterone</e2>; all were cases of clitoral hypertrophy not requiring surgical treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3864	"<e1>Norethisterone</e1> in these 69 pregnancies accounted for 33.3% (5 of 15) cases of <e2>clitoral hypertrophy</e2> diagnosed in 100,756 consecutive births."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3865	"An adverse reaction to <e1>IFN</e1> was strongly suspected as the cause of <e2>CHF</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3866	"Multiple myeloma complicated by <e1>congestive heart failure</e1> following first administration of <e2>recombinant alpha-interferon</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3867	"Sixteen hours after the first administration of <e1>IFN</e1>, <e1>IFN</e1> was suspended by the symptoms of congestive heart failure (<e2>CHF</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3868	"Sixteen hours after the first administration of <e1>IFN</e1>, <e1>IFN</e1> was suspended by the symptoms of <e2>congestive heart failure</e2> (CHF)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3869	"<e1>Neutrophilic eccrine hidradenitis</e1> mimicking cutaneous vasculitis in a lupus patient: a complication of <e2>cyclophosphamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3870	"We report a case of <e1>NEH</e1> masquerading as cutaneous vasculitis in a woman receiving <e2>cyclophosphamide</e2> for lupus nephritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3871	"<e1>Generalised cutaneous rash</e1> associated with <e2>ganciclovir</e2> therapy has rarely been reported in literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3872	"<e1>Skin rash</e1> and splinter hemorrhages from <e2>ganciclovir</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3873	"Skin rash and <e1>splinter hemorrhages</e1> from <e2>ganciclovir</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3874	"Can roxithromycin and <e1>betamethasone</e1> induce <e2>acute pancreatitis</e2>? A case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3875	"Can <e1>roxithromycin</e1> and betamethasone induce <e2>acute pancreatitis</e2>? A case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3876	"CASE REPORT: We report the case of a 58 year old patient who, after 2 days of treatment with roxithromycin and <e1>betamethasone</e1>, manifested <e2>acute pancreatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3877	"CASE REPORT: We report the case of a 58 year old patient who, after 2 days of treatment with <e1>roxithromycin</e1> and betamethasone, manifested <e2>acute pancreatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3878	"<e1>Renal tubular acidosis</e1> secondary to <e2>FK506</e2> in living donor liver transplantation: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3879	"RTA is one type of <e1>nephrotoxicity</e1> induced by <e2>FK506</e2>, and it is reversible in mild cases when appropriately treated."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3880	"<e1>RTA</e1> is one type of nephrotoxicity induced by <e2>FK506</e2>, and it is reversible in mild cases when appropriately treated."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3881	"Surgeons and physicians should therefore be aware of the potential for <e1>RTA</e1> to occur with <e2>FK506</e2> after any organ transplantation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3882	"The mechanism of <e1>RTA</e1> induced by <e2>FK506</e2> has not yet been clearly elucidated."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3883	"The treatment for acidosis and hyperkalaemia should be started as soon as <e1>RTA</e1> is diagnosed, and the dosage of <e2>FK506</e2> should also be reduced if possible."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3884	"We report a case of <e1>RTA</e1> secondary to <e2>FK506</e2> administration in liver transplantation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3885	"A 74-year-old patient with idiopathic Parkinson's disease was evaluated for <e1>unintended sleep episodes</e1> that occurred after long-term treatment with 400 mg/day of <e2>L-dopa</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3886	"<e1>L-DOPA</e1> -induced excessive <e2>daytime sleepiness</e2> in PD: a placebo-controlled case with MSLT assessment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3887	"The authors' results suggest that <e1>L-dopa</e1> may cause <e2>daytime somnolence</e2> in some patients with Parkinson's disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3888	"<e1>Neurotoxicity</e1> of intrathecal <e2>methotrexate</e2>: MR imaging findings."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3889	"We attribute the clinical and radiographic findings to <e1>cytotoxic edema</e1> secondary to intrathecal <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3890	"We report a case of intrathecal <e1>methotrexate</e1> neurotoxicity manifesting as left arm weakness and <e2>aphasia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3891	"We report a case of intrathecal <e1>methotrexate</e1> neurotoxicity manifesting as <e2>left arm weakness</e2> and aphasia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3892	"We report a case of intrathecal <e1>methotrexate</e1> <e2>neurotoxicity</e2> manifesting as left arm weakness and aphasia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3893	"In this article <e1>lithium</e1> is not discussed, although there are a number of concerns about <e1>lithium</e1>'s potential teratogenicity, and it has been implicated in <e2>Epstein's anomaly</e2>, a congenital heart defect among infants born to women taking <e1>lithium</e1>; as with other medications, however, the data have specific limitations."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3894	"In this article <e1>lithium</e1> is not discussed, although there are a number of concerns about <e1>lithium</e1>'s potential teratogenicity, and it has been implicated in <e2>Epstein's anomaly</e2>, a congenital heart defect among infants born to women taking <e1>lithium</e1>; as with other medications, however, the data have specific limitations."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3895	"In this article <e1>lithium</e1> is not discussed, although there are a number of concerns about <e1>lithium</e1>'s potential <e2>teratogenicity</e2>, and it has been implicated in Epstein's anomaly, a congenital heart defect among infants born to women taking <e1>lithium</e1>; as with other medications, however, the data have specific limitations."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3896	"In this article <e1>lithium</e1> is not discussed, although there are a number of concerns about <e1>lithium</e1>'s potential <e2>teratogenicity</e2>, and it has been implicated in Epstein's anomaly, a congenital heart defect among infants born to women taking <e1>lithium</e1>; as with other medications, however, the data have specific limitations."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3897	"We present a case of a 20-year-old woman who ingested 900 mg of <e1>glyburide</e1> causing refractory <e2>hypoglycemia</e2> resistant to treatment with intravenous dextrose, glucagon, and diazoxide."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3898	"Ocular <e2>ethambutol</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3899	"The most commonly recognized toxic effect of <e1>ethambutol</e1> is <e2>optic neuropathy</e2>, which generally is considered uncommon and reversible in medical literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3900	"This case and a review of the literature show the severe and unpredictable nature of <e2>ethambutol</e2> toxicity and its potential for irreversible vision loss despite careful ophthalmologic monitoring."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3901	"This case and a review of the literature show the severe and unpredictable nature of <e1>ethambutol</e1> toxicity and its potential for irreversible <e2>vision loss</e2> despite careful ophthalmologic monitoring."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3902	"We describe a 43-year-old man who developed signs and symptoms of <e1>bilateral optic neuropathy</e1> during treatment with <e2>ethambutol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3903	"The case history and toxicological findings of an infant <e1>fatality</e1> involving pseudoephedrine, <e2>brompheniramine</e2>, and dextromethorphan are presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3904	"The case history and toxicological findings of an infant <e1>fatality</e1> involving pseudoephedrine, brompheniramine, and <e2>dextromethorphan</e2> are presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3905	"The case history and toxicological findings of an infant <e1>fatality</e1> involving <e2>pseudoephedrine</e2>, brompheniramine, and dextromethorphan are presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3906	"Early <e1>overanticoagulation</e1> with <e2>acenocoumarol</e2> due to a genetic polymorphism of cytochrome P450 CYP2C9."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3907	"We report the case of a young healthy woman who presented an early <e1>overanticoagulation</e1> when receiving <e2>acenocoumarol</e2> for a first thromboembolic episode."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3908	"<e1>Colchicine</e1> -induced <e2>myopathy</e2> in a teenager with familial Mediterranean fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3909	"CONCLUSIONS: <e1>Colchicine</e1> -induced <e2>myopathy</e2> should be excluded in patients with FMF who present with generalized muscle weakness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3910	"DISCUSSION: <e1>Colchicine</e1>, the most important drug in treatment of FMF, can cause <e2>myopathy</e2> in patients with impaired renal and hepatic function."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3911	"In our patient, an objective causality scale showed that therapeutic doses of <e1>colchicine</e1> for FMF were the definite cause of <e2>myopathy</e2>, even though his renal and hepatic function were normal."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3912	"OBJECTIVE: To report a case of <e1>colchicine</e1> -induced <e2>myopathy</e2> in a teenager with familial Mediterranean fever (FMF)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3913	"<e1>Angioedema</e1> and dysphagia caused by contact allergy to inhaled <e2>budesonide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3914	"Angioedema and <e1>dysphagia</e1> caused by contact allergy to inhaled <e2>budesonide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3915	"We report a 43-year-old woman who developed sore throat, swelling of the lips and oral cavity and <e1>dysphagia</e1>, 2 weeks after the use of budesonide spray (<e2>Budefat</e2>) for treatment of bronchial asthma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3916	"We report a 43-year-old woman who developed sore throat, swelling of the lips and oral cavity and <e1>dysphagia</e1>, 2 weeks after the use of <e2>budesonide</e2> spray (Budefat) for treatment of bronchial asthma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3917	"We report a 43-year-old woman who developed <e1>sore throat</e1>, swelling of the lips and oral cavity and dysphagia, 2 weeks after the use of budesonide spray (<e2>Budefat</e2>) for treatment of bronchial asthma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3918	"We report a 43-year-old woman who developed <e1>sore throat</e1>, swelling of the lips and oral cavity and dysphagia, 2 weeks after the use of <e2>budesonide</e2> spray (Budefat) for treatment of bronchial asthma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3919	"We report a 43-year-old woman who developed sore throat, <e1>swelling of the lips and oral cavity</e1> and dysphagia, 2 weeks after the use of budesonide spray (<e2>Budefat</e2>) for treatment of bronchial asthma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3920	"We report a 43-year-old woman who developed sore throat, <e1>swelling of the lips and oral cavity</e1> and dysphagia, 2 weeks after the use of <e2>budesonide</e2> spray (Budefat) for treatment of bronchial asthma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3921	"<e1>Infectious toxicity</e1> of <e2>dexamethasone</e2> during all remission-induction chemotherapy: report of two cases and literature review."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3922	"We describe the infectious toxicities experienced by the first two patients in our institution treated with <e1>dexamethasone</e1> (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the <e1>dexamethasone</e1> arm of BFM 2000 and review the relevant literature that suggests an increased risk of <e2>infectious complications</e2> with <e1>dexamethasone</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3923	"We describe the <e1>infectious toxicities</e1> experienced by the first two patients in our institution treated with <e2>dexamethasone</e2> (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the <e2>dexamethasone</e2> arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with <e2>dexamethasone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3924	"We describe a patient who developed <e1>NEH</e1> on three separate occasions provoked by two different chemotherapeutic agents--<e2>cytarabine</e2> and mitoxantrone."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3925	"We describe a patient who developed <e1>NEH</e1> on three separate occasions provoked by two different chemotherapeutic agents--cytarabine and <e2>mitoxantrone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3926	"A diagnosis of <e1>infliximab</e1> -induced <e2>lupus</e2> was made and the drug treatment was withdrawn."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3927	"<e1>Infliximab</e1> -induced <e2>lupus</e2> in Crohn's disease: a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3928	"This is the first case, to our knowledge, of onset of prolonged <e1>infliximab</e1> -induced <e2>lupus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3929	"Treatment with <e1>infliximab</e1> is known to produce an increase of autoantibodies (antinuclear antibodies, <e2>anti-double-stranded DNA</e2>), but not clinical disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3930	"Treatment with <e1>infliximab</e1> is known to produce an increase of autoantibodies (<e2>antinuclear antibodies</e2>, anti-double-stranded DNA), but not clinical disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3931	"Treatment with <e1>infliximab</e1> is known to produce an <e2>increase of autoantibodies</e2> (antinuclear antibodies, anti-double-stranded DNA), but not clinical disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3932	"<e1>Severe Raynaud's phenomenon</e1> with <e2>yohimbine</e2> therapy for erectile dysfunction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3933	"We describe a patient with CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, and telangiectasia) who paradoxically experienced <e1>worsening of Raynaud's phenomenon</e1> when using <e2>yohimbine</e2> for ED."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3934	"After initiation of topical <e1>vitamin D3</e1> ointment (20 micro g/g of tacalcitol) 10 g/day for the skin lesions, both the <e2>serum level of calcium and urinary excretion of calcium increased</e2> gradually."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3935	"Iatrogenic <e1>hypercalcemia</e1> due to vitamin D3 ointment (<e2>1,24(OH)2D3</e2>) combined with thiazide diuretics in a case of psoriasis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3936	"Iatrogenic <e1>hypercalcemia</e1> due to vitamin D3 ointment (1,24(OH)2D3) combined with <e2>thiazide</e2> diuretics in a case of psoriasis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3937	"Iatrogenic <e1>hypercalcemia</e1> due to <e2>vitamin D3</e2> ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3938	"The present case is the first report of <e1>hypercalcemia</e1> induced by vitamin D3 ointment and <e2>thiazide</e2> simultaneously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3939	"The present case is the first report of <e1>hypercalcemia</e1> induced by <e2>vitamin D3</e2> ointment and thiazide simultaneously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3940	"We experienced a male patient with psoriasis and hypertension whose conditions were treated with <e1>tacalcitol</e1> ointment and thiazide, respectively, resulting in hypercalciuria and <e2>hypercalcemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3941	"We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and <e1>thiazide</e1>, respectively, resulting in hypercalciuria and <e2>hypercalcemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3942	"We experienced a male patient with psoriasis and hypertension whose conditions were treated with <e1>tacalcitol</e1> ointment and thiazide, respectively, resulting in <e2>hypercalciuria</e2> and hypercalcemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3943	"We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and <e1>thiazide</e1>, respectively, resulting in <e2>hypercalciuria</e2> and hypercalcemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3944	"<e1>2-CdA</e1> typically causes a long-lasting state of <e2>immunodeficiency</e2> and the profound influence of this drug on the immune system has raised questions concerning the emergence of secondary neoplasms after its use."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3945	"<e1>2-CdA</e1> typically causes a long-lasting state of immunodeficiency and the profound influence of this drug on the immune system has raised questions concerning the emergence of <e2>secondary neoplasms</e2> after its use."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3946	"<e1>2-Chloro-deoxyadenosine</e1> induces durable complete remission in Castleman's disease but may accelerate its transformation to <e2>non-Hodgkin's lymphoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3947	"Therefore, it is reasonable to conclude that: 1) <e1>2-CdA</e1> can induce durable complete remission in MCD patients but unfortunately it cannot cure the disease; 2) the possibility that <e1>2-CdA</e1> may accelerate the <e2>transformation of MCD to NHL</e2> cannot be ruled out."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3948	"Since this amount of FAB was insufficient to bind all <e1>DGTX</e1> present in the serum, cardiac <e1>DGTX</e1> toxicity (total AV-block) persisted."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3949	"Since this amount of FAB was insufficient to bind all <e1>DGTX</e1> present in the serum, cardiac <e1>DGTX</e1> toxicity (<e2>total AV-block</e2>) persisted."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3950	"All patients had taken <e1>phenytoin</e1> for variable time periods (range 16-80 days; mean: 40) and were on the medication when the <e2>skin lesions</e2> first appeared."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3951	"<e1>Erythema multiforme</e1> associated with <e2>phenytoin</e2> and cranial radiation therapy: a report of three patients and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3952	"In conclusion, <e1>RSDS</e1> is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (<e2>CyA</e2> or tacrolimus), even under monotherapy or with a low steroid dose."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3953	"In conclusion, <e1>RSDS</e1> is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (CyA or <e2>tacrolimus</e2>), even under monotherapy or with a low steroid dose."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3954	"<e1>Reflex sympathetic dystrophy syndrome</e1> in renal transplanted patients under immunosuppression with <e2>tacrolimus</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3955	"We now present four cases of <e1>RSDS</e1> in kidney transplant recipients treated with <e2>tacrolimus</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3956	"CONCLUSIONS: <e1>Topiramate</e1> may be associated with ciliochoroidal effusion with forward displacement of the lens-iris diaphragm and anterior chamber shallowing, resulting in <e2>acute myopia</e2> and angle-closure glaucoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3957	"CONCLUSIONS: <e1>Topiramate</e1> may be associated with ciliochoroidal effusion with forward displacement of the lens-iris diaphragm and anterior chamber shallowing, resulting in acute myopia and <e2>angle-closure glaucoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3958	"CONCLUSIONS: <e1>Topiramate</e1> may be associated with ciliochoroidal effusion with forward displacement of the lens-iris diaphragm and <e2>anterior chamber shallowing</e2>, resulting in acute myopia and angle-closure glaucoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3959	"CONCLUSIONS: <e1>Topiramate</e1> may be associated with <e2>ciliochoroidal effusion</e2> with forward displacement of the lens-iris diaphragm and anterior chamber shallowing, resulting in acute myopia and angle-closure glaucoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3960	"CONCLUSIONS: <e1>Topiramate</e1> may be associated with ciliochoroidal effusion with forward <e2>displacement of the lens-iris diaphragm</e2> and anterior chamber shallowing, resulting in acute myopia and angle-closure glaucoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3961	"Mechanism of <e1>topiramate</e1> -induced <e2>acute-onset myopia</e2> and angle closure glaucoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3962	"Mechanism of <e1>topiramate</e1> -induced acute-onset myopia and <e2>angle closure glaucoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3963	"METHODS: In an institutional practice setting, two women, aged 25 and 45, developed <e1>acute myopia</e1> after starting <e2>topiramate</e2> for epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3964	"<e1>Doxycycline</e1> -induced <e2>photo-onycholysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3965	"We present a case of <e1>photo-onycholysis</e1> in a patient treated with <e2>doxycycline</e2> for acne vulgaris."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3966	"A new type of <e1>minocycline</e1> -induced <e2>cutaneous hyperpigmentation</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3967	"<e1>Pigmentary disorders</e1> are recognized adverse effects of the semi-synthetic tetracycline derivative antibiotic, <e2>minocycline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3968	"This fourth type of cutaneous <e1>minocycline</e1> <e2>hyperpigmentation</e2> may be a variant of Type I, but based on clinical, pathological and microanalytical differences, appears to be a new entity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3969	"Three distinct types of <e1>minocycline</e1> -induced <e2>cutaneous pigmentation</e2> have been described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3970	"We report two patients with acne vulgaris with a fourth type of <e1>minocycline</e1> -induced <e2>cutaneous pigmentation</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3971	"<e1>Ciprofloxacin</e1> -induced <e2>toxic epidermal necrolysis</e2> in a patient with systemic lupus erythematosus."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3972	"We report here a case of <e1>TEN</e1> after administration of <e2>ciprofloxacin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3973	"A 56-year-old Caucasian man who received concomitant chemotherapy and radiation for head and neck cancer developed <e1>fever</e1> concurrent with the administration of <e2>amifostine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3974	"<e1>Amifostine</e1> -induced <e2>fever</e2>: case report and review of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3975	"Patients receiving <e1>amifostine</e1> who develop only <e2>fever</e2> should be evaluated for an adverse drug reaction, as well as for sepsis and <e2>fever</e2>s of neutropenia, and it may be necessary to discontinue the drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3976	"Patients receiving <e1>amifostine</e1> who develop only fever should be evaluated for an adverse drug reaction, as well as for sepsis and <e2>fevers of neutropenia</e2>, and it may be necessary to discontinue the drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3977	"Patients receiving <e1>amifostine</e1> who develop only fever should be evaluated for an adverse drug reaction, as well as for <e2>sepsis</e2> and fevers of neutropenia, and it may be necessary to discontinue the drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3978	"To our knowledge, this is the first case report that demonstrates the occurrence of <e1>fever</e1> with low-dose <e2>amifostine</e2> therapy without the manifestation of accompanying rash or hypotension."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3979	"<e1>Acute interstitial nephritis</e1> due to <e2>pantoprazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3980	"After 5 weeks of therapy, she stopped taking <e1>pantoprazole</e1> due to <e2>general malaise</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3981	"OBJECTIVE: To describe what is believed, as of November 4, 2003, to be the first case published in the literature of <e1>acute interstitial nephritis</e1> (AIN) due to <e2>pantoprazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3982	"The Naranjo probability scale suggests a highly probable relationship between <e1>AIN</e1> and <e2>pantoprazole</e2> therapy in this patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3983	"There have been several reported cases of <e1>omeprazole</e1> -induced <e2>AIN</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3984	"It was highly suspected that <e1>finasteride</e1> was associated with the <e2>anterior subcapsular opacity on the lens</e2>, and the patient therefore discontinued use of <e1>finasteride</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3985	"It was highly suspected that <e1>finasteride</e1> was associated with the <e2>anterior subcapsular opacity on the lens</e2>, and the patient therefore discontinued use of <e1>finasteride</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3986	"<e1>Propecia</e1> -associated <e2>bilateral cataract</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3987	"To the best of the authors' knowledge, this is the first reported case of <e1>Propecia</e1> -associated <e2>cataract</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3988	"<e1>Scleromyxedema</e1> in a patient with multiple sclerosis and monoclonal gammopathy on <e2>interferon beta-1a</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3989	"CASE SUMMARY: Two children with attention deficit disorder treated with <e1>methylphenidate</e1> as a simple drug developed <e2>fixed drug eruption of the scrotum</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3990	"CONCLUSIONS: <e1>Fixed drug rash</e1> induced by <e2>methylphenidate</e2> is a possible but rare phenomenon."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3991	"<e1>Fixed drug eruption of the scrotum</e1> due to <e2>methylphenidate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3992	"OBJECTIVE: To report two cases of <e1>fixed drug eruption</e1> induced by <e2>methylphenidate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3993	"<e1>Methotrexate</e1> <e2>pneumonitis</e2> in nonsurgical treatment of ectopic pregnancy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3994	"We describe a case of <e1>pneumonitis</e1> following local administration of <e2>methotrexate</e2> for nonsurgical termination of an ectopic pregnancy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3995	"BACKGROUND: The risk/benefit ratio of <e1>warfarin</e1> therapy changes in the over 75s, when <e2>haemorrhagic side-effects</e2> become more common."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3996	"CASE REPORT: A woman of 80 years, on long-term <e1>warfarin</e1> therapy presented with an <e2>acute dissecting thoracic aortic aneurysm</e2>; on investigation the only precipitating factor found was an international normalised ratio of 4.8."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3997	"<e1>Warfarin</e1> -associated <e2>thoracic aortic dissection</e2> in an elderly woman."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3998	"<e1>Cutaneous vasculitis</e1> secondary to <e2>ramipril</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3999	"Here we report <e1>ramipril</e1> -induced <e2>cutaneous vasculitis</e2> in a patient who required steroid therapy to control it."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4000	"<e1>Ramipril</e1> -induced <e2>cutaneous vasculitis</e2> is particularly rare and our case was atypical because the patient had tolerated lisinopril before."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4001	"CONCLUSION: This is, to our knowledge, the first report of <e1>severe myelopathy</e1> following accidental intrathecal administration of <e2>doxorubicin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4002	"Neurological improvement and rehabilitation potential following <e1>toxic myelopathy</e1> due to intrathecal injection of <e2>doxorubicin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4003	"RESULTS: Evidence of neurological improvement and rehabilitation potential after <e1>severe myelopathy</e1> due to intrathecal injection of <e2>doxorubicin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4004	"STUDY DESIGN: Case report of a 31-year-old woman who presented with <e1>toxic myelopathy</e1> due to intrathecal administration of <e2>doxorubicin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4005	"After <e1>infliximab</e1> treatment, additional sleep studies revealed an <e2>increase in the number of apneic events</e2> and SaO2 dips suggesting that TNFalpha plays an important role in the pathophysiology of sleep apnea."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4006	"After <e1>infliximab</e1> treatment, additional sleep studies revealed an increase in the number of apneic events and <e2>SaO2 dips</e2> suggesting that TNFalpha plays an important role in the pathophysiology of sleep apnea."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4007	"Thus, clinical recognition of <e1>sleep disordered breathing</e1> should be taken into account when rheumatoid arthritis patients are to be treated with <e2>infliximab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4008	"<e1>Hypernatraemia</e1> induced by sodium polystyrene sulphonate (<e2>Kayexalate</e2>) in two extremely low birth weight newborns."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4009	"<e1>Hypernatraemia</e1> induced by <e2>sodium polystyrene sulphonate</e2> (Kayexalate) in two extremely low birth weight newborns."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4010	"We describe two ELBW infants affected by hyperkalaemia, treated with <e1>Kayexalate</e1>, who developed serious <e2>hypernatraemia</e2>, that has never been reported before in preterm infants."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4011	"<e1>Bull's-eye maculopathy</e1> associated with <e2>quinacrine</e2> therapy for malaria."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4012	"CONCLUSIONS: Low dosages of quinacrine used for malaria prophylaxis can be associated with a delayed, severe <e1>maculopathy</e1> indistinguishable from <e2>chloroquine</e2> <e1>maculopathy</e1> in certain patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4013	"CONCLUSIONS: Low dosages of <e1>quinacrine</e1> used for malaria prophylaxis can be associated with a delayed, <e2>severe maculopathy</e2> indistinguishable from chloroquine maculopathy in certain patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4014	"RESULTS: A patient developed a <e1>bilaterally symmetric bull's-eye maculopathy</e1> 45 years after taking <e2>quinacrine</e2> for 18 months as prophylaxis against malaria."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4015	"The clinical picture was identical to that of <e1>chloroquine</e1> and hydroxy<e1>chloroquine</e1> <e2>maculopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4016	"The clinical picture was identical to that of chloroquine and <e1>hydroxychloroquine</e1> <e2>maculopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4017	"<e1>Cerebral infarcts</e1> in a pediatric patient secondary to <e2>phenylpropanolamine</e2>, a recalled medication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4018	"<e1>Phenylpropanolamine</e1> (PPA) recently has been publicly implicated as a cause of stroke and other <e2>neurologic events</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4019	"Phenylpropanolamine (<e1>PPA</e1>) recently has been publicly implicated as a cause of stroke and other <e2>neurologic events</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4020	"<e1>Phenylpropanolamine</e1> (PPA) recently has been publicly implicated as a cause of <e2>stroke</e2> and other neurologic events."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4021	"Phenylpropanolamine (<e1>PPA</e1>) recently has been publicly implicated as a cause of <e2>stroke</e2> and other neurologic events."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4022	"The patient developed occipital infarcts and was found to have extremely elevated levels of <e2>PPA</e2> in his blood and dialysis fluid."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4023	"The patient developed <e1>occipital infarcts</e1> and was found to have extremely elevated levels of <e2>PPA</e2> in his blood and dialysis fluid."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4024	"We present a case of <e1>stroke</e1> after <e2>PPA</e2> ingestion that occurred 4 months after the recall in an 8-year-old boy on chronic peritoneal dialysis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4025	"Central nervous system effects secondary to <e1>ciprofloxacin</e1> treatment are uncommon and usually consist only of minor dizziness or mild headache, although rare occurrences of seizures and <e2>hallucinations</e2> have been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4026	"Central nervous system effects secondary to <e1>ciprofloxacin</e1> treatment are uncommon and usually consist only of minor dizziness or <e2>mild headache</e2>, although rare occurrences of seizures and hallucinations have been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4027	"Central nervous system effects secondary to <e1>ciprofloxacin</e1> treatment are uncommon and usually consist only of <e2>minor dizziness</e2> or mild headache, although rare occurrences of seizures and hallucinations have been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4028	"Central nervous system effects secondary to <e1>ciprofloxacin</e1> treatment are uncommon and usually consist only of minor dizziness or mild headache, although rare occurrences of <e2>seizures</e2> and hallucinations have been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4029	"<e1>Ciprofloxacin</e1> -induced <e2>psychosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4030	"DATA SYNTHESIS: A 49-year-old man developed symptoms of <e1>severe psychosis</e1> concomitant with <e2>ciprofloxacin</e2> (250 mg bid) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4031	"OBJECTIVE: To report a case of <e1>ciprofloxacin</e1> -induced <e2>psychosis</e2> and to discuss occurrence rates, risk factors, possible etiologies, preventive measures, and treatment courses for this adverse reaction."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4032	"<e1>Agranulocytosis</e1> induced by <e2>vancomycin</e2> in an ESRD patient on CAPD."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4033	"<e1>Agranulocytosis</e1> is a rare adverse effect associated with prolonged <e2>vancomycin</e2> therapy, and is potentially serious, especially in end stage renal disease (ESRD) patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4034	"We describe a continuous ambulatory peritoneal dialysis (CAPD) patient that developed <e1>vancomycin</e1> -induced <e2>agranulocytosis</e2> during treatment for methicillin-resistant Staphylococcus aureus (MRSA)-associated external cuff infection and pneumonia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4035	"It is very likely that the <e1>dexamethasone</e1> used in the antiemetic drug regimen contributed to the development of <e2>osteonecrosis</e2> in these patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4036	"<e1>Osteonecrosis</e1> is a serious side effect of antiemetic treatment with <e2>dexamethasone</e2> and this serious complication should be incorporated in the current guidelines."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4037	"Patients should be informed about the risk of <e1>osteonecrosis</e1> when taking <e2>dexamethasone</e2> as an antiemetic drug."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4038	"Development of <e1>Peyronie's disease</e1> during long-term <e2>colchicine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4039	"However here we reported two patients, presenting with <e1>PD</e1> during high dose <e2>colchicine</e2> treatment for familiar mediterranean fever (FMF)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4040	"A patient developed <e1>cholestatic hepatitis</e1> while being treated with <e2>nitrofurantoin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4041	"A second episode of <e1>jaundice</e1> followed the intravaginal administration of a mixture of <e2>furazolidone</e2> and nifuroxime."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4042	"A second episode of <e1>jaundice</e1> followed the intravaginal administration of a mixture of furazolidone and <e2>nifuroxime</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4043	"A case of <e1>phenobarbital</e1> <e2>exacerbation of a preexisting maladaptive behavior</e2> partially suppressed by chlorpromazine and misinterpreted as chlorpromazine efficacy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4044	"Ten years of behavioral data are presented to support the hypothesis that <e1>phenobarbital</e1> was exacerbating <e2>maladaptive behaviors</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4045	"This profile should trigger a "red flag" as to the possibility of <e1>phenobarbital</e1> <e2>behavioral side effects</e2> or exacerbation of preexisting maladaptive behaviors."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4046	"This profile should trigger a "red flag" as to the possibility of <e1>phenobarbital</e1> behavioral side effects or <e2>exacerbation of preexisting maladaptive behaviors</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4047	"<e2>Pilocarpine</e2> toxicity and the treatment of xerostomia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4048	"We report a case of unintentional overdose of oral <e1>pilocarpine</e1> tablets that resulted in <e2>bradycardia</e2>, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4049	"We report a case of unintentional overdose of oral <e1>pilocarpine</e1> tablets that resulted in bradycardia, <e2>mild hypotension</e2>, and muscarinic symptoms in a patient with Sjogren's syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4050	"We report a case of unintentional overdose of oral <e1>pilocarpine</e1> tablets that resulted in bradycardia, mild hypotension, and <e2>muscarinic symptoms</e2> in a patient with Sjogren's syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4051	"Although combinations of <e1>belladonna</e1>, ergotamine, and phenobarbital have been used for medical treatment of menopausal symptoms since the 1960s, this is the first known case report of its association with <e2>anticonvulsant hypersensitivity syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4052	"Although combinations of belladonna, <e1>ergotamine</e1>, and phenobarbital have been used for medical treatment of menopausal symptoms since the 1960s, this is the first known case report of its association with <e2>anticonvulsant hypersensitivity syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4053	"Although combinations of belladonna, ergotamine, and <e1>phenobarbital</e1> have been used for medical treatment of menopausal symptoms since the 1960s, this is the first known case report of its association with <e2>anticonvulsant hypersensitivity syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4054	"<e1>Anticonvulsant hypersensitivity syndrome</e1> associated with <e2>Bellamine S</e2>, a therapy for menopausal symptoms."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4055	"We report a case of a previously healthy, postmenopausal woman who developed <e1>anticonvulsant hypersensitivity syndrome</e1> while taking Bellamine S (<e2>belladonna alkaloids</e2>; ergotamine; phenobarbital) for hot flashes."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4056	"We report a case of a previously healthy, postmenopausal woman who developed <e1>anticonvulsant hypersensitivity syndrome</e1> while taking <e2>Bellamine S</e2> (belladonna alkaloids; ergotamine; phenobarbital) for hot flashes."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4057	"We report a case of a previously healthy, postmenopausal woman who developed <e1>anticonvulsant hypersensitivity syndrome</e1> while taking Bellamine S (belladonna alkaloids; <e2>ergotamine</e2>; phenobarbital) for hot flashes."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4058	"We report a case of a previously healthy, postmenopausal woman who developed <e1>anticonvulsant hypersensitivity syndrome</e1> while taking Bellamine S (belladonna alkaloids; ergotamine; <e2>phenobarbital</e2>) for hot flashes."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4059	"A case of <e1>heatstroke</e1> is reported in a 32-year-old man diagnosed with schizophrenia and on <e2>clozapine</e2> monotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4060	"<e1>Heat stroke</e1> in schizophrenia during <e2>clozapine</e2> treatment: rapid recognition and management."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4061	"<e1>Gemcitabine</e1> -related <e2>radiation recall</e2> preferentially involves internal tissue and organs."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4062	"The authors also determined that their case of <e1>myositis</e1> developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of radiation recall, thereby bringing the number of patients who developed radiation recall to <e2>gemcitabine</e2> and were discussed in the current study to 13."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4063	"The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of <e1>radiation recall</e1>, thereby bringing the number of patients who developed <e1>radiation recall</e1> to <e2>gemcitabine</e2> and were discussed in the current study to 13."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4064	"The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of <e1>radiation recall</e1>, thereby bringing the number of patients who developed <e1>radiation recall</e1> to <e2>gemcitabine</e2> and were discussed in the current study to 13."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4065	"The literature search found 12 cases of <e1>radiation recall</e1> caused by <e2>gemcitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4066	"The majority of <e1>radiation recall reactions</e1> attributed to <e2>gemcitabine</e2> are reported to affect internal tissue or organs."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4067	"<e1>Cystoid macular edema</e1> in a low-risk patient after switching from latanoprost to <e2>bimatoprost</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4068	"<e1>Cystoid macular edema</e1> in a low-risk patient after switching from <e2>latanoprost</e2> to bimatoprost."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4069	"METHODS: A 68-year-old man developed intense conjunctival hyperemia and <e1>cystoid macula edema</e1> after switching from latanoprost to <e2>bimatoprost</e2> 9 months after cataract surgery in an eye at low-risk for this cystoid macular edema."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4070	"METHODS: A 68-year-old man developed intense conjunctival hyperemia and <e1>cystoid macula edema</e1> after switching from <e2>latanoprost</e2> to bimatoprost 9 months after cataract surgery in an eye at low-risk for this cystoid macular edema."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4071	"METHODS: A 68-year-old man developed intense conjunctival hyperemia and cystoid macula edema after switching from latanoprost to <e1>bimatoprost</e1> 9 months after cataract surgery in an eye at low-risk for this <e2>cystoid macular edema</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4072	"METHODS: A 68-year-old man developed intense conjunctival hyperemia and cystoid macula edema after switching from <e1>latanoprost</e1> to bimatoprost 9 months after cataract surgery in an eye at low-risk for this <e2>cystoid macular edema</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4073	"METHODS: A 68-year-old man developed <e1>intense conjunctival hyperemia</e1> and cystoid macula edema after switching from latanoprost to <e2>bimatoprost</e2> 9 months after cataract surgery in an eye at low-risk for this cystoid macular edema."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4074	"METHODS: A 68-year-old man developed <e1>intense conjunctival hyperemia</e1> and cystoid macula edema after switching from <e2>latanoprost</e2> to bimatoprost 9 months after cataract surgery in an eye at low-risk for this cystoid macular edema."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4075	"PURPOSE: To report a case of angiographically documented <e1>cystoid macula edema</e1> occurring after switching a pseudophakic patient from latanoprost to <e2>bimatoprost</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4076	"PURPOSE: To report a case of angiographically documented <e1>cystoid macula edema</e1> occurring after switching a pseudophakic patient from <e2>latanoprost</e2> to bimatoprost."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4077	"An immediate <e1>hemolytic reaction</e1> induced by repeated administration of <e2>oxaliplatin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4078	"CASE REPORT: We report a patient who developed a <e1>DAT-positive hemolytic episode</e1> after a red cell (RBC) transfusion was delivered during the infusion of her 17th cycle of <e2>oxaliplatin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4079	"Although neurotoxicity is a frequent complication of <e1>methotrexate</e1> therapy, <e2>fatal acute neurotoxicity</e2> is extremely uncommon, especially in adults."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4080	"Although <e1>neurotoxicity</e1> is a frequent complication of <e2>methotrexate</e2> therapy, fatal acute <e1>neurotoxicity</e1> is extremely uncommon, especially in adults."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4081	"Clinicians should be aware of the signs and symptoms of <e1>neurotoxicity</e1> during treatment, as well as predisposing factors that put patients receiving <e2>methotrexate</e2> at risk for neurotoxic effects."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4082	"<e1>Fatal acute encephalomyelitis</e1> after a single dose of intrathecal <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4083	"The day after <e1>methotrexate</e1> administration, the patient complained of <e2>severe back pain</e2> and urinary retention."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4084	"The day after <e1>methotrexate</e1> administration, the patient complained of severe back pain and <e2>urinary retention</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4085	"This patient rapidly progressed from mild neurotoxicity to <e1>fatal encephalopathy</e1> after one dose of intrathecal <e2>methotrexate</e2> during his third cycle of chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4086	"This patient rapidly progressed from <e1>mild neurotoxicity</e1> to fatal encephalopathy after one dose of intrathecal <e2>methotrexate</e2> during his third cycle of chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4087	"We report a third case of a 6-week-old infant with Escherichia coli sepsis who received <e1>ampicillin</e1> and other antibiotics and subsequently developed <e2>TEN</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4088	"One patient developed <e1>large intramural esophageal hematoma</e1> as a complication of <e2>heparin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4089	"<e1>Eosinophilic cystitis</e1> after bladder instillation with <e2>dimethyl sulfoxide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4090	"We report the first case of an acute flare of <e1>eosinophilic cystitis</e1> in a 51-year-old woman after bladder instillation with <e2>dimethyl sulfoxide</e2> (DMSO) for presumed interstitial cystitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4091	"We report the first case of an acute flare of <e1>eosinophilic cystitis</e1> in a 51-year-old woman after bladder instillation with dimethyl sulfoxide (<e2>DMSO</e2>) for presumed interstitial cystitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4092	"<e1>Acute dystonia</e1> during <e2>pegylated interferon alpha</e2> therapy in a case with chronic hepatitis B infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4093	"In this case report, we present clinical and laboratory findings of a case with chronic hepatitis B that developed <e1>acute dystonia</e1> soon after the first dose of <e2>pegylated interferon alpha</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4094	"Therapy with <e1>IFN-alpha</e1> may be associated with a number of neuropsychiatric symptoms, such as Parkinsonism, <e2>akathisia</e2>, seizure, and depressive disorders."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4095	"Therapy with <e1>IFN-alpha</e1> may be associated with a number of neuropsychiatric symptoms, such as Parkinsonism, akathisia, seizure, and <e2>depressive disorders</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4096	"Therapy with <e1>IFN-alpha</e1> may be associated with a number of <e2>neuropsychiatric symptoms</e2>, such as Parkinsonism, akathisia, seizure, and depressive disorders."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4097	"Therapy with <e1>IFN-alpha</e1> may be associated with a number of neuropsychiatric symptoms, such as <e2>Parkinsonism</e2>, akathisia, seizure, and depressive disorders."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4098	"Therapy with <e1>IFN-alpha</e1> may be associated with a number of neuropsychiatric symptoms, such as Parkinsonism, akathisia, <e2>seizure</e2>, and depressive disorders."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4099	"A patient developed <e1>restless legs symptoms</e1> paralleling the course of interferon-alpha (<e2>IFN alpha</e2>) therapy for chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4100	"A patient developed <e1>restless legs symptoms</e1> paralleling the course of <e2>interferon-alpha</e2> (IFN alpha) therapy for chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4101	"<e1>Restless legs syndrome</e1> due to <e2>interferon-alpha</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4102	"<e1>Restless legs syndrome</e1> may thus be an adverse effect of <e2>IFN alpha</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4103	"Many clinicians appear to be concerned about the potential <e1>hepatotoxicity</e1> of the opiate antagonist <e2>naltrexone</e2> (NTX) and this may be one reason why it is not used more widely in treating both heroin and alcohol abusers."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4104	"Many clinicians appear to be concerned about the potential <e1>hepatotoxicity</e1> of the opiate antagonist naltrexone (<e2>NTX</e2>) and this may be one reason why it is not used more widely in treating both heroin and alcohol abusers."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4105	"We describe a heroin abuser in whom clinical and laboratory manifestations of <e1>acute hepatitis B and C</e1> appeared a few days after the insertion of a subcutaneous <e2>naltrexone</e2> implant."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4106	"<e1>Sweet's syndrome</e1> associated with <e2>sargramostim</e2> (granulocyte-macrophage colony stimulating factor) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4107	"Sweet's syndrome is an <e1>acute febrile neutrophilic dermatosis</e1> that is a known complication of the administration of <e2>filgrastim</e2>, a drug that causes increased neutrophil proliferation and differentiation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4108	"<e1>Sweet's syndrome</e1> is an acute febrile neutrophilic dermatosis that is a known complication of the administration of <e2>filgrastim</e2>, a drug that causes increased neutrophil proliferation and differentiation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4109	"We report a case of <e1>Sweet's syndrome</e1> in association with <e2>sargramostim</e2> treatment following chemotherapy for acute myelogenous leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4110	"Sudden cardiac death due to <e1>hypersensitivity myocarditis</e1> during <e2>clozapine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4111	"<e1>Sudden cardiac death</e1> due to hypersensitivity myocarditis during <e2>clozapine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4112	"The autopsy findings and a detailed medical history supported the conclusion that <e1>clozapine</e1> -induced <e2>hypersensitivity myocarditis</e2> was the most likely cause of death."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4113	"The case concerns the <e1>sudden death</e1> of a 29-year-old male during <e2>clozapine</e2> therapy started 2 weeks before."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4114	"Purple glove syndrome, named for its distinctive <e1>purple discoloration</e1> and swelling of the hands in the distribution of a glove, is an uncommon complication of intravenous <e2>phenytoin</e2> administration through small dorsal veins of the hands."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4115	"<e1>Purple glove syndrome</e1>, named for its distinctive purple discoloration and swelling of the hands in the distribution of a glove, is an uncommon complication of intravenous <e2>phenytoin</e2> administration through small dorsal veins of the hands."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4116	"Purple glove syndrome, named for its distinctive purple discoloration and <e1>swelling of the hands</e1> in the distribution of a glove, is an uncommon complication of intravenous <e2>phenytoin</e2> administration through small dorsal veins of the hands."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4117	"The findings were judged to be consistent with soft-tissue injury associated with intravenous administration of <e1>phenytoin</e1>, also termed <e2>purple glove syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4118	"The findings were judged to be consistent with <e1>soft-tissue injury</e1> associated with intravenous administration of <e2>phenytoin</e2>, also termed purple glove syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4119	"Our patient was a 72-year-old man with advanced Parkinson's disease (PD) who received <e1>levodopa</e1> and anti-cholinergic drugs and whose head had become almost <e2>completely bald</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4120	"A patient with monocular open-angle glaucoma had <e1>trichiasis</e1>, a condition associated with the use of a <e2>prostaglandin</e2> analog."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4121	"<e1>Increased lash length</e1>, thickness, and pigmentation are well-documented side effects of <e2>prostaglandin</e2> analog glaucoma drops."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4122	"Increased lash length, thickness, and <e1>pigmentation</e1> are well-documented side effects of <e2>prostaglandin</e2> analog glaucoma drops."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4123	"<e1>Trichiasis</e1> associated with <e2>prostaglandin</e2> analog use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4124	"<e1>Fatal pulmonary fibrosis</e1> associated with <e2>BCNU</e2>: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4125	"<e1>Pulmonary fibrosis</e1> is a severe complication associated with bis-chloronitrosourea (<e2>BCNU</e2>) therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4126	"<e1>Pulmonary fibrosis</e1> is a severe complication associated with <e2>bis-chloronitrosourea</e2> (BCNU) therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4127	"These novel findings may offer specific therapeutic targets in the treatment of <e1>BCNU</e1> -associated <e2>pulmonary fibrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4128	"We further used immunohistochemistry (IHC) to examine the relative role of platelet-derived growth factor-B (PDGF-B), insulin-like growth factor I (IGF-I), transforming growth factor-beta1 (TGF-beta1) and cyclooxygenase-2 (COX-2) in the pathogenesis of <e1>BCNU</e1> -related <e2>pulmonary fibrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4129	"We report here a 26-year-old female with diffuse large B-cell lymphoma who died of <e1>severe pulmonary fibrosis</e1> 81 days after the administration of high-dose <e2>BCNU</e2> (600 mg/m2)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4130	"<e1>Dorzolamide</e1> -induced <e2>choroidal detachment</e2> in a surgically untreated eye."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4131	"METHODS: A 76-year-old woman with primary open-angle glaucoma and no history of ocular surgery developed a <e1>choroidal detachment</e1> 12 hours after initiation of therapy with <e2>dorzolamide</e2> eye drops."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4132	"We document the abrupt development of an extensive <e1>choroidal detachment</e1> after initiation of <e2>dorzolamide</e2> therapy in a surgically untreated eye with primary open-angle glaucoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4133	"<e1>Deepening of lid sulcus</e1> from topical <e2>bimatoprost</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4134	"In each of the three reported patients, <e1>alteration of eyelid appearance</e1> with deepening of the lid sulcus was evident as the result of topical <e2>bimatoprost</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4135	"In each of the three reported patients, alteration of eyelid appearance with <e1>deepening of the lid sulcus</e1> was evident as the result of topical <e2>bimatoprost</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4136	"<e1>Lichen planus</e1> induced by <e2>hepatitis B vaccination</e2>: a new case and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4137	"Case report: <e1>life-threatening hypoglycaemia</e1> associated with <e2>sulfadoxine-pyrimethamine</e2>, a commonly used antimalarial drug."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4138	"In this report, we present a case of <e1>hypoglycaemic coma</e1> associated with <e2>SP</e2>, an adverse reaction that is likely to be underreported and expected to occur with greater frequency as the use of <e2>SP</e2> increases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4139	"In this report, we present a case of <e1>hypoglycaemic coma</e1> associated with <e2>SP</e2>, an adverse reaction that is likely to be underreported and expected to occur with greater frequency as the use of <e2>SP</e2> increases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4140	"Initial treatment with <e1>heparin</e1> was substituted with thrombolysis, which resulted in clinical improvement and dissolution of right heart thrombus but was followed by <e2>fatal intracerebral haemorrhage</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4141	"<e1>Extensive forearm deep venous thrombosis</e1> following a severe <e2>infliximab</e2> infusion reaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4142	"Here we describe a patient with Crohn's disease who developed a severe <e1>infliximab</e1> infusion reaction (<e2>IIR</e2>), complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of <e1>infliximab</e1> infusion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4143	"Here we describe a patient with Crohn's disease who developed a severe <e1>infliximab</e1> infusion reaction (<e2>IIR</e2>), complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of <e1>infliximab</e1> infusion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4144	"Here we describe a patient with Crohn's disease who developed a severe <e2>infliximab</e2> infusion reaction (IIR), complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of <e2>infliximab</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4145	"Here we describe a patient with Crohn's disease who developed a severe <e2>infliximab</e2> infusion reaction (IIR), complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of <e2>infliximab</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4146	"Here we describe a patient with Crohn's disease who developed a severe <e1>infliximab</e1> infusion reaction (IIR), complicated 1 day later by <e2>severe swelling of the forearm and hand ipsilateral</e2> to the site of <e1>infliximab</e1> infusion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4147	"Here we describe a patient with Crohn's disease who developed a severe <e1>infliximab</e1> infusion reaction (IIR), complicated 1 day later by <e2>severe swelling of the forearm and hand ipsilateral</e2> to the site of <e1>infliximab</e1> infusion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4148	"The site of thrombosis and the chronological relationship with the IIR implicates a <e1>hypersensitivity</e1> to <e2>infliximab</e2> in the causation of the venous thrombosis in this case."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4149	"The site of thrombosis and the chronological relationship with the <e1>IIR</e1> implicates a hypersensitivity to <e2>infliximab</e2> in the causation of the venous thrombosis in this case."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4150	"The site of thrombosis and the chronological relationship with the IIR implicates a hypersensitivity to <e1>infliximab</e1> in the causation of the <e2>venous thrombosis</e2> in this case."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4151	"After 3- to 13-month period of therapy without <e1>indapamide</e1>, glucose levels of all patients decreased and <e2>diabetes</e2> disappeared."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4152	"After stopping <e1>indapamide</e1>, <e2>glucose tolerance impairing</e2> may be reversed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4153	"CONCLUSION: Therapy with <e1>indapamide</e1> may induce <e2>diabetes</e2> in essential hypertension patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4154	"OBJECTIVE: To study therapy with <e1>indapamide</e1> impairing carbohydrate metabolism in essential hypertension patients and achieve earlier prevention, diagnoses and treatment of <e2>diabetes</e2> induced by <e1>indapamide</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4155	"OBJECTIVE: To study therapy with <e1>indapamide</e1> impairing carbohydrate metabolism in essential hypertension patients and achieve earlier prevention, diagnoses and treatment of <e2>diabetes</e2> induced by <e1>indapamide</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4156	"OBJECTIVE: To study therapy with <e1>indapamide</e1> <e2>impairing carbohydrate metabolism</e2> in essential hypertension patients and achieve earlier prevention, diagnoses and treatment of diabetes induced by <e1>indapamide</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4157	"Possible induction of <e1>diabetes</e1> by treatment of hypertension with <e2>indapamide</e2> (with four case reports)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4158	"RESULTS: After 4- to 14-month period of therapy with the combination of indapamide (2.5 mg/day) and <e1>fosinopril</e1> (10 mg/day) in three patients and 6-month period of monotherapy with indapamide (2.5 mg/day) in one patient, glucose levels of all patients increased and achieve criteria of <e2>diabetes</e2> diagnoses."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4159	"RESULTS: After 4- to 14-month period of therapy with the combination of <e1>indapamide</e1> (2.5 mg/day) and fosinopril (10 mg/day) in three patients and 6-month period of monotherapy with <e1>indapamide</e1> (2.5 mg/day) in one patient, glucose levels of all patients increased and achieve criteria of <e2>diabetes</e2> diagnoses."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4160	"RESULTS: After 4- to 14-month period of therapy with the combination of <e1>indapamide</e1> (2.5 mg/day) and fosinopril (10 mg/day) in three patients and 6-month period of monotherapy with <e1>indapamide</e1> (2.5 mg/day) in one patient, glucose levels of all patients increased and achieve criteria of <e2>diabetes</e2> diagnoses."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4161	"CONTEXT: Previous investigators have reported <e1>discrepancies between hematologic, marrow morphologic, and cytogenetic responses</e1> to <e2>imatinib mesylate</e2> among patients with chronic myeloid leukemia (CML)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4162	"Despite a hematologic response in all 3 patients, none of them achieved cytogenetic remission, and all progressed to <e1>blast crisis</e1> at 7 to 10 months of <e2>imatinib</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4163	"In addition to disease refractoriness, rare instances of disease progression from chronic phase to <e1>blast crisis</e1> during <e2>imatinib</e2> therapy have recently been anecdotally reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4164	"OBJECTIVES: To describe the clinicopathologic features of 3 patients with CML who rapidly progressed from chronic phase to <e1>blast crisis</e1> while taking <e2>imatinib</e2> and to perform a review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4165	"Our findings suggest that significant <e1>progression of marrow reticulin fibrosis</e1> during <e2>imatinib</e2> therapy can be an indicator for a return or progression of CML and, in some patients with CML, <e2>imatinib</e2> may promote cytogenetic clonal evolution, resulting in a poor response to treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4166	"Progression of chronic myeloid leukemia to <e1>blast crisis</e1> during treatment with <e2>imatinib mesylate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4167	"Easily reversible hypoxemia and <e1>hypotension</e1> induced by <e2>nimodipine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4168	"Easily reversible <e1>hypoxemia</e1> and hypotension induced by <e2>nimodipine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4169	"In this paper we report a case of <e1>nimodipine</e1> overdosage resulting in prolonged hypotension and <e2>hypoxemia</e2>, which was successfully treated with calcium gluconate."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4170	"In this paper we report a case of <e1>nimodipine</e1> overdosage resulting in <e2>prolonged hypotension</e2> and hypoxemia, which was successfully treated with calcium gluconate."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4171	"<e1>Refractory hypoglycemia</e1> from <e2>ciprofloxacin</e2> and glyburide interaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4172	"<e1>Refractory hypoglycemia</e1> from ciprofloxacin and <e2>glyburide</e2> interaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4173	"We present a case of a diabetic patient taking glyburide who was prescribed <e1>ciprofloxacin</e1> and developed <e2>prolonged hypoglycemia</e2>, which persisted for over 24 hours."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4174	"We present a case of a diabetic patient taking <e1>glyburide</e1> who was prescribed ciprofloxacin and developed <e2>prolonged hypoglycemia</e2>, which persisted for over 24 hours."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4175	"<e2>Aminophylline</e2> hypersensitivity apparently due to ethylenediamine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4176	"<e1>Aminophylline hypersensitivity</e1> apparently due to <e2>ethylenediamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4177	"We present a case of ethylenediamine-induced <e1>delayed hypersensitivity reaction</e1> in a 46-year-old woman who received parenteral <e2>aminophylline</e2> for an acute asthma exacerbation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4178	"We present a case of <e1>ethylenediamine</e1> -induced <e2>delayed hypersensitivity reaction</e2> in a 46-year-old woman who received parenteral aminophylline for an acute asthma exacerbation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4179	"<e1>L-asparaginase</e1> -induced pancreatitis is an uncommon but potential <e2>lethal complication</e2> of the treatment of leukemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4180	"<e1>L-asparaginase</e1> -induced <e2>pancreatitis</e2> is an uncommon but potential lethal complication of the treatment of leukemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4181	"<e1>L-asparaginase</e1> -induced <e2>severe necrotizing pancreatitis</e2> successfully treated with percutaneous drainage."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4182	"Most cases of <e1>pancreatitis</e1> associated with <e2>L-asparaginase</e2> toxicity are self-limiting and respond favorably to nasogastric decompression and intravenous hyperalimentation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4183	"<e1>Pancreatitis</e1> has been noted to be a complication in 2-16% of patients undergoing treatment with <e2>L-asparaginase</e2> for a variety of pediatric neoplasms."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4184	"We present a pediatric patient with leukemia and a severe, <e1>L-asparaginase</e1> -induced <e2>necrotizing pancreatitis</e2>, treated successfully with percutaneous drainage used to flush the infected necrotic parts."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4185	"<e1>Disulfiram</e1> -induced <e2>fulminant hepatic failure</e2> in an active duty soldier."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4186	"<e1>Fulminant hepatic failure</e1> is a rare complication of <e2>disulfiram</e2> treatment for alcoholism."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4187	"This case describes <e1>fulminant hepatic failure</e1> in a patient taking <e2>disulfiram</e2> with no previous liver disease and report of being compliant with alcohol abstinence."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4188	"<e1>Tiagabine</e1> overdose causes an <e2>unusual array of neurological symptoms</e2>, many similar to reported adverse effects during therapeutic use."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4189	"A case of <e1>sideroblastic anemia</e1> is presented in a patient with a left ventricular assist device drive-line infection who was receiving <e2>linezolid</e2>, an antibiotic used for serious infections with gram-positive organisms."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4190	"As <e1>linezolid</e1> has been shown to have <e2>hematologic side effects</e2>, blood count monitoring is recommended in patients receiving this drug for long-term therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4191	"<e1>Sideroblastic anemia</e1> due to <e2>linezolid</e2> in a patient with a left ventricular assist device."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4192	"In this report, two newborns with congenital heart anomalies demonstrated the <e1>harlequin color change</e1>, one whose skin findings showed a course related to the dose of systemic <e2>prostaglandin E1</e2>, suggesting a possible association."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4193	"The <e1>harlequin color change</e1> and association with <e2>prostaglandin E1</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4194	"<e1>Acute renal insufficiency</e1> is known to occur in patients who are taking <e2>ciprofloxacin</e2>, particularly the elderly."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4195	"<e1>Ciprofloxacin</e1> -induced <e2>renal insufficiency</e2> in cystic fibrosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4196	"Multiple mechanisms for <e1>ciprofloxacin</e1> -induced <e2>nephrotoxicity</e2> have been proposed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4197	"We report two young patients with cystic fibrosis who presented with <e1>acute renal insufficiency</e1> after 2-3 weeks of oral <e2>ciprofloxacin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4198	"Sensory neuropathy revealing <e1>necrotizing vasculitis</e1> during <e2>infliximab</e2> therapy for rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4199	"<e1>Sensory neuropathy</e1> revealing necrotizing vasculitis during <e2>infliximab</e2> therapy for rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4200	"We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom <e1>infliximab</e1> therapy was associated with peripheral neuropathy due to <e2>necrotizing vasculitis</e2> in one patient and to progression of preexisting mononeuritis multiplex in the other."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4201	"We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom <e1>infliximab</e1> therapy was associated with <e2>peripheral neuropathy</e2> due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4202	"We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom <e1>infliximab</e1> therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to <e2>progression of preexisting mononeuritis multiplex</e2> in the other."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4203	"<e1>Progressive anemia</e1> following combination therapy with <e2>interferon-alpha</e2> and interleukin-2 in a patient with metastatic renal cell carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4204	"<e1>Progressive anemia</e1> following combination therapy with interferon-alpha and <e2>interleukin-2</e2> in a patient with metastatic renal cell carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4205	"We report a case of <e1>severe anemia</e1>, which responded well to steroid therapy, in a patient receiving IL-2 plus <e2>IFN-alpha</e2> for metastatic renal cell carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4206	"We report a case of <e1>severe anemia</e1>, which responded well to steroid therapy, in a patient receiving <e2>IL-2</e2> plus IFN-alpha for metastatic renal cell carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4207	"An objective causality assessment indicated a probable relationship between <e1>clotting abnormality</e1> and <e2>warfarin</e2> administration, although the degree of elevation of the INR was unusual in the light of the daily <e2>warfarin</e2> dose and duration of its exposure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4208	"Based on the clinical status of the patient, it was suspected that several conditions contributed to the <e1>abnormal hypersensitivity</e1> to <e2>warfarin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4209	"Despite the low dosage of <e1>warfarin</e1>, international normalized ratio (INR) was markedly elevated from 1.15 to 11.28 for only 4 days, and <e2>bleeding symptoms</e2> concurrently developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4210	"In view of our experience in the present case, it should be stressed that close monitoring of coagulation capacity is necessary in critically ill patients in order to avoid <e1>fatal haemorrhage</e1> after initiating <e2>warfarin</e2> therapy regardless of the dosage."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4211	"Unusual <e1>hypersensitivity</e1> to <e2>warfarin</e2> in a critically ill patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4212	"We report an allogeneic bone marrow transplant recipient who developed <e1>CMV infection</e1> refractory to sequential therapy with ganciclovir, foscarnet, and <e2>cidofovir</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4213	"We report an allogeneic bone marrow transplant recipient who developed <e1>CMV infection</e1> refractory to sequential therapy with ganciclovir, <e2>foscarnet</e2>, and cidofovir."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4214	"We report an allogeneic bone marrow transplant recipient who developed <e1>CMV infection</e1> refractory to sequential therapy with <e2>ganciclovir</e2>, foscarnet, and cidofovir."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4215	"<e1>5-fluorouracil</e1> (5-FU)-associated <e2>peripheral neuropathy</e2> is an uncommon event."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4216	"5-fluorouracil (<e1>5-FU</e1>)-associated <e2>peripheral neuropathy</e2> is an uncommon event."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4217	"During analysis of 28 patients receiving <e1>CAP</e1> with concomitant radiation (XRT) for pancreatic cancer (resected or locally advanced), two patients developed signs and symptoms consistent with <e2>peripheral neuropathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4218	"Knowledge regarding potential adverse effects of <e1>CAP</e1> is paramount and dose modification is indicated with development of <e2>neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4219	"<e1>Neurologic symptoms</e1> resolved after stopping <e2>CAP</e2> for 4 weeks in Patient A, with no recurrence after reinitiating <e2>CAP</e2> alone at 2000 mg/m2."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4220	"<e1>Neurologic symptoms</e1> resolved after stopping <e2>CAP</e2> for 4 weeks in Patient A, with no recurrence after reinitiating <e2>CAP</e2> alone at 2000 mg/m2."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4221	"Patient A reported right leg weakness (<e1>foot drop</e1>) during week 4 of <e2>CAP-XRT</e2> (1600 mg/m2)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4222	"Patient A reported <e1>right leg weakness</e1> (foot drop) during week 4 of <e2>CAP-XRT</e2> (1600 mg/m2)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4223	"Patient B developed <e1>perioral and upper extremity paresthesias</e1> during the fourth cycle of <e2>CAP</e2> alone (2500 mg/m2)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4224	"<e1>Peripheral neuropathy</e1> associated with <e2>capecitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4225	"We conclude <e1>peripheral neuropathy</e1> with <e2>5-FU</e2> is rare."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4226	"<e1>Severe hypo-alpha-lipoproteinemia</e1> during treatment with <e2>rosiglitazone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4227	"We report three patients, all of whom had preexisting diabetic dyslipidemia, who showed a profound <e1>reduction in plasma HDL cholesterol and apolipoprotein AI levels</e1> soon after the initiation of <e2>rosiglitazone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4228	"Severe leukopenia associated with <e1>mild hepatotoxicity</e1> in an HIV carrier treated with <e2>nevirapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4229	"<e1>Severe leukopenia</e1> associated with mild hepatotoxicity in an HIV carrier treated with <e2>nevirapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4230	"We report an HIV-infected woman who developed mild <e1>leukopenia</e1> as the first sign of a <e2>nevirapine</e2> -related adverse event, which was followed by skin and hepatic toxicity associated with a more severe <e1>leukopenia</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4231	"We report an HIV-infected woman who developed mild <e1>leukopenia</e1> as the first sign of a <e2>nevirapine</e2> -related adverse event, which was followed by skin and hepatic toxicity associated with a more severe <e1>leukopenia</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4232	"We report an HIV-infected woman who developed mild leukopenia as the first sign of a <e1>nevirapine</e1> -related adverse event, which was followed by <e2>skin and hepatic toxicity</e2> associated with a more severe leukopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4233	"In all cases, drugs in addition to <e1>quetiapine</e1> were detected, but in cases #1 and #2, the cause of <e2>death</e2> was considered to be a <e1>quetiapine</e1> overdose and the other drugs were not considered to be contributory."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4234	"These cases were chosen for study because they were all <e1>deaths</e1> as a result of suicidal ingestion of drugs in which <e2>quetiapine</e2> was considered a significant factor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4235	"We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which <e1>suicidal overdose deaths</e1> were associated with <e2>quetiapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4236	"After approximately two weeks of <e1>sertraline</e1> treatment he noted an <e2>intense itching sensation</e2> in his scalp after eating a piece of chocolate cake."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4237	"<e1>Itch</e1> and skin rash from chocolate during <e2>fluoxetine</e2> and sertraline treatment: case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4238	"<e1>Itch</e1> and skin rash from chocolate during fluoxetine and <e2>sertraline</e2> treatment: case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4239	"Itch and <e1>skin rash</e1> from chocolate during <e2>fluoxetine</e2> and sertraline treatment: case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4240	"Itch and <e1>skin rash</e1> from chocolate during fluoxetine and <e2>sertraline</e2> treatment: case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4241	"<e1>Pulmonary lymphohistiocytic reactions</e1> temporally related to <e2>etanercept</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4242	"This report details the pulmonary pathologic findings in four patients with rheumatoid arthritis, who developed new onset of <e1>pulmonary signs and symptoms with alveolar infiltrates</e1> temporally related to the institution of <e2>etanercept</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4243	"<e1>Paradoxical cerebral cortical hyperexcitability</e1> following <e2>flupirtine</e2> overdose."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4244	"We report the case of a patient with <e1>increased cerebral cortical excitability</e1> following intoxication with <e2>flupirtine</e2>, a centrally acting analgesic and antispastic drug."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4245	"AIM: Report of a case of a woman patient who developed <e1>celiac disease</e1> after <e2>pegylated interferon alpha-2a</e2> and ribavirin use for chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4246	"AIM: Report of a case of a woman patient who developed <e1>celiac disease</e1> after pegylated interferon alpha-2a and <e2>ribavirin</e2> use for chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4247	"<e1>Celiac disease</e1> onset after <e2>pegylated interferon</e2> and ribavirin treatment of chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4248	"<e1>Celiac disease</e1> onset after pegylated interferon and <e2>ribavirin</e2> treatment of chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4249	"PATIENT AND METHOD: A 34-year-old woman with chronic hepatitis C, genotype 3, receiving <e1>pegylated interferon alpha-2a</e1> and ribavirin for 6 months, developed progressive malaise and <e2>anemia</e2> 6 months after the end of treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4250	"PATIENT AND METHOD: A 34-year-old woman with chronic hepatitis C, genotype 3, receiving pegylated interferon alpha-2a and <e1>ribavirin</e1> for 6 months, developed progressive malaise and <e2>anemia</e2> 6 months after the end of treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4251	"PATIENT AND METHOD: A 34-year-old woman with chronic hepatitis C, genotype 3, receiving <e1>pegylated interferon alpha-2a</e1> and ribavirin for 6 months, developed <e2>progressive malaise</e2> and anemia 6 months after the end of treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4252	"PATIENT AND METHOD: A 34-year-old woman with chronic hepatitis C, genotype 3, receiving pegylated interferon alpha-2a and <e1>ribavirin</e1> for 6 months, developed <e2>progressive malaise</e2> and anemia 6 months after the end of treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4253	"We present two cases of <e1>anaphylaxis</e1> under anaesthesia where return of spontaneous circulation was refractory to epinephrine, but occurred following the administration of the alpha-agonist <e2>metaraminol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4254	"In this article, we describe another case of subcutaneous changes following repeated <e1>glatiramer acetate</e1> injection, presented as <e2>localized panniculitis</e2> in the area around the injection sites, in a 46-year-old female patient who was treated with <e1>glatiramer acetate</e1> for 18 months."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4255	"In this article, we describe another case of subcutaneous changes following repeated <e1>glatiramer acetate</e1> injection, presented as <e2>localized panniculitis</e2> in the area around the injection sites, in a 46-year-old female patient who was treated with <e1>glatiramer acetate</e1> for 18 months."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4256	"In this article, we describe another case of <e1>subcutaneous changes</e1> following repeated <e2>glatiramer acetate</e2> injection, presented as localized panniculitis in the area around the injection sites, in a 46-year-old female patient who was treated with <e2>glatiramer acetate</e2> for 18 months."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4257	"Localized panniculitis and subsequent <e1>lipoatrophy</e1> with subcutaneous glatiramer acetate (<e2>Copaxone</e2>) injection for the treatment of multiple sclerosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4258	"Localized panniculitis and subsequent <e1>lipoatrophy</e1> with subcutaneous <e2>glatiramer acetate</e2> (Copaxone) injection for the treatment of multiple sclerosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4259	"<e1>Localized panniculitis</e1> and subsequent lipoatrophy with subcutaneous glatiramer acetate (<e2>Copaxone</e2>) injection for the treatment of multiple sclerosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4260	"<e1>Localized panniculitis</e1> and subsequent lipoatrophy with subcutaneous <e2>glatiramer acetate</e2> (Copaxone) injection for the treatment of multiple sclerosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4261	"In a postoperative patient with pre-existent myasthenia gravis, oral <e1>verapamil</e1> caused a marked <e2>exacerbation in myasthenic weakness</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4262	"In four patients, thrombosis occurred 2-45 days after severe <e1>hepatic veno-occlusive disease</e1> (HVOD) secondary to intensive chemotherapy containing <e2>busulfan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4263	"In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (<e1>HVOD</e1>) secondary to intensive chemotherapy containing <e2>busulfan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4264	"In four patients, <e1>thrombosis</e1> occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing <e2>busulfan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4265	"PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing <e1>busulfan</e1> and to be associated with <e2>HVOD</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4266	"<e1>PVT</e1> during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing <e2>busulfan</e2> and to be associated with HVOD."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4267	"Here, we describe a case of <e1>Vogt-Koyanagi-Harada disease</e1> occurring 4 months after the start of <e2>interferon</e2> alpha treatment, probably induced by the immunomodulatory effects of <e2>interferon</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4268	"Here, we describe a case of <e1>Vogt-Koyanagi-Harada disease</e1> occurring 4 months after the start of <e2>interferon alpha</e2> treatment, probably induced by the immunomodulatory effects of interferon."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4269	"Retinal abnormalities, including retinal hemorrhage and "cotton-wool" spots, often occur within the first 8 weeks in the course of <e2>interferon</e2> therapy in patients with chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4270	"<e1>Retinal abnormalities</e1>, including retinal hemorrhage and "cotton-wool" spots, often occur within the first 8 weeks in the course of <e2>interferon</e2> therapy in patients with chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4271	"Retinal abnormalities, including <e1>retinal hemorrhage</e1> and "cotton-wool" spots, often occur within the first 8 weeks in the course of <e2>interferon</e2> therapy in patients with chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4272	"<e1>Vogt-Koyanagi-Harada disease</e1> occurring during <e2>interferon alpha</e2> therapy for chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4273	"<e1>Acute hepatic failure</e1> is a rare and potentially lethal complication of <e2>propylthiouracil</e2> (PTU) use for hyperthyroidism."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4274	"<e1>Acute hepatic failure</e1> is a rare and potentially lethal complication of propylthiouracil (<e2>PTU</e2>) use for hyperthyroidism."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4275	"After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with <e1>PTU</e1> -induced <e2>fulminant hepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4276	"Successful treatment of hyperthyroidism with amiodarone in a patient with <e1>propylthiouracil</e1> -induced <e2>acute hepatic failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4277	"We present a 20-year-old woman with Basedow-Graves' disease who developed <e1>PTU</e1> -induced <e2>fulminant hepatitis</e2>, which progressed to acute hepatic failure with grade III hepatic encephalopathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4278	"<e1>Epstein-Barr virus-associated lymphoproliferative disorder</e1> in a patient with rheumatoid arthritis on <e2>methotrexate</e2> and rofecoxib: idiosyncratic reaction or pharmacogenetics?"
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4279	"<e1>Epstein-Barr virus-associated lymphoproliferative disorder</e1> in a patient with rheumatoid arthritis on methotrexate and <e2>rofecoxib</e2>: idiosyncratic reaction or pharmacogenetics?"
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4280	"<e1>Methotrexate</e1> (MTX) is a commonly used second line agent for RA, and there have been several recent reports of <e2>Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder</e2> in MTX-treated RA patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4281	"Methotrexate (<e1>MTX</e1>) is a commonly used second line agent for RA, and there have been several recent reports of <e2>Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder</e2> in <e1>MTX</e1> -treated RA patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4282	"Methotrexate (<e1>MTX</e1>) is a commonly used second line agent for RA, and there have been several recent reports of <e2>Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder</e2> in <e1>MTX</e1> -treated RA patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4283	"Previous studies have demonstrated the interaction of <e1>MTX</e1> and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including <e2>acute renal failure</e2>, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4284	"Previous studies have demonstrated the interaction of <e1>MTX</e1> and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, <e2>diarrhea</e2>, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4285	"Previous studies have demonstrated the interaction of <e1>MTX</e1> and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, <e2>elevated liver transaminases</e2>, jaundice, mucosal ulcerations, and pyrexia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4286	"Previous studies have demonstrated the interaction of <e1>MTX</e1> and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, <e2>jaundice</e2>, mucosal ulcerations, and pyrexia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4287	"Previous studies have demonstrated the interaction of <e1>MTX</e1> and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, <e2>mucosal ulcerations</e2>, and pyrexia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4288	"Previous studies have demonstrated the interaction of <e1>MTX</e1> and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, <e2>pancytopenia</e2>, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4289	"Previous studies have demonstrated the interaction of <e1>MTX</e1> and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and <e2>pyrexia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4290	"Previous studies have demonstrated the interaction of <e1>MTX</e1> and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, <e2>vomiting</e2>, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4291	"We hypothesize that decreased renal elimination of <e1>MTX</e1> induced by the COX-2 inhibitor resulted in enhanced hematopoietic toxicity and immunosuppression causing the <e2>EBV-associated lymphoproliferative disease</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4292	"We hypothesize that decreased renal elimination of <e1>MTX</e1> induced by the COX-2 inhibitor resulted in enhanced <e2>hematopoietic toxicity</e2> and immunosuppression causing the EBV-associated lymphoproliferative disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4293	"We hypothesize that decreased renal elimination of <e1>MTX</e1> induced by the COX-2 inhibitor resulted in enhanced hematopoietic toxicity and <e2>immunosuppression</e2> causing the EBV-associated lymphoproliferative disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4294	"OBSERVATIONS: We observed <e1>aggravation and spreading of a psoriatic plaque</e1> when treated topically with the toll-like receptor (TLR) 7 agonist <e2>imiquimod</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4295	"<e1>Psoriasis</e1> triggered by toll-like receptor 7 agonist <e2>imiquimod</e2> in the presence of dermal plasmacytoid dendritic cell precursors."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4296	"Since <e1>imiquimod</e1> induces <e2>large amounts of type I interferon production</e2> from TLR7-expressing plasmacytoid dendritic cell precursors (PDCs), the natural interferon-producing cells of the peripheral blood, we asked whether PDCs are present in psoriatic skin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4297	"The <e1>exacerbation of psoriasis</e1> was accompanied by a massive induction of lesional type I interferon activity, detected by MxA expression after <e2>imiquimod</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4298	"<e1>Vision declined</e1> after treatment with <e2>methylprednisolone</e2>, after which fundus examination became consistent with progressive outer retinal necrosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4299	"Allergic side effects of <e1>AZA</e1> are rare, and reported <e2>allergic skin eruptions</e2> from <e1>AZA</e1> are very limited in Japan."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4300	"Allergic side effects of <e1>AZA</e1> are rare, and reported <e2>allergic skin eruptions</e2> from <e1>AZA</e1> are very limited in Japan."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4301	"DLST is a good diagnostic tool for <e1>AZA</e1> <e2>allergy</e2>, especially for severe drug <e2>allergy</e2> cases."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4302	"<e1>Drug eruption</e1> caused by <e2>azathioprine</e2>: value of using the drug-induced lymphocytes stimulation test for diagnosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4303	"We report <e1>AZA</e1> -induced <e2>drug eruption</e2> that developed in two cases of systemic scleroderma with polymyositis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4304	"<e1>Tardive dyskinesia</e1> in 2 patients treated with <e2>ziprasidone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4305	"Two of our patients developed <e1>TD</e1> after 23 months and 34 months of <e2>ziprasidone</e2> monotherapy, respectively."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4306	"<e1>Ziprasidone</e1> is an atypical antipsychotic drug that is believed to have a low propensity for inducing <e2>extrapyramidal symptoms</e2>, including tardive dyskinesia (TD)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4307	"<e1>Ziprasidone</e1> is an atypical antipsychotic drug that is believed to have a low propensity for inducing extrapyramidal symptoms, including <e2>tardive dyskinesia</e2> (TD)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4308	"<e1>Ziprasidone</e1> is an atypical antipsychotic drug that is believed to have a low propensity for inducing extrapyramidal symptoms, including tardive dyskinesia (<e2>TD</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4309	"<e1>Asthenozoospermia</e1>: possible association with long-term exposure to an anti-epileptic drug of <e2>carbamazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4310	"The patient was found to have <e1>no motile sperm</e1> with a normal sperm count, while taking a dose of 400 mg/day of <e2>carbamazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4311	"<e1>Scrotal ulceration</e1> induced by all-trans <e2>retinoic acid</e2> in a patient with acute promyelocytic leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4312	"The <e1>ulcer</e1> did not respond to antibiotic treatment and healed shortly after withholding <e2>ATRA</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4313	"We report the development of <e1>scrotal ulcer</e1> in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with <e2>ATRA</e2> at a dose of 40 mg orally twice daily."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4314	"A case of <e1>clozapine</e1> -induced <e2>tonic-clonic seizures</e2> managed with valproate: implications for clinical care."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4315	"Following discontinuation of <e1>clozapine</e1>, she was rechallenged and again was observed to have <e2>seizures</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4316	"These findings suggest that <e1>clozapine</e1> -induced <e2>seizures</e2> can be successfully treated, that gradual dose titration can reduce the likelihood of further episodes of <e2>seizures</e2> and that concomitant use of a suitable mood stabilizer/anti-epileptic medication can improve the outcome of treatment-resistant schizophrenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4317	"We describe a case of <e1>clozapine</e1> -induced <e2>seizures</e2> in a patient with treatment-resistant schizophrenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4318	"CONCLUSIONS: Symptoms and pathologic changes of <e1>colitis</e1> are associated with exposure to <e2>rofecoxib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4319	"OBJECTIVES: To describe clinical and pathologic findings in patients noted to develop <e1>lower gastrointestinal symptoms</e1> when exposed to <e2>rofecoxib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4320	"RESULTS: Three patients who developed symptoms of inflammatory bowel disease (<e1>IBD</e1>) during <e2>rofecoxib</e2> exposure are described along with pathology findings."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4321	"RESULTS: Three patients who developed symptoms of <e1>inflammatory bowel disease</e1> (IBD) during <e2>rofecoxib</e2> exposure are described along with pathology findings."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4322	"After administration of Oxybutynin concomitantly with an increase in the dose of Dantrolene, she presented the clinical symptoms and laboratory finding of <e2>Carbamazepine</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4323	"After administration of Oxybutynin concomitantly with an increase in the dose of <e1>Dantrolene</e1>, she presented the clinical symptoms and laboratory finding of <e2>Carbamazepine intoxication</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4324	"After administration of <e1>Oxybutynin</e1> concomitantly with an increase in the dose of Dantrolene, she presented the clinical symptoms and laboratory finding of <e2>Carbamazepine intoxication</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4325	"<e2>Carbamazepine</e2> toxicity following Oxybutynin and Dantrolene administration: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4326	"<e1>Carbamazepine toxicity</e1> following Oxybutynin and <e2>Dantrolene</e2> administration: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4327	"<e1>Carbamazepine toxicity</e1> following <e2>Oxybutynin</e2> and Dantrolene administration: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4328	"OBJECTIVE: To report a case of <e2>Carbamazepine</e2> toxicity following the administration of Oxybutynin and Dantrolene."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4329	"OBJECTIVE: To report a case of <e1>Carbamazepine toxicity</e1> following the administration of Oxybutynin and <e2>Dantrolene</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4330	"OBJECTIVE: To report a case of <e1>Carbamazepine toxicity</e1> following the administration of <e2>Oxybutynin</e2> and Dantrolene."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4331	"To the best of our knowledge, this is the first reported patient with <e1>captopril</e1> -induced <e2>pemphigus</e2> in whom no new lesions developed after subsequent treatment with enalapril."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4332	"We report a case of drug-induced <e1>pemphigus</e1> caused by an angiotensin-converting enzyme inhibitor, <e2>captopril</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4333	"<e1>Neuropathy</e1> is a significant side effect of <e2>thalidomide</e2> therapy, which may limit its clinical use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4334	"<e1>Thalidomide</e1> <e2>neuropathy</e2> in childhood."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4335	"<e1>Thalidomide</e1> <e2>neuropathy</e2> is often associated with proximal weakness and may progress even after discontinuation of treatment, in the phenomenon of 'coasting'."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4336	"<e1>Thalidomide</e1> neuropathy is often associated with <e2>proximal weakness</e2> and may progress even after discontinuation of treatment, in the phenomenon of 'coasting'."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4337	"<e1>Thalidomide</e1> was withdrawn from world markets in 1961 following recognition of its <e2>teratogenic effects</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4338	"We report four cases of <e1>sensorimotor axonal neuropathy</e1> in children aged 10-15 years, treated with <e2>thalidomide</e2> for myxopapillary ependymoma, Crohn's disease and recurrent giant aphthous ulceration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4339	"<e1>Cerebral edema</e1> associated with <e2>Gliadel</e2> wafers: two case studies."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4340	"Following are two clinical case reports demonstrating profound <e1>cerebral edema</e1> associated with implantation of <e2>Gliadel</e2> wafers."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4341	"While the introduction of <e1>carmustine</e1> wafers (Gliadel wafers) into the tumor resection cavity has been shown to be a beneficial therapy for malignant glioma, it is recognized that clinically significant <e2>cerebral edema</e2> is a potential adverse effect."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4342	"While the introduction of carmustine wafers (<e1>Gliadel</e1> wafers) into the tumor resection cavity has been shown to be a beneficial therapy for malignant glioma, it is recognized that clinically significant <e2>cerebral edema</e2> is a potential adverse effect."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4343	"<e1>Cis-retinoic acid</e1> (RA) may further increase the risk of developing <e2>BMTN</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4344	"Cis-retinoic acid (<e1>RA</e1>) may further increase the risk of developing <e2>BMTN</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4345	"It is likely that <e1>RA</e1> contributed to the <e2>deterioration in renal function</e2> in these patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4346	"<e1>Retinoic acid</e1> may increase the risk of <e2>bone marrow transplant nephropathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4347	"The occurrence of <e1>BMTN</e1> in two children treated with <e2>RA</e2> in our unit is unlikely to be coincidental."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4348	"He developed a late <e1>secondary infection</e1> in some sites treated with <e2>imiquimod</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4349	"A 64-year-old man with schizophrenia developed <e1>myoclonic jerks</e1> when given higher doses of <e2>quetiapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4350	"<e1>Quetiapine</e1> -induced <e2>myoclonus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4351	"We report a case of <e1>myoclonus</e1> induced by <e2>quetiapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4352	"Treatment-related <e1>myelodysplastic syndrome</e1> after <e2>temozolomide</e2> for recurrent high-grade glioma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4353	"We report a 44-year-old woman with t-MDS (<e1>refractory anemia with excess blasts</e1>) following treatment of recurrent anaplastic astrocytoma with <e2>temozolomide</e2> (TMZ)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4354	"We report a 44-year-old woman with t-MDS (<e1>refractory anemia with excess blasts</e1>) following treatment of recurrent anaplastic astrocytoma with temozolomide (<e2>TMZ</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4355	"Typically, drug-induced <e1>neutropenia</e1> occurs in a patient receiving a semisynthetic <e2>penicillin</e2> for two weeks or more."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4356	"<e1>Livedo reticularis</e1> associated with <e2>interferon alpha</e2> therapy in two melanoma patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4357	"These cases highlight the occurrence of <e1>livedo reticularis</e1> as an uncommon side-effect of <e2>interferon alpha</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4358	"We report two patients who developed intense <e1>livedo reticularis</e1> clearly related to the administration of <e2>interferon alpha 2b</e2> as an adjuvant therapy for melanoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4359	"CONCLUSION: This rare case of <e1>PTU</e1> -induced <e2>ANCA-associated vasculitis</e2> manifested with ototoxicity in combination with systemic involvement."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4360	"CONCLUSION: This rare case of <e1>PTU</e1> -induced ANCA-associated vasculitis manifested with <e2>ototoxicity</e2> in combination with systemic involvement."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4361	"OBJECTIVE: To report the case of a young woman with Graves' disease in whom ototoxicity developed because of <e1>propylthiouracil</e1> (PTU)-induced <e2>antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4362	"OBJECTIVE: To report the case of a young woman with Graves' disease in whom ototoxicity developed because of propylthiouracil (<e1>PTU</e1>)-induced <e2>antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4363	"OBJECTIVE: To report the case of a young woman with Graves' disease in whom <e1>ototoxicity</e1> developed because of <e2>propylthiouracil</e2> (PTU)-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4364	"OBJECTIVE: To report the case of a young woman with Graves' disease in whom <e1>ototoxicity</e1> developed because of propylthiouracil (<e2>PTU</e2>)-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4365	"<e1>Propylthiouracil</e1> -induced sensorineural hearing loss associated with <e2>antineutrophil cytoplasmic antibodies</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4366	"<e1>Propylthiouracil</e1> -induced <e2>sensorineural hearing loss</e2> associated with antineutrophil cytoplasmic antibodies."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4367	"RESULTS: In a 22-year-old Thai woman with Graves' disease, tinnitus, <e1>hearing impairment in the left ear (with progression to the right ear)</e1>, and vertigo developed after 3 years of therapy with <e2>PTU</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4368	"RESULTS: In a 22-year-old Thai woman with Graves' disease, <e1>tinnitus</e1>, hearing impairment in the left ear (with progression to the right ear), and vertigo developed after 3 years of therapy with <e2>PTU</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4369	"RESULTS: In a 22-year-old Thai woman with Graves' disease, tinnitus, hearing impairment in the left ear (with progression to the right ear), and <e1>vertigo</e1> developed after 3 years of therapy with <e2>PTU</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4370	"The <e1>hearing impairment</e1> and tinnitus were gradually reduced after <e2>PTU</e2> withdrawal and corticosteroid and azathioprine treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4371	"The hearing impairment and <e1>tinnitus</e1> were gradually reduced after <e2>PTU</e2> withdrawal and corticosteroid and azathioprine treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4372	"Anti-tuberculous drugs had been stopped on the 2nd day of therapy due to development of <e1>optic neuritis</e1> secondary to <e2>ethambutol</e2> administration at another hospital."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4373	"During the anti-tuberculous therapy, <e1>visual loss</e1> can be related to <e2>ethambutol</e2> toxicity or the tuberculosis infection itself."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4374	"In addition, <e1>ethambutol</e1> rarely causes <e2>visual loss</e2> during the early period or when given at lower doses."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4375	"<e1>Flucloxacillin</e1> -induced <e2>aplastic anaemia</e2> and liver failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4376	"<e1>Flucloxacillin</e1> -induced aplastic anaemia and <e2>liver failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4377	"It is well-recognized that <e1>flucloxacillin</e1> may occasionally result in <e2>fatal hepatic injury</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4378	"We report the case of a 40-year-old woman who developed fulminant hepatic failure and <e1>aplastic anaemia</e1> following a course of oral <e2>flucloxacillin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4379	"We report the case of a 40-year-old woman who developed <e1>fulminant hepatic failure</e1> and aplastic anaemia following a course of oral <e2>flucloxacillin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4380	"Four days after intravenous <e1>Zoledronic acid</e1>, the patient presented to emergency room with complaints of carpopedal spasm and <e2>bronchospasm</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4381	"Four days after intravenous <e1>Zoledronic acid</e1>, the patient presented to emergency room with complaints of <e2>carpopedal spasm</e2> and bronchospasm."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4382	"<e1>Zoledronic acid</e1> -induced <e2>severe hypocalcaemia</e2> in a prostate cancer patient with extensive osteoblastic bone metastases."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4383	"This case report describes an adolescent with <e1>severe lupus erythematosus</e1> who received cyclophosphamide (<e2>CY</e2>) paired with taste (cod liver oil) and smell (rose perfume) as conditioned stimuli."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4384	"This case report describes an adolescent with <e1>severe lupus erythematosus</e1> who received <e2>cyclophosphamide</e2> (CY) paired with taste (cod liver oil) and smell (rose perfume) as conditioned stimuli."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4385	"<e1>Mucosal pigmentation</e1> after oral lichen planus treatment with topical <e2>tacrolimus</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4386	"The relation between <e1>tacrolimus</e1> treatment and staining was suggested by the appearance of <e2>pigmentation</e2> during topical <e1>tacrolimus</e1> treatment and its clinical disappearance when treatment was stopped."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4387	"The relation between <e1>tacrolimus</e1> treatment and staining was suggested by the appearance of <e2>pigmentation</e2> during topical <e1>tacrolimus</e1> treatment and its clinical disappearance when treatment was stopped."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4388	"We report the first histopathologically documented case of <e1>oral mucosa pigmentation</e1> after OLP treatment with topical <e2>tacrolimus</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4389	"Recently, some studies have also reported association between patients with juvenile rheumatoid arthritis (JRA) treated with <e1>Methotrexate</e1> (MTX) and <e2>malignant lymphoma</e2> developing."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4390	"Recently, some studies have also reported association between patients with juvenile rheumatoid arthritis (JRA) treated with Methotrexate (<e1>MTX</e1>) and <e2>malignant lymphoma</e2> developing."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4391	"<e1>Risperidone</e1> is a frequently used member of a new class of atypical antipsychotics-the serotonin-dopamine antagonists (SDAs)-due to its comparatively high efficacy and low D2/5HT2 binding ratio, which results in a low incidence of extrapyramidal side effects including <e2>tardive dyskinesia</e2> (TD)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4392	"<e1>Risperidone</e1> is a frequently used member of a new class of atypical antipsychotics-the serotonin-dopamine antagonists (SDAs)-due to its comparatively high efficacy and low D2/5HT2 binding ratio, which results in a low incidence of extrapyramidal side effects including tardive dyskinesia (<e2>TD</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4393	"<e1>Risperidone</e1> withdrawal-related <e2>respiratory dyskinesia</e2>: a case diagnosed by spirography and fibroscopy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4394	"The authors present an elderly patient with mixed dementia who developed TD at multiple sites, (including respiratory dyskinesia [RD], <e1>limb dyskinesia</e1>, and orofacial dyskinesia) following abrupt withdrawal of <e2>risperidone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4395	"The authors present an elderly patient with mixed dementia who developed TD at multiple sites, (including respiratory dyskinesia [RD], limb dyskinesia, and <e1>orofacial dyskinesia</e1>) following abrupt withdrawal of <e2>risperidone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4396	"The authors present an elderly patient with mixed dementia who developed TD at multiple sites, (including respiratory dyskinesia [<e1>RD</e1>], limb dyskinesia, and orofacial dyskinesia) following abrupt withdrawal of <e2>risperidone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4397	"The authors present an elderly patient with mixed dementia who developed TD at multiple sites, (including <e1>respiratory dyskinesia</e1> [RD], limb dyskinesia, and orofacial dyskinesia) following abrupt withdrawal of <e2>risperidone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4398	"The authors present an elderly patient with mixed dementia who developed <e1>TD</e1> at multiple sites, (including respiratory dyskinesia [RD], limb dyskinesia, and orofacial dyskinesia) following abrupt withdrawal of <e2>risperidone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4399	"Therefore, clinicians should pay close attention to possible onset of <e1>RD</e1> in patients with multiple risk factors for TD, even when <e2>SDA</e2> therapy is used."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4400	"In this study, we report on three individual patients who received <e1>BTX-B</e1> and who subsequently developed <e2>parasympathetic dysfunction of the visual system</e2> after injections of <e1>BTX-B</e1> at remote sites."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4401	"In this study, we report on three individual patients who received <e1>BTX-B</e1> and who subsequently developed <e2>parasympathetic dysfunction of the visual system</e2> after injections of <e1>BTX-B</e1> at remote sites."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4402	"To date, there have been few reports of <e1>visual disturbances</e1> associated with <e2>BTX-B</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4403	"Visual system side effects caused by <e1>parasympathetic dysfunction</e1> after <e2>botulinum toxin type B</e2> injections."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4404	"<e1>Visual system side effects</e1> caused by parasympathetic dysfunction after <e2>botulinum toxin type B</e2> injections."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4405	"<e1>Enalapril</e1> -induced <e2>anemia</e2> in two kidney transplant recipients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4406	"Two renal transplant patients developed <e1>anemia</e1> during treatment of hypertension with <e2>enalapril</e2> medication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4407	"A 74-year-old hypercholestrerolaemic woman taking <e1>cerivastatin</e1> (0.15 mg/day) for 22 days complained of general muscle weakness and <e2>muscle pain</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4408	"A 74-year-old hypercholestrerolaemic woman taking <e1>cerivastatin</e1> (0.15 mg/day) for 22 days complained of general <e2>muscle weakness</e2> and muscle pain."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4409	"Clearance rates of <e1>cerivastatin</e1> metabolites in a patient with <e1>cerivastatin</e1> -induced <e2>rhabdomyolysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4410	"We report on a patient who developed <e1>acute rhabdomyolysis</e1> after taking <e2>cerivastatin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4411	"<e1>Carboplatin</e1> <e2>hypersensitivity</e2> induced by low-dose paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4412	"Carboplatin <e1>hypersensitivity</e1> induced by low-dose paclitaxel/<e2>carboplatin</e2> in multiple platinum-treated patients with recurrent ovarian cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4413	"Carboplatin <e1>hypersensitivity</e1> induced by low-dose <e2>paclitaxel</e2>/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4414	"However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and <e1>apnea</e1>, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of <e2>CBDCA</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4415	"However, one patient exhibited severe hypersensitivity reactions including <e1>cardiac arrest</e1> and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of <e2>CBDCA</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4416	"However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed <e1>eruptions</e1>, hypotension, and tachycardia soon after administration of <e2>CBDCA</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4417	"However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, <e1>hypotension</e1>, and tachycardia soon after administration of <e2>CBDCA</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4418	"However, one patient exhibited <e1>severe hypersensitivity reactions</e1> including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of <e2>CBDCA</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4419	"However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and <e1>tachycardia</e1> soon after administration of <e2>CBDCA</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4420	"Our report suggested that <e1>CBDCA</e1> <e2>hypersensitivity</e2> was correlated with the total dose of previously administered platinum agents and that <e1>CBDCA</e1> should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because <e1>CBDCA</e1> <e2>hypersensitivity</e2> can occur even with low-dose <e1>CBDCA</e1> administration."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4421	"Our report suggested that <e1>CBDCA</e1> <e2>hypersensitivity</e2> was correlated with the total dose of previously administered platinum agents and that <e1>CBDCA</e1> should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because <e1>CBDCA</e1> <e2>hypersensitivity</e2> can occur even with low-dose <e1>CBDCA</e1> administration."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4422	"Our report suggested that <e1>CBDCA</e1> <e2>hypersensitivity</e2> was correlated with the total dose of previously administered platinum agents and that <e1>CBDCA</e1> should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because <e1>CBDCA</e1> <e2>hypersensitivity</e2> can occur even with low-dose <e1>CBDCA</e1> administration."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4423	"Our report suggested that <e1>CBDCA</e1> <e2>hypersensitivity</e2> was correlated with the total dose of previously administered platinum agents and that <e1>CBDCA</e1> should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because <e1>CBDCA</e1> <e2>hypersensitivity</e2> can occur even with low-dose <e1>CBDCA</e1> administration."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4424	"We report five cases of <e1>carboplatin</e1> (CBDCA) <e2>hypersensitivity</e2> after weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4425	"We report five cases of carboplatin (<e1>CBDCA</e1>) <e2>hypersensitivity</e2> after weekly low-dose paclitaxel (60 mg/m2)/<e1>CBDCA</e1> (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4426	"We report five cases of carboplatin (CBDCA) <e1>hypersensitivity</e1> after weekly low-dose <e2>paclitaxel</e2> (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4427	"TREATMENT/OUTCOME: Standard anti-tuberculosis therapy was administered but was complicated by interaction with <e1>cyclosporine</e1> and drug-induced <e2>cholestasis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4428	"Chronic <e1>fentanyl</e1> application induces <e2>adrenocortical insufficiency</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4429	"We report a case of a 64-year-old man with secondary <e1>adrenocortical insufficiency</e1> who has been on a chronic transdermal <e2>fentanyl</e2> treatment because of sciatic pain syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4430	"<e1>Fluphenazine</e1> -induced <e2>neuroleptic malignant syndrome</e2> in a schizophrenic patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4431	"OBJECTIVE: To report a case of <e1>neuroleptic malignant syndrome</e1> (NMS) associated with <e2>fluphenazine</e2> in a schizophrenic patient and review the literature related to this condition."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4432	"OBJECTIVE: To report a case of neuroleptic malignant syndrome (<e1>NMS</e1>) associated with <e2>fluphenazine</e2> in a schizophrenic patient and review the literature related to this condition."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4433	"Intraventricular <e1>vancomycin</e1> -induced <e2>cerebrospinal fluid eosinophilia</e2>: report of two patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4434	"We propose a mechanism of <e1>vancomycin</e1> -induced mast cell degranulation and subsequent release of eosinophil chemotactic factor as a cause of <e2>CSFE</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4435	"We report two cases of <e1>cerebrospinal fluid eosinophilia</e1> (CSFE) secondary to the intraventricular administration of <e2>vancomycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4436	"We report two cases of cerebrospinal fluid eosinophilia (<e1>CSFE</e1>) secondary to the intraventricular administration of <e2>vancomycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4437	"Successful recovery from <e1>interstitial pneumonitis</e1>, induced by <e2>bicalutamide</e2> and leuprorelin acetate given as treatment for prostate cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4438	"Successful recovery from <e1>interstitial pneumonitis</e1>, induced by bicalutamide and <e2>leuprorelin acetate</e2> given as treatment for prostate cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4439	"We report a case of <e1>interstitial pneumonitis</e1> induced by <e2>bicalutamide</e2> and/or leuprorelin acetate given as therapy for prostate cancer, in which the pneumonitis was successfully managed by steroid treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4440	"We report a case of <e1>interstitial pneumonitis</e1> induced by bicalutamide and/or <e2>leuprorelin acetate</e2> given as therapy for prostate cancer, in which the pneumonitis was successfully managed by steroid treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4441	"CONCLUSIONS: In these 3 cases, the unique positive ocular finding was <e1>corneal endothelial deposits</e1>, which may be related to the use of <e2>rifabutin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4442	"<e1>Corneal endothelial deposits</e1> associated with <e2>rifabutin</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4443	"PURPOSE: The aim of this study was to report on the possible development of <e1>corneal endothelial deposits</e1> resulting from the use of <e2>rifabutin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4444	"RESULTS: All cases developed <e1>corneal endothelial deposits</e1> after previous use of <e2>rifabutin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4445	"CASE: A <e1>malignant mixed mesodermal tumor</e1> was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking <e2>raloxifene</e2> for osteoporosis prevention."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4446	"CONCLUSION: There may be an association between <e1>raloxifene</e1> and the development of <e2>malignant mixed mesodermal tumor</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4447	"<e1>Malignant mixed mullerian tumor of the uterus</e1> in a patient taking <e2>raloxifene</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4448	"We report a case of a women in whom a <e1>malignant mixed mesodermal tumor</e1> was diagnosed while she was taking <e2>raloxifene</e2>, which is also a selective estrogen receptor modulator."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4449	"Herein we report four patients who underwent liver transplantation and developed <e1>neutropenia</e1> while receiving <e2>MMF</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4450	"<e1>Mycophenolate mofetil</e1> -induced <e2>neutropenia</e2> in liver transplantation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4451	"The mean time from starting <e1>MMF</e1> to the development of <e2>neutropenia</e2> was 4 months."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4452	"The side effects of <e1>MMF</e1>, such as <e2>bone marrow toxicity</e2>, have been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4453	"A previous review described data on 15 patients who experienced <e1>acute hemoglobinemia</e1> or hemoglobinuria following <e2>anti-D IGIV</e2> administration for ITP or secondary thrombocytopenia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4454	"A previous review described data on 15 patients who experienced acute hemoglobinemia or <e1>hemoglobinuria</e1> following <e2>anti-D IGIV</e2> administration for ITP or secondary thrombocytopenia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4455	"Disseminated intravascular coagulation associated with <e1>acute hemoglobinemia</e1> or hemoglobinuria following <e2>Rh(0)(D) immune globulin</e2> intravenous administration for immune thrombocytopenic purpura."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4456	"<e1>Disseminated intravascular coagulation</e1> associated with acute hemoglobinemia or hemoglobinuria following <e2>Rh(0)(D) immune globulin</e2> intravenous administration for immune thrombocytopenic purpura."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4457	"Disseminated intravascular coagulation associated with acute hemoglobinemia or <e1>hemoglobinuria</e1> following <e2>Rh(0)(D) immune globulin</e2> intravenous administration for immune thrombocytopenic purpura."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4458	"That review suggested that patients receiving <e1>anti-D IGIV</e1> be monitored for those and other potential complications of hemoglobinemia, particularly disseminated intravascular coagulation (<e2>DIC</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4459	"That review suggested that patients receiving <e1>anti-D IGIV</e1> be monitored for those and other potential complications of hemoglobinemia, particularly <e2>disseminated intravascular coagulation</e2> (DIC)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4460	"That review suggested that patients receiving <e1>anti-D IGIV</e1> be monitored for those and other potential complications of <e2>hemoglobinemia</e2>, particularly disseminated intravascular coagulation (DIC)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4461	"The purpose of this review is to increase awareness among physicians and other health care professionals that <e1>DIC</e1> may be a rare but potentially severe complication of <e2>anti-D IGIV</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4462	"This review presents the first case series of DIC associated with <e1>acute hemoglobinemia</e1> or hemoglobinuria following <e2>anti-D IGIV</e2> administration for ITP."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4463	"This review presents the first case series of <e1>DIC</e1> associated with acute hemoglobinemia or hemoglobinuria following <e2>anti-D IGIV</e2> administration for ITP."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4464	"This review presents the first case series of DIC associated with acute hemoglobinemia or <e1>hemoglobinuria</e1> following <e2>anti-D IGIV</e2> administration for ITP."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4465	"After the second <e1>infliximab</e1> infusion, he was found to have a <e2>severe transient neutropenia</e2> (0.5 x 10(9)/L)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4466	"Drug-induced <e1>agranulocytosis</e1> during treatment with <e2>infliximab</e2> in enteropathic spondyloarthropathy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4467	"These data indicated that <e1>infliximab</e1> possibly triggered production of granulocyte and neutrophil autoantibodies with resultant <e2>autoimmune agranulocytosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4468	"These data indicated that <e1>infliximab</e1> possibly triggered <e2>production of granulocyte and neutrophil autoantibodies</e2> with resultant autoimmune agranulocytosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4469	"However, peripheral neuropathy and <e1>bone marrow depression</e1> led to <e2>linezolid</e2> withdrawal in seven patients, and neuropathy may not be fully reversible in all patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4470	"However, peripheral <e1>neuropathy</e1> and bone marrow depression led to <e2>linezolid</e2> withdrawal in seven patients, and <e1>neuropathy</e1> may not be fully reversible in all patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4471	"However, <e1>peripheral neuropathy</e1> and bone marrow depression led to <e2>linezolid</e2> withdrawal in seven patients, and neuropathy may not be fully reversible in all patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4472	"Six patients developed peripheral neuropathy and five patients <e1>bone marrow depression</e1>, blood transfusions were given to three patients and in all five patients bone marrow function normalized after cessation of <e2>linezolid</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4473	"Six patients developed <e1>peripheral neuropathy</e1> and five patients bone marrow depression, blood transfusions were given to three patients and in all five patients bone marrow function normalized after cessation of <e2>linezolid</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4474	"A case of <e1>high-grade endometrial stromal sarcoma</e1>, confined into an intrauterine polypoid growth, in a woman with a history of breast cancer who was treated with adjuvant <e2>tamoxifen</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4475	"A case of high-grade endometrial stromal sarcoma, confined into an <e1>intrauterine polypoid growth</e1>, in a woman with a history of breast cancer who was treated with adjuvant <e2>tamoxifen</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4476	"<e1>High-grade endometrial stromal sarcoma</e1> after <e2>tamoxifen</e2> therapy for breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4477	"In deciding if <e1>tamoxifen</e1> therapy is warranted, all potentially life-threatening adverse events associated with <e1>tamoxifen</e1> should be considered, including <e2>endometrial adenocarcinoma</e2> or uterine sarcoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4478	"In deciding if <e1>tamoxifen</e1> therapy is warranted, all potentially life-threatening adverse events associated with <e1>tamoxifen</e1> should be considered, including <e2>endometrial adenocarcinoma</e2> or uterine sarcoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4479	"In deciding if <e1>tamoxifen</e1> therapy is warranted, all potentially life-threatening adverse events associated with <e1>tamoxifen</e1> should be considered, including endometrial adenocarcinoma or <e2>uterine sarcoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4480	"In deciding if <e1>tamoxifen</e1> therapy is warranted, all potentially life-threatening adverse events associated with <e1>tamoxifen</e1> should be considered, including endometrial adenocarcinoma or <e2>uterine sarcoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4481	"After only the third dose of <e1>pentamidine</e1>, it was noted that the patient's <e2>heart rate had decreased</e2> to 48 beats/minute."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4482	"Although various manifestations of <e1>pentamidine</e1> -induced <e2>cardiotoxicity</e2> have been reported, to our knowledge, second-degree heart block associated with this agent has not been described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4483	"Although various manifestations of <e1>pentamidine</e1> -induced cardiotoxicity have been reported, to our knowledge, <e2>second-degree heart block</e2> associated with this agent has not been described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4484	"Clinicians should be vigilant when monitoring for <e1>cardiotoxicity</e1> in patients receiving <e2>pentamidine</e2> throughout the duration of therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4485	"Early-onset <e1>pentamidine</e1> -associated <e2>second-degree heart block</e2> and sinus bradycardia: case report and review of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4486	"Early-onset <e1>pentamidine</e1> -associated second-degree heart block and <e2>sinus bradycardia</e2>: case report and review of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4487	"<e1>Falling backward</e1> in two elderly patients taking <e2>bupropion</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4488	"RESULTS: Both patients experienced a previously unreported side effect--<e1>falling backward</e1> --associated with <e2>bupropion</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4489	"<e1>Ophthalmologic and neurologic findings</e1> in two children exposed to <e2>vigabatrin</e2> in utero."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4490	"The knowledge concerning <e1>VGB</e1> -associated <e2>visual dysfunction</e2> in pediatric patients, particularly in those who have been exposed to <e1>VGB</e1> in utero is limited."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4491	"<e1>Vigabatrin</e1> -induced <e2>visual field defects</e2> are at present the most important safety issue in the use of the drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4492	"We explored <e1>ophthalmic and neurologic findings</e1> in two children who have been exposed prenatally to <e2>VGB</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4493	"BACKGROUND: Interferon (<e1>IFN</e1>)-associated retinopathy is typically characterized by retinal hemorrhages and <e2>cotton wool spots</e2> at the posterior fundus, but visual function is usually maintained."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4494	"BACKGROUND: <e1>Interferon</e1> (IFN)-associated retinopathy is typically characterized by retinal hemorrhages and <e2>cotton wool spots</e2> at the posterior fundus, but visual function is usually maintained."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4495	"BACKGROUND: Interferon (<e1>IFN</e1>)-associated retinopathy is typically characterized by <e2>retinal hemorrhages</e2> and cotton wool spots at the posterior fundus, but visual function is usually maintained."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4496	"BACKGROUND: <e1>Interferon</e1> (IFN)-associated retinopathy is typically characterized by <e2>retinal hemorrhages</e2> and cotton wool spots at the posterior fundus, but visual function is usually maintained."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4497	"BACKGROUND: Interferon (<e1>IFN</e1>)-associated <e2>retinopathy</e2> is typically characterized by retinal hemorrhages and cotton wool spots at the posterior fundus, but visual function is usually maintained."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4498	"BACKGROUND: <e1>Interferon</e1> (IFN)-associated <e2>retinopathy</e2> is typically characterized by retinal hemorrhages and cotton wool spots at the posterior fundus, but visual function is usually maintained."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4499	"Clinical course of <e1>macular edema</e1> in two cases of <e2>interferon</e2> -associated retinopathy observed by optical coherence tomography."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4500	"Clinical course of macular edema in two cases of <e1>interferon</e1> -associated <e2>retinopathy</e2> observed by optical coherence tomography."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4501	"CONCLUSION: During and after <e1>IFN</e1> therapy, OCT is a useful examination technique for revealing macular edema in patients who have <e2>decreased vision</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4502	"CONCLUSION: During and after <e1>IFN</e1> therapy, OCT is a useful examination technique for revealing <e2>macular edema</e2> in patients who have decreased vision."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4503	"Ophthalmologists should be aware of the ocular side effects of <e1>IFN</e1> therapy and carefully monitor patients for the possible occurrence of <e2>hypoalbuminemia</e2> and thrombocytopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4504	"Ophthalmologists should be aware of the <e1>ocular side effects</e1> of <e2>IFN</e2> therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and thrombocytopenia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4505	"Ophthalmologists should be aware of the ocular side effects of <e1>IFN</e1> therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and <e2>thrombocytopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4506	"The former patient had complained once that his <e1>visual acuity had decreased</e1> after the termination of <e2>IFN</e2> therapy, and the latter patient complained twice during <e2>IFN</e2> therapy that his <e1>visual acuity had decreased</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4507	"The former patient had complained once that his <e1>visual acuity had decreased</e1> after the termination of <e2>IFN</e2> therapy, and the latter patient complained twice during <e2>IFN</e2> therapy that his <e1>visual acuity had decreased</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4508	"With the use of optical coherence tomography (OCT), two patients with <e1>IFN</e1> -associated retinopathy who had developed <e2>macular edema</e2> and reduced visual acuity during the clinical course of <e1>IFN</e1> therapy were observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4509	"With the use of optical coherence tomography (OCT), two patients with <e1>IFN</e1> -associated retinopathy who had developed <e2>macular edema</e2> and reduced visual acuity during the clinical course of <e1>IFN</e1> therapy were observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4510	"With the use of optical coherence tomography (OCT), two patients with <e1>IFN</e1> -associated retinopathy who had developed macular edema and <e2>reduced visual acuity</e2> during the clinical course of <e1>IFN</e1> therapy were observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4511	"With the use of optical coherence tomography (OCT), two patients with <e1>IFN</e1> -associated retinopathy who had developed macular edema and <e2>reduced visual acuity</e2> during the clinical course of <e1>IFN</e1> therapy were observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4512	"With the use of optical coherence tomography (OCT), two patients with <e1>IFN</e1> -associated <e2>retinopathy</e2> who had developed macular edema and reduced visual acuity during the clinical course of <e1>IFN</e1> therapy were observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4513	"With the use of optical coherence tomography (OCT), two patients with <e1>IFN</e1> -associated <e2>retinopathy</e2> who had developed macular edema and reduced visual acuity during the clinical course of <e1>IFN</e1> therapy were observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4514	"Late development of <e1>diabetes mellitus</e1> after <e2>interferon-alfa</e2> and ribavirin therapy for chronic hepatitis C: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4515	"Late development of <e1>diabetes mellitus</e1> after interferon-alfa and <e2>ribavirin</e2> therapy for chronic hepatitis C: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4516	"OBJECTIVE: To report the late development of <e1>immune-mediated diabetes mellitus</e1> after completion of <e2>alfa-interferon</e2> therapy for hepatitis C in an Asian patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4517	"<e1>Cutaneous necrosis</e1> after injection of polyethylene glycol-modified <e2>interferon alfa</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4518	"<e1>Cutaneous necrosis</e1> as a result of <e2>interferon alfa</e2> is an infrequent complication with unknown pathogenesis, in which a cutaneous local immune-mediated inflammatory process might be involved."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4519	"We report 5 patients (3 patients with chronic hepatitis C treated with <e1>pegylated interferon alfa-2b</e1> in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed <e2>local cutaneous reactions</e2> at sites of injection after the administration of weekly subcutaneous injections of <e1>pegylated interferon alfa-2b</e1> at different doses."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4520	"We report 5 patients (3 patients with chronic hepatitis C treated with <e1>pegylated interferon alfa-2b</e1> in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed <e2>local cutaneous reactions</e2> at sites of injection after the administration of weekly subcutaneous injections of <e1>pegylated interferon alfa-2b</e1> at different doses."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4521	"We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral <e1>ribavirin</e1> and two patients with chronic myelocytic leukemia) who developed <e2>local cutaneous reactions</e2> at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4522	"We review the literature on previously reported cases of <e1>cutaneous necrosis</e1> after injection of standard <e2>interferon alfa</e2> or pegylated <e2>interferon alfa</e2> -2b and discuss the different pathophysiologic mechanisms that might be involved."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4523	"We review the literature on previously reported cases of <e1>cutaneous necrosis</e1> after injection of standard interferon alfa or <e2>pegylated interferon alfa-2b</e2> and discuss the different pathophysiologic mechanisms that might be involved."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4524	"Potential mechanisms involved in the occurrence of <e1>ischemic colitis</e1> in patients receiving <e2>tegaserod</e2> are also discussed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4525	"<e1>Tegaserod</e1> -associated <e2>ischemic colitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4526	"We describe the development of ischemic colitis in a woman who was treated with <e1>tegaserod</e1> and review the relationship among ischemic colitis, <e1>tegaserod</e1> use, and <e2>irritable bowel syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4527	"We describe the development of ischemic colitis in a woman who was treated with <e1>tegaserod</e1> and review the relationship among ischemic colitis, <e1>tegaserod</e1> use, and <e2>irritable bowel syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4528	"We describe the development of <e1>ischemic colitis</e1> in a woman who was treated with <e2>tegaserod</e2> and review the relationship among <e1>ischemic colitis</e1>, <e2>tegaserod</e2> use, and irritable bowel syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4529	"We describe the development of <e1>ischemic colitis</e1> in a woman who was treated with <e2>tegaserod</e2> and review the relationship among <e1>ischemic colitis</e1>, <e2>tegaserod</e2> use, and irritable bowel syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4530	"We describe the development of <e1>ischemic colitis</e1> in a woman who was treated with <e2>tegaserod</e2> and review the relationship among <e1>ischemic colitis</e1>, <e2>tegaserod</e2> use, and irritable bowel syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4531	"We describe the development of <e1>ischemic colitis</e1> in a woman who was treated with <e2>tegaserod</e2> and review the relationship among <e1>ischemic colitis</e1>, <e2>tegaserod</e2> use, and irritable bowel syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4532	"A 57-year-old man developed <e1>chronic, watery diarrhea</e1> four weeks after Helicobacter pylori eradication therapy including <e2>lansoprazole</e2> followed by <e2>lansoprazole</e2> monotherapy for gastroesophageal reflux disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4533	"A 57-year-old man developed <e1>chronic, watery diarrhea</e1> four weeks after Helicobacter pylori eradication therapy including <e2>lansoprazole</e2> followed by <e2>lansoprazole</e2> monotherapy for gastroesophageal reflux disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4534	"<e1>Lansoprazole</e1> -associated <e2>collagenous colitis</e2>: a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4535	"The reported case represents an unusual association between medication with the proton pump inhibitor <e1>lansoprazole</e1> and the development of <e2>collagenous colitis</e2> suggesting the importance of evaluation of drug use in patients with microscopic colitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4536	"46-year-old woman developed <e1>painful ulcers</e1> over her lower abdomen in the form of reticulate erythema after injecting <e2>interferon beta-1b</e2> subcutaneously for multiple sclerosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4537	"46-year-old woman developed painful ulcers over her lower abdomen in the form of <e1>reticulate erythema</e1> after injecting <e2>interferon beta-1b</e2> subcutaneously for multiple sclerosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4538	"<e1>Abdominal wall ulceration</e1> and mucinosis secondary to <e2>recombinant human interferon-beta-1b</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4539	"Abdominal wall ulceration and <e1>mucinosis</e1> secondary to <e2>recombinant human interferon-beta-1b</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4540	"<e1>Itraconazole</e1> -related increased <e2>vincristine neurotoxicity</e2>: case report and review of literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4541	"Itraconazole-related increased <e2>vincristine</e2> neurotoxicity: case report and review of literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4542	"Nineteen cases of unusual enhanced vincristine <e1>neurotoxicity</e1> related to <e2>itraconazole</e2> have been reported in children."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4543	"Nineteen cases of unusual enhanced <e1>vincristine</e1> <e2>neurotoxicity</e2> related to itraconazole have been reported in children."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4544	"Ten days after <e1>itraconazole</e1> was started, he developed paralytic ileus, neurogenic bladder, mild left ptosis, and <e2>absence of deep reflexes</e2>, with severe paralysis of the lower extremities and mild weakness of the upper extremities."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4545	"Ten days after <e1>itraconazole</e1> was started, he developed paralytic ileus, neurogenic bladder, <e2>mild left ptosis</e2>, and absence of deep reflexes, with severe paralysis of the lower extremities and mild weakness of the upper extremities."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4546	"Ten days after <e1>itraconazole</e1> was started, he developed paralytic ileus, neurogenic bladder, mild left ptosis, and absence of deep reflexes, with severe paralysis of the lower extremities and <e2>mild weakness of the upper extremities</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4547	"Ten days after <e1>itraconazole</e1> was started, he developed paralytic ileus, <e2>neurogenic bladder</e2>, mild left ptosis, and absence of deep reflexes, with severe paralysis of the lower extremities and mild weakness of the upper extremities."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4548	"Ten days after <e1>itraconazole</e1> was started, he developed <e2>paralytic ileus</e2>, neurogenic bladder, mild left ptosis, and absence of deep reflexes, with severe paralysis of the lower extremities and mild weakness of the upper extremities."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4549	"Ten days after <e1>itraconazole</e1> was started, he developed paralytic ileus, neurogenic bladder, mild left ptosis, and absence of deep reflexes, with <e2>severe paralysis of the lower extremities</e2> and mild weakness of the upper extremities."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4550	"The authors suggest that in the absence of any proven benefit of <e1>itraconazole</e1> prophylaxis, and given the interaction of this drug with vincristine leading to severe and even potentially <e2>fatal toxicities</e2>, the combination use of these drugs should be avoided."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4551	"The authors suggest that in the absence of any proven benefit of itraconazole prophylaxis, and given the interaction of this drug with <e1>vincristine</e1> leading to severe and even potentially <e2>fatal toxicities</e2>, the combination use of these drugs should be avoided."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4552	"CASE REPORT: We report a case of <e1>intracerebral hemorrhage</e1> occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting <e2>pseudoephedrine</e2> daily for one year."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4553	"Only one report links <e1>phenylpropanolamine</e1> consumption to an <e2>intracerebral hemorrhage</e2> in a patient with an AVM."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4554	"<e1>Pseudoephedrine</e1> -induced hemorrhage associated with a <e2>cerebral vascular malformation</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4555	"<e1>Pseudoephedrine</e1> -induced <e2>hemorrhage</e2> associated with a cerebral vascular malformation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4556	"Since 1979, over 30 published case reports have documented the relationship between <e1>phenylpropanolamine</e1> and <e2>stroke</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4557	"This is a case of <e1>pseudoephedrine</e1> -induced <e2>intracerebral hemorrhage</e2> in a patient with an underlying vascular malformation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4558	"Rapid onset of <e1>quetiapine</e1> -induced <e2>diabetic ketoacidosis</e2> in an elderly patient: a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4559	"We report a case of reversible <e1>DKA</e1> and new-onset DM that developed in a demented patient who was treated with <e2>quetiapine</e2> for 14 days."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4560	"We report a case of reversible DKA and new-onset <e1>DM</e1> that developed in a demented patient who was treated with <e2>quetiapine</e2> for 14 days."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4561	"<e1>Pulmonary leukostasis</e1> secondary to <e2>all-trans retinoic acid</e2> in the treatment of acute promyelocytic leukemia in first relapse."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4562	"<e1>Eruptive epidermoid cysts</e1> resulting from treatment with <e2>imiquimod</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4563	"METHODS: A 79-year-old woman being treated with <e1>imiquimod</e1> 5 days per week for a nodular basal cell developed a <e2>verrucous plaque</e2> over the treatment area after 7 weeks of therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4564	"The <e1>multiple comedones</e1> and ruptured epidermoid cysts are newly reported adverse effects of <e2>imiquimod</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4565	"The multiple comedones and <e1>ruptured epidermoid cysts</e1> are newly reported adverse effects of <e2>imiquimod</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4566	"We report an unusual case of massive <e1>fluoxetine</e1> ingestion resulting in neurological and cardiovascular toxicity resulting in <e2>death</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4567	"We report an unusual case of massive <e1>fluoxetine</e1> ingestion resulting in <e2>neurological and cardiovascular toxicity</e2> resulting in death."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4568	"<e1>Hepatocellular damage</e1> following therapeutic intravenous <e2>iron sucrose</e2> infusion in a child."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4569	"The case reported here is of a child given a large dose of intravenous <e1>iron sucrose</e1> (16 mg/kg) over 3 hours, who subsequently developed features of <e2>systemic iron toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4570	"Five personal observations of an <e1>acute amnestic episode</e1> in younger individuals after intake of <e2>clioquinol</e2> are described together with three observations from the medical literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4571	"The clinical aspect closely resembled classical transient global amnesia but the episode after <e1>clioquinol</e1> lasted longer (24 hours to three days) and a more or less extensive <e2>retrograde amnesia</e2> persisted permanently."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4572	"The clinical aspect closely resembled classical <e1>transient global amnesia</e1> but the episode after <e2>clioquinol</e2> lasted longer (24 hours to three days) and a more or less extensive retrograde amnesia persisted permanently."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4573	"<e1>Transient global amnesia</e1> after <e2>clioquinol</e2>: five personal observations from outside Japan."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4574	"In the other patient, a 78-year-old woman, <e1>Neisseria mucosa knee arthritis</e1> occurred after a single <e2>sodium hyaluronate</e2> injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4575	"One patient was an 80-year-old woman who was admitted for <e1>Staphylococcus aureus knee arthritis</e1> after several intraarticular injections of sodium hyaluronate and <e2>corticosteroids</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4576	"One patient was an 80-year-old woman who was admitted for <e1>Staphylococcus aureus knee arthritis</e1> after several intraarticular injections of <e2>sodium hyaluronate</e2> and corticosteroids."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4577	"<e1>Septic knee arthritis</e1> after intra-articular <e2>hyaluronate</e2> injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4578	"<e1>Acute dystonia</e1> induced by <e2>lamivudine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4579	"<e1>ADR</e1> induced by drug treatment can be a side effect of treatment with antipsychotic drugs and other drugs; however, there have been no reports of <e2>lamivudine</e2> -induced <e1>ADR</e1> in the English literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4580	"The authors report two cases of <e1>acute dystonic reactions</e1> (ADRs) as a side effect of <e2>lamivudine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4581	"The authors report two cases of acute dystonic reactions (<e1>ADRs</e1>) as a side effect of <e2>lamivudine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4582	"The authors think that although <e1>lamivudine</e1> is widely used and well tolerated, it can cause <e2>ADRs</e2>, which are reversible after drug withdrawal."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4583	"<e1>Pleuropulmonary fibrosis</e1> after long-term treatment with the dopamine agonist <e2>pergolide</e2> for Parkinson Disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4584	"CONCLUSIONS: This observation of "on-off" <e1>risperidone</e1> treatment suggests that <e1>risperidone</e1> may have worsened both <e2>psychiatric and physical manifestations</e2> of the mitochondrial disorder in this adolescent."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4585	"CONCLUSIONS: This observation of "on-off" <e1>risperidone</e1> treatment suggests that <e1>risperidone</e1> may have worsened both <e2>psychiatric and physical manifestations</e2> of the mitochondrial disorder in this adolescent."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4586	"OBJECTIVE: To our knowledge, this is the first published case report of an adolescent girl with a mitochondrial disorder and depression who displayed both new-onset psychotic and <e1>increased mood symptoms</e1> during treatment with <e2>risperidone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4587	"<e1>Risperidone</e1> -induced psychosis and <e2>depression</e2> in a child with a mitochondrial disorder."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4588	"<e1>Risperidone</e1> -induced <e2>psychosis</e2> and depression in a child with a mitochondrial disorder."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4589	"<e1>Fatal radiation myelopathy</e1> after high-dose <e2>busulfan</e2> and melphalan chemotherapy and radiotherapy for Ewing's sarcoma: a review of the literature and implications for practice."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4590	"<e1>Fatal radiation myelopathy</e1> after high-dose busulfan and <e2>melphalan</e2> chemotherapy and radiotherapy for Ewing's sarcoma: a review of the literature and implications for practice."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4591	"<e1>Gemcitabine</e1> -induced <e2>pericardial effusion</e2> and tamponade after unblocked cardiac irradiation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4592	"<e1>Gemcitabine</e1> -induced pericardial effusion and <e2>tamponade</e2> after unblocked cardiac irradiation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4593	"<e1>Gemcitabine</e1> therapy has been associated with <e2>radiation recall reactions</e2> when used in the treatment of carcinoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4594	"Physicians should be aware of the potential for developing a <e1>gemcitabine</e1> -induced radiation recall reaction resulting in hemodynamically significant <e2>pericardial effusion</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4595	"Physicians should be aware of the potential for developing a <e1>gemcitabine</e1> -induced <e2>radiation recall reaction</e2> resulting in hemodynamically significant pericardial effusion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4596	"We report four cases of hemodynamically significant <e1>pericardial effusion</e1> in patients with refractory lymphoma who were receiving <e2>gemcitabine</e2>, all of whom had a history of mediastinal radiation without subcarinal blocking."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4597	"A patient with generalized MG was effectively managed with <e1>MM</e1> but developed <e2>CNS lymphoma</e2> after 3 years of treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4598	"Despite minimal short-term side effects and apparent efficacy, chronic treatment of MG with <e1>MM</e1> may be associated with increased risk of <e2>lymphoproliferative disorders</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4599	"Primary <e1>CNS lymphoma</e1> complicating treatment of myasthenia gravis with <e2>mycophenolate mofetil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4600	"Primary <e1>CNS lymphoma</e1> regressed on withdrawal of <e2>MM</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4601	"<e1>Baclofen</e1> withdrawal: a cause of prolonged <e2>fever</e2> in the intensive care unit."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4602	"<e1>Baclofen</e1> <e2>withdrawal syndrome</e2> resulting from underdosing of oral baclofen should be considered as a potential source of prolonged fever in the intensive care unit."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4603	"Baclofen <e1>withdrawal syndrome</e1> resulting from underdosing of oral <e2>baclofen</e2> should be considered as a potential source of prolonged fever in the intensive care unit."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4604	"The patient continued to have fever and <e1>autonomic instability</e1> without evidence of infection which entirely resolved within 24 hours of reinstitution of full preadmission dosing of oral <e2>baclofen</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4605	"The patient continued to have <e1>fever</e1> and autonomic instability without evidence of infection which entirely resolved within 24 hours of reinstitution of full preadmission dosing of oral <e2>baclofen</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4606	"We report a case of <e1>baclofen</e1> <e2>withdrawal syndrome</e2> resulting from oral <e1>baclofen</e1> underdosing."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4607	"We report a case of <e1>baclofen</e1> <e2>withdrawal syndrome</e2> resulting from oral <e1>baclofen</e1> underdosing."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4608	"After discontinuing <e1>captopril</e1> and starting systemic steroids, her symptomatology rapidly improved, and her <e2>eosinophilia</e2> and radiographic abnormalities both resolved."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4609	"After discontinuing <e1>captopril</e1> and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and <e2>radiographic abnormalities</e2> both resolved."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4610	"<e1>Captopril</e1> -induced <e2>pulmonary infiltrates with eosinophilia</e2> in an infant with congenital heart disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4611	"We report a case of an infant with complex congenital heart disease who was placed on <e1>captopril</e1> for afterload reduction following cardiac surgery and subsequently developed <e2>pulmonary infiltrates with eosinophilia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4612	"Can <e1>propofol</e1> precipitate <e2>pancreatitis</e2> in patients with Cushing's syndrome?"
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4613	"Since elevated cortisol levels in Cushing's disease poses a threat for pancreatitis, there is a possibility that patients with Cushing's disease might be more prone to <e1>acute pancreatitis</e1> following <e2>propofol</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4614	"Since recent studies have reported no negative interactions with concurrent use, we here report three cases (one case of a prolonged seizure, a serotonin syndrome and a <e1>focal seizure</e1>) of severe <e2>lithium</e2> -induced side effects while patients underwent ECT without complications and <e2>lithium</e2> serum levels were still subtherapeutic."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4615	"Since recent studies have reported no negative interactions with concurrent use, we here report three cases (one case of a <e1>prolonged seizure</e1>, a serotonin syndrome and a focal seizure) of severe <e2>lithium</e2> -induced side effects while patients underwent ECT without complications and <e2>lithium</e2> serum levels were still subtherapeutic."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4616	"Since recent studies have reported no negative interactions with concurrent use, we here report three cases (one case of a prolonged seizure, a <e1>serotonin syndrome</e1> and a focal seizure) of severe <e2>lithium</e2> -induced side effects while patients underwent ECT without complications and <e2>lithium</e2> serum levels were still subtherapeutic."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4617	"<e1>CD20-negative T-cell-rich B-cell lymphoma</e1> as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with <e2>rituximab</e2>: a molecular analysis using laser capture microdissection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4618	"Recently, <e1>CD20-negative tumors</e1> have been described after <e2>Rituximab</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4619	"A 51-year old physically fit woman experienced <e1>angio-oedema</e1> and hypotensive shock after <e2>irbesartan</e2> ingestion requiring noradrenaline infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4620	"A 51-year old physically fit woman experienced angio-oedema and <e1>hypotensive shock</e1> after <e2>irbesartan</e2> ingestion requiring noradrenaline infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4621	"To our knowledge, our report is one of the first on shock and <e1>angio-oedema</e1> from <e2>irbesartan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4622	"To our knowledge, our report is one of the first on <e1>shock</e1> and angio-oedema from <e2>irbesartan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4623	"She died within six weeks of developing <e1>congestive heart failure</e1> coupled with liver failure due to haemosiderosis despite regular use of <e2>desferrioxamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4624	"She died within six weeks of developing congestive heart failure coupled with liver failure due to <e1>haemosiderosis</e1> despite regular use of <e2>desferrioxamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4625	"She died within six weeks of developing congestive heart failure coupled with <e1>liver failure</e1> due to haemosiderosis despite regular use of <e2>desferrioxamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4626	"<e1>Transfusion haemosiderosis</e1> inspite of regular use of <e2>desferrioxamine</e2>: case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4627	"One of the side-effects of intravitreal <e1>triamcinolone</e1> is the development of <e2>cataract</e2>, and it is known that <e2>cataract</e2> extraction can exacerbate macular degeneration."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4628	"Severe loss of vision after removal of <e1>cataract</e1> caused by intravitreal <e2>triamcinolone</e2> in combination with photodynamic therapy for exudative age-related macular degeneration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4629	"<e1>Severe loss of vision</e1> after removal of cataract caused by intravitreal <e2>triamcinolone</e2> in combination with photodynamic therapy for exudative age-related macular degeneration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4630	"<e1>Rhabdomyolysis</e1> caused by tocolysis with oral <e2>ritodrine hydrochloride</e2> in a pregnant patient with myotonic dystrophy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4631	"<e1>Rhabdomyolysis</e1> has been recognized as a complication of tocolytic therapy with <e2>ritodrine hydrochloride</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4632	"We report here a rare case of <e1>ritodrine-hydrochloride</e1> -induced <e2>rhabdomyolysis</e2> in a pregnant patient with myotonic dystrophy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4633	"<e1>Acute myocardial ischemia</e1> following accidental intravenous administration of <e2>epinephrine</e2> in high concentration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4634	"Inadvertent and accidental <e1>epinephrine</e1> overdose might result in potentially <e2>lethal complications</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4635	"We present a case of acute <e1>epinephrine</e1> toxicity resulting in <e2>acute myocardial ischemia</e2> in a young boy with combined variable immunodeficiency syndrome who developed severe allergic reaction to intravenous immunoglobulin, and was subsequently given <e1>epinephrine</e1> by mistake intravenously rather than subcutaneously."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4636	"We present a case of acute <e1>epinephrine</e1> toxicity resulting in acute myocardial ischemia in a young boy with combined variable immunodeficiency syndrome who developed <e2>severe allergic reaction</e2> to intravenous immunoglobulin, and was subsequently given <e1>epinephrine</e1> by mistake intravenously rather than subcutaneously."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4637	"We present a case of acute <e1>epinephrine</e1> toxicity resulting in acute myocardial ischemia in a young boy with combined variable immunodeficiency syndrome who developed <e2>severe allergic reaction</e2> to intravenous immunoglobulin, and was subsequently given <e1>epinephrine</e1> by mistake intravenously rather than subcutaneously."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4638	"Polysomnographic and pharmacokinetic findings in <e1>levodopa</e1> -induced augmentation of <e2>restless legs syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4639	"Symptoms and signs of <e1>augmentation</e1> were related to low plasma <e2>levodopa</e2> levels, abating 75 minutes after oral <e2>levodopa</e2> administration and reappearing after 3 hours, closely mirroring the rapid rise and fall of plasma <e2>levodopa</e2> concentration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4640	"Symptoms and signs of <e1>augmentation</e1> were related to low plasma <e2>levodopa</e2> levels, abating 75 minutes after oral <e2>levodopa</e2> administration and reappearing after 3 hours, closely mirroring the rapid rise and fall of plasma <e2>levodopa</e2> concentration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4641	"Videopolysomnographic and pharmacokinetic studies with monitoring of plasma <e1>levodopa</e1> levels demonstrated marked motor hyperactivity during augmentation, with <e2>anarchic discharges of motor unit potentials</e2>, tonic grouped discharges and flexor spasms, associated with painful dysesthesia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4642	"Videopolysomnographic and pharmacokinetic studies with monitoring of plasma <e1>levodopa</e1> levels demonstrated marked motor hyperactivity during augmentation, with anarchic discharges of motor unit potentials, tonic grouped discharges and <e2>flexor spasms</e2>, associated with painful dysesthesia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4643	"Videopolysomnographic and pharmacokinetic studies with monitoring of plasma <e1>levodopa</e1> levels demonstrated <e2>marked motor hyperactivity</e2> during augmentation, with anarchic discharges of motor unit potentials, tonic grouped discharges and flexor spasms, associated with painful dysesthesia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4644	"Videopolysomnographic and pharmacokinetic studies with monitoring of plasma <e1>levodopa</e1> levels demonstrated marked motor hyperactivity during augmentation, with anarchic discharges of motor unit potentials, tonic grouped discharges and flexor spasms, associated with <e2>painful dysesthesia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4645	"Videopolysomnographic and pharmacokinetic studies with monitoring of plasma <e1>levodopa</e1> levels demonstrated marked motor hyperactivity during augmentation, with anarchic discharges of motor unit potentials, <e2>tonic grouped discharges</e2> and flexor spasms, associated with painful dysesthesia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4646	"We describe a patient with idiopathic RLS who developed <e1>augmentation</e1> after 8 months of <e2>levodopa</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4647	"The major side effect of <e1>infliximab</e1> is <e2>infection</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4648	"This report describes a probable case of <e1>infliximab</e1> -induced <e2>membranous nephropathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4649	"<e1>Linezolid</e1> -induced <e2>dyserythropoiesis</e2>: chloramphenicol toxicity revisited."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4650	"We report here two cases of <e1>dyserythropoietic anaemia</e1> associated with long-term <e2>linezolid</e2> use that share striking similarities to chloramphenicol-associated myelotoxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4651	"We report here two cases of dyserythropoietic anaemia associated with long-term linezolid use that share striking similarities to <e1>chloramphenicol</e1> -associated <e2>myelotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4652	"A selective association between <e1>fluoxetine</e1> and extensive, prominent <e2>eye movements in nonrapid eye movement (NREM) sleep</e2> was detected, utilizing Fisher's exact one-tailed statistic (p less than 0.00001 for each comparison)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4653	"In addition, a 31-year-old man with obsessive-compulsive disorder developed <e1>RBD</e1> soon after starting <e2>fluoxetine</e2> therapy, which persisted at PSG study 19 months after <e2>fluoxetine</e2> discontinuation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4654	"In addition, a 31-year-old man with obsessive-compulsive disorder developed <e1>RBD</e1> soon after starting <e2>fluoxetine</e2> therapy, which persisted at PSG study 19 months after <e2>fluoxetine</e2> discontinuation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4655	"<e1>Prominent eye movements during NREM sleep</e1> and REM sleep behavior disorder associated with <e2>fluoxetine</e2> treatment of depression and obsessive-compulsive disorder."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4656	"Prominent eye movements during NREM sleep and <e1>REM sleep behavior disorder</e1> associated with <e2>fluoxetine</e2> treatment of depression and obsessive-compulsive disorder."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4657	"Because of serious side effects of an <e1>increase in the QT interval</e1> causing torsades de pointes, <e2>dofetilide</e2> must be initiated with close monitoring of the QT interval in an inpatient setting."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4658	"Because of serious side effects of an increase in the QT interval causing <e1>torsades de pointes</e1>, <e2>dofetilide</e2> must be initiated with close monitoring of the QT interval in an inpatient setting."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4659	"Marked QT prolongation and torsades de pointes secondary to <e1>acute ischemia</e1> in an elderly man taking <e2>dofetilide</e2> for atrial fibrillation: a cautionary tale."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4660	"<e1>Marked QT prolongation</e1> and torsades de pointes secondary to acute ischemia in an elderly man taking <e2>dofetilide</e2> for atrial fibrillation: a cautionary tale."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4661	"Marked QT prolongation and <e1>torsades de pointes</e1> secondary to acute ischemia in an elderly man taking <e2>dofetilide</e2> for atrial fibrillation: a cautionary tale."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4662	"We report marked QT prolongation and torsades de pointes in a setting of flash pulmonary edema resulting from <e1>acute myocardial ischemia</e1> in a patient who was being treated with <e2>dofetilide</e2> for atrial fibrillation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4663	"We report marked QT prolongation and torsades de pointes in a setting of <e1>flash pulmonary edema</e1> resulting from acute myocardial ischemia in a patient who was being treated with <e2>dofetilide</e2> for atrial fibrillation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4664	"We report marked <e1>QT prolongation</e1> and torsades de pointes in a setting of flash pulmonary edema resulting from acute myocardial ischemia in a patient who was being treated with <e2>dofetilide</e2> for atrial fibrillation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4665	"We report marked QT prolongation and <e1>torsades de pointes</e1> in a setting of flash pulmonary edema resulting from acute myocardial ischemia in a patient who was being treated with <e2>dofetilide</e2> for atrial fibrillation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4666	"Prominent <e1>positive U waves</e1> appearing with high-dose intravenous <e2>phenylephrine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4667	"While on a maximal dose of <e1>phenylephrine</e1> she developed prominent <e2>positive U waves</e2>, which disappeared with the cessation of the drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4668	"<e1>Hepatoxicity</e1> is a rare complication of <e2>SRL</e2> therapy and may be connected with some diagnostic and/or therapeutic problems."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4669	"<e1>Sirolimus</e1> -associated <e2>hepatotoxicity</e2> in the kidney graft recipient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4670	"The aim of our paper was to describe <e1>hepatotoxicity</e1> of <e2>sirolimus</e2> (SRL) in a kidney graft recipient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4671	"CASE REPORT: We present a case of a 28-yr-old male who developed a severe case of <e1>nephrotic syndrome</e1> while being treated for relapsing/remitting Multiple Sclerosis (RRMS) with weekly injections of <e2>interferon beta 1a</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4672	"<e1>Nephrotic syndrome</e1> in a multiple sclerosis patient treated with <e2>interferon beta 1a</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4673	"SUBSEQUENT COURSE: The <e1>nephrosis</e1> resolved almost completely once the <e2>interferon</e2> was stopped and after immunosuppressive treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4674	"This latest (third) report suggests that the safety profile should be reexamined and at least raises the question of potential <e1>renal toxicity</e1> of <e2>interferons</e2> in MS."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4675	"<e1>Capecitabine</e1> -induced <e2>multifocal leukoencephalopathy</e2>: a report of five cases."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4676	"The authors report five additional cases of <e1>capecitabine</e1> -induced <e2>multifocal leukoencephalopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4677	"A 56-year-old white woman with a diagnosis of reactive depression developed severe <e1>UI</e1> after a 30 days' treatment with <e2>venlafaxine</e2> 75 mg/day."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4678	"The authors report a case of urinary incontinence (<e1>UI</e1>) that occurred in a woman after administration of <e2>venlafaxine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4679	"The authors report a case of <e1>urinary incontinence</e1> (UI) that occurred in a woman after administration of <e2>venlafaxine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4680	"<e1>Venlafaxine</e1> -induced <e2>urinary incontinence</e2> resolved after switching to sertraline."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4681	"Diagnosis of <e1>hypothyroidism</e1> during treatment can be difficult because of the common side effects of <e2>alpha interferon</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4682	"<e1>Sustained hypothyroidism</e1> induced by <e2>recombinant alpha interferon</e2> in patients with chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4683	"<e1>Thyroid dysfunction</e1> has been reported in patients with malignant disease treated with <e2>recombinant alpha interferon</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4684	"Two cases of <e1>hypothyroidism</e1> in patients with chronic hepatitis C treated with <e2>recombinant alpha interferon</e2> are reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4685	"<e1>Atrial fibrillation</e1> after <e2>vardenafil</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4686	"We report a case admitted with a first-detected, <e1>symptomatic paroxysmal atrial fibrillation</e1> in a healthy patient after self-medication with <e2>vardenafil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4687	"We describe a case of infection with <e1>Mycobacterium abscessus</e1> in a 67-year-old woman receiving <e2>infliximab</e2> as a component of her therapy for RA."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4688	"DIAGNOSIS: <e1>Interferon alpha-2b</e1> -induced <e2>cardiomyopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4689	"<e1>Reversible cardiomyopathy</e1> caused by administration of <e2>interferon alpha</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4690	"In this case <e1>senna</e1> was likely the cause of a subacute cholestatic hepatitis exemplifying again the potential role of herbal related <e2>liver injury</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4691	"In this case <e1>senna</e1> was likely the cause of a <e2>subacute cholestatic hepatitis</e2> exemplifying again the potential role of herbal related liver injury."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4692	"<e1>Subacute cholestatic hepatitis</e1> likely related to the use of <e2>senna</e2> for chronic constipation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4693	"We report a case of <e1>senna</e1> -induced <e2>cholestatic hepatitis</e2> which was not diagnosed at presentation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4694	"Based on the history and clinical features, a diagnosis of <e1>insulin</e1> -induced <e2>lipohypertrophy</e2> was made."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4695	"<e1>Insulin</e1> -induced <e2>lipohypertrophy</e2>: report of a case with histopathology."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4696	"Thus, the possible in vivo effects of <e1>insulin</e1> on adipocytes were clearly observed in this case of <e1>insulin</e1> -induced <e2>lipohypertrophy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4697	"To our knowledge, this is the first report of <e1>insulin</e1> -induced <e2>lipohypertrophy</e2> with detailed histological examinations."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4698	"A 7-year-old girl developed <e1>diabetes mellitus</e1> and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with <e2>azathioprine</e2> and/or prednisone for idiopathic auto-immune haemolytic anaemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4699	"A 7-year-old girl developed <e1>diabetes mellitus</e1> and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with azathioprine and/or <e2>prednisone</e2> for idiopathic auto-immune haemolytic anaemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4700	"A 7-year-old girl developed diabetes mellitus and <e1>exocrine pancreatic insufficiency</e1> after 3.5 years of almost continuous treatment with <e2>azathioprine</e2> and/or prednisone for idiopathic auto-immune haemolytic anaemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4701	"A 7-year-old girl developed diabetes mellitus and <e1>exocrine pancreatic insufficiency</e1> after 3.5 years of almost continuous treatment with azathioprine and/or <e2>prednisone</e2> for idiopathic auto-immune haemolytic anaemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4702	"An objective causality assessment suggests that the <e1>JHR</e1> in our patient was probably related to <e2>penicillin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4703	"CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with <e1>JHR</e1> after an initial intravenous dose of <e2>penicillin G</e2> for presumed neurosyphilis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4704	"<e1>Penicillin</e1> -induced <e2>Jarisch-Herxheimer reaction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4705	"The patient described feeling cold with worsening headache and <e1>chills</e1> approximately one hour after infusion of the first dose of <e2>penicillin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4706	"The patient described <e1>feeling cold</e1> with worsening headache and chills approximately one hour after infusion of the first dose of <e2>penicillin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4707	"The patient described feeling cold with <e1>worsening headache</e1> and chills approximately one hour after infusion of the first dose of <e2>penicillin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4708	"<e1>Acute respiratory distress syndrome</e1> after <e2>rituximab</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4709	"<e1>ARDS</e1> has been associated with the administration of other monoclonal antibodies, such as infliximab, <e2>gemtuzumab ozogamicin</e2>, and OKT3 and is believed to be directly mediated by release of proinflammatory cytokines."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4710	"<e1>ARDS</e1> has been associated with the administration of other monoclonal antibodies, such as <e2>infliximab</e2>, gemtuzumab ozogamicin, and OKT3 and is believed to be directly mediated by release of proinflammatory cytokines."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4711	"<e1>ARDS</e1> has been associated with the administration of other monoclonal antibodies, such as infliximab, gemtuzumab ozogamicin, and <e2>OKT3</e2> and is believed to be directly mediated by release of proinflammatory cytokines."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4712	"<e1>ARDS</e1> is rarely associated with <e2>rituximab</e2> infusion for lympho-proliferative disorders, but it should be considered by those administering <e2>rituximab</e2>, especially when a patient develops severe pulmonary symptoms soon after infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4713	"<e1>ARDS</e1> is rarely associated with <e2>rituximab</e2> infusion for lympho-proliferative disorders, but it should be considered by those administering <e2>rituximab</e2>, especially when a patient develops severe pulmonary symptoms soon after infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4714	"ARDS is rarely associated with <e1>rituximab</e1> infusion for lympho-proliferative disorders, but it should be considered by those administering <e1>rituximab</e1>, especially when a patient develops <e2>severe pulmonary symptoms</e2> soon after infusion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4715	"<e1>Dyspnea</e1>, hypoxemia, and pleuritic chest pain occurred within 24 hours of <e2>rituximab</e2> administration, and there was no other apparent explanation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4716	"Dyspnea, <e1>hypoxemia</e1>, and pleuritic chest pain occurred within 24 hours of <e2>rituximab</e2> administration, and there was no other apparent explanation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4717	"Dyspnea, hypoxemia, and <e1>pleuritic chest pain</e1> occurred within 24 hours of <e2>rituximab</e2> administration, and there was no other apparent explanation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4718	"<e1>Progressive hypoxemia</e1> mandated endotracheal intubation 1 week after <e2>rituximab</e2> administration and led to death 4 weeks after admission."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4719	"We report the case of a 43-year-old man with ITP refractory to steroids and intravenous immunoglobulin who developed <e1>acute respiratory distress syndrome</e1> (ARDS) after a single infusion of <e2>rituximab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4720	"We report the case of a 43-year-old man with ITP refractory to steroids and intravenous immunoglobulin who developed acute respiratory distress syndrome (<e1>ARDS</e1>) after a single infusion of <e2>rituximab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4721	"Symptomatic hypocalcaemia and <e1>renal impairment</e1> associated with <e2>bisphosphonate</e2> treatment in patients with multiple myeloma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4722	"<e1>Symptomatic hypocalcaemia</e1> and renal impairment associated with <e2>bisphosphonate</e2> treatment in patients with multiple myeloma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4723	"We report three cases of <e1>severe hypocalcaemia</e1> associated with i.v. <e2>bisphosphonate</e2> treatment in patients with multiple myeloma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4724	"<e1>Gemcitabine</e1> -related <e2>radiation recall</e2> in a patient with pancreatic cancer."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4725	"<e1>Gemcitabine</e1> should be added to the list of drugs known to cause <e2>radiation recall</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4726	"<e1>Radiation recall</e1> from <e2>gemcitabine</e2> is rare, but can potentially arise in any site that has been previously irradiated."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4727	"<e1>Radiation recall</e1> related to <e2>gemcitabine</e2> has been reported in lung and breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4728	"We report a patient with inoperable pancreatic cancer who developed <e1>gastrointestinal bleeding</e1> secondary to radiation-recall related to <e2>gemcitabine</e2> and review literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4729	"We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to <e1>radiation-recall</e1> related to <e2>gemcitabine</e2> and review literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4730	"We suggest discontinuing <e1>gemcitabine</e1> if <e2>radiation recall</e2> is observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4731	"A 17-year-old boy with acute lymphoblastic leukemia developed <e1>acute renal failure</e1> within 48 h of an intravenous high-dose <e2>methotrexate</e2> (5 g/m2) infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4732	"High-dose <e1>methotrexate</e1> -associated <e2>acute renal failure</e2> may be an avoidable complication."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4733	"<e1>Methotrexate</e1> -associated <e2>nephropathy</e2> is a rare complication in pediatric oncology, and a review of the literature suggests that exposure to nephrotoxic agents may be a significant but perhaps underrecognized risk factor for its development."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4734	"Massive <e1>prolapse of the urethral mucosa</e1> following periurethral injection of <e2>calcium hydroxylapatite</e2> for stress urinary incontinence."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4735	"The authors present a case report of a <e1>granulomatous reaction</e1> leading to urethral prolapse, 3 months after the transurethral injection of <e2>calcium hydroxylapatite</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4736	"The authors present a case report of a granulomatous reaction leading to <e1>urethral prolapse</e1>, 3 months after the transurethral injection of <e2>calcium hydroxylapatite</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4737	"To our knowledge, this is the first <e1>granulomatous reaction</e1> described after <e2>calcium hydroxylapatite</e2> injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4738	"CASE SUMMARY: A 57-year-old female with cardiomyopathy and "sulfa" (trimethoprim/sulfamethoxazole) allergy documented as <e1>pancreatitis</e1> presented with symptoms consistent with <e1>pancreatitis</e1> after use of <e2>furosemide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4739	"In addition, while cases of loop diuretic-induced <e1>pancreatitis</e1>, including <e2>furosemide</e2>, have been published, the allergic manifestations with both sulfonamide antibiotics and non-antibiotics in our patient suggest possible cross-reactivity between these 2 drug classes."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4740	"<e1>Torsemide</e1> appears to also be a part of a long list of agents that can cause <e2>pancreatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4741	"<e1>Heparin</e1> -induced thrombocytopenia complicated with <e2>massive thrombosis of the inferior vena cava</e2> after filter placement."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4742	"<e1>Heparin</e1> -induced <e2>thrombocytopenia</e2> complicated with massive thrombosis of the inferior vena cava after filter placement."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4743	"On the 3rd day, an inferior vena cava (IVC) filter was placed with a <e1>heparin</e1> flush, after which massive <e2>IVC thrombosis</e2> developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4744	"The patient was positive for antibody against complexes of <e1>heparin</e1> and platelet factor 4, and was diagnosed as <e1>heparin</e1> -induced <e2>thrombocytopenia</e2> with thrombosis syndrome (HITTS)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4745	"The patient was positive for antibody against complexes of <e1>heparin</e1> and platelet factor 4, and was diagnosed as <e1>heparin</e1> -induced thrombocytopenia with <e2>thrombosis syndrome</e2> (HITTS)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4746	"When <e1>thrombosis</e1> develops during <e2>heparin</e2> treatment, it is important to suspect HITTs and to assay for the associated antibodies, regardless of the actual platelet count."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4747	"After <e1>gastric-outlet obstruction</e1> was recognized in several infants who received <e2>prostaglandin E1</e2>, we studied the association between the drug and this complication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4748	"CONCLUSIONS: The administration of <e1>prostaglandin E1</e1> to neonates can cause gastric-outlet obstruction due to <e2>antral hyperplasia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4749	"CONCLUSIONS: The administration of <e1>prostaglandin E1</e1> to neonates can cause <e2>gastric-outlet obstruction</e2> due to antral hyperplasia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4750	"Moreover, treatment with immunosuppressive drugs such as cyclosporine, <e1>cisplatin</e1>, tacrolimus, and interferon-alpha can induce a condition resembling <e2>RPLS</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4751	"Moreover, treatment with immunosuppressive drugs such as <e1>cyclosporine</e1>, cisplatin, tacrolimus, and interferon-alpha can induce a condition resembling <e2>RPLS</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4752	"Moreover, treatment with immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and <e1>interferon-alpha</e1> can induce a condition resembling <e2>RPLS</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4753	"Moreover, treatment with immunosuppressive drugs such as cyclosporine, cisplatin, <e1>tacrolimus</e1>, and interferon-alpha can induce a condition resembling <e2>RPLS</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4754	"<e1>Reversible posterior leukoencephalopathy syndrome</e1> in systemic lupus erythematosus with thrombocytopenia treated with <e2>cyclosporine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4755	"We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, <e1>headache</e1>, and seizure after receiving <e2>cyclosporine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4756	"We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and <e1>seizure</e1> after receiving <e2>cyclosporine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4757	"We report a case of a young woman with SLE and thrombocytopenia, who developed <e1>severe perspiration</e1>, headache, and seizure after receiving <e2>cyclosporine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4758	"OBJECTIVE: To describe a case of exacerbated <e1>mania</e1> potentially related to an interaction between <e2>lopinavir</e2>/ritonavir and valproic acid (VPA) and propose a mechanism of action for this interaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4759	"OBJECTIVE: To describe a case of exacerbated <e1>mania</e1> potentially related to an interaction between lopinavir/<e2>ritonavir</e2> and valproic acid (VPA) and propose a mechanism of action for this interaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4760	"OBJECTIVE: To describe a case of exacerbated <e1>mania</e1> potentially related to an interaction between lopinavir/ritonavir and <e2>valproic acid</e2> (VPA) and propose a mechanism of action for this interaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4761	"OBJECTIVE: To describe a case of exacerbated <e1>mania</e1> potentially related to an interaction between lopinavir/ritonavir and valproic acid (<e2>VPA</e2>) and propose a mechanism of action for this interaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4762	"Possible interaction between <e1>lopinavir</e1>/ritonavir and valproic Acid exacerbates <e2>bipolar disorder</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4763	"Possible interaction between lopinavir/<e1>ritonavir</e1> and valproic Acid exacerbates <e2>bipolar disorder</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4764	"Possible interaction between lopinavir/ritonavir and <e1>valproic Acid</e1> exacerbates <e2>bipolar disorder</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4765	"After intravitreal injection of <e1>triamcinolone acetonide</e1>, <e2>cataract</e2> may rapidly develop in eyes that have been intensively treated, topically and systemically, by corticosteroids for several years."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4766	"<e1>Arthritis</e1> and bursitis in multiple sclerosis patients treated with <e2>interferon-beta</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4767	"Arthritis and <e1>bursitis</e1> in multiple sclerosis patients treated with <e2>interferon-beta</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4768	"Our literature review revealed an additional six cases of onset of <e1>inflammatory arthritis</e1> in MS patients receiving <e2>IFN-beta</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4769	"The first patient developed a <e1>monoarthritis</e1> 2 weeks after initiation of <e2>IFN-beta</e2>, which persisted during the 14 months of therapy and resolved with discontinuation of the medication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4770	"Therapy with <e1>IFN-beta</e1> has rarely been associated with the development of <e2>autoimmune disorders</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4771	"The second patient developed both <e1>autoimmune thyroid disease</e1> and a refractory pre-patellar bursitis after 50 months of <e2>IFN-beta</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4772	"The second patient developed both autoimmune thyroid disease and a <e1>refractory pre-patellar bursitis</e1> after 50 months of <e2>IFN-beta</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4773	"We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed <e1>inflammatory musculoskeletal manifestations</e1>, following <e2>IFN-beta</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4774	"<e1>Trimethoprim-sulfamethoxazole</e1> -induced <e2>aseptic meningitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4775	"We present a 46-year-old African-American man with AIDS who was admitted on two different occasions within three weeks for signs and symptoms of <e1>meningitis</e1> after using trimethoprim/sulfamethoxazole (TMP/<e2>SMX</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4776	"We present a 46-year-old African-American man with AIDS who was admitted on two different occasions within three weeks for signs and symptoms of <e1>meningitis</e1> after using trimethoprim/<e2>sulfamethoxazole</e2> (TMP/SMX)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4777	"We present a 46-year-old African-American man with AIDS who was admitted on two different occasions within three weeks for signs and symptoms of <e1>meningitis</e1> after using trimethoprim/sulfamethoxazole (<e2>TMP</e2>/SMX)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4778	"We present a 46-year-old African-American man with AIDS who was admitted on two different occasions within three weeks for signs and symptoms of <e1>meningitis</e1> after using <e2>trimethoprim</e2>/sulfamethoxazole (TMP/SMX)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4779	"We reviewed the literature in an attempt to characterize the pattern and predictors of TMP/<e1>SMX</e1> -induced <e2>aseptic meningitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4780	"We reviewed the literature in an attempt to characterize the pattern and predictors of <e1>TMP</e1>/SMX-induced <e2>aseptic meningitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4781	"In this paper, we report a patient with primary anti-phospholipid syndrome treated by <e1>corticosteroid</e1>, who developed <e2>disseminated nocardiosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4782	"<e1>Chloroquine</e1> -induced <e2>bilateral ptosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4783	"<e1>Ptosis</e1> occurring 24 h after <e2>chloroquine</e2> therapy, with full recovery 48 h after cessation of <e2>chloroquine</e2>, has not been described previously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4784	"<e1>Ptosis</e1> occurring 24 h after <e2>chloroquine</e2> therapy, with full recovery 48 h after cessation of <e2>chloroquine</e2>, has not been described previously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4785	"This report describes a case of <e1>bilateral ptosis</e1> induced by <e2>chloroquine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4786	"DESIGN: We reviewed the medical records of four patients, who were seen by us between July 2000 and February 2004 for sudden onset of a <e1>central neurological syndrome</e1> within days of intrathecal <e2>MTX</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4787	"Diffusion-weighted MRI correlates of subacute <e1>methotrexate</e1> -related <e2>neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4788	"OBJECTIVES: A delayed <e1>stroke-like leukoencephalopathy</e1> has been observed in patients receiving <e2>methotrexate</e2> (MTX) for childhood leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4789	"OBJECTIVES: A delayed <e1>stroke-like leukoencephalopathy</e1> has been observed in patients receiving methotrexate (<e2>MTX</e2>) for childhood leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4790	"Our objective is to present a retrospective analysis of the DWI findings in four patients who suffered <e1>subacute neurotoxicity</e1> after intrathecal <e2>MTX</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4791	"This is a rare case of <e1>ARDS</e1> associated with <e2>lithium</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4792	"CONCLUSION: The present findings suggest that: (i) amantadine probably exerts its anti-dyskinetic effect by acting on the "indirect" pathway; (ii) the pathophysiological mechanisms of subthalamotomy induced <e1>dyskinesias</e1> may differ from those involved in <e2>L-dopa</e2> induced <e1>dyskinesias</e1>; (iii) <e1>dyskinesias</e1> induced by STN surgery resolve spontaneously as compensatory mechanisms develop."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4793	"Prior to surgery, <e1>levodopa</e1> induced <e2>dyskinesia</e2> had improved (< or = 50%) under treatment with amantadine (400 mg/day, po) in all three patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4794	"A combination of behavioural and cognitive adverse effects is illustrated in this case report of a recurrent <e1>triazolam</e1> -induced <e2>eating disorder</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4795	"<e1>Triazolam</e1> -induced nocturnal bingeing with <e2>amnesia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4796	"<e1>Triazolam</e1> -induced <e2>nocturnal bingeing</e2> with amnesia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4797	"Although interferon gamma has been implicated in the pathogenesis of <e1>sarcoidosis</e1>, only a few cases of <e1>sarcoidosis</e1> associated with <e2>interferon alpha</e2> therapy have been reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4798	"Development of <e1>sarcoidosis</e1> during <e2>interferon alpha 2b</e2> and ribavirin combination therapy for chronic hepatitis C--a case report and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4799	"Development of <e1>sarcoidosis</e1> during interferon alpha 2b and <e2>ribavirin</e2> combination therapy for chronic hepatitis C--a case report and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4800	"We report a case with chronic hepatitis C (CHC) who developed <e1>sarcoidosis</e1> after the treatment by <e2>interferon alpha</e2> and ribavirin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4801	"We report a case with chronic hepatitis C (CHC) who developed <e1>sarcoidosis</e1> after the treatment by interferon alpha and <e2>ribavirin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4802	"We suggest that <e1>sarcoidosis</e1> may develop in chronic hepatitis C patients during <e2>interferon alpha</e2> and/or ribavirin treatment, and diagnostic tests for this adverse effect should be performed during the follow-ups."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4803	"We suggest that <e1>sarcoidosis</e1> may develop in chronic hepatitis C patients during interferon alpha and/or <e2>ribavirin</e2> treatment, and diagnostic tests for this adverse effect should be performed during the follow-ups."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4804	"<e1>Neutropenic colitis</e1> during standard dose combination chemotherapy with nedaplatin and <e2>irinotecan</e2> for testicular cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4805	"<e1>Neutropenic colitis</e1> during standard dose combination chemotherapy with <e2>nedaplatin</e2> and irinotecan for testicular cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4806	"In this paper, we report a case of <e1>severe hypercalcemia</e1> of immobilization in a 40-year-old hemodialyzed woman treated by <e2>cinacalcet HCl</e2> for a severe HPTH-II (PTH>1,000 pg/mL)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4807	"Here, we present a case of <e1>sirolimus</e1> -associated <e2>interstitial pneumonitis</e2> in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4808	"Reversible <e1>sirolimus</e1> -associated <e2>pneumonitis</e2> after heart transplantation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4809	"Two cases of <e1>sirolimus</e1> -associated <e2>pneumonitis</e2> have been reported after cardiac transplantation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4810	"An objective causality assessment by use of the Naranjo probability scale revealed that <e1>NCSE</e1> due to <e2>ifosfamide</e2> was probable."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4811	"CASE SUMMARIES: Two patients who received <e1>ifosfamide</e1> -containing chemotherapy developed <e2>NCSE</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4812	"CONCLUSIONS: Among the many presentations of <e1>ifosfamide</e1> <e2>neurotoxicity</e2>, clinicians should consider NCSE as a possible explanation for changes in consciousness in a patient receiving this agent."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4813	"<e1>NCSE</e1>, an epileptic disorder in which typical convulsive activity is absent, has previously been reported in only 4 patients receiving <e2>ifosfamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4814	"<e1>Nonconvulsive status epilepticus</e1> due to <e2>ifosfamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4815	"OBJECTIVE: To report 2 cases of nonconvulsive status epilepticus (<e1>NCSE</e1>) following infusion of <e2>ifosfamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4816	"OBJECTIVE: To report 2 cases of <e1>nonconvulsive status epilepticus</e1> (NCSE) following infusion of <e2>ifosfamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4817	"We describe a case of intraoperative <e1>gelatine</e1> -induced <e2>anaphylaxis</e2> whose diagnosis was delayed as the use of <e1>gelatine</e1> during surgical procedures was omitted for two times in patient's medical records."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4818	"We describe a case of intraoperative <e1>gelatine</e1> -induced <e2>anaphylaxis</e2> whose diagnosis was delayed as the use of <e1>gelatine</e1> during surgical procedures was omitted for two times in patient's medical records."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4819	"<e1>Cutaneous mycobacterial infection</e1> post intravesical <e2>BCG</e2> installation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4820	"<e1>Disseminated tuberculous lesions</e1> post intravesical <e2>BCG</e2> therapy are rare but need to be identified and treated quickly."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4821	"Some patients develop <e1>hypersensitivity rash</e1> in response to <e2>HCQ</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4822	"Administration of <e1>sumatriptan</e1> in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce <e2>symptomatic cerebral vasospasm</e2> with potentially dangerous consequences."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4823	"METHOD: We describe two patients who presented with <e1>diabetic ketoacidosis</e1> after treatment with <e2>quetiapine</e2> and risperidone, respectively."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4824	"METHOD: We describe two patients who presented with <e1>diabetic ketoacidosis</e1> after treatment with quetiapine and <e2>risperidone</e2>, respectively."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4825	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, <e1>atypical lymphocytosis</e1>, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (<e2>SMX</e2>) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4826	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, <e1>atypical lymphocytosis</e1>, and eosinophilia two weeks after receiving trimethoprim (TMP)-<e2>sulfamethoxazole</e2> (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4827	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, <e1>atypical lymphocytosis</e1>, and eosinophilia two weeks after receiving trimethoprim (<e2>TMP</e2>)-sulfamethoxazole (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4828	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, <e1>atypical lymphocytosis</e1>, and eosinophilia two weeks after receiving <e2>trimethoprim</e2> (TMP)-sulfamethoxazole (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4829	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, <e1>cervical lymphadenopathy</e1>, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (<e2>SMX</e2>) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4830	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, <e1>cervical lymphadenopathy</e1>, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-<e2>sulfamethoxazole</e2> (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4831	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, <e1>cervical lymphadenopathy</e1>, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (<e2>TMP</e2>)-sulfamethoxazole (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4832	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, <e1>cervical lymphadenopathy</e1>, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving <e2>trimethoprim</e2> (TMP)-sulfamethoxazole (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4833	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and <e1>eosinophilia</e1> two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (<e2>SMX</e2>) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4834	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and <e1>eosinophilia</e1> two weeks after receiving trimethoprim (TMP)-<e2>sulfamethoxazole</e2> (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4835	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and <e1>eosinophilia</e1> two weeks after receiving trimethoprim (<e2>TMP</e2>)-sulfamethoxazole (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4836	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and <e1>eosinophilia</e1> two weeks after receiving <e2>trimethoprim</e2> (TMP)-sulfamethoxazole (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4837	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with <e1>fever</e1>, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (<e2>SMX</e2>) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4838	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with <e1>fever</e1>, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-<e2>sulfamethoxazole</e2> (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4839	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with <e1>fever</e1>, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (<e2>TMP</e2>)-sulfamethoxazole (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4840	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with <e1>fever</e1>, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving <e2>trimethoprim</e2> (TMP)-sulfamethoxazole (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4841	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, <e1>hepatosplenomegaly</e1>, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (<e2>SMX</e2>) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4842	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, <e1>hepatosplenomegaly</e1>, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-<e2>sulfamethoxazole</e2> (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4843	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, <e1>hepatosplenomegaly</e1>, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (<e2>TMP</e2>)-sulfamethoxazole (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4844	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, <e1>hepatosplenomegaly</e1>, atypical lymphocytosis, and eosinophilia two weeks after receiving <e2>trimethoprim</e2> (TMP)-sulfamethoxazole (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4845	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, <e1>skin eruptions</e1>, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (<e2>SMX</e2>) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4846	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, <e1>skin eruptions</e1>, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-<e2>sulfamethoxazole</e2> (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4847	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, <e1>skin eruptions</e1>, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (<e2>TMP</e2>)-sulfamethoxazole (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4848	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, <e1>skin eruptions</e1>, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving <e2>trimethoprim</e2> (TMP)-sulfamethoxazole (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4849	"This is the first case of <e1>TMP-SMX</e1> -induced <e2>hypersensitivity syndrome</e2> associated with the reactivation of a latent viral infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4850	"<e1>Trimethoprim-sulfamethoxazole</e1> -induced <e2>hypersensitivity syndrome</e2> associated with reactivation of human herpesvirus-6."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4851	"PURPOSE: To report a case of severe <e1>corticosteroid</e1> -induced <e2>glaucoma</e2> after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of <e2>glaucoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4852	"PURPOSE: To report a case of severe corticosteroid-induced <e1>glaucoma</e1> after intravitreal injection of <e2>triamcinolone acetate</e2> in a 34-year-old man without a history of <e1>glaucoma</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4853	"RESULTS: A 34-year-old man acquired visual field defects and <e1>severe vision loss</e1> in both eyes after intravitreal injection of <e2>triamcinolone</e2> for diabetic macular edema."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4854	"RESULTS: A 34-year-old man acquired <e1>visual field defects</e1> and severe vision loss in both eyes after intravitreal injection of <e2>triamcinolone</e2> for diabetic macular edema."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4855	"Severe <e1>steroid</e1> -induced <e2>glaucoma</e2> following intravitreal injection of triamcinolone acetonide."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4856	"Severe steroid-induced <e1>glaucoma</e1> following intravitreal injection of <e2>triamcinolone acetonide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4857	"This treatment has the potential to cause severe vision loss as a result of intractable <e1>corticosteroid</e1> -induced <e2>glaucoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4858	"This treatment has the potential to cause <e1>severe vision loss</e1> as a result of intractable <e2>corticosteroid</e2> -induced glaucoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4859	"<e1>Autoimmune thyroid disease</e1> is a common side-effect of interferon-alpha (<e2>IFN-alpha</e2>) treatment of viral hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4860	"<e1>Autoimmune thyroid disease</e1> is a common side-effect of <e2>interferon-alpha</e2> (IFN-alpha) treatment of viral hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4861	"Destructive thyrotoxicosis appeared 4-6 months after starting <e1>IFN-alpha</e1>, followed by <e2>Graves' hyperthyroidism</e2> within 8 to 11 months."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4862	"Destructive <e1>thyrotoxicosis</e1> appeared 4-6 months after starting <e2>IFN-alpha</e2>, followed by Graves' hyperthyroidism within 8 to 11 months."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4863	"Hence, <e1>hyperthyroidism</e1> induced by <e2>IFN-alpha</e2> could correspond to the first phase of silent thyroiditis, to Graves' disease or to the succession of both."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4864	"<e1>Interferon-alpha</e1> -induced <e2>hyperthyroidism</e2>: a three-stage evolution from silent thyroiditis towards Graves' disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4865	"We have described three patients with hepatitis C for whom <e1>IFN-alpha</e1> and ribavirin were prescribed and who developed two successive phases of silent thyroiditis followed by <e2>hyperthryroidism</e2> relapse due to Graves' disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4866	"We have described three patients with hepatitis C for whom IFN-alpha and <e1>ribavirin</e1> were prescribed and who developed two successive phases of silent thyroiditis followed by <e2>hyperthryroidism</e2> relapse due to Graves' disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4867	"We have described three patients with hepatitis C for whom <e1>IFN-alpha</e1> and ribavirin were prescribed and who developed two successive phases of silent <e2>thyroiditis</e2> followed by hyperthryroidism relapse due to Graves' disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4868	"We have described three patients with hepatitis C for whom IFN-alpha and <e1>ribavirin</e1> were prescribed and who developed two successive phases of silent <e2>thyroiditis</e2> followed by hyperthryroidism relapse due to Graves' disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4869	"<e1>Dipyrone</e1>, also known as metamizole, is an analgesic and antipyretic drug that was banned by the United States Food and Drug Administration because of its association with <e2>agranulocytosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4870	"Dipyrone, also known as <e1>metamizole</e1>, is an analgesic and antipyretic drug that was banned by the United States Food and Drug Administration because of its association with <e2>agranulocytosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4871	"<e1>Dipyrone</e1> -induced <e2>granulocytopenia</e2>: a case for awareness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4872	"We describe a patient who developed <e1>granulocytopenia</e1> and fever after taking <e2>dipyrone</e2> and discuss the available literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4873	"Herein, we describe 2 patients who developed unusual <e1>CD8+ cutaneous lymphoproliferative disorders</e1> after treatment with <e2>efalizumab</e2> and infliximab."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4874	"Herein, we describe 2 patients who developed unusual <e1>CD8+ cutaneous lymphoproliferative disorders</e1> after treatment with efalizumab and <e2>infliximab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4875	"A 7-year-old with congenital toxoplasmosis who took <e1>pyrimethamine</e1> and sulfadiazine for reactivated chorioretinitis developed fever, severe cutaneous involvement, swelling, <e2>abdominal pain</e2> and transaminitis, persisting weeks after withholding medicines."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4876	"A 7-year-old with congenital toxoplasmosis who took pyrimethamine and <e1>sulfadiazine</e1> for reactivated chorioretinitis developed fever, severe cutaneous involvement, swelling, <e2>abdominal pain</e2> and transaminitis, persisting weeks after withholding medicines."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4877	"A 7-year-old with congenital toxoplasmosis who took <e1>pyrimethamine</e1> and sulfadiazine for reactivated chorioretinitis developed <e2>fever</e2>, severe cutaneous involvement, swelling, abdominal pain and transaminitis, persisting weeks after withholding medicines."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4878	"A 7-year-old with congenital toxoplasmosis who took pyrimethamine and <e1>sulfadiazine</e1> for reactivated chorioretinitis developed <e2>fever</e2>, severe cutaneous involvement, swelling, abdominal pain and transaminitis, persisting weeks after withholding medicines."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4879	"A 7-year-old with congenital toxoplasmosis who took <e1>pyrimethamine</e1> and sulfadiazine for reactivated chorioretinitis developed fever, <e2>severe cutaneous involvement</e2>, swelling, abdominal pain and transaminitis, persisting weeks after withholding medicines."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4880	"A 7-year-old with congenital toxoplasmosis who took pyrimethamine and <e1>sulfadiazine</e1> for reactivated chorioretinitis developed fever, <e2>severe cutaneous involvement</e2>, swelling, abdominal pain and transaminitis, persisting weeks after withholding medicines."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4881	"A 7-year-old with congenital toxoplasmosis who took <e1>pyrimethamine</e1> and sulfadiazine for reactivated chorioretinitis developed fever, severe cutaneous involvement, <e2>swelling</e2>, abdominal pain and transaminitis, persisting weeks after withholding medicines."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4882	"A 7-year-old with congenital toxoplasmosis who took pyrimethamine and <e1>sulfadiazine</e1> for reactivated chorioretinitis developed fever, severe cutaneous involvement, <e2>swelling</e2>, abdominal pain and transaminitis, persisting weeks after withholding medicines."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4883	"A 7-year-old with congenital toxoplasmosis who took <e1>pyrimethamine</e1> and sulfadiazine for reactivated chorioretinitis developed fever, severe cutaneous involvement, swelling, abdominal pain and <e2>transaminitis</e2>, persisting weeks after withholding medicines."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4884	"A 7-year-old with congenital toxoplasmosis who took pyrimethamine and <e1>sulfadiazine</e1> for reactivated chorioretinitis developed fever, severe cutaneous involvement, swelling, abdominal pain and <e2>transaminitis</e2>, persisting weeks after withholding medicines."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4885	"Severe <e1>sulfadiazine</e1> <e2>hypersensitivity</e2> in a child with reactivated congenital toxoplasmic chorioretinitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4886	"This case underscores problems in clinical management with <e1>sulfadiazine</e1> <e2>hypersensitivity</e2>, potential immunosuppression from corticosteroids and selection of medications for recurrences of toxoplasmic chorioretinitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4887	"<e1>Fatal lung fibrosis</e1> caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and <e2>carboplatin</e2> as combination chemotherapy for advanced ovarian cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4888	"<e1>Fatal lung fibrosis</e1> caused by <e2>paclitaxel</e2> toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of <e2>paclitaxel</e2> and carboplatin as combination chemotherapy for advanced ovarian cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4889	"<e1>Fatal lung fibrosis</e1> caused by <e2>paclitaxel</e2> toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of <e2>paclitaxel</e2> and carboplatin as combination chemotherapy for advanced ovarian cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4890	"<e1>Fatal pulmonary fibrosis</e1> induced by <e2>paclitaxel</e2>: a case report and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4891	"Physicians should keep in mind that taxanes such as <e1>paclitaxel</e1> have the potential to cause pneumonitis and <e2>lung fibrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4892	"Physicians should keep in mind that taxanes such as <e1>paclitaxel</e1> have the potential to cause <e2>pneumonitis</e2> and lung fibrosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4893	"<e1>Pulmonary fibrosis</e1> is a complication of <e2>paclitaxel</e2> therapy that may occur despite treatments with corticosteroids."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4894	"<e1>Infections</e1> are a major adverse effect during the treatment with <e2>anti-TNF-alpha</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4895	"In this case report, we have described a patient with Crohn's disease who developed <e1>subfulminant hepatitis B</e1> after the fourth infusion of <e2>infliximab</e2> due to an unrecognized HBs-antigen carrier state."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4896	"<e1>Subfulminant hepatitis B</e1> after <e2>infliximab</e2> in Crohn's disease: need for HBV-screening?"
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4897	"<e1>Acute unilateral total visual loss</e1> after retrogasserian <e2>phenol</e2> injection for the treatment of trigeminal neuralgia: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4898	"The visual loss in this patient seems to result from <e1>phenol</e1> <e2>neurotoxicity</e2> rather than mechanical compression of the intraorbital optic nerve."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4899	"The <e1>visual loss</e1> in this patient seems to result from <e2>phenol</e2> neurotoxicity rather than mechanical compression of the intraorbital optic nerve."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4900	"We report a 78-year-old man who had <e1>acute unilateral total visual loss</e1> after retrogasserian <e2>phenol</e2> injection for the treatment of trigeminal neuralgia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4901	"Drug induced <e1>liver injury</e1> secondary to interferon-beta (<e2>IFN-beta</e2>) in multiple sclerosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4902	"Drug induced <e1>liver injury</e1> secondary to <e2>interferon-beta</e2> (IFN-beta) in multiple sclerosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4903	"<e1>Grade 3 hepatotoxicity</e1> (AST and ALT > 5 to 20 upper limit normal) or higher has been observed in as many as 1.4% of MS patients on <e2>IFN beta</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4904	"Post marketing studies of Interferon-beta (<e1>IFN beta</e1>) therapy in multiple sclerosis (MS) have demonstrated surprisingly high rates of <e2>hepatotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4905	"Post marketing studies of <e1>Interferon-beta</e1> (IFN beta) therapy in multiple sclerosis (MS) have demonstrated surprisingly high rates of <e2>hepatotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4906	"We report three cases of <e1>IFN beta</e1> induced <e2>hepatitis</e2> in MS and discuss the pathology findings and possible mechanisms of drug-induced liver injury."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4907	"We report three cases of <e1>IFN beta</e1> induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug-induced <e2>liver injury</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4908	"A 55-year-old woman presented an episode of <e1>acute urticaria</e1> and labial angioedema 60 minutes after ingesting 500 mg of <e2>cloxacillin</e2> for a skin abscess."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4909	"A 55-year-old woman presented an episode of acute urticaria and <e1>labial angioedema</e1> 60 minutes after ingesting 500 mg of <e2>cloxacillin</e2> for a skin abscess."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4910	"<e1>Allergy</e1> to <e2>cloxacillin</e2> with normal tolerance to amoxicillin and cefuroxime."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4911	"Several <e1>hypersensitivity</e1> reactions to <e2>cloxacillin</e2> have been reported, although IgE-mediated allergic reactions to the drug are rare and there is little information about possible tolerance to other semisynthetic penicillins or cephalosporins in patients with <e2>cloxacillin</e2> allergy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4912	"Several hypersensitivity reactions to <e1>cloxacillin</e1> have been reported, although <e2>IgE-mediated allergic reactions</e2> to the drug are rare and there is little information about possible tolerance to other semisynthetic penicillins or cephalosporins in patients with <e1>cloxacillin</e1> allergy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4913	"<e1>Cardiac toxicity</e1> related to <e2>BCNU</e2> has not been described well."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4914	"<e1>Myocardial ischemia</e1> associated with high-dose <e2>carmustine</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4915	"Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of <e1>myocardial ischemia</e1> during and immediately after <e2>BCNU</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4916	"Adverse reaction in a patient with <e1>aspirin</e1> -induced <e2>asthma</e2> treated with zafirlukast."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4917	"We present a case of <e1>hypereosinophilia</e1> related to <e2>zafirlukast</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4918	"Shortly after chemotherapy and an injection of <e1>pegfilgrastim</e1>, the patient developed poorly defined, rapidly progressive erythema, <e2>edema</e2>, and pain in his right forearm."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4919	"Shortly after chemotherapy and an injection of <e1>pegfilgrastim</e1>, the patient developed poorly defined, rapidly progressive erythema, edema, and <e2>pain in his right forearm</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4920	"Shortly after chemotherapy and an injection of <e1>pegfilgrastim</e1>, the patient developed poorly defined, <e2>rapidly progressive erythema</e2>, edema, and pain in his right forearm."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4921	"A few recent individual case reports have suggested that a <e1>myasthenic syndrome</e1> may be associated with <e2>statin</e2> treatment, but this association is not well described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4922	"<e1>Statin</e1> -associated <e2>myasthenia gravis</e2>: report of 4 cases and review of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4923	"We report 4 patients who developed symptoms of <e1>myasthenia gravis</e1> within 2 weeks of starting treatment with a <e2>statin</e2> drug."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4924	"<e1>Reactivation of cytomegalovirus</e1> probably followed the treatment of Wegener's granulomatosis with corticosteroids and <e2>azathioprine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4925	"After excluding other causes of long QT syndrome, the <e1>HCQ</e1> was suspected as the cause of her <e2>ventricular tachycardia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4926	"Chronic <e1>hydroxychloroquine</e1> use associated with <e2>QT prolongation</e2> and refractory ventricular arrhythmia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4927	"Chronic <e1>hydroxychloroquine</e1> use associated with QT prolongation and <e2>refractory ventricular arrhythmia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4928	"CONCLUSION: The chronic use of <e1>HCQ</e1> for rheumatic diseases, or as an anti-malarial drug, should be balanced against the risk of developing potentially lethal <e2>cardiac arrhythmias</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4929	"We report a case of chronic use of <e1>HCQ</e1> associated with <e2>torsade de pointes</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4930	"CONCLUSIONS: The increasing prevalence of Type 2 diabetes and its treatment with <e1>metformin</e1> might result in more cases of <e2>lactic acidosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4931	"<e1>Severe acidosis</e1> in patients taking <e2>metformin</e2> --rapid reversal and survival despite high APACHE score."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4932	"Case report: lack of control of <e1>diabetes</e1> and weight gain in a patient on initiation and rechallenge of therapy with <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4933	"Case report: lack of control of diabetes and <e1>weight gain</e1> in a patient on initiation and rechallenge of therapy with <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4934	"The following is a case report analysis intended to draw attention to the need for better care coordination by describing the observed relationship of <e1>olanzapine</e1> to metabolic changes manifested as <e2>uncontrolled diabetes mellitus</e2> and weight gain."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4935	"The following is a case report analysis intended to draw attention to the need for better care coordination by describing the observed relationship of <e1>olanzapine</e1> to metabolic changes manifested as uncontrolled diabetes mellitus and <e2>weight gain</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4936	"The patient was enrolled in a weight-loss clinic, and his diabetes medications were adjusted.Subsequently, <e1>olanzapine</e1> was discontinued because of weight gain and <e2>uncontrolled diabetes</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4937	"The patient was enrolled in a weight-loss clinic, and his diabetes medications were adjusted.Subsequently, <e1>olanzapine</e1> was discontinued because of <e2>weight gain</e2> and uncontrolled diabetes."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4938	"PURPOSE: To report a case of traumatic flap dehiscence and <e1>Enterobacter keratitis</e1> 34 months after <e2>LASIK</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4939	"PURPOSE: To report a case of <e1>traumatic flap dehiscence</e1> and Enterobacter keratitis 34 months after <e2>LASIK</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4940	"Traumatic late flap dehiscence and <e1>Enterobacter keratitis</e1> following <e2>LASIK</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4941	"<e1>Traumatic late flap dehiscence</e1> and Enterobacter keratitis following <e2>LASIK</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4942	"We report the case of a lung cancer patient with bronquiloalveolar carcinoma (BAC) presenting with <e1>BOOP</e1> after chemotherapy with <e2>docetaxel</e2> and gemcitabine producing severe respiratory insufficiency, and simulating a progression of the tumor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4943	"We report the case of a lung cancer patient with bronquiloalveolar carcinoma (BAC) presenting with <e1>BOOP</e1> after chemotherapy with docetaxel and <e2>gemcitabine</e2> producing severe respiratory insufficiency, and simulating a progression of the tumor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4944	"We report the case of a lung cancer patient with bronquiloalveolar carcinoma (BAC) presenting with BOOP after chemotherapy with <e1>docetaxel</e1> and gemcitabine producing severe respiratory insufficiency, and simulating a <e2>progression of the tumor</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4945	"We report the case of a lung cancer patient with bronquiloalveolar carcinoma (BAC) presenting with BOOP after chemotherapy with docetaxel and <e1>gemcitabine</e1> producing severe respiratory insufficiency, and simulating a <e2>progression of the tumor</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4946	"We report the case of a lung cancer patient with bronquiloalveolar carcinoma (BAC) presenting with BOOP after chemotherapy with <e1>docetaxel</e1> and gemcitabine producing <e2>severe respiratory insufficiency</e2>, and simulating a progression of the tumor."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4947	"We report the case of a lung cancer patient with bronquiloalveolar carcinoma (BAC) presenting with BOOP after chemotherapy with docetaxel and <e1>gemcitabine</e1> producing <e2>severe respiratory insufficiency</e2>, and simulating a progression of the tumor."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4948	"A 65-year-old man on <e1>warfarin</e1> therapy with a sudden spontaneous onset of sub-conjunctival haematoma associated with <e2>bloody tears</e2> was assessed in the clinic following a referral from an optometrist."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4949	"A 65-year-old man on <e1>warfarin</e1> therapy with a sudden spontaneous onset of <e2>sub-conjunctival haematoma</e2> associated with bloody tears was assessed in the clinic following a referral from an optometrist."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4950	"An unusual presentation of spontaneous <e1>sub-conjunctival haematoma</e1> in a patient receiving <e2>warfarin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4951	"Due to discomfort, <e1>diplopia</e1> and lagophthalmos, the haematoma necessitated suspension of <e2>warfarin</e2> therapy and a surgical evacuation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4952	"Due to <e1>discomfort</e1>, diplopia and lagophthalmos, the haematoma necessitated suspension of <e2>warfarin</e2> therapy and a surgical evacuation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4953	"Due to discomfort, diplopia and lagophthalmos, the <e1>haematoma</e1> necessitated suspension of <e2>warfarin</e2> therapy and a surgical evacuation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4954	"Due to discomfort, diplopia and <e1>lagophthalmos</e1>, the haematoma necessitated suspension of <e2>warfarin</e2> therapy and a surgical evacuation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4955	"The <e1>sub-conjunctival haematoma</e1> in a patient receiving <e2>warfarin</e2> can pose a significant management challenge."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4956	"<e1>Angioedema</e1> and maculopapular eruptions associated with <e2>carbamazepine</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4957	"Angioedema and <e1>maculopapular eruptions</e1> associated with <e2>carbamazepine</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4958	"<e1>Angioedema</e1>, a rare side effect of <e2>carbamazepine</e2>, involves vascular leakage in dermis and subcutis mediated by immunoglobulin E and/or bradykinins."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4959	"<e1>Cutaneous eruptions</e1> occur in 3% of individuals administered <e2>carbamazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4960	"<e1>Cutaneous rashes</e1> and eruptions can be caused by many medications, including <e2>carbamazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4961	"Cutaneous rashes and <e1>eruptions</e1> can be caused by many medications, including <e2>carbamazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4962	"We report the case of a 27-year-old Indian woman who developed maculopapular rash and <e1>angioedema</e1> secondary to <e2>carbamazepine</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4963	"We report the case of a 27-year-old Indian woman who developed <e1>maculopapular rash</e1> and angioedema secondary to <e2>carbamazepine</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4964	"Severe adenovirus pneumonia (<e1>AVP</e1>) following <e2>infliximab</e2> infusion for the treatment of Crohn's disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4965	"<e1>Severe adenovirus pneumonia</e1> (AVP) following <e2>infliximab</e2> infusion for the treatment of Crohn's disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4966	"We report a case of <e1>severe AVP</e1> three weeks following the administration of <e2>infliximab</e2> for the treatment of Crohn's disease (CD)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4967	"First case of <e1>ivermectin</e1> -induced <e2>severe hepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4968	"To our knowledge, this is the first case of <e1>ivermectin</e1> -induced <e2>severe liver disease</e2> published in the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4969	"We report the case of a 20-year-old woman originally from Cameroon who was infected by the L. loa parasite and developed <e1>severe hepatitis</e1>, identified 1 month after a single dose of <e2>ivermectin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4970	"CASE REPORT: We hereby report a case of radiation recall dermatitis and <e1>myositis</e1> occurring on <e2>gemcitabine</e2> monotherapy, five months after completing chemoradiation for locally advanced pancreatic cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4971	"CASE REPORT: We hereby report a case of <e1>radiation recall dermatitis</e1> and myositis occurring on <e2>gemcitabine</e2> monotherapy, five months after completing chemoradiation for locally advanced pancreatic cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4972	"CONCLUSIONS: This is the second case report that describes <e1>gemcitabine</e1> -induced <e2>radiation recall</e2> in rectus abdominus muscles after <e1>gemcitabine</e1> -based radiation therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4973	"<e1>Gemcitabine</e1> -induced <e2>rectus abdominus radiation recall</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4974	"<e1>Sporadic rippling muscle disease</e1> unmasked by <e2>simvastatin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4975	"We report a 53-year-old-man who developed <e1>rippling muscle disease</e1> (RMD) 2 months after starting <e2>simvastatin</e2> therapy for hypercholesterolemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4976	"We report a 53-year-old-man who developed rippling muscle disease (<e1>RMD</e1>) 2 months after starting <e2>simvastatin</e2> therapy for hypercholesterolemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4977	"<e1>Acute coronary syndrome</e1> induced by <e2>capecitabine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4978	"This case highlights the possible development of <e1>acute coronary syndrome</e1> as a side effect of <e2>Capecitabine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4979	"Acute severe intoxication with <e1>carbamazepine</e1> is associated with seizures, <e2>coma</e2> and respiratory depression."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4980	"Acute severe intoxication with <e1>carbamazepine</e1> is associated with seizures, coma and <e2>respiratory depression</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4981	"Acute severe intoxication with <e1>carbamazepine</e1> is associated with <e2>seizures</e2>, coma and respiratory depression."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4982	"After rechallenge with monotherapy <e1>pegvisomant</e1>, however, the <e2>hepatic enzyme disturbances</e2> reappeared within a few weeks, indicating that most likely <e1>pegvisomant</e1> alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced hepatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4983	"After rechallenge with monotherapy <e1>pegvisomant</e1>, however, the <e2>hepatic enzyme disturbances</e2> reappeared within a few weeks, indicating that most likely <e1>pegvisomant</e1> alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced hepatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4984	"After rechallenge with monotherapy <e1>pegvisomant</e1>, however, the hepatic enzyme disturbances reappeared within a few weeks, indicating that most likely <e1>pegvisomant</e1> alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced <e2>hepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4985	"Drug-induced <e1>hepatitis</e1> in an acromegalic patient during combined treatment with pegvisomant and <e2>octreotide</e2> long-acting repeatable attributed to the use of pegvisomant."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4986	"Drug-induced <e1>hepatitis</e1> in an acromegalic patient during combined treatment with <e2>pegvisomant</e2> and octreotide long-acting repeatable attributed to the use of <e2>pegvisomant</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4987	"Drug-induced <e1>hepatitis</e1> in an acromegalic patient during combined treatment with <e2>pegvisomant</e2> and octreotide long-acting repeatable attributed to the use of <e2>pegvisomant</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4988	"The <e1>hepatic enzyme disturbances</e1> normalized after discontinuation of <e2>pegvisomant</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4989	"We report on a patient with acromegaly who developed severe drug-induced <e1>hepatitis</e1> during combined treatment with the long-acting somatostatin-analog <e2>octreotide</e2> and the GH receptor antagonist pegvisomant."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4990	"We report on a patient with acromegaly who developed severe drug-induced <e1>hepatitis</e1> during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist <e2>pegvisomant</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4991	"Amphotericin B (<e1>AmB</e1>) is effective, but its use is limited by toxicity: renal impairment, <e2>anaemia</e2>, fever, malaise, and hypokalaemia are common."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4992	"<e1>Amphotericin B</e1> (AmB) is effective, but its use is limited by toxicity: renal impairment, <e2>anaemia</e2>, fever, malaise, and hypokalaemia are common."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4993	"Amphotericin B (<e1>AmB</e1>) is effective, but its use is limited by toxicity: renal impairment, anaemia, <e2>fever</e2>, malaise, and hypokalaemia are common."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4994	"<e1>Amphotericin B</e1> (AmB) is effective, but its use is limited by toxicity: renal impairment, anaemia, <e2>fever</e2>, malaise, and hypokalaemia are common."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4995	"Amphotericin B (<e1>AmB</e1>) is effective, but its use is limited by toxicity: renal impairment, anaemia, fever, malaise, and <e2>hypokalaemia</e2> are common."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4996	"<e1>Amphotericin B</e1> (AmB) is effective, but its use is limited by toxicity: renal impairment, anaemia, fever, malaise, and <e2>hypokalaemia</e2> are common."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4997	"Amphotericin B (<e1>AmB</e1>) is effective, but its use is limited by toxicity: renal impairment, anaemia, fever, <e2>malaise</e2>, and hypokalaemia are common."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4998	"<e1>Amphotericin B</e1> (AmB) is effective, but its use is limited by toxicity: renal impairment, anaemia, fever, <e2>malaise</e2>, and hypokalaemia are common."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4999	"Amphotericin B (<e1>AmB</e1>) is effective, but its use is limited by toxicity: <e2>renal impairment</e2>, anaemia, fever, malaise, and hypokalaemia are common."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5000	"<e1>Amphotericin B</e1> (AmB) is effective, but its use is limited by toxicity: <e2>renal impairment</e2>, anaemia, fever, malaise, and hypokalaemia are common."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5001	"DIAGNOSIS: Severe <e1>temozolomide</e1> -induced immunosuppression, exacerbated by corticosteroids, with profound T-cell lymphocytopenia and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia, <e2>brain abscess with Listeria monocytogenes</e2>, and cutaneous Kaposi's sarcoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5002	"DIAGNOSIS: Severe <e1>temozolomide</e1> -induced immunosuppression, exacerbated by corticosteroids, with profound T-cell lymphocytopenia and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia, brain abscess with Listeria monocytogenes, and <e2>cutaneous Kaposi's sarcoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5003	"DIAGNOSIS: Severe <e1>temozolomide</e1> -induced <e2>immunosuppression</e2>, exacerbated by corticosteroids, with profound T-cell lymphocytopenia and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia, brain abscess with Listeria monocytogenes, and cutaneous Kaposi's sarcoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5004	"DIAGNOSIS: Severe <e1>temozolomide</e1> -induced immunosuppression, exacerbated by corticosteroids, with profound T-cell lymphocytopenia and simultaneous opportunistic <e2>infections with Pneumocystis jiroveci pneumonia</e2>, brain abscess with Listeria monocytogenes, and cutaneous Kaposi's sarcoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5005	"DIAGNOSIS: Severe <e1>temozolomide</e1> -induced immunosuppression, exacerbated by corticosteroids, with profound <e2>T-cell lymphocytopenia</e2> and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia, brain abscess with Listeria monocytogenes, and cutaneous Kaposi's sarcoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5006	"Listeria brain abscess, Pneumocystis pneumonia and <e1>Kaposi's sarcoma</e1> after <e2>temozolomide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5007	"<e1>Listeria brain abscess</e1>, Pneumocystis pneumonia and Kaposi's sarcoma after <e2>temozolomide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5008	"Listeria brain abscess, <e1>Pneumocystis pneumonia</e1> and Kaposi's sarcoma after <e2>temozolomide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5009	"PURPOSE: <e1>Topiramate</e1> -induced <e2>angle-closure glaucoma</e2> (TiACG) is believed to be related to its sulfonamide moiety."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5010	"Rapid resolution of topiramate-induced <e1>angle-closure glaucoma</e1> with methylprednisolone and <e2>mannitol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5011	"Rapid resolution of topiramate-induced <e1>angle-closure glaucoma</e1> with <e2>methylprednisolone</e2> and mannitol."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5012	"Rapid resolution of <e1>topiramate</e1> -induced <e2>angle-closure glaucoma</e2> with methylprednisolone and mannitol."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5013	"<e1>Spontaneous splenic infarction</e1> associated with <e2>sumatriptan</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5014	"Though they are generally considered safe, there have been a few reports of <e1>myocardial infarction</e1> and stroke associated with <e2>triptan</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5015	"Though they are generally considered safe, there have been a few reports of myocardial infarction and <e1>stroke</e1> associated with <e2>triptan</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5016	"We report a patient who developed <e1>spontaneous splenic infarction</e1> after the use of <e2>sumatriptan</e2> for the treatment of migraine headache."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5017	"<e1>Acute myocardial infarction</e1> during high-dose <e2>methylprednisolone</e2> therapy for Graves' ophthalmopathy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5018	"Except <e1>hypothyroidism</e1> after <e2>radioiodine</e2> treatment (euthyroid under substitutional therapy), she suffered from no other diseases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5019	"Here we present the case of a woman who received high doses of <e1>methylprednisolone</e1> (1 g iv daily) for active Graves' ophthalmopathy, and developed severe hypertension followed by <e2>myocardial infarction</e2> on the fifth day of treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5020	"Here we present the case of a woman who received high doses of <e1>methylprednisolone</e1> (1 g iv daily) for active Graves' ophthalmopathy, and developed <e2>severe hypertension</e2> followed by myocardial infarction on the fifth day of treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5021	"We conclude that <e1>myocardial infarction</e1> may develop in patients treated with high-dose <e2>glucocorticoids</e2> for Graves' ophthalmopathy, and increased blood pressure may herald this complication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5022	"Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (<e1>SASP</e1>) therapy developed a severe and lasting <e2>psoriasis-like skin reaction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5023	"Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of <e1>sulphasalazine</e1> (SASP) therapy developed a severe and lasting <e2>psoriasis-like skin reaction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5024	"<e1>Psoriasis-like skin reaction</e1> in a patient with rheumatoid arthritis after <e2>sulphasalazine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5025	"Five days after the fourth dose of <e1>vincristine</e1>, she presented with <e2>bilateral ptosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5026	"<e1>Vincristine</e1> induced <e2>cranial polyneuropathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5027	"We describe a 5-year-old girl showed recovery of <e1>vincristine</e1> induced <e2>cranial polyneuropathy</e2> with pyridoxine and pyridostigmine treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5028	"<e1>Acute generalized exanthematous pustulosis</e1> caused by <e2>morphine</e2>, confirmed by positive patch test and lymphocyte transformation test."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5029	"<e1>Morphine</e1>, an opium alkaloid, frequently causes side effects such as hyperhidrosis and <e2>facial flushing</e2>, but serious cutaneous adverse drug reactions are seldom observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5030	"<e1>Morphine</e1>, an opium alkaloid, frequently causes side effects such as <e2>hyperhidrosis</e2> and facial flushing, but serious cutaneous adverse drug reactions are seldom observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5031	"We describe a case of a man treated with an EGFR-inhibitor (<e1>erlotinib</e1>) for a cell lung cancer who developed <e2>skin manifestations</e2> localized in an uncommon area and with an atypical evolution."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5032	"<e1>Olanzapine</e1> -associated <e2>neuroleptic malignant syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5033	"<e1>Allergic contact angioedema</e1> to <e2>benzoyl peroxide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5034	"Factors that suggested an association between the <e1>severe angioedematous reaction</e1> and <e2>BP</e2> topical application include the strong reaction to <e2>BP</e2> in the patch-test, the temporal relationship, the complete resolution of symptoms after the drug was withdrawn and the absence of other identified explanations."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5035	"A 35-year-old woman presented with neurotoxicity correlated to an i.v. regimen of <e1>5-fluorouracil</e1> as episodes of <e2>acute confusional state</e2> and abnormalities of symmetrically restricted diffusion in the periventricular white matter and corpus callosum."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5036	"A 35-year-old woman presented with <e1>neurotoxicity</e1> correlated to an i.v. regimen of <e2>5-fluorouracil</e2> as episodes of acute confusional state and abnormalities of symmetrically restricted diffusion in the periventricular white matter and corpus callosum."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5037	"Reversible findings of restricted diffusion in <e1>5-fluorouracil</e1> <e2>neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5038	"We present the case of a 58-year-old woman who ingested more than 35 g of <e1>caffeine</e1> in a <e2>suicide attempt</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5039	"It may cause a severe adverse drug reaction with multiorgan involvement known as <e1>dapsone</e1> <e2>hypersensitivity syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5040	"Severe <e1>dapsone</e1> <e2>hypersensitivity syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5041	"We report the case of a 21-year-old female patient with <e1>dapsone</e1> <e2>hypersensitivity syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5042	"<e1>Anaphylaxis</e1> to intrathecal <e2>diamorphine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5043	"We believe this is the first report of intrathecal <e1>diamorphine</e1> causing <e2>anaphylaxis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5044	"We highlight two instances of <e1>systemic allergic reaction</e1>, and discuss the potential side effects of local <e2>aprotinin</e2> injections in the orthopaedic setting as well as the evidence base for its use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5045	"METHOD: Case analysis of a poly-drug overdose (venlafaxine, topiramate, divalproex sodium, risperidone, and <e1>carbamazepine</e1>) presenting with mixed SS/<e2>NMS</e2> features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/<e2>NMS</e2> in critical care settings."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5046	"METHOD: Case analysis of a poly-drug overdose (venlafaxine, topiramate, <e1>divalproex sodium</e1>, risperidone, and carbamazepine) presenting with mixed SS/<e2>NMS</e2> features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/<e2>NMS</e2> in critical care settings."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5047	"METHOD: Case analysis of a poly-drug overdose (venlafaxine, topiramate, divalproex sodium, <e1>risperidone</e1>, and carbamazepine) presenting with mixed SS/<e2>NMS</e2> features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/<e2>NMS</e2> in critical care settings."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5048	"METHOD: Case analysis of a poly-drug overdose (venlafaxine, <e1>topiramate</e1>, divalproex sodium, risperidone, and carbamazepine) presenting with mixed SS/<e2>NMS</e2> features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/<e2>NMS</e2> in critical care settings."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5049	"METHOD: Case analysis of a poly-drug overdose (<e1>venlafaxine</e1>, topiramate, divalproex sodium, risperidone, and carbamazepine) presenting with mixed SS/<e2>NMS</e2> features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/<e2>NMS</e2> in critical care settings."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5050	"METHOD: Case analysis of a poly-drug overdose (venlafaxine, topiramate, divalproex sodium, risperidone, and <e1>carbamazepine</e1>) presenting with mixed <e2>SS</e2>/NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated <e2>SS</e2>/NMS in critical care settings."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5051	"METHOD: Case analysis of a poly-drug overdose (venlafaxine, topiramate, <e1>divalproex sodium</e1>, risperidone, and carbamazepine) presenting with mixed <e2>SS</e2>/NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated <e2>SS</e2>/NMS in critical care settings."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5052	"METHOD: Case analysis of a poly-drug overdose (venlafaxine, topiramate, divalproex sodium, <e1>risperidone</e1>, and carbamazepine) presenting with mixed <e2>SS</e2>/NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated <e2>SS</e2>/NMS in critical care settings."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5053	"METHOD: Case analysis of a poly-drug overdose (venlafaxine, <e1>topiramate</e1>, divalproex sodium, risperidone, and carbamazepine) presenting with mixed <e2>SS</e2>/NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated <e2>SS</e2>/NMS in critical care settings."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5054	"METHOD: Case analysis of a poly-drug overdose (<e1>venlafaxine</e1>, topiramate, divalproex sodium, risperidone, and carbamazepine) presenting with mixed <e2>SS</e2>/NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated <e2>SS</e2>/NMS in critical care settings."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5055	"<e1>Fever</e1> and maculopapular rashes appeared at 10 days after <e2>phenytoin</e2> initiation, and then the drug was discontinued."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5056	"Fever and <e1>maculopapular rashes</e1> appeared at 10 days after <e2>phenytoin</e2> initiation, and then the drug was discontinued."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5057	"<e1>Localized purpura</e1> associated with <e2>lamotrigine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5058	"This case study is the second report of <e1>localized purpura</e1> after prolonged <e2>lamotrigine</e2> treatment suggesting this may be an atypical <e2>lamotrigine</e2> -induced drug reaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5059	"This report describes a 13-year-old female with a right frontal high-grade glioma and complex partial seizures who developed <e1>localized purpura</e1> after 23 months of <e2>lamotrigine</e2> monotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5060	"<e1>Acute renal failure</e1> during <e2>lisinopril</e2> and losartan therapy for proteinuria."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5061	"<e1>Acute renal failure</e1> during lisinopril and <e2>losartan</e2> therapy for proteinuria."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5062	"This report describes a case of acute compromise of renal function associated with <e1>hypotension</e1> in a 7-year-old boy treated with the ACE inhibitor <e2>lisinopril</e2> and the ARB losartan."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5063	"This report describes a case of acute compromise of renal function associated with <e1>hypotension</e1> in a 7-year-old boy treated with the ACE inhibitor lisinopril and the ARB <e2>losartan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5064	"<e1>Reversible corneal keratinization</e1> following trabeculectomy and treatment with <e2>5-fluorouracil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5065	"<e1>Bronchiolitis obliterans with organizing pneumonia</e1> after <e2>rituximab</e2> therapy for non-Hodgkin's lymphoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5066	"Moreover, these findings suggest that the incidence of <e1>BOOP</e1> following <e2>rituximab</e2> therapy may be higher than has been previously appreciated."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5067	"This is the first reported case of <e1>BOOP</e1> associated with single-agent <e2>rituximab</e2>, and along with two other patients we describe, as well as two prior reports of <e1>BOOP</e1> in NHL patients receiving <e2>rituximab</e2> -based combinations, strengthens the possibility of a causal relationship."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5068	"This is the first reported case of <e1>BOOP</e1> associated with single-agent <e2>rituximab</e2>, and along with two other patients we describe, as well as two prior reports of <e1>BOOP</e1> in NHL patients receiving <e2>rituximab</e2> -based combinations, strengthens the possibility of a causal relationship."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5069	"We describe a case of an NHL patient who received <e1>rituximab</e1> and developed symptomatic, biopsy-proven multinodular <e2>bronchiolitis obliterans with organizing pneumonia</e2> (BOOP)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5070	"Despite a very low complication rate, several <e1>severe arterial thrombotic events</e1> have been reported following <e2>thrombin</e2> injection of pseudoaneurysms."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5071	"Lower extremity <e1>arterial thrombosis</e1> following sonographically guided <e2>thrombin</e2> injection of a femoral pseudoaneurysm."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5072	"Native <e1>arterial thrombosis</e1>, though recognized as a severe complication of <e2>thrombin</e2> injection, has not been well described in the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5073	"We report a case of successful surgical management of <e1>arterial thrombosis</e1> after percutaneous <e2>thrombin</e2> injection of a femoral artery pseudoaneurysm in a 69-year-old woman."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5074	"A small number of <e1>oxaliplatin</e1> -related <e2>hemolytic and/or thrombocytopenic reactions</e2> have been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5075	"<e1>Hemolytic uremic syndrome</e1> following the infusion of <e2>oxaliplatin</e2>: case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5076	"We present a case of <e1>hemolytic-uremic syndrome</e1> that developed during the 4th cycle of combination chemotherapy with oxaliplatin, <e2>5-fluorouracil</e2> and leucovorin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5077	"We present a case of <e1>hemolytic-uremic syndrome</e1> that developed during the 4th cycle of combination chemotherapy with oxaliplatin, 5-fluorouracil and <e2>leucovorin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5078	"We present a case of <e1>hemolytic-uremic syndrome</e1> that developed during the 4th cycle of combination chemotherapy with <e2>oxaliplatin</e2>, 5-fluorouracil and leucovorin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5079	"First, a review of the literature produced 41 anecdotic cases of neutropenia or <e1>agranulocytosis</e1> during treatment with <e2>olanzapine</e2> (Zyprexa) reported in a total of 24 publications."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5080	"First, a review of the literature produced 41 anecdotic cases of neutropenia or <e1>agranulocytosis</e1> during treatment with olanzapine (<e2>Zyprexa</e2>) reported in a total of 24 publications."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5081	"First, a review of the literature produced 41 anecdotic cases of <e1>neutropenia</e1> or agranulocytosis during treatment with <e2>olanzapine</e2> (Zyprexa) reported in a total of 24 publications."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5082	"First, a review of the literature produced 41 anecdotic cases of <e1>neutropenia</e1> or agranulocytosis during treatment with olanzapine (<e2>Zyprexa</e2>) reported in a total of 24 publications."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5083	"Neutropenia and <e1>agranulocytosis</e1> are risks known to occur with phenothiazines and <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5084	"Neutropenia and <e1>agranulocytosis</e1> are risks known to occur with <e2>phenothiazines</e2> and clozapine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5085	"<e1>Neutropenia</e1> and agranulocytosis are risks known to occur with phenothiazines and <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5086	"<e1>Neutropenia</e1> and agranulocytosis are risks known to occur with <e2>phenothiazines</e2> and clozapine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5087	"Second, we report a case of <e1>neutropenia</e1>, which proved to be fatal in a schizophrenia patient receiving <e2>olanzapine</e2> and thiazide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5088	"Second, we report a case of <e1>neutropenia</e1>, which proved to be fatal in a schizophrenia patient receiving olanzapine and <e2>thiazide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5089	"Thus any case of <e1>severe neutropenia</e1> occurring in a patient receiving <e2>olanzapine</e2> is alarming to clinicians."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5090	"We present a depressive patient who developed mild parkinsonian signs and <e1>camptocormia</e1> after the introduction of <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5091	"We present a depressive patient who developed <e1>mild parkinsonian signs</e1> and camptocormia after the introduction of <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5092	"Five months after initiating <e1>mirtazapine</e1> therapy, she developed <e2>symptomatic hyponatremia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5093	"In this case, unlike those previously reported, <e1>hyponatremia</e1> recurred 5 months after switching from <e2>citalopram</e2> to mirtazapine, which is believed to be a safe antidepressant."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5094	"In this case, unlike those previously reported, <e1>hyponatremia</e1> recurred 5 months after switching from citalopram to <e2>mirtazapine</e2>, which is believed to be a safe antidepressant."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5095	"<e1>Recurrent hyponatremia</e1> associated with <e2>citalopram</e2> and mirtazapine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5096	"<e1>Recurrent hyponatremia</e1> associated with citalopram and <e2>mirtazapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5097	"A 43-year-old woman with multiple sclerosis (MS) had <e1>nephrotic syndrome</e1> 21 months after starting treatment with <e2>interferon (IFN)-beta-1b</e2> (subcutaneous administration)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5098	"Because <e1>nephrotic syndrome</e1> may be induced by <e2>IFN</e2> therapy, the <e2>IFN</e2> was stopped."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5099	"Because <e1>nephrotic syndrome</e1> may be induced by <e2>IFN</e2> therapy, the <e2>IFN</e2> was stopped."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5100	"<e1>Nephrotic syndrome</e1> associated with <e2>interferon-beta-1b</e2> therapy for multiple sclerosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5101	"Though proteinuria and <e1>nephrotic syndrome</e1> is a rare adverse effect of <e2>IFN-beta-1b</e2> therapy, physicians treating MS patients with this agent should pay careful attention to new clinical symptoms and laboratory findings."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5102	"Though <e1>proteinuria</e1> and nephrotic syndrome is a rare adverse effect of <e2>IFN-beta-1b</e2> therapy, physicians treating MS patients with this agent should pay careful attention to new clinical symptoms and laboratory findings."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5103	"A 70-year-old man was admitted to our hospital because of <e1>dyspnea</e1> after taking an antihistaminic agent (<e2>homochlorcyclizine hydrochloride</e2>) for itching."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5104	"<e1>Acute eosinophilic pneumonia</e1> caused by <e2>calcium stearate</e2>, an additive agent for an oral antihistaminic medication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5105	"Therefore, we concluded that this patient's <e1>pulmonary disease</e1> was caused by <e2>calcium stearate</e2>, an additive for an antihistaminic drug."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5106	"<e1>Scleritis</e1> complicating <e2>zoledronic acid</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5107	"We present a case of <e1>severe unilateral posterior scleritis</e1> associated with <e2>zoledronic acid</e2> administration that was recognized and treated in a timely manner."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5108	"Late lethal <e1>hepatitis B virus reactivation</e1> after <e2>rituximab</e2> treatment of low-grade cutaneous B-cell lymphoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5109	"Several such <e1>HBV reactivations</e1> were reported after combined <e2>rituximab</e2> and multiagent chemotherapy for B-cell lymphomas."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5110	"This is the first case of <e1>HBV reactivation</e1> occurring during the year following <e2>rituximab</e2> monotherapy in the absence of any other immunosuppressive factor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5111	"This is a case report of fatal <e1>cryptococcal meningitis</e1> in a child with systemic lupus erythematosus being treated with prednisolone and <e2>azathioprine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5112	"This is a case report of fatal <e1>cryptococcal meningitis</e1> in a child with systemic lupus erythematosus being treated with <e2>prednisolone</e2> and azathioprine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5113	"An <e1>intertrigo-like eruption</e1> from pegylated liposomal <e2>doxorubicin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5114	"This <e1>eruption</e1> appears to be a distinct cutaneous toxicity of <e2>PLD</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5115	"We report the case of a 60-year-old woman who developed erythema and <e1>erosions in the axilla and groin</e1> while on <e2>PLD</e2> for breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5116	"We report the case of a 60-year-old woman who developed <e1>erythema</e1> and erosions in the axilla and groin while on <e2>PLD</e2> for breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5117	"Herein is reported an unusual case of coexistent <e1>warfarin</e1> -induced <e2>skin necrosis</e2> and heparin-induced thrombocytopenia following mitral valve replacement for thromboembolic phenomena associated with marantic endocarditis and bronchial adenocarcinoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5118	"Herein is reported an unusual case of coexistent warfarin-induced skin necrosis and <e1>heparin</e1> -induced <e2>thrombocytopenia</e2> following mitral valve replacement for thromboembolic phenomena associated with marantic endocarditis and bronchial adenocarcinoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5119	"<e1>Warfarin</e1> -induced <e2>skin necrosis</e2> and heparin-induced thrombocytopenia following mitral valve replacement for marantic endocarditis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5120	"Warfarin-induced skin necrosis and <e1>heparin</e1> -induced <e2>thrombocytopenia</e2> following mitral valve replacement for marantic endocarditis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5121	"Exposure of the fetus to <e1>indomethacin</e1> by administration of the drug to the mother may cause many side effects, including <e2>premature closure of the ductus arteriosus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5122	"<e1>Hypoxia</e1> is a predisposing factor for premature ductal closure and often occurs after maternal <e2>indomethacin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5123	"Hypoxia is a predisposing factor for <e1>premature ductal closure</e1> and often occurs after maternal <e2>indomethacin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5124	"<e1>Premature closure of the ductus arteriosus</e1>: variable response among monozygotic twins after in utero exposure to <e2>indomethacin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5125	"This selective closure of the ductus arteriosus suggests that the affected twin was predisposed to hypoxia and thus was more susceptible to <e1>ductal closure</e1> in response to <e2>indomethacin</e2> exposure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5126	"This selective closure of the ductus arteriosus suggests that the affected twin was predisposed to <e1>hypoxia</e1> and thus was more susceptible to ductal closure in response to <e2>indomethacin</e2> exposure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5127	"CONCLUSION: These cases suggest that <e1>moxifloxacin</e1> may interfere with the healing of <e2>corneal ulcers</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5128	"RESULTS: Both cases presented here describe <e1>corneal ulcers</e1> that persisted and showed signs of worsening during weeks of frequent topical dosing with <e2>moxifloxacin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5129	"<e1>Severe corneal toxicity</e1> after topical <e2>fluoroquinolone</e2> therapy: report of two cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5130	"<e1>Acute generalized exanthematous pustulosis</e1> induced by <e2>nimesulide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5131	"We report a case of <e1>acute generalized exanthematous pustulosis</e1> (AGEP) in a 50-year-old woman that was attributed to the ingestion of <e2>nimesulide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5132	"We report a case of acute generalized exanthematous pustulosis (<e1>AGEP</e1>) in a 50-year-old woman that was attributed to the ingestion of <e2>nimesulide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5133	"DISCUSSION: <e1>Amphotericin B deoxycholate</e1> has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and <e2>bradycardia</e2> reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5134	"DISCUSSION: <e1>Amphotericin B deoxycholate</e1> has been reported to produce significant <e2>cardiac toxicity</e2>, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5135	"DISCUSSION: <e1>Amphotericin B deoxycholate</e1> has been reported to produce significant cardiac toxicity, with <e2>ventricular arrhythmias</e2> and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5136	"OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a <e1>fatal cardiac arrhythmia</e1> after an acute overdose of <e2>amphotericin B</e2> and to review its toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5137	"Use of the Naranjo probability scale indicated a highly probable relationship between the observed <e1>cardiac toxicity</e1> and <e2>amphotericin B deoxycholate</e2> therapy in this patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5138	"The authors describe a case of <e1>valvular heart disease</e1> in a 48-year-old woman receiving <e2>benfluorex</e2> (150 mg t.i.d. for 8 years) and leading to surgical mitral valve replacement."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5139	"<e1>Valvular heart disease</e1> in a patient taking <e2>benfluorex</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5140	"The main side-effects of <e1>Lp-TAE</e1> combined with HT were low-grade fever, localized pain, myelo-suppression and <e2>liver dysfunction</e2>, but these were transient and eventually disappeared."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5141	"The main side-effects of <e1>Lp-TAE</e1> combined with HT were low-grade fever, <e2>localized pain</e2>, myelo-suppression and liver dysfunction, but these were transient and eventually disappeared."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5142	"The main side-effects of <e1>Lp-TAE</e1> combined with HT were <e2>low-grade fever</e2>, localized pain, myelo-suppression and liver dysfunction, but these were transient and eventually disappeared."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5143	"The main side-effects of <e1>Lp-TAE</e1> combined with HT were low-grade fever, localized pain, <e2>myelo-suppression</e2> and liver dysfunction, but these were transient and eventually disappeared."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5144	"<e1>Tacrolimus</e1> -induced HUS: an unusual cause of <e2>acute renal failure</e2> in nephrotic syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5145	"<e1>Tacrolimus</e1> -induced <e2>HUS</e2>: an unusual cause of acute renal failure in nephrotic syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5146	"Thus, <e1>tacrolimus</e1> -induced HUS is a rare cause of <e2>ARF</e2> in nephrotic syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5147	"Thus, <e1>tacrolimus</e1> -induced <e2>HUS</e2> is a rare cause of ARF in nephrotic syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5148	"Liver transplantation for <e1>fulminant hepatitis</e1> related to <e2>nevirapine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5149	"We describe a detailed case of <e1>fulminant hepatitis</e1> induced by <e2>nevirapine</e2> (Viramune) and treated by liver transplantation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5150	"We describe a detailed case of <e1>fulminant hepatitis</e1> induced by nevirapine (<e2>Viramune</e2>) and treated by liver transplantation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5151	"<e1>Cholelithiasis</e1> and thrombosis of the central retinal vein in a renal transplant recipient treated with <e2>cyclosporin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5152	"Cholelithiasis and <e1>thrombosis of the central retinal vein</e1> in a renal transplant recipient treated with <e2>cyclosporin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5153	"In this report, a patient who had undergone a renal transplantation as a result of malignant hypertension, and who was on immunosuppressive therapy consisting of cyclosporin, prednisone and <e1>azathioprine</e1>, developed <e2>thrombosis</e2> of the central retinal vein 5 years following the transplantation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5154	"In this report, a patient who had undergone a renal transplantation as a result of malignant hypertension, and who was on immunosuppressive therapy consisting of <e1>cyclosporin</e1>, prednisone and azathioprine, developed <e2>thrombosis</e2> of the central retinal vein 5 years following the transplantation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5155	"In this report, a patient who had undergone a renal transplantation as a result of malignant hypertension, and who was on immunosuppressive therapy consisting of cyclosporin, <e1>prednisone</e1> and azathioprine, developed <e2>thrombosis</e2> of the central retinal vein 5 years following the transplantation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5156	"The use of <e1>cyclosporin</e1> has been associated with the development of <e2>cholelithiasis</e2> in transplant recipients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5157	"<e1>Hepatotoxicity</e1> induced by <e2>cyproterone acetate</e2>: a report of three cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5158	"Three male patients aged 78-83 years are presented, in whom <e1>severe hepatotoxic reactions</e1> emerged after <e2>CPA</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5159	"CASE PRESENTATION: Three cases of Leishmania infantum leishmaniasis in corticosteroid (<e1>CS</e1>)-treated patients are reported: an isolated lingual leishmaniasis in a farmer treated with <e1>CS</e1> for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after <e2>cutaneous leishmaniasis</e2> in a man receiving <e1>CS</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5160	"CASE PRESENTATION: Three cases of <e1>Leishmania infantum leishmaniasis</e1> in <e2>corticosteroid</e2> (CS)-treated patients are reported: an isolated lingual leishmaniasis in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving CS."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5161	"CASE PRESENTATION: Three cases of <e1>Leishmania infantum leishmaniasis</e1> in corticosteroid (<e2>CS</e2>)-treated patients are reported: an isolated lingual leishmaniasis in a farmer treated with <e2>CS</e2> for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving <e2>CS</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5162	"CASE PRESENTATION: Three cases of Leishmania infantum leishmaniasis in <e1>corticosteroid</e1> (CS)-treated patients are reported: an isolated <e2>lingual leishmaniasis</e2> in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving CS."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5163	"CASE PRESENTATION: Three cases of Leishmania infantum leishmaniasis in corticosteroid (<e1>CS</e1>)-treated patients are reported: an isolated <e2>lingual leishmaniasis</e2> in a farmer treated with <e1>CS</e1> for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving <e1>CS</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5164	"<e1>Leishmania infantum leishmaniasis</e1> in <e2>corticosteroid</e2> --treated patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5165	"However, an association of <e1>Ritalin</e1> with <e2>glaucoma</e2> has been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5166	"Large dose of <e1>methylphenidate</e1> may cause <e2>cataract</e2> and glaucoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5167	"Large dose of <e1>methylphenidate</e1> may cause cataract and <e2>glaucoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5168	"<e1>Methylphenidate</e1> (Ritalin)-associated <e2>cataract</e2> and glaucoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5169	"Methylphenidate (<e1>Ritalin</e1>)-associated <e2>cataract</e2> and glaucoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5170	"<e1>Methylphenidate</e1> (Ritalin)-associated cataract and <e2>glaucoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5171	"Methylphenidate (<e1>Ritalin</e1>)-associated cataract and <e2>glaucoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5172	"We report a case of <e1>Ritalin</e1> -associated <e2>cataract</e2> and glaucoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5173	"We report a case of <e1>Ritalin</e1> -associated cataract and <e2>glaucoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5174	"CONCLUSIONS: We report a typical symptoms of Charles-Bonnet syndrome (<e1>CBS</e1>) in patients with severe AMD after intravitreal <e2>Avastin</e2> -injections."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5175	"CONCLUSIONS: We report a typical symptoms of <e1>Charles-Bonnet syndrome</e1> (CBS) in patients with severe AMD after intravitreal <e2>Avastin</e2> -injections."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5176	"PURPOSE: To describe <e1>transient structured visual hallucinations</e1> in a patient with vascular age-related macular degeneration (AMD), following an intravitreal <e2>Avastin</e2> -injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5177	"<e1>Visual hallucinations</e1> after intravitreal injection of <e2>bevacizumab</e2> in vascular age-related macular degeneration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5178	"A case of <e1>metoclopramide</e1> -induced <e2>oculogyric crisis</e2> in a 16-year-old girl with cystic fibrosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5179	"A case of <e1>oculogyric crisis</e1> induced by <e2>metoclopramide</e2> is described in this paper."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5180	"However, <e1>cyclosporine</e1> dependency is associated with the risk of <e2>nephrotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5181	"<e1>Quinapril</e1> is an angiotensin-converting enzyme inhibitor (ACE-inhibitor) and overdose can lead to <e2>prolonged hypotension</e2> and, less frequently, transient renal impairment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5182	"<e1>Quinapril</e1> is an angiotensin-converting enzyme inhibitor (ACE-inhibitor) and overdose can lead to prolonged hypotension and, less frequently, <e2>transient renal impairment</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5183	"<e1>Cardiomyopathy</e1> after widely separated courses of adriamycin exacerbated by <e2>actinomycin-D</e2> and mithramycin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5184	"<e1>Cardiomyopathy</e1> after widely separated courses of <e2>adriamycin</e2> exacerbated by actinomycin-D and mithramycin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5185	"<e1>Cardiomyopathy</e1> after widely separated courses of adriamycin exacerbated by actinomycin-D and <e2>mithramycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5186	"<e1>Exacerbations of the heart failure</e1> were temporally related to the administration of the antitumor antibiotics <e2>actinomycin-D</e2> (NSC-3053) and mithramycin (NSC-24559)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5187	"<e1>Exacerbations of the heart failure</e1> were temporally related to the administration of the antitumor antibiotics actinomycin-D (NSC-3053) and <e2>mithramycin</e2> (NSC-24559)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5188	"<e1>Exacerbations of the heart failure</e1> were temporally related to the administration of the antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (<e2>NSC-24559</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5189	"<e1>Exacerbations of the heart failure</e1> were temporally related to the administration of the antitumor antibiotics actinomycin-D (<e2>NSC-3053</e2>) and mithramycin (NSC-24559)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5190	"The pathogenic mechanisms involved in the development of <e1>adriamycin</e1> <e2>cardiomyopathy</e2> are reviewed, and the possible synergistic effect of other antitumor antibiotics is discussed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5191	"<e1>Cardiac hypersensitivity</e1> and myopericarditis have been reported during long-term treatment with <e2>mesalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5192	"Cardiac hypersensitivity and <e1>myopericarditis</e1> have been reported during long-term treatment with <e2>mesalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5193	"We report the case of a man, treated with <e1>mesalazine</e1> for Crohn's disease who developed drug-induced <e2>pericarditis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5194	"Acute drug induced <e1>hepatitis</e1> due to <e2>erlotinib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5195	"CASE REPORT: We report a case of <e1>acute severe hepatitis</e1> resulting from <e2>erlotinib</e2> monotherapy in a patient with locally advanced pancreatic cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5196	"CONCLUSIONS: <e1>Acute severe hepatitis</e1> though rare is occasionally observed with EGFR inhibitors gefitinib or <e2>erlotinib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5197	"CONCLUSIONS: <e1>Acute severe hepatitis</e1> though rare is occasionally observed with EGFR inhibitors <e2>gefitinib</e2> or erlotinib."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5198	"<e1>Hepatotoxicity</e1> resolved once <e2>erlotinib</e2> was discontinued and serum transaminases returned to baseline normal values."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5199	"<e1>Heparin</e1> -associated <e2>thrombocytopenia</e2> and thrombosis is a severe complication of systemic heparin therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5200	"Heparin-associated <e1>thrombocytopenia</e1> and thrombosis is a severe complication of systemic <e2>heparin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5201	"<e1>Heparin</e1> -associated thrombocytopenia and <e2>thrombosis</e2> is a severe complication of systemic heparin therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5202	"Heparin-associated thrombocytopenia and <e1>thrombosis</e1> is a severe complication of systemic <e2>heparin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5203	"This experience supports the hypothesis that <e1>heparin</e1> can be readministered early to patients with <e1>heparin</e1> -associated <e2>thrombocytopenia</e2> and thrombosis, provided antiplatelet therapy is given."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5204	"This experience supports the hypothesis that <e1>heparin</e1> can be readministered early to patients with <e1>heparin</e1> -associated thrombocytopenia and <e2>thrombosis</e2>, provided antiplatelet therapy is given."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5205	"Usefulness of antiplatelet drugs in the management of <e1>heparin</e1> -associated <e2>thrombocytopenia</e2> and thrombosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5206	"Usefulness of antiplatelet drugs in the management of <e1>heparin</e1> -associated thrombocytopenia and <e2>thrombosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5207	"RESULTS: A clinical diagnosis of <e1>fixed drug eruption</e1> owing to use of the PDE5 inhibitor tadalafil (<e2>Cialis</e2>) was made."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5208	"RESULTS: A clinical diagnosis of <e1>fixed drug eruption</e1> owing to use of the PDE5 inhibitor <e2>tadalafil</e2> (Cialis) was made."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5209	"Even though only a few cases of this adverse event have been reported in the literature, severe <e1>docetaxel</e1> -induced <e2>pulmonary toxicity</e2> needs to be considered in the differential diagnosis when such patients present with respiratory symptoms."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5210	"<e1>Fatal interstitial pneumonitis</e1> associated with <e2>docetaxel</e2> administration in a patient with hormone-refractory prostate cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5211	"The case is presented of a 72-year-old man with hormone-refractory prostate cancer and weekly administration of 30 mg/m2 <e1>docetaxel</e1> who developed <e2>subacute interstitial pneumonitis-related pulmonary fibrosis</e2> after seven doses and died despite mechanical ventilation and high-dose corticosteroid treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5212	"The patient presented with <e1>fulminant microangiopathic hemolytic anemia</e1> and thrombocytopenia within 48 hr of initiating therapy with trimethoprim-<e2>sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5213	"The patient presented with <e1>fulminant microangiopathic hemolytic anemia</e1> and thrombocytopenia within 48 hr of initiating therapy with <e2>trimethoprim</e2> -sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5214	"The patient presented with fulminant microangiopathic hemolytic anemia and <e1>thrombocytopenia</e1> within 48 hr of initiating therapy with trimethoprim-<e2>sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5215	"The patient presented with fulminant microangiopathic hemolytic anemia and <e1>thrombocytopenia</e1> within 48 hr of initiating therapy with <e2>trimethoprim</e2> -sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5216	"<e1>Thrombotic thrombocytopenic purpura</e1> induced by trimethoprim-<e2>sulfamethoxazole</e2> in a Jehovah's Witness."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5217	"<e1>Thrombotic thrombocytopenic purpura</e1> induced by <e2>trimethoprim</e2> -sulfamethoxazole in a Jehovah's Witness."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5218	"We report a case of <e1>Thrombotic Thrombocytopenic Purpura</e1> occurring as an allergic response to trimethoprim-<e2>sulfamethoxazole</e2> therapy (Bactrim, Septra) in a Jehovah's Witness patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5219	"We report a case of <e1>Thrombotic Thrombocytopenic Purpura</e1> occurring as an allergic response to <e2>trimethoprim</e2> -sulfamethoxazole therapy (Bactrim, Septra) in a Jehovah's Witness patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5220	"<e1>Juvenile absence epilepsy</e1> exacerbated by <e2>valproic acid</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5221	"This report describes a case of <e1>paradoxical</e1>, intravenous valproic acid-induced <e2>seizure exacerbation</e2> in a child with juvenile absence epilepsy, documented by video-electroencephalography."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5222	"This report describes a case of paradoxical, intravenous <e1>valproic acid</e1> -induced <e2>seizure exacerbation</e2> in a child with juvenile absence epilepsy, documented by video-electroencephalography."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5223	"<e1>Acute endophthalmitis</e1> following intravitreal bevacizumab (<e2>Avastin</e2>) injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5224	"<e1>Acute endophthalmitis</e1> following intravitreal <e2>bevacizumab</e2> (Avastin) injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5225	"CONCLUSIONS: <e1>Infectious endophthalmitis</e1> is a potential complication of intravitreal <e2>bevacizumab</e2> injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5226	"METHODS: Two patients with exudative <e1>age-related macular degeneration</e1> were treated sequentially with an intravitreal injection of <e2>bevacizumab</e2> and developed signs of severe but painless infectious endophthalmitis 2 days later."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5227	"METHODS: Two patients with exudative age-related macular degeneration were treated sequentially with an intravitreal injection of <e1>bevacizumab</e1> and developed signs of severe but <e2>painless infectious endophthalmitis</e2> 2 days later."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5228	"PURPOSE: To report two cases of <e1>acute endophthalmitis</e1> following intravitreal <e2>bevacizumab</e2> injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5229	"<e1>Pulmonary hypertension</e1> during <e2>lithium</e2> therapy: clinical case study."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5230	"The authors presented a case of <e1>pulmonary hypertension</e1> during <e2>lithium</e2> therapy, while she has been on <e2>lithium</e2> for 6 years."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5231	"This is the first report of <e1>pulmonary hypertension</e1> in an adult patient during <e2>lithium</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5232	"The patient's <e1>arthritis</e1> flared after the second infusion of <e2>infliximab</e2>, which was discontinued."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5233	"A 32-year-old man with a family history of type 2 diabetes mellitus presented with <e1>circulatory collapse</e1> and deep coma after 9 days of treatment with <e2>perospirone hydrochloride</e2>, a recently developed atypical antipsychotic agent available only in Japan."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5234	"A 32-year-old man with a family history of type 2 diabetes mellitus presented with circulatory collapse and <e1>deep coma</e1> after 9 days of treatment with <e2>perospirone hydrochloride</e2>, a recently developed atypical antipsychotic agent available only in Japan."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5235	"The risk of new-onset <e1>diabetic ketoacidosis</e1> in patients with diabetic risk factors who are taking <e2>perospirone hydrochloride</e2> or other atypical antipsychotics should be kept in mind."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5236	"<e1>Fatal venous thrombembolism</e1> complicating <e2>imatinib</e2> therapy in a patient with metastatic gastrointestinal stromal tumor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5237	"The possibility of <e1>deep vein thrombosis</e1> caused by the compression of the veins by necrotic tumor should be considered in patients with abdominal or pelvic metastases of GIST, including patients treated with <e2>imatinib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5238	"We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed <e1>status epilepticus</e1> shortly after receiving <e2>cisplatin</e2> and gemcitabine chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5239	"We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed <e1>status epilepticus</e1> shortly after receiving cisplatin and <e2>gemcitabine</e2> chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5240	"Of particular interest in this patient is the <e1>fluctuation of the QT interval</e1> at a stable dose of <e2>methadone</e2>, suggesting that a single normal electrocardiogram (ECG) does not guarantee that the patient is not at risk of ventricular arrhythmias."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5241	"We present a case report of a patient who developed a <e1>prolonged QT</e1> while being treated with oral <e2>methadone</e2> for a chronic pain syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5242	"AIMS: To present a case of <e1>piloerection</e1> after replacing <e2>fluvoxamine maleate</e2> with milnacipran hydrochloride, and to analyse this effect based on receptor occupancy theory."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5243	"AIMS: To present a case of <e1>piloerection</e1> after replacing fluvoxamine maleate with <e2>milnacipran hydrochloride</e2>, and to analyse this effect based on receptor occupancy theory."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5244	"CONCLUSIONS: The <e1>piloerection</e1> observed after the replacement of <e2>fluvoxamine</e2> with milnacipran in this patient appears to have been due to an increase in the alpha(1)-adrenoceptor occupancy by endogenous norepinephrine induced by milnacipran."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5245	"CONCLUSIONS: The <e1>piloerection</e1> observed after the replacement of fluvoxamine with <e2>milnacipran</e2> in this patient appears to have been due to an increase in the alpha(1)-adrenoceptor occupancy by endogenous norepinephrine induced by <e2>milnacipran</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5246	"<e1>Piloerection</e1> induced by replacing <e2>fluvoxamine</e2> with milnacipran."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5247	"<e1>Piloerection</e1> induced by replacing fluvoxamine with <e2>milnacipran</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5248	"CASE PRESENTATION: We report a patient with CF who developed <e1>recurrent eosinophilia</e1> and severe persistent bronchospasm following repeated administration of preservative-free <e2>tobramycin</e2> by inhalation, beginning at 16 months of age."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5249	"CASE PRESENTATION: We report a patient with CF who developed recurrent eosinophilia and <e1>severe persistent bronchospasm</e1> following repeated administration of preservative-free <e2>tobramycin</e2> by inhalation, beginning at 16 months of age."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5250	"CONCLUSION: Hypersensitivity reaction should be considered in patients who develop recurrent eosinophilia and <e1>deterioration of pulmonary function</e1> following the use of <e2>tobramycin</e2> by inhalation or by intravenous administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5251	"CONCLUSION: Hypersensitivity reaction should be considered in patients who develop <e1>recurrent eosinophilia</e1> and deterioration of pulmonary function following the use of <e2>tobramycin</e2> by inhalation or by intravenous administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5252	"Inhaled <e1>tobramycin</e1> solution-associated <e2>recurrent eosinophilia</e2> and severe persistent bronchospasm in a patient with cystic fibrosis: a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5253	"Inhaled <e1>tobramycin</e1> solution-associated recurrent eosinophilia and <e2>severe persistent bronchospasm</e2> in a patient with cystic fibrosis: a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5254	"The most serious dental side effect of <e1>bisphosphonate</e1> treatment (particularly when it is administered intravenously) is, paradoxically, <e2>osteonecrosis of the mandible</e2> or the maxilla represented by exposed nonhealing bone."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5255	"Adverse effects of <e1>amiodarone</e1> including pulmonary toxicity, hepatotoxicity, <e2>aggravation of arrhythmia</e2>, and thyroid diseases are well understood."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5256	"Adverse effects of <e1>amiodarone</e1> including pulmonary toxicity, <e2>hepatotoxicity</e2>, aggravation of arrhythmia, and thyroid diseases are well understood."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5257	"Adverse effects of <e1>amiodarone</e1> including <e2>pulmonary toxicity</e2>, hepatotoxicity, aggravation of arrhythmia, and thyroid diseases are well understood."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5258	"Adverse effects of <e1>amiodarone</e1> including pulmonary toxicity, hepatotoxicity, aggravation of arrhythmia, and <e2>thyroid diseases</e2> are well understood."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5259	"<e1>Pancreatitis</e1> is a very rare adverse effect associated with the use of <e2>amiodarone</e2>, and only four cases of <e2>amiodarone</e2> -induced pancreatitis have been reported in literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5260	"Pancreatitis is a very rare adverse effect associated with the use of <e1>amiodarone</e1>, and only four cases of <e1>amiodarone</e1> -induced <e2>pancreatitis</e2> have been reported in literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5261	"Under the suspicion of <e1>amiodarone</e1> -induced <e2>acute pancreatitis</e2>, <e1>amiodarone</e1> was substituted by propafenone."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5262	"We report a patient who developed <e1>acute pancreatitis</e1> during <e2>amiodarone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5263	"DISCUSSION: To our knowledge this is the first reported case of <e1>tuberculous uveitis</e1> following treatment with <e2>etanercept</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5264	"<e1>Tuberculous uveitis</e1> after treatment with <e2>etanercept</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5265	"We report the first case of <e1>tuberculous uveitis</e1> due to <e2>etanercept</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5266	"A complex pattern of <e1>melanonychia</e1> and onycholysis after treatment with <e2>pemetrexed</e2> for lung cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5267	"A complex pattern of melanonychia and <e1>onycholysis</e1> after treatment with <e2>pemetrexed</e2> for lung cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5268	"<e1>Infliximab</e1> and its serious adverse effects are discussed, and other cases of <e2>osteomyelitis</e2> with infliximab use are also reviewed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5269	"Infliximab and its serious adverse effects are discussed, and other cases of <e1>osteomyelitis</e1> with <e2>infliximab</e2> use are also reviewed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5270	"<e1>Osteomyelitis</e1> occurring during <e2>infliximab</e2> treatment of severe psoriasis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5271	"Based on the Naranjo probability scale, <e1>serotonin syndrome</e1> was a probable adverse reaction associated with co-administration of <e2>citalopram</e2> and fentanyl."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5272	"Based on the Naranjo probability scale, <e1>serotonin syndrome</e1> was a probable adverse reaction associated with co-administration of citalopram and <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5273	"CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) <e1>citalopram</e1> developed confusion, <e2>agitation</e2>, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5274	"CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, <e1>agitation</e1>, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of <e2>fentanyl</e2>, and all symptoms and signs resolved following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5275	"CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, <e1>agitation</e1>, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of <e2>fentanyl</e2>, and all symptoms and signs resolved following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5276	"CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) <e1>citalopram</e1> developed <e2>confusion</e2>, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5277	"CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed <e1>confusion</e1>, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of <e2>fentanyl</e2>, and all symptoms and signs resolved following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5278	"CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed <e1>confusion</e1>, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of <e2>fentanyl</e2>, and all symptoms and signs resolved following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5279	"CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) <e1>citalopram</e1> developed confusion, agitation, tachycardia, tremors, <e2>myoclonic jerks</e2> and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5280	"CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, <e1>myoclonic jerks</e1> and unsteady gait, consistent with serotonin syndrome, following initiation of <e2>fentanyl</e2>, and all symptoms and signs resolved following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5281	"CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, <e1>myoclonic jerks</e1> and unsteady gait, consistent with serotonin syndrome, following initiation of <e2>fentanyl</e2>, and all symptoms and signs resolved following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5282	"CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) <e1>citalopram</e1> developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with <e2>serotonin syndrome</e2>, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5283	"CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with <e1>serotonin syndrome</e1>, following initiation of <e2>fentanyl</e2>, and all symptoms and signs resolved following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5284	"CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with <e1>serotonin syndrome</e1>, following initiation of <e2>fentanyl</e2>, and all symptoms and signs resolved following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5285	"CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) <e1>citalopram</e1> developed confusion, agitation, <e2>tachycardia</e2>, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5286	"CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, <e1>tachycardia</e1>, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of <e2>fentanyl</e2>, and all symptoms and signs resolved following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5287	"CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, <e1>tachycardia</e1>, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of <e2>fentanyl</e2>, and all symptoms and signs resolved following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5288	"CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) <e1>citalopram</e1> developed confusion, agitation, tachycardia, <e2>tremors</e2>, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5289	"CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, <e1>tremors</e1>, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of <e2>fentanyl</e2>, and all symptoms and signs resolved following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5290	"CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, <e1>tremors</e1>, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of <e2>fentanyl</e2>, and all symptoms and signs resolved following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5291	"CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) <e1>citalopram</e1> developed confusion, agitation, tachycardia, tremors, myoclonic jerks and <e2>unsteady gait</e2>, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5292	"CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and <e1>unsteady gait</e1>, consistent with serotonin syndrome, following initiation of <e2>fentanyl</e2>, and all symptoms and signs resolved following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5293	"CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and <e1>unsteady gait</e1>, consistent with serotonin syndrome, following initiation of <e2>fentanyl</e2>, and all symptoms and signs resolved following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5294	"CONCLUSION: Healthcare professionals should be aware of the possible development of <e1>serotonin syndrome</e1> as a complication of initiation of <e2>fentanyl</e2> and other phenylpiperidine opioids in patients treated with SSRIs."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5295	"OBJECTIVE: To report a case of <e1>serotonin syndrome</e1> associated with interaction between fentanyl and <e2>citalopram</e2>, as evidenced by medication history, clinical features and reversal following discontinuation of fentanyl."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5296	"OBJECTIVE: To report a case of <e1>serotonin syndrome</e1> associated with interaction between <e2>fentanyl</e2> and citalopram, as evidenced by medication history, clinical features and reversal following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5297	"OBJECTIVE: To report a case of <e1>serotonin syndrome</e1> associated with interaction between <e2>fentanyl</e2> and citalopram, as evidenced by medication history, clinical features and reversal following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5298	"<e1>Serotonin syndrome</e1> caused by interaction between <e2>citalopram</e2> and fentanyl."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5299	"<e1>Serotonin syndrome</e1> caused by interaction between citalopram and <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5300	"<e1>Renal failure</e1> after high-dose <e2>methotrexate</e2> in a child homozygous for MTHFR C677T polymorphism."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5301	"We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented <e1>renal failure</e1> following the second cycle of high-dose methotrexate (<e2>HDMTX</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5302	"We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented <e1>renal failure</e1> following the second cycle of high-dose <e2>methotrexate</e2> (HDMTX)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5303	"<e1>Docetaxel</e1> induced <e2>Meibomian duct inflammation and blockage</e2> is the likely cause of this presentation in a patient with no history of eyelid masses in the past."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5304	"<e1>Docetaxel</e1> -induced Meibomian duct inflammation and blockage leading to <e2>chalazion</e2> formation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5305	"<e1>Docetaxel</e1> -induced <e2>Meibomian duct inflammation and blockage</e2> leading to chalazion formation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5306	"We report a 71-year male with castration-resistant metastatic prostate cancer who was treated with weekly <e1>docetaxel</e1> for 12 weeks and developed significant <e2>eye irritation and dryness</e2> during treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5307	"A case of <e1>recall pneumonitis</e1> induced by <e2>gemcitabine</e2> is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5308	"After having received <e1>gemcitabine</e1> on day 1 of the second course, the patient developed <e2>dry cough</e2>, subfebrile temperatures and dyspnea within 48 h."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5309	"After having received <e1>gemcitabine</e1> on day 1 of the second course, the patient developed dry cough, subfebrile temperatures and <e2>dyspnea</e2> within 48 h."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5310	"After having received <e1>gemcitabine</e1> on day 1 of the second course, the patient developed dry cough, <e2>subfebrile temperatures</e2> and dyspnea within 48 h."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5311	"CONCLUSION: <e1>Gemcitabine</e1> -induced <e2>recall pneumonitis</e2> is a rarely reported phenomenon and should be taken into account even after extended time interval to the previous radiotherapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5312	"<e1>Radiation recall pneumonitis</e1> induced by <e2>gemcitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5313	"CONCLUSIONS: For all patients with <e1>vancomycin</e1> -induced <e2>neutropenia</e2>, possible cross-reactivity of teicoplanin should be monitored."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5314	"However, a new episode of <e1>neutropenia</e1>, with a WBC count of 2.8 x 10(3)/mm3 and ANC of 0.448 x 10(3)/mm3, occurred 11 days after <e2>teicoplanin</e2> initiation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5315	"OBJECTIVE: To report <e1>teicoplanin</e1> -related <e2>neutropenia</e2> that developed after an episode of <e2>neutropenia</e2> induced by vancomycin therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5316	"OBJECTIVE: To report teicoplanin-related <e1>neutropenia</e1> that developed after an episode of <e1>neutropenia</e1> induced by <e2>vancomycin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5317	"<e1>Teicoplanin</e1> -induced <e2>agranulocytosis</e2> that followed vancomycin-induced <e2>agranulocytosis</e2> suggests a possible cross-reactivity between the 2 drugs."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5318	"Teicoplanin-induced <e1>agranulocytosis</e1> that followed <e2>vancomycin</e2> -induced <e1>agranulocytosis</e1> suggests a possible cross-reactivity between the 2 drugs."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5319	"<e1>Cutaneous ulceration</e1>: an unusual complication of intravenous <e2>pentamidine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5320	"This is a report of a renal transplant patient with Pneumocystis pneumonia who developed <e1>chemical cellulitis</e1> and ulceration following the extravasation of intravenous <e2>pentamidine</e2> into the soft tissues of the left hand and forearm."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5321	"This is a report of a renal transplant patient with Pneumocystis pneumonia who developed chemical cellulitis and <e1>ulceration</e1> following the extravasation of intravenous <e2>pentamidine</e2> into the soft tissues of the left hand and forearm."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5322	"OBSERVATIONS: A 48-year-old woman presented with <e1>disfiguring facial edema</e1> 10 weeks after she began antiviral therapy with <e2>peginterferon alfa-2a</e2> and ribavirin for chronic hepatitis C infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5323	"OBSERVATIONS: A 48-year-old woman presented with <e1>disfiguring facial edema</e1> 10 weeks after she began antiviral therapy with peginterferon alfa-2a and <e2>ribavirin</e2> for chronic hepatitis C infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5324	"<e1>Tumor-volume increase</e1> at beginning of primary treatment with topical <e2>interferon alpha 2-beta</e2> in a case of conjunctiva-cornea intraepithelial neoplasia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5325	"<e1>Flecainide</e1> overdose can rapidly result in profound <e2>cardiovascular collapse</e2>, and is associated with a relatively high mortality."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5326	"Managing <e1>cardiovascular collapse</e1> in severe <e2>flecainide</e2> overdose without recourse to extracorporeal therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5327	"<e1>Ezetimibe</e1> -induced <e2>acute pancreatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5328	"Since its FDA approval in 2002, there are no known citations of <e1>ezetimibe</e1> -induced <e2>pancreatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5329	"Selective estrogen receptor modulator <e1>raloxifene</e1> -associated <e2>aggravation of nonalcoholic steatohepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5330	"This is the first histologically confirmed case of <e1>NASH</e1> that was aggravated by <e2>raloxifene</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5331	"A case of <e1>liver damage</e1> following treatment with <e2>Danazol</e2> for fibrocystic breast disease is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5332	"<e1>Hepatic damage</e1> after <e2>danazol</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5333	"<e1>Hypersensitivity pneumonitis-like syndrome</e1> associated with the use of <e2>lenalidomide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5334	"In this report, we describe a patient receiving <e1>lenalidomide</e1> in whom dyspnea, fever, hypoxia, and <e2>diffuse pulmonary infiltrates</e2> developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5335	"In this report, we describe a patient receiving <e1>lenalidomide</e1> in whom <e2>dyspnea</e2>, fever, hypoxia, and diffuse pulmonary infiltrates developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5336	"In this report, we describe a patient receiving <e1>lenalidomide</e1> in whom dyspnea, <e2>fever</e2>, hypoxia, and diffuse pulmonary infiltrates developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5337	"In this report, we describe a patient receiving <e1>lenalidomide</e1> in whom dyspnea, fever, <e2>hypoxia</e2>, and diffuse pulmonary infiltrates developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5338	"Physicians should be cognizant of this potential complication in patients receiving <e1>thalidomide</e1> or <e1>thalidomide</e1> -like drugs who present with <e2>fever</e2> and pulmonary infiltrates and fail to improve despite treatment with broad-spectrum antibiotics."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5339	"Physicians should be cognizant of this potential complication in patients receiving <e1>thalidomide</e1> or <e1>thalidomide</e1> -like drugs who present with fever and <e2>pulmonary infiltrates</e2> and fail to improve despite treatment with broad-spectrum antibiotics."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5340	"Thus, the patient's clinical course and workup strongly support a diagnosis of <e1>lenalidomide</e1> -induced <e2>hypersensitivity pneumonitis-like syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5341	"Intravitreal <e1>triamcinolone</e1> may have had an influence on the <e2>exacerbation of retinochoroiditis</e2> in the posterior pole of the patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5342	"A 40-year-old man with advanced HIV infection and Mycobacterium avium complex infection experienced <e1>rapid cognitive decline</e1> after commencement of <e2>ethambutol</e2>, and symptoms fully resolved with cessation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5343	"<e1>Ethambutol</e1> toxicity manifesting as <e2>acute onset psychosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5344	"<e1>Psoriasis</e1> induced by <e2>interferon-alpha</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5345	"<e1>Recombinant human interferon-alpha</e1> has been used in the treatment of several cancers, but there have been several reports that it may <e2>exacerbate psoriasis or trigger off its onset</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5346	"We report four patients, three of whom first developed <e1>psoriasis</e1> and one who had an aggravation of the condition during treatment with <e2>interferon-alpha</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5347	"A 61-year-old man with early diffuse cutaneous scleroderma with myositis and progressive interstitial pneumonia developed <e1>generalized erythema</e1> with high fever 3 weeks after taking <e2>sulfamethoxazole</e2>/trimethoprim."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5348	"A 61-year-old man with early diffuse cutaneous scleroderma with myositis and progressive interstitial pneumonia developed <e1>generalized erythema</e1> with high fever 3 weeks after taking sulfamethoxazole/<e2>trimethoprim</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5349	"INTRODUCTION: We describe the neurointensive care (NIC) management of a patient with severe cerebral swelling and <e1>raised intracranial pressure</e1> (ICP) after severe <e2>sodium valproic acid</e2> (VPA) intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5350	"INTRODUCTION: We describe the neurointensive care (NIC) management of a patient with severe cerebral swelling and <e1>raised intracranial pressure</e1> (ICP) after severe sodium valproic acid (<e2>VPA</e2>) intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5351	"INTRODUCTION: We describe the neurointensive care (NIC) management of a patient with <e1>severe cerebral swelling</e1> and raised intracranial pressure (ICP) after severe <e2>sodium valproic acid</e2> (VPA) intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5352	"INTRODUCTION: We describe the neurointensive care (NIC) management of a patient with <e1>severe cerebral swelling</e1> and raised intracranial pressure (ICP) after severe sodium valproic acid (<e2>VPA</e2>) intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5353	"Neurointensive care management of <e1>raised intracranial pressure</e1> caused by severe <e2>valproic acid</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5354	"<e1>Bleomycin</e1> induced <e2>hyperpigmentation</e2> with yolk sac tumor."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5355	"The hyperpigmentation was diffuse scattered, flagellate like and linear streaking which was thought to be mainly related to the <e1>skin toxicity</e1> of <e2>bleomycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5356	"We report a child with yolk sac tumor who developed <e1>localized pigmentation</e1> after the first course of chemotherapy regimen that included cisplatin, etoposide and <e2>bleomycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5357	"We report a child with yolk sac tumor who developed <e1>localized pigmentation</e1> after the first course of chemotherapy regimen that included <e2>cisplatin</e2>, etoposide and bleomycin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5358	"We report a child with yolk sac tumor who developed <e1>localized pigmentation</e1> after the first course of chemotherapy regimen that included cisplatin, <e2>etoposide</e2> and bleomycin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5359	"A cause-effect relationship to <e1>capecitabine</e1> was suggested due to resolution of <e2>headache</e2> with <e1>capecitabine</e1> withdrawal and reappearance with <e1>capecitabine</e1> rechallenge."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5360	"BACKGROUND: <e1>Headaches</e1> have been reported as a potential side effect of <e2>capecitabine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5361	"<e1>Capecitabine</e1> -induced <e2>headache</e2> responding to diltiazem."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5362	"CCBs should be considered in the treatment of <e1>5-FU</e1> or capecitabine-induced <e2>headaches</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5363	"CCBs should be considered in the treatment of 5-FU or <e1>capecitabine</e1> -induced <e2>headaches</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5364	"The patient developed grade 3 <e1>capecitabine</e1> -induced <e2>headache</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5365	"We hypothesize that <e1>capecitabine</e1> -induced <e2>headache</e2> is vascular in nature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5366	"<e1>Brugada type electrocardiographic changes</e1> induced by concomitant use of <e2>lithium</e2> and propafenone in patient with Wolff-Parkinson-White syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5367	"<e1>Brugada type electrocardiographic changes</e1> induced by concomitant use of lithium and <e2>propafenone</e2> in patient with Wolff-Parkinson-White syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5368	"We report a case of <e1>ST elevation in right precordial leads</e1> compatible with type 1 Brugada syndrome following administration of <e2>propafenone</e2> in a patient with Wolff-Parkinson-White syndrome who was receiving lithium at concentrations within therapeutic levels."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5369	"We report a case of ST elevation in right precordial leads compatible with <e1>type 1 Brugada syndrome</e1> following administration of <e2>propafenone</e2> in a patient with Wolff-Parkinson-White syndrome who was receiving lithium at concentrations within therapeutic levels."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5370	"We postulate that <e1>gastritis</e1> caused by <e2>dexamethasone</e2>, mucositis caused by doxorubicin, and the unique anatomic nature of a Meckel diverticulum may have contributed to this extremely unlikely and previously unreported event."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5371	"We postulate that gastritis caused by dexamethasone, <e1>mucositis</e1> caused by <e2>doxorubicin</e2>, and the unique anatomic nature of a Meckel diverticulum may have contributed to this extremely unlikely and previously unreported event."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5372	"<e1>Bortezomib</e1> -induced paralytic ileus is a potential <e2>gastrointestinal side effect</e2> of this first-in-class anticancer proteasome inhibitor."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5373	"<e1>Bortezomib</e1> -induced <e2>paralytic ileus</e2> is a potential gastrointestinal side effect of this first-in-class anticancer proteasome inhibitor."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5374	"<e1>Paralytic ileus</e1> in patients undergoing <e2>bortezomib</e2> treatment has been reported, although a definite attribution to <e2>bortezomib</e2> administration has not been established."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5375	"We report a myeloma patient who developed <e1>severe paralytic ileus</e1> during <e2>bortezomib</e2> therapy, which presented in the context of progressive constipation without other known causes and which regressed promptly with medical management after drug cessation, suggesting a direct causal relationship."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5376	"A woman developed <e1>delusional parasitosis</e1> when taking <e2>phenelzine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5377	"<e1>Delusional parasitosis</e1> associated with <e2>phenelzine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5378	"Interstitial pneumonitis and <e1>alveolar hemorrhage</e1> complicating use of <e2>rituximab</e2>: case report and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5379	"<e1>Interstitial pneumonitis</e1> and alveolar hemorrhage complicating use of <e2>rituximab</e2>: case report and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5380	"The use of <e1>rituximab</e1> has been uncommonly associated with <e2>delayed pulmonary toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5381	"Fulminant <e1>metoclopramide</e1> induced <e2>neuroleptic malignant syndrome</e2> rapidly responsive to intravenous dantrolene."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5382	"We report a case of fulminant <e1>neuroleptic malignant syndrome</e1> in a man aged 70 developing within 12 hours of starting six-hourly intravenous <e2>metoclopramide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5383	"The clinical symptoms of <e1>gastric mucosa foveolar hyperplasia</e1> due to long-term <e2>PGE1</e2> therapy simulate hypertrophic pyloric stenosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5384	"The results of the ultrasound examination combined with clinical anamnesis allowed diagnosis of <e1>gastric mucosa foveolar hyperplasia</e1> due to prolonged <e2>PGE1</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5385	"A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of <e1>fatigue</e1>, myalgia, and leg weakness, shortly after starting treatment with <e2>colchicine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5386	"A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and <e1>leg weakness</e1>, shortly after starting treatment with <e2>colchicine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5387	"A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, <e1>myalgia</e1>, and leg weakness, shortly after starting treatment with <e2>colchicine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5388	"A case of <e1>colchicine</e1> -induced <e2>rhabdomyolysis</e2> is reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5389	"<e1>Colchicine</e1> -induced <e2>rhabdomyolysis</e2> is a rare complication, and the postulated mechanisms and risk factors for this severe complication are discussed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5390	"<e1>Colchicine</e1> -induced <e2>rhabdomyolysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5391	"Investigation confirmed the diagnosis of rhabdomyolysis, and discontinuation of <e1>colchicine</e1> resulted in resolution of clinical and biochemical features of <e2>rhabdomylysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5392	"<e1>5-Fluorouracil</e1> <e2>cardiotoxicity</e2> complicating treatment of stage IIB cervical cancer--case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5393	"CONCLUSION: <e1>Acetic acid</e1> is corrosive and may cause <e2>vagina bleeding</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5394	"Induction of <e1>systemic lupus erythematosus</e1> by <e2>interferon-gamma</e2> in a patient with rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5395	"The development of systemic lupus erythematosus (<e1>SLE</e1>) after 38 months of therapy with <e2>recombinant human interferon gamma</e2> (rIFN-gamma) was observed in a patient with rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5396	"The development of systemic lupus erythematosus (<e1>SLE</e1>) after 38 months of therapy with recombinant human interferon gamma (<e2>rIFN-gamma</e2>) was observed in a patient with rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5397	"The development of <e1>systemic lupus erythematosus</e1> (SLE) after 38 months of therapy with <e2>recombinant human interferon gamma</e2> (rIFN-gamma) was observed in a patient with rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5398	"The development of <e1>systemic lupus erythematosus</e1> (SLE) after 38 months of therapy with recombinant human interferon gamma (<e2>rIFN-gamma</e2>) was observed in a patient with rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5399	"We assume that <e1>rIFN-gamma</e1> induced the de novo development of <e2>SLE</e2> in our patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5400	"<e1>Bisphosphonate</e1> induced <e2>osteochemonecrosis of the jaw</e2> mimicking a tumour."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5401	"<e1>Clozapine</e1> -induced <e2>eosinophilia</e2> and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5402	"Drug-induced <e1>eosinophilia</e1> is a non-dose-dependent side effect of <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5403	"Occasionally, despite good therapeutic response, <e1>clozapine</e1> must be stopped due to dangerous side effects such as <e2>agranulocytosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5404	"Metformin-associated <e1>lactic acidosis</e1> (MALA) is a serious metabolic complication that occurs because of <e2>metformin</e2> accumulation in patients who become dehydrated or developed acute renal failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5405	"<e1>Metformin</e1> -associated <e2>lactic acidosis</e2> (MALA) is a serious metabolic complication that occurs because of metformin accumulation in patients who become dehydrated or developed acute renal failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5406	"<e1>Metformin</e1> -associated <e2>lactic acidosis</e2> precipitated by diarrhea."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5407	"An apparent link is described between the use of <e1>MMF</e1> with prednisone to treat pemphigus vulgaris and the development of <e2>red blood cell anemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5408	"An apparent link is described between the use of MMF with <e1>prednisone</e1> to treat pemphigus vulgaris and the development of <e2>red blood cell anemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5409	"<e1>Red blood cell anemia</e1> in a patient with pemphigus vulgaris induced by the use of <e2>mycophenolate mofetil</e2> and prednisone."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5410	"<e1>Red blood cell anemia</e1> in a patient with pemphigus vulgaris induced by the use of mycophenolate mofetil and <e2>prednisone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5411	"The dermatology literature heretofore has not noted that <e1>anemia</e1> is a side effect of patients taking <e2>MMF</e2> to treat pemphigus."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5412	"This report suggests that <e1>anemia</e1> can occur due to MMF, in particular when it is given with prednisone, a side effect well documented in the transplantation literature when the triple combination of MMF, <e2>cyclosporine</e2> and prednisone is used."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5413	"This report suggests that <e1>anemia</e1> can occur due to <e2>MMF</e2>, in particular when it is given with prednisone, a side effect well documented in the transplantation literature when the triple combination of <e2>MMF</e2>, cyclosporine and prednisone is used."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5414	"This report suggests that <e1>anemia</e1> can occur due to <e2>MMF</e2>, in particular when it is given with prednisone, a side effect well documented in the transplantation literature when the triple combination of <e2>MMF</e2>, cyclosporine and prednisone is used."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5415	"This report suggests that <e1>anemia</e1> can occur due to MMF, in particular when it is given with <e2>prednisone</e2>, a side effect well documented in the transplantation literature when the triple combination of MMF, cyclosporine and <e2>prednisone</e2> is used."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5416	"This report suggests that <e1>anemia</e1> can occur due to MMF, in particular when it is given with <e2>prednisone</e2>, a side effect well documented in the transplantation literature when the triple combination of MMF, cyclosporine and <e2>prednisone</e2> is used."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5417	"A search of the United States Food and Drug Administration's Adverse Event Reporting System identified nine cases of <e1>oxcarbazepine</e1> -associated <e2>angioedema</e2> in pediatric patients aged 16 years and younger."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5418	"Clinical profile of <e1>oxcarbazepine</e1> -related <e2>angioneurotic edema</e2>: case report and review."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5419	"<e1>Oxcarbazepine</e1> -associated <e2>angioedema</e2> manifested by swelling of the face, eyes, lips, or tongue or difficulty swallowing or breathing (or both) is a rare but potentially life-threatening reaction for which early recognition and management are vital."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5420	"We describe in detail the first U.S. case report, of a 4(1/2)-year-old boy who experienced <e1>angioedema</e1> during treatment with <e2>oxcarbazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5421	"Here we describe another case of <e1>VOD</e1> occurring after LT, but in which the causative role was played by <e2>azathioprine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5422	"One case of <e1>tacrolimus</e1> -induced <e2>hepatic VOD</e2> developing after lung transplantation (LT) has been recently reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5423	"<e1>Carbamazepine</e1> <e2>hypersensitivity syndrome</e2> is a rare, life-threatening condition."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5424	"A patient with chronic myelomonocytic leukemia developed drug-induced <e1>pulmonary toxicity</e1> after using low dose oral <e2>etoposide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5425	"Because <e1>etoposide</e1> -induced <e2>pulmonary toxicity</e2> is an uncommon but serious adverse event, clinicians must be vigilant about the possibility of it, so that the optimal treatment can start as soon as possible."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5426	"PET scintigraphy of <e1>etoposide</e1> -induced <e2>pulmonary toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5427	"Detection of antineutrophil cytoplasmic antibody in a patient with <e1>L-tryptophan</e1> induced <e2>eosinophilia-myalgia syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5428	"The Center for Disease Control has received numerous reports of an <e1>eosinophilia-myalgia syndrome</e1> related to products containing <e2>L-tryptophan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5429	"Here, we report a case of <e1>RFP</e1> -induced <e2>hypothyroidism</e2> without underlying thyroid disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5430	"<e1>Rifampin</e1> -induced <e2>hypothyroidism</e2> without underlying thyroid disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5431	"Rifampin (<e1>RFP</e1>) increases hepatic microsomal enzyme activity, and there are case reports of <e1>RFP</e1> -induced hypothyroidism, all associated with <e2>Hashimoto's thyroiditis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5432	"<e1>Rifampin</e1> (RFP) increases hepatic microsomal enzyme activity, and there are case reports of RFP-induced hypothyroidism, all associated with <e2>Hashimoto's thyroiditis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5433	"Rifampin (<e1>RFP</e1>) increases hepatic microsomal enzyme activity, and there are case reports of <e1>RFP</e1> -induced <e2>hypothyroidism</e2>, all associated with Hashimoto's thyroiditis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5434	"<e1>Rifampin</e1> (RFP) increases hepatic microsomal enzyme activity, and there are case reports of RFP-induced <e2>hypothyroidism</e2>, all associated with Hashimoto's thyroiditis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5435	"A patient is described who developed a rapid onset of <e1>pulmonary fibrosis</e1> following treatment with a new non-steroidal anti-inflammatory drug, <e2>nabumetone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5436	"<e1>Pulmonary fibrosis</e1> associated with <e2>nabumetone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5437	"<e1>Cyclosporine</e1> is a potent inhibitor of simvastatin metabolism, and may therefore facilitate simvastatin-induced <e2>rhabdomyolysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5438	"Cyclosporine is a potent inhibitor of <e1>simvastatin</e1> metabolism, and may therefore facilitate <e1>simvastatin</e1> -induced <e2>rhabdomyolysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5439	"Discontinuation of simvastatin and <e1>cyclosporine</e1> resulted in resolution of <e2>rhabdomyolysis</e2> and normalization of renal function."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5440	"Discontinuation of <e1>simvastatin</e1> and cyclosporine resulted in resolution of <e2>rhabdomyolysis</e2> and normalization of renal function."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5441	"Simvastatin-induced <e1>rhabdomyolysis</e1> following <e2>cyclosporine</e2> treatment for uveitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5442	"<e1>Simvastatin</e1> -induced <e2>rhabdomyolysis</e2> following cyclosporine treatment for uveitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5443	"<e1>Generalized lichen nitidus</e1> with involvement of the palms following <e2>interferon alpha</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5444	"Here we present the case of a <e1>generalized lichen nitidus</e1> with involvement of the palms in a patient with hepatitis C after systemic treatment with <e2>interferon alpha</e2> and ribavirin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5445	"Here we present the case of a <e1>generalized lichen nitidus</e1> with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and <e2>ribavirin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5446	"It is tempting to speculate that <e1>interferon alpha</e1> may be involved in the pathogenesis of <e2>lichen nitidus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5447	"<e1>Sirolimus-eluting stent thrombosis</e1> several years after <e2>clopidogrel</e2> discontinuation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5448	"Treatment of APL in pregnancy is controversial as the use of <e1>ATRA</e1> has been questioned due to the <e2>teratogenic effect</e2> of retinoids."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5449	"Interstitial lung disease (<e1>ILD</e1>) related to therapy with the drug <e2>gefitinib</e2> has been well reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5450	"<e1>Interstitial lung disease</e1> (ILD) related to therapy with the drug <e2>gefitinib</e2> has been well reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5451	"<e1>Pulmonary toxicity</e1> associated with <e2>erlotinib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5452	"Similar to reports in patients receiving gefitinib, those with pathologic findings of UIP on resected lung specimens or known <e1>pulmonary fibrosis</e1> may be at particular risk for <e2>erlotinib</e2> pulmonary toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5453	"Similar to reports in patients receiving gefitinib, those with pathologic findings of UIP on resected lung specimens or known pulmonary fibrosis may be at particular risk for <e1>erlotinib</e1> <e2>pulmonary toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5454	"This case and other published evidence should alert physicians to the possibility of fatal <e1>erlotinib</e1> -induced <e2>ILD</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5455	"We report a case of <e1>fatal pulmonary toxicity</e1> in a patient with advanced non-small cell lung cancer who received <e2>erlotinib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5456	"It has been reported that <e1>fluoroquinolone</e1> antimicrobials prolong the corrected QT interval but rarely cause <e2>torsade de pointes</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5457	"<e1>Torsade de pointes</e1> associated with <e2>moxifloxacin</e2>: a rare but potentially fatal adverse event."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5458	"AIM: To report three cases of extensive <e1>skin necrosis</e1> in cirrhotic patients treated with the vasoconstrictor agent terlipressin (<e2>Glypressin</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5459	"AIM: To report three cases of extensive <e1>skin necrosis</e1> in cirrhotic patients treated with the vasoconstrictor agent <e2>terlipressin</e2> (Glypressin)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5460	"Both <e1>colchicine</e1> and statin therapy may be associated with <e2>myopathy</e2>, which usually occurs after several months of therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5461	"Both colchicine and <e1>statin</e1> therapy may be associated with <e2>myopathy</e2>, which usually occurs after several months of therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5462	"Rapid onset of <e1>muscle weakness</e1> (rhabdomyolysis) associated with the combined use of simvastatin and <e2>colchicine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5463	"Rapid onset of <e1>muscle weakness</e1> (rhabdomyolysis) associated with the combined use of <e2>simvastatin</e2> and colchicine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5464	"Rapid onset of muscle weakness (<e1>rhabdomyolysis</e1>) associated with the combined use of simvastatin and <e2>colchicine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5465	"Rapid onset of muscle weakness (<e1>rhabdomyolysis</e1>) associated with the combined use of <e2>simvastatin</e2> and colchicine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5466	"The concomitant use, however, of <e1>colchicine</e1> and statin has been associated with the rapid onset of <e2>muscle weakness</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5467	"The concomitant use, however, of colchicine and <e1>statin</e1> has been associated with the rapid onset of <e2>muscle weakness</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5468	"We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed <e1>acute weakness</e1> within 3 weeks after the start of treatment with <e2>colchicine</e2> for acute gouty bursitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5469	"We report a case of a patient with mild chronic renal insufficiency who had been taking <e1>simvastatin</e1> for over a year and developed <e2>acute weakness</e2> within 3 weeks after the start of treatment with colchicine for acute gouty bursitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5470	"We report a case of a patient with <e1>mild chronic renal insufficiency</e1> who had been taking <e2>simvastatin</e2> for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5471	"<e1>Pneumocystis carinii pneumonia</e1> as a complication of <e2>methotrexate</e2> treatment of asthma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5472	"Pneumocystis pneumonia should be considered in asthmatic patients taking <e1>methotrexate</e1> who present with <e2>fever</e2>, pulmonary infiltrates, and hypoxia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5473	"Pneumocystis pneumonia should be considered in asthmatic patients taking <e1>methotrexate</e1> who present with fever, pulmonary infiltrates, and <e2>hypoxia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5474	"<e1>Pneumocystis pneumonia</e1> should be considered in asthmatic patients taking <e2>methotrexate</e2> who present with fever, pulmonary infiltrates, and hypoxia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5475	"Pneumocystis pneumonia should be considered in asthmatic patients taking <e1>methotrexate</e1> who present with fever, <e2>pulmonary infiltrates</e2>, and hypoxia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5476	"CASE REPORT: A six-year-old boy with transfusion-dependent beta-thalassaemia developed a <e1>unilateral hearing loss</e1> shortly after commencing <e2>desferrioxamine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5477	"Eleven patients developed infection requiring hospitalization while taking <e1>leflunomide</e1> including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), <e2>abdominal sepsis</e2> (1), mycotic aneurysm (1) and gastroenteritis (1)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5478	"Eleven patients developed infection requiring hospitalization while taking <e1>leflunomide</e1> including: lower respiratory tract infections (3), <e2>cellulitis</e2> (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5479	"Eleven patients developed infection requiring hospitalization while taking <e1>leflunomide</e1> including: lower respiratory tract infections (3), cellulitis (2), <e2>disseminated herpes zoster</e2> (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5480	"Eleven patients developed infection requiring hospitalization while taking <e1>leflunomide</e1> including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and <e2>gastroenteritis</e2> (1)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5481	"Eleven patients developed <e1>infection</e1> requiring hospitalization while taking <e2>leflunomide</e2> including: lower respiratory tract <e1>infection</e1>s (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5482	"Eleven patients developed infection requiring hospitalization while taking <e1>leflunomide</e1> including: <e2>lower respiratory tract infections</e2> (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5483	"Eleven patients developed infection requiring hospitalization while taking <e1>leflunomide</e1> including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), <e2>mycotic aneurysm</e2> (1) and gastroenteritis (1)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5484	"Eleven patients developed infection requiring hospitalization while taking <e1>leflunomide</e1> including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable <e2>TB liver</e2> (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5485	"<e1>Leflunomide</e1> -associated <e2>infections</e2> in rheumatoid arthritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5486	"The NZ Pharmacovigilance Centre has received 7 additional reports of <e1>severe infections</e1> in patients with RA taking <e2>leflunomide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5487	"A 58-year-old woman with rheumatoid arthritis (RA) developed <e1>fever</e1>, skin eruptions, leukocytopenia, and thrombocytopenia, 3 weeks after treatment with <e2>sulfasalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5488	"A 58-year-old woman with rheumatoid arthritis (RA) developed fever, skin eruptions, <e1>leukocytopenia</e1>, and thrombocytopenia, 3 weeks after treatment with <e2>sulfasalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5489	"A 58-year-old woman with rheumatoid arthritis (RA) developed fever, <e1>skin eruptions</e1>, leukocytopenia, and thrombocytopenia, 3 weeks after treatment with <e2>sulfasalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5490	"A 58-year-old woman with rheumatoid arthritis (RA) developed fever, skin eruptions, leukocytopenia, and <e1>thrombocytopenia</e1>, 3 weeks after treatment with <e2>sulfasalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5491	"<e1>Sulfasalazine</e1> -induced hypersensitivity syndrome and <e2>hemophagocytic syndrome</e2> associated with reactivation of Epstein-Barr virus."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5492	"<e1>Sulfasalazine</e1> -induced <e2>hypersensitivity syndrome</e2> and hemophagocytic syndrome associated with reactivation of Epstein-Barr virus."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5493	"This case illustrates that the <e1>hemophagocytic syndrome</e1> associated with reactivation of EBV can occur as part of drug hypersensitivity reactions in RA patients taking <e2>sulfasalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5494	"The goal of this study is to describe three patients diagnosed with migraine and epilepsy (both under control) who evolved into <e1>status migrainosus</e1> after the introduction of oxcarbazepine (OXC), as part of a switch off from <e2>carbamazepine</e2> (CBZ)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5495	"The goal of this study is to describe three patients diagnosed with migraine and epilepsy (both under control) who evolved into <e1>status migrainosus</e1> after the introduction of oxcarbazepine (OXC), as part of a switch off from carbamazepine (<e2>CBZ</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5496	"The goal of this study is to describe three patients diagnosed with migraine and epilepsy (both under control) who evolved into <e1>status migrainosus</e1> after the introduction of oxcarbazepine (<e2>OXC</e2>), as part of a switch off from carbamazepine (CBZ)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5497	"The goal of this study is to describe three patients diagnosed with migraine and epilepsy (both under control) who evolved into <e1>status migrainosus</e1> after the introduction of <e2>oxcarbazepine</e2> (OXC), as part of a switch off from carbamazepine (CBZ)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5498	"Uncontrolled <e1>headache</e1> induced by <e2>oxcarbazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5499	"CONCLUSION: A patient with CHF and ESRD developed <e1>myoclonic muscle spasms</e1> after receiving <e2>dobutamine</e2> by continuous i.v. infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5500	"<e1>Myoclonus</e1> associated with continuous <e2>dobutamine</e2> infusion in a patient with end-stage renal disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5501	"PURPOSE: The occurrence of <e1>myoclonus</e1> associated with continuous i.v. infusion of <e2>dobutamine</e2> in a patient with end-stage renal disease (ESRD) is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5502	"Reports of <e1>colonic perforation</e1> as a result of the administration of <e2>calcium polystyrene sulfonate</e2> and sorbitol are rare."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5503	"Reports of <e1>colonic perforation</e1> as a result of the administration of calcium polystyrene sulfonate and <e2>sorbitol</e2> are rare."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5504	"We concluded that the <e1>colonic ulcer</e1> and the sigmoidovesical fistula had been caused by the administration of <e2>calcium polystyrene sulfonate</e2> and sorbitol."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5505	"We concluded that the <e1>colonic ulcer</e1> and the sigmoidovesical fistula had been caused by the administration of calcium polystyrene sulfonate and <e2>sorbitol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5506	"We concluded that the colonic ulcer and the <e1>sigmoidovesical fistula</e1> had been caused by the administration of <e2>calcium polystyrene sulfonate</e2> and sorbitol."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5507	"We concluded that the colonic ulcer and the <e1>sigmoidovesical fistula</e1> had been caused by the administration of calcium polystyrene sulfonate and <e2>sorbitol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5508	"<e1>Psychosis</e1> in a 12-year-old HIV-positive girl with an increased serum concentration of <e2>efavirenz</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5509	"We report (to our knowledge, for the first time in a child) the emergence of <e1>psychosis</e1> in a 12-year old white girl with an increased <e2>efavirenz</e2> concentration and heterozygous gene polymorphism of the CYP2B6-G516T."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5510	"<e1>Mycobacterium marinum infection</e1> complicating Crohn's disease, treated with <e2>infliximab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5511	"<e1>Sustained monomorphic ventricular tachycardia</e1> after <e2>adenosine</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5512	"We present a case of a <e1>sustained monomorphic ventricular tachycardia</e1> following <e2>adenosine</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5513	"Surprisingly, we found that three patients appeared to develop <e1>tardive OGC</e1> while taking <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5514	"<e1>Tardive oculogyric crisis</e1> during treatment with <e2>clozapine</e2>: report of three cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5515	"<e1>Metronidazole</e1> <e2>neuropathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5516	"Two patients are described who developed <e1>sensory neuropathy</e1> after the ingestion of 30.6 and 114 g <e2>metronidazole</e2> respectively."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5517	"We report a case of a patient with rheumatoid arthritis treated with low-dose <e1>methotrexate</e1> (15 mg/week) who developed <e2>infection with both M. tuberculosis and M. chelonae</e2> after the revision of a prosthetic hip."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5518	"DIAGNOSIS: <e1>Sustained ventricular tachycardia</e1> possibly owing to <e2>thalidomide</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5519	"<e1>Multiple syncopal episodes</e1> started to occur during <e2>thalidomide</e2> treatment, and a Holter electrocardiogram showed multiple abnormalities, with an episode of sustained ventricular tachycardia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5520	"Multiple syncopal episodes started to occur during <e1>thalidomide</e1> treatment, and a Holter electrocardiogram showed multiple abnormalities, with an episode of <e2>sustained ventricular tachycardia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5521	"<e1>Sustained ventricular tachycardia</e1> in a <e2>thalidomide</e2> -treated patient with primary plasma-cell leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5522	"A patient developed typical <e1>ECM</e1> after subcutaneous selfinjection of <e2>glatiramer acetate</e2> for multiple sclerosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5523	"<e1>Embolia cutis medicamentosa</e1> following subcutaneous injection of <e2>glatiramer acetate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5524	"This case is remarkable since 1) ECM developed after subcutaneous and not after intramuscular injection, 2) the injection was given by the patient himself, and 3) <e1>glatiramer acetate</e1> can induce <e2>skin necrosis</e2> as a side effect."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5525	"Although it is difficult to be certain of the direct link of <e1>amiodarone</e1> on the basis of a single case, it is reasonable to presume that this histopathology is associated with <e1>amiodarone</e1> -induced <e2>hypothyroidism</e2> and that involution changes represent the hypofunctional status of this drug-induced disorder."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5526	"<e1>Amiodarone</e1> is well recognized as an anti-arrhythmic drug containing a high dose of iodine with considerable potential to cause <e2>thyroid dysfunction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5527	"Histopathology of the thyroid in <e1>amiodarone</e1> -induced <e2>hypothyroidism</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5528	"This is the first report on the histopathological findings of thyroid tissue from a patient with <e1>amiodarone</e1> -induced <e2>hypothyroidism</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5529	"Although adverse effects are usually mild, the author reports here a case of <e1>leucocytopenia</e1> and thrombocytopenia with <e2>quetiapine</e2> treatment that required its discontinuation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5530	"Although adverse effects are usually mild, the author reports here a case of leucocytopenia and <e1>thrombocytopenia</e1> with <e2>quetiapine</e2> treatment that required its discontinuation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5531	"<e1>Quetiapine</e1> -induced <e2>leucopenia</e2> and thrombocytopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5532	"<e1>Quetiapine</e1> -induced leucopenia and <e2>thrombocytopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5533	"<e1>Amphotericin B</e1> -induced <e2>cutaneous leucocytoclastic vasculitis</e2>: case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5534	"<e1>Palpable purpuric skin lesions</e1> on the anterior surface of both legs appeared on the 55th day of <e2>amphotericin B</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5535	"We present a case of <e1>cutaneous leucocytoclastic vasculitis</e1> in which <e2>amphotericin B</e2> might presumably be the aetiological factor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5536	"The incidence of <e1>5-fluorouracil</e1> (5-FU)-related <e2>cardiotoxicity</e2> seems to be dosage and schedule dependent."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5537	"The incidence of 5-fluorouracil (<e1>5-FU</e1>)-related <e2>cardiotoxicity</e2> seems to be dosage and schedule dependent."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5538	"<e1>Transient asymptomatic bradycardia</e1> in patients on infusional <e2>5-fluorouracil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5539	"We report such a series of patients who had <e1>transient asymptomatic bradycardia</e1> after being treated with continuous infusion <e2>5-FU</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5540	"According to the Naranjo probability scale, the <e1>papular eruption</e1> was probably caused by <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5541	"CONCLUSIONS: The pathogenesis of <e1>methotrexate</e1> -induced <e2>papular eruption</e2> in collagen vascular diseases may suggest cutaneous small-vessel vasculitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5542	"DISCUSSION: <e1>Methotrexate</e1> -induced <e2>papular eruption</e2> is rarely reported shortly after beginning methotrexate therapy in patients with acute exacerbation of collagen vascular diseases."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5543	"<e1>Methotrexate</e1> -induced <e2>papular eruption</e2> following treatment of psoriasis has not been previously reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5544	"<e1>Methotrexate</e1> -induced <e2>papular eruption</e2> following treatment of psoriasis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5545	"OBJECTIVE: To report a case of a <e1>diffuse papular eruption</e1> following treatment of psoriasis with <e2>methotrexate</e2> injections."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5546	"Pathogenesis of <e1>methotrexate</e1> -induced papular eruption in psoriasis may involve immune mechanisms other than those of <e1>methotrexate</e1> -induced <e2>cutaneous vasculitis</e2> in collagen vascular disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5547	"Pathogenesis of <e1>methotrexate</e1> -induced <e2>papular eruption</e2> in psoriasis may involve immune mechanisms other than those of <e1>methotrexate</e1> -induced cutaneous vasculitis in collagen vascular disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5548	"Ten hours after the second <e1>methotrexate</e1> injection, the patient experienced a <e2>diffuse pruritic papular eruption</e2> located mainly on the limbs."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5549	"<e1>Metabolic acidosis</e1> induced by <e2>acetazolamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5550	"<e1>Pericardial hemorrhage</e1> due to <e2>acetylsalicylic acid</e2> in a patient with essential thrombocythemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5551	"The authors describe <e1>pericardial hemorrhage</e1>, which is related to the use of low-dose <e2>acetylsalicylic acid</e2> in a patient with essential thrombocythemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5552	"From 1996 to 2002 several medications were changed due to their adverse effects: indinavir (renal colic and fever), <e1>nelfinavir</e1> (<e2>cutaneous rash</e2>), and efavirenz (nausea and temporary memory loss)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5553	"From 1996 to 2002 several medications were changed due to their adverse effects: <e1>indinavir</e1> (renal colic and <e2>fever</e2>), nelfinavir (cutaneous rash), and efavirenz (nausea and temporary memory loss)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5554	"From 1996 to 2002 several medications were changed due to their adverse effects: indinavir (renal colic and fever), nelfinavir (cutaneous rash), and <e1>efavirenz</e1> (<e2>nausea</e2> and temporary memory loss)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5555	"From 1996 to 2002 several medications were changed due to their adverse effects: <e1>indinavir</e1> (<e2>renal colic</e2> and fever), nelfinavir (cutaneous rash), and efavirenz (nausea and temporary memory loss)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5556	"From 1996 to 2002 several medications were changed due to their adverse effects: indinavir (renal colic and fever), nelfinavir (cutaneous rash), and <e1>efavirenz</e1> (nausea and <e2>temporary memory loss</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5557	"Conventional and diffusion-weighted MRI findings of <e1>methotrexate</e1> related <e2>sub-acute neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5558	"This case demonstrates the value of DWI in evaluation and diagnosis of <e1>sub-acute toxic leukoencephalopathy</e1> in patients being treated with <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5559	"We describe longitudinal diffusion-weighted MRI findings of <e1>sub-acute leukoencephalopathy</e1> following <e2>methotrexate</e2> therapy in a 24-year-old man diagnosed with pre-B-cell acute lymphoblastic leukemia (ALL), presenting with right-sided paralysis and aphasia after second consolidation with intrathecal triple-drug therapy given intrathecally."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5560	"New onset of <e1>CD</e1> may be considered as an immune-mediated injury induced by <e2>etanercept</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5561	"New onset of CD may be considered as an <e1>immune-mediated injury</e1> induced by <e2>etanercept</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5562	"New onset of <e1>Crohn's disease</e1> during treatment of active ankylosing spondylitis with <e2>etanercept</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5563	"Typical symptoms of active <e1>CD</e1> occurred 11, 12, and 26 months after start of <e2>etanercept</e2> therapy, respectively."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5564	"We describe 3 AS patients treated with <e1>etanercept</e1> for active AS who developed new onset of <e2>CD</e2> while AS related symptoms responded well to <e1>etanercept</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5565	"<e1>Upper gastrointestinal haemorrhage</e1> is a serious complication of <e2>aspirin</e2> and clopidogrel (dual) anti-platelet therapy with a high morbidity and mortality."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5566	"<e1>Upper gastrointestinal haemorrhage</e1> is a serious complication of aspirin and <e2>clopidogrel</e2> (dual) anti-platelet therapy with a high morbidity and mortality."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5567	"While <e1>doxorubicin</e1> was administered, the patient presented thoracic pain and <e2>breathing distress</e2> due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5568	"While <e1>doxorubicin</e1> was administered, the patient presented <e2>thoracic pain</e2> and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5569	"<e1>Severe hepatocellular dysfunction</e1> following <e2>cyproterone acetate</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5570	"We report 3 patients with severe hepatocellular damage due to <e1>CPA</e1> therapy, 2 with <e2>fatal fulminant hepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5571	"We report 3 patients with <e1>severe hepatocellular damage</e1> due to <e2>CPA</e2> therapy, 2 with fatal fulminant hepatitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5572	"She was treated with <e1>acyclovir</e1> and subsequently developed <e2>VZV antigen-positive zoster</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5573	"According to the Naranjo adverse drug reaction probability scale, the likelihood that <e1>temozolomide</e1> was responsible for the adverse drug reaction of <e2>fever</e2> was probable (score of 6)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5574	"Clinicians should be aware that an erythematous and <e1>exfoliative rash</e1> may be induced by <e2>temozolomide</e2>, and be familiar with the pharmacologic and supportive measures necessary for its treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5575	"Due to the severity of the <e1>rash</e1>, <e2>temozolomide</e2> was permanently discontinued."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5576	"<e1>Temozolomide</e1> -induced <e2>desquamative skin rash</e2> in a patient with metastatic melanoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5577	"<e1>Temozolomide</e1> was restarted 2 months later; the patient again developed a <e2>fever</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5578	"<e1>Exfoliative dermatitis</e1> secondary to <e2>tobramycin sulfate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5579	"We report a case of <e1>exfoliative dermatitis</e1> clearly linked to intravenous and intraperitoneal administration of <e2>tobramycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5580	"<e1>Rituximab-CHOP</e1> induced <e2>interstitial pneumonitis</e2> in patients with disseminated extranodal marginal zone B cell lymphoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5581	"<e1>Phenytoin</e1> toxicity: an easily missed cause of <e2>cerebellar syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5582	"A diagnosis of <e1>trastuzumab</e1> -induced <e2>pneumonitis</e2> was made."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5583	"A female patient with HER2 positive, metastatic breast cancer presented with pulmonary infiltrates, and a <e1>plural effusion dyspnoea</e1> after several months of <e2>trastuzumab</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5584	"A female patient with HER2 positive, metastatic breast cancer presented with <e1>pulmonary infiltrates</e1>, and a plural effusion dyspnoea after several months of <e2>trastuzumab</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5585	"Life-threatening <e1>interstitial lung disease</e1> associated with <e2>trastuzumab</e2>: case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5586	"A 30-year-old pharmacist suffered from <e1>acute allergic contact dermatitis</e1> due to <e2>4-chloro-7-nitrobenzofurazan</e2> (NBD-Cl)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5587	"A 30-year-old pharmacist suffered from <e1>acute allergic contact dermatitis</e1> due to 4-chloro-7-nitrobenzofurazan (<e2>NBD-Cl</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5588	"<e1>Allergic contact dermatitis</e1> from <e2>4-chloro-7-nitrobenzofurazan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5589	"<e1>Photo-onycholysis</e1> caused by olanzapine and <e2>aripiprazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5590	"<e1>Photo-onycholysis</e1> caused by <e2>olanzapine</e2> and aripiprazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5591	"We report the case of a woman who developed <e1>photo-onycholysis</e1> on multiple nails after uptake of <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5592	"<e1>Diffuse alveolar hemorrhage</e1> after <e2>leflunomide</e2> therapy in a patient with rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5593	"We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, <e1>hemoptysis</e1>, and severe weakness, about 2 weeks after the administration of <e2>leflunomide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5594	"We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and <e1>severe weakness</e1>, about 2 weeks after the administration of <e2>leflunomide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5595	"We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset <e1>short-of-breath</e1>, hemoptysis, and severe weakness, about 2 weeks after the administration of <e2>leflunomide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5596	"<e1>Hyponatraemia</e1> developed after rechallenge with controlled release <e2>carbamazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5597	"<e1>Hyponatraemia</e1> during low-dose <e2>carbamazepine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5598	"We report the syndrome of inappropriate <e1>antidiuresis</e1> as a much earlier side-effect of <e2>carbamazepine</e2> administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5599	"In the present paper, we describe two patients with active UC who developed a <e1>severe systemic CMV infection</e1> during a treatment with an oral microemulsion form of <e2>cyclosporine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5600	"A short review on <e1>imatinib</e1> -related <e2>hepatotoxicity</e2> is also presented."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5601	"<e1>Imatinib mesylate</e1> -related <e2>fatal acute hepatic failure</e2> in a patient with chronic myeloid leukaemia and chronic hepatitis B infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5602	"Up to four percent of patients treated with <e1>imatinib</e1> may develop <e2>hepatotoxicity</e2>, which usually resolves with discontinuation of the drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5603	"We report a 45-year-old Chinese man with CML and chronic hepatitis B virus infection, on <e1>imatinib</e1> treatment, presenting with herpetic rash and <e2>acute liver failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5604	"We report a 45-year-old Chinese man with CML and chronic hepatitis B virus infection, on <e1>imatinib</e1> treatment, presenting with <e2>herpetic rash</e2> and acute liver failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5605	"CONCLUSIONS: Clinicians treating elderly patients with <e1>olanzapine</e1> should be aware of the potential for rapidly developing <e2>hyperglycemia</e2> and monitor such patients accordingly."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5606	"OBJECTIVE: To report a case of rapidly occurring <e1>hyperglycemia</e1> that occurred in a geriatric patient 3 days after treatment with <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5607	"Rapidly developing <e1>hyperglycemia</e1> during treatment with <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5608	"Subsequently, he developed <e1>hyperglycemia</e1> (fasting blood glucose 138 mg/dL) that resolved when <e2>olanzapine</e2> was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with <e2>olanzapine</e2> 2.5 mg twice daily."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5609	"There have been numerous case reports of <e1>hyperglycemia</e1> with <e2>olanzapine</e2> in the literature, but none reported <e1>hyperglycemia</e1> within days of initiation of the medication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5610	"<e1>Adult respiratory distress syndrome</e1> after treatment with <e2>pegylated interferon alpha-2a</e2> and ribavirin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5611	"<e1>Adult respiratory distress syndrome</e1> after treatment with pegylated interferon alpha-2a and <e2>ribavirin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5612	"We report the first case of fulminant <e1>adult respiratory distress syndrome</e1> (ARDS) associated with pegylated interferon alpha-2a (<e2>pegIFNalpha-2a</e2>) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5613	"We report the first case of fulminant <e1>adult respiratory distress syndrome</e1> (ARDS) associated with <e2>pegylated interferon alpha-2a</e2> (pegIFNalpha-2a) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5614	"We report the first case of fulminant <e1>adult respiratory distress syndrome</e1> (ARDS) associated with pegylated interferon alpha-2a (pegIFNalpha-2a) and <e2>ribavirin</e2> use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5615	"We report the first case of fulminant adult respiratory distress syndrome (<e1>ARDS</e1>) associated with pegylated interferon alpha-2a (<e2>pegIFNalpha-2a</e2>) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5616	"We report the first case of fulminant adult respiratory distress syndrome (<e1>ARDS</e1>) associated with <e2>pegylated interferon alpha-2a</e2> (pegIFNalpha-2a) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5617	"We report the first case of fulminant adult respiratory distress syndrome (<e1>ARDS</e1>) associated with pegylated interferon alpha-2a (pegIFNalpha-2a) and <e2>ribavirin</e2> use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5618	"<e1>Bilateral anterior uveitis</e1> associated with <e2>clomiphene citrate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5619	"PURPOSE: To report a case of <e1>bilateral anterior uveitis</e1> associated with ovulation induction therapy using <e2>clomiphene citrate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5620	"Development of <e1>tics</e1> in a thirteen-year-old male following <e2>atomoxetine</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5621	"There are, however, case studies describing patients experiencing recurrences of <e1>tics</e1> following treatment with <e2>atomoxetine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5622	"A 51-year-old man developed <e1>type 1 diabetes mellitus</e1> following 24 weeks of treatment with recombinant <e2>alpha-2b peginterferon</e2> plus ribavirin for chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5623	"A 51-year-old man developed <e1>type 1 diabetes mellitus</e1> following 24 weeks of treatment with recombinant alpha-2b peginterferon plus <e2>ribavirin</e2> for chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5624	"The clinical course suggested that <e1>recombinant alpha-2b peginterferon</e1> plus ribavirin provoked <e2>type 1 diabetes mellitus</e2>, therefore, in patients who are candidates for interferon therapy the presence of pancreatic autoantibodies and the fasting plasma glucose level should be investigated before and during treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5625	"The clinical course suggested that recombinant alpha-2b peginterferon plus <e1>ribavirin</e1> provoked <e2>type 1 diabetes mellitus</e2>, therefore, in patients who are candidates for interferon therapy the presence of pancreatic autoantibodies and the fasting plasma glucose level should be investigated before and during treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5626	"<e1>Type 1 diabetes mellitus</e1> provoked by <e2>peginterferon alpha-2b</e2> plus ribavirin treatment for chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5627	"<e1>Type 1 diabetes mellitus</e1> provoked by peginterferon alpha-2b plus <e2>ribavirin</e2> treatment for chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5628	"BACKGROUND: To describe the occurrence of <e1>ocular hypertension</e1> in four patients following injection of <e2>ranibizumab</e2> intravitreally."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5629	"CONCLUSION: Severe and <e1>sustained ocular hypertension</e1> may occur after intravitreal <e2>ranibizumab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5630	"<e1>Ocular hypertension</e1> occurred 1 month after the second <e2>ranibizumab</e2> injection in patients 1 and 3, and 1 month after the first <e2>ranibizumab</e2> in patient 2."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5631	"<e1>Persisent ocular hypertension</e1> following intravitreal <e2>ranibizumab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5632	"Methylphenidate and <e1>dextroamphetamine</e1> -induced <e2>peripheral vasculopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5633	"<e1>Methylphenidate</e1> and dextroamphetamine-induced <e2>peripheral vasculopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5634	"We report 4 patients, 2 on methylphenidate and 2 on <e1>dextroamphetamine</e1> who presented with <e2>acral cyanosis</e2>, livedo reticularis, or Raynaud phenomenon."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5635	"We report 4 patients, 2 on <e1>methylphenidate</e1> and 2 on dextroamphetamine who presented with <e2>acral cyanosis</e2>, livedo reticularis, or Raynaud phenomenon."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5636	"We report 4 patients, 2 on methylphenidate and 2 on <e1>dextroamphetamine</e1> who presented with acral cyanosis, <e2>livedo reticularis</e2>, or Raynaud phenomenon."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5637	"We report 4 patients, 2 on <e1>methylphenidate</e1> and 2 on dextroamphetamine who presented with acral cyanosis, <e2>livedo reticularis</e2>, or Raynaud phenomenon."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5638	"We report 4 patients, 2 on methylphenidate and 2 on <e1>dextroamphetamine</e1> who presented with acral cyanosis, livedo reticularis, or <e2>Raynaud phenomenon</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5639	"We report 4 patients, 2 on <e1>methylphenidate</e1> and 2 on dextroamphetamine who presented with acral cyanosis, livedo reticularis, or <e2>Raynaud phenomenon</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5640	"<e1>Disseminated eruptive giant mollusca contagiosa</e1> in an adult psoriasis patient during <e2>efalizumab</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5641	"We report a 45-year-old psoriasis patient who developed <e1>eruptive mollusca contagiosa</e1> during an antipsoriatic treatment with <e2>efalizumab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5642	"Gastric tumor, endometrial carcinoma and <e1>cervical adenocarcinoma</e1> in situ were detected after treatment with <e2>tamoxifen</e2> for breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5643	"Gastric tumor, <e1>endometrial carcinoma</e1> and cervical adenocarcinoma in situ were detected after treatment with <e2>tamoxifen</e2> for breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5644	"<e1>Gastric tumor</e1>, endometrial carcinoma and cervical adenocarcinoma in situ were detected after treatment with <e2>tamoxifen</e2> for breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5645	"<e1>Incomplete posterior hyaloid detachment</e1> after intravitreal <e2>pegaptanib</e2> injection in diabetic macular edema."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5646	"The authors report one case of <e1>incomplete posterior hyaloid detachment</e1> (PHD) following intravitreal <e2>pegaptanib</e2> to treat DME."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5647	"<e1>Enalaprilat</e1> induced <e2>acute parotitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5648	"We present here a female patient who developed <e1>acute bilateral parotitis</e1> within minutes of i.v. <e2>enalaprilat</e2> injection and recovered within 24 hours of stopping the drug and with symptomatic treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5649	"We report a 4-year-old girl who presented with <e1>acute bilateral blindness</e1>, a focal seizure and hypertension 10 days after commencing <e2>oxybutynin</e2> to treat enuresis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5650	"We report a 4-year-old girl who presented with acute bilateral blindness, a <e1>focal seizure</e1> and hypertension 10 days after commencing <e2>oxybutynin</e2> to treat enuresis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5651	"We report a 4-year-old girl who presented with acute bilateral blindness, a focal seizure and <e1>hypertension</e1> 10 days after commencing <e2>oxybutynin</e2> to treat enuresis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5652	"<e1>Severe symptomatic hyponatremia</e1> during <e2>sibutramine</e2> therapy: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5653	"The known side effects of <e1>sibutramine</e1>, ie, <e2>hypertension</e2> and tachycardia, depend on its adrenergic and serotoninergic effects."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5654	"The known side effects of <e1>sibutramine</e1>, ie, hypertension and <e2>tachycardia</e2>, depend on its adrenergic and serotoninergic effects."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5655	"We describe a case of life-threatening <e1>hyponatremia</e1> associated with <e2>sibutramine</e2> use in an obese woman."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5656	"Our findings reveal that even in patients without a history of seizures, <e1>pregabalin</e1> can cause a <e2>cortical negative myoclonus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5657	"<e1>Pregabalin</e1> -induced <e2>cortical negative myoclonus</e2> in a patient with neuropathic pain."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5658	"We describe a patient who, after receiving his first dose of <e1>pregabalin</e1> to relieve neuropathic pain, presented with a <e2>negative myoclonus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5659	"<e1>Muzolimine</e1> -induced <e2>severe neuromyeloencephalopathy</e2>: report of seven cases."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5660	"We report on 7 patients (2 women, 5 men) with chronic renal failure, who developed under a high dosage of the new diuretic <e1>muzolimine</e1> (range 240 to 1440 mg per day) <e2>fatal neuromyeloencephalopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5661	"<e1>L-asparaginase</e1> -induced <e2>posterior reversible encephalopathy</e2> syndrome during acute lymphoblastic leukemia treatment in children."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5662	"The purpose of this article is to present the first case-series of <e1>posterior reversible encephalopathy syndrome</e1> (PRES) associated with <e2>L-asparaginase</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5663	"The purpose of this article is to present the first case-series of posterior reversible encephalopathy syndrome (<e1>PRES</e1>) associated with <e2>L-asparaginase</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5664	"We report 3 cases of children with acute lymphoblastic leukemia who developed seizures and <e1>altered sensorium</e1> after <e2>L-asparaginase</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5665	"We report 3 cases of children with acute lymphoblastic leukemia who developed <e1>seizures</e1> and altered sensorium after <e2>L-asparaginase</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5666	"<e1>Anastrozole</e1> -associated <e2>sclerosing glomerulonephritis</e2> in a patient with breast cancer."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5667	"CONCLUSIONS: <e1>Anastrozole</e1> may be the causative factor in patients with <e2>sclerosing glomerulonephritis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5668	"Diagnosis of <e1>sclerosing glomerulonephritis</e1> occurred in this patient during <e2>anastrozole</e2> use, suggesting a newly defined side effect of <e2>anastrozole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5669	"<e1>Renal injury</e1> due to <e2>anastrozole</e2> has not been published in the English literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5670	"There are major side effects of <e1>anastrozole</e1> including <e2>decrease in both lumbar spine</e2> and total hip bone mineral density, increase in the incidence of all bone fractures (especially fractures of spine, hip and wrist), joint disorders and increase in the cholesterol level."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5671	"There are major side effects of <e1>anastrozole</e1> including decrease in both lumbar spine and total hip bone mineral density, increase in the incidence of all bone fractures (especially fractures of spine, hip and wrist), joint disorders and <e2>increase in the cholesterol level</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5672	"There are major side effects of <e1>anastrozole</e1> including decrease in both lumbar spine and total hip bone mineral density, <e2>increase in the incidence of all bone fractures</e2> (especially fractures of spine, hip and wrist), joint disorders and increase in the cholesterol level."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5673	"There are major side effects of <e1>anastrozole</e1> including decrease in both lumbar spine and total hip bone mineral density, increase in the incidence of all bone fractures (especially fractures of spine, hip and wrist), <e2>joint disorders</e2> and increase in the cholesterol level."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5674	"We believe that the <e1>acute renal failure</e1> in our patient was associated with <e2>anastrozole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5675	"CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed <e1>acute hepatitis</e1> one week after the final dose of a long-term course of pulse <e2>itraconazole</e2> therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5676	"CONCLUSIONS: Prolonged exposure to <e1>itraconazole</e1>, administered either continuously or intermittently, may precipitate <e2>severe and irreversible hepatotoxic events</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5677	"<e1>Fatal hepatitis</e1> after long-term pulse <e2>itraconazole</e2> treatment for onychomycosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5678	"OBJECTIVE: To report the occurrence of <e1>acute cytolytic hepatitis</e1> in a patient exposed to pulse <e2>itraconazole</e2> therapy for 24 weeks and provide a concise review of the literature on cases of <e2>itraconazole</e2> -induced hepatitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5679	"OBJECTIVE: To report the occurrence of acute cytolytic <e1>hepatitis</e1> in a patient exposed to pulse <e2>itraconazole</e2> therapy for 24 weeks and provide a concise review of the literature on cases of <e2>itraconazole</e2> -induced <e1>hepatitis</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5680	"Only one case of <e1>severe symptomatic hepatitis</e1> occurring after pulse therapy with <e2>itraconazole</e2> for onychomycosis and requiring transplantation has been reported previously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5681	"CONCLUSIONS: Intrathecal <e1>baclofen</e1> can <e2>impair sexual function</e2> and ejaculation in some patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5682	"RESULTS: A male and a female patient with spasticity treated with intrathecal <e1>baclofen</e1> were recognized to have <e2>sexual dysfunction</e2> side effects from treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5683	"<e1>Sexual dysfunction</e1> associated with intrathecal <e2>baclofen</e2> use: a report of two cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5684	"<e1>Anaphylactic reaction</e1> to <e2>recombinant insulin-like growth factor-I</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5685	"We report a 13 year-old male who developed life-threatening <e1>anaphylaxis</e1> early in the course of <e2>Increlex</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5686	"Increasing the <e1>olanzapine</e1> dosage severely aggravated the symptoms of <e2>RLS</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5687	"Restless legs syndrome and <e1>periodic limb movements during sleep</e1> probably associated with <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5688	"<e1>Restless legs syndrome</e1> and periodic limb movements during sleep probably associated with <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5689	"The fifth patient exhibited paraesthesia and <e1>agitation</e1> caused by <e2>olanzapine</e2> that was misdiagnosed as psychotic <e1>agitation</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5690	"The fifth patient exhibited <e1>paraesthesia</e1> and agitation caused by <e2>olanzapine</e2> that was misdiagnosed as psychotic agitation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5691	"The fourth patient showed <e1>RLS symptoms</e1> that were initially caused by a 20-mg daily <e2>olanzapine</e2> dosage and were later mitigated when <e2>olanzapine</e2> was reduced and ropinirole was administered."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5692	"The second patient exhibited sudden <e1>PLMS</e1> following <e2>olanzapine</e2> injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5693	"The third patient had been suffering from serious <e1>akathisia</e1> while on risperidone, and was cured after switching to <e2>olanzapine</e2>, but thereafter the patient suffered from RLS at nighttime."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5694	"The third patient had been suffering from serious <e1>akathisia</e1> while on <e2>risperidone</e2>, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5695	"The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to <e1>olanzapine</e1>, but thereafter the patient suffered from <e2>RLS</e2> at nighttime."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5696	"The third patient had been suffering from serious akathisia while on <e1>risperidone</e1>, and was cured after switching to olanzapine, but thereafter the patient suffered from <e2>RLS</e2> at nighttime."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5697	"We report five cases of restless legs syndrome (RLS) and <e1>periodic limb movements during sleep</e1> (PLMS) that were probably associated with <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5698	"We report five cases of restless legs syndrome (RLS) and periodic limb movements during sleep (<e1>PLMS</e1>) that were probably associated with <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5699	"We report five cases of <e1>restless legs syndrome</e1> (RLS) and periodic limb movements during sleep (PLMS) that were probably associated with <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5700	"We report five cases of restless legs syndrome (<e1>RLS</e1>) and periodic limb movements during sleep (PLMS) that were probably associated with <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5701	"CONCLUSION: <e1>Alendronate</e1> led to <e2>nodular scleritis</e2> and rechallenge caused recurrence of scleritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5702	"CONCLUSION: <e1>Alendronate</e1> led to nodular <e2>scleritis</e2> and rechallenge caused recurrence of <e2>scleritis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5703	"<e1>Nodular scleritis</e1> following <e2>alendronate</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5704	"PURPOSE: To report a case of <e1>nodular scleritis</e1> following <e2>alendronate sodium</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5705	"Two weeks following rechallenge with <e1>alendronate sodium</e1> resulted in recurrence of his <e2>scleritis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5706	"In addition, there is a report on <e1>prolonged ECT seizure</e1> related to <e2>ciprofloxacin</e2>, which has an epileptogenic property with a similar action to beta-lactam antibiotics."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5707	"Thus, <e1>tardive seizures</e1> in our cases are thought to be related to piperacillin and <e2>cefotiam</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5708	"Thus, <e1>tardive seizures</e1> in our cases are thought to be related to <e2>piperacillin</e2> and cefotiam."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5709	"<e1>Acute delirium</e1> resulting from <e2>levofloxacin</e2> therapy is an exceedingly rare complication that has been thought to occur more commonly in elderly patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5710	"CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, <e1>gatifloxacin</e1> and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, <e2>dizziness</e2> and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5711	"CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, <e1>grepafloxacin</e1>, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, <e2>dizziness</e2> and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5712	"CONCLUSION: The new quinolone derivatives (<e1>levofloxacin</e1>, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, <e2>dizziness</e2> and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5713	"CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and <e1>moxifloxacin</e1>), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, <e2>dizziness</e2> and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5714	"CONCLUSION: The new quinolone derivatives (levofloxacin, <e1>sparfloxacin</e1>, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, <e2>dizziness</e2> and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5715	"CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, <e1>trovafloxacin</e1>, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, <e2>dizziness</e2> and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5716	"CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, <e1>gatifloxacin</e1> and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including <e2>headache</e2>, dizziness and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5717	"CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, <e1>grepafloxacin</e1>, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including <e2>headache</e2>, dizziness and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5718	"CONCLUSION: The new quinolone derivatives (<e1>levofloxacin</e1>, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including <e2>headache</e2>, dizziness and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5719	"CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and <e1>moxifloxacin</e1>), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including <e2>headache</e2>, dizziness and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5720	"CONCLUSION: The new quinolone derivatives (levofloxacin, <e1>sparfloxacin</e1>, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including <e2>headache</e2>, dizziness and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5721	"CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, <e1>trovafloxacin</e1>, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including <e2>headache</e2>, dizziness and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5722	"CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, <e1>gatifloxacin</e1> and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and <e2>insomnia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5723	"CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, <e1>grepafloxacin</e1>, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and <e2>insomnia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5724	"CONCLUSION: The new quinolone derivatives (<e1>levofloxacin</e1>, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and <e2>insomnia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5725	"CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and <e1>moxifloxacin</e1>), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and <e2>insomnia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5726	"CONCLUSION: The new quinolone derivatives (levofloxacin, <e1>sparfloxacin</e1>, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and <e2>insomnia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5727	"CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, <e1>trovafloxacin</e1>, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and <e2>insomnia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5728	"Here, we describe <e1>levofloxacin</e1> -induced <e2>delirium with psychotic features</e2> in a relatively young, otherwise healthy female."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5729	"<e1>Levofloxacin</e1> -induced <e2>delirium with psychotic features</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5730	"RESULTS: A previously healthy 42-year-old woman presented with <e1>acute-onset delirium with psychotic features</e1> as a consequence of <e2>levofloxacin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5731	"CONCLUSIONS: Clinicians should be aware that <e1>Crohn's disease</e1> is a potential novel adverse drug effect of <e2>Copaxone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5732	"Development of <e1>Crohn's disease</e1> in a patient with multiple sclerosis treated with <e2>copaxone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5733	"RESULTS: Our patient developed <e1>Crohn's disease</e1> while on <e2>Copaxone</e2> treatment as a consequence of long-term immunosuppression."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5734	"RESULTS: Our patient developed Crohn's disease while on <e1>Copaxone</e1> treatment as a consequence of <e2>long-term immunosuppression</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5735	"She had been on <e1>Copaxone</e1> 20 mg/day treatment for 2 years when she first exhibited <e2>gastrointestinal symptoms</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5736	"The authors present a case study of a mentally healthy man who repeatedly experienced short-lived, <e1>obsessional-like suicidal ideas and images</e1> after ingestion of the anti-fungal drug <e2>ketoconazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5737	"During intravenous treatment with <e1>terlipressin</e1> for recurrent gastrointestinal (GI) bleeding, a 50-year-old male with no history of heart disease developed a newly <e2>prolonged QT interval</e2> and torsade de pointes."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5738	"During intravenous treatment with <e1>terlipressin</e1> for recurrent gastrointestinal (GI) bleeding, a 50-year-old male with no history of heart disease developed a newly prolonged QT interval and <e2>torsade de pointes</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5739	"<e1>Terlipressin</e1> -induced <e2>ventricular arrhythmia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5740	"<e1>Spontaneous nasal septal perforation</e1> with antiangiogenic <e2>bevacizumab</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5741	"This case describes a 52-year-old white woman who developed a <e1>spontaneous nasal septal perforation</e1> after given the antiangiogenic drug, <e2>bevacizumab</e2>, for metastatic ovarian cancer treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5742	"A 37-year-old woman with relapsing invasive vertebral aspergillosis received intravenous <e1>VRC</e1> and developed <e2>angio-oedema</e2> 10 days after starting therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5743	"<e1>Angio-oedema</e1> as an unusual tolerable side effect of <e2>voriconazole</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5744	"Here, we report a case of <e1>angio-oedema</e1> associated with <e2>VRC</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5745	"To our knowledge, this is the first report of an <e1>angio-oedema</e1> associated with <e2>VRC</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5746	"<e1>Voriconazole</e1> (VRC) has not previously been reported to cause <e2>angio-oedema</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5747	"Voriconazole (<e1>VRC</e1>) has not previously been reported to cause <e2>angio-oedema</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5748	"<e1>Multiple seizures</e1> after <e2>bupropion</e2> overdose in a small child."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5749	"The patient experienced hallucinations, <e1>agitation</e1>, vomiting, tachycardia and seizures after ingestion of 1050 (48 mg/kg) of extended-release <e2>bupropion</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5750	"The patient experienced <e1>hallucinations</e1>, agitation, vomiting, tachycardia and seizures after ingestion of 1050 (48 mg/kg) of extended-release <e2>bupropion</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5751	"The patient experienced hallucinations, agitation, vomiting, tachycardia and <e1>seizures</e1> after ingestion of 1050 (48 mg/kg) of extended-release <e2>bupropion</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5752	"The patient experienced hallucinations, agitation, vomiting, <e1>tachycardia</e1> and seizures after ingestion of 1050 (48 mg/kg) of extended-release <e2>bupropion</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5753	"The patient experienced hallucinations, agitation, <e1>vomiting</e1>, tachycardia and seizures after ingestion of 1050 (48 mg/kg) of extended-release <e2>bupropion</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5754	"We report a case of pediatric <e1>bupropion</e1> ingestion resulting in <e2>multiple seizures</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5755	"<e1>Methylphenidate</e1> -associated <e2>enuresis</e2> in attention deficit hyperactivity disorder."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5756	"This is a case report of possible association of <e1>methylphenidate</e1> and <e2>enuresis</e2> in an 11-year-old boy with attention deficit hyperactivity disorder."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5757	"<e1>Cephalosporin</e1> -induced <e2>leukopenia</e2> following rechallenge with cefoxitin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5758	"CONCLUSIONS: <e1>Cefazolin</e1> was a probable cause of this patient's <e2>leukopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5759	"OBJECTIVE: To describe a case of <e1>cefazolin</e1> -induced <e2>leukopenia</e2> in a critically ill patient who developed this adverse reaction upon rechallenge with cefoxitin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5760	"Use of the Naranjo probability scale determined the association between <e1>cephalosporin</e1> use and <e2>leukopenia</e2> to be probable."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5761	"Posterior reversible encephalopathy syndrome (<e1>PRES</e1>) induced by <e2>cyclosporine</e2> use in a patient with collapsing focal glomeruloesclerosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5762	"<e1>Posterior reversible encephalopathy syndrome</e1> (<e2>PRES</e2>) induced by cyclosporine use in a patient with collapsing focal glomeruloesclerosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5763	"We describe a case of <e1>PRES</e1> in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (<e2>CSA</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5764	"We describe a case of <e1>PRES</e1> in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of <e2>cyclosporine</e2> (CSA)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5765	"<e1>Stuttering priapism</e1> complicating <e2>warfarin</e2> therapy in a patient with protein C deficiency."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5766	"This therapy was also complicated by <e1>Warfarin</e1> -induced <e2>skin necrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5767	"We report a rare case of recurrent (stuttering) <e1>priapism</e1> in a patient with protein C deficiency while maintained on <e2>Warfarin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5768	"We report a rare case of recurrent (<e1>stuttering</e1>) priapism in a patient with protein C deficiency while maintained on <e2>Warfarin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5769	"The patient expired after seven cycles of treatment had been completed because of <e1>pulmonary fibrosis</e1> and the drug toxicity of <e2>bleomycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5770	"CASE SUMMARY: An 80-year-old white female, followed up at the Memory Clinic for <e1>mild cognitive impairment</e1>, had been taking <e2>propafenone</e2> 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5771	"CONCLUSIONS: This is the first report of a possible interaction between propafenone and <e1>citalopram</e1>, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked <e2>coronary artery disease</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5772	"CONCLUSIONS: This is the first report of a possible interaction between <e1>propafenone</e1> and citalopram, which caused <e1>propafenone</e1> adverse effects (eg, dizziness, falls) and mimicked <e2>coronary artery disease</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5773	"CONCLUSIONS: This is the first report of a possible interaction between propafenone and <e1>citalopram</e1>, which caused propafenone adverse effects (eg, <e2>dizziness</e2>, falls) and mimicked coronary artery disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5774	"CONCLUSIONS: This is the first report of a possible interaction between <e1>propafenone</e1> and citalopram, which caused <e1>propafenone</e1> adverse effects (eg, <e2>dizziness</e2>, falls) and mimicked coronary artery disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5775	"CONCLUSIONS: This is the first report of a possible interaction between propafenone and <e1>citalopram</e1>, which caused propafenone adverse effects (eg, dizziness, <e2>falls</e2>) and mimicked coronary artery disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5776	"CONCLUSIONS: This is the first report of a possible interaction between <e1>propafenone</e1> and citalopram, which caused <e1>propafenone</e1> adverse effects (eg, dizziness, <e2>falls</e2>) and mimicked coronary artery disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5777	"Three months after starting <e1>citalopram</e1>, she experienced episodes of <e2>chest tightness</e2> and dizziness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5778	"Three months after starting <e1>citalopram</e1>, she experienced episodes of chest tightness and <e2>dizziness</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5779	"CONCLUSIONS: Clinicians should be aware of this adverse reaction when facing similar complex <e1>neurologic symptoms</e1> in patients who are receiving the antibiotic treatment described here, especially <e2>vancomycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5780	"DISCUSSION: To our knowledge, this is the first case report illustrating <e1>neuralgic amyotrophy</e1> triggered by exposure to the antibiotics vancomycin, tobramycin, and <e2>piperacillin</e2>/tazobactam."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5781	"DISCUSSION: To our knowledge, this is the first case report illustrating <e1>neuralgic amyotrophy</e1> triggered by exposure to the antibiotics vancomycin, tobramycin, and piperacillin/<e2>tazobactam</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5782	"DISCUSSION: To our knowledge, this is the first case report illustrating <e1>neuralgic amyotrophy</e1> triggered by exposure to the antibiotics vancomycin, <e2>tobramycin</e2>, and piperacillin/tazobactam."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5783	"DISCUSSION: To our knowledge, this is the first case report illustrating <e1>neuralgic amyotrophy</e1> triggered by exposure to the antibiotics <e2>vancomycin</e2>, tobramycin, and piperacillin/tazobactam."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5784	"<e1>Seizures</e1> and transient blindness following intravenous pulse <e2>methylprednisolone</e2> in children with primary glomerulonephritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5785	"Seizures and <e1>transient blindness</e1> following intravenous pulse <e2>methylprednisolone</e2> in children with primary glomerulonephritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5786	"Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of <e1>seizures</e1> and transient blindness at different times after i.v. pulse <e2>methylprednisolone</e2> (IVPMP) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5787	"Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and <e1>transient blindness</e1> at different times after i.v. pulse <e2>methylprednisolone</e2> (IVPMP) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5788	"BACKGROUND: <e1>Hydroxyurea</e1> is a cytostatic agent used to treat myeloproliferative disorders and long-term treatment is associated with <e2>mucocutaneous adverse events</e2> and nail hyperpigmentation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5789	"BACKGROUND: <e1>Hydroxyurea</e1> is a cytostatic agent used to treat myeloproliferative disorders and long-term treatment is associated with mucocutaneous adverse events and <e2>nail hyperpigmentation</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5790	"Based on the Naranjo algorithm, the adverse reaction observed was probably related to the <e1>hydroxyurea</e1> treatment (score = 6); however, the <e1>hydroxyurea</e1> chemotherapy could not be discontinued because of the <e2>myeloproliferative disorder</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5791	"Both the <e1>longitudinal melanonychia</e1> and the multiple skin cancers first appeared after approximately 6 months of <e2>hydroxyurea</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5792	"Both the longitudinal melanonychia and the <e1>multiple skin cancers</e1> first appeared after approximately 6 months of <e2>hydroxyurea</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5793	"CONCLUSIONS: We report this case of the concomitant appearance of <e1>multiple skin cancers</e1> and nail changes associated with <e2>hydroxyurea</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5794	"CONCLUSIONS: We report this case of the concomitant appearance of multiple skin cancers and <e1>nail changes</e1> associated with <e2>hydroxyurea</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5795	"<e1>Hydroxyurea</e1> associated with concomitant occurrence of <e2>diffuse longitudinal melanonychia</e2> and multiple squamous cell carcinomas in an elderly subject."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5796	"<e1>Hydroxyurea</e1> associated with concomitant occurrence of diffuse longitudinal melanonychia and <e2>multiple squamous cell carcinomas</e2> in an elderly subject."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5797	"OBJECTIVE: The purpose of this study was to report the concomitant occurrence of multiple squamous cell carcinomas and <e1>diffuse nail hyperpigmentation</e1> associated with <e2>hydroxyurea</e2> treatment, and to describe a successful therapeutic approach using imiquimod 5%."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5798	"OBJECTIVE: The purpose of this study was to report the concomitant occurrence of <e1>multiple squamous cell carcinomas</e1> and diffuse nail hyperpigmentation associated with <e2>hydroxyurea</e2> treatment, and to describe a successful therapeutic approach using imiquimod 5%."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5799	"The patient completed a 10-month follow-up, maintaining a complete resolution of the treated skin lesions; however, the development of a <e1>painful hand ulcer</e1>, possibly associated with the <e2>hydroxyurea</e2>, and new skin cancers were observed at the last follow-up visit."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5800	"The patient completed a 10-month follow-up, maintaining a complete resolution of the treated skin lesions; however, the development of a painful hand ulcer, possibly associated with the <e1>hydroxyurea</e1>, and new <e2>skin cancers</e2> were observed at the last follow-up visit."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5801	"It is the first case of <e1>ciprofloxacin</e1> -induced <e2>VBDS</e2> successfully treated with tacrolimus."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5802	"Vanishing bile duct and <e1>Stevens-Johnson syndrome</e1> associated with <e2>ciprofloxacin</e2> treated with tacrolimus."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5803	"<e1>Vanishing bile duct</e1> and Stevens-Johnson syndrome associated with <e2>ciprofloxacin</e2> treated with tacrolimus."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5804	"We report a case of a patient with <e1>ciprofloxacin</e1> -induced <e2>SJS</e2> and acute onset of VBDS, and reviewed the related literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5805	"We report a case of a patient with <e1>ciprofloxacin</e1> -induced SJS and acute onset of <e2>VBDS</e2>, and reviewed the related literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5806	"A 64 year old woman with previous history of coronary stenting five days before was admitted in our institution for <e1>intracranial bleeding</e1> while receiving <e2>aspirin</e2> and clopidogrel."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5807	"A 64 year old woman with previous history of coronary stenting five days before was admitted in our institution for <e1>intracranial bleeding</e1> while receiving aspirin and <e2>clopidogrel</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5808	"<e1>Disseminated salmonellosis</e1> in a patient treated with <e2>temozolomide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5809	"We describe the first case of <e1>disseminated salmonellosis</e1> in a patient treated with <e2>temozolomide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5810	"<e1>Ceftriaxone</e1> -induced <e2>fixed drug eruption</e2>: first report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5811	"<e1>FDE</e1> from <e2>cephalosporins</e2> has been rarely reported, and to the best of our knowledge there is no published report of ceftriaxone-induced <e1>FDE</e1> in the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5812	"<e1>FDE</e1> from cephalosporins has been rarely reported, and to the best of our knowledge there is no published report of <e2>ceftriaxone</e2> -induced <e1>FDE</e1> in the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5813	"We report the first case of a 54-year-old Turkish woman who presented with <e1>ceftriaxone</e1> -induced <e2>FDE</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5814	"CONCLUSION: All doctors need to be aware of the need to review the indications for <e1>gabapentin</e1> use during periods of acute illness, especially with regard to <e2>renal impairment</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5815	"<e1>Gabapentin</e1> toxicity in <e2>renal failure</e2>: the importance of dose adjustment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5816	"OBJECTIVE: This case report outlines a significant type of morbidity due to continued use of <e1>gabapentin</e1> during an episode of <e2>acute renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5817	"<e1>Acute syphilitic posterior placoid chorioretinitis</e1> following intravitreal <e2>triamcinolone acetonide</e2> injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5818	"BACKGROUND: We describe the ophthalmic features and clinical course of two cases of <e1>acute syphilitic posterior placoid chorioretinitis</e1> (ASPPC) that developed after intravitreal triamcinolone acetonide (<e2>IVTA</e2>) injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5819	"BACKGROUND: We describe the ophthalmic features and clinical course of two cases of <e1>acute syphilitic posterior placoid chorioretinitis</e1> (ASPPC) that developed after intravitreal <e2>triamcinolone acetonide</e2> (IVTA) injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5820	"BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (<e1>ASPPC</e1>) that developed after intravitreal triamcinolone acetonide (<e2>IVTA</e2>) injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5821	"BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (<e1>ASPPC</e1>) that developed after intravitreal <e2>triamcinolone acetonide</e2> (IVTA) injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5822	"CONCLUSIONS: The fundus picture shown in these cases may be typical of <e1>ASPPC</e1> after <e2>IVTA</e2> injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5823	"RESULTS: Two patients with ocular inflammation of unknown origin developed <e1>severe chorioretinitis</e1> after <e2>IVTA</e2> injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5824	"Although it is difficult to solely attribute <e1>intratumoral hemorrhage</e1> to <e2>aspirin</e2>, we have to be careful when prescribing <e2>aspirin</e2> for patients who have asymptomatic meningioma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5825	"<e1>Hemorrhage</e1> from a falx meningioma after internal use of low-dose <e2>aspirin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5826	"On the other hand, <e1>aspirin</e1> may have promoted the <e2>enlargement of spontaneous hemorrhage</e2> from meningioma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5827	"Our case is the second one in which <e1>hemorrhage</e1> from a meningioma may have been induced by <e2>aspirin</e2> prophylaxis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5828	"We report a case in which <e1>hemorrhage</e1> occurred in an asymptomatic falx meningioma known beforehand, after the internal use of low-dose <e2>aspirin</e2> for 16 months."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5829	"<e1>Acute coronary syndromes</e1> can be associated with the infusion of <e2>rituximab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5830	"<e1>Acute coronary syndromes</e1> complicating the first infusion of <e2>rituximab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5831	"The aim of this study was to describe the occurrence of <e1>acute coronary syndromes</e1> in 3 cases of <e2>rituximab</e2> infusions."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5832	"The occurrence of symptoms that could be ascribed to an <e1>acute coronary syndrome</e1> should always be taken seriously during the first <e2>rituximab</e2> infusion and investigated aggressively."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5833	"We reviewed the records of 3 patients with lymphoproliferative disorders who experienced <e1>acute coronary syndromes</e1> associated with their initial infusion of <e2>rituximab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5834	"CONCLUSION: This report describes a case of a probable interaction between topical econazole lotion 1% and <e1>acenocoumarol</e1> that resulted in overanticoagulation and a life-threatening <e2>laryngeal hematoma</e2> in this elderly patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5835	"CONCLUSION: This report describes a case of a probable interaction between topical <e1>econazole</e1> lotion 1% and acenocoumarol that resulted in overanticoagulation and a life-threatening <e2>laryngeal hematoma</e2> in this elderly patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5836	"<e1>Laryngeal dyspnea</e1> in relation to an interaction between <e2>acenocoumarol</e2> and topical econazole lotion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5837	"<e1>Laryngeal dyspnea</e1> in relation to an interaction between acenocoumarol and topical <e2>econazole</e2> lotion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5838	"<e1>Adrenal suppression in a fetus</e1> due to administration of <e2>methylprednisolone</e2> has hitherto been rarely published."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5839	"CONCLUSIONS: Life-threatening <e1>adrenal suppression</e1>, requiring hydrocortisone supplementation and intensive therapy, was observed and successfully treated in a newborn, whose mother had received high-dose <e2>methylprednisolone</e2> in late pregnancy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5840	"High-dose <e1>methylprednisolone</e1> in a pregnant woman with Crohn's disease and <e2>adrenal suppression</e2> in her newborn."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5841	"A 10-year-old asthmatic boy began to suffer from urticarial rash and <e1>moderately severe bronchospasm</e1> after 8 weeks' treatment with <e2>disodium cromoglycate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5842	"A 10-year-old asthmatic boy began to suffer from <e1>urticarial rash</e1> and moderately severe bronchospasm after 8 weeks' treatment with <e2>disodium cromoglycate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5843	"<e1>Asthma</e1> and urticaria during <e2>disodium cromoglycate</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5844	"Asthma and <e1>urticaria</e1> during <e2>disodium cromoglycate</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5845	"When <e1>DSCG</e1> was withdrawn, <e2>urticaria</e2> vanished and the child remained symptom-free."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5846	"After the first oral dose of <e1>propranolol</e1>, syncope developed together with <e2>atrioventricular block</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5847	"After the first oral dose of <e1>propranolol</e1>, <e2>syncope</e2> developed together with atrioventricular block."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5848	"<e1>Syncope</e1> induced by <e2>propranolol</e2> in hypertrophic cardiomyopathy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5849	"<e1>Olanzapine</e1> -induced <e2>hyperglycaemic coma</e2> and neuroleptic malignant syndrome: case report and review of literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5850	"<e1>Olanzapine</e1> -induced hyperglycaemic coma and <e2>neuroleptic malignant syndrome</e2>: case report and review of literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5851	"DISCUSSION: The main adverse effects of <e1>leflunomide</e1> consist of diarrhea, nausea, liver enzyme elevation, hypertension, alopecia, and <e2>allergic skin reactions</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5852	"DISCUSSION: The main adverse effects of <e1>leflunomide</e1> consist of diarrhea, nausea, liver enzyme elevation, hypertension, <e2>alopecia</e2>, and allergic skin reactions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5853	"DISCUSSION: The main adverse effects of <e1>leflunomide</e1> consist of <e2>diarrhea</e2>, nausea, liver enzyme elevation, hypertension, alopecia, and allergic skin reactions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5854	"DISCUSSION: The main adverse effects of <e1>leflunomide</e1> consist of diarrhea, nausea, liver enzyme elevation, <e2>hypertension</e2>, alopecia, and allergic skin reactions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5855	"DISCUSSION: The main adverse effects of <e1>leflunomide</e1> consist of diarrhea, nausea, <e2>liver enzyme elevation</e2>, hypertension, alopecia, and allergic skin reactions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5856	"DISCUSSION: The main adverse effects of <e1>leflunomide</e1> consist of diarrhea, <e2>nausea</e2>, liver enzyme elevation, hypertension, alopecia, and allergic skin reactions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5857	"<e1>Leflunomide</e1> -induced <e2>toxic epidermal necrolysis</e2> in a patient with rheumatoid arthritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5858	"In this report we described a case of juvenile idiopathic arthritis patient who developed thymic enlargement (true thymic hyperplasia), <e1>mediastinal lymphadenopathy</e1> and pleurisy associated with systemic symptoms under <e2>Etanercept</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5859	"In this report we described a case of juvenile idiopathic arthritis patient who developed thymic enlargement (true thymic hyperplasia), mediastinal lymphadenopathy and <e1>pleurisy</e1> associated with systemic symptoms under <e2>Etanercept</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5860	"In this report we described a case of juvenile idiopathic arthritis patient who developed <e1>thymic enlargement</e1> (true thymic hyperplasia), mediastinal lymphadenopathy and pleurisy associated with systemic symptoms under <e2>Etanercept</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5861	"In this report we described a case of juvenile idiopathic arthritis patient who developed thymic enlargement (true <e1>thymic hyperplasia</e1>), mediastinal lymphadenopathy and pleurisy associated with systemic symptoms under <e2>Etanercept</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5862	"<e1>Thymic enlargement</e1> in a patient with juvenile idiopathic arthritis during <e2>etanercept</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5863	"<e1>Oxcarbazepine</e1> -induced Drug Reaction with Eosinophilia and Systemic Symptoms (<e2>DRESS</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5864	"<e1>Oxcarbazepine</e1> -induced <e2>Drug Reaction with Eosinophilia and Systemic Symptoms</e2> (DRESS)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5865	"This is an image and brief case report of a 13-year-old boy who presented with <e1>severe rash</e1> and systemic symptoms after starting <e2>oxcarbazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5866	"After treatment with a beta-sympathomimetic drug (<e1>Partusisten</e1>) one fetus developed <e2>supraventricular tachycardia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5867	"<e1>Rosaceiform eruption</e1> induced by <e2>erlotinib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5868	"The aim of this paper is to report the case of <e1>rosaceiform eruption</e1> induced by <e2>erlotinib</e2> in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5869	"In patients with <e1>methotrexate</e1> -induced <e2>anaphylaxis</e2>, discontinuation of treatment may increase the risk of death due to cancer progression."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5870	"Management and successful desensitization in <e1>methotrexate</e1> -induced <e2>anaphylaxis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5871	"Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience <e1>methotrexate</e1> -induced <e2>anaphylaxis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5872	"We report the case of a child with metastatic osteosarcoma, who experienced an <e1>anaphylactic/anaphylactoid reaction</e1> to <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5873	"Drug-induced <e1>fever</e1> due to <e2>diltiazem</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5874	"Drug-induced <e1>fever</e1> should be considered in patients who have unexplained high temperatures during <e2>diltiazem</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5875	"To our knowledge, drug-induced <e1>fever</e1> has not been reported with the use of <e2>diltiazem hydrochloride</e2>, a commonly prescribed calcium channel blocker."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5876	"A case of <e1>congestive heart failure</e1> in a child with Wilms' tumor treated <e2>Adriamycin</e2> is presented and discussed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5877	"Radiologic recognition of <e1>adriamycin</e1> <e2>cardiotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5878	"The role of <e1>Adriamycin</e1> in the production of <e2>cardiotoxicity</e2> is reviewed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5879	"<e1>Carbamazepine</e1> -induced <e2>Diabetes mellitus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5880	"<e1>Diabetes Mellitus</e1> was observed in a patient given <e2>carbamazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5881	"The present study describes a patient who had <e1>unusual weight fluctuation</e1> under corticosteroid and psychotropic treatment such as mianserin and <e2>aripiprazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5882	"The present study describes a patient who had <e1>unusual weight fluctuation</e1> under corticosteroid and psychotropic treatment such as <e2>mianserin</e2> and aripiprazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5883	"Although <e1>heparin</e1> -dependent antibodies (HDAs) typically manifest with <e2>thrombocytopenia</e2> as in <e1>heparin</e1> -induced <e2>thrombocytopenia</e2> (HIT), they may also manifest with preserved platelet counts."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5884	"Clinicians should be cognizant of this possibility and consider a diagnosis of HDAs in patients with ongoing <e1>thrombosis</e1> who are receiving <e2>heparin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5885	"Heparin-dependent antibodies and thrombosis without <e1>heparin</e1> -induced <e2>thrombocytopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5886	"Despite these antithrombotic effects, the patient developed repeated <e1>venous thromboembolism</e1> during treatment with low-molecular-weight <e2>heparin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5887	"Four months after receiving an orthotopic liver transplant, a 51-year-old man was admitted for <e1>progressive liver failure</e1> and severe hepatocellular necrosis thought to be due to <e2>tacrolimus</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5888	"Four months after receiving an orthotopic liver transplant, a 51-year-old man was admitted for progressive liver failure and <e1>severe hepatocellular necrosis</e1> thought to be due to <e2>tacrolimus</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5889	"Initiation of <e1>posaconazole</e1> led to clinical improvement until the patient's demise from bacteremic vancomycin-resistant <e2>enterococcal peritonitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5890	"<e1>Iatrogenic Cushing syndrome</e1> after epidural <e2>triamcinolone</e2> injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5891	"We report the first case of a human immunodeficiency virus type 1 (HIV-1)-infected individual receiving combination antiretroviral therapy, which included ritonavir, who developed <e1>Cushing syndrome</e1> with profound complications after epidural <e2>triamcinolone</e2> injections."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5892	"A 22-year-old drug-abuser injected <e1>flunitrazepam</e1> tablets dissolved in tap water into her left femoral artery and presented with clinical signs of <e2>acute ischaemia of the left leg</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5893	"<e1>Acute ischaemia of the leg</e1> following accidental intra-arterial injection of dissolved <e2>flunitrazepam</e2> tablets."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5894	"A 17-year-old boy with refractory psoriatic arthritis and alpha-1 antitrypsin deficiency who developed a <e1>syringotropic hypersensitivity reaction</e1> after 9 months of therapy with <e2>infliximab</e2> and leflunomide is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5895	"A 17-year-old boy with refractory psoriatic arthritis and alpha-1 antitrypsin deficiency who developed a <e1>syringotropic hypersensitivity reaction</e1> after 9 months of therapy with infliximab and <e2>leflunomide</e2> is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5896	"<e1>Syringotropic hypersensitivity reaction</e1> associated with <e2>infliximab</e2> and leflunomide combination therapy in a child with psoriatic arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5897	"<e1>Syringotropic hypersensitivity reaction</e1> associated with infliximab and <e2>leflunomide</e2> combination therapy in a child with psoriatic arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5898	"A case of <e1>severe aplastic anemia</e1> secondary to treatment with <e2>lenalidomide</e2> for multiple myeloma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5899	"Although moderate myelosuppression is not uncommonly seen in patients treated with <e1>lenalidomide</e1>, <e2>aplastic anemia</e2> has not previously been reported to be associated with this agent."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5900	"We describe a case of severe aplastic anemia (<e1>AA</e1>) that was probably induced by <e2>lenalidomide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5901	"We describe a case of <e1>severe aplastic anemia</e1> (AA) that was probably induced by <e2>lenalidomide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5902	"After cessation of <e1>amantadine</e1>, the <e2>edema</e2> resolved, and the endothelial cell densities were <or=600/mm."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5903	"CONCLUSIONS: <e1>Amantadine</e1> can cause <e2>reversible corneal edema</e2> but can irreversibly reduce the density of endothelial cells."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5904	"<e1>Corneal edema</e1> recurred when the administration of <e2>amantadine</e2> was resumed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5905	"<e1>Corneal endothelial dysfunction</e1> associated with <e2>amantadine</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5906	"PURPOSE: To describe <e1>bilateral corneal endothelial dysfunction</e1> in a patient with Parkinson disease who was treated with long-term <e2>amantadine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5907	"RESULTS: A 52-year-old woman with Parkinson disease who had taken <e1>amantadine</e1> for 6 years had <e2>bilateral corneal edema</e2> for 2 months at baseline."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5908	"Therefore, <e1>amantadine</e1> was permanently discontinued and the <e2>cornea</e2> cleared again."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5909	"Biopsy-proven <e1>acute interstitial nephritis</e1> associated with the tyrosine kinase inhibitor <e2>sunitinib</e2>: a class effect?"
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5910	"We report the first biopsy confirmed occurrence of <e1>acute interstitial nephritis</e1> in a patient receiving treatment with <e2>Sunitinib</e2> for metastatic renal cell cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5911	"<e1>Extrapyramidal symptoms</e1> are well-documented complications of therapy with <e2>haloperidol</e2>, even when small doses are used."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5912	"This report highlights a case of drug-induced <e1>dysphagia</e1> in a patient receiving <e2>haloperidol</e2> for obsessive nocturnal thoughts and auditory disturbances."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5913	"A 52 year-old male patient diagnosed of ankylosing spondylitis presented with an <e1>iron deficiency anemia</e1> after a ten-month treatment of <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5914	"<e1>Methotrexate</e1> induced <e2>sprue-like syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5915	"Only 3 cases of <e1>imatinib</e1> -induced <e2>tumor lysis syndrome</e2> have been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5916	"We herein described an additional patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia who developed <e1>tumor lysis syndrome</e1> after 10-day treatment with <e2>imatinib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5917	"<e1>IFNalpha</e1> -induced recurrence of <e2>Graves' disease</e2> ten years after thyroidectomy in chronic viral hepatitis C."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5918	"In contrast to chronic or subacute thyroiditis, <e1>Graves' disease</e1> rarely complicates <e2>IFN-alpha</e2> therapy for chronic viral C hepatitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5919	"In contrast to chronic or <e1>subacute thyroiditis</e1>, Graves' disease rarely complicates <e2>IFN-alpha</e2> therapy for chronic viral C hepatitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5920	"We report the case of a 51-year-old man in whom <e1>IFN-alpha</e1> treatment was followed by recurrence of <e2>Graves' disease</e2> 10 years after thyroidectomy was performed and the patient was declared cured."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5921	"<e1>Interstitial granulomatous dermatitis</e1> associated with <e2>darifenacin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5922	"The authors describe a case of <e1>interstitial granulomatous dermatitis</e1> associated with <e2>darifenacin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5923	"<e1>Gemcitabine</e1> is a known risk factor for <e2>hemolytic uremic syndrome</e2> (HUS), which can often have a rapidly fatal clinical course despite intervention with steroids, plasmapheresis and hemodialysis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5924	"<e1>Gemcitabine</e1> is a known risk factor for hemolytic uremic syndrome (<e2>HUS</e2>), which can often have a rapidly fatal clinical course despite intervention with steroids, plasmapheresis and hemodialysis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5925	"METHODS: A retrospective report of the first case of <e1>gemcitabine</e1> -related <e2>HUS</e2>, in a patient with metastatic pancreatic adenocarcinoma, treated with a variety of standard therapies in addition to rituximab is presented."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5926	"Rituximab-based therapy for <e1>gemcitabine</e1> -induced <e2>hemolytic uremic syndrome</e2> in a patient with metastatic pancreatic adenocarcinoma: a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5927	"<e1>Drug rash with eosinophilia and systemic symptoms</e1> after <e2>chlorambucil</e2> treatment in chronic lymphocytic leukaemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5928	"He developed recurrent skin rash, fever, hypereosinophilia, and <e1>acute renal failure</e1> after rechallenge with <e2>chlorambucil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5929	"He developed recurrent skin rash, <e1>fever</e1>, hypereosinophilia, and acute renal failure after rechallenge with <e2>chlorambucil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5930	"He developed recurrent skin rash, fever, <e1>hypereosinophilia</e1>, and acute renal failure after rechallenge with <e2>chlorambucil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5931	"He developed recurrent <e1>skin rash</e1>, fever, hypereosinophilia, and acute renal failure after rechallenge with <e2>chlorambucil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5932	"We report the first case of <e1>chlorambucil</e1> -induced <e2>DRESS syndrome</e2> in a 70-year-old man recently diagnosed with chronic lymphocytic leukaemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5933	"A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose <e1>methotrexate</e1> (MTX) (12 g/m2), and went on to develop <e2>acute renal failure</e2> with life-threatening hyperkalemia 29 hours later."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5934	"A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (<e1>MTX</e1>) (12 g/m2), and went on to develop <e2>acute renal failure</e2> with life-threatening hyperkalemia 29 hours later."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5935	"A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme <e1>elevation of aspartate aminotrasferase</e1> and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose <e2>methotrexate</e2> (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5936	"A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme <e1>elevation of aspartate aminotrasferase</e1> and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (<e2>MTX</e2>) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5937	"A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending <e1>renal toxicity</e1> and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose <e2>methotrexate</e2> (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5938	"A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending <e1>renal toxicity</e1> and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (<e2>MTX</e2>) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5939	"Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of <e1>renal toxicity</e1> may be present as early as 2 hours after the completion of a 4-hour <e2>MTX</e2> infusion, and to suggest that monitoring for <e2>MTX</e2> toxicity should perhaps begin within a few hours after the completion of 4-hour <e2>MTX</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5940	"Early recognition of <e1>renal toxicity</e1> of high-dose <e2>methotrexate</e2> therapy: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5941	"Multifocal electroretinographic abnormalities in <e1>ethambutol</e1> -induced <e2>visual loss</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5942	"These are the first reported patients to show mfERG abnormalities that correspond to <e1>bitemporal visual field defects</e1> and add to the growing evidence that <e2>ethambutol</e2> damages the retina."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5943	"These are the first reported patients to show <e1>mfERG abnormalities</e1> that correspond to bitemporal visual field defects and add to the growing evidence that <e2>ethambutol</e2> damages the retina."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5944	"Two patients who developed decreased visual acuity after several months of <e1>ethambutol</e1> treatment for Mycobacterium avium-intracellulare infection had <e2>bitemporal visual field defects</e2> that suggested optic chiasm damage."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5945	"Two patients who developed <e1>decreased visual acuity</e1> after several months of <e2>ethambutol</e2> treatment for Mycobacterium avium-intracellulare infection had bitemporal visual field defects that suggested optic chiasm damage."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5946	"<e1>Tenofovir</e1> -associated <e2>nephrotoxicity</e2> in two HIV-infected adolescent males."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5947	"To our knowledge, these cases represent the first reports of <e1>TDF</e1> -associated <e2>irreversible renal failure</e2> and rickets in pediatric patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5948	"To our knowledge, these cases represent the first reports of <e1>TDF</e1> -associated irreversible renal failure and <e2>rickets</e2> in pediatric patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5949	"We report two cases of tenofovir (<e1>TDF</e1>)-associated <e2>nephrotoxicity</e2> in perinatally HIV-infected adolescents."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5950	"We report two cases of <e1>tenofovir</e1> (TDF)-associated <e2>nephrotoxicity</e2> in perinatally HIV-infected adolescents."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5951	"In this case, discontinuing <e1>piroxicam</e1>, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment plan helped resolve a patient's <e2>ulcers</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5952	"<e1>Acute renal failure</e1> following intravenous <e2>immunoglobulin</e2> therapy in a HIV-infected patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5953	"<e1>Acute renal failure</e1> is a rare complication following the administration of intravenous <e2>immunoglobulin</e2> (IVIG)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5954	"The exact mechanism of <e1>IVIG</e1> -associated <e2>acute renal failure</e2> remains unclear."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5955	"A 58-year-old man with advanced renal cell carcinoma developed grade 3 <e1>proteinuria</e1> (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after <e2>temsirolimus</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5956	"<e1>Temsirolimus</e1> -induced <e2>glomerulopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5957	"<e1>Hypoglycemia</e1> can be a serious side effect of <e2>etanercept</e2> in patients already on antidiabetic medications known to cause hypoglycemia, such as sulfonylureas, meglitinides, and insulin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5958	"Hypoglycemia can be a serious side effect of <e1>etanercept</e1> in patients already on antidiabetic medications known to cause <e2>hypoglycemia</e2>, such as sulfonylureas, meglitinides, and insulin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5959	"Hypoglycemia can be a serious side effect of etanercept in patients already on antidiabetic medications known to cause <e1>hypoglycemia</e1>, such as sulfonylureas, meglitinides, and <e2>insulin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5960	"Hypoglycemia can be a serious side effect of etanercept in patients already on antidiabetic medications known to cause <e1>hypoglycemia</e1>, such as sulfonylureas, <e2>meglitinides</e2>, and insulin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5961	"Hypoglycemia can be a serious side effect of etanercept in patients already on antidiabetic medications known to cause <e1>hypoglycemia</e1>, such as <e2>sulfonylureas</e2>, meglitinides, and insulin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5962	"<e1>Persistent hypoglycemia</e1> in a patient with diabetes taking <e2>etanercept</e2> for the treatment of psoriasis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5963	"We report a patient with type 2 diabetes mellitus who, while treated with the antitumor necrosis factor-alpha blocking agent <e1>etanercept</e1> for severe plaque psoriasis, experienced <e2>persistent hypoglycemia</e2> requiring the lowering and eventual elimination of his previous insulin regimen."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5964	"We report on three cases wherein treatment of <e1>dexmedetomidine</e1> -induced <e2>bradycardia</e2> with i.v. glycopyrrolate (5.0 microg/kg) not only resulting in resolution of <e2>bradycardia</e2> but also resulting in an exaggerated increase of arterial blood pressure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5965	"We report on three cases wherein treatment of dexmedetomidine-induced bradycardia with i.v. <e1>glycopyrrolate</e1> (5.0 microg/kg) not only resulting in resolution of bradycardia but also resulting in an <e2>exaggerated increase of arterial blood pressure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5966	"<e1>Bisphosphonate</e1> -related <e2>osteonecrosis of the jaw</e2> (BRONJ) is reported in up to 18.6% of patients treated with intravenous bisphosphonates and can result in significant morbidity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5967	"<e1>Bisphosphonate</e1> -related <e2>osteonecrosis of the skull base</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5968	"A previous study of patients with "<e1>quinine</e1> -associated <e2>TTP/HUS</e2>" found that ADAMTS13 activities were not abnormal in 12/12 patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5969	"A retrospective review of TTP patients with <e1>quinine</e1> -associated <e2>thrombotic microangiopathy</e2> (TMA) for whom ADAMTS13 was measured before plasma exchange was performed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5970	"A retrospective review of TTP patients with <e1>quinine</e1> -associated thrombotic microangiopathy (<e2>TMA</e2>) for whom ADAMTS13 was measured before plasma exchange was performed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5971	"<e1>Thrombocytopenia</e1> with or without microangiopathy following <e2>quinine</e2> is often referred to as <e2>quinine</e2> "hypersensitivity." When schistocytes are present it is frequently termed "<e2>quinine</e2> -associated TTP/HUS." A severe deficiency of the vWF-cleaving protease, ADAMTS13, is associated with idiopathic TTP."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5972	"Thrombocytopenia with or without microangiopathy following <e1>quinine</e1> is often referred to as <e1>quinine</e1> "hypersensitivity." When schistocytes are present it is frequently termed "<e1>quinine</e1> -associated <e2>TTP/HUS</e2>." A severe deficiency of the vWF-cleaving protease, ADAMTS13, is associated with idiopathic TTP."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5973	"We conclude that while thrombocytopenia and <e1>schistocytosis</e1> can be seen in <e2>quinine</e2> -associated TTP/HUS, the pathophysiology seems to be distinct from that seen in most cases of idiopathic TTP (i.e., severely decreased ADAMTS13 with an inhibitor)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5974	"We conclude that while <e1>thrombocytopenia</e1> and schistocytosis can be seen in <e2>quinine</e2> -associated TTP/HUS, the pathophysiology seems to be distinct from that seen in most cases of idiopathic TTP (i.e., severely decreased ADAMTS13 with an inhibitor)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5975	"We conclude that while thrombocytopenia and schistocytosis can be seen in <e1>quinine</e1> -associated <e2>TTP/HUS</e2>, the pathophysiology seems to be distinct from that seen in most cases of idiopathic TTP (i.e., severely decreased ADAMTS13 with an inhibitor)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5976	"We recommend that a TMA in association with <e1>quinine</e1> be consistently referred to as <e1>quinine</e1> -associated <e2>thrombotic microangiopathy</e2> (<e1>quinine</e1> -TMA) to better distinguish this entity from idiopathic TTP."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5977	"Complications associated with <e1>primary and secondary perforation of the bladder</e1> following immediate instillations of <e2>epirubicin</e2> after transurethral resection of superficial urothelial tumours."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5978	"MATERIALS AND METHODS: We present two cases of significant morbidity related to <e1>primary and secondary perforation of the bladder</e1> following two instillations of <e2>epirubicin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5979	"<e1>Aliskiren</e1> -associated <e2>acute renal failure</e2> with hyperkalemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5980	"We report the first case of <e1>acute renal failure</e1> with hyperkalemia associated with the recently marketed direct renin inhibitor <e2>aliskiren</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5981	"We report the first case of acute renal failure with <e1>hyperkalemia</e1> associated with the recently marketed direct renin inhibitor <e2>aliskiren</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5982	"A case of <e1>acute cardiomyopathy</e1> and pericarditis associated with <e2>methylphenidate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5983	"A case of acute cardiomyopathy and <e1>pericarditis</e1> associated with <e2>methylphenidate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5984	"However, <e1>acute cardiomyopathy</e1> and pericarditis secondary to <e2>methylphenidate</e2> use has been rarely reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5985	"However, acute cardiomyopathy and <e1>pericarditis</e1> secondary to <e2>methylphenidate</e2> use has been rarely reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5986	"We report the case of a 17-year-old male who developed chest pain, elevated cardiac biomarkers, and <e1>acute left ventricular dysfunction</e1> following a single dose of <e2>methylphenidate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5987	"We report the case of a 17-year-old male who developed <e1>chest pain</e1>, elevated cardiac biomarkers, and acute left ventricular dysfunction following a single dose of <e2>methylphenidate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5988	"We report the case of a 17-year-old male who developed chest pain, <e1>elevated cardiac biomarkers</e1>, and acute left ventricular dysfunction following a single dose of <e2>methylphenidate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5989	"According to the Naranjo et al. adverse-reaction probability scale, <e1>enoxaparin</e1> was the probable cause of <e2>hepatotoxicity</e2> in this patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5990	"CONCLUSION: A woman receiving <e1>enoxaparin</e1> every 12 hours developed signs and symptoms of <e2>hepatotoxicity</e2> after the second dose."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5991	"Probable <e1>enoxaparin</e1> -induced <e2>hepatotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5992	"PURPOSE: A case of probable <e1>enoxaparin</e1> -induced <e2>hepatotoxicity</e2> is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5993	"<e1>Posterior reversible encephalopathy syndrome</e1> associated with <e2>methotrexate</e2> neurotoxicity: conventional magnetic resonance and diffusion-weighted imaging findings."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5994	"The addition of intrathecal <e1>methotrexate</e1> to treatment protocols has increased survival rates in children with acute lymphoblastic leukemia but is also associated with varying degrees of <e2>neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5995	"We describe a 15-year-old female patient diagnosed with <e1>acute lymphoblastic leukemia</e1> presenting with status epilepticus after receiving intrathecal <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5996	"<e1>Cyclosporine</e1> -induced <e2>pain syndrome</e2> in a child undergoing hematopoietic stem cell transplant."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5997	"In this case, <e1>CIPS</e1> was considered to be probably associated with <e2>cyclosporine</e2> according to the Naranjo probability scale."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5998	"OBJECTIVE: To report a case of <e1>calcineurin</e1> -induced <e2>pain syndrome</e2> (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5999	"With the first <e1>cyclosporine</e1> dose, the patient complained of <e2>leg pain</e2> that was most severe during the <e1>cyclosporine</e1> infusion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6000	"With the first <e1>cyclosporine</e1> dose, the patient complained of <e2>leg pain</e2> that was most severe during the <e1>cyclosporine</e1> infusion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6001	"<e1>Neuroleptic malignant syndrome</e1> due to <e2>risperidone</e2> treatment in a child with Joubert syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6002	"This report describes a case of <e1>neuroleptic malignant syndrome</e1> due to <e2>risperidone</e2> in a child with Joubert syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6003	"A case of <e1>tuberculosis</e1> in a patient on <e2>Efalizumab</e2> and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6004	"A case of <e1>tuberculosis</e1> in a patient on Efalizumab and <e2>Etanercept</e2> for treatment of refractory palmopustular psoriasis and psoriatic arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6005	"The most common complication of <e1>warfarin</e1> use is adverse <e2>bleeding</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6006	"CASE REPORT: We describe here a case of a 60 year old female that experienced a relapse of <e1>symptomatic hyperlactatemia</e1> after being switched from <e2>stavudine</e2> to zidovudine and how the case was managed at the Infectious Diseases Institute, Kampala, Uganda."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6007	"CASE REPORT: We describe here a case of a 60 year old female that experienced a relapse of <e1>symptomatic hyperlactatemia</e1> after being switched from stavudine to <e2>zidovudine</e2> and how the case was managed at the Infectious Diseases Institute, Kampala, Uganda."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6008	"DISCUSSION: This case shows that switching to <e1>zidovudine</e1> potentially can lead to a <e2>hyperlactatemia relapse</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6009	"INTRODUCTION: In resource limited settings patients on antiretroviral treatment who develop <e1>stavudine</e1> induced <e2>hyperlactatemia</e2> are often switched to zidovudine on the basis of published studies that demonstrate that this agent can be a safe alternative."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6010	"<e1>Anaphylactic reaction</e1> to <e2>bacitracin</e2> ointment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6011	"We report a case of an 11-year-old boy who experienced an <e1>anaphylactic reaction</e1> after administration of <e2>bacitracin</e2> ointment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6012	"Herein, we present a patient with severe and <e1>prolonged hypoglycemia</e1> after long-acting <e2>octreotide</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6013	"<e1>Hypoglycemia</e1> induced by long-acting <e2>somatostatin</e2> analogues in a patient with nonfunctional neuroendocrine tumor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6014	"In these patients, long-acting <e1>octreotide</e1> may trigger <e2>serious hypoglycemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6015	"<e1>Leukopenia</e1> due to parvovirus B19 in a Crohn's disease patient using <e2>azathioprine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6016	"The uncomplicated long-term use of adequately-dosed <e1>AZA</e1> and stable non-toxic metabolite levels could not acknowledge TPMT deficiency as a primary cause of the <e2>leukopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6017	"We present the case of an adult Crohn's disease patient with a parvovirus B19 infection and <e1>leukopenia</e1> during long-term <e2>AZA</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6018	"<e1>Isoniazid</e1> causing <e2>breast tissue enlargement</e2> has been very rarely reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6019	"<e1>Isoniazid</e1> induced <e2>gynaecomastia</e2>: a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6020	"<e1>Cryptococcus neoformans fatal sepsis</e1> in a chronic lymphocytic leukemia patient treated with <e2>alemtuzumab</e2>: case report and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6021	"The international literature regarding opportunistic infections after immunosuppressive therapy with <e1>alemtuzumab</e1> with particular attention on <e2>fungal infections</e2> has also been reviewed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6022	"The international literature regarding <e1>opportunistic infections</e1> after immunosuppressive therapy with <e2>alemtuzumab</e2> with particular attention on fungal infections has also been reviewed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6023	"Secondary <e1>acute myeloid leukemia</e1> after <e2>etoposide</e2> therapy for haemophagocytic lymphohistiocytosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6024	"The risk of developing <e1>sAML</e1> is estimated to be between 1% and 5%, 2-20 years after exposure to <e2>etoposide</e2> but may also be related to cumulative drug doses, treatment schedules, host factors and co-administration of other antineoplastic agents."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6025	"Two patients with HLH developed <e1>etoposide</e1> -related secondary acute myeloid leukemia (<e2>sAML</e2>) following therapy for HLH."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6026	"Two patients with HLH developed <e1>etoposide</e1> -related <e2>secondary acute myeloid leukemia</e2> (sAML) following therapy for HLH."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6027	"<e1>Polymyoclonus seizure</e1> resulting from accidental injection of <e2>tranexamic acid</e2> in spinal anesthesia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6028	"<e1>Rhabdomyolysis</e1> following <e2>clarithromycin</e2> monotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6029	"We report the first case of <e1>rhabdomyolysis</e1> related to the administration of <e2>clarithromycin</e2> without concurrent use of other medications."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6030	"At the end of his fifth cycle of <e1>sunitinib</e1> therapy, the patient complained of the <e2>development of abnormally large mammary glands</e2> associated with pain and peri-areolar erythema."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6031	"At the end of his fifth cycle of <e1>sunitinib</e1> therapy, the patient complained of the development of abnormally large mammary glands associated with <e2>pain</e2> and peri-areolar erythema."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6032	"At the end of his fifth cycle of <e1>sunitinib</e1> therapy, the patient complained of the development of abnormally large mammary glands associated with pain and <e2>peri-areolar erythema</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6033	"However, re-initiation of <e1>sunitinib</e1> treatment was followed by <e2>bilateral breast enlargement</e2> again."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6034	"Onset of male <e1>gynaecomastia</e1> in a patient treated with <e2>sunitinib</e2> for metastatic renal cell carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6035	"The mechanism by which <e1>sunitinib</e1> induces <e2>gynaecomastia</e2> is thought to be associated with an unknown direct action on breast hormonal receptors."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6036	"The more common grade 3 or 4 adverse effects of <e1>sunitinib</e1> include hypertension, fatigue, hand-foot syndrome, <e2>elevated lipase</e2> and lymphopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6037	"The more common grade 3 or 4 adverse effects of <e1>sunitinib</e1> include hypertension, <e2>fatigue</e2>, hand-foot syndrome, elevated lipase and lymphopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6038	"The more common grade 3 or 4 adverse effects of <e1>sunitinib</e1> include hypertension, fatigue, <e2>hand-foot syndrome</e2>, elevated lipase and lymphopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6039	"The more common grade 3 or 4 adverse effects of <e1>sunitinib</e1> include <e2>hypertension</e2>, fatigue, hand-foot syndrome, elevated lipase and lymphopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6040	"The more common grade 3 or 4 adverse effects of <e1>sunitinib</e1> include hypertension, fatigue, hand-foot syndrome, elevated lipase and <e2>lymphopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6041	"<e1>Divalproex sodium</e1> -induced <e2>eosinophilic pleural effusion</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6042	"We report a case of 48-year-old woman with seizure disorder on divalproex sodium (<e1>Depakote</e1>) who presented with <e2>dyspnea</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6043	"We report a case of 48-year-old woman with seizure disorder on <e1>divalproex sodium</e1> (Depakote) who presented with <e2>dyspnea</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6044	"Withdrawal of <e1>Depakote</e1> resulted in resolution of the <e2>effusion</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6045	"<e1>Flurbiprofen</e1> -associated <e2>acute tubulointerstitial nephritis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6046	"We report a case of biopsy-proven <e1>acute tubulointerstitial nephritis</e1> associated with a second course of <e2>flurbiprofen</e2>, a nonsteroidal anti-inflammatory drug of the propionic acid class."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6047	"<e1>Stupor</e1> and fast activity on electroencephalography in a child treated with <e2>valproate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6048	"The case of a 4-year-old girl with <e1>valproate</e1> -induced <e2>stupor</e2> and electroencephalographic pattern of increased fast activity is reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6049	"<e1>Localized dyskeratotic plaque</e1> with milia associated with <e2>sorafenib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6050	"Localized dyskeratotic plaque with <e1>milia</e1> associated with <e2>sorafenib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6051	"This article presents a case of an <e1>atypical localized cutaneous eruption</e1> with an unusual course and protracted resolution time associated with <e2>sorafenib</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6052	"According to the Naranjo adverse drug reaction probability scale, <e1>tigecycline</e1> was the probable cause of her <e2>acute pancreatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6053	"Following 7 days of <e1>tigecycline</e1> she developed severe abdominal pain and elevated pancreatic enzymes suggesting <e2>acute pancreatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6054	"Following 7 days of <e1>tigecycline</e1> she developed severe abdominal pain and <e2>elevated pancreatic enzymes</e2> suggesting acute pancreatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6055	"Following 7 days of <e1>tigecycline</e1> she developed <e2>severe abdominal pain</e2> and elevated pancreatic enzymes suggesting acute pancreatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6056	"Pancreatitis has been associated with the tetracycline class of antibiotics and concerns about <e1>tigecycline</e1> -induced <e2>acute pancreatitis</e2> have recently been raised."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6057	"<e1>Tigecycline</e1> -induced <e2>acute pancreatitis</e2>: case report and literature review."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6058	"We recommend that clinicians monitor patients for signs and symptoms of pancreatitis, including <e1>abdominal pain</e1>, during treatment with <e2>tigecycline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6059	"We recommend that clinicians monitor patients for signs and symptoms of <e1>pancreatitis</e1>, including abdominal pain, during treatment with <e2>tigecycline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6060	"Drug induced <e1>polymyositis</e1> secondary to <e2>leuprolide acetate</e2> (Lupron) therapy for prostate carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6061	"Drug induced <e1>polymyositis</e1> secondary to leuprolide acetate (<e2>Lupron</e2>) therapy for prostate carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6062	"We report a case of biopsy proven <e1>myositis</e1> whose symptoms began within 10 days of receiving <e2>leuprolide acetate</e2> therapy for prostate cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6063	"<e1>Aripiprazole</e1> -induced <e2>hiccups</e2>: a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6064	"We report a patient of organic bipolar affective disorder who developed <e1>hiccups</e1> with the atypical antipsychotic <e2>aripiprazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6065	"CONCLUSIONS: This patient's <e1>rhabdomyolysis</e1> was probably induced by <e2>sertraline</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6066	"DISCUSSION: The Naranjo probability scale indicated a probable relationship between <e1>sertraline</e1> treatment and the onset of <e2>rhabdomyolysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6067	"OBJECTIVE: To describe a case of <e1>sertraline</e1> -induced <e2>rhabdomyolysis</e2> in an elderly patient with dementia and comorbidities."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6068	"<e1>Sertraline</e1> -induced <e2>rhabdomyolysis</e2> in an elderly patient with dementia and comorbidities."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6069	"The patient's other comorbidities and medications have not been suggested as possible interactions with <e1>sertraline</e1> that can cause <e2>rhabdomyolysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6070	"<e1>Tumor lysis syndrome</e1> after transcatheter arterial infusion of <e2>cisplatin</e2> and embolization therapy for liver metastases of melanoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6071	"He had <e1>priapism</e1> following the use of <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6072	"<e1>Priapism</e1> associated with <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6073	"Can <e1>ketamine</e1> prescribed for pain cause <e2>damage to the urinary tract</e2>?"
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6074	"Possible mechanisms for <e1>damage to the urothelium</e1> by <e2>ketamine</e2> are suggested."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6075	"Presentation of three palliative care patients who were given <e1>ketamine</e1> as an analgesic and subsequently developed significant and debilitating <e2>urological symptoms</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6076	"These two cases highlight the importance of considering <e1>lopinavir</e1>/ritonavir induced <e2>arrhythmias</e2> when dealing with HIV-positive individuals."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6077	"These two cases highlight the importance of considering lopinavir/<e1>ritonavir</e1> induced <e2>arrhythmias</e2> when dealing with HIV-positive individuals."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6078	"<e1>Transient cardiac arrhythmias</e1> related to <e2>lopinavir</e2>/ritonavir in two patients with HIV infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6079	"<e1>Transient cardiac arrhythmias</e1> related to lopinavir/<e2>ritonavir</e2> in two patients with HIV infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6080	"<e1>Colitis</e1> as a manifestation of <e2>infliximab</e2> -associated disseminated cryptococcosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6081	"Colitis as a manifestation of <e1>infliximab</e1> -associated <e2>disseminated cryptococcosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6082	"After three weeks of <e1>carbamazepine</e1> therapy, the patient arrived at the emergency department (ED) with severe agitation and <e2>aggressive behavior</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6083	"After three weeks of <e1>carbamazepine</e1> therapy, the patient arrived at the emergency department (ED) with <e2>severe agitation</e2> and aggressive behavior."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6084	"<e1>Carbamazepine</e1> -induced <e2>hyperammonemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6085	"CONCLUSION: A 26-year-old man with bipolar disorder developed <e1>hyperammonemia</e1> three weeks after initiating <e2>carbamazepine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6086	"He had also developed <e1>elevated serum ammonia levels</e1> while on <e2>valproic acid</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6087	"PURPOSE: A case of <e1>carbamazepine</e1> -induced <e2>hyperammonemia</e2> is presented."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6088	"<e1>Adriamycin</e1> -induced <e2>cardiomyopathy</e2> aggravated by cis-platinum nephrotoxicity requiring dialysis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6089	"Adriamycin-induced cardiomyopathy aggravated by <e1>cis-platinum</e1> <e2>nephrotoxicity</e2> requiring dialysis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6090	"Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and <e1>adriamycin</e1> <e2>cardiotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6091	"Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included <e1>cisplatinum</e1> <e2>nephrotoxicity</e2> and adriamycin cardiotoxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6092	"A 65-year-old female patient presented with <e1>jaundice</e1> followed 2 days later by severe dyspnea and tachypnea which worsened when patient was lying flat, 1 week after the fourth dose of <e2>adalimumab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6093	"A 65-year-old female patient presented with jaundice followed 2 days later by <e1>severe dyspnea</e1> and tachypnea which worsened when patient was lying flat, 1 week after the fourth dose of <e2>adalimumab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6094	"A 65-year-old female patient presented with jaundice followed 2 days later by severe dyspnea and <e1>tachypnea</e1> which worsened when patient was lying flat, 1 week after the fourth dose of <e2>adalimumab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6095	"A case of <e1>acute respiratory failure</e1> due to diaphragmatic weakness following <e2>adalimumab</e2> therapy for psoriasis is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6096	"<e1>Acute bilateral phrenic neuropathy</e1> following treatment with <e2>adalimumab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6097	"The potential development of <e1>SJS</e1>/TEN, a severe life-threatening illness, emphasizes the need for judicious use of <e2>TMP-Sx</e2> and close monitoring and follow-up for patients who were given <e2>TMP-Sx</e2> for SSTIs."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6098	"The potential development of SJS/<e1>TEN</e1>, a severe life-threatening illness, emphasizes the need for judicious use of <e2>TMP-Sx</e2> and close monitoring and follow-up for patients who were given <e2>TMP-Sx</e2> for SSTIs."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6099	"We report a case of Stevens-Johnson syndrome/toxic epidermal necrolysis (<e1>SJS</e1>/TEN) secondary to trimethoprim-sulfamethoxazole (<e2>TMP-Sx</e2>) therapy for presumed community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6100	"We report a case of Stevens-Johnson syndrome/toxic epidermal necrolysis (<e1>SJS</e1>/TEN) secondary to <e2>trimethoprim-sulfamethoxazole</e2> (TMP-Sx) therapy for presumed community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6101	"We report a case of <e1>Stevens-Johnson syndrome</e1>/toxic epidermal necrolysis (SJS/TEN) secondary to trimethoprim-sulfamethoxazole (<e2>TMP-Sx</e2>) therapy for presumed community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6102	"We report a case of <e1>Stevens-Johnson syndrome</e1>/toxic epidermal necrolysis (SJS/TEN) secondary to <e2>trimethoprim-sulfamethoxazole</e2> (TMP-Sx) therapy for presumed community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6103	"We report a case of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/<e1>TEN</e1>) secondary to trimethoprim-sulfamethoxazole (<e2>TMP-Sx</e2>) therapy for presumed community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6104	"We report a case of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/<e1>TEN</e1>) secondary to <e2>trimethoprim-sulfamethoxazole</e2> (TMP-Sx) therapy for presumed community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6105	"We report a case of Stevens-Johnson syndrome/<e1>toxic epidermal necrolysis</e1> (SJS/TEN) secondary to trimethoprim-sulfamethoxazole (<e2>TMP-Sx</e2>) therapy for presumed community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6106	"We report a case of Stevens-Johnson syndrome/<e1>toxic epidermal necrolysis</e1> (SJS/TEN) secondary to <e2>trimethoprim-sulfamethoxazole</e2> (TMP-Sx) therapy for presumed community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6107	"CONCLUSIONS: <e1>Spontaneous hemothorax</e1> is a rare phenomenon in conjunction with <e2>LMWH</e2> but should be considered in cases of acute respiratory distress following commencement of <e2>LMWH</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6108	"On day 4, following 3 doses of <e1>dalteparin</e1>, the patient developed <e2>acute respiratory distress</e2> attributable to a massive right hemothorax confirmed by computed tomography pulmonary angiography (CTPA) and intercostal drainage of 1500 mL of frank blood."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6109	"<e1>Spontaneous hemothorax</e1> following anticoagulation with low-molecular-weight <e2>heparin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6110	"<e1>Acute ocular ischemic change</e1> may be associated with intravitreal injection of <e2>bevacizumab</e2> in patients with vascular compromised diabetic retinopathy and/or underlying stenosis of the carotid artery."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6111	"<e1>Acute vision loss</e1> after intravitreal injection of bevacizumab (<e2>avastin</e2>) associated with ocular ischemic syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6112	"<e1>Acute vision loss</e1> after intravitreal injection of <e2>bevacizumab</e2> (avastin) associated with ocular ischemic syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6113	"Acute vision loss after intravitreal injection of bevacizumab (<e1>avastin</e1>) associated with <e2>ocular ischemic syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6114	"Acute vision loss after intravitreal injection of <e1>bevacizumab</e1> (avastin) associated with <e2>ocular ischemic syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6115	"AIM: To report a patient with diabetic rubeosis who suffered from <e1>acute retinal ischemic change</e1> and stroke after intravitreal injection of <e2>bevacizumab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6116	"AIM: To report a patient with diabetic rubeosis who suffered from acute retinal ischemic change and <e1>stroke</e1> after intravitreal injection of <e2>bevacizumab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6117	"CONCLUSIONS: Patients receiving intravitreal injections of <e1>bevacizumab</e1> should be evaluated for potential systemic risk factors such as <e2>carotid insufficiency</e2>, coagulopathy and poorly controlled diabetes mellitus."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6118	"CONCLUSIONS: Patients receiving intravitreal injections of <e1>bevacizumab</e1> should be evaluated for potential systemic risk factors such as carotid insufficiency, <e2>coagulopathy</e2> and poorly controlled diabetes mellitus."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6119	"CONCLUSIONS: Patients receiving intravitreal injections of <e1>bevacizumab</e1> should be evaluated for potential systemic risk factors such as carotid insufficiency, coagulopathy and <e2>poorly controlled diabetes mellitus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6120	"Three days after intravitreal injection of <e1>bevacizumab</e1>, <e2>acute ocular ischemic syndrome</e2> occurred."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6121	"Three days after receiving intravitreal injection of <e1>bevacizumab</e1> (1.25 mg in 0.1 ml), he developed <e2>acute vision loss</e2> and change of consciousness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6122	"Three days after receiving intravitreal injection of <e1>bevacizumab</e1> (1.25 mg in 0.1 ml), he developed acute vision loss and <e2>change of consciousness</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6123	"Herein, we describe a patient with AIDS who presented to medical attention with <e1>pancytopenia</e1> 48 months postchemotherapy with etoposide, prednisone, vincristine, <e2>cyclophosphamide</e2>, doxorubicin, and rituximab (R-EPOCH) for diffuse large B-cell lymphoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6124	"Herein, we describe a patient with AIDS who presented to medical attention with <e1>pancytopenia</e1> 48 months postchemotherapy with etoposide, prednisone, vincristine, cyclophosphamide, <e2>doxorubicin</e2>, and rituximab (R-EPOCH) for diffuse large B-cell lymphoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6125	"Herein, we describe a patient with AIDS who presented to medical attention with <e1>pancytopenia</e1> 48 months postchemotherapy with <e2>etoposide</e2>, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (R-EPOCH) for diffuse large B-cell lymphoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6126	"Herein, we describe a patient with AIDS who presented to medical attention with <e1>pancytopenia</e1> 48 months postchemotherapy with etoposide, <e2>prednisone</e2>, vincristine, cyclophosphamide, doxorubicin, and rituximab (R-EPOCH) for diffuse large B-cell lymphoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6127	"Herein, we describe a patient with AIDS who presented to medical attention with <e1>pancytopenia</e1> 48 months postchemotherapy with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and <e2>rituximab</e2> (R-EPOCH) for diffuse large B-cell lymphoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6128	"Herein, we describe a patient with AIDS who presented to medical attention with <e1>pancytopenia</e1> 48 months postchemotherapy with etoposide, prednisone, <e2>vincristine</e2>, cyclophosphamide, doxorubicin, and rituximab (R-EPOCH) for diffuse large B-cell lymphoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6129	"Favorable outcome of de novo <e1>hepatitis B infection</e1> after liver transplantation with lamivudine and <e2>adefovir</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6130	"Favorable outcome of de novo <e1>hepatitis B infection</e1> after liver transplantation with <e2>lamivudine</e2> and adefovir therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6131	"<e1>Linezolid</e1> -associated <e2>acute interstitial nephritis</e2> and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6132	"<e1>Linezolid</e1> -associated acute interstitial nephritis and drug rash with eosinophilia and systemic symptoms (<e2>DRESS</e2>) syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6133	"<e1>Linezolid</e1> -associated acute interstitial nephritis and <e2>drug rash with eosinophilia and systemic symptoms</e2> (DRESS) syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6134	"On day 7 of <e1>linezolid</e1> treatment, the patient developed severe pruritus, macular rash, facial edema, <e2>eosinophilia</e2>, marked increase in serum creatinine level, and mild hepatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6135	"On day 7 of <e1>linezolid</e1> treatment, the patient developed severe pruritus, macular rash, <e2>facial edema</e2>, eosinophilia, marked increase in serum creatinine level, and mild hepatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6136	"On day 7 of <e1>linezolid</e1> treatment, the patient developed severe pruritus, <e2>macular rash</e2>, facial edema, eosinophilia, marked increase in serum creatinine level, and mild hepatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6137	"On day 7 of <e1>linezolid</e1> treatment, the patient developed severe pruritus, macular rash, facial edema, eosinophilia, <e2>marked increase in serum creatinine level</e2>, and mild hepatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6138	"On day 7 of <e1>linezolid</e1> treatment, the patient developed severe pruritus, macular rash, facial edema, eosinophilia, marked increase in serum creatinine level, and <e2>mild hepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6139	"On day 7 of <e1>linezolid</e1> treatment, the patient developed <e2>severe pruritus</e2>, macular rash, facial edema, eosinophilia, marked increase in serum creatinine level, and mild hepatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6140	"This case of <e1>linezolid</e1> -associated <e2>acute interstitial nephritis</e2> within the context of a drug rash with eosinophilia and systemic symptoms (DRESS) syndrome in a patient treated with <e1>linezolid</e1> raises concerns about the presumed renal safety of this drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6141	"This case of <e1>linezolid</e1> -associated <e2>acute interstitial nephritis</e2> within the context of a drug rash with eosinophilia and systemic symptoms (DRESS) syndrome in a patient treated with <e1>linezolid</e1> raises concerns about the presumed renal safety of this drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6142	"This case of <e1>linezolid</e1> -associated acute interstitial nephritis within the context of a drug rash with eosinophilia and systemic symptoms (<e2>DRESS</e2>) syndrome in a patient treated with <e1>linezolid</e1> raises concerns about the presumed renal safety of this drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6143	"This case of <e1>linezolid</e1> -associated acute interstitial nephritis within the context of a drug rash with eosinophilia and systemic symptoms (<e2>DRESS</e2>) syndrome in a patient treated with <e1>linezolid</e1> raises concerns about the presumed renal safety of this drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6144	"This case of <e1>linezolid</e1> -associated acute interstitial nephritis within the context of a <e2>drug rash with eosinophilia and systemic symptoms</e2> (DRESS) syndrome in a patient treated with <e1>linezolid</e1> raises concerns about the presumed renal safety of this drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6145	"This case of <e1>linezolid</e1> -associated acute interstitial nephritis within the context of a <e2>drug rash with eosinophilia and systemic symptoms</e2> (DRESS) syndrome in a patient treated with <e1>linezolid</e1> raises concerns about the presumed renal safety of this drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6146	"Increased awareness is needed on the possible occurrence of <e1>LPD</e1> resembling gastric cancer in rheumatoid arthritis patients treated with <e2>MTX</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6147	"Reversible <e1>methotrexate</e1> -associated <e2>lymphoproliferative disorder</e2> resembling advanced gastric cancer in a patient with rheumatoid arthritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6148	"She was diagnosed with <e1>Epstein-Barr virus-associated polymorphic lymphoproliferative disorder</e1> (LPD) due to immunodeficiency caused by <e2>MTX</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6149	"She was diagnosed with Epstein-Barr virus-associated polymorphic lymphoproliferative disorder (LPD) due to <e1>immunodeficiency</e1> caused by <e2>MTX</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6150	"She was diagnosed with Epstein-Barr virus-associated polymorphic lymphoproliferative disorder (<e1>LPD</e1>) due to immunodeficiency caused by <e2>MTX</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6151	"To our knowledge, this is the first case of spontaneous remission of <e1>MTX</e1> -associated <e2>gastric LPD</e2> after discontinuation of <e1>MTX</e1> therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6152	"However, he developed <e1>acute renal failure</e1>, hyperkalemia, and hyperuricemia 30 d after receiving the <e2>sorafenib</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6153	"However, he developed acute renal failure, <e1>hyperkalemia</e1>, and hyperuricemia 30 d after receiving the <e2>sorafenib</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6154	"However, he developed acute renal failure, hyperkalemia, and <e1>hyperuricemia</e1> 30 d after receiving the <e2>sorafenib</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6155	"<e1>Sorafenib</e1> induced <e2>tumor lysis syndrome</e2> in an advanced hepatocellular carcinoma patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6156	"Are nasal decongestants safer than rhinitis? A case of <e1>oxymetazoline</e1> -induced <e2>syncope</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6157	"We report here a case of cardiovascular and <e1>neurological depression</e1> induced by <e2>oxymetalzoline</e2> in a toddler."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6158	"Given that discontinuation of <e1>nitrofurantoin</e1> and introduction of methylprednisolon therapy significantly lowered liver enzyme levels, restoring most of them to normal, we concluded that this was probably the case of <e2>toxic liver damage</e2> caused by <e1>nitrofurantoin</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6159	"<e1>Nitrofurantoin</e1> -induced <e2>acute liver damage</e2> in pregnancy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6160	"A 40-year-old man with relapsing-remitting multiple sclerosis (MS) developed primary central nervous system lymphoma (<e1>PCNSL</e1>) after having received 21 doses of <e2>natalizumab</e2> monotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6161	"A 40-year-old man with relapsing-remitting multiple sclerosis (MS) developed <e1>primary central nervous system lymphoma</e1> (PCNSL) after having received 21 doses of <e2>natalizumab</e2> monotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6162	"<e1>Primary central nervous system lymphoma</e1> in a patient treated with <e2>natalizumab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6163	"The first patient is undergoing hemodialysis and, though responding to <e1>sunitinib</e1>, is having significant <e2>fatigue</e2> and hypertension."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6164	"The first patient is undergoing hemodialysis and, though responding to <e1>sunitinib</e1>, is having significant fatigue and <e2>hypertension</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6165	"OBJECTIVE: To report a case of <e1>severe apnea</e1> in an infant exposed to <e2>lamotrigine</e2> through breast-feeding."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6166	"<e1>Severe apnea</e1> in an infant exposed to <e2>lamotrigine</e2> in breast milk."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6167	"The Naranjo probability scale indicated a probable relationship between <e1>apnea</e1> and exposure to <e2>lamotrigine</e2> through breast-feeding in this infant."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6168	"Although there have been numerous reports of effusions, none have provided complete pleural fluid analysis; therefore, we report 2 patients with <e1>dasatinib</e1> -induced <e2>pleural effusion</e2> with complete pleural fluid analysis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6169	"<e1>Dasatinib</e1> -induced <e2>pleural effusions</e2>: a lymphatic network disorder?"
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6170	"RESULTS: One case of recurrent primary peritoneal carcinoma previously treated with a <e1>carboplatin</e1> -based regimen, developed a <e2>platinum hypersensitivity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6171	"One week after the initial-dose of <e1>adalimumab</e1> (160 mg), which was initiated due to an acute exacerbation of Crohn's disease, the patient developed a <e2>fulminant cardiomyopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6172	"<e1>Severe cardiomyopathy</e1> following treatment with the tumour necrosis factor-alpha inhibitor <e2>adalimumab</e2> for Crohn's disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6173	"<e1>Amikacin</e1> -induced type 5 Bartter-like syndrome with <e2>severe hypocalcemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6174	"<e1>Amikacin</e1> -induced <e2>type 5 Bartter-like syndrome</e2> with severe hypocalcemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6175	"Recovery of the <e1>tubular dysfunction</e1> took 15 days following cessation of the offending drug, <e2>Amikacin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6176	"We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with <e1>Amikacin</e1>, resulting in refractory hypokalemia, <e2>hypocalcemia</e2>, hypomagnesemia, metabolic alkalosis, and polyuria."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6177	"We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with <e1>Amikacin</e1>, resulting in refractory hypokalemia, hypocalcemia, <e2>hypomagnesemia</e2>, metabolic alkalosis, and polyuria."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6178	"We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with <e1>Amikacin</e1>, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, <e2>metabolic alkalosis</e2>, and polyuria."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6179	"We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with <e1>Amikacin</e1>, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and <e2>polyuria</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6180	"We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with <e1>Amikacin</e1>, resulting in <e2>refractory hypokalemia</e2>, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6181	"We discuss a patient who developed <e1>severe renal tubular dysfunction</e1> secondary to short-term therapy with <e2>Amikacin</e2>, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6182	"Postoperatively, the first two patients treated with 1 to 2 cc of <e1>thrombin</e1> were slow to awaken; one had evidence of vasospasm by transcranial Doppler ultrasound studies and <e2>multiple infarcts</e2> on cranial computerized tomography, while the other had a moderate-sized frontal hematoma with intracranial hypertension."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6183	"Postoperatively, the first two patients treated with 1 to 2 cc of <e1>thrombin</e1> were <e2>slow to awaken</e2>; one had evidence of vasospasm by transcranial Doppler ultrasound studies and multiple infarcts on cranial computerized tomography, while the other had a moderate-sized frontal hematoma with intracranial hypertension."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6184	"Postoperatively, the first two patients treated with 1 to 2 cc of <e1>thrombin</e1> were slow to awaken; one had evidence of <e2>vasospasm</e2> by transcranial Doppler ultrasound studies and multiple infarcts on cranial computerized tomography, while the other had a moderate-sized frontal hematoma with intracranial hypertension."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6185	"<e1>Thrombin</e1> is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the <e2>cerebral infarctions</e2> in one patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6186	"<e1>Ciprofloxacin</e1> -induced <e2>hemorrhagic vasculitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6187	"<e1>Ciprofloxacin</e1> -induced <e2>hemorrhagic vasculitis</e2> is a rare side effect."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6188	"Ciprofloxacin is among the standard treatments for infected ischemic ulcers; in the rare case of <e1>ciprofloxacin</e1> -induced <e2>hemorrhagic vasculitis</e2>, it might be interpreted as progression of infection, instead of a complication of the treatment, thus leading to faulty diagnosis and treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6189	"In one patient the vasculitis resolved after termination of the <e1>ciprofloxacin</e1> therapy; in the other patient the <e1>ciprofloxacin</e1> -induced hemorrhagic vasculitis was superimposed on a severe forefoot infection, leading to progressive gangrene and a <e2>below-knee amputation</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6190	"In one patient the vasculitis resolved after termination of the <e1>ciprofloxacin</e1> therapy; in the other patient the <e1>ciprofloxacin</e1> -induced <e2>hemorrhagic vasculitis</e2> was superimposed on a severe forefoot infection, leading to progressive gangrene and a below-knee amputation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6191	"In one patient the vasculitis resolved after termination of the <e1>ciprofloxacin</e1> therapy; in the other patient the <e1>ciprofloxacin</e1> -induced hemorrhagic vasculitis was superimposed on a severe forefoot infection, leading to <e2>progressive gangrene</e2> and a below-knee amputation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6192	"In one patient the vasculitis resolved after termination of the <e1>ciprofloxacin</e1> therapy; in the other patient the <e1>ciprofloxacin</e1> -induced hemorrhagic vasculitis was superimposed on a <e2>severe forefoot infection</e2>, leading to progressive gangrene and a below-knee amputation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6193	"In one patient the <e1>vasculitis</e1> resolved after termination of the <e2>ciprofloxacin</e2> therapy; in the other patient the <e2>ciprofloxacin</e2> -induced hemorrhagic <e1>vasculitis</e1> was superimposed on a severe forefoot infection, leading to progressive gangrene and a below-knee amputation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6194	"However, a recent post-marketing survey in Japan revealed that <e1>interstitial pneumonia</e1> occurred in 4 among approximately 2 000 Japanese patients treated with <e2>sorafenib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6195	"<e1>Interstitial pneumonia</e1> probably associated with <e2>sorafenib</e2> treatment: An alert of an adverse event."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6196	"In this article, we describe a Japanese patient with <e1>severe interstitial pneumonia</e1> probably caused by <e2>sorafenib</e2> treatment for metastatic renal cell carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6197	"Oncologists supervising future clinical trials for lung cancer should be alert to the fact that <e1>sorafenib</e1> can potentially induce serious <e2>interstitial lung disease</e2>, although this might depend on racial differences."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6198	"Fatal <e1>gemcitabine</e1> -induced <e2>pulmonary toxicity</e2> in metastatic   gallbladder adenocarcinoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6199	"<e1>Gemcitabine</e1> -induced <e2>pulmonary toxicity</e2> is usually a dramatic condition."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6200	"In this report, we describe a fatal <e1>gemcitabine</e1> -induced <e2>pulmonary toxicity</e2> in a patient with gallbladder metastatic adenocarcinoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6201	"He had <e1>hypokalemia</e1> (K 2.3 mmol/L) induced by <e2>licorice</e2> and also had received disopyramide for arrhythmia, bicalutamide for prostate cancer, and silodosin for prostate hypertrophy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6202	"Therefore, although <e1>garenoxacin</e1> reportedly causes fewer adverse reactions for <e2>cardiac rhythms</e2> than third-generation quinolone antibiotics, one must be cautious of the interference of other drugs during hypokalemia in order to prevent TdP."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6203	"Therefore, although <e1>garenoxacin</e1> reportedly causes fewer adverse reactions for cardiac rhythms than third-generation quinolone antibiotics, one must be cautious of the interference of other drugs during <e2>hypokalemia</e2> in order to prevent TdP."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6204	"<e1>Torsades de Pointes</e1> induced by a combination of garenoxacin and <e2>disopyramide</e2> and other cytochrome P450, family 3, subfamily A polypeptide-4-influencing drugs during hypokalemia due to licorice."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6205	"<e1>Torsades de Pointes</e1> induced by a combination of <e2>garenoxacin</e2> and disopyramide and other cytochrome P450, family 3, subfamily A polypeptide-4-influencing drugs during hypokalemia due to licorice."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6206	"We report an 82-year-old man who developed ventricular tachycardia and Torsades de Pointes (<e1>TdP</e1>) after oral administration of <e2>garenoxacin</e2>, a novel quinolone antibiotic agent that differs from the third-generation quinolones, for pneumonia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6207	"We report an 82-year-old man who developed ventricular tachycardia and <e1>Torsades de Pointes</e1> (TdP) after oral administration of <e2>garenoxacin</e2>, a novel quinolone antibiotic agent that differs from the third-generation quinolones, for pneumonia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6208	"We report an 82-year-old man who developed <e1>ventricular tachycardia</e1> and Torsades de Pointes (TdP) after oral administration of <e2>garenoxacin</e2>, a novel quinolone antibiotic agent that differs from the third-generation quinolones, for pneumonia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6209	"Of 371 patients treated with <e1>8MOP</e1>, three (0.8%) developed an <e2>acute dermatitis</e2> in the PUVA-treated areas."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6210	"<e1>Hepatotoxicity</e1> after high-dose <e2>methylprednisolone</e2> for demyelinating disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6211	"We observed 2 cases of <e1>hepatotoxicity</e1> after a high-dose <e2>methylprednisolone</e2> treatment of a demyelinating disease and evaluated the potential relationship in the light of available evidence."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6212	"<e1>Colonic mucosal necrosis</e1> following administration of <e2>calcium polystryrene sulfonate</e2> (Kalimate) in a uremic patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6213	"<e1>Colonic mucosal necrosis</e1> following administration of calcium polystryrene sulfonate (<e2>Kalimate</e2>) in a uremic patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6214	"<e1>Colonic necrosis</e1> is known as a rare complication following the administration of <e2>Kayexalate</e2> (sodium polystryrene sulfonate) in sorbitol."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6215	"<e1>Colonic necrosis</e1> is known as a rare complication following the administration of Kayexalate (<e2>sodium polystryrene sulfonate</e2>) in sorbitol."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6216	"Two days after administration of <e1>Kalimate</e1> enema, he had profuse hematochezia, and a sigmoidoscopy showed diffuse <e2>colonic mucosal necrosis in the rectum</e2> and sigmoid colon."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6217	"Two days after administration of <e1>Kalimate</e1> enema, he had <e2>profuse hematochezia</e2>, and a sigmoidoscopy showed diffuse colonic mucosal necrosis in the rectum and sigmoid colon."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6218	"We report a rare case of <e1>colonic mucosal necrosis</e1> following Kalimate (<e2>calcium polystryrene sulfonate</e2>), an analogue of Kayexalate without sorbitol in a 34-yr-old man."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6219	"We report a rare case of <e1>colonic mucosal necrosis</e1> following <e2>Kalimate</e2> (calcium polystryrene sulfonate), an analogue of Kayexalate without sorbitol in a 34-yr-old man."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6220	"We report a rare case of <e1>colonic mucosal necrosis</e1> following Kalimate (calcium polystryrene sulfonate), an analogue of <e2>Kayexalate</e2> without sorbitol in a 34-yr-old man."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6221	"<e1>Clozapine</e1> -induced <e2>tardive dyskinesia</e2> in schizophrenic patients taking clozapine as a first-line antipsychotic drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6222	"CONCLUSIONS: These results suggest that <e1>clozapine</e1> may cause TD; however, the prevalence is low and the severity is relatively mild, with no or mild self-reported <e2>discomfort</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6223	"CONCLUSIONS: These results suggest that <e1>clozapine</e1> may cause <e2>TD</e2>; however, the prevalence is low and the severity is relatively mild, with no or mild self-reported discomfort."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6224	"However, several case reports have suggested that <e1>clozapine</e1> could also cause <e2>TD</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6225	"OBJECTIVE: <e1>Clozapine</e1> causes few <e2>extrapyramidal symptoms</e2> and is recommended as a treatment drug for severe tardive dyskinesia (TD)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6226	"<e1>All-trans retinoic acid</e1> -induced <e2>focal myositis</e2>, synovitis, and mononeuritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6227	"<e1>All-trans retinoic acid</e1> -induced focal myositis, synovitis, and <e2>mononeuritis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6228	"<e1>All-trans retinoic acid</e1> -induced focal myositis, <e2>synovitis</e2>, and mononeuritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6229	"Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed <e1>acute focal myositis</e1>, synovitis, and possible vasculitis, after receiving <e2>all-trans retinoic acid</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6230	"Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis, synovitis, and <e1>possible vasculitis</e1>, after receiving <e2>all-trans retinoic acid</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6231	"Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis, <e1>synovitis</e1>, and possible vasculitis, after receiving <e2>all-trans retinoic acid</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6232	"BACKGROUND: To assess the nature, incidence, and risk factors of <e1>retinopathy</e1> associated with <e2>pegylated interferon</e2> and ribavirin combination therapy in chronic hepatitis C patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6233	"BACKGROUND: To assess the nature, incidence, and risk factors of <e1>retinopathy</e1> associated with pegylated interferon and <e2>ribavirin</e2> combination therapy in chronic hepatitis C patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6234	"CONCLUSION: Significant ocular complications such as an <e1>irreversible decrease of visual acuity</e1> may develop in patients treated with <e2>pegylated interferon</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6235	"CONCLUSION: Significant <e1>ocular complications</e1> such as an irreversible decrease of visual acuity may develop in patients treated with <e2>pegylated interferon</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6236	"<e1>Retinopathy</e1> in hepatitis C patients due to combination therapy with <e2>pegylated interferon</e2> and ribavirin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6237	"<e1>Retinopathy</e1> in hepatitis C patients due to combination therapy with pegylated interferon and <e2>ribavirin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6238	"Administration of cisplatin in three patients with <e1>carboplatin</e1> <e2>hypersensitivity</e2>: is skin testing useful?"
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6239	"<e1>Hypersensitivity</e1> to <e2>carboplatin</e2> has been reported in up to 44% of patients receiving this antineoplastic agent, usually occurring after several courses of treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6240	"Prick tests and intradermal tests with a series of dilutions of <e1>carboplatin</e1> and cisplatin were performed on three patients who had exhibited medium and <e2>severe hypersensitivity</e2> reactions to <e1>carboplatin</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6241	"<e1>Aseptic meningitis</e1>, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim-<e2>sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6242	"<e1>Aseptic meningitis</e1>, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with <e2>trimethoprim</e2> -sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6243	"Aseptic meningitis, <e1>hemolytic anemia</e1>, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim-<e2>sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6244	"Aseptic meningitis, <e1>hemolytic anemia</e1>, hepatitis, and orthostatic hypotension in a patient treated with <e2>trimethoprim</e2> -sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6245	"Aseptic meningitis, hemolytic anemia, <e1>hepatitis</e1>, and orthostatic hypotension in a patient treated with trimethoprim-<e2>sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6246	"Aseptic meningitis, hemolytic anemia, <e1>hepatitis</e1>, and orthostatic hypotension in a patient treated with <e2>trimethoprim</e2> -sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6247	"Aseptic meningitis, hemolytic anemia, hepatitis, and <e1>orthostatic hypotension</e1> in a patient treated with trimethoprim-<e2>sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6248	"Aseptic meningitis, hemolytic anemia, hepatitis, and <e1>orthostatic hypotension</e1> in a patient treated with <e2>trimethoprim</e2> -sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6249	"CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and <e1>aseptic meningitis</e1> simultaneously after using trimethoprim-<e2>sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6250	"CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and <e1>aseptic meningitis</e1> simultaneously after using <e2>trimethoprim</e2> -sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6251	"CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed <e1>hemolytic anemia</e1>, hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim-<e2>sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6252	"CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed <e1>hemolytic anemia</e1>, hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using <e2>trimethoprim</e2> -sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6253	"CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, <e1>hepatitis</e1>, orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim-<e2>sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6254	"CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, <e1>hepatitis</e1>, orthostatic hypotension, and aseptic meningitis simultaneously after using <e2>trimethoprim</e2> -sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6255	"CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, <e1>orthostatic hypotension</e1>, and aseptic meningitis simultaneously after using trimethoprim-<e2>sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6256	"CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, <e1>orthostatic hypotension</e1>, and aseptic meningitis simultaneously after using <e2>trimethoprim</e2> -sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6257	"He had been taking trimethoprim-<e1>sulfamethoxazole</e1> for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, <e2>difficulty with speech</e2>, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6258	"He had been taking <e1>trimethoprim</e1> -sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, <e2>difficulty with speech</e2>, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6259	"He had been taking trimethoprim-<e1>sulfamethoxazole</e1> for approximately eight days when he revisited his family physician, complaining of headaches, <e2>dizziness</e2>, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6260	"He had been taking <e1>trimethoprim</e1> -sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, <e2>dizziness</e2>, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6261	"He had been taking trimethoprim-<e1>sulfamethoxazole</e1> for approximately eight days when he revisited his family physician, complaining of <e2>headaches</e2>, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6262	"He had been taking <e1>trimethoprim</e1> -sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of <e2>headaches</e2>, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6263	"He had been taking trimethoprim-<e1>sulfamethoxazole</e1> for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and <e2>itching on the trunk</e2> of his body and legs, where a maculopapular rash was noted."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6264	"He had been taking <e1>trimethoprim</e1> -sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and <e2>itching on the trunk</e2> of his body and legs, where a maculopapular rash was noted."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6265	"He had been taking trimethoprim-<e1>sulfamethoxazole</e1> for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a <e2>maculopapular rash</e2> was noted."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6266	"He had been taking <e1>trimethoprim</e1> -sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a <e2>maculopapular rash</e2> was noted."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6267	"He had been taking trimethoprim-<e1>sulfamethoxazole</e1> for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, <e2>weakness</e2>, and itching on the trunk of his body and legs, where a maculopapular rash was noted."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6268	"He had been taking <e1>trimethoprim</e1> -sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, <e2>weakness</e2>, and itching on the trunk of his body and legs, where a maculopapular rash was noted."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6269	"PURPOSE: The case of a patient who developed <e1>aseptic meningitis</e1>, hemolytic anemia, hepatitis, and orthostatic hypotension simultaneously during treatment with trimethoprim-<e2>sulfamethoxazole</e2> is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6270	"PURPOSE: The case of a patient who developed <e1>aseptic meningitis</e1>, hemolytic anemia, hepatitis, and orthostatic hypotension simultaneously during treatment with <e2>trimethoprim</e2> -sulfamethoxazole is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6271	"PURPOSE: The case of a patient who developed aseptic meningitis, <e1>hemolytic anemia</e1>, hepatitis, and orthostatic hypotension simultaneously during treatment with trimethoprim-<e2>sulfamethoxazole</e2> is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6272	"PURPOSE: The case of a patient who developed aseptic meningitis, <e1>hemolytic anemia</e1>, hepatitis, and orthostatic hypotension simultaneously during treatment with <e2>trimethoprim</e2> -sulfamethoxazole is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6273	"PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, <e1>hepatitis</e1>, and orthostatic hypotension simultaneously during treatment with trimethoprim-<e2>sulfamethoxazole</e2> is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6274	"PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, <e1>hepatitis</e1>, and orthostatic hypotension simultaneously during treatment with <e2>trimethoprim</e2> -sulfamethoxazole is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6275	"PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, hepatitis, and <e1>orthostatic hypotension</e1> simultaneously during treatment with trimethoprim-<e2>sulfamethoxazole</e2> is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6276	"PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, hepatitis, and <e1>orthostatic hypotension</e1> simultaneously during treatment with <e2>trimethoprim</e2> -sulfamethoxazole is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6277	"A patient, while on intravenous <e1>ritodrine</e1> therapy for preterm labor, experienced an episode of <e2>acute chest pain</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6278	"The electrocardiogram (ECG), which was read as normal prior to <e1>ritodrine</e1> infusion, demonstrated a <e2>type I second-degree AV block</e2> which disappeared upon discontinuation of <e1>ritodrine</e1> therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6279	"The electrocardiogram (ECG), which was read as normal prior to <e1>ritodrine</e1> infusion, demonstrated a <e2>type I second-degree AV block</e2> which disappeared upon discontinuation of <e1>ritodrine</e1> therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6280	"Type I second-degree AV block (<e1>Mobitz type I</e1>, Wenckebach AV block) during <e2>ritodrine</e2> therapy for preterm labor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6281	"<e1>Type I second-degree AV block</e1> (Mobitz type I, Wenckebach AV block) during <e2>ritodrine</e2> therapy for preterm labor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6282	"Type I second-degree AV block (Mobitz type I, <e1>Wenckebach AV block</e1>) during <e2>ritodrine</e2> therapy for preterm labor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6283	"Exacerbation of <e1>anthracycline</e1> -induced <e2>early chronic cardiomyopathy</e2> with ATRA: role of B-type natriuretic peptide as an indicator of cardiac dysfunction."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6284	"We report the case of a 14-year-old female with acute promyelocytic leukemia who developed <e1>symptomatic cardiomyopathy</e1> only 4 months into treatment with a combination of daunomycin and <e2>all-trans retinoic acid</e2> (ATRA)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6285	"We report the case of a 14-year-old female with acute promyelocytic leukemia who developed <e1>symptomatic cardiomyopathy</e1> only 4 months into treatment with a combination of daunomycin and all-trans retinoic acid (<e2>ATRA</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6286	"We report the case of a 14-year-old female with acute promyelocytic leukemia who developed <e1>symptomatic cardiomyopathy</e1> only 4 months into treatment with a combination of <e2>daunomycin</e2> and all-trans retinoic acid (ATRA)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6287	"CONCLUSIONS: We present a case of a patient with CML who developed <e1>KS</e1> 12 months after starting treatment with <e2>imatinib</e2> 400 mg/d."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6288	"Flare of <e1>Kaposi's sarcoma</e1> (KS) is well described in immunosuppressed patients treated with corticosteroids and <e2>rituximab</e2>, but has not yet been reported during treatment with imatinib."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6289	"Flare of Kaposi's sarcoma (<e1>KS</e1>) is well described in immunosuppressed patients treated with corticosteroids and <e2>rituximab</e2>, but has not yet been reported during treatment with imatinib."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6290	"<e1>Kaposi's sarcoma</e1> in a patient treated with <e2>imatinib mesylate</e2> for chronic myeloid leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6291	"OBJECTIVE: We report a case of <e1>cutaneous KS lesions</e1> in a patient affected by CML treated with <e2>imatinib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6292	"<e1>Bulbar</e1> and pseudobulbar palsy complicating therapy with high-dose <e2>cytosine arabinoside</e2> in children with leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6293	"Bulbar and <e1>pseudobulbar palsy</e1> complicating therapy with high-dose <e2>cytosine arabinoside</e2> in children with leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6294	"<e1>Interferon</e1> -based treatments have the potential to decrease the burden of disease, but are complicated by side effects, including <e2>neuropsychiatric symptoms</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6295	"<e1>Interferon</e1> -induced <e2>psychosis</e2> as a "psychiatric contraindication" to hepatitis C treatment: a review and case-based discussion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6296	"METHOD: The authors followed a patient with chronic HCV who received <e1>interferon</e1> and ribavirin and who developed <e2>hallucinations</e2> ultimately requiring psychiatric hospitalization."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6297	"METHOD: The authors followed a patient with chronic HCV who received interferon and <e1>ribavirin</e1> and who developed <e2>hallucinations</e2> ultimately requiring psychiatric hospitalization."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6298	"OBJECTIVE: The authors described a case of <e1>interferon</e1> -induced <e2>psychosis</e2> as a framework to review the literature and discuss the decision to pursue antiviral treatment in psychiatrically ill patients with hepatitis C."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6299	"CONCLUSION: <e1>Zidovudine</e1> is well a known cause of <e2>anaemia</e2> and thus should be used with caution in the initiation of antiretroviral therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6300	"We report a case of <e1>Zidovudine</e1> induced <e2>anaemia</e2> and bone marrow aplasia in a patient infected with HIV."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6301	"We report a case of <e1>Zidovudine</e1> induced anaemia and <e2>bone marrow aplasia</e2> in a patient infected with HIV."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6302	"<e1>Zidovudine</e1> induced <e2>pure red cell aplasia</e2>: a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6303	"CONCLUSIONS: SD-OCT and AO detected abnormalities that correlate topographically with visual field loss from <e1>hydroxychloroquine</e1> toxicity as demonstrated by HVF 10-2 and may be useful in the detection of subclinical abnormalities that precede symptoms or <e2>objective visual field loss</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6304	"CONCLUSIONS: SD-OCT and AO detected abnormalities that correlate topographically with <e1>visual field loss</e1> from <e2>hydroxychloroquine</e2> toxicity as demonstrated by HVF 10-2 and may be useful in the detection of subclinical abnormalities that precede symptoms or objective <e1>visual field loss</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6305	"PURPOSE: To describe spectral-domain optical coherence tomography (SD-OCT) and adaptive optics (AO) imaging in <e1>hydroxychloroquine</e1> <e2>retinal toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6306	"Spectral-domain optical coherence tomography and adaptive optics may detect <e1>hydroxychloroquine</e1> <e2>retinal toxicity</e2> before symptomatic vision loss."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6307	"Transient <e1>trazodone</e1> -induced <e2>hypomanic symptoms</e2> occurred in three depressed patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6308	"<e1>Trazodone</e1> -induced <e2>transient hypomanic symptoms</e2> and their management."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6309	"Introduction of <e1>etanercept</e1> was also clinically effective but followed by development of <e2>severe heart failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6310	"<e1>Reversible heart failure</e1> in a patient receiving <e2>etanercept</e2> for ankylosing spondylitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6311	"Combining <e1>methylephedrine</e1> and Chinese herbal drugs might carry a risk of <e2>stroke</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6312	"We describe a patient who experienced <e1>chronic nausea</e1> and an episode of confusion while treated with a small, stable dose of oral <e2>morphine</e2> in the setting of mild renal insufficiency."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6313	"We describe a patient who experienced chronic nausea and an episode of <e1>confusion</e1> while treated with a small, stable dose of oral <e2>morphine</e2> in the setting of mild renal insufficiency."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6314	"Common adverse events (frequency 10%) of <e1>lacosamide</e1> doses up to 600 mg/day include nonspecific central nervous system effects (e.g., dizziness, <e2>ataxia</e2>, diplopia, and somnolence)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6315	"Common adverse events (frequency 10%) of <e1>lacosamide</e1> doses up to 600 mg/day include nonspecific central nervous system effects (e.g., dizziness, ataxia, <e2>diplopia</e2>, and somnolence)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6316	"Common adverse events (frequency 10%) of <e1>lacosamide</e1> doses up to 600 mg/day include nonspecific central nervous system effects (e.g., <e2>dizziness</e2>, ataxia, diplopia, and somnolence)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6317	"Common adverse events (frequency 10%) of <e1>lacosamide</e1> doses up to 600 mg/day include nonspecific central nervous system effects (e.g., dizziness, ataxia, diplopia, and <e2>somnolence</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6318	"A case of <e1>aseptic pleuropericarditis</e1> in a patient with chronic plaque psoriasis under <e2>methotrexate</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6319	"<e1>Methotrexate</e1> may rarely provoke <e2>serositis</e2>, even with low doses and after just a few weeks of therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6320	"We report here a rare case of <e1>pleuropericarditis</e1> due to <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6321	"The authors report five cases of <e1>tremor</e1> related to <e2>itraconazole</e2> therapy, which occurred within 1-12 months of initiating treatment and resolved gradually following <e2>itraconazole</e2> withdrawal."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6322	"The authors report five cases of <e1>tremor</e1> related to <e2>itraconazole</e2> therapy, which occurred within 1-12 months of initiating treatment and resolved gradually following <e2>itraconazole</e2> withdrawal."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6323	"<e1>Tremor</e1>: a newly described adverse event with long-term <e2>itraconazole</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6324	"<e1>Acute kidney injury</e1> caused by <e2>zonisamide</e2> -induced hypersensitivity syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6325	"Acute kidney injury caused by <e1>zonisamide</e1> -induced <e2>hypersensitivity syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6326	"<e1>Hypersensitivity</e1> to <e2>zonisamide</e2> was confirmed by the skin patch test."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6327	"The current report describes a man who was prescribed <e1>zonisamide</e1> for epilepsy and subsequently developed widespread skin rash, <e2>acute kidney injury</e2>, high-grade fever, eosinophilia, liver dysfunction, lymphadenopathy and an increase in antihuman herpesvirus-6 immunoglobulin G titer."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6328	"The current report describes a man who was prescribed <e1>zonisamide</e1> for epilepsy and subsequently developed widespread skin rash, acute kidney injury, high-grade fever, eosinophilia, liver dysfunction, lymphadenopathy and <e2>an increase in antihuman herpesvirus-6 immunoglobulin G titer</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6329	"The current report describes a man who was prescribed <e1>zonisamide</e1> for epilepsy and subsequently developed widespread skin rash, acute kidney injury, high-grade fever, <e2>eosinophilia</e2>, liver dysfunction, lymphadenopathy and an increase in antihuman herpesvirus-6 immunoglobulin G titer."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6330	"The current report describes a man who was prescribed <e1>zonisamide</e1> for epilepsy and subsequently developed widespread skin rash, acute kidney injury, <e2>high-grade fever</e2>, eosinophilia, liver dysfunction, lymphadenopathy and an increase in antihuman herpesvirus-6 immunoglobulin G titer."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6331	"The current report describes a man who was prescribed <e1>zonisamide</e1> for epilepsy and subsequently developed widespread skin rash, acute kidney injury, high-grade fever, eosinophilia, <e2>liver dysfunction</e2>, lymphadenopathy and an increase in antihuman herpesvirus-6 immunoglobulin G titer."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6332	"The current report describes a man who was prescribed <e1>zonisamide</e1> for epilepsy and subsequently developed widespread skin rash, acute kidney injury, high-grade fever, eosinophilia, liver dysfunction, <e2>lymphadenopathy</e2> and an increase in antihuman herpesvirus-6 immunoglobulin G titer."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6333	"The current report describes a man who was prescribed <e1>zonisamide</e1> for epilepsy and subsequently developed widespread <e2>skin rash</e2>, acute kidney injury, high-grade fever, eosinophilia, liver dysfunction, lymphadenopathy and an increase in antihuman herpesvirus-6 immunoglobulin G titer."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6334	"This is the first report of <e1>acute kidney injury</e1> due to <e2>zonisamide</e2> -induced DRESS/DIHS."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6335	"This is the first report of acute kidney injury due to <e1>zonisamide</e1> -induced DRESS/<e2>DIHS</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6336	"This is the first report of acute kidney injury due to <e1>zonisamide</e1> -induced <e2>DRESS</e2>/DIHS."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6337	"Only two case reports of adults with <e1>allergic contact dermatitis</e1> to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential <e1>allergic contact dermatitis</e1> to <e2>bisabolol</e2> - a component of the Aquaphor emollient they were using to treat their atopic dermatitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6338	"Case report: <e1>acute renal failure</e1> after administering intravenous <e2>immunoglobulin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6339	"The hospital course of the <e1>acute renal failure</e1> is presented with a review of the literature on cases of <e1>acute renal failure</e1> after <e2>IVIG</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6340	"We report the case of an 87-year-old white woman with myasthenia gravis who presented with nausea, shortness of breath, <e1>azotemia</e1>, and hyperkalemia shortly after completing a course of intravenous <e2>immunoglobulin</e2> (IVIG)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6341	"We report the case of an 87-year-old white woman with myasthenia gravis who presented with nausea, shortness of breath, <e1>azotemia</e1>, and hyperkalemia shortly after completing a course of intravenous immunoglobulin (<e2>IVIG</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6342	"We report the case of an 87-year-old white woman with myasthenia gravis who presented with nausea, shortness of breath, azotemia, and <e1>hyperkalemia</e1> shortly after completing a course of intravenous <e2>immunoglobulin</e2> (IVIG)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6343	"We report the case of an 87-year-old white woman with myasthenia gravis who presented with nausea, shortness of breath, azotemia, and <e1>hyperkalemia</e1> shortly after completing a course of intravenous immunoglobulin (<e2>IVIG</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6344	"We report the case of an 87-year-old white woman with myasthenia gravis who presented with <e1>nausea</e1>, shortness of breath, azotemia, and hyperkalemia shortly after completing a course of intravenous <e2>immunoglobulin</e2> (IVIG)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6345	"We report the case of an 87-year-old white woman with myasthenia gravis who presented with <e1>nausea</e1>, shortness of breath, azotemia, and hyperkalemia shortly after completing a course of intravenous immunoglobulin (<e2>IVIG</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6346	"We report the case of an 87-year-old white woman with myasthenia gravis who presented with nausea, <e1>shortness of breath</e1>, azotemia, and hyperkalemia shortly after completing a course of intravenous <e2>immunoglobulin</e2> (IVIG)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6347	"We report the case of an 87-year-old white woman with myasthenia gravis who presented with nausea, <e1>shortness of breath</e1>, azotemia, and hyperkalemia shortly after completing a course of intravenous immunoglobulin (<e2>IVIG</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6348	"However, the use of <e1>lithium</e1> should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of <e2>cardiac toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6349	"However, the use of <e1>lithium</e1> should be avoided with any patient who is purging, since it may exacerbate the <e2>loss of intracellular potassium</e2>, thereby increasing the risk of cardiac toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6350	"Severe <e1>vancomycin</e1> -induced <e2>anaphylactic reaction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6351	"<e1>Vancomycin</e1> is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an <e2>anaphylactoid</e2> reaction known as "red man syndrome" and anaphylaxis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6352	"<e1>Vancomycin</e1> is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as "red man syndrome" and <e2>anaphylaxis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6353	"<e1>Vancomycin</e1> is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, <e2>blood disorders</e2>, and two types of hypersensitivity reactions - an anaphylactoid reaction known as "red man syndrome" and anaphylaxis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6354	"<e1>Vancomycin</e1> is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, <e2>gastrointestinal disturbances</e2>, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as "red man syndrome" and anaphylaxis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6355	"<e1>Vancomycin</e1> is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of <e2>hypersensitivity reactions</e2> - an anaphylactoid reaction known as "red man syndrome" and anaphylaxis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6356	"<e1>Vancomycin</e1> is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as <e2>nephrotoxicity</e2>, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as "red man syndrome" and anaphylaxis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6357	"<e1>Vancomycin</e1> is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, <e2>ototoxicity</e2>, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as "red man syndrome" and anaphylaxis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6358	"<e1>Vancomycin</e1> is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as "<e2>red man syndrome</e2>" and anaphylaxis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6359	"We report a case of a 23-year-old man who developed a <e1>vancomycin</e1> -induced <e2>anaphylactic reaction</e2> in the treatment of methicillin-resistant Staphylococcus aureus infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6360	"Four patients in whom <e1>pulmonary oedema</e1> developed during tocolysis with <e2>hexoprenaline</e2> are described and the aetiological factors and pathogenesis of this potentially lethal complication discussed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6361	"<e1>Pulmonary oedema</e1> after <e2>hexoprenaline</e2> administration in preterm labour."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6362	"<e1>Fatal interstitial lung disease</e1> after <e2>erlotinib</e2> administration in a patient with radiation fibrosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6363	"High-resolution computed tomography scan findings were consistent with <e1>ILD</e1>, which was sufficient to diagnose as <e2>erlotinib</e2> -induced <e1>ILD</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6364	"INTRODUCTION: Although <e1>gefitinib</e1> used for the treatment of non-small-cell lung cancer is a well-known cause of interstitial lung disease (<e2>ILD</e2>), few case reports on erlotinib-induced <e2>ILD</e2> have been issued."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6365	"INTRODUCTION: Although gefitinib used for the treatment of non-small-cell lung cancer is a well-known cause of interstitial lung disease (<e1>ILD</e1>), few case reports on <e2>erlotinib</e2> -induced <e1>ILD</e1> have been issued."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6366	"INTRODUCTION: Although <e1>gefitinib</e1> used for the treatment of non-small-cell lung cancer is a well-known cause of <e2>interstitial lung disease</e2> (ILD), few case reports on erlotinib-induced ILD have been issued."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6367	"RESULTS: We recently experienced a case of fatal <e1>erlotinib</e1> -induced <e2>ILD</e2>, diagnosed based on clinical and radiologic findings, which occurred in a patient with radiation fibrosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6368	"This case had radiation fibrosis, so we suggest that radiation fibrosis may be another contributor of the occurrence of <e1>ILD</e1> in patients taking <e2>erlotinib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6369	"One patient suffered <e1>coronary artery vasospasm</e1>, attributed to the use of topical 1:1000 <e2>epinephrine</e2> during surgery."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6370	"The other patient developed <e1>transient intraoperative hypertension</e1> immediately after inadvertent submucosal injection of concentrated <e2>epinephrine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6371	"<e1>Cisplatin</e1> -induced syndrome of inappropriate antidiuretic hormone (<e2>SIADH</e2>) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6372	"<e1>Cisplatin</e1> -induced <e2>syndrome of inappropriate antidiuretic hormone</e2> (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6373	"We present a case of the syndrome of inappropriate antidiuretic hormone (<e1>SIADH</e1>) secondary to <e2>cisplatin</e2> therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6374	"We present a case of the <e1>syndrome of inappropriate antidiuretic hormone</e1> (SIADH) secondary to <e2>cisplatin</e2> therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6375	"However, to our knowledge, in newborns there have been no reported cases to date of <e1>thrombocytosis</e1> induced by <e2>enoxaparin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6376	"<e1>Thrombocytosis</e1> associated with <e2>enoxaparin</e2>: A very rare cause in newborns."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6377	"<e1>Thrombocytosis</e1> induced by <e2>enoxaparin</e2> has been reported as a rare adverse effect of this medication in adults."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6378	"OBJECTIVE: 1) To describe a patient with rheumatoid arthritis receiving <e1>adalimumab</e1> who developed fever, pancytopenia, splenomegaly, and <e2>extreme hyperferritinemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6379	"OBJECTIVE: 1) To describe a patient with rheumatoid arthritis receiving <e1>adalimumab</e1> who developed <e2>fever</e2>, pancytopenia, splenomegaly, and extreme hyperferritinemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6380	"OBJECTIVE: 1) To describe a patient with rheumatoid arthritis receiving <e1>adalimumab</e1> who developed fever, <e2>pancytopenia</e2>, splenomegaly, and extreme hyperferritinemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6381	"OBJECTIVE: 1) To describe a patient with rheumatoid arthritis receiving <e1>adalimumab</e1> who developed fever, pancytopenia, <e2>splenomegaly</e2>, and extreme hyperferritinemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6382	"Visceral leishmaniasis and <e1>macrophagic activation syndrome</e1> in a patient with rheumatoid arthritis under treatment with <e2>adalimumab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6383	"<e1>Visceral leishmaniasis</e1> and macrophagic activation syndrome in a patient with rheumatoid arthritis under treatment with <e2>adalimumab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6384	"This case presentation is of a patient who had the clinical appearance of <e1>epiglottitis</e1>, but actually had an oro-pharyngeal dystonic reaction to <e2>prochlorperazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6385	"This case presentation is of a patient who had the clinical appearance of epiglottitis, but actually had an <e1>oro-pharyngeal dystonic reaction</e1> to <e2>prochlorperazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6386	"Normalization of generalized retinal function and progression of maculopathy after cessation of therapy in a case of severe <e1>hydroxychloroquine</e1> <e2>retinopathy</e2> with 19 years follow-up."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6387	"After other potential causes of liver toxicity were excluded, <e1>TMP-SMX</e1> was determined to be the cause of his <e2>acute liver toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6388	"After other potential causes of <e1>liver toxicity</e1> were excluded, <e2>TMP-SMX</e2> was determined to be the cause of his acute <e1>liver toxicity</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6389	"Although this combination agent has been associated with a hypersensitivity syndrome involving <e1>cutaneous skin eruptions</e1>, pediatric cases of <e2>TMP-SMX</e2> -induced hepatotoxicity are rare."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6390	"Although this combination agent has been associated with a hypersensitivity syndrome involving cutaneous skin eruptions, pediatric cases of <e1>TMP-SMX</e1> -induced <e2>hepatotoxicity</e2> are rare."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6391	"Although this combination agent has been associated with a <e1>hypersensitivity syndrome</e1> involving cutaneous skin eruptions, pediatric cases of <e2>TMP-SMX</e2> -induced hepatotoxicity are rare."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6392	"Due to the increasing use of <e1>TMP-SMX</e1> in children, clinicians should be aware of this potentially life-threatening, <e2>immunemediated hypersensitivity reaction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6393	"<e1>Trimethoprim-sulfamethoxazole</e1> -induced <e2>hepatotoxicity</e2> in a pediatric patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6394	"Use of the Naranjo adverse drug reaction probability scale indicated a probable relationship (score of 5) between the patient's development of <e1>hepatotoxicity</e1> and the <e2>TMP-SMX</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6395	"We describe a relatively healthy, 9-year-old boy who developed a CA-MRSA skin and <e1>soft tissue infection</e1> and was treated with <e2>TMP-SMX</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6396	"<e1>Amiodarone</e1> was discontinued, and <e2>thyrotoxicosis</e2> gradually abated."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6397	"<e1>Goiter</e1> and hypothyroidism during re-treatment with <e2>amiodarone</e2> in a patient who previously experienced <e2>amiodarone</e2> -induced thyrotoxicosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6398	"Goiter and <e1>hypothyroidism</e1> during re-treatment with <e2>amiodarone</e2> in a patient who previously experienced <e2>amiodarone</e2> -induced thyrotoxicosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6399	"Goiter and hypothyroidism during re-treatment with <e1>amiodarone</e1> in a patient who previously experienced <e1>amiodarone</e1> -induced <e2>thyrotoxicosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6400	"BACKGROUND: <e1>Aphthous stomatitis</e1>, a common mucocutaneous disorder, is a well accepted complication of <e2>sirolimus</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6401	"CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound <e1>worsening of chronic aphthous ulcers</e1> after immunosuppressive therapy was changed from tacrolimus to <e2>sirolimus</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6402	"CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound <e1>worsening of chronic aphthous ulcers</e1> after immunosuppressive therapy was changed from <e2>tacrolimus</e2> to sirolimus."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6403	"<e1>Severe aphthous stomatitis</e1> associated with oral <e2>calcineurin</e2> and mTOR inhibitors."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6404	"These findings mean that the effect of the <e1>MP</e1> pulse therapy on renal function depends on the clinical state of the patient and that renal deterioration after the pulse therapy may be more marked in patients who are more nephrotic and more impaired in renal function and suggest that increasing sodium and water retention during an <e1>MP</e1> therapy and the associated renal interstitial edema, proposed as one of the mechanisms of acute renal failure occurring in patients with minimal-change nephrotic syndrome, may be responsible for the <e1>MP</e1> -induced <e2>transient renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6405	"Three nephrotic patients who had reduced renal function and active renal disease with progressive deterioration of renal function prior to the use of <e1>MP</e1> developed <e2>transient renal failure</e2> following an <e1>MP</e1> pulse therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6406	"Three nephrotic patients who had reduced renal function and active renal disease with progressive deterioration of renal function prior to the use of <e1>MP</e1> developed <e2>transient renal failure</e2> following an <e1>MP</e1> pulse therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6407	"A 67-year-old patient, with primary polymyositis and without previous evidence of liver disease, developed clinical and biochemical features of <e1>severe cholestasis</e1> 3 months after initiation of <e2>azathioprine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6408	"It is believed that this is the first reported case of reversible <e1>azathioprine</e1> -induced <e2>cholestasis</e2> associated with histological evidence of bile duct injury."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6409	"Reversible cholestasis with <e1>bile duct injury</e1> following <e2>azathioprine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6410	"Reversible <e1>cholestasis</e1> with bile duct injury following <e2>azathioprine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6411	"A case of the Rett syndrome with <e1>acute encephalopathy</e1> induced during <e2>calcium hopantenate</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6412	"We report a girl with the Rett syndrome who had <e1>acute encephalopathy</e1> probably induced by <e2>calcium hopantenate</e2> (HOPA)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6413	"We report a girl with the Rett syndrome who had <e1>acute encephalopathy</e1> probably induced by calcium hopantenate (<e2>HOPA</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6414	"<e1>Persistent light reactivity</e1> from systemic <e2>quinine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6415	"The <e1>photosensitivity</e1> is still present 3 years after the withdrawal of <e2>quinine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6416	"Two cases are reported of patients who developed a <e1>hematologic malignancy</e1> several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, <e2>doxorubicin</e2>, and mitomycin C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6417	"Two cases are reported of patients who developed a <e1>hematologic malignancy</e1> several years after intravesical chemotherapy of superficial bladder cancer with <e2>etoglucid</e2>, doxorubicin, and mitomycin C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6418	"Two cases are reported of patients who developed a <e1>hematologic malignancy</e1> several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and <e2>mitomycin C</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6419	"A patient with Wegener's granulomatosis rapidly developed a <e1>circumferential subglottic stenosis</e1> while on a <e2>cyclophosphamide</e2> regimen that had caused resolution of systemic symptoms and pulmonary infiltrates."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6420	"<e1>Subglottic stenosis</e1> in Wegener's granulomatosis: development during <e2>cyclophosphamide</e2> treatment with response to carbon dioxide laser therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6421	"A case is described of <e1>severe splenic hemorrhage and rupture</e1> which developed 3 h after completion of <e2>tPA</e2> infusion for suspected acute myocardial infarction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6422	"<e1>Splenic hemorrhage</e1>: a complication of <e2>tissue plasminogen activator</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6423	"Thrombolytic therapy with <e1>tissue plasminogen activator</e1> (tPA) for acute myocardial infarction may result in major bleeding complications such as <e2>gastrointestinal or intracranial bleeding</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6424	"Thrombolytic therapy with tissue plasminogen activator (<e1>tPA</e1>) for acute myocardial infarction may result in major bleeding complications such as <e2>gastrointestinal or intracranial bleeding</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6425	"A case of <e1>severe acute hepatitis</e1> caused by <e2>cyproterone acetate</e2> in a 71 year old man with prostatic carcinoma is reported with a review of the literature on hepatic reactions to this drug."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6426	"Monitoring of liver function tests should be mandatory in patients receiving high doses of <e1>cyproterone acetate</e1>; the drug should be withdrawn immediately if <e2>abnormal liver function tests</e2> are found."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6427	"<e1>Severe hepatitis</e1> caused by <e2>cyproterone acetate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6428	"A unique case of a transient, nonpigmenting <e1>fixed drug eruption</e1> caused by the radiopaque contrast medium <e2>iothalamate</e2> is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6429	"One patient with systemic lupus erythematosus developed <e1>erythema multiforme</e1> after taking <e2>griseofulvin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6430	"<e1>Aminoglutethimide</e1> was discontinued until completion of radiotherapy, and the <e2>rash</e2> resolved."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6431	"Concomitant irradiation apparently enhanced the <e1>skin toxicity</e1> of <e2>aminoglutethimide</e2> or possibly <e2>aminoglutethimide</e2> had a radiosensitizing role in this patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6432	"We report a case of radiotherapy-enhanced <e1>aminoglutethimide</e1> <e2>skin toxicity</e2> in a patient with metastatic breast cancer."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6433	"Data have been published regarding the possibility that <e1>tamoxifen</e1> may be responsible for the subsequent development of <e2>carcinoma of the corpus uteri</e2> in these patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6434	"The authors intend to carry out a case-control study on patients treated with <e1>tamoxifen</e1> for breast carcinoma to reveal the possible presence of <e2>endometrial carcinoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6435	"<e1>Disulfiram</e1> -induced <e2>hepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6436	"Our patient had headache, mild fever, nausea, vomiting, rash, and <e1>eosinophilia</e1> after 3 weeks of <e2>disulfiram</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6437	"Our patient had <e1>headache</e1>, mild fever, nausea, vomiting, rash, and eosinophilia after 3 weeks of <e2>disulfiram</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6438	"Our patient had headache, <e1>mild fever</e1>, nausea, vomiting, rash, and eosinophilia after 3 weeks of <e2>disulfiram</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6439	"Our patient had headache, mild fever, <e1>nausea</e1>, vomiting, rash, and eosinophilia after 3 weeks of <e2>disulfiram</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6440	"Our patient had headache, mild fever, nausea, vomiting, <e1>rash</e1>, and eosinophilia after 3 weeks of <e2>disulfiram</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6441	"Our patient had headache, mild fever, nausea, <e1>vomiting</e1>, rash, and eosinophilia after 3 weeks of <e2>disulfiram</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6442	"We reported a case of <e1>disulfiram</e1> -induced <e2>hepatitis</e2> with unique clinical features and compared our case with others in the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6443	"An episode of <e1>leukoencephalopathy</e1> is reported in a 13-year-old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 <e2>methotrexate</e2> and 12 mg intrathecal <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6444	"An episode of <e1>leukoencephalopathy</e1> is reported in a 13-year-old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 <e2>methotrexate</e2> and 12 mg intrathecal <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6445	"<e1>Methotrexate</e1> -induced <e2>leukoencephalopathy</e2> is treatable with high-dose folinic acid: a case report and analysis of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6446	"Severe <e1>heparin</e1> associated <e2>thrombocytopenia</e2> is a rare complication of <e1>heparin</e1> therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6447	"Severe <e1>heparin</e1> associated <e2>thrombocytopenia</e2> is a rare complication of <e1>heparin</e1> therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6448	"We report a patient who developed <e1>heparin</e1> associated <e2>thrombocytopenia</e2> during continuous arteriovenous haemofiltration and discuss its implications and alternative anticoagulant treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6449	"Acute <e2>alum</e2>inum toxicity after continuous intravesical <e2>alum</e2> irrigation for hemorrhagic cystitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6450	"An encephalopathy and <e1>cardiomyopathy</e1> developed in a seventeen-year-old girl with chemotherapy-induced renal failure while receiving an intravesical <e2>aluminum</e2> infusion for hemorrhagic cystitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6451	"An <e1>encephalopathy</e1> and cardiomyopathy developed in a seventeen-year-old girl with chemotherapy-induced renal failure while receiving an intravesical <e2>aluminum</e2> infusion for hemorrhagic cystitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6452	"A 62-year-old woman who was being treated for squamous cell carcinoma of the head and neck developed a chemotherapy-related <e1>hemolytic-uremic syndrome</e1> during the second cycle of neoadjuvant chemotherapy consisting of cisplatin, <e2>bleomycin</e2>, and methotrexate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6453	"A 62-year-old woman who was being treated for squamous cell carcinoma of the head and neck developed a chemotherapy-related <e1>hemolytic-uremic syndrome</e1> during the second cycle of neoadjuvant chemotherapy consisting of <e2>cisplatin</e2>, bleomycin, and methotrexate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6454	"A 62-year-old woman who was being treated for squamous cell carcinoma of the head and neck developed a chemotherapy-related <e1>hemolytic-uremic syndrome</e1> during the second cycle of neoadjuvant chemotherapy consisting of cisplatin, bleomycin, and <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6455	"Awareness of this route of intoxication might be important in patients in whom neurologic or <e1>psychiatric symptoms</e1> develop while large amounts of <e2>lidocaine</e2> cream are being used."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6456	"<e1>Nitrendipine</e1> -induced <e2>gingival hyperplasia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6457	"<e1>Nitrendipine</e1> is an experimental calcium channel blocking agent that also appears to cause the side effect of drug-induced <e2>gingival hyperplasia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6458	"Physicians using this "new" drug must be aware of the potential danger of <e1>sulfonamide</e1> -induced <e2>injury to the urinary tract</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6459	"<e1>Sulfadiazine</e1> <e2>crystalluria</e2> revisited."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6460	"We describe two cases of <e1>sulfadiazine</e1> -induced <e2>crystalluria</e2> and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6461	"We describe two cases of <e1>sulfadiazine</e1> -induced crystalluria and <e2>renal failure</e2> in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6462	"<e1>Glaucoma</e1> secondary to epithelial downgrowth and <e2>5-fluorouracil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6463	"We report a case of secondary <e1>glaucoma</e1> caused by epithelial downgrowth in which filtration surgery was performed with adjunctive use of subconjunctival <e2>5-fluorouracil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6464	"Antacid and <e1>sucralfate</e1> -induced <e2>hypophosphatemic osteomalacia</e2>: a case report and review of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6465	"Because of a <e1>hypersensitivity reaction</e1>, initial therapy with penicillin G and <e2>gentamicin</e2> was stopped and substituted with cefazolin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6466	"Because of a <e1>hypersensitivity reaction</e1>, initial therapy with <e2>penicillin G</e2> and gentamicin was stopped and substituted with cefazolin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6467	"Prenatal cytomegalovirus (CMV) infection associated with severe <e1>brain damage</e1> was detected in an infant whose mother had been treated with prednisolone and <e2>azathioprine</e2> for systemic lupus erythematosus (SLE)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6468	"Prenatal cytomegalovirus (CMV) infection associated with severe <e1>brain damage</e1> was detected in an infant whose mother had been treated with <e2>prednisolone</e2> and azathioprine for systemic lupus erythematosus (SLE)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6469	"<e1>Prenatal cytomegalovirus (CMV) infection</e1> associated with severe brain damage was detected in an infant whose mother had been treated with prednisolone and <e2>azathioprine</e2> for systemic lupus erythematosus (SLE)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6470	"<e1>Prenatal cytomegalovirus (CMV) infection</e1> associated with severe brain damage was detected in an infant whose mother had been treated with <e2>prednisolone</e2> and azathioprine for systemic lupus erythematosus (SLE)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6471	"<e1>Acute coronary events</e1> following <e2>cisplatin</e2> -based chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6472	"Six patients with no previous signs or symptoms suggestive of coronary artery disease developed <e1>acute coronary ischemia</e1>/infarction shortly after <e2>cis-diamine-dichloroplatinum II</e2> (cisplatin) -based chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6473	"Six patients with no previous signs or symptoms suggestive of coronary artery disease developed <e1>acute coronary ischemia</e1>/infarction shortly after cis-diamine-dichloroplatinum II (<e2>cisplatin</e2>) -based chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6474	"Six patients with no previous signs or symptoms suggestive of coronary artery disease developed acute coronary ischemia/<e1>infarction</e1> shortly after <e2>cis-diamine-dichloroplatinum II</e2> (cisplatin) -based chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6475	"Six patients with no previous signs or symptoms suggestive of coronary artery disease developed acute coronary ischemia/<e1>infarction</e1> shortly after cis-diamine-dichloroplatinum II (<e2>cisplatin</e2>) -based chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6476	"<e1>Bowel perforation</e1> associated with intraperitoneal <e2>chromic phosphate</e2> instillation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6477	"Delayed <e1>bowel injury</e1> is an infrequently observed complication of <e2>chromic phosphate</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6478	"This report presents a case of <e1>colon perforation</e1> which occurred 4 months after treatment with intraperitoneal <e2>chromic phosphate</e2> for stage IB ovarian papillary serous cystadenocarcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6479	"Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent <e1>Ara-C</e1> treatment and led to <e2>death</e2> within 3 weeks."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6480	"Despite a response of the meningeal tumor the patient developed in the third week of <e1>MTX</e1> treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to <e2>death</e2> within 3 weeks."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6481	"Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and <e1>loss of consciousness</e1> which worsened during subsequent <e2>Ara-C</e2> treatment and led to death within 3 weeks."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6482	"Despite a response of the meningeal tumor the patient developed in the third week of <e1>MTX</e1> treatment a progressive visual loss and <e2>loss of consciousness</e2> which worsened during subsequent Ara-C treatment and led to death within 3 weeks."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6483	"Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a <e1>progressive visual loss</e1> and loss of consciousness which worsened during subsequent <e2>Ara-C</e2> treatment and led to death within 3 weeks."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6484	"Despite a response of the meningeal tumor the patient developed in the third week of <e1>MTX</e1> treatment a <e2>progressive visual loss</e2> and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6485	"A 59-year-old woman with myasthenia gravis who received a large dose of <e1>pyridostigmine bromide</e1> developed postoperative psychosis and was diagnosed as having <e2>bromide intoxication</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6486	"A 59-year-old woman with myasthenia gravis who received a large dose of <e1>pyridostigmine bromide</e1> developed <e2>postoperative psychosis</e2> and was diagnosed as having bromide intoxication."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6487	"<e1>Bromide intoxication</e1> secondary to <e2>pyridostigmine bromide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6488	"To our knowledge , this is the first reported case of <e1>bromide intoxication</e1> due to <e2>pyridostigmine bromide</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6489	"<e1>Diazepam</e1> use by pregnant women can be associated with a later presentation of <e2>withdrawal symptoms</e2> in the neonate than that induced by the use of other drugs."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6490	"We conclude that neurosurgeons and neurologists should be aware of calcium antagonist--related <e1>ileus</e1> in patients treated with <e2>nimodipine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6491	"We report on a patient with subarachnoid haemorrhage who developed an acute life-threatening pseudo-obstruction of the colon, a variant of <e1>adynamic ileus</e1>, while being treated with intravenous <e2>nimodipine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6492	"We report on a patient with subarachnoid haemorrhage who developed an acute life-threatening <e1>pseudo-obstruction of the colon</e1>, a variant of adynamic ileus, while being treated with intravenous <e2>nimodipine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6493	"After discontinuation of <e1>danazol</e1> the <e2>diabetes</e2> completely resolved."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6494	"<e1>Insulin-dependent diabetes mellitus</e1> associated with <e2>danazol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6495	"<e1>Insulin-dependent diabetes mellitus</e1> developed in a young woman 8 weeks after the initiation of <e2>danazol</e2> for treatment of pelvic endometriosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6496	"An 83-year-old man receiving <e1>glipizide</e1> 10 mg bid developed <e2>symptomatic hypoglycemia</e2> within three days of adding trimethoprim/sulfamethoxazole (TMP/SMX) to his regimen."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6497	"An 83-year-old man receiving glipizide 10 mg bid developed <e1>symptomatic hypoglycemia</e1> within three days of adding trimethoprim/sulfamethoxazole (TMP/<e2>SMX</e2>) to his regimen."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6498	"An 83-year-old man receiving glipizide 10 mg bid developed <e1>symptomatic hypoglycemia</e1> within three days of adding trimethoprim/<e2>sulfamethoxazole</e2> (TMP/SMX) to his regimen."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6499	"An 83-year-old man receiving glipizide 10 mg bid developed <e1>symptomatic hypoglycemia</e1> within three days of adding trimethoprim/sulfamethoxazole (<e2>TMP</e2>/SMX) to his regimen."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6500	"An 83-year-old man receiving glipizide 10 mg bid developed <e1>symptomatic hypoglycemia</e1> within three days of adding <e2>trimethoprim</e2>/sulfamethoxazole (TMP/SMX) to his regimen."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6501	"<e1>Symptomatic hypoglycemia</e1> secondary to a <e2>glipizide</e2> -trimethoprim/sulfamethoxazole drug interaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6502	"<e1>Symptomatic hypoglycemia</e1> secondary to a glipizide-trimethoprim/<e2>sulfamethoxazole</e2> drug interaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6503	"<e1>Symptomatic hypoglycemia</e1> secondary to a glipizide-<e2>trimethoprim</e2>/sulfamethoxazole drug interaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6504	"A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with <e1>anuria</e1>, the day after 5 g/m2 bolus <e2>ifosfamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6505	"A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an <e1>irreversible lethal renal failure</e1> with anuria, the day after 5 g/m2 bolus <e2>ifosfamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6506	"<e1>Ifosfamide</e1> is a known nephrotoxic drug with demonstrated <e2>tubulopathies</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6507	"<e1>Lethal anuria</e1> complicating high dose <e2>ifosfamide</e2> chemotherapy in a breast cancer patient with an impaired renal function."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6508	"We strongly suspect that this <e1>lethal anuria</e1> was mainly due to <e2>ifosfamide</e2>, occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6509	"<e1>Ciprofloxacin</e1> is one drug that has been reported to cause <e2>interstitial nephritis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6510	"<e1>Renal toxicities</e1> have been reported in less than one percent of the patients receiving <e2>ciprofloxacin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6511	"Suspected <e1>ciprofloxacin</e1> -induced <e2>interstitial nephritis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6512	"This article describes a patient with suspected <e1>ciprofloxacin</e1> -induced <e2>interstitial nephritis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6513	"In a female with acute lymphoblastic leukemia, inadvertent <e1>doxorubicin</e1> administration intrathecally caused severe, life-threatening, <e2>acute encephalopathy</e2> with high-pressure hydrocephalus."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6514	"In a female with acute lymphoblastic leukemia, inadvertent <e1>doxorubicin</e1> administration intrathecally caused severe, life-threatening, acute encephalopathy with <e2>high-pressure hydrocephalus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6515	"<e1>Severe acute encephalopathy</e1> following inadvertent intrathecal <e2>doxorubicin</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6516	"<e1>Phenobarbital</e1> <e2>hepatotoxicity</e2> in an 8-month-old infant."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6517	"<e1>Severe hepatotoxicity</e1> from <e2>phenobarbital</e2> occurred in an infant boy who had a complicated illness with chronic bilateral subdural hematomas and sepsis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6518	"Skin rash began after 2 weeks of treatment, and signs of <e1>hepatocellular failure</e1> developed 3 weeks after <e2>phenobarbital</e2> had been started."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6519	"<e1>Skin rash</e1> began after 2 weeks of treatment, and signs of hepatocellular failure developed 3 weeks after <e2>phenobarbital</e2> had been started."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6520	"<e1>Atenolol</e1> -induced <e2>pseudolymphoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6521	"Although <e1>tardive dyskinesia</e1> is a known adverse reaction of sustained treatment with traditional neuroleptic agents, it was only rarely reported in association with <e2>sulpiride</e2>, a selective D2-receptor antagonist."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6522	"<e1>Tardive dyskinesia</e1> induced by <e2>sulpiride</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6523	"These cases indicate that <e1>sulpiride</e1> can cause <e2>tardive dyskinesia</e2> and that this drug should be administered with caution."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6524	"We describe six patients who developed <e1>tardive dyskinesia</e1> after treatment with <e2>sulpiride</e2> for depression or gastrointestinal symptoms."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6525	"A patient with seropositive rheumatoid arthritis developed <e1>ascites</e1> while taking weekly doses of <e2>methotrexate</e2> (MTX)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6526	"A patient with seropositive rheumatoid arthritis developed <e1>ascites</e1> while taking weekly doses of methotrexate (<e2>MTX</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6527	"Hepatitis with <e1>bridging fibrosis</e1> and reversible hepatic insufficiency in a woman with rheumatoid arthritis taking <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6528	"<e1>Hepatitis</e1> with bridging fibrosis and reversible hepatic insufficiency in a woman with rheumatoid arthritis taking <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6529	"Hepatitis with bridging fibrosis and <e1>reversible hepatic insufficiency</e1> in a woman with rheumatoid arthritis taking <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6530	"This is the third report of reversible <e1>hepatic decompensation</e1> associated with prolonged <e2>MTX</e2> therapy in patients with rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6531	"Upon discontinuation of <e1>MTX</e1>, her <e2>ascites</e2> resolved, and her arthritis became more active."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6532	"Although high-dose <e1>methotrexate</e1> has been shown to be useful in the treatment of primary osteogenic sarcoma, the tumoricidal effects of therapy appear to have caused a <e2>fatal rise in intracranial pressure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6533	"A patient with intracranial osteosarcoma that arose 16 years after radiation therapy for hereditary retinoblastoma developed fatal cerebral edema and <e1>brainstem herniation</e1> after she received a single dose of intravenous <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6534	"A patient with intracranial osteosarcoma that arose 16 years after radiation therapy for hereditary retinoblastoma developed <e1>fatal cerebral edema</e1> and brainstem herniation after she received a single dose of intravenous <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6535	"Transtentorial herniation caused by an <e1>intracranial mass lesion</e1> following high-dose <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6536	"<e1>Transtentorial herniation</e1> caused by an intracranial mass lesion following high-dose <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6537	"<e1>Fever</e1>, pulmonary infiltrates, and pleural effusion following <e2>acyclovir</e2> therapy for herpes zoster ophthalmicus."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6538	"Fever, pulmonary infiltrates, and <e1>pleural effusion</e1> following <e2>acyclovir</e2> therapy for herpes zoster ophthalmicus."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6539	"Fever, <e1>pulmonary infiltrates</e1>, and pleural effusion following <e2>acyclovir</e2> therapy for herpes zoster ophthalmicus."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6540	"Following the institution of intravenous therapy with <e1>acyclovir</e1>, the patient developed <e2>fever</e2>, hemoptysis, and a pleural friction rub."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6541	"Following the institution of intravenous therapy with <e1>acyclovir</e1>, the patient developed fever, <e2>hemoptysis</e2>, and a pleural friction rub."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6542	"Following the institution of intravenous therapy with <e1>acyclovir</e1>, the patient developed fever, hemoptysis, and a <e2>pleural friction rub</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6543	"The <e1>fever</e1> abated promptly following discontinuation of <e2>acyclovir</e2>, and radiographic abnormalities resolved over ten days."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6544	"To our knowledge, the syndrome of <e1>fever</e1>, pulmonary infiltrates, and pleural effusion following use of <e2>acyclovir</e2> has not been previously reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6545	"To our knowledge, the syndrome of fever, pulmonary infiltrates, and <e1>pleural effusion</e1> following use of <e2>acyclovir</e2> has not been previously reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6546	"To our knowledge, the syndrome of fever, <e1>pulmonary infiltrates</e1>, and pleural effusion following use of <e2>acyclovir</e2> has not been previously reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6547	"<e1>Quinine</e1> -induced <e2>hearing loss</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6548	"<e1>Sensorineural hearing loss</e1> due to <e2>quinine</e2> therapy for malaria has frequently been mentioned in the literature but has not been a subject of research during the last decades."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6549	"The case of a 29-year-old man suffering from falciparum malaria disease who got a <e1>reversible hearing loss</e1> from <e2>quinine</e2> therapy is presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6550	"The <e1>ototoxicity</e1> of <e2>quinine</e2> can accurately be studied with ultrahigh frequency audiometry (up to 20 kHz)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6551	"<e1>Hemolytic uremic syndrome</e1> in a patient on cis-platinum, vinblastine and <e2>bleomycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6552	"<e1>Hemolytic uremic syndrome</e1> in a patient on <e2>cis-platinum</e2>, vinblastine and bleomycin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6553	"<e1>Hemolytic uremic syndrome</e1> in a patient on cis-platinum, <e2>vinblastine</e2> and bleomycin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6554	"A case of a 53-year-old man who developed <e1>acute pneumonitis</e1> after <e2>bleomycin</e2> and moderate oxygen administration is presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6555	"A case of a 53-year-old man who developed <e1>acute pneumonitis</e1> after bleomycin and moderate <e2>oxygen</e2> administration is presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6556	"Autopsy findings were consistent with <e1>bleomycin</e1> and oxygen-induced <e2>pulmonary damage</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6557	"Autopsy findings were consistent with bleomycin and <e1>oxygen</e1> -induced <e2>pulmonary damage</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6558	"<e1>Bleomycin</e1> <e2>pneumonitis</e2> potentiated by oxygen administration."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6559	"Oxygen potentiation of <e1>bleomycin</e1> -induced <e2>pulmonary toxicity</e2> is discussed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6560	"<e1>Oxygen</e1> potentiation of bleomycin-induced <e2>pulmonary toxicity</e2> is discussed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6561	"A patient with the Wolff-Parkinson-White syndrome presented with <e1>incessant orthodromic atrioventricular tachycardia</e1> following initiation of <e2>procainamide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6562	"Escape atrial complexes, which occurred following junctional premature complexes, failed to initiate <e1>tachycardia</e1> in the control state but <e1>tachycardia</e1> was always reinitiated by an identical escape sequence after <e2>procainamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6563	"In addition, the <e1>tachycardia</e1> persisted and was repeatedly spontaneously reinitiated for prolonged periods after <e2>procainamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6564	"<e1>Procainamide</e1> -induced <e2>incessant supraventricular tachycardia</e2> in the Wolff-Parkinson-White syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6565	"The <e1>pro-arrhythmic effects</e1> of <e2>procainamide</e2> may be explained on the basis of both its vagolytic action on the atrioventricular node as well as by prolongation of refractoriness in the accessory pathway."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6566	"<e1>Multicentric hepatocellular carcinoma</e1> following <e2>phosphate diethylstilbestrol</e2> therapy for prostatic cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6567	"This is a unique autopsy case of <e1>hepatocellular carcinoma</e1> closely related to diethylstilbestrol (<e2>DES</e2>) therapy for prostatic cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6568	"This is a unique autopsy case of <e1>hepatocellular carcinoma</e1> closely related to <e2>diethylstilbestrol</e2> (DES) therapy for prostatic cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6569	"This paper reports an autopsy case of a 78-year-old male with <e1>multiple nodules in the liver</e1> developed after long-termed administration of phosphate diethylstilbestrol (<e2>PDES</e2>) for prostatic cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6570	"This paper reports an autopsy case of a 78-year-old male with <e1>multiple nodules in the liver</e1> developed after long-termed administration of <e2>phosphate diethylstilbestrol</e2> (PDES) for prostatic cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6571	"A 52-year-old woman developed symmetric sensorimotor polyneuropathy and <e1>cerebellar syndrome</e1> after 24 months of <e2>amiodarone</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6572	"A 52-year-old woman developed <e1>symmetric sensorimotor polyneuropathy</e1> and cerebellar syndrome after 24 months of <e2>amiodarone</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6573	"Peripheral neuropathy and <e1>cerebellar syndrome</e1> associated with <e2>amiodarone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6574	"<e1>Peripheral neuropathy</e1> and cerebellar syndrome associated with <e2>amiodarone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6575	"Life-threatening <e1>hyponatremia</e1> caused by <e2>vinblastine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6576	"The most likely cause of such <e1>hyponatremic episode</e1> is <e2>vinblastine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6577	"Although this type of <e1>hyperpigmentation</e1> has been previously seen in patients with cancer who are receiving <e2>bleomycin</e2>, this is, to our knowledge, the first reported case of <e2>bleomycin</e2> -induced <e1>hyperpigmentation</e1> in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6578	"Although this type of <e1>hyperpigmentation</e1> has been previously seen in patients with cancer who are receiving <e2>bleomycin</e2>, this is, to our knowledge, the first reported case of <e2>bleomycin</e2> -induced <e1>hyperpigmentation</e1> in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6579	"We report a case of <e1>hyperpigmentation</e1> due to <e2>bleomycin</e2> treatment in a patient with acquired immune deficiency syndrome (AIDS)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6580	"A typical case of <e1>dextran-40</e1> associated <e2>acute renal failure</e2> is presented."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6581	"<e1>Renal failure</e1> associated with the use of <e2>dextran-40</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6582	"Several possible explanations of the mechanism of <e1>renal failure</e1> associated with the use of <e2>dextran-40</e2> are discussed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6583	"While the mechanism of <e1>dextran</e1> -associated <e2>renal failure</e2> remains unsolved, plasma exchange seems to be effective therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6584	"MR findings in <e1>methotrexate</e1> -induced <e2>CNS abnormalities</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6585	"A 57-year-old man developed <e1>morphea</e1> while taking <e2>bromocriptine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6586	"<e1>Morphea</e1> after <e2>bromocriptine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6587	"A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from <e1>dapsone</e1> -induced <e2>erythroderma</e2> is reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6588	"<e1>Dapsone</e1> -induced <e2>erythroderma</e2> with Beau's lines."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6589	"<e1>Akathisia</e1> appeared to be a common side effect of <e2>fluoxetine</e2> and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6590	"Five patients receiving <e1>fluoxetine</e1> for the treatment of obsessive compulsive disorder or major depression developed <e2>akathisia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6591	"<e1>Fluoxetine</e1> -induced <e2>akathisia</e2>: clinical and theoretical implications."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6592	"The authors suggest that <e1>fluoxetine</e1> -induced <e2>akathisia</e2> may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of <e1>fluoxetine</e1> -induced <e2>akathisia</e2> and tricyclic antidepressant-induced "jitteriness" may be identical."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6593	"The authors suggest that <e1>fluoxetine</e1> -induced <e2>akathisia</e2> may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of <e1>fluoxetine</e1> -induced <e2>akathisia</e2> and tricyclic antidepressant-induced "jitteriness" may be identical."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6594	"The typical <e1>fluoxetine</e1> -induced symptoms of restlessness, <e2>constant pacing</e2>, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6595	"The typical <e1>fluoxetine</e1> -induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and <e2>marked anxiety</e2> were indistinguishable from those of neuroleptic-induced akathisia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6596	"The typical <e1>fluoxetine</e1> -induced symptoms of restlessness, constant pacing, <e2>purposeless movements of the feet and legs</e2>, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6597	"The typical <e1>fluoxetine</e1> -induced symptoms of <e2>restlessness</e2>, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6598	"Three patients who had experienced neuroleptic-induced <e1>akathisia</e1> in the past reported that the symptoms of <e2>fluoxetine</e2> -induced <e1>akathisia</e1> were identical, although somewhat milder."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6599	"Horner's syndrome and <e1>demyelinating peripheral neuropathy</e1> caused by high-dose <e2>cytosine arabinoside</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6600	"<e1>Horner's syndrome</e1> and demyelinating peripheral neuropathy caused by high-dose <e2>cytosine arabinoside</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6601	"<e1>Peripheral nerve dysfunction</e1> is a potentially serious complication of high-dose <e2>cytosine arabinoside</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6602	"<e1>Peripheral nervous system disturbances</e1> caused by <e2>cytosine arabinoside</e2> have rarely been reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6603	"We describe a patient with acute leukemia who developed Horner's syndrome and a severe demyelinating peripheral neuropathy leading to <e1>death</e1> after receiving high-dose <e2>cytosine arabinoside</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6604	"We describe a patient with acute leukemia who developed <e1>Horner's syndrome</e1> and a severe demyelinating peripheral neuropathy leading to death after receiving high-dose <e2>cytosine arabinoside</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6605	"We describe a patient with acute leukemia who developed Horner's syndrome and a <e1>severe demyelinating peripheral neuropathy</e1> leading to death after receiving high-dose <e2>cytosine arabinoside</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6606	"<e1>Nail-changes</e1> induced by <e2>penicillamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6607	"Peculiar <e1>nail-changes</e1> in a 70-year-old woman with rheumatoid arthritis occurring after approximately 1 year of <e2>penicillamine</e2> treatment are described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6608	"Reinstitution of <e1>penicillamine</e1> treatment caused a recurrence thus proving a causal relationship between <e1>penicillamine</e1> and the described <e2>nail-changes</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6609	"<e1>Ibuprofen</e1> -induced <e2>meningitis</e2>: detection of intrathecal IgG synthesis and immune complexes."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6610	"We report a case of <e1>ibuprofen</e1> -induced <e2>meningitis</e2> in an otherwise healthy individual."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6611	"<e1>Metoclopramide</e1> -induced <e2>parkinsonism</e2> is not rare, and appropriate dose reduction in patients with renal failure will help reduce the incidence of this morbidity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6612	"<e1>Metoclopramide</e1> -induced <e2>parkinsonism</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6613	"Their <e1>parkinsonism</e1> improved on discontinuation of <e2>metoclopramide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6614	"We have reported six cases of <e1>metoclopramide</e1> -induced <e2>parkinsonism</e2> seen in consultation over a two-year period."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6615	"It is suggested that the fatal stroke may have resulted from <e1>arterial spasm</e1> caused by <e2>ergotamine</e2> overdosage and possibly complicated by thrombosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6616	"It is suggested that the <e1>fatal stroke</e1> may have resulted from arterial spasm caused by <e2>ergotamine</e2> overdosage and possibly complicated by thrombosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6617	"Life-threatening <e1>acute hyponatraemia</e1> induced by low dose <e2>cyclophosphamide</e2> and indomethacin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6618	"Life-threatening <e1>acute hyponatraemia</e1> induced by low dose cyclophosphamide and <e2>indomethacin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6619	"We report the case of a patient with multiple myeloma who developed acute <e1>life-threatening water intoxication</e1> following treatment with oral indomethacin and low dose intravenous <e2>cyclophosphamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6620	"We report the case of a patient with multiple myeloma who developed acute <e1>life-threatening water intoxication</e1> following treatment with oral <e2>indomethacin</e2> and low dose intravenous cyclophosphamide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6621	"<e1>Clofazimine</e1> induced <e2>nail changes</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6622	"These <e1>nail changes</e1> gradually disappeared when the dose of <e2>clofazimine</e2> was reduced."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6623	"Two cases of lepromatous leprosy with erythema nodosum leprosum who were on high doses of <e1>clofazimine</e1>, showed <e2>discoloration of nail plate</e2>, subungual hyperkeratosis and onycholysis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6624	"Two cases of lepromatous leprosy with erythema nodosum leprosum who were on high doses of <e1>clofazimine</e1>, showed discoloration of nail plate, subungual hyperkeratosis and <e2>onycholysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6625	"Two cases of lepromatous leprosy with erythema nodosum leprosum who were on high doses of <e1>clofazimine</e1>, showed discoloration of nail plate, <e2>subungual hyperkeratosis</e2> and onycholysis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6626	"Attenuation of <e1>asparaginase</e1> -induced <e2>hyperglycemia</e2> after substitution of the Erwinia carotovora for the Escherichia coli enzyme preparation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6627	"Development of <e1>persistent late onset asthma</e1> following treatment with <e2>captopril</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6628	"We describe the first case of de novo <e1>asthma</e1> following treatment with the angiotensin converting enzyme (ACE) inhibitor <e2>captopril</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6629	"A case report of a patient with probable cisplatin and <e1>bleomycin</e1> -induced <e2>TMA</e2> is presented."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6630	"A case report of a patient with probable <e1>cisplatin</e1> and bleomycin-induced <e2>TMA</e2> is presented."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6631	"A patient with chronic myeloid leukaemia treated with <e1>busulphan</e1> for 4-5 years, developed signs of <e1>busulphan</e1> toxicity and portal hypertension with <e2>ascites</e2>, oesophageal varices and jaundice."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6632	"A patient with chronic myeloid leukaemia treated with <e1>busulphan</e1> for 4-5 years, developed signs of <e1>busulphan</e1> toxicity and portal hypertension with ascites, oesophageal varices and <e2>jaundice</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6633	"A patient with chronic myeloid leukaemia treated with <e1>busulphan</e1> for 4-5 years, developed signs of <e1>busulphan</e1> toxicity and portal hypertension with ascites, <e2>oesophageal varices</e2> and jaundice."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6634	"A patient with chronic myeloid leukaemia treated with <e1>busulphan</e1> for 4-5 years, developed signs of <e1>busulphan</e1> toxicity and <e2>portal hypertension</e2> with ascites, oesophageal varices and jaundice."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6635	"Although a lot of <e1>amiodarone</e1> -induced <e2>torsades de pointe</e2> have been published, a review of all these cases and the underlying risk-factors has never been made."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6636	"<e1>Amiodarone</e1> induced <e2>torsades de pointe</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6637	"We report three cases of <e1>amiodarone</e1> -induced <e2>torsades de pointe</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6638	"The syndrome of irreversible <e1>lithium</e1> -effectuated <e2>neurotoxicity</e2> (SILENT)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6639	"Long lasting <e1>respiratory depression</e1> induced by <e2>morphine-6-glucuronide</e2>?"
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6640	"We report a case of long lasting <e1>respiratory depression</e1> after intravenous administration of <e2>morphine</e2> to a 7 year old girl with haemolytic uraemic syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6641	"<e1>Rifampin</e1> -associated <e2>thrombocytopenia</e2> secondary to poor compliance."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6642	"<e1>Rifampin</e1> can be associated with severe adverse effects such as hepatitis, <e2>acute renal failure</e2>, hemolytic anemia, and thrombocytopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6643	"<e1>Rifampin</e1> can be associated with severe adverse effects such as hepatitis, acute renal failure, <e2>hemolytic anemia</e2>, and thrombocytopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6644	"<e1>Rifampin</e1> can be associated with severe adverse effects such as <e2>hepatitis</e2>, acute renal failure, hemolytic anemia, and thrombocytopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6645	"<e1>Rifampin</e1> can be associated with severe adverse effects such as hepatitis, acute renal failure, hemolytic anemia, and <e2>thrombocytopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6646	"This article reports the occurrence of <e1>rifampin</e1> -associated <e2>thrombocytopenia</e2> in an indigent patient after a four-month lapse in therapy for pulmonary tuberculosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6647	"We present the first case of <e1>WES</e1> in an infant born to a mother taking <e2>haloperidol</e2> during her pregnancy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6648	"<e1>Withdrawal emergent syndrome</e1> in an infant associated with maternal <e2>haloperidol</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6649	"This report describes two patients who developed <e1>acute myelocytic leukemia</e1> only after exposure to cyclophosphamide, methotrexate, and <e2>5-fluorouracil</e2> adjuvant therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6650	"This report describes two patients who developed <e1>acute myelocytic leukemia</e1> only after exposure to <e2>cyclophosphamide</e2>, methotrexate, and 5-fluorouracil adjuvant therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6651	"This report describes two patients who developed <e1>acute myelocytic leukemia</e1> only after exposure to cyclophosphamide, <e2>methotrexate</e2>, and 5-fluorouracil adjuvant therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6652	"<e1>Ibuprofen</e1> rarely causes lower <e2>gastrointestinal adverse reactions</e2> but has been implicated in systemic and local side effects in patients with lupus."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6653	"<e1>Ulcerative proctitis</e1> in juvenile systemic lupus erythematosus after <e2>ibuprofen</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6654	"We describe a case of <e1>ulcerative proctitis</e1> after <e2>ibuprofen</e2> treatment in a girl with juvenile systemic lupus erythematosus."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6655	"Intravenous <e1>cytarabine</e1> and methotrexate appear to act synergistically to enhance the potential for <e2>central nervous system toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6656	"Intravenous cytarabine and <e1>methotrexate</e1> appear to act synergistically to enhance the potential for <e2>central nervous system toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6657	"We present two children with acute lymphocytic leukemia who developed <e1>leukoencephalopathy</e1> following administration of a combination of intravenous <e2>ara = C</e2> and methotrexate during the consolidation phase of chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6658	"We present two children with acute lymphocytic leukemia who developed <e1>leukoencephalopathy</e1> following administration of a combination of intravenous ara = C and <e2>methotrexate</e2> during the consolidation phase of chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6659	"Dexamethasone treatment of <e1>amiodarone</e1> -induced <e2>thyrotoxicosis</e2> (AIT) with or without persistent administration of the drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6660	"Treatment of <e1>amiodarone</e1> -induced <e2>thyrotoxicosis</e2> (AIT) with thionamide, lithium or radioactive iodine is ineffective."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6661	"<e1>Acute myelogenous leukemia</e1> in patients receiving <e2>chlorambucil</e2> as long-term adjuvant chemotherapy for stage II breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6662	"After the <e1>chlorambucil</e1> was discontinued, the wbc count began to slowly rise and the patient developed clinical <e2>AML</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6663	"<e1>Panic anxiety</e1> after abrupt discontinuation of <e2>mianserin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6664	"This <e1>panic anxiety</e1> was not relieved by taking etizolam and flunitrazepam again, but subsided rapidly by the re-administration of <e2>mianserin</e2> 30 mg/day, and because of that the depressive symptom also disappeared."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6665	"Prior neurologic illness and the syndrome of irreversible <e1>lithium</e1> -effectuated <e2>neurotoxicity</e2> (SILENT)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6666	"Prior neurologic illness or CNS insult of any kind is known to increase the vulnerability to <e1>neurotoxicity</e1> of <e2>lithium</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6667	"The authors describe a patient with hemiparesis who developed the syndrome of irreversible <e1>lithium</e1> -effectuated <e2>neurotoxicity</e2> (SILENT) while being treated with <e1>lithium</e1> for a manic episode."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6668	"Abrupt, accidental withdrawal of <e1>trihexyphenidyl</e1> triggered severe exacerbation of the cranial dystonia associated with inspiratory stridor and <e2>acute respiratory difficulties</e2>, prompting emergency admission."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6669	"Abrupt, accidental withdrawal of <e1>trihexyphenidyl</e1> triggered severe exacerbation of the <e2>cranial dystonia</e2> associated with inspiratory stridor and acute respiratory difficulties, prompting emergency admission."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6670	"Abrupt, accidental withdrawal of <e1>trihexyphenidyl</e1> triggered severe exacerbation of the cranial dystonia associated with <e2>inspiratory stridor</e2> and acute respiratory difficulties, prompting emergency admission."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6671	"Life-threatening <e1>cranial dystonia</e1> following <e2>trihexyphenidyl</e2> withdrawal."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6672	"MR findings in <e1>methotrexate</e1> -induced <e2>CNS abnormalities</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6673	"Administration of intrathecal <e1>Ara-C</e1> in the same dose over longer intervals within 3-5 days between consecutive doses resulted in mild, transient neurological symptoms (<e2>paresthesias</e2>) in only one of 30 patients so treated."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6674	"<e1>Paraplegia</e1> following intrathecal <e2>cytosine arabinoside</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6675	"<e1>Paraplegia</e1> following prophylactic intrathecal cytosine arabinoside (<e2>Ara-C</e2>) is described in a patient with acute myelogenous leukemia in remission who received doses of 100 mg/m2/d for 5 consecutive days."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6676	"<e1>Paraplegia</e1> following prophylactic intrathecal <e2>cytosine arabinoside</e2> (Ara-C) is described in a patient with acute myelogenous leukemia in remission who received doses of 100 mg/m2/d for 5 consecutive days."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6677	"Both patients developed <e1>hypoadrenalism</e1> while on <e2>o,p'-DDD</e2> and apparently adequate dexamethasone replacement therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6678	"<e1>Alprazolam</e1> -induced <e2>mania</e2>: two clinical cases."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6679	"The authors caution that treatment with <e1>alprazolam</e1> may be complicated by the induction of <e2>mania</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6680	"Two patients treated with <e1>alprazolam</e1> had histories suggestive of a bipolar disorder and developed lithium-responsive <e2>manic episodes</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6681	"A case is presented in which a 68-year-old man became <e1>delirious</e1> after being withdrawn from a low dosage of <e2>alprazolam</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6682	"<e1>Alprazolam</e1> withdrawal <e2>delirium</e2> unresponsive to diazepam: case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6683	"<e1>Sulfasalazine</e1> has been associated with <e2>bronchopulmonary complications of inflammatory bowel disease</e2> (IBD) in adults."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6684	"<e1>Sulfasalazine</e1> has been associated with bronchopulmonary complications of inflammatory bowel disease (<e2>IBD</e2>) in adults."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6685	"We discuss a variety of bronchopulmonary complications of <e1>IBD</e1> and their association with <e2>sulfasalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6686	"Administration of <e1>amantadine</e1> was associated with <e2>psychotic decompensations</e2> in two schizophrenic patients being maintained on concomitant neuroleptic medication."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6687	"Despite a postulated dopaminergic mechanism, there seems to have been only one previous report of <e1>amantadine</e1>'s <e2>precipitating psychosis</e2> in a schizophrenic patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6688	"Exacerbation of <e1>schizophrenia</e1> associated with <e2>amantadine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6689	"Soon after its introduction in 1952, <e1>chlorpromazine</e1> was noted to induce <e2>symptoms resembling Parkinson's disease</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6690	"It is suggested that the patient had <e1>sulfasalazine</e1> -induced <e2>lupus</e2>, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6691	"It is suggested that the patient had <e1>sulfasalazine</e1> -induced lupus, which manifested with serositis and <e2>pulmonary parenchymal involvement</e2> in the absence of joint symptoms."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6692	"It is suggested that the patient had <e1>sulfasalazine</e1> -induced lupus, which manifested with <e2>serositis</e2> and pulmonary parenchymal involvement in the absence of joint symptoms."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6693	"Physicians who use <e1>sulfasalazine</e1> to treat patients with inflammatory bowel disease should be aware of the signs of <e1>sulfasalazine</e1> -induced <e2>lupus syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6694	"Pneumonitis, <e1>bilateral pleural effusions</e1>, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term <e2>sulfasalazine</e2> therapy for chronic ulcerative colitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6695	"Pneumonitis, bilateral pleural effusions, echocardiographic evidence of <e1>cardiac tamponade</e1>, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term <e2>sulfasalazine</e2> therapy for chronic ulcerative colitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6696	"<e1>Pneumonitis</e1>, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term <e2>sulfasalazine</e2> therapy for chronic ulcerative colitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6697	"Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and <e1>positive autoantibodies</e1> developed in a 43-year-old man, who was receiving long-term <e2>sulfasalazine</e2> therapy for chronic ulcerative colitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6698	"<e1>Sulfasalazine</e1> -induced <e2>lupus erythematosus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6699	"<e1>Acute myocardial infarction</e1> due to coronary spasm associated with <e2>L-thyroxine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6700	"Acute myocardial infarction due to <e1>coronary spasm</e1> associated with <e2>L-thyroxine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6701	"Electrocardiographic findings and laboratory data indicated a diagnosis of <e1>acute myocardial infarction</e1> due to the <e2>L-thyroxine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6702	"We believe this is the first report of myocardial infarction due to <e1>coronary spasm</e1>, demonstrated by angiography associated with <e2>L-thyroxine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6703	"We believe this is the first report of <e1>myocardial infarction</e1> due to coronary spasm, demonstrated by angiography associated with <e2>L-thyroxine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6704	"A study of in vitro reactivity to <e1>L-T4</e1>, as assessed by peripheral blood lymphocyte transformation, was carried out in a patient with Hashimoto's disease who developed <e2>leukopenia</e2> during treatment with <e1>L-T4</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6705	"<e1>L-Thyroxine</e1> -induced <e2>leukopenia</e2> in a patient with Hashimoto's disease: involvement of suppressor-cytotoxic T cells."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6706	"<e1>Ampicillin</e1> -induced interstitial nephritis with <e2>generalised exfoliative dermatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6707	"<e1>Ampicillin</e1> -induced <e2>interstitial nephritis</e2> with generalised exfoliative dermatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6708	"However, there are few reports in the literature of <e1>ampicillin</e1> as a cause of <e2>acute interstitial nephritis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6709	"In the following case report, a patient developed <e1>acute interstitial nephritis</e1> with renal failure and exfoliative dermatitis following <e2>ampicillin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6710	"In the following case report, a patient developed acute interstitial nephritis with renal failure and <e1>exfoliative dermatitis</e1> following <e2>ampicillin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6711	"In the following case report, a patient developed acute interstitial nephritis with <e1>renal failure</e1> and exfoliative dermatitis following <e2>ampicillin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6712	"The diagnosis was based on the rapid onset of renal failure, presence of <e1>eosinophilia</e1>, skin rash, and characteristic renal biopsy finding, following the administration of <e2>ampicillin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6713	"The diagnosis was based on the rapid onset of <e1>renal failure</e1>, presence of eosinophilia, skin rash, and characteristic renal biopsy finding, following the administration of <e2>ampicillin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6714	"The diagnosis was based on the rapid onset of renal failure, presence of eosinophilia, <e1>skin rash</e1>, and characteristic renal biopsy finding, following the administration of <e2>ampicillin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6715	"A patient receiving <e1>vancomycin</e1> for a serious staphylococcal infection had a lupus-like syndrome characterized by a malar rash, pain and <e2>erythema of the cartilage of both ears</e2>, and tender erythematous and hemorrhagic lesions of the finger tips."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6716	"A patient receiving <e1>vancomycin</e1> for a serious staphylococcal infection had a lupus-like syndrome characterized by a malar rash, pain and erythema of the cartilage of both ears, and tender erythematous and <e2>hemorrhagic lesions of the finger tips</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6717	"A patient receiving <e1>vancomycin</e1> for a serious staphylococcal infection had a <e2>lupus-like syndrome</e2> characterized by a malar rash, pain and erythema of the cartilage of both ears, and tender erythematous and hemorrhagic lesions of the finger tips."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6718	"A patient receiving <e1>vancomycin</e1> for a serious staphylococcal infection had a lupus-like syndrome characterized by a <e2>malar rash</e2>, pain and erythema of the cartilage of both ears, and tender erythematous and hemorrhagic lesions of the finger tips."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6719	"A patient receiving <e1>vancomycin</e1> for a serious staphylococcal infection had a lupus-like syndrome characterized by a malar rash, <e2>pain</e2> and erythema of the cartilage of both ears, and tender erythematous and hemorrhagic lesions of the finger tips."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6720	"A patient receiving <e1>vancomycin</e1> for a serious staphylococcal infection had a lupus-like syndrome characterized by a malar rash, pain and erythema of the cartilage of both ears, and <e2>tender erythematous</e2> and hemorrhagic lesions of the finger tips."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6721	"The possible development of a drug-induced vasculitis or <e1>lupus-like syndrome</e1> should be added to the list of rare toxic effects of <e2>vancomycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6722	"The possible development of a drug-induced <e1>vasculitis</e1> or lupus-like syndrome should be added to the list of rare toxic effects of <e2>vancomycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6723	"<e1>Vancomycin</e1> -induced <e2>vasculitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6724	"<e1>Abnormal retinal function</e1> associated with <e2>isotretinoin</e2> therapy for acne."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6725	"Three of 50 patients treated with <e1>isotretinoin</e1> (1 mg/kg/day) for cystic acne complained of poor night vision and/or <e2>excessive glare sensitivity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6726	"Three of 50 patients treated with <e1>isotretinoin</e1> (1 mg/kg/day) for cystic acne complained of <e2>poor night vision</e2> and/or excessive glare sensitivity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6727	"<e1>Neurologic toxicity</e1> associated with hepatic artery infusion HAI of <e2>FUdR</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6728	"<e1>Ethambutol</e1> is frequently used in the treatment of tuberculosis, and, although <e2>optic neuropathies</e2> have been reported with the use of ethambutol, this adverse side effect has been considered to be rare and generally reversible with discontinuation of the medication."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6729	"However, we recently saw two patients with renal tuberculosis treated with <e1>ethambutol</e1> in whom visual loss from <e2>toxic optic neuropathies</e2> was severe and irreversible despite careful ophthalmological monitoring and prompt discontinuation of the agent at the first sign of impaired visual function."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6730	"However, we recently saw two patients with renal tuberculosis treated with <e1>ethambutol</e1> in whom <e2>visual loss</e2> from toxic optic neuropathies was severe and irreversible despite careful ophthalmological monitoring and prompt discontinuation of the agent at the first sign of impaired visual function."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6731	"<e1>Optic neuropathy</e1> in <e2>ethambutol</e2> -treated renal tuberculosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6732	"Since <e1>ethambutol</e1> is actively excreted via the renal system, compromise of renal function such as due to renal tuberculosis may lead to serum concentration elevations of <e1>ethambutol</e1> sufficient to produce <e2>optic neuropathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6733	"A 57-year-old woman presented with a 3-week history of <e1>dysphagia for solids</e1>, 6 months after starting treatment with <e2>nifedipine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6734	"<e1>Gastro-oesophageal reflux</e1> associated with <e2>nifedipine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6735	"<e1>Nifedipine</e1> may induce, or aggravate, pre-existing, <e2>gastro-oesophageal reflux</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6736	"A young diamond dealer developed visual impairment attributed to <e1>bilateral posterior subcapsular cataracts</e1> following only four courses of intermittent <e2>Decadron</e2> used as part of a five-drug antiemetic regimen for cisplatin-associated nausea."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6737	"A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for <e1>cisplatin</e1> -associated <e2>nausea</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6738	"A young diamond dealer developed <e1>visual impairment</e1> attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent <e2>Decadron</e2> used as part of a five-drug antiemetic regimen for cisplatin-associated nausea."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6739	"<e1>Cataracts</e1> induced by intermittent <e2>Decadron</e2> used as an antiemetic."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6740	"Recent reports have shown that Decadron (dexamethasone; Merck Sharp & Dohme, West Point, Pa) has a significant antiemetic effect on <e1>cisplatin</e1> -induced <e2>vomiting</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6741	"Transient <e1>phenytoin</e1> induced <e2>IgA deficiency</e2> and permanent IgE increase."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6742	"Transient <e1>phenytoin</e1> induced IgA deficiency and permanent <e2>IgE increase</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6743	"The pharmacology and toxicology of <e1>chloral hydrate</e1> are discussed with particular reference to the <e2>cardiac arrhythmias</e2> that are seen with overdosage."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6744	"<e1>Adrenaline</e1> <e2>dacryolith</e2>: detection by ultrasound examination of the nasolacrimal duct."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6745	"Histological examination of the <e1>dacryolith</e1> suggested its derivation from breakdown products of <e2>adrenaline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6746	"Possible pathophysiological mechanisms which may have been operative in this case include: a direct central nervous system (CNS) toxic effect of <e1>valproic acid</e1>; a paradoxical epileptogenic effect secondary to the drug; and an indirect CNS toxic effect mediated through <e1>valproic acid</e1> -induced <e2>hyperammonemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6747	"Reversible <e1>valproic acid</e1> -induced <e2>dementia</e2>: a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6748	"Reversible <e1>valproic acid</e1> -induced <e2>dementia</e2> was documented in a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6749	"<e1>Co-trimoxazole</e1> <e2>red cell aplasia</e2> in leukaemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6750	"When <e1>co-trimoxazole</e1> was stopped the <e2>red cell aplasia</e2> resolved."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6751	"A patient developed <e1>optic neuropathy</e1> while being treated with isoniazid and <e2>ethambutol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6752	"A patient developed <e1>optic neuropathy</e1> while being treated with <e2>isoniazid</e2> and ethambutol."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6753	"A well-recognized complication of ethambutol use is optic neuropathy, but the potential <e1>ocular toxicity</e1> of <e2>isoniazid</e2> is often overlooked."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6754	"A well-recognized complication of <e1>ethambutol</e1> use is <e2>optic neuropathy</e2>, but the potential ocular toxicity of isoniazid is often overlooked."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6755	"Isoniazid and <e1>ethambutol</e1> as a cause of <e2>optic neuropathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6756	"<e1>Isoniazid</e1> and ethambutol as a cause of <e2>optic neuropathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6757	"A woman 38-year-old, suffering for about ten years from multiple sclerosis and treated with repeated therapy cycles of intrathecal <e1>Depo-Medrol</e1>, developed a <e2>spastic paraparesis at the lower limbs</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6758	"<e1>Calcification</e1> and ossification of the spinal arachnoid after intrathecal administration of <e2>Depo-Medrol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6759	"Calcification and <e1>ossification of the spinal arachnoid</e1> after intrathecal administration of <e2>Depo-Medrol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6760	"A young woman with epilepsy had <e1>tonic-clonic seizures</e1> during antineoplastic therapy with <e2>adriamycin</e2> and cisplatin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6761	"A young woman with epilepsy had <e1>tonic-clonic seizures</e1> during antineoplastic therapy with adriamycin and <e2>cisplatin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6762	"<e1>Hyperkalemia</e1> as a late side effect of prolonged <e2>adrenocorticotropic hormone</e2> therapy for infantile spasms."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6763	"Two infants developed <e1>hyperkalemia</e1> shortly after cessation of prolonged <e2>ACTH</e2> therapy for infantile spasms."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6764	"We wish to call for cautious approach at time of cessation of prolonged <e1>ACTH</e1> therapy because of possible unexpected and only partially understood hazardous side effects such as <e2>hyperkalemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6765	"Three patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with <e1>folinic acid</e1> rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and <e2>acute renal impairment</e2>) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6766	"Three patients, in whom tumour overkill by cytotoxic treatment, including high dose <e1>methotrexate</e1> with folinic acid rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and <e2>acute renal impairment</e2>) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6767	"Three patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with <e1>folinic acid</e1> rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, <e2>hyperkalaemia</e2> and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6768	"Three patients, in whom tumour overkill by cytotoxic treatment, including high dose <e1>methotrexate</e1> with folinic acid rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, <e2>hyperkalaemia</e2> and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6769	"Three patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with <e1>folinic acid</e1> rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and <e2>hyperphosphataemia</e2> with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6770	"Three patients, in whom tumour overkill by cytotoxic treatment, including high dose <e1>methotrexate</e1> with folinic acid rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and <e2>hyperphosphataemia</e2> with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6771	"Three patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with <e1>folinic acid</e1> rescue, resulted in the 'phosphate shower syndrome' (<e2>hyper-uricaemia</e2>, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6772	"Three patients, in whom tumour overkill by cytotoxic treatment, including high dose <e1>methotrexate</e1> with folinic acid rescue, resulted in the 'phosphate shower syndrome' (<e2>hyper-uricaemia</e2>, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6773	"Three patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with <e1>folinic acid</e1> rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with <e2>hypocalcaemia</e2> and tetany, with metabolic acidosis and acute renal impairment) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6774	"Three patients, in whom tumour overkill by cytotoxic treatment, including high dose <e1>methotrexate</e1> with folinic acid rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with <e2>hypocalcaemia</e2> and tetany, with metabolic acidosis and acute renal impairment) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6775	"Three patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with <e1>folinic acid</e1> rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with <e2>metabolic acidosis</e2> and acute renal impairment) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6776	"Three patients, in whom tumour overkill by cytotoxic treatment, including high dose <e1>methotrexate</e1> with folinic acid rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with <e2>metabolic acidosis</e2> and acute renal impairment) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6777	"Three patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with <e1>folinic acid</e1> rescue, resulted in the '<e2>phosphate shower syndrome</e2>' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6778	"Three patients, in whom tumour overkill by cytotoxic treatment, including high dose <e1>methotrexate</e1> with folinic acid rescue, resulted in the '<e2>phosphate shower syndrome</e2>' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6779	"Three patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with <e1>folinic acid</e1> rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and <e2>tetany</e2>, with metabolic acidosis and acute renal impairment) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6780	"Three patients, in whom tumour overkill by cytotoxic treatment, including high dose <e1>methotrexate</e1> with folinic acid rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and <e2>tetany</e2>, with metabolic acidosis and acute renal impairment) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6781	"Accordingly, <e1>camptocormia</e1> is a dose-dependent side effect of <e2>valproate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6782	"A mentally retarded 23-year-old woman with myoclonic astatic epilepsy developed an <e1>abnormal posture of extreme forward flexion</e1>, called camptocormia, during <e2>valproate</e2> monotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6783	"A mentally retarded 23-year-old woman with myoclonic astatic epilepsy developed an abnormal posture of extreme forward flexion, called <e1>camptocormia</e1>, during <e2>valproate</e2> monotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6784	"<e1>Camptocormia</e1>, a new side effect of <e2>sodium valproate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6785	"Four weeks earlier she had developed <e1>hepatopathy</e1> during a regimen of <e2>carbamazepine</e2>, lynestrenol and sodium valproate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6786	"Four weeks earlier she had developed <e1>hepatopathy</e1> during a regimen of carbamazepine, <e2>lynestrenol</e2> and sodium valproate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6787	"Four weeks earlier she had developed <e1>hepatopathy</e1> during a regimen of carbamazepine, lynestrenol and <e2>sodium valproate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6788	"<e1>Hepatopathy</e1> subsided after the cessation of <e2>carbamazepine</e2> and lynestrenol."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6789	"<e1>Hepatopathy</e1> subsided after the cessation of carbamazepine and <e2>lynestrenol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6790	"A 10-year-old girl with Lennox-Gastaut syndrome who received intravenous <e1>lorazepam</e1> for atypical absence status <e2>seizures</e2> is reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6791	"<e1>Paradoxical precipitation of tonic seizures</e1> by <e2>lorazepam</e2> in a child with atypical absence seizures."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6792	"<e1>Atrial fibrillation</e1> following <e2>methylprednisolone</e2> pulse therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6793	"<e1>Isotretinoin</e1>, a drug used for the treatment of acne, has been shown to have <e2>teratogenic effects</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6794	"<e1>Isotretinoin</e1> <e2>teratogenicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6795	"We report an additional case of <e1>isotretinoin</e1> teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and <e2>abnormalities of the corticospinal tracts</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6796	"We report an additional case of <e1>isotretinoin</e1> teratogenicity in which the patient had <e2>agenesis of the cerebellar vermis</e2>, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6797	"We report an additional case of <e1>isotretinoin</e1> teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, <e2>hydrocephalus</e2>, and abnormalities of the corticospinal tracts."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6798	"We report an additional case of <e1>isotretinoin</e1> teratogenicity in which the patient had agenesis of the cerebellar vermis, <e2>multiple leptomeningeal neuroglial heterotopias</e2>, hydrocephalus, and abnormalities of the corticospinal tracts."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6799	"We report an additional case of <e1>isotretinoin</e1> <e2>teratogenicity</e2> in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6800	"A case of <e1>allopurinol</e1> <e2>hypersensitivity</e2>, possibly the first in a black African, is reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6801	"<e1>Allopurinol</e1> <e2>hypersensitivity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6802	"The <e1>allopurinol</e1> <e2>hypersensitivity syndrome</e2> is a rare adverse drug reaction."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6803	"<e1>Bone formation</e1> induced in an infant by systemic <e2>prostaglandin-E2</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6804	"A case of <e1>severe visual loss</e1> following a single dose of <e2>vincristine</e2> is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6805	"Although differential diagnostic alternatives can be considered in all described cases it is very likely that <e1>vincristine</e1> does cause <e2>severe visual loss</e2> in a small number of patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6806	"<e1>Severe visual loss</e1> after a single dose of <e2>vincristine</e2> in a patient with spinal cord astrocytoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6807	"The literature of <e1>vincristine</e1> <e2>optic nerve toxicity</e2> is reviewed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6808	"<e1>Visual loss</e1> after a single small dose of <e2>vincristine</e2> has never been reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6809	"<e1>Niacin</e1> causes a <e2>reversible toxic cystoid maculopathy</e2> that occurs in approximately 0.67% of patients taking high doses of the drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6810	"<e1>Niacin</e1> <e2>maculopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6811	"The authors conclude that among patients taking high doses of oral <e1>niacin</e1> only those who experience <e2>visual symptoms</e2> need to be ophthalmologically evaluated."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6812	"Three patients with <e1>niacin</e1> -induced visual symptoms had <e2>cystoid maculopathy</e2> without leakage on fluorescein angiography, and a fourth patient with no fundus abnormality experienced cessation of visual symptoms upon discontinuation of <e1>niacin</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6813	"Three patients with <e1>niacin</e1> -induced <e2>visual symptoms</e2> had cystoid maculopathy without leakage on fluorescein angiography, and a fourth patient with no fundus abnormality experienced cessation of <e2>visual symptoms</e2> upon discontinuation of <e1>niacin</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6814	"Three patients with <e1>niacin</e1> -induced <e2>visual symptoms</e2> had cystoid maculopathy without leakage on fluorescein angiography, and a fourth patient with no fundus abnormality experienced cessation of <e2>visual symptoms</e2> upon discontinuation of <e1>niacin</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6815	"A case report of the <e1>hypersensitivity syndrome</e1> occurring in a patient being treated with <e2>dapsone</e2> for a brown recluse spider bite is presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6816	"A <e1>dapsone</e1> hypersensitivity syndrome, consisting of <e2>fever</e2>, headache, nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6817	"A <e1>dapsone</e1> hypersensitivity syndrome, consisting of fever, <e2>headache</e2>, nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6818	"A <e1>dapsone</e1> hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, lymphadenopathy, hepatitis, <e2>hemolysis</e2>, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6819	"A <e1>dapsone</e1> hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, lymphadenopathy, <e2>hepatitis</e2>, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6820	"A <e1>dapsone</e1> <e2>hypersensitivity syndrome</e2>, consisting of fever, headache, nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6821	"A <e1>dapsone</e1> hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, <e2>leukopenia</e2>, and mononucleosis, has been described in patients treated with the drug for leprosy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6822	"A <e1>dapsone</e1> hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, <e2>lymphadenopathy</e2>, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6823	"A <e1>dapsone</e1> hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and <e2>mononucleosis</e2>, has been described in patients treated with the drug for leprosy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6824	"A <e1>dapsone</e1> hypersensitivity syndrome, consisting of fever, headache, <e2>nausea</e2>, vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6825	"A <e1>dapsone</e1> hypersensitivity syndrome, consisting of fever, headache, nausea, <e2>vomiting</e2>, lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6826	"Case report: <e1>dapsone</e1> <e2>hypersensitivity syndrome</e2> associated with treatment of the bite of a brown recluse spider."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6827	"<e1>Rifampicin</e1> -induced <e2>adrenal insufficiency</e2> in the acquired immunodeficiency syndrome: difficulties in diagnosis and treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6828	"We report the case of a patient with the acquired immunodeficiency syndrome treated with <e1>rifampicin</e1> who had a 'normal' screening test for adrenal insufficiency, yet had clinical evidence of <e2>adrenal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6829	"Two cases of widespread <e1>cutaneous vasculitis</e1> are described in association with <e2>diltiazem</e2>, a recently introduced calcium antagonist."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6830	"Widespread <e1>cutaneous vasculitis</e1> associated with <e2>diltiazem</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6831	"Intraventricular <e1>nafcillin</e1> -induced <e2>seizures</e2> in a neonate."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6832	"We report a premature infant who developed <e1>seizures</e1> associated with intraventricular administration of <e2>nafcillin</e2> and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6833	"A 58-year old patient is reported who developed an <e1>ischaemic cerebrovascular accident</e1> 22 hours after successful thrombolysis with <e2>streptokinase</e2> for life-threatening pulmonary emboli."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6834	"<e1>Thrombo-embolic complication</e1> after <e2>streptokinase</e2> therapy of pulmonary emboli."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6835	"<e1>Renal hypophosphatemia</e1> in this patient was caused by the erroneous intake of 1 g <e2>doxycycline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6836	"A clinically atypical, neuropathologically verified case of <e1>Creutzfeldt-Jakob disease</e1> is described in a 32-year-old New Zealand woman with idiopathic hypopituitarism who had been treated in late adolescence (1970 to 1973) with <e2>human growth hormone</e2> processed from pooled cadaveric pituitary glands."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6837	"A new case of <e1>Creutzfeldt-Jakob disease</e1> associated with <e2>human growth hormone</e2> therapy in New Zealand."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6838	"A case of a 21-year-old woman who had developed mild <e1>hepatotoxicity</e1> while receiving <e2>choline magnesium trisalicylate</e2> therapy is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6839	"Hepatotoxicity associated with choline magnesium tri<e1>salicylate</e1>: case report and review of <e1>salicylate</e1> -induced <e2>hepatotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6840	"<e1>Hepatotoxicity</e1> associated with <e2>choline magnesium trisalicylate</e2>: case report and review of salicylate-induced hepatotoxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6841	"<e1>Salicylate</e1> -induced <e2>hepatotoxicity</e2> is reviewed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6842	"They continued to rise for five more days before <e1>salicylate</e1> <e2>hepatotoxicity</e2> was suspected."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6843	"A 51-yr-old nonsmoking male patient without any history of previous allergies, asthma, hay fever, or urticaria developed <e1>attacks of asthma</e1> when <e2>captopril</e2> was added to the nadolol and dyazide treatment for his high blood pressure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6844	"A 51-yr-old nonsmoking male patient without any history of previous allergies, asthma, hay fever, or urticaria developed <e1>attacks of asthma</e1> when captopril was added to the nadolol and <e2>dyazide</e2> treatment for his high blood pressure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6845	"A 51-yr-old nonsmoking male patient without any history of previous allergies, asthma, hay fever, or urticaria developed <e1>attacks of asthma</e1> when captopril was added to the <e2>nadolol</e2> and dyazide treatment for his high blood pressure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6846	"<e1>Captopril</e1> -related (and -induced?) <e2>asthma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6847	"This confirmed the history of <e1>captopril</e1> -related <e2>asthma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6848	"We also describe a case of <e1>timolol</e1> -induced <e2>ocular pemphigoid</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6849	"<e1>Deposits of plasma proteins in the skin</e1> during treatment with <e2>carbamazepine</e2> and diphenylhydantoin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6850	"<e1>Deposits of plasma proteins in the skin</e1> during treatment with carbamazepine and <e2>diphenylhydantoin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6851	"The observations suggest that testicular swelling and <e1>pain</e1> are side effects of <e2>desipramine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6852	"The observations suggest that <e1>testicular swelling</e1> and pain are side effects of <e2>desipramine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6853	"Two patients are described who developed testicular swelling and <e1>pain</e1> during treatment with <e2>desipramine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6854	"Two patients are described who developed <e1>testicular swelling</e1> and pain during treatment with <e2>desipramine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6855	"<e1>Benzocaine</e1>, an ester-type local anesthetic, was believed responsible for apparent <e2>methemoglobinemia</e2> in a cat."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6856	"<e1>Benzocaine</e1> -induced <e2>methemoglobinemia</e2> has been reported in man, dogs, and cats."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6857	"<e1>Methemoglobinemia</e1> associated with dermal application of <e2>benzocaine</e2> cream in a cat."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6858	"A 43-year-old white man developed a shallow <e1>erosion of a psoriatic plaque</e1> after chronic administration of <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6859	"<e1>Erosion of psoriatic plaques</e1> after chronic <e2>methotrexate</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6860	"After a six-week course of low-dose <e1>cyclosporine A</e1>, she developed a severe but reversible loss of glomerular filtration rate and <e2>effective renal plasma flow</e2> despite of low <e1>cyclosporine A</e1> plasma levels."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6861	"After a six-week course of low-dose <e1>cyclosporine A</e1>, she developed a severe but reversible <e2>loss of glomerular filtration rate</e2> and effective renal plasma flow despite of low <e1>cyclosporine A</e1> plasma levels."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6862	"Based upon the observed <e1>fall of the filtration fraction</e1>, the rise in the relative clearance of 99Tc-dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and/or interstitium are the main targets for <e2>cyclosporine A</e2> nephrotoxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6863	"Based upon the observed fall of the filtration fraction, the rise in the relative clearance of 99Tc-dimercaptosuccinic acid and the <e1>increase in proteinuria</e1>, we suggest that in this case the tubules and/or interstitium are the main targets for <e2>cyclosporine A</e2> nephrotoxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6864	"Based upon the observed fall of the filtration fraction, the rise in the relative clearance of 99Tc-dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and/or interstitium are the main targets for <e1>cyclosporine A</e1> <e2>nephrotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6865	"Based upon the observed fall of the filtration fraction, the <e1>rise in the relative clearance of 99Tc-dimercaptosuccinic acid</e1> and the increase in proteinuria, we suggest that in this case the tubules and/or interstitium are the main targets for <e2>cyclosporine A</e2> nephrotoxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6866	"Unexpected severe reversible <e1>cyclosporine A</e1> -induced <e2>nephrotoxicity</e2> in a patient with systemic lupus erythematosus and tubulointerstitial renal disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6867	"A patient is presented with typical <e1>hyperthyroidism</e1>, who developed a severe proximal muscle weakness and a raised creatine phosphokinase after treatment for <e1>hyperthyroidism</e1> with <e2>propylthiouracil</e2> (100 mg orally, three times a day)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6868	"A patient is presented with typical hyperthyroidism, who developed a severe proximal muscle weakness and a <e1>raised creatine phosphokinase</e1> after treatment for hyperthyroidism with <e2>propylthiouracil</e2> (100 mg orally, three times a day)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6869	"A patient is presented with typical hyperthyroidism, who developed a <e1>severe proximal muscle weakness</e1> and a raised creatine phosphokinase after treatment for hyperthyroidism with <e2>propylthiouracil</e2> (100 mg orally, three times a day)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6870	"<e1>Polymyositis</e1> after <e2>propylthiouracil</e2> treatment for hyperthyroidism."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6871	"<e1>Cardiopulmonary arrest</e1> following intravenous <e2>phenytoin</e2> loading."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6872	"Evidence obtained indicated that the Reye-like syndrome might be caused by <e1>calcium hopantenate</e1> possibly due to the induction of <e2>pantothenic acid deficiency</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6873	"Evidence obtained indicated that the <e1>Reye-like syndrome</e1> might be caused by <e2>calcium hopantenate</e2> possibly due to the induction of pantothenic acid deficiency."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6874	"<e1>Reye-like syndrome</e1> following treatment with the pantothenic acid antagonist, <e2>calcium hopantenate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6875	"Three senile patients developed <e1>fatal acute encephalopathy</e1> while receiving <e2>calcium hopantenate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6876	"<e1>Dyspnea</e1> possibly associated with controlled-release <e2>morphine sulfate</e2> tablets."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6877	"<e1>Anhedonic ejaculation</e1> with <e2>desipramine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6878	"We report two patients with <e1>anhedonic ejaculation</e1> (ejaculation without orgasm) associated with initiation of treatment with <e2>desipramine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6879	"We report two patients with anhedonic ejaculation (<e1>ejaculation without orgasm</e1>) associated with initiation of treatment with <e2>desipramine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6880	"<e1>Myoclonic spasms</e1> following intrathecal <e2>morphine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6881	"A case of <e1>halothane</e1> induced <e2>hepatitis</e2> is reported in a middle aged woman who underwent gastric surgery for morbid obesity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6882	"<e1>Halothane</e1> <e2>hepatitis</e2> and prompt resolution with methionine therapy: case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6883	"Development of <e1>porphyria cutanea tarda</e1> after treatment with <e2>cyclophosphamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6884	"We report a 46-yr-old woman with ovarian carcinoma who developed <e1>porphyria cutanea tarda</e1> while undergoing treatment with <e2>cisplatin</e2> and cyclophosphamide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6885	"We report a 46-yr-old woman with ovarian carcinoma who developed <e1>porphyria cutanea tarda</e1> while undergoing treatment with cisplatin and <e2>cyclophosphamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6886	"<e1>Acute renal failure</e1> in a patient treated by continuous povidone-<e2>iodine</e2> mediastinal irrigation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6887	"<e1>Acute renal failure</e1> in a patient treated by continuous <e2>povidone</e2> -iodine mediastinal irrigation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6888	"We describe a 63 year old woman with a suppurative mediastinitis, treated with continuous <e1>PI</e1> irrigation who developed an <e2>acute oliguric renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6889	"A 56-year-old woman with scleroderma developed rapidly progressive glomerulonephritis with <e1>epithelial crescents</e1> associated with hemoptysis after 27 months of <e2>D-penicillamine</e2> therapy and a cumulative dose of 1,200 g."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6890	"A 56-year-old woman with scleroderma developed rapidly progressive glomerulonephritis with epithelial crescents associated with <e1>hemoptysis</e1> after 27 months of <e2>D-penicillamine</e2> therapy and a cumulative dose of 1,200 g."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6891	"A 56-year-old woman with scleroderma developed <e1>rapidly progressive glomerulonephritis</e1> with epithelial crescents associated with hemoptysis after 27 months of <e2>D-penicillamine</e2> therapy and a cumulative dose of 1,200 g."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6892	"<e1>D-penicillamine</e1> induced <e2>crescentic glomerulonephritis</e2>: report and review of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6893	"The 9 other reported cases of <e1>D-penicillamine</e1> induced <e2>rapidly progressive glomerulonephritis</e2> have been reviewed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6894	"<e1>Gold</e1> -induced <e2>pneumonitis</e2> is a rare complication of gold salt therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6895	"<e1>Gold</e1> -induced <e2>pneumonitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6896	"This case supports the view that in <e1>gold</e1> -induced <e2>pneumonitis</e2> a prolonged treatment with corticosteroids may be necessary, as lung function continued to improve."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6897	"We describe a patient with rheumatoid arthritis treated with <e1>gold</e1> salts, who developed <e2>bilateral interstitial pulmonary abnormalities</e2> and showed a dramatic response on corticosteroid therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6898	"<e1>Gold</e1> -induced <e2>aplastic anemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6899	"Three patients receiving <e1>gold</e1> salt treatment for rheumatoid arthritis developed severe <e2>aplastic anemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6900	"Pharmacokinetic determinants of <e1>6-mercaptopurine</e1> <e2>myelotoxicity</e2> and therapeutic failure in children with acute lymphoblastic leukemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6901	"Because the <e1>cerebellar toxicity</e1> may be worsened by continuation of therapy after initial onset of symptoms, prompt termination of <e2>HDARAC</e2> is recommended."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6902	"<e1>Cytarabine</e1> -induced <e2>cerebellar syndrome</e2>: case report and literature review."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6903	"During the first treatment, dysarthria and <e1>ataxia</e1> were seen after completion of the patient's eighth and final dose of <e2>HDARAC</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6904	"During the first treatment, <e1>dysarthria</e1> and ataxia were seen after completion of the patient's eighth and final dose of <e2>HDARAC</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6905	"The <e1>neurotoxicity</e1> seen with <e2>HDARAC</e2> is dose-related and has occurred in up to 60 percent of treated patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6906	"This case report illustrates the <e1>neurotoxicity</e1> unique to <e2>HDARAC</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6907	"<e1>Macular infarction</e1> after endophthalmitis treated with vitrectomy and intravitreal <e2>gentamicin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6908	"We are concerned that the <e1>macular lesion</e1> was a retinal toxic effect of <e2>gentamicin</e2> because of the recent description of similar lesions occurring after the inadvertent intraocular injection of massive doses of this drug."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6909	"A woman with a 20-year history of acral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs, developed a <e1>B-cell lymphoma</e1> of the lip following 4 1/2 years of treatment with <e2>razoxane</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6910	"Extensive immunological investigations were performed in a patient with definite seronegative rheumatoid arthritis who developed <e1>hypogammaglobulinemia</e1> in the course of <e2>gold</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6911	"<e1>Hypogammaglobulinemia</e1> associated with <e2>gold</e2> therapy: evidence for a partial maturation blockade of B cells."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6912	"Transient <e1>leucopenia</e1> and thrombocytopenia associated with <e2>sodium nitroprusside</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6913	"Transient leucopenia and <e1>thrombocytopenia</e1> associated with <e2>sodium nitroprusside</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6914	"<e1>Herpes simplex esophagitis</e1> in a renal transplant patient treated with <e2>cyclosporine A</e2>: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6915	"We report the first case of <e1>herpes esophagitis</e1> in a renal transplant patient treated with <e2>Cyclosporine A</e2> while on chronic steroid therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6916	"With the increasing use of <e1>Cyclosporine A</e1> in transplant patients, the incidence of <e2>herpes esophagitis</e2> may increase."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6917	"Administration of excessive <e1>insulin</e1> induced <e2>hypoglycemia</e2> within 4 to 8 hours, followed by rebound hyperglycemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6918	"Administration of excessive <e1>insulin</e1> induced hypoglycemia within 4 to 8 hours, followed by <e2>rebound hyperglycemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6919	"<e1>Posthypoglycemic hyperglycemia</e1> (rebound hyperglycemia) after overdosing of <e2>insulin</e2> was diagnosed in 6 cats with diabetes mellitus."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6920	"Posthypoglycemic hyperglycemia (<e1>rebound hyperglycemia</e1>) after overdosing of <e2>insulin</e2> was diagnosed in 6 cats with diabetes mellitus."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6921	"Rebound <e1>hyperglycemia</e1> following overdosing of <e2>insulin</e2> in cats with diabetes mellitus."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6922	"<e1>Rebound hyperglycemia</e1> was observed with both intermediate (neutral <e2>protamine hagedorn</e2>) and long-acting (protamine zinc iletin) insulins, and the range of insulin doses at which the disorder developed overlapped previously determined therapeutic doses for these insulins in the cat."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6923	"<e1>Rebound hyperglycemia</e1> was observed with both intermediate (neutral protamine hagedorn) and long-acting (<e2>protamine zinc iletin</e2>) insulins, and the range of insulin doses at which the disorder developed overlapped previously determined therapeutic doses for these insulins in the cat."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6924	"<e1>Captopril</e1> -induced <e2>lichen planus pemphigoides</e2> with pemphigus-like features."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6925	"We report a case of a <e1>bullous lichenoid eruption</e1> due to the intake of <e2>captopril</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6926	"An 8-year-old girl, who had been vaccinated with <e1>BCG</e1> without subsequent regional reactions, developed <e2>osteomyelitis in the left calcaneus</e2> 7 months later."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6927	"<e1>Metastatic osteomyelitis</e1> following <e2>BCG</e2> vaccination."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6928	"One of the subjects who was using extemporaneous topical <e1>minoxidil</e1> had hypertension and <e2>arteriosclerotic disease</e2> and the other died of a myocardial infarction."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6929	"One of the subjects who was using extemporaneous topical <e1>minoxidil</e1> had <e2>hypertension</e2> and arteriosclerotic disease and the other died of a myocardial infarction."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6930	"One of the subjects who was using extemporaneous topical <e1>minoxidil</e1> had hypertension and arteriosclerotic disease and the other died of a <e2>myocardial infarction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6931	"<e1>Amoxapine</e1> -induced <e2>cognitive impairment</e2> in two patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6932	"Two patients are described in whom subtle <e1>cognitive impairments</e1> are associated with therapeutic doses of <e2>amoxapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6933	"A 23-year-old woman with systemic lupus erythematosus had a <e1>severe hypersensitivity reaction</e1> to the drug <e2>ibuprofen</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6934	"<e1>Severe systemic hypersensitivity reaction</e1> to <e2>ibuprofen</e2> occurring after prolonged therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6935	"A brief review of reported cases of <e1>chloramphenicol</e1> <e2>hypersensitivity</e2> in the English-language literature, as well as possible alternative explanations in this case, are provided."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6936	"<e1>Hypersensitivity reaction</e1> following <e2>chloramphenicol</e2> administration in a patient with typhoid fever."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6937	"<e1>Hypersensitivity reactions</e1> due to <e2>chloramphenicol</e2> are rarely reported in the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6938	"We present a case report of a patient with typhoid fever who experienced a <e1>hypersensitivity reaction</e1> subsequent to the infusion of <e2>chloramphenicol sodium succinate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6939	"Replicate brain magnetic resonance imaging examinations after six weeks and 11 months of <e1>penicillamine</e1> therapy documented the development of new <e2>brain lesions</e2> during this period, while liver biopsy specimen data disclosed that excellent hepatic decoppering had occurred."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6940	"To develop information on the relative rarity or frequency of neurologic worsening with the initiation of <e1>penicillamine</e1> therapy, we conducted a retrospective survey of 25 additional patients with Wilson's disease who met the criteria of presenting with <e2>neurologic disease</e2> and having been treated with <e1>penicillamine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6941	"To develop information on the relative rarity or frequency of <e1>neurologic worsening</e1> with the initiation of <e2>penicillamine</e2> therapy, we conducted a retrospective survey of 25 additional patients with Wilson's disease who met the criteria of presenting with neurologic disease and having been treated with <e2>penicillamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6942	"We describe a patient with Wilson's disease who presented with neurologic disease, was treated with <e1>D-penicillamine</e1>, and suffered sudden <e2>neurologic deterioration</e2> coincident with therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6943	"<e1>Worsening of neurologic syndrome</e1> in patients with Wilson's disease with initial <e2>penicillamine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6944	"Other <e1>upper tract neoplasms</e1> after <e2>cyclophosphamide</e2> are reviewed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6945	"<e1>Upper tract urothelial malignancy</e1> after <e2>cyclophosphamide</e2> therapy: a case report and literature review."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6946	"We report an unusual case of simultaneous transitional cell carcinoma of the renal pelvis and <e1>distal ureter without transitional cell carcinoma of the bladder</e1> occurring after chronic <e2>cyclophosphamide</e2> therapy for nonHodgkin's lymphoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6947	"We report an unusual case of simultaneous <e1>transitional cell carcinoma of the renal pelvis</e1> and distal ureter without transitional cell carcinoma of the bladder occurring after chronic <e2>cyclophosphamide</e2> therapy for nonHodgkin's lymphoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6948	"<e1>Progressive pulmonary fibrosis</e1> complicating <e2>cyclophosphamide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6949	"The changes were progressive regardless of discontinuation of <e1>cyclophosphamide</e1> and led to <e2>severe restrictive ventilatory defect</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6950	"<e1>Torsade de pointes</e1> during loading with <e2>amiodarone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6951	"<e1>Torsade de pointes</e1> represents a potential complication of chronic <e2>amiodarone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6952	"We report a case of <e1>torsade de pointes</e1> following a single oral dose of <e2>amiodarone</e2> (1400 mg or 30 mg kg-1) administered after short intravenous loading for prevention of paroxysmal atrial flutter."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6953	"<e1>Pulmonary edema</e1> as a delayed complication of <e2>ritodrine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6954	"<e1>Pulmonary edema</e1> occurred 24 hours after intravenous <e2>ritodrine</e2> therapy and 10 hours after subcutaneous terbutaline therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6955	"<e1>Pulmonary edema</e1> occurred 24 hours after intravenous ritodrine therapy and 10 hours after subcutaneous <e2>terbutaline</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6956	"<e1>Cyclosporin</e1> side effects included hirsutism, hypertension, increased blood levels of urea and creatinine, and <e2>abnormalities in liver function tests</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6957	"<e1>Cyclosporin</e1> side effects included <e2>hirsutism</e2>, hypertension, increased blood levels of urea and creatinine, and abnormalities in liver function tests."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6958	"<e1>Cyclosporin</e1> side effects included hirsutism, <e2>hypertension</e2>, increased blood levels of urea and creatinine, and abnormalities in liver function tests."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6959	"<e1>Cyclosporin</e1> side effects included hirsutism, hypertension, <e2>increased blood levels of urea and creatinine</e2>, and abnormalities in liver function tests."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6960	"<e1>Rupture of a cerebral aneurysm</e1> associated with <e2>nifedipine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6961	"We describe <e1>rupture of a cerebral arterial aneurysm</e1> in a 32 year old hypertensive woman following the introduction of <e2>nifedipine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6962	"A small initial dose of <e1>prazosin</e1> ranging from 0.5 to 1 mg has been recommended to avoid the first-dose phenomenon characterized by a sudden and <e2>severe drop in blood pressure</e2> after the administration of the first dose of <e1>prazosin</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6963	"A small initial dose of <e1>prazosin</e1> ranging from 0.5 to 1 mg has been recommended to avoid the first-dose phenomenon characterized by a sudden and <e2>severe drop in blood pressure</e2> after the administration of the first dose of <e1>prazosin</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6964	"<e1>Prazosin</e1> -induced first-dose phenomenon possibly associated with <e2>hemorrhagic stroke</e2>: a report of three cases."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6965	"A <e1>fatal massive pulmonary embolus</e1> developed in a patient treated with <e2>streptokinase</e2> for acute deep vein thrombosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6966	"<e1>Massive pulmonary embolism</e1> complicating <e2>streptokinase</e2> treatment for deep vein thrombosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6967	"Fatal <e2>digoxin</e2> poisoning: an unsuccessful resuscitation with use of <e2>digoxin</e2> -immune Fab."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6968	"A case of <e1>phenytoin</e1> -induced <e2>hepatitis</e2> with mononucleosis is reported, and syndromes associated with <e1>phenytoin</e1> hypersensitivity reactions are discussed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6969	"A case of <e1>phenytoin</e1> -induced hepatitis with mononucleosis is reported, and syndromes associated with <e1>phenytoin</e1> <e2>hypersensitivity reactions</e2> are discussed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6970	"A case of <e1>phenytoin</e1> -induced hepatitis with <e2>mononucleosis</e2> is reported, and syndromes associated with <e1>phenytoin</e1> hypersensitivity reactions are discussed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6971	"<e1>Phenytoin</e1> -induced <e2>hypersensitivity reactions</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6972	"Phenytoin was discontinued after admission; however, <e1>phenytoin</e1> 1 g i.v. was given for a tonic-clonic seizure two days after admission, after which swelling of the face and legs and <e2>pruritus</e2> developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6973	"Phenytoin was discontinued after admission; however, <e1>phenytoin</e1> 1 g i.v. was given for a tonic-clonic seizure two days after admission, after which <e2>swelling of the face and legs</e2> and pruritus developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6974	"Serious <e1>phenytoin</e1> hypersensitivity reactions may appear as <e2>dermatologic, lymphoid, or hepatic syndromes</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6975	"Serious <e1>phenytoin</e1> <e2>hypersensitivity reactions</e2> may appear as dermatologic, lymphoid, or hepatic syndromes."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6976	"She was receiving phenytoin sodium 300 mg/day; <e1>carbamazepine</e1> 200 mg four times daily had been discontinued four days before admission because of <e2>leukopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6977	"She was receiving <e1>phenytoin sodium</e1> 300 mg/day; carbamazepine 200 mg four times daily had been discontinued four days before admission because of <e2>leukopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6978	"The possibility of <e1>phenytoin</e1> hypersensitivity reactions should be considered when patients receiving <e1>phenytoin</e1> have unusual symptoms, particularly <e2>fever</e2>, rash, and lymphadenopathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6979	"The possibility of <e1>phenytoin</e1> hypersensitivity reactions should be considered when patients receiving <e1>phenytoin</e1> have unusual symptoms, particularly <e2>fever</e2>, rash, and lymphadenopathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6980	"The possibility of <e1>phenytoin</e1> <e2>hypersensitivity reactions</e2> should be considered when patients receiving <e1>phenytoin</e1> have unusual symptoms, particularly fever, rash, and lymphadenopathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6981	"The possibility of <e1>phenytoin</e1> <e2>hypersensitivity reactions</e2> should be considered when patients receiving <e1>phenytoin</e1> have unusual symptoms, particularly fever, rash, and lymphadenopathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6982	"The possibility of <e1>phenytoin</e1> hypersensitivity reactions should be considered when patients receiving <e1>phenytoin</e1> have unusual symptoms, particularly fever, rash, and <e2>lymphadenopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6983	"The possibility of <e1>phenytoin</e1> hypersensitivity reactions should be considered when patients receiving <e1>phenytoin</e1> have unusual symptoms, particularly fever, rash, and <e2>lymphadenopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6984	"The possibility of <e1>phenytoin</e1> hypersensitivity reactions should be considered when patients receiving <e1>phenytoin</e1> have unusual symptoms, particularly fever, <e2>rash</e2>, and lymphadenopathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6985	"The possibility of <e1>phenytoin</e1> hypersensitivity reactions should be considered when patients receiving <e1>phenytoin</e1> have unusual symptoms, particularly fever, <e2>rash</e2>, and lymphadenopathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6986	"It was restarted 6 weeks later, and 10 weeks after that, the patient presented with <e1>fulminant hepatic failure</e1>, which resolved rapidly after cessation of <e2>nicotinic acid</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6987	"<e1>Nicotinic acid</e1> -induced <e2>fulminant hepatic failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6988	"We suggest that <e1>nicotinic acid</e1> was the cause of his liver disease, that this case is of particular note because of the rather short period of therapy before the onset of liver injury and the severity of the hepatic failure, and that the probable increased use of <e1>nicotinic acid</e1> for serum cholesterol control makes it especially important for physicians and their patients to be alert to the signs of <e2>hepatotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6989	"We suggest that <e1>nicotinic acid</e1> was the cause of his <e2>liver disease</e2>, that this case is of particular note because of the rather short period of therapy before the onset of liver injury and the severity of the hepatic failure, and that the probable increased use of <e1>nicotinic acid</e1> for serum cholesterol control makes it especially important for physicians and their patients to be alert to the signs of hepatotoxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6990	"We suggest that <e1>nicotinic acid</e1> was the cause of his <e2>liver disease</e2>, that this case is of particular note because of the rather short period of therapy before the onset of liver injury and the severity of the hepatic failure, and that the probable increased use of <e1>nicotinic acid</e1> for serum cholesterol control makes it especially important for physicians and their patients to be alert to the signs of hepatotoxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6991	"An infant girl with choanal atresia, <e1>athelia</e1>, minor anomalies, and mild to moderate mental retardation was born to a woman treated for hyperthyroidism throughout pregnancy with <e2>methimazole</e2> and propranolol."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6992	"An infant girl with choanal atresia, <e1>athelia</e1>, minor anomalies, and mild to moderate mental retardation was born to a woman treated for hyperthyroidism throughout pregnancy with methimazole and <e2>propranolol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6993	"An infant girl with <e1>choanal atresia</e1>, athelia, minor anomalies, and mild to moderate mental retardation was born to a woman treated for hyperthyroidism throughout pregnancy with <e2>methimazole</e2> and propranolol."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6994	"An infant girl with <e1>choanal atresia</e1>, athelia, minor anomalies, and mild to moderate mental retardation was born to a woman treated for hyperthyroidism throughout pregnancy with methimazole and <e2>propranolol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6995	"An infant girl with choanal atresia, athelia, minor anomalies, and mild to moderate <e1>mental retardation</e1> was born to a woman treated for hyperthyroidism throughout pregnancy with <e2>methimazole</e2> and propranolol."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6996	"An infant girl with choanal atresia, athelia, minor anomalies, and mild to moderate <e1>mental retardation</e1> was born to a woman treated for hyperthyroidism throughout pregnancy with methimazole and <e2>propranolol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6997	"Choanal atresia and <e1>athelia</e1>: <e2>methimazole</e2> teratogenicity or a new syndrome?"
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6998	"<e1>Choanal atresia</e1> and athelia: <e2>methimazole</e2> teratogenicity or a new syndrome?"
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6999	"Choanal atresia and athelia: <e1>methimazole</e1> <e2>teratogenicity</e2> or a new syndrome?"
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7000	"The patient's defects may be due to <e1>methimazole</e1> <e2>teratogenicity</e2> or could represent a previously undescribed syndrome affecting ectodermal structures."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7001	"<e1>Toxic epidermal necrolysis</e1> resulted after 19 days of treatment with <e2>5-fluorocytosine</e2> and amphotericin B."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7002	"<e1>Toxic epidermal necrolysis</e1> resulted after 19 days of treatment with 5-fluorocytosine and <e2>amphotericin B</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7003	"Five and one-half years after the diagnosis of myeloma, while in remission on <e1>cyclophosphamide</e1> therapy, the patient experienced severe <e2>abdominal right lower quadrant pain</e2> due to a large cecal lymphoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7004	"Five and one-half years after the diagnosis of myeloma, while in remission on <e1>cyclophosphamide</e1> therapy, the patient experienced severe abdominal right lower quadrant pain due to a large <e2>cecal lymphoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7005	"After therapy with parenteral <e1>amiodarone</e1> (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and <e2>fall in prothrombin time</e2>, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7006	"After therapy with parenteral <e1>amiodarone</e1> (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed <e2>jaundice</e2>, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7007	"After therapy with parenteral <e1>amiodarone</e1> (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, <e2>marked increase in serum transaminase levels</e2> and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7008	"After therapy with parenteral <e1>amiodarone</e1> (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of <e2>severe centrilobular necrosis</e2> were observed in hepatic biopsy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7009	"A patient with acute changes suggesting <e1>acute hepatitis</e1> after parenteral <e2>amiodarone</e2> administration is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7010	"Probable early <e1>acute hepatitis</e1> with parenteral <e2>amiodarone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7011	"Therefore, parenteral <e1>amiodarone</e1> was implicated as the cause of <e2>acute hepatitis</e2> in this patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7012	"He became <e1>hyperkalemic</e1> on rechallenge with <e2>timolol</e2> and normokalemic following its withdrawal."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7013	"<e1>Severe hyperkalemia</e1> as a complication of <e2>timolol</e2>, a topically applied beta-adrenergic antagonist."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7014	"<e1>Severe hyperkalemia</e1> occurred in a patient with radiation pneumonitis and glaucoma shortly after beginning <e2>prednisone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7015	"<e1>Noncardiogenic pulmonary edema</e1> during intrabiliary infusion of <e2>mono-octanoin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7016	"We describe a patient in whom <e1>noncardiogenic pulmonary edema</e1> developed during intrabiliary infusion of <e2>monooctanoin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7017	"<e1>Paroxysmal supraventricular tachycardia</e1> during treatment with <e2>cisplatin</e2> and etoposide combination."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7018	"<e1>Paroxysmal supraventricular tachycardia</e1> during treatment with cisplatin and <e2>etoposide</e2> combination."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7019	"We report a case of a 60-year-old woman affected by squamous lung carcinoma, who developed <e1>paroxysmal supraventricular tachycardia</e1> during <e2>cisplatin</e2> and etoposide combination chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7020	"We report a case of a 60-year-old woman affected by squamous lung carcinoma, who developed <e1>paroxysmal supraventricular tachycardia</e1> during cisplatin and <e2>etoposide</e2> combination chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7021	"A case is reported of theophylline intoxication due to a dramatic <e1>decrease in theophylline clearance</e1> following concomitant administration of <e2>viloxazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7022	"A case is reported of <e2>theophylline</e2> intoxication due to a dramatic decrease in <e2>theophylline</e2> clearance following concomitant administration of viloxazine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7023	"A case is reported of <e1>theophylline intoxication</e1> due to a dramatic decrease in theophylline clearance following concomitant administration of <e2>viloxazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7024	"Theophylline intoxication following <e1>viloxazine</e1> induced <e2>decrease in clearance</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7025	"<e2>Theophylline</e2> intoxication following viloxazine induced decrease in clearance."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7026	"<e1>Theophylline intoxication</e1> following <e2>viloxazine</e2> induced decrease in clearance."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7027	"Idiosyncratic pulmonary reactions to <e1>nitrofurantoin</e1> are not unusual, often presenting as <e2>eosinophilic pneumonia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7028	"<e1>Idiosyncratic pulmonary reactions</e1> to <e2>nitrofurantoin</e2> are not unusual, often presenting as eosinophilic pneumonia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7029	"<e1>Acute myocardial necrosis</e1> during administration of <e2>amsacrine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7030	"In addition to the recognized arrhythmic complications, the authors emphasize myocardial necrosis as a possible further manifestation of <e1>amsacrine</e1> -related <e2>cardiotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7031	"In addition to the recognized arrhythmic complications, the authors emphasize <e1>myocardial necrosis</e1> as a possible further manifestation of <e2>amsacrine</e2> -related cardiotoxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7032	"The authors report a case of focal myocardial necrosis, presenting clinically as an <e1>acute myocardial infarction</e1> during the administration of the antineoplastic drug, <e2>amsacrine</e2>, in a patient without coronary artery disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7033	"The authors report a case of <e1>focal myocardial necrosis</e1>, presenting clinically as an acute myocardial infarction during the administration of the antineoplastic drug, <e2>amsacrine</e2>, in a patient without coronary artery disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7034	"A child in whom a <e1>phenobarbital</e1> hypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, <e2>alopecia</e2>, icterus, protein-losing enteropathy, myositis, and nephritis, is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7035	"A child in whom a <e1>phenobarbital</e1> hypersensitivity drug reaction developed which consisted of fever, <e2>a pruritic desquamating erythrodermic rash</e2>, alopecia, icterus, protein-losing enteropathy, myositis, and nephritis, is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7036	"A child in whom a <e1>phenobarbital</e1> hypersensitivity drug reaction developed which consisted of <e2>fever</e2>, a pruritic desquamating erythrodermic rash, alopecia, icterus, protein-losing enteropathy, myositis, and nephritis, is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7037	"A child in whom a <e1>phenobarbital</e1> <e2>hypersensitivity</e2> drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, icterus, protein-losing enteropathy, myositis, and nephritis, is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7038	"A child in whom a <e1>phenobarbital</e1> hypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, <e2>icterus</e2>, protein-losing enteropathy, myositis, and nephritis, is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7039	"A child in whom a <e1>phenobarbital</e1> hypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, icterus, protein-losing enteropathy, <e2>myositis</e2>, and nephritis, is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7040	"A child in whom a <e1>phenobarbital</e1> hypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, icterus, protein-losing enteropathy, myositis, and <e2>nephritis</e2>, is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7041	"A child in whom a <e1>phenobarbital</e1> hypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, icterus, <e2>protein-losing enteropathy</e2>, myositis, and nephritis, is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7042	"<e1>Graft versus host-like illness</e1> in a child with <e2>phenobarbital</e2> hypersensitivity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7043	"Graft versus host-like illness in a child with <e1>phenobarbital</e1> <e2>hypersensitivity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7044	"The clinical findings and laboratory studies suggested an <e1>autoimmune cell-mediated hypersensitivity</e1> reaction triggered by <e2>phenobarbital</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7045	"<e1>Duodenal ulceration</e1>: a complication of <e2>tolazoline</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7046	"Two patients who were receiving <e1>Tolazoline</e1> by infusion developed <e2>duodenal ulceration</e2> and subsequent intestinal perforation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7047	"Two patients who were receiving <e1>Tolazoline</e1> by infusion developed duodenal ulceration and subsequent <e2>intestinal perforation</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7048	"The latter form (<e1>Macrodantin</e1>) is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form--liver damage, <e2>acute and chronic pulmonary reactions</e2>, peripheral neuropathy, blood dyscrasias and allergic reactions--and does so just as rapidly and floridly; one such case is reported here."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7049	"The latter form (<e1>Macrodantin</e1>) is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form--liver damage, acute and chronic pulmonary reactions, peripheral neuropathy, blood dyscrasias and <e2>allergic reactions</e2> --and does so just as rapidly and floridly; one such case is reported here."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7050	"The latter form (<e1>Macrodantin</e1>) is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form--liver damage, acute and chronic pulmonary reactions, peripheral neuropathy, <e2>blood dyscrasias</e2> and allergic reactions--and does so just as rapidly and floridly; one such case is reported here."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7051	"The latter form (<e1>Macrodantin</e1>) is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form--<e2>liver damage</e2>, acute and chronic pulmonary reactions, peripheral neuropathy, blood dyscrasias and allergic reactions--and does so just as rapidly and floridly; one such case is reported here."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7052	"The latter form (<e1>Macrodantin</e1>) is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form--liver damage, acute and chronic pulmonary reactions, <e2>peripheral neuropathy</e2>, blood dyscrasias and allergic reactions--and does so just as rapidly and floridly; one such case is reported here."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7053	"<e1>Generalized pustular psoriasis</e1> precipitated by <e2>trazodone</e2> in the treatment of depression."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7054	"We report a patient in whom the anti-depressant trazodone hydrochloride (<e1>Molipaxin</e1>, Roussel), a serotonin antagonist, provoked <e2>generalized pustular psoriasis</e2> (GPP)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7055	"We report a patient in whom the anti-depressant <e1>trazodone hydrochloride</e1> (Molipaxin, Roussel), a serotonin antagonist, provoked <e2>generalized pustular psoriasis</e2> (GPP)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7056	"We report a patient in whom the anti-depressant trazodone hydrochloride (<e1>Molipaxin</e1>, Roussel), a serotonin antagonist, provoked generalized pustular psoriasis (<e2>GPP</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7057	"We report a patient in whom the anti-depressant <e1>trazodone hydrochloride</e1> (Molipaxin, Roussel), a serotonin antagonist, provoked generalized pustular psoriasis (<e2>GPP</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7058	"Intravenous verapamil therapy in babies may cause <e1>apnea</e1>, hypotension, and bradycardia; continued episodes of atrial flutter in a child may cause sudden death; <e2>quinidine</e2> may be related to the death; children with "familial seizure disorders" may in fact have the long QT interval syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7059	"Intravenous <e1>verapamil</e1> therapy in babies may cause <e2>apnea</e2>, hypotension, and bradycardia; continued episodes of atrial flutter in a child may cause sudden death; quinidine may be related to the death; children with "familial seizure disorders" may in fact have the long QT interval syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7060	"Intravenous <e1>verapamil</e1> therapy in babies may cause apnea, hypotension, and bradycardia; continued episodes of <e2>atrial flutter</e2> in a child may cause sudden death; quinidine may be related to the death; children with "familial seizure disorders" may in fact have the long QT interval syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7061	"Intravenous <e1>verapamil</e1> therapy in babies may cause apnea, hypotension, and <e2>bradycardia</e2>; continued episodes of atrial flutter in a child may cause sudden death; quinidine may be related to the death; children with "familial seizure disorders" may in fact have the long QT interval syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7062	"Intravenous verapamil therapy in babies may cause apnea, hypotension, and bradycardia; continued episodes of atrial flutter in a child may cause sudden <e1>death</e1>; <e2>quinidine</e2> may be related to the <e1>death</e1>; children with "familial seizure disorders" may in fact have the long QT interval syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7063	"Intravenous <e1>verapamil</e1> therapy in babies may cause apnea, <e2>hypotension</e2>, and bradycardia; continued episodes of atrial flutter in a child may cause sudden death; quinidine may be related to the death; children with "familial seizure disorders" may in fact have the long QT interval syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7064	"Intravenous verapamil therapy in babies may cause apnea, hypotension, and bradycardia; continued episodes of atrial flutter in a child may cause sudden death; <e1>quinidine</e1> may be related to the death; children with "familial seizure disorders" may in fact have the <e2>long QT interval syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7065	"Intravenous <e1>verapamil</e1> therapy in babies may cause apnea, hypotension, and bradycardia; continued episodes of atrial flutter in a child may cause <e2>sudden death</e2>; quinidine may be related to the death; children with "familial seizure disorders" may in fact have the long QT interval syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7066	"<e1>Methimazole</e1> -associated <e2>cholestatic liver injury</e2>: case report and brief literature review."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7067	"The authors report a further case of <e1>methimazole</e1> -associated <e2>liver damage</e2> and present a brief review of eleven previous cases found in the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7068	"The main clinical features of this 58-year-old female patient were laboratory evidence of leucopenia and cholestasis, and biopsy features of fatty liver parenchyma degeneration with granulocytic portal infiltration and <e1>bile stasis</e1>, demonstrated 20 days after the initiation of antithyroid therapy with 20 mg <e2>methimazole</e2> daily."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7069	"The main clinical features of this 58-year-old female patient were laboratory evidence of leucopenia and <e1>cholestasis</e1>, and biopsy features of fatty liver parenchyma degeneration with granulocytic portal infiltration and bile stasis, demonstrated 20 days after the initiation of antithyroid therapy with 20 mg <e2>methimazole</e2> daily."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7070	"The main clinical features of this 58-year-old female patient were laboratory evidence of leucopenia and cholestasis, and biopsy features of <e1>fatty liver parenchyma degeneration</e1> with granulocytic portal infiltration and bile stasis, demonstrated 20 days after the initiation of antithyroid therapy with 20 mg <e2>methimazole</e2> daily."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7071	"The main clinical features of this 58-year-old female patient were laboratory evidence of leucopenia and cholestasis, and biopsy features of fatty liver parenchyma degeneration with <e1>granulocytic portal infiltration</e1> and bile stasis, demonstrated 20 days after the initiation of antithyroid therapy with 20 mg <e2>methimazole</e2> daily."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7072	"The main clinical features of this 58-year-old female patient were laboratory evidence of <e1>leucopenia</e1> and cholestasis, and biopsy features of fatty liver parenchyma degeneration with granulocytic portal infiltration and bile stasis, demonstrated 20 days after the initiation of antithyroid therapy with 20 mg <e2>methimazole</e2> daily."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7073	"<e1>Fibrosis of corpus cavernosum</e1> after intracavernous injection of phentolamine/<e2>papaverine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7074	"<e1>Fibrosis of corpus cavernosum</e1> after intracavernous injection of <e2>phentolamine</e2>/papaverine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7075	"We report a case of <e1>penile fibrosis</e1> after intracavernous self-injection of a combination of phentolamine and <e2>papaverine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7076	"We report a case of <e1>penile fibrosis</e1> after intracavernous self-injection of a combination of <e2>phentolamine</e2> and papaverine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7077	"A 57-year-old woman developed <e1>pulmonary sarcoidosis</e1> during therapy with <e2>interferon beta</e2> for advanced renal cell carcinoma metastatic to mediastinal lymph nodes."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7078	"The possible role of <e1>interferon beta</e1> in the pathogenesis of <e2>sarcoidosis</e2> in this patient is discussed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7079	"<e1>Fatal outcome</e1> of intravesical <e2>formalin</e2> instillation, with changes mimicking renal tuberculosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7080	"We present a case report of a patient with alveolar hydatid disease, whose treatment with <e1>mebendazole</e1> was brief due to side effects of <e2>alopecia</e2> and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7081	"We present a case report of a patient with alveolar hydatid disease, whose treatment with <e1>mebendazole</e1> was brief due to side effects of alopecia and <e2>granulocytopenia</e2>; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7082	"Antibiotic-associated <e1>colitis</e1> (pseudomembranous <e1>colitis</e1>) developed in four patients with spinal cord injury and taking oral trimethoprim-<e2>sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7083	"Antibiotic-associated <e1>colitis</e1> (pseudomembranous <e1>colitis</e1>) developed in four patients with spinal cord injury and taking oral <e2>trimethoprim</e2> -sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7084	"Antibiotic-associated colitis (<e1>pseudomembranous colitis</e1>) developed in four patients with spinal cord injury and taking oral trimethoprim-<e2>sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7085	"Antibiotic-associated colitis (<e1>pseudomembranous colitis</e1>) developed in four patients with spinal cord injury and taking oral <e2>trimethoprim</e2> -sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7086	"<e1>Pseudomembranous colitis</e1> readily occurs in at least certain population groups receiving trimethoprim-<e2>sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7087	"<e1>Pseudomembranous colitis</e1> readily occurs in at least certain population groups receiving <e2>trimethoprim</e2> -sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7088	"A <e1>lethal complication</e1> of peripheral vein <e2>vasopressin</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7089	"The condition should be suspected in patients who develop unexplained <e1>abdominal pain</e1> or collapse following <e2>vasopressin</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7090	"The condition should be suspected in patients who develop unexplained abdominal pain or <e1>collapse</e1> following <e2>vasopressin</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7091	"Although adverse reactions to <e1>protamine</e1> are reported infrequently and are usually mild, we recently observed the first fatal case of <e2>type I anaphylaxis</e2> resulting from <e1>protamine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7092	"<e1>Protamine</e1> -induced <e2>fatal anaphylaxis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7093	"<e1>Ototoxicity</e1> as a result of <e2>cis-platinum</e2> administration is well documented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7094	"Controversy concerning the <e1>nephrotoxicity</e1> of <e2>lithium</e2> is discussed, and recommendations for the evaluation of renal failure during <e2>lithium</e2> therapy are provided."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7095	"Controversy concerning the nephrotoxicity of <e1>lithium</e1> is discussed, and recommendations for the evaluation of <e2>renal failure</e2> during <e1>lithium</e1> therapy are provided."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7096	"Controversy concerning the nephrotoxicity of <e1>lithium</e1> is discussed, and recommendations for the evaluation of <e2>renal failure</e2> during <e1>lithium</e1> therapy are provided."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7097	"Administration of intravenous <e1>nitroglycerin</e1> in a patient with idiopathic pulmonary hypertension resulted in an increase in pulmonary artery pressure associated with a <e2>decrease in blood flow</e2> that is best explained by an increase in pulmonary vascular resistance."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7098	"Administration of intravenous <e1>nitroglycerin</e1> in a patient with idiopathic pulmonary hypertension resulted in an <e2>increase in pulmonary artery pressure</e2> associated with a decrease in blood flow that is best explained by an increase in pulmonary vascular resistance."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7099	"Administration of intravenous <e1>nitroglycerin</e1> in a patient with idiopathic pulmonary hypertension resulted in an increase in pulmonary artery pressure associated with a decrease in blood flow that is best explained by an <e2>increase in pulmonary vascular resistance</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7100	"<e1>Paradoxical pulmonary vasoconstriction</e1> induced by <e2>nitroglycerin</e2> in idiopathic pulmonary hypertension."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7101	"<e1>Atrioventricular block</e1> complicating <e2>amiodarone</e2> -induced hypothyroidism in a patient with pre-excitation and rate-dependent bilateral bundle branch block."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7102	"Atrioventricular block complicating <e1>amiodarone</e1> -induced <e2>hypothyroidism</e2> in a patient with pre-excitation and rate-dependent bilateral bundle branch block."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7103	"Such a case induced by <e1>hypothyroidism</e1> complicating long-term therapy with <e2>amiodarone</e2> in a 45 year old woman with pre-excitation is presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7104	"<e1>Ampicillin</e1> increased the preexisting <e2>electrical decrement</e2> in three rabbits with experimental autoimmune myasthenia gravis while the drug had no deleterious effects in less affected or normal animals."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7105	"<e1>Ampicillin</e1> may aggravate clinical and experimental <e2>myasthenia gravis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7106	"Myasthenic patients receiving <e1>ampicillin</e1> should be closely monitored for possible <e2>acute exacerbations</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7107	"One patient had <e1>severe temporary weakness</e1> after an <e2>ampicillin sodium</e2> challenge."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7108	"A study following large patient groups on <e1>theophylline</e1> and a combination of <e1>theophylline</e1> and steroids might clarify the risk of <e2>ulcer</e2> formation in patients being treated with these medications for asthma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7109	"A study following large patient groups on <e1>theophylline</e1> and a combination of <e1>theophylline</e1> and steroids might clarify the risk of <e2>ulcer</e2> formation in patients being treated with these medications for asthma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7110	"We presented a patient with status asthmaticus treated with a combination of theophylline and <e1>prednisone</e1> who developed a <e2>perforated gastric ulcer</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7111	"We presented a patient with status asthmaticus treated with a combination of <e1>theophylline</e1> and prednisone who developed a <e2>perforated gastric ulcer</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7112	"A case of <e1>propranolol</e1> overdose complicated by <e2>esophageal spasm</e2> preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7113	"<e1>Esophageal spasm</e1> following <e2>propranolol</e2> overdose relieved by glucagon."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7114	"<e1>Hypotension</e1> and sinus arrest with <e2>nifedipine</e2> in pulmonary hypertension."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7115	"Hypotension and <e1>sinus arrest</e1> with <e2>nifedipine</e2> in pulmonary hypertension."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7116	"A patient presented with a <e1>painful, oedematous, cyanosed hand</e1> having injected a solution of <e2>diamorphine</e2> and methylphenidate into his radial artery."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7117	"A patient presented with a <e1>painful, oedematous, cyanosed hand</e1> having injected a solution of diamorphine and <e2>methylphenidate</e2> into his radial artery."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7118	"<e1>Ischaemia</e1> following selfadministered intra-arterial injection of methylphenidate and <e2>diamorphine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7119	"<e1>Ischaemia</e1> following selfadministered intra-arterial injection of <e2>methylphenidate</e2> and diamorphine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7120	"<e1>Chronic photosensitivity</e1> associated with <e2>hydrochlorothiazide</e2> ingestion occurred in four patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7121	"<e1>Cardiac decompensation</e1> following <e2>verapamil</e2> therapy in infants with supraventricular tachycardia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7122	"However, each infant demonstrated <e1>hemodynamic decompensation</e1> shortly after <e2>verapamil</e2> administration and required cardiopulmonary resuscitation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7123	"The risk of <e1>cardiac decompensation</e1> in infants with supraventricular tachycardia and congestive cardiac failure should be kept in mind prior to administration of <e2>verapamil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7124	"Pneumonitis with pleural and pericardial effusion and <e1>neuropathy</e1> during <e2>amiodarone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7125	"Pneumonitis with <e1>pleural and pericardial effusion</e1> and neuropathy during <e2>amiodarone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7126	"<e1>Pneumonitis</e1> with pleural and pericardial effusion and neuropathy during <e2>amiodarone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7127	"Review of this and previously reported cases indicates the need for early diagnosis of <e1>amiodarone</e1> <e2>pneumonitis</e2>, immediate withdrawal of <e1>amiodarone</e1>, and prompt but continued steroid therapy to ensure full recovery."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7128	"<e1>Heparin</e1> -induced <e2>hyperkalemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7129	"Our findings suggest that <e1>hyperkalemia</e1> can develop with the use of low-dose <e2>heparin</e2>, within seven days of initiating <e2>heparin</e2> therapy, and that patients with diabetes mellitus or chronic renal insufficiency are especially predisposed to this complication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7130	"Our findings suggest that <e1>hyperkalemia</e1> can develop with the use of low-dose <e2>heparin</e2>, within seven days of initiating <e2>heparin</e2> therapy, and that patients with diabetes mellitus or chronic renal insufficiency are especially predisposed to this complication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7131	"We present four cases in which the use of <e1>heparin</e1> was associated with <e2>hyperkalemia</e2> and discuss the pathophysiology."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7132	"While most physicians are aware of <e1>heparin</e1> -induced thrombocytopenia and skin necrosis, the association of <e1>heparin</e1> and <e2>hyperkalemia</e2> is less well recognized."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7133	"While most physicians are aware of <e1>heparin</e1> -induced thrombocytopenia and <e2>skin necrosis</e2>, the association of <e1>heparin</e1> and hyperkalemia is less well recognized."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7134	"While most physicians are aware of <e1>heparin</e1> -induced <e2>thrombocytopenia</e2> and skin necrosis, the association of <e1>heparin</e1> and hyperkalemia is less well recognized."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7135	"Careful follow-up of so-called "self-limited" <e1>insulin</e1> <e2>edema</e2> is encouraged, and the early institution of diuretic therapy is advocated in elderly patients to prevent the development of overt cardiac failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7136	"<e1>Insulin</e1> -induced <e2>cardiac failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7137	"<e1>Self-limited edema</e1> is a well-recognized complication of <e2>insulin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7138	"This report describes the first case of <e1>insulin</e1> -induced <e2>cardiac failure</e2> in a patient without underlying heart disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7139	"A case of <e1>pyridoxine</e1> -dependent <e2>seizures</e2> is reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7140	"Administration of <e1>pyridoxine</e1> to an infant after a long period of convulsions was followed by <e2>acute hypotonia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7141	"Prolonged <e1>severe cholestasis</e1> induced by <e2>oxacillin</e2> derivatives."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7142	"Two patients with osteomyelitis who developed <e1>reversible cholestatic jaundice</e1> during treatment with <e2>oxacillin</e2> derivatives are described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7143	"In all the patients, <e1>pellagra</e1> symptoms appeared during <e2>isoniazid</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7144	"<e1>Isoniazid</e1> inhibits the conversion of tryptophan to niacin and may induce <e2>pellagra</e2>, particularly in poorly nourished patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7145	"<e1>Pellagra encephalopathy</e1> among tuberculous patients: its relation to <e2>isoniazid</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7146	"Pellagra should be suspected whenever tuberculous patients under treatment with <e1>isoniazid</e1> develop <e2>mental, neurological or gastrointestinal symptoms</e2>, even in the absence of typical pellagra dermatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7147	"Physicians should be aware of the potential for the development of <e1>RS</e1> among children who are receiving long-term <e2>aspirin</e2> therapy for the treatment of systemic inflammatory illnesses."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7148	"<e1>Reye syndrome</e1> (RS) is believed to occur infrequently among children receiving long-term <e2>aspirin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7149	"Reye syndrome (<e1>RS</e1>) is believed to occur infrequently among children receiving long-term <e2>aspirin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7150	"These findings support previous studies that showed that the use of <e1>aspirin</e1> during the antecedent illness may be a risk factor for the development of <e2>RS</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7151	"<e1>Atrial fibrillation</e1> was induced by <e2>diltiazem</e2> in two patients and verapamil induced syncope in one patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7152	"Atrial fibrillation was induced by diltiazem in two patients and <e1>verapamil</e1> induced <e2>syncope</e2> in one patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7153	"A 54-year-old man, treated with <e1>amiodarone</e1>, developed <e2>thyrotoxicosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7154	"<e1>Amiodarone</e1> -induced <e2>dysthyroidism</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7155	"IV <e1>propranolol</e1> was used as the initial treatment for his hyperadrenergic state, resulting in a <e2>decrease in heart rate</e2> but a paroxsymal increase in blood pressure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7156	"IV <e1>propranolol</e1> was used as the initial treatment for his hyperadrenergic state, resulting in a decrease in heart rate but a <e2>paroxsymal increase in blood pressure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7157	"<e1>Propranolol</e1> -induced <e2>hypertension</e2> in treatment of cocaine intoxication."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7158	"According to the literature, <e1>chlorambucil</e1> <e2>central nervous toxicity</e2> is found almost exclusively in childhood nephrotic syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7159	"<e1>Chlorambucil</e1> <e2>central nervous toxicity</e2>: a significant side effect of chlorambucil therapy in childhood nephrotic syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7160	"<e1>EEG abnormalities</e1> were observed in two of the nine children during <e2>chlorambucil</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7161	"A 35-year-old man with seropositive rheumatoid arthritis developed selective <e1>IgA deficiency</e1> during treatment with <e2>fenclofenac</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7162	"<e1>Fenclofenac</e1> -induced selective <e2>IgA deficiency</e2> in rheumatoid arthritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7163	"This case demonstrates the association of selective <e1>IgA deficiency</e1> with remission in rheumatoid arthritis induced by fenclofenac as well as <e2>aurothiomalate</e2> and sulphasalazine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7164	"This case demonstrates the association of selective <e1>IgA deficiency</e1> with remission in rheumatoid arthritis induced by <e2>fenclofenac</e2> as well as aurothiomalate and sulphasalazine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7165	"This case demonstrates the association of selective <e1>IgA deficiency</e1> with remission in rheumatoid arthritis induced by fenclofenac as well as aurothiomalate and <e2>sulphasalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7166	"A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance <e1>lithium</e1> therapy developed a <e2>movement disorder</e2> following high doses of trazodone for treatment of an acute depression."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7167	"A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a <e1>movement disorder</e1> following high doses of <e2>trazodone</e2> for treatment of an acute depression."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7168	"Although the <e1>movement disorder</e1> could not with certainty be attributed to <e2>trazodone</e2> alone, the drug at least acted as an eliciting agent."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7169	"The elicitation of a <e1>movement disorder</e1> by <e2>trazodone</e2>: case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7170	"When the <e1>trazodone</e1> was reduced, the <e2>involuntary movements</e2> promptly ceased."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7171	"A review of the literature showed no previous description of this pattern in <e1>benzodiazepine</e1> <e2>coma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7172	"<e1>Spindle coma</e1> in <e2>benzodiazepine</e2> toxicity: case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7173	"Two reports of <e1>spindle coma</e1> are noted with alcohol and <e2>imipramine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7174	"A literature review revealed 83 other reported cases of <e1>rifampicin</e1> -induced <e2>renal insufficiency</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7175	"<e1>Renal failure</e1> is a rare complication associated with the use of <e2>rifampicin</e2> for the treatment of tuberculosis, usually occurring well into the course of therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7176	"<e1>Rifampicin</e1> -induced <e2>renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7177	"The following is a report of 2 cases of <e1>rifampicin</e1> -induced <e2>renal insufficiency</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7178	"<e1>Cerebral and ocular toxicity</e1> induced by <e2>desferrioxamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7179	"Subsequent in vivo/vitro studies clearly demonstrated that the <e1>neurological effects</e1> were due to a synergistic action of <e2>desferrioxamine</e2> and prochlorperazine, probably resulting in exceptional fluxes of intra/extra cellular iron/copper disturbing noradrenergic and serotonergic systems."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7180	"Subsequent in vivo/vitro studies clearly demonstrated that the <e1>neurological effects</e1> were due to a synergistic action of desferrioxamine and <e2>prochlorperazine</e2>, probably resulting in exceptional fluxes of intra/extra cellular iron/copper disturbing noradrenergic and serotonergic systems."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7181	"Two of these patients, who also received the anti-emetic <e1>prochlorperazine</e1>, <e2>lost consciousness</e2> for 48-72 h and then fully recovered."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7182	"Two other patients who did not receive prochlorperazine, developed <e1>retinal problems</e1> which later improved, one after only 15 g of <e2>desferrioxamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7183	"<e1>Gold</e1> <e2>nephropathy</e2>: tissue analysis by X-ray fluorescent spectroscopy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7184	"These findings are consistent with an immune-complex form of glomerulopathy in which <e1>gold</e1> is neither the antigen nor a hapten in the glomerular deposits, and they suggest the hypothesis that antibodies to tubular epithelial antigens induced by <e1>gold</e1> therapy may be a causative factor in the <e2>renal disease</e2> associated with <e1>gold</e1> therapy in rheumatoid arthritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7185	"These findings are consistent with an immune-complex form of glomerulopathy in which <e1>gold</e1> is neither the antigen nor a hapten in the glomerular deposits, and they suggest the hypothesis that antibodies to tubular epithelial antigens induced by <e1>gold</e1> therapy may be a causative factor in the <e2>renal disease</e2> associated with <e1>gold</e1> therapy in rheumatoid arthritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7186	"Three patients developed <e1>proteinuria</e1> following <e2>gold</e2> therapy for rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7187	"Four cases of <e1>fat embolism</e1> are described in infants receiving prolonged intravenous infusion of fat (<e2>Intralipid</e2> 20%)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7188	"Conversely, diffuse interstitial pulmonary fibrosis should be considered in the differential diagnosis of patients receiving <e1>methotrexate</e1> who develop <e2>bilateral pulmonary infiltrates</e2> seen on chest roentgenograms."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7189	"Conversely, <e1>diffuse interstitial pulmonary fibrosis</e1> should be considered in the differential diagnosis of patients receiving <e2>methotrexate</e2> who develop bilateral pulmonary infiltrates seen on chest roentgenograms."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7190	"In all three cases, autopsy revealed gross and microscopic features indistinguishable from those seen in the Hamman-Rich syndrome, and <e1>methotrexate</e1> <e2>hepatotoxicity</e2> was present in one."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7191	"It is suggested therefore that <e1>methotrexate</e1> be added to the list of agents capable of inducing <e2>diffuse interstitial pulmonary fibrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7192	"<e1>Methotrexate</e1> -induced <e2>diffuse interstitial pulmonary fibrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7193	"Pulmonary eosinophilia or <e1>granulomas</e1>, classically seen in previously reported cases of <e2>methotrexate</e2> pneumonitis, were not observed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7194	"Pulmonary eosinophilia or granulomas, classically seen in previously reported cases of <e1>methotrexate</e1> <e2>pneumonitis</e2>, were not observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7195	"<e1>Pulmonary eosinophilia</e1> or granulomas, classically seen in previously reported cases of <e2>methotrexate</e2> pneumonitis, were not observed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7196	"Three patients received respectively 190 mg, 175 mg, and 196 mg of <e1>methotrexate</e1> and developed <e2>bilateral pulmonary infiltrates</e2> without evidence of peripheral blood eosinophilia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7197	"A patient with disseminated herpes zoster developed a syndrome of inappropriate antidiuretic hormone and profound <e1>hyponatremia</e1> secondary to the administration of <e2>adenine arabinoside</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7198	"A patient with disseminated herpes zoster developed a <e1>syndrome of inappropriate antidiuretic hormone</e1> and profound hyponatremia secondary to the administration of <e2>adenine arabinoside</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7199	"<e1>Inappropriate antidiuretic hormone</e1> following <e2>adenine arabinoside</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7200	"The toxic effects of <e1>methotrexate</e1> included elevated liver transaminases (3/4), nausea (2/4), <e2>abdominal pain</e2> (2/4), bone pain (2/4), mild neutropenia (1/4), and mild pruritus (1/4)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7201	"The toxic effects of <e1>methotrexate</e1> included elevated liver transaminases (3/4), nausea (2/4), abdominal pain (2/4), <e2>bone pain</e2> (2/4), mild neutropenia (1/4), and mild pruritus (1/4)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7202	"The toxic effects of <e1>methotrexate</e1> included <e2>elevated liver transaminases</e2> (3/4), nausea (2/4), abdominal pain (2/4), bone pain (2/4), mild neutropenia (1/4), and mild pruritus (1/4)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7203	"The toxic effects of <e1>methotrexate</e1> included elevated liver transaminases (3/4), nausea (2/4), abdominal pain (2/4), bone pain (2/4), <e2>mild neutropenia</e2> (1/4), and mild pruritus (1/4)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7204	"The toxic effects of <e1>methotrexate</e1> included elevated liver transaminases (3/4), nausea (2/4), abdominal pain (2/4), bone pain (2/4), mild neutropenia (1/4), and <e2>mild pruritus</e2> (1/4)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7205	"The toxic effects of <e1>methotrexate</e1> included elevated liver transaminases (3/4), <e2>nausea</e2> (2/4), abdominal pain (2/4), bone pain (2/4), mild neutropenia (1/4), and mild pruritus (1/4)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7206	"<e1>Dystonia</e1> associated with <e2>carbamazepine</e2> administration: experience in brain-damaged children."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7207	"In one child, a second course of <e1>carbamazepine</e1> resulted in a return of the <e2>dystonia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7208	"The currently available clinical and neuropharmacologic data suggest that <e1>carbamazepine</e1> may be an antagonist of dopamine and that this property is responsible for the production of <e2>dystonia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7209	"We have cared for three children in whom four episodes of <e1>dystonia</e1> proceeding to opisthotonus occurred in association with <e2>carbamazepine</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7210	"We have cared for three children in whom four episodes of dystonia proceeding to <e1>opisthotonus</e1> occurred in association with <e2>carbamazepine</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7211	"Aplastic anemia and <e1>agranulocytosis</e1> in patients using <e2>methazolamide</e2> for glaucoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7212	"<e1>Aplastic anemia</e1> and agranulocytosis in patients using <e2>methazolamide</e2> for glaucoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7213	"Several case reports of <e1>aplastic anemia</e1> with use of <e2>acetazolamide</e2>, and two cases with use of methazolamide, have appeared in the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7214	"Several case reports of <e1>aplastic anemia</e1> with use of acetazolamide, and two cases with use of <e2>methazolamide</e2>, have appeared in the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7215	"This article describes two cases of aplastic anemia, at least one of which was almost certainly induced by the use of <e1>methazolamide</e1>, and one case of <e2>agranulocytosis</e2> related to the use of <e1>methazolamide</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7216	"This article describes two cases of <e1>aplastic anemia</e1>, at least one of which was almost certainly induced by the use of <e2>methazolamide</e2>, and one case of agranulocytosis related to the use of <e2>methazolamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7217	"<e1>Squamous-cell carcinoma</e1> arising in a basal-cell epithelioma treated with <e2>5-fluorouracil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7218	"We report the development of <e1>squamous-cell carcinoma</e1> within a basal-cell epithelioma that was treated with intralesional injections of <e2>5-FU</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7219	"Lower extremity <e1>arterial insufficiency</e1> after long-term <e2>methysergide maleate</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7220	"The patient whose case is reviewed had <e1>migraine headaches</e1> and received <e2>methysergide</e2> maleate for 13 years."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7221	"A case of <e1>Erythema Multiforme Bullosum</e1> in patient of lepromatous leprosy with pulmonary tuberculosis due to <e2>Rifampicin</e2> is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7222	"<e1>Erythema multiforme bullosum</e1> due to <e2>rifampicin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7223	"<e1>Renal damage</e1> associated with long term use of <e2>lithium carbonate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7224	"The authors report 2 cases of <e1>renal damage</e1> associated with <e2>lithium carbonate</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7225	"In two patients with mycosis fungoides, a <e1>squamous cell carcinoma</e1> developed during therapy with <e2>psoralens</e2> plus long-wave ultraviolet radiation (PUVA)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7226	"Hyperglycemia and <e1>diabetic coma</e1>: possible relationship to diuretic-<e2>propranolol</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7227	"<e1>Hyperglycemia</e1> and diabetic coma: possible relationship to diuretic-<e2>propranolol</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7228	"Two patients developed <e1>diabetic coma</e1> when taking a combination of a thiazide diuretic and <e2>propranolol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7229	"Two patients developed <e1>diabetic coma</e1> when taking a combination of a <e2>thiazide</e2> diuretic and propranolol."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7230	"An insulin-dependent diabetic patient with nephropathy developed <e1>severe acidosis</e1> after treatment with <e2>acetazolamide</e2> for glaucoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7231	"<e1>Severe acidosis</e1> from <e2>acetazolamide</e2> in a diabetic patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7232	"This progressed to <e1>tracheal compression</e1> with stridor after he had taken some <e2>aspirin</e2> for relief of the neck pain."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7233	"Five cases of <e1>clindamycin</e1> -associated <e2>pseudomembranous colitis</e2> in leukaemic patients are reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7234	"An infertile patient with amenorrhea-galactorrhea syndrome <e1>lost vision</e1> during a pregnancy occurring after <e2>Bromocryptine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7235	"<e1>Fatal acute tubular necrosis</e1> occurred in 1 patient in whom intravesical <e2>formalin</e2> was used to control massive persistent hemorrhage from radiation cystitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7236	"<e1>Fatal complication</e1> of intravesical <e2>formalin</e2> during control of intractable hemorrhage from radiation cystitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7237	"Intravenous sodium bicarbonate appears to be indicated prophylactically in combating the associated <e1>metabolic acidosis</e1> due to absorbed <e2>formic acid</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7238	"A young woman developed <e1>galactorrhea</e1> during treatment with a new dibenzoxazepine antidepressant, <e2>amoxapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7239	"A young woman developed <e1>galactorrhea</e1> during treatment with a new <e2>dibenzoxazepine</e2> antidepressant, amoxapine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7240	"A <e1>15-kg weight gain</e1> developed in a patient during the third week of <e2>ibuprofen</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7241	"<e1>Edema</e1> associated with <e2>ibuprofen</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7242	"It should be recognized that <e1>ibuprofen</e1> may be associated with <e2>salt and water retention</e2> in the same fashion as previously described with phenylbutazone and indomethacin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7243	"It should be recognized that ibuprofen may be associated with <e1>salt and water retention</e1> in the same fashion as previously described with phenylbutazone and <e2>indomethacin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7244	"It should be recognized that ibuprofen may be associated with <e1>salt and water retention</e1> in the same fashion as previously described with <e2>phenylbutazone</e2> and indomethacin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7245	"<e1>Allopurinol</e1> -associated <e2>hand and foot deformities</e2> in chronic tophaceous gout."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7246	"<e1>Telescoped digits of the hands and feet</e1> developed in a 69-year-old male with severe chronic tophaceous gout during <e2>allopurinol</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7247	"A patient with coccidioidal meningitis was treated with intrathecally administered <e1>amphotericin B</e1>, and an <e2>acute toxic delirium</e2> with EEG abnormalities developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7248	"A patient with coccidioidal meningitis was treated with intrathecally administered <e1>amphotericin B</e1>, and an acute toxic delirium with <e2>EEG abnormalities</e2> developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7249	"<e1>Neurotoxicity</e1> of intrathecal administration of <e2>amphotericin B</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7250	"In keeping with findings in the literature, the <e1>aortic wall in this case was damaged</e1> by secondary changes following irradiation and <e2>Bleomycin</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7251	"Cardiac glycosides are thought to prevent <e1>doxorubicin</e1> <e2>cardiomyopathy</e2> by competitively inhibiting <e1>doxorubicin</e1> at its receptor sites, but ouabain has a much shorter half life than <e1>doxorubicin</e1> and its metabolites and so is less effective than digoxin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7252	"<e1>Doxorubicin</e1> <e2>cardiotoxicity</e2>: possible role of digoxin in its prevention."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7253	"<e1>Minor electrocardiographical changes</e1> were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving <e2>ouabain</e2>, and none of the 16 who were receiving digoxin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7254	"One other patient on <e1>digoxin</e1> stopped taking it and developed <e2>cardiomyopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7255	"One patient on <e1>ouabain</e1> also developed <e2>cardiomyopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7256	"A healthy, 30-year-old man, exposed to <e1>sulindac</e1> on two separate occasions, had an incapacitating <e2>isolated idential sensory neuropathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7257	"Sulindac (<e1>Clinoril</e1>), a nonsteroidal anti-inflammatory agent, has few reported <e2>neurologic toxic effects</e2>, all of which have been associated with systemic disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7258	"<e1>Sulindac</e1> (Clinoril), a nonsteroidal anti-inflammatory agent, has few reported <e2>neurologic toxic effects</e2>, all of which have been associated with systemic disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7259	"To our knowledge, we describe the first reported case of <e1>isolated paresthesia</e1> and peripheral neuropathy, without systemic involvement, secondary to <e2>sulindac</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7260	"To our knowledge, we describe the first reported case of isolated paresthesia and <e1>peripheral neuropathy</e1>, without systemic involvement, secondary to <e2>sulindac</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7261	"In addition, loading with one low oral dose of <e1>serine</e1> produced <e2>psychotic symptoms</e2> 5 h later which lasted 3-6 h."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7262	"Reversal of <e1>ergotamine</e1> -induced <e2>arteriospasm</e2> by mechanical intra-arterial dilatation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7263	"Two patients with imminent gangrene of the extremities caused by <e1>ergot</e1> -induced <e2>arteriospasm</e2> underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7264	"Two patients with imminent <e1>gangrene of the extremities</e1> caused by <e2>ergot</e2> -induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7265	"The authors describe a case of combined lithium and <e1>haloperidol</e1> toxicity characterized by <e2>hyperpyrexia</e2>, severe rigidity, mutism, and development of irreversible tardive dyskinesia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7266	"The authors describe a case of combined <e1>lithium</e1> and haloperidol toxicity characterized by <e2>hyperpyrexia</e2>, severe rigidity, mutism, and development of irreversible tardive dyskinesia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7267	"The authors describe a case of combined lithium and <e1>haloperidol</e1> toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of <e2>irreversible tardive dyskinesia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7268	"The authors describe a case of combined <e1>lithium</e1> and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of <e2>irreversible tardive dyskinesia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7269	"The authors describe a case of combined lithium and <e1>haloperidol</e1> toxicity characterized by hyperpyrexia, severe rigidity, <e2>mutism</e2>, and development of irreversible tardive dyskinesia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7270	"The authors describe a case of combined <e1>lithium</e1> and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, <e2>mutism</e2>, and development of irreversible tardive dyskinesia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7271	"The authors describe a case of combined lithium and <e1>haloperidol</e1> toxicity characterized by hyperpyrexia, <e2>severe rigidity</e2>, mutism, and development of irreversible tardive dyskinesia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7272	"The authors describe a case of combined <e1>lithium</e1> and haloperidol toxicity characterized by hyperpyrexia, <e2>severe rigidity</e2>, mutism, and development of irreversible tardive dyskinesia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7273	"The authors postulate that two types of combined <e1>lithium</e1> -neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a <e1>lithium</e1> toxicity that occurs in combination with phenothiazines, primarily thioridazine."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7274	"The authors postulate that two types of combined lithium-neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a <e1>lithium toxicity</e1> that occurs in combination with phenothiazines, primarily <e2>thioridazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7275	"The authors postulate that two types of combined <e1>lithium</e1> -neuroleptic toxicity occur: a <e2>neuroleptic malignant extrapyramidal syndrome</e2> and a <e1>lithium</e1> toxicity that occurs in combination with phenothiazines, primarily thioridazine."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7276	"The authors postulate that two types of combined lithium-neuroleptic toxicity occur: a <e1>neuroleptic malignant extrapyramidal syndrome</e1> and a lithium toxicity that occurs in combination with phenothiazines, primarily <e2>thioridazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7277	"<e1>Chlorambucil</e1> -induced <e2>chromosome damage</e2> to human lymphocytes is dose-dependent and cumulative."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7278	"<e1>Anaphylactoid reaction</e1> to 50% solution of <e2>dextrose</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7279	"Preliminary results suggest that the higher concentrations of <e1>dextrose</e1> induce <e2>increased histamine release</e2> from blood cells, and that this phenomenon is more marked in diabetic, and particularly diabetic-allergic, individuals."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7280	"Two patients with extrinsic asthma and coexistent insulin-dependent diabetes mellitus sustained an <e1>anaphylactoid reaction</e1> after the intravenous administration of 50% solution of <e2>dextrose</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7281	"<e1>Salicylate</e1> <e2>hepato toxicity</e2> in rheumatic fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7282	"Two children with rheumatic fever developed <e1>anicteric hepatitis</e1> while on high-dose <e2>aspirin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7283	"A 36-year-old man being treated with cisplatinum, vinblastine, and <e1>bleomycin</e1> for testicular carcinoma developed a dense left homonymous hemianopsia, <e2>encephalopathy</e2>, and a partial nondominant parietal lobe syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7284	"A 36-year-old man being treated with <e1>cisplatinum</e1>, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, <e2>encephalopathy</e2>, and a partial nondominant parietal lobe syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7285	"A 36-year-old man being treated with cisplatinum, <e1>vinblastine</e1>, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, <e2>encephalopathy</e2>, and a partial nondominant parietal lobe syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7286	"A 36-year-old man being treated with cisplatinum, vinblastine, and <e1>bleomycin</e1> for testicular carcinoma developed a dense <e2>left homonymous hemianopsia</e2>, encephalopathy, and a partial nondominant parietal lobe syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7287	"A 36-year-old man being treated with <e1>cisplatinum</e1>, vinblastine, and bleomycin for testicular carcinoma developed a dense <e2>left homonymous hemianopsia</e2>, encephalopathy, and a partial nondominant parietal lobe syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7288	"A 36-year-old man being treated with cisplatinum, <e1>vinblastine</e1>, and bleomycin for testicular carcinoma developed a dense <e2>left homonymous hemianopsia</e2>, encephalopathy, and a partial nondominant parietal lobe syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7289	"A 36-year-old man being treated with cisplatinum, vinblastine, and <e1>bleomycin</e1> for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a <e2>partial nondominant parietal lobe syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7290	"A 36-year-old man being treated with <e1>cisplatinum</e1>, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a <e2>partial nondominant parietal lobe syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7291	"A 36-year-old man being treated with cisplatinum, <e1>vinblastine</e1>, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a <e2>partial nondominant parietal lobe syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7292	"Transient left homonymous hemianopsia and <e1>encephalopathy</e1> following treatment of testicular carcinoma with cisplatinum, vinblastine, and <e2>bleomycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7293	"Transient left homonymous hemianopsia and <e1>encephalopathy</e1> following treatment of testicular carcinoma with <e2>cisplatinum</e2>, vinblastine, and bleomycin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7294	"Transient left homonymous hemianopsia and <e1>encephalopathy</e1> following treatment of testicular carcinoma with cisplatinum, <e2>vinblastine</e2>, and bleomycin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7295	"<e1>Transient left homonymous hemianopsia</e1> and encephalopathy following treatment of testicular carcinoma with cisplatinum, vinblastine, and <e2>bleomycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7296	"<e1>Transient left homonymous hemianopsia</e1> and encephalopathy following treatment of testicular carcinoma with <e2>cisplatinum</e2>, vinblastine, and bleomycin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7297	"<e1>Transient left homonymous hemianopsia</e1> and encephalopathy following treatment of testicular carcinoma with cisplatinum, <e2>vinblastine</e2>, and bleomycin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7298	"An association of granulocytopenia, <e1>eosinophilia</e1>, skin reaction and hepatitis during <e2>propylthiouracil</e2> (PTU) therapy for thyrotoxicosis in a 47 year old black female is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7299	"An association of granulocytopenia, <e1>eosinophilia</e1>, skin reaction and hepatitis during propylthiouracil (<e2>PTU</e2>) therapy for thyrotoxicosis in a 47 year old black female is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7300	"An association of <e1>granulocytopenia</e1>, eosinophilia, skin reaction and hepatitis during <e2>propylthiouracil</e2> (PTU) therapy for thyrotoxicosis in a 47 year old black female is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7301	"An association of <e1>granulocytopenia</e1>, eosinophilia, skin reaction and hepatitis during propylthiouracil (<e2>PTU</e2>) therapy for thyrotoxicosis in a 47 year old black female is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7302	"An association of granulocytopenia, eosinophilia, skin reaction and <e1>hepatitis</e1> during <e2>propylthiouracil</e2> (PTU) therapy for thyrotoxicosis in a 47 year old black female is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7303	"An association of granulocytopenia, eosinophilia, skin reaction and <e1>hepatitis</e1> during propylthiouracil (<e2>PTU</e2>) therapy for thyrotoxicosis in a 47 year old black female is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7304	"An association of granulocytopenia, eosinophilia, <e1>skin reaction</e1> and hepatitis during <e2>propylthiouracil</e2> (PTU) therapy for thyrotoxicosis in a 47 year old black female is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7305	"An association of granulocytopenia, eosinophilia, <e1>skin reaction</e1> and hepatitis during propylthiouracil (<e2>PTU</e2>) therapy for thyrotoxicosis in a 47 year old black female is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7306	"Multiple complications of <e1>propylthiouracil</e1> treatment: granulocytopenia, <e2>eosinophilia</e2>, skin reaction and hepatitis with lymphocyte sensitization."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7307	"Multiple complications of <e1>propylthiouracil</e1> treatment: <e2>granulocytopenia</e2>, eosinophilia, skin reaction and hepatitis with lymphocyte sensitization."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7308	"Multiple complications of <e1>propylthiouracil</e1> treatment: granulocytopenia, eosinophilia, skin reaction and <e2>hepatitis</e2> with lymphocyte sensitization."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7309	"Multiple complications of <e1>propylthiouracil</e1> treatment: granulocytopenia, eosinophilia, skin reaction and hepatitis with <e2>lymphocyte sensitization</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7310	"Multiple complications of <e1>propylthiouracil</e1> treatment: granulocytopenia, eosinophilia, <e2>skin reaction</e2> and hepatitis with lymphocyte sensitization."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7311	"A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and <e1>ataxia</e1> developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of <e2>pentobarbital</e2> and pyrilamine maleate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7312	"A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and <e1>ataxia</e1> developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and <e2>pyrilamine maleate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7313	"A toxic encephalopathy characterized by <e1>depressed level of consciousness</e1>, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of <e2>pentobarbital</e2> and pyrilamine maleate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7314	"A toxic encephalopathy characterized by <e1>depressed level of consciousness</e1>, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and <e2>pyrilamine maleate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7315	"A toxic encephalopathy characterized by depressed level of consciousness, <e1>marked irritability</e1>, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of <e2>pentobarbital</e2> and pyrilamine maleate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7316	"A toxic encephalopathy characterized by depressed level of consciousness, <e1>marked irritability</e1>, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and <e2>pyrilamine maleate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7317	"A <e1>toxic encephalopathy</e1> characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of <e2>pentobarbital</e2> and pyrilamine maleate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7318	"A <e1>toxic encephalopathy</e1> characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and <e2>pyrilamine maleate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7319	"<e1>Optic neuropathy</e1> associated with <e2>penicillamine</e2> therapy in a patient with rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7320	"<e1>Optic neuropathy</e1> developed in a patient with rheumatoid arthritis who had been receiving <e2>D-penicillamine</e2> for about 1 year."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7321	"The case resembles two previously reported cases of <e1>optic neuropathy</e1> which occurred in patients with Wilson's disease who were receiving <e2>penicillamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7322	"A patient developed transient, <e1>acute myopia</e1> while on isotretinoin (<e2>Accutane</e2>) therapy for acne."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7323	"A patient developed transient, <e1>acute myopia</e1> while on <e2>isotretinoin</e2> (Accutane) therapy for acne."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7324	"There was a clear relationship between restarting the <e1>Accutane</e1> and recurrence of the <e2>transient myopia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7325	"<e1>Transient acute myopia</e1> resulting from isotretinoin (<e2>accutane</e2>) therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7326	"<e1>Transient acute myopia</e1> resulting from <e2>isotretinoin</e2> (accutane) therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7327	"<e1>Allergic contact dermatitis</e1> to compound tincture of <e2>benzoin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7328	"Nineteen cases of <e1>allergic contact dermatitis</e1> to compound tincture of <e2>benzoin</e2> are described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7329	"Autopsy evidence of <e1>herpesvirus infection</e1> was found in visceral organs of four leukemic patients who had received large doses of cytarabine (cytosine arabinoside; <e2>Ara-C</e2>) shortly before their death."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7330	"Autopsy evidence of <e1>herpesvirus infection</e1> was found in visceral organs of four leukemic patients who had received large doses of <e2>cytarabine</e2> (cytosine arabinoside; Ara-C) shortly before their death."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7331	"Autopsy evidence of <e1>herpesvirus infection</e1> was found in visceral organs of four leukemic patients who had received large doses of cytarabine (<e2>cytosine arabinoside</e2>; Ara-C) shortly before their death."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7332	"In three of these patients the infection was clinically unsuspected; in the fourth, <e1>cutaneous herpes zoster</e1> developed after administration of 300 mg of <e2>cytarabine</e2> daily for the preceding five days."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7333	"<e1>Visceral herpesvirus infections</e1> in leukemic patients receiving <e2>cytarabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7334	"Clinical and morphological features of <e1>gold</e1> <e2>neuropathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7335	"Three cases of <e1>gold</e1> -related <e2>neuropathy</e2> are reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7336	"<e1>Intra-neural ceroid-like pigment</e1> following the treatment of lepromatous leprosy with clofazimine (<e2>B663</e2>; Lamprene)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7337	"<e1>Intra-neural ceroid-like pigment</e1> following the treatment of lepromatous leprosy with <e2>clofazimine</e2> (B663; Lamprene)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7338	"<e1>Intra-neural ceroid-like pigment</e1> following the treatment of lepromatous leprosy with clofazimine (B663; <e2>Lamprene</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7339	"One of these was <e1>clofazimine</e1>, an aniline aposafranine derivative known to produce a <e2>ceroid-like pigment</e2> in the tissues of patients treated with this drug or lepromatous leprosy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7340	"<e1>Severe neurotoxicity</e1> with <e2>methyl G: CALGB</e2> experience."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7341	"A young patient experienced marked <e1>sinus tachycardia</e1> while smoking marijuana and receiving therapeutic doses of <e2>nortriptyline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7342	"Marked <e1>sinus tachycardia</e1> resulting from the synergistic effects of marijuana and <e2>nortriptyline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7343	"It is concluded that '<e1>cerebral atrophy</e1>' on CT scans may represent an accumulative effect of <e2>ACTH</e2> and that <e2>ACTH</e2> should be given with the utmost discretion, and in as low a dose as possible."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7344	"<e1>Disulfiram-like reactions</e1> with newer cephalosporins: <e2>cefmenoxime</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7345	"This is the first report of a <e1>disulfiram-like reaction</e1> with <e2>cefmenoxime</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7346	"k bipolar manic-depressive patient, developed while on <e1>lithium</e1> prophylaxis, <e2>akathisia</e2> at therapeutic serum <e1>lithium</e1> levels and subsequently bucco-linguo-masticatory dyskinesia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7347	"k bipolar manic-depressive patient, developed while on <e1>lithium</e1> prophylaxis, akathisia at therapeutic serum <e1>lithium</e1> levels and subsequently <e2>bucco-linguo-masticatory dyskinesia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7348	"<e1>Acute leukopenia</e1> associated with <e2>silver sulfadiazine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7349	"Patients from endemic areas referred to transplant centers may be at high risk for <e1>disseminated histoplasmosis</e1> when treated with long-term <e2>prednisone</e2> for graft-versus-host disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7350	"<e1>Acute renal failure</e1> most likely was secondary to the nephrotoxic effect of <e2>captopril</e2> on chronically hypoperfused kidneys."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7351	"In a patient with severe renovascular hypertension, <e1>nonoliguric acute renal failure</e1> developed after she received <e2>captopril</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7352	"<e1>Nonoliguric acute renal failure</e1> after <e2>captopril</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7353	"<e1>Captopril</e1> -induced <e2>acute reversible renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7354	"The 5 patients had severe renovascular disease which might thus represent a significant risk factor in the development of <e1>captopril</e1> -induced <e2>acute renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7355	"We report 5 cases of <e1>acute reversible renal failure</e1> coinciding with the onset of treatment with <e2>captopril</e2> in patients with severe drug-resistant hypertension."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7356	"A case of <e1>mania</e1> associated with <e2>fluoxetine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7357	"A depressed woman with no history of bipolar illness developed a <e1>manic episode</e1> during treatment with <e2>fluoxetine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7358	"<e1>Alopecia</e1>, nausea, and vomiting were attributed to the <e2>cyclophosphamide</e2> component of the therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7359	"Alopecia, <e1>nausea</e1>, and vomiting were attributed to the <e2>cyclophosphamide</e2> component of the therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7360	"Alopecia, nausea, and <e1>vomiting</e1> were attributed to the <e2>cyclophosphamide</e2> component of the therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7361	"<e1>Haemolytic-uraemic syndrome</e1> complicating long-term mitomycin C and <e2>5-fluorouracil</e2> therapy for gastric carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7362	"<e1>Haemolytic-uraemic syndrome</e1> complicating long-term <e2>mitomycin C</e2> and 5-fluorouracil therapy for gastric carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7363	"Three cases of <e1>acute renal toxicity</e1> in patients receiving long-term therapy with mitomycin C and <e2>5-fluorouracil</e2> are reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7364	"Three cases of <e1>acute renal toxicity</e1> in patients receiving long-term therapy with <e2>mitomycin C</e2> and 5-fluorouracil are reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7365	"Oral <e1>25-hydroxyvitain D3</e1> in treatment of osteomalacia associated with <e2>ileal resection</e2> and cholestyramine therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7366	"Severe histological <e1>osteomalacia</e1> developed in a woman with Crohn's disease 2 years after ileal resection and the start of <e2>cholestyramine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7367	"Treatment of <e1>lithium</e1> <e2>tremor</e2> with metoprolol."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7368	"Two patients with bipolar affective disorder and a history of bronchospastic phenomena experienced <e1>tremor</e1> during <e2>lithium carbonate</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7369	"Intravenous <e1>diazepam</e1> exacerbated the <e2>seizures</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7370	"A 52-year-old Black woman on <e1>phenytoin</e1> therapy for post-traumatic epilepsy developed <e2>transient hemiparesis</e2> contralateral to the injury."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7371	"A possible mechanism for <e1>focal neurological deficit</e1> in brain-damaged patients on <e2>phenytoin</e2> therapy is discussed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7372	"<e1>Transient hemiparesis</e1> caused by <e2>phenytoin</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7373	"A 7-year-old boy developed a <e1>severe unilateral grand mal seizure</e1> at the age of 5 years (phenobarbitone therapy); 1.5 years later valproate (<e2>2-propylpentanoic acid</e2>, VPA) was added to the therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7374	"A 7-year-old boy developed a <e1>severe unilateral grand mal seizure</e1> at the age of 5 years (<e2>phenobarbitone</e2> therapy); 1.5 years later valproate (2-propylpentanoic acid, VPA) was added to the therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7375	"A 7-year-old boy developed a <e1>severe unilateral grand mal seizure</e1> at the age of 5 years (phenobarbitone therapy); 1.5 years later <e2>valproate</e2> (2-propylpentanoic acid, VPA) was added to the therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7376	"A 7-year-old boy developed a <e1>severe unilateral grand mal seizure</e1> at the age of 5 years (phenobarbitone therapy); 1.5 years later valproate (2-propylpentanoic acid, <e2>VPA</e2>) was added to the therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7377	"<e1>Cefoxitin</e1> therapy for Mycobacterium fortuitum bacteremia with associated <e2>granulomatous hepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7378	"<e1>Stroke-like syndrome</e1> after <e2>gold sodium thiomalate</e2> induced vasomotor reaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7379	"Stroke-like syndrome after <e1>gold sodium thiomalate</e1> induced <e2>vasomotor reaction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7380	"<e1>Vasomotor reactions</e1> after <e2>gold sodium thiomalate</e2> are well recognized."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7381	"<e1>Gold nephropathy</e1> due to <e2>auranofin</e2> obscured by tolmetin pseudoproteinuria."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7382	"<e2>Gold</e2> nephropathy due to auranofin obscured by tolmetin pseudoproteinuria."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7383	"<e1>Gold nephropathy</e1> due to auranofin obscured by <e2>tolmetin</e2> pseudoproteinuria."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7384	"Gold nephropathy due to auranofin obscured by <e1>tolmetin</e1> <e2>pseudoproteinuria</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7385	"A 52-year-old, white female developed low-grade fever, <e1>cough</e1>, and dyspnea after 8 weeks treatment with <e2>sodium aurothiomalate</e2> for rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7386	"A 52-year-old, white female developed low-grade fever, cough, and <e1>dyspnea</e1> after 8 weeks treatment with <e2>sodium aurothiomalate</e2> for rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7387	"A 52-year-old, white female developed <e1>low-grade fever</e1>, cough, and dyspnea after 8 weeks treatment with <e2>sodium aurothiomalate</e2> for rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7388	"Pulmonary <e2>gold</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7389	"<e1>Cyclophosphamide</e1> can rarely cause interstitial pneumonitis and <e2>fibrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7390	"<e1>Cyclophosphamide</e1> can rarely cause <e2>interstitial pneumonitis</e2> and fibrosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7391	"<e1>Cyclophosphamide</e1> <e2>pneumonitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7392	"The temporal sequence of the respiratory insufficiency and the histopathology, when compared to the previous examples in the literature, suggest that <e1>cyclophosphamide</e1> was aetiologically responsible for the <e2>lung disease</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7393	"The temporal sequence of the <e1>respiratory insufficiency</e1> and the histopathology, when compared to the previous examples in the literature, suggest that <e2>cyclophosphamide</e2> was aetiologically responsible for the lung disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7394	"A <e1>reversible toxic liver damage</e1> was observed in a non-alcoholic woman treated with <e2>disulfiram</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7395	"<e1>Toxic hepatitis</e1> induced by <e2>disulfiram</e2> in a non-alcoholic."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7396	"One type of SMON is associated with <e1>acrodermatitis enteropathica</e1> which has a very high frequency of occurrence in association with administration of <e2>clioquinol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7397	"One type of <e1>SMON</e1> is associated with acrodermatitis enteropathica which has a very high frequency of occurrence in association with administration of <e2>clioquinol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7398	"Four patients receiving high-dose <e1>tamoxifen</e1> for greater than 1 year have demonstrated similar <e2>retinal changes</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7399	"<e1>Tamoxifen</e1> <e2>retinopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7400	"These findings suggest that the <e1>corneal and retinal changes</e1> are the result of a toxic effect of <e2>tamoxifen</e2> when used in the doses and duration described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7401	"<e1>Mammary gigantism</e1> is a rare complication of <e2>D-penicillamine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7402	"Although they had complex medical problems, the high serum concentrations of <e1>ampicillin</e1> at the time of <e2>seizures</e2> without their recurrence after discontinuing the antibiotic suggest that the <e2>seizures</e2> were related to the <e1>ampicillin</e1> therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7403	"Although they had complex medical problems, the high serum concentrations of <e1>ampicillin</e1> at the time of <e2>seizures</e2> without their recurrence after discontinuing the antibiotic suggest that the <e2>seizures</e2> were related to the <e1>ampicillin</e1> therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7404	"<e1>Ampicillin</e1> -associated <e2>seizures</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7405	"Two patients had <e1>ampicillin</e1> -associated <e2>seizures</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7406	"After the patient discontinued <e1>rifampicin</e1>, the <e2>skin lesions</e2> cleared completely within 5 weeks without any systemic medication."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7407	"<e1>Pemphigus foliaceus</e1> induced by <e2>rifampicin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7408	"<e1>Pemphigus foliaceus</e1> was seen in a patient with pulmonary tuberculosis during <e2>rifampicin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7409	"<e1>Hyponatremia</e1> in patients treated with <e2>lorcainide</e2>, a new antiarrhythmic drug."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7410	"In eight patients, a mean <e1>decrease in serum Na+</e1> of 8.25 +/- 3.2 mEq/L was observed after a single 200 mg intravenous dose of <e2>lorcainide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7411	"It is concluded that <e1>SIADH</e1> is an important side effect of <e2>lorcainide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7412	"One patient developed <e1>severe hyponatremia</e1> with serum Na+ of 108 mEq/L when <e2>hydrochlorothiazide</e2> was given to control hypertension."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7413	"Sixteen of 33 patients developed significant <e1>hyponatremia</e1> and hypoosmolality during oral treatment with <e2>lorcainide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7414	"Sixteen of 33 patients developed significant hyponatremia and <e1>hypoosmolality</e1> during oral treatment with <e2>lorcainide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7415	"<e1>Acute intravascular hemolysis</e1> developed when a diabetic patient, previously treated with glyburide, was started on another oral sulfonylurea drug, <e2>chlorpropamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7416	"<e1>Acute intravascular hemolysis</e1> developed when a diabetic patient, previously treated with <e2>glyburide</e2>, was started on another oral sulfonylurea drug, chlorpropamide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7417	"<e1>Chlorpropamide</e1> -induced <e2>hemolytic anemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7418	"In a 61-year-old man receiving chronic low-dosage <e1>amiodarone</e1> an <e2>interstitial pneumopathy</e2> was observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7419	"<e1>Interstitial pneumopathy</e1> and low-dosage <e2>amiodarone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7420	"<e1>Alternating sinus rhythm</e1> and intermittent sinoatrial block induced by <e2>propranolol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7421	"Alternating sinus rhythm and <e1>intermittent sinoatrial block</e1> induced by <e2>propranolol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7422	"<e1>Alternating sinus rhythm</e1> and intermittent sinoatrial (S-A) block was observed in a 57-year-old woman, under treatment for angina with 80 mg <e2>propranolol</e2> daily."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7423	"Alternating sinus rhythm and <e1>intermittent sinoatrial (S-A) block</e1> was observed in a 57-year-old woman, under treatment for angina with 80 mg <e2>propranolol</e2> daily."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7424	"The <e1>abnormal rhythm</e1> disappeared with the withdrawal of <e2>propranolol</e2> and when the drug was restarted a 2/1 S-A block was seen."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7425	"This was accepted as evidence for <e1>propranolol</e1> being the cause of this <e2>conduction disorder</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7426	"A further case of <e1>anaphylactoid reaction</e1> to <e2>methylprednisolone</e2> is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7427	"<e1>Anaphylactoid reaction</e1> to <e2>methylprednisolone</e2> pulsed therapy for multiple sclerosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7428	"Although lung specimens were lacking from these three patients, it is suggested that the <e1>pulmonary toxicity</e1> of <e2>CCNU</e2> may be dose-related."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7429	"<e1>Pulmonary fibrosis</e1> subsequent to high doses of <e2>CCNU</e2> for chronic myeloid leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7430	"The responsibility of <e1>CCNU</e1> in the pathogenesis of <e2>pulmonary fibrosis</e2> seems very likely."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7431	"Two patients treated for chronic myeloid leukemia with high doses of <e1>CCNU</e1> (1100 mg/m2 and 1240 mg/m2, respectively) developed a <e2>fatal pulmonary fibrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7432	"<e1>Additive pulmonary toxicity</e1> with melphalan and <e2>busulfan</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7433	"<e1>Additive pulmonary toxicity</e1> with <e2>melphalan</e2> and busulfan therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7434	"We report a 59-year-old patient with chronic myeloid leukemia, who developed <e1>severe interstitial lung fibrosis</e1> after short term and sequential treatment with melphalan and <e2>busulfan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7435	"We report a 59-year-old patient with chronic myeloid leukemia, who developed <e1>severe interstitial lung fibrosis</e1> after short term and sequential treatment with <e2>melphalan</e2> and busulfan."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7436	"After taking <e1>cholestyramine II</e1> sachets twice daily for two months she presented with lethargy, <e2>confusion</e2> and drowsiness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7437	"After taking <e1>cholestyramine II</e1> sachets twice daily for two months she presented with lethargy, confusion and <e2>drowsiness</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7438	"After taking <e1>cholestyramine II</e1> sachets twice daily for two months she presented with <e2>lethargy</e2>, confusion and drowsiness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7439	"<e1>Cholestyramine</e1> induced <e2>hyperchloremic metabolic acidosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7440	"It is presumed that her <e1>hyperchloremic metabolic acidosis</e1> was secondary to <e2>cholestyramine</e2> because of the similarity to pediatric reports; the rapid and lasting response to intravenous sodium bicarbonate; the absence of another etiology; normal serum potassium, chloride and bicarbonate despite continued spironolactone therapy after recovery."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7441	"The first reported case, in an adult, of <e1>cholestyramine</e1> induced <e2>hyperchloremic metabolic acidosis</e2> is a 70 year old female with a two year history of primary biliary cirrhosis confirmed by histologic and immunologic criteria."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7442	"Although myelosuppression is mild, <e1>immunosuppression</e1> and superinfection are potential hazards of treatment with <e2>DCF</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7443	"Although myelosuppression is mild, immunosuppression and <e1>superinfection</e1> are potential hazards of treatment with <e2>DCF</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7444	"The ocular toxicity of <e1>DCF</e1>, previously described as <e2>conjunctivitis</e2>, appears to be a keratitis of moderate severity which requires further study."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7445	"The ocular toxicity of <e1>DCF</e1>, previously described as conjunctivitis, appears to be a <e2>keratitis</e2> of moderate severity which requires further study."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7446	"The <e1>ocular toxicity</e1> of <e2>DCF</e2>, previously described as conjunctivitis, appears to be a keratitis of moderate severity which requires further study."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7447	"Because there were no other obvious causes of renal failure in either patient, we propose that skeletal muscle ischemia developed during <e1>vasopressin</e1> infusion, followed by release of myoglobin and <e2>renal damage</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7448	"Because there were no other obvious causes of renal failure in either patient, we propose that <e1>skeletal muscle ischemia</e1> developed during <e2>vasopressin</e2> infusion, followed by release of myoglobin and renal damage."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7449	"Myoglobinuria and <e1>acute renal failure</e1> associated with intravenous <e2>vasopressin</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7450	"<e1>Myoglobinuria</e1> and acute renal failure associated with intravenous <e2>vasopressin</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7451	"Myoglobinuria and <e1>acute renal failure</e1> were observed in two patients with <e2>vasopressin</e2> -treated gastrointestinal hemorrhage."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7452	"<e1>Myoglobinuria</e1> and acute renal failure were observed in two patients with <e2>vasopressin</e2> -treated gastrointestinal hemorrhage."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7453	"A major limitation in the use of <e1>amphotericin B</e1> is its potential to cause <e2>nephrotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7454	"<e1>Amphotericin B</e1> <e2>nephrotoxicity</e2> in humans decreased by salt repletion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7455	"Experience with five patients in whom <e1>impaired renal function</e1> developed early during <e2>amphotericin B</e2> therapy is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7456	"<e1>Gynecomastia</e1> developed in two epileptic patients some months after the addition of oral <e2>fluoresone</e2> 750 mg daily to the phenobarbital and phenytoin already being administered."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7457	"<e1>Gynecomastia</e1> developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the <e2>phenobarbital</e2> and phenytoin already being administered."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7458	"<e1>Gynecomastia</e1> developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and <e2>phenytoin</e2> already being administered."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7459	"<e1>Gynecomastia</e1> in epileptics treated with phenobarbital, phenytoin and <e2>fluoresone</e2>: two case reports."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7460	"<e1>Gynecomastia</e1> in epileptics treated with <e2>phenobarbital</e2>, phenytoin and fluoresone: two case reports."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7461	"<e1>Gynecomastia</e1> in epileptics treated with phenobarbital, <e2>phenytoin</e2> and fluoresone: two case reports."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7462	"Case report of withdrawal <e1>dyskinesia</e1> associated with <e2>amoxapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7463	"Occurrence of withdrawal <e1>dyskinesia</e1> indicates that the neuroleptic effects of <e2>amoxapine</e2> may be clinically significant."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7464	"The authors describe a case of <e1>oral-facial dyskinesia</e1> that occurred after discontinuation of <e2>amoxapine</e2>, and antidepressant which may also have neuroleptic effects."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7465	"A case of <e1>toxic hepatitis</e1> caused by combination therapy with methotrexate and <e2>etretinate</e2> in the treatment of severe psoriasis is presented in a 47-year-old woman."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7466	"A case of <e1>toxic hepatitis</e1> caused by combination therapy with <e2>methotrexate</e2> and etretinate in the treatment of severe psoriasis is presented in a 47-year-old woman."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7467	"<e1>Toxic hepatitis</e1> due to combination therapy with methotrexate and <e2>etretinate</e2> in psoriasis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7468	"<e1>Toxic hepatitis</e1> due to combination therapy with <e2>methotrexate</e2> and etretinate in psoriasis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7469	"Metabolic balance studies and rechallenge with <e1>hydrochlorothiazide</e1> were undertaken to investigate the mechanism of the thiazide-induced <e2>hyponatremia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7470	"A 58-year-old woman developed <e1>unilateral acute angle-closure glaucoma</e1> four days after the application of a patch of transdermal <e2>scopolamine</e2> delivery system (TRANSDERM-V)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7471	"A case history of a 15-year-old boy who developed incapacitating <e1>tardive dyskinesia</e1> that resolved during treatment with <e2>deanol</e2> is presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7472	"<e1>Cephalosporins</e1> are most likely associated with <e2>Vitamin K deficiency</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7473	"<e1>Coagulopathy</e1> associated with the use of <e2>cephalosporin</e2> or moxalactam antibiotics in acute and chronic renal failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7474	"<e1>Coagulopathy</e1> associated with the use of cephalosporin or <e2>moxalactam</e2> antibiotics in acute and chronic renal failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7475	"<e1>Moxalactam</e1> is more likely to be associated with <e2>platelet dysfunction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7476	"Nevertheless, the <e1>coagulopathy</e1> seemed to be most closely associated with the administration of the <e2>cephalosporin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7477	"Nine azotemic patients who developed a <e1>coagulopathy</e1> associated with the use of either <e2>cephalosporin</e2> or moxalactam antibiotics are reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7478	"Nine azotemic patients who developed a <e1>coagulopathy</e1> associated with the use of either cephalosporin or <e2>moxalactam</e2> antibiotics are reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7479	"A case is reported of a child with <e1>fatal pulmonary fibrosis</e1> following <e2>BCNU</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7480	"<e1>Fatal pulmonary fibrosis</e1> following <e2>1,3-bis(2-chloroethyl)-1-nitrosourea</e2> (BCNU) therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7481	"<e1>Fatal pulmonary fibrosis</e1> following 1,3-bis(2-chloroethyl)-1-nitrosourea (<e2>BCNU</e2>) therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7482	"<e1>Thrombotic thrombocytopenic purpura</e1> during <e2>penicillamine</e2> therapy in rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7483	"<e1>Thrombotic thrombocytopenic purpura</e1> (TTP) developed in a patient with seropositive rheumatoid arthritis (RA) after 2 1/2 months of treatment with <e2>penicillamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7484	"Thrombotic thrombocytopenic purpura (<e1>TTP</e1>) developed in a patient with seropositive rheumatoid arthritis (RA) after 2 1/2 months of treatment with <e2>penicillamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7485	"To our knowledge, no prior cases of <e1>penicillamine</e1> -induced <e2>TTP</e2> in RA have been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7486	"<e1>Amiodarone hydrochloride</e1>, a new antiarrhythmic agent, has been associated with pulmonary toxicity characterized by <e2>cough</e2>, dyspnea and diffuse pulmonary infiltrates."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7487	"<e1>Amiodarone hydrochloride</e1>, a new antiarrhythmic agent, has been associated with pulmonary toxicity characterized by cough, dyspnea and <e2>diffuse pulmonary infiltrates</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7488	"<e1>Amiodarone hydrochloride</e1>, a new antiarrhythmic agent, has been associated with pulmonary toxicity characterized by cough, <e2>dyspnea</e2> and diffuse pulmonary infiltrates."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7489	"<e1>Amiodarone hydrochloride</e1>, a new antiarrhythmic agent, has been associated with <e2>pulmonary toxicity</e2> characterized by cough, dyspnea and diffuse pulmonary infiltrates."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7490	"Possible recurrence of <e1>amiodarone</e1> <e2>pulmonary toxicity</e2> following corticosteroid therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7491	"To our knowledge, this recurrence of <e1>amiodarone</e1> <e2>pulmonary toxicity</e2> has not been reported previously."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7492	"We describe a case of <e1>fibrosing alveolitis</e1>, diagnosed by lung biopsy, in a patient receiving <e2>amiodarone</e2> which responded to corticosteroid therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7493	"A 61 year-old male patient developed <e1>gynecomastia</e1> after starting <e2>theophylline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7494	"<e1>Gynecomastia</e1> associated with <e2>theophylline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7495	"No other endogenous or exogenous cause for the <e1>gynecomastia</e1> could be found except for the <e2>theophylline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7496	"The <e1>gynecomastia</e1> regressed when the <e2>theophylline</e2> was discontinued."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7497	"Parenteral-<e1>verapamil</e1> -induced <e2>sustained hypotension</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7498	"The incidence of oral-<e1>verapamil</e1> -induced <e2>hypotension</e2> in the presence of concomitant beta-adrenergic blockade by the oral route is quite rare."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7499	"We report a case of <e1>sustained hypotension</e1> after administration of parenteral <e2>verapamil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7500	"A 69-year-old man developed <e1>pure red cell aplasia</e1> after taking <e2>fenoprofen</e2> for ten months."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7501	"<e1>Pure red cell aplasia</e1> associated with <e2>fenoprofen</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7502	"This case represents the third example of <e1>erythroid aplasia</e1> associated with an anti-inflammatory agent and the first instance due to <e2>fenoprofen</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7503	"Drug-induced <e1>psychosis</e1> resulted from the administration of <e2>quinacrine hydrochloride</e2> at a dosage of 100 mg twice daily for the treatment of discoid lupus."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7504	"A case of <e1>priapism</e1> associated with <e2>trazodone</e2> is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7505	"<e1>Priapism</e1> associated with <e2>trazodone</e2> therapy: case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7506	"Charcoal haemoperfusion and cysteamine therapy led to the rapid removal of the <e1>paracetamol</e1> from the body and consequently prevented the development of <e2>severe hepatic necrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7507	"<e1>Anaphylactoid shock</e1>, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving <e2>zomepirac</e2> sodium for toothache."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7508	"Anaphylactoid shock, disseminated intravascular coagulation, and <e1>anuric renal failure</e1> requiring dialysis occurred in a patient receiving <e2>zomepirac</e2> sodium for toothache."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7509	"Anaphylactoid shock, <e1>disseminated intravascular coagulation</e1>, and anuric renal failure requiring dialysis occurred in a patient receiving <e2>zomepirac</e2> sodium for toothache."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7510	"<e1>Focal renal cortical necrosis</e1> associated with <e2>zomepirac</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7511	"The mechanism of <e1>anaphylactoid reaction</e1> to <e2>zomepirac</e2> in this case, therefore, remains unclear."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7512	"<e1>Cimetidine</e1> -induced <e2>fever</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7513	"<e1>Cimetidine</e1> is a rare cause of drug-induced <e2>fever</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7514	"A 56-year-old male parkinsonian patient developed a unique <e1>behavioral change</e1> following the oral administration of <e2>cinepazide</e2>, a cerebral vasodilator."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7515	"Unique <e1>behavioral change</e1> with <e2>cinepazide</e2> in parkinsonism."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7516	"A 65-year-old woman, in the intensive care unit because of septic shock and acute renal failure, had a <e1>small-bowel obstruction</e1> due to <e2>Amphojel</e2> concretions."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7517	"A patient with alcoholic cerebellar degeneration had <e1>periodic alternating nystagmus</e1> during a period of <e2>phenytoin</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7518	"Although the data indicate an immune-complex cause for <e1>gold-salt</e1> <e2>nephropathy</e2>, the incident antigen (or antigens) and mechanism of action remain unidentified."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7519	"<e1>Gold</e1> <e2>nephropathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7520	"<e1>Gold-salt</e1> therapy may result in <e2>damage to proximal tubules</e2> that leak renal tubular antigens, which in turn complex with autoantibody and produce an autoimmune membranous nephropathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7521	"The <e1>nephrotic syndrome</e1> developed in a patient receiving therapy with <e2>gold</e2> for rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7522	"Intrahepatic cholestasis and <e1>cutaneous bullae</e1> associated with <e2>glibenclamide</e2> therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7523	"<e1>Intrahepatic cholestasis</e1> and cutaneous bullae associated with <e2>glibenclamide</e2> therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7524	"Intrahepatic cholestasis and <e1>cutaneous bullae</e1> associated with <e2>glibenclamide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7525	"<e1>Intrahepatic cholestasis</e1> and cutaneous bullae associated with <e2>glibenclamide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7526	"These features have not previously been reported as side effects of glibenclamide therapy, but <e1>intrahepatic cholestasis</e1> may occur with <e2>chlorpropamide</e2>, a similar sulphonylurea agent."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7527	"In four patients, <e1>spasm</e1> occurred spontaneous and in one patient after 0.05 mg of <e2>ergonovine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7528	"The authors describe a woman with chronic schizophrenia who experienced <e1>delirium</e1>, grand mal seizure, and photosensitivity after the addition of <e2>propranolol</e2> to her neuroleptic regimen."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7529	"The authors describe a woman with chronic schizophrenia who experienced delirium, <e1>grand mal seizure</e1>, and photosensitivity after the addition of <e2>propranolol</e2> to her neuroleptic regimen."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7530	"The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and <e1>photosensitivity</e1> after the addition of <e2>propranolol</e2> to her neuroleptic regimen."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7531	"<e1>Catatonia</e1> associated with <e2>disulfiram</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7532	"Neurophysiological mechanisms which aid in elucidating the role of <e1>disulfiram</e1> in the etiology of <e2>catatonia</e2> are discussed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7533	"This is the first report of a <e1>catatonic syndrome</e1> occurring in a patient receiving <e2>disulfiram</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7534	"<e1>Hepatic reactions</e1> to <e2>cyclofenil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7535	"Thirty patients with <e1>hepatic reactions</e1> to <e2>cyclofenil</e2>, a non-steroidal drug with a stimulating effect on ovulation, are reviewed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7536	"Since early symptoms of the toxic effects of <e1>theophylline</e1> can mimic <e2>peptic ulcer disease</e2>, cimetidine might be prescribed for the gastrointestinal symptoms with subsequent worsening of <e1>theophylline</e1> poisoning."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7537	"A case of <e1>SIADH</e1> associated with <e2>desipramine</e2> treatment in an elderly depressed woman is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7538	"<e1>Desipramine</e1> -associated <e2>SIADH</e2> in an elderly woman: case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7539	"Prior reports have emphasized the <e1>tubular and interstitial lesions</e1> associated with intermittent or discontinuous <e2>rifampin</e2> therapy for tuberculosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7540	"The spectrum of <e1>renal lesions</e1> occurring during antituberculous therapy, particularly in association with <e2>rifampin</e2>, may be wider than previously suspected."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7541	"Within 3 weeks of beginning continuous daily <e1>isoniazid</e1> and rifampin therapy for pulmonary tuberculosis, a patient developed <e2>acute renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7542	"Within 3 weeks of beginning continuous daily isoniazid and <e1>rifampin</e1> therapy for pulmonary tuberculosis, a patient developed <e2>acute renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7543	"<e1>Nephrotic range pseudoproteinuria</e1> in a <e2>tolmetin</e2> -treated patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7544	"When tuberculosis patients on <e1>isoniazid</e1> eat certain varieties of fish they may develop a <e2>histamine reaction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7545	"<e1>Fulminant hepatitis</e1> associated with <e2>disulfiram</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7546	"We report a case of <e1>fatal fulminant hepatitis</e1> caused by the use of <e2>disulfiram</e2> in a man with previously normal hepatocellular function."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7547	"A 45-year-old woman with thyrotoxicosis developed <e1>agranulocytosis</e1> after treatment with <e2>propylthiouracil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7548	"The patient was given <e1>methimazole</e1> instead of propylthiouracil but, 10 weeks later, <e2>agranulocytosis</e2> again occurred."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7549	"This is, to the best of our knowledge, the first report of a case in which <e1>agranulocytosis</e1> followed treatment with both propylthiouracil and <e2>methimazole</e2> in the same patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7550	"This is, to the best of our knowledge, the first report of a case in which <e1>agranulocytosis</e1> followed treatment with both <e2>propylthiouracil</e2> and methimazole in the same patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7551	"A 55-yr-old man developed <e1>prolonged jaundice</e1> and sicca complex after a course of <e2>thiabendazole</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7552	"A 55-yr-old man developed prolonged jaundice and <e1>sicca complex</e1> after a course of <e2>thiabendazole</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7553	"<e1>Intrahepatic cholestasis</e1> and sicca complex after <e2>thiabendazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7554	"Intrahepatic cholestasis and <e1>sicca complex</e1> after <e2>thiabendazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7555	"The literature on <e1>thiabendazole</e1> -induced <e2>cholestasis</e2> and its association with sicca complex is reviewed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7556	"The literature on <e1>thiabendazole</e1> -induced cholestasis and its association with <e2>sicca complex</e2> is reviewed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7557	"She was placed on adjuvant <e1>Adriamycin</e1> (doxorubicin) chemotherapy, but 6 months later died of <e1>Adriamycin</e1> toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7558	"She was placed on adjuvant <e1>Adriamycin</e1> (doxorubicin) chemotherapy, but 6 months later died of <e1>Adriamycin</e1> toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7559	"She was placed on adjuvant Adriamycin (<e1>doxorubicin</e1>) chemotherapy, but 6 months later died of <e2>Adriamycin toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7560	"She was placed on adjuvant <e1>Adriamycin</e1> (doxorubicin) chemotherapy, but 6 months later <e2>died</e2> of <e1>Adriamycin</e1> toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7561	"She was placed on adjuvant <e1>Adriamycin</e1> (doxorubicin) chemotherapy, but 6 months later <e2>died</e2> of <e1>Adriamycin</e1> toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7562	"She was placed on adjuvant Adriamycin (<e1>doxorubicin</e1>) chemotherapy, but 6 months later <e2>died</e2> of Adriamycin toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7563	"Intracranial hemorrhage and <e1>focal seizures</e1> secondary to use of <e2>L-asparaginase</e2> during induction therapy of acute lymphocytic leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7564	"<e1>Intracranial hemorrhage</e1> and focal seizures secondary to use of <e2>L-asparaginase</e2> during induction therapy of acute lymphocytic leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7565	"<e1>Dural sinus thrombosis</e1> developed in two children with acute lymphoblastic leukemia during induction treatment with vincristine sulfate, prednisone, and <e2>asparaginase</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7566	"<e1>Dural sinus thrombosis</e1> developed in two children with acute lymphoblastic leukemia during induction treatment with vincristine sulfate, <e2>prednisone</e2>, and asparaginase."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7567	"<e1>Dural sinus thrombosis</e1> developed in two children with acute lymphoblastic leukemia during induction treatment with <e2>vincristine sulfate</e2>, prednisone, and asparaginase."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7568	"The cause is presumed to be secondary to hypercoagulability due to <e1>asparaginase</e1> -induced <e2>antithrombin III deficiency</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7569	"Six patients with rheumatoid arthritis developed a syndrome resembling <e1>lupus erythematosus</e1> while being treated with <e2>penicillamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7570	"<e1>Systemic lupus erythematosus</e1> during <e2>penicillamine</e2> therapy for rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7571	"However, the amount of <e1>prednisone</e1> required to maintain normotension resulted in <e2>Cushingoid features</e2> and has been discontinued."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7572	"Clinicians should be aware of <e1>fasting hypoglycemia</e1> as an unusual but potentially serious complication of <e2>disopyramide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7573	"<e1>Disopyramide</e1> (Norpace)-induced <e2>hypoglycemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7574	"Disopyramide (<e1>Norpace</e1>)-induced <e2>hypoglycemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7575	"<e1>Cefoxitin</e1> -associated <e2>renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7576	"The other woman had rheumatoid arthritis and developed <e1>acute tubular necrosis</e1> after treatment with gentamicin and <e2>cefoxitin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7577	"The other woman had rheumatoid arthritis and developed <e1>acute tubular necrosis</e1> after treatment with <e2>gentamicin</e2> and cefoxitin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7578	"Two elderly women suffered an <e1>acute deterioration of renal function</e1> after treatment with <e2>cefoxitin sodium</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7579	"<e1>Transient anuria</e1> following administration of angiotensin I-converting enzyme inhibitor (<e2>SQ 14225</e2>) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7580	"We report on a patient with renal artery stenosis who had only 1 kidney and in whom <e1>acute renal impairment</e1> developed with transient anuria after the administration of <e2>captopril</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7581	"We report on a patient with renal artery stenosis who had only 1 kidney and in whom acute renal impairment developed with <e1>transient anuria</e1> after the administration of <e2>captopril</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7582	"A 44-year-old woman is described in whom <e1>amiodarone</e1>, disopyramide, and quinidine, administered alone separately, induced <e2>atypical ventricular tachycardia</e2> (AVT, torsade de pointes)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7583	"A 44-year-old woman is described in whom amiodarone, <e1>disopyramide</e1>, and quinidine, administered alone separately, induced <e2>atypical ventricular tachycardia</e2> (AVT, torsade de pointes)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7584	"A 44-year-old woman is described in whom amiodarone, disopyramide, and <e1>quinidine</e1>, administered alone separately, induced <e2>atypical ventricular tachycardia</e2> (AVT, torsade de pointes)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7585	"A 44-year-old woman is described in whom <e1>amiodarone</e1>, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (<e2>AVT</e2>, torsade de pointes)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7586	"A 44-year-old woman is described in whom amiodarone, <e1>disopyramide</e1>, and quinidine, administered alone separately, induced atypical ventricular tachycardia (<e2>AVT</e2>, torsade de pointes)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7587	"A 44-year-old woman is described in whom amiodarone, disopyramide, and <e1>quinidine</e1>, administered alone separately, induced atypical ventricular tachycardia (<e2>AVT</e2>, torsade de pointes)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7588	"A 44-year-old woman is described in whom <e1>amiodarone</e1>, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, <e2>torsade de pointes</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7589	"A 44-year-old woman is described in whom amiodarone, <e1>disopyramide</e1>, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, <e2>torsade de pointes</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7590	"A 44-year-old woman is described in whom amiodarone, disopyramide, and <e1>quinidine</e1>, administered alone separately, induced atypical ventricular tachycardia (AVT, <e2>torsade de pointes</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7591	"<e1>Amiodarone</e1> was the third drug to induce <e2>AVT</e2> in this patient; she received 200 mg/day six days per week for six months."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7592	"Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone: <e1>arrhythmia</e1> previously induced by quinidine and <e2>disopyramide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7593	"Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone: <e1>arrhythmia</e1> previously induced by <e2>quinidine</e2> and disopyramide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7594	"<e1>Atypical ventricular tachycardia</e1> (torsade de pointes) induced by <e2>amiodarone</e2>: arrhythmia previously induced by quinidine and disopyramide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7595	"Atypical ventricular tachycardia (<e1>torsade de pointes</e1>) induced by <e2>amiodarone</e2>: arrhythmia previously induced by quinidine and disopyramide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7596	"Two years later, 24 hours following an increase in the dose of <e1>disopyramide</e1> from 300 to 600 mg/day, <e2>AVT</e2> with syncope occurred; isoproterenol abolished the arrhythmia instantly."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7597	"Two years later, 24 hours following an increase in the dose of <e1>disopyramide</e1> from 300 to 600 mg/day, AVT with <e2>syncope</e2> occurred; isoproterenol abolished the arrhythmia instantly."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7598	"Although the existence of an acute pericarditis or an acute myocarditis as possible causes of the ST elevation cannot be fully ruled out, the sudden onset, prominent magnitude, and brief duration of the ST elevation are perhaps more indicative of an acute ischemic event, possibly related to a transient <e1>coronary vasoconstriction</e1> induced by the <e2>dopamine</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7599	"Complete remission of the <e1>nephrosis</e1> occurred after discontinuation of <e2>hydroxychloroquine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7600	"<e1>Hepatitis</e1> following <e2>cimetidine</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7601	"The case of an adult who developed both <e1>hepatic dysfunction</e1> and an impaired macrophage migration after exposure to <e2>cimetidine</e2> is discussed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7602	"The case of an adult who developed both hepatic dysfunction and an <e1>impaired macrophage migration</e1> after exposure to <e2>cimetidine</e2> is discussed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7603	"There have been only two reports of <e1>cimetidine</e1> -induced <e2>hepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7604	"A 66-year-old mand suffering from severe coronary heart disease took <e1>digoxin</e1> with suicidal intent an was treated for the ensuing <e2>complete atrioventricular block</e2> with <e1>digoxin</e1> -specific antibody fragments."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7605	"<e1>Verapamil</e1> in effort-induced <e2>angina pectoris</e2> in patients with normal coronary arteries."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7606	"<e1>Flucytosine</e1> -associated <e2>diarrhea</e2> has been previously described in 6%-10% of patients receiving the drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7607	"This report describes a case of <e1>flucytosine</e1> -associated ulcerating enteritis in which the small bowel x-ray demonstrated severe luminal narrowing, ulceration, and <e2>marked separation of loops of bowel</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7608	"This report describes a case of <e1>flucytosine</e1> -associated ulcerating enteritis in which the small bowel x-ray demonstrated <e2>severe luminal narrowing</e2>, ulceration, and marked separation of loops of bowel."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7609	"This report describes a case of <e1>flucytosine</e1> -associated <e2>ulcerating enteritis</e2> in which the small bowel x-ray demonstrated severe luminal narrowing, ulceration, and marked separation of loops of bowel."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7610	"This report describes a case of <e1>flucytosine</e1> -associated ulcerating enteritis in which the small bowel x-ray demonstrated severe luminal narrowing, <e2>ulceration</e2>, and marked separation of loops of bowel."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7611	"<e1>Ulcerating enteritis</e1> associated with <e2>flucytosine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7612	"<e1>Papilledema</e1> without peripheral neuropathy in a patient taking <e2>perhexiline maleate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7613	"An adolescent male developed <e1>acute pancreatitis</e1> and pseudocyst of the pancreas 16 weeks after cessation of intramuscular <e2>L-asparaginase</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7614	"An adolescent male developed acute pancreatitis and <e1>pseudocyst of the pancreas</e1> 16 weeks after cessation of intramuscular <e2>L-asparaginase</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7615	"<e1>Delayed pseudocyst of the pancreas</e1> can be a complication of intramuscular <e2>L-asparaginase</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7616	"<e1>L-asparaginase</e1> -induced <e2>pancreatitis</e2> has been reported during or closely following administration of the drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7617	"Three cases of <e1>pseudocyst of the pancreas</e1> in two women and one man have previously been reported with the use of intravenous <e2>L-asparaginase</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7618	"In one patient, treatment with <e1>DCA</e1> was associated with a <e2>decrease in blood lactate levels</e2> from 11.2 mM before treatment to 0.8 mM 16 h later."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7619	"Nine <e1>delirious</e1> patients suffering from <e2>lithium</e2> intoxication were examined with the Mini-Mental State Exam (MMS) to describe the clinical course of the disorder."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7620	"The course of <e1>delirium</e1> due to <e2>lithium</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7621	"Life-threatening <e1>hyperkalemia</e1> induced by <e2>arginine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7622	"<e1>Marked hyperkalemia</e1> was observed during and immediately after an infusion of <e2>arginine monohydrochloride</e2> in two patients with severe hepatic disease and moderate renal insufficiency."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7623	"A 58-year-old man with rheumatoid arthritis developed <e1>lichen planus</e1> during treatment with <e2>gold</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7624	"<e1>Acne</e1> provoked by <e2>gold</e2> seems not to have been described elsewhere."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7625	"Lichen planus and <e1>acne</e1> provoked by <e2>gold</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7626	"<e1>Lichen planus</e1> and acne provoked by <e2>gold</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7627	"The case history confirms that <e1>gold</e1> treatment, even in the same patient, can give rise to a wide range of <e2>skin disturbances</e2>, which in many cases do not break out until long after the drug has been withdrawn."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7628	"Secondary hyperparathyroidism in certain patients with <e1>lithium</e1> <e2>nephrotoxicity</e2> is also possible."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7629	"<e1>Secondary hyperparathyroidism</e1> in certain patients with <e2>lithium</e2> nephrotoxicity is also possible."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7630	"These results indicate that <e1>lithium</e1> may cause <e2>biochemical hyperparathyroidism</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7631	"A 57-year-old woman with right bundle branch block +LPH and ventricular premature contractions developed complete heart block (<e1>CHB</e1>) following administration of <e2>disopyramide phosphate</e2> (Norpace)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7632	"A 57-year-old woman with right bundle branch block +LPH and ventricular premature contractions developed complete heart block (<e1>CHB</e1>) following administration of disopyramide phosphate (<e2>Norpace</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7633	"A 57-year-old woman with right bundle branch block +LPH and ventricular premature contractions developed <e1>complete heart block</e1> (CHB) following administration of <e2>disopyramide phosphate</e2> (Norpace)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7634	"A 57-year-old woman with right bundle branch block +LPH and ventricular premature contractions developed <e1>complete heart block</e1> (CHB) following administration of disopyramide phosphate (<e2>Norpace</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7635	"<e1>Disopyramide</e1> -induced <e2>heart block</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7636	"Although transient increases in ectopy after <e1>bretylium</e1> therapy have been described, presumably due to catecholamine release, the occurrence of life-threatening ventricular arrhythmia leading to <e2>cardiac arrest</e2> has not previously been emphasized."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7637	"Although transient increases in ectopy after <e1>bretylium</e1> therapy have been described, presumably due to catecholamine release, the occurrence of life-threatening <e2>ventricular arrhythmia</e2> leading to cardiac arrest has not previously been emphasized."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7638	"In the first patient, two episodes of <e1>ventricular tachycardia</e1> requiring cardioversion occurred in close temporal sequence with administering <e2>bretylium</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7639	"In the second case, five <e1>cardiac arrests</e1> due to ventricular tachycardia and fibrillation occurred during several hours after beginning a trial of <e2>bretylium</e2> maintenance therapy for complex ventricular ectopy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7640	"In the second case, five cardiac arrests due to ventricular tachycardia and <e1>fibrillation</e1> occurred during several hours after beginning a trial of <e2>bretylium</e2> maintenance therapy for complex ventricular ectopy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7641	"In the second case, five cardiac arrests due to <e1>ventricular tachycardia</e1> and fibrillation occurred during several hours after beginning a trial of <e2>bretylium</e2> maintenance therapy for complex ventricular ectopy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7642	"Paradoxical ventricular tachycardia and <e1>fibrillation</e1> after intravenous <e2>bretylium</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7643	"<e1>Paradoxical ventricular tachycardia</e1> and fibrillation after intravenous <e2>bretylium</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7644	"<e1>Lithium</e1> is known to cause <e2>acute renal failure</e2> and tubulo-interstitial disease, but the recently described association with proteinuria or nephrotic syndrome is little recognized."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7645	"<e1>Lithium</e1> is known to cause acute renal failure and tubulo-interstitial disease, but the recently described association with proteinuria or <e2>nephrotic syndrome</e2> is little recognized."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7646	"<e1>Lithium</e1> is known to cause acute renal failure and tubulo-interstitial disease, but the recently described association with <e2>proteinuria</e2> or nephrotic syndrome is little recognized."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7647	"<e1>Lithium</e1> is known to cause acute renal failure and <e2>tubulo-interstitial disease</e2>, but the recently described association with proteinuria or nephrotic syndrome is little recognized."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7648	"<e1>Nephrotic syndrome</e1> associated with <e2>lithium</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7649	"Two patients on long-term <e1>lithium</e1> therapy developed the <e2>nephrotic syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7650	"A 67-year-old man developed <e1>diarrhea</e1> shortly after a 10-day course of oral <e2>ampicillin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7651	"A 73-year-old woman with non-Hodgkin's lymphoma had two episodes of severe, bilateral, <e1>sensori-neural hearing loss</e1> after <e2>vincristine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7652	"<e1>Acute acoustic nerve palsy</e1> associated with <e2>vincristine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7653	"<e1>Bilateral acoustic (VIII) nerve palsy</e1> in this patient was most likely a manifestation of <e2>vincristine</e2> neurotoxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7654	"Bilateral acoustic (VIII) nerve palsy in this patient was most likely a manifestation of <e1>vincristine</e1> <e2>neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7655	"A case of <e1>timolol</e1> -associated <e2>heart failure</e2> in a 73-year old white man is reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7656	"<e1>Bradycardia</e1> and congestive heart failure associated with ocular <e2>timolol maleate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7657	"Bradycardia and <e1>congestive heart failure</e1> associated with ocular <e2>timolol maleate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7658	"On the second day of hospitalization, it was noted that the patient's <e1>dyspnea</e1> and sinus bradycardia could be related to a recent increase in his <e2>timolol</e2> dosage."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7659	"On the second day of hospitalization, it was noted that the patient's dyspnea and <e1>sinus bradycardia</e1> could be related to a recent increase in his <e2>timolol</e2> dosage."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7660	"<e1>Fatal ventricular fibrillation</e1> after treatment with <e2>digoxin</e2> in a 27-year-old man with mitral leaflet prolapse syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7661	"He was started on <e1>digoxin</e1>, 0.25 mg daily, because of echocardiographically demonstrated left ventricular dilatation and <e2>functional impairment</e2>; he died of ventricular fibrillation 15 days later."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7662	"He was started on <e1>digoxin</e1>, 0.25 mg daily, because of echocardiographically demonstrated <e2>left ventricular dilatation</e2> and functional impairment; he died of ventricular fibrillation 15 days later."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7663	"He was started on <e1>digoxin</e1>, 0.25 mg daily, because of echocardiographically demonstrated left ventricular dilatation and functional impairment; he died of <e2>ventricular fibrillation</e2> 15 days later."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7664	"Induction of <e1>rapid mood cycling</e1> during <e2>L-dopa</e2> treatment in a bipolar patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7665	"The authors report a longitudinal case study of a woman with a history of bipolar affective disorder in which <e1>L-dopa</e1> <e2>shortened the manic-depressive cycle</e2> length when administered in a double-blind trial."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7666	"<e1>Liver disease</e1> induced by <e2>perhexiline maleate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7667	"This paper reports a case of fatal <e2>perhexiline maleate</e2> liver injury."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7668	"<e1>Acute non-lymphocytic leukemia</e1> in patients with ovarian carcinoma following long-term treatment with Treosulfan (= <e2>dihydroxybusulfan</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7669	"<e1>Acute non-lymphocytic leukemia</e1> in patients with ovarian carcinoma following long-term treatment with <e2>Treosulfan</e2> (= dihydroxybusulfan)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7670	"<e1>Acute non-lymphocytic leukemia</e1> occurred in eight women following long-term treatment with Treosulfan (= <e2>dihydroxybusulfan</e2>) for ovarian carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7671	"<e1>Acute non-lymphocytic leukemia</e1> occurred in eight women following long-term treatment with <e2>Treosulfan</e2> (= dihydroxybusulfan) for ovarian carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7672	"Seven of the eight cases of <e1>acute leukemia</e1> occurred in a series of 553 patients treated with <e2>Treosulfan</e2> for ovarian cancer in the period from 1970 to 1977 and followed closely for a total of 1159 patient-years up to February 1978."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7673	"The probability of developing <e1>acute leukemia</e1> in this study was not significantly correlated to the total cumulative dosage of <e2>Treosulfan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7674	"<e1>Propranolol</e1> -related <e2>bronchospasm</e2> in patients without history of asthma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7675	"Regardless of a negative history of asthma, therefore, life-threatening <e1>bronchospasm</e1> must be considered a possible complication of <e2>propranolol</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7676	"Since the <e1>bronchospasm</e1> was relieved with discontinuation of <e2>propranolol</e2> and supportive bronchodilator therapy, the <e1>bronchospasm</e1> was believed to be caused by <e2>propranolol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7677	"Since the <e1>bronchospasm</e1> was relieved with discontinuation of <e2>propranolol</e2> and supportive bronchodilator therapy, the <e1>bronchospasm</e1> was believed to be caused by <e2>propranolol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7678	"Three patients with no history of asthma or allergy developed <e1>bronchospasm</e1> while taking <e2>propranolol</e2> for hypertension."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7679	"<e1>Propranolol</e1>: an unrecognized cause of <e2>central nervous system dysfunction</e2> in patients undergoing cardiopulmonary bypass."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7680	"The potential role of <e1>propranolol</e1> in inducing <e2>central nervous system disturbances</e2> is emphasized, and the literature on the subject is reviewed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7681	"<e1>Interstitial fibrosis of the lung</e1> is a potential complication of <e2>methotrexate</e2> therapy for psoriasis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7682	"<e1>Progressive interstitial fibrosis</e1> with roentgenographic honeycombing developed in the case of a psoriatic patient who had been on a regimen of <e2>methotrexate</e2> for 18 years."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7683	"<e1>Progressive interstitial lung disease</e1> from prolonged <e2>methotrexate</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7684	"<e1>Abnormalities of the pupil</e1> and visual-evoked potential in <e2>quinine</e2> amblyopia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7685	"Abnormalities of the pupil and visual-evoked potential in <e1>quinine</e1> <e2>amblyopia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7686	"A transient tonic pupillary response, denervation supersensitivity, and <e1>abnormal visual-evoked potentials</e1> in <e2>quinine</e2> toxicity, to our knowledge, have not been previously reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7687	"A transient tonic pupillary response, <e1>denervation supersensitivity</e1>, and abnormal visual-evoked potentials in <e2>quinine</e2> toxicity, to our knowledge, have not been previously reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7688	"A <e1>transient tonic pupillary response</e1>, denervation supersensitivity, and abnormal visual-evoked potentials in <e2>quinine</e2> toxicity, to our knowledge, have not been previously reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7689	"Total blindness with a transient tonic pupillary response, denervation supersensitivity, and <e1>abnormal visual-evoked potentials</e1> developed in a 54-year-old man after the use of <e2>quinine sulfate</e2> for leg cramps."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7690	"Total blindness with a transient tonic pupillary response, <e1>denervation supersensitivity</e1>, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of <e2>quinine sulfate</e2> for leg cramps."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7691	"<e1>Total blindness with a transient tonic pupillary response</e1>, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of <e2>quinine sulfate</e2> for leg cramps."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7692	"Diagnosis: <e1>practolol</e1> induced <e2>sclerosing peritonitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7693	"A case of <e1>skeletal fluorosis</e1> induced by prolonged treatment with <e2>niflumic acid</e2>, a fast-acting non-steroid antiinflammatory agent, is reported in a 35-year-old woman suffering from rheumatoid arthritis and treated, in addition, with corticosteroids."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7694	"After ruling out a hydrotelluric source of fluorine, the patient's <e1>fluorosis</e1> was linked to chronic use of <e2>niflumic acid</e2>, following the publication in 1978 of the 2 previously reported cases affected by this drug."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7695	"<e1>Niflumic acid</e1> -induced <e2>skeletal fluorosis</e2>: iatrogenic disease or therapeutic perspective for osteoporosis?"
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7696	"The fluorine contained in <e1>niflumic acid</e1> induced a marked <e2>densification of trabecular bone</e2> in all 3 cases."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7697	"<e1>Hepatotoxicity</e1> associated with use of <e2>D-penicillamine</e2> in rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7698	"These cases and a review of the literature suggested that <e1>hepatotoxicity</e1>, though rare, should be added to the list of adverse reactions to <e2>D-penicillamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7699	"Two patients with rheumatoid arthritis developed evidence of <e1>hepatotoxicity</e1> while receiving <e2>D-penicillamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7700	"A 62-year-old Indian with diabetic nephropathy controlled with <e1>metformin</e1>, developed <e2>miliary tuberculosis</e2> for which he was treated with rifampicin, isoniazid and ethambutol."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7701	"<e1>Para-aminosalicylic acid</e1> -induced <e2>hypoglycaemia</e2> in a patient with diabetic nephropathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7702	"The induction of <e1>hypoglycaemia</e1> with <e2>PAS</e2> in this patient suggests a potential role for <e2>PAS</e2> in the treatment of diabetes mellitus."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7703	"The introduction of <e1>para-aminosalicylic acid</e1> (PAS) led to <e2>hypoglycaemic coma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7704	"The introduction of para-aminosalicylic acid (<e1>PAS</e1>) led to <e2>hypoglycaemic coma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7705	"A patient developed papilloedema and <e1>hepatic dysfunction</e1> while being treated with <e2>perhexiline maleate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7706	"A patient developed <e1>papilloedema</e1> and hepatic dysfunction while being treated with <e2>perhexiline maleate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7707	"Papilloedema and <e1>hepatic dysfunction</e1> apparently induced by <e2>perhexiline maleate</e2> (Pexid)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7708	"Papilloedema and <e1>hepatic dysfunction</e1> apparently induced by perhexiline maleate (<e2>Pexid</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7709	"<e1>Papilloedema</e1> and hepatic dysfunction apparently induced by <e2>perhexiline maleate</e2> (Pexid)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7710	"<e1>Papilloedema</e1> and hepatic dysfunction apparently induced by perhexiline maleate (<e2>Pexid</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7711	"Markedly <e1>increased pigmementation of skin</e1> immediately overlying veins used for multiple <e2>5-fluorouracil</e2> infusions was noted."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7712	"Unusual <e1>pigmentary changes</e1> associated with <e2>5-fluorouracil</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7713	"Although useful in the management of chronic alcoholism, <e1>disulfiram</e1> is being increasingly associated with a wide spectrum of side effects and untoward medical sequelae, which now include <e2>catatonia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7714	"<e1>Disulfiram</e1> encephalopathy as a cause of the <e2>catatonia syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7715	"<e1>Disulfiram</e1> <e2>encephalopathy</e2> as a cause of the catatonia syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7716	"The authors describe a case of the <e1>catatonia syndrome</e1> associated with <e2>disulfiram</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7717	"<e1>Inappropriate antidiuretic hormone secretion</e1> after high dose <e2>vinblastine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7718	"We report on a patient with an embryonal teratocarcinoma of the testicle who had the syndrome of <e1>inappropriate secretion of antidiuretic hormone</e1> after receiving a high dose of <e2>vinblastine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7719	"Four cases of <e1>oesophageal damage</e1> associated with ingestion of the urinary anti-spasmodic agent <e2>emepronium bromide</e2> are described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7720	"<e1>Oesophageal ulceration</e1> due to <e2>emepronium bromide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7721	"<e1>Cardiorespiratory toxicity</e1> due to <e2>miconazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7722	"None of them had a history of cardiac disease, and with the possible exception of one case of <e1>cardiac arrest</e1>, where the patient received <e2>doxorubicin</e2>, no predisposing factors could be found."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7723	"Seven patients with hematologic malignancies who were treated with <e1>miconazole</e1> for either suspected or proven fungal infections developed eight episodes of major adverse <e2>cardiorespiratory and anaphylactic reactions</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7724	"<e1>Clofibrate</e1> -induced <e2>myopathy</e2> in patients with diabetes insipidus."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7725	"However, we have recently had four cases of <e1>clofibrate</e1> -induced <e2>myopathy</e2> in patients with diabetes insipidus due to hypothalamic lesions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7726	"Physicians should therefore be aware of its occurrence and carefully monitor serum levels of CPK, GOT and GPT during the treatment of diabetes insipidus with <e1>clofibrate</e1>, especially in patients with associated hypothyroidism, latent or overt, which possibly favors the development of <e2>myopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7727	"<e1>Hepatotoxicity</e1> of <e2>hycanthone</e2> in patients with metastatic breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7728	"In a phase II study of <e1>hycanthone</e1> in patients with breast cancer we have recently observed <e2>severe hepatotoxicity</e2>, even at lower doses, which resulted in two drug-related deaths."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7729	"<e1>Fatal interstitial pneumonitis</e1> following high-dose intermittent <e2>chlorambucil</e2> therapy for chronic lymphocyte leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7730	"Following several of these courses of therapy, <e1>respiratory distress</e1> occurred 9 to 12 days after the <e2>chlorambucil</e2> was given."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7731	"A case of <e1>barbiturate</e1> -induced <e2>submassive hepatic necrosis</e2> is presented and the literature is reviewed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7732	"<e1>Barbiturate</e1> -induced <e2>submassive hepatic necrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7733	"The patient's clinical presentation, histologic features on liver biopsy and favorable course after stopping the drug suggest that <e1>barbiturates</e1> can be added to the list of agents which can cause <e2>submassive hepatic necrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7734	"A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction exhibited <e1>granulocytopenia</e1> 8 days following the administration of oral sustained-release <e2>procainamide</e2> (750 mg/day)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7735	"Sustained-release <e1>procainamide</e1> -induced <e2>reversible granulocytopenia</e2> after myocardial infarction."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7736	"The frequency and relationship of <e1>granulocytopenia</e1> caused by sustained-release <e2>procainamide</e2> in patients with tachyarrhythmias are briefly discussed, and prior reported cases are reviewed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7737	"<e1>Monoclonal gammopathy</e1> and subsequent multiple myeloma in a patient on chronic <e2>diphenylhydantoin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7738	"Monoclonal gammopathy and subsequent <e1>multiple myeloma</e1> in a patient on chronic <e2>diphenylhydantoin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7739	"The development of an <e1>IgG lambda-type monoclonal gammopathy</e1> and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (<e2>DILANTIN</e2>) therapy for 20 years is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7740	"The development of an <e1>IgG lambda-type monoclonal gammopathy</e1> and subsequent multiple myeloma in an epilepsy patient on <e2>diphenylhydantoin</e2> (DILANTIN) therapy for 20 years is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7741	"The development of an IgG lambda-type monoclonal gammopathy and subsequent <e1>multiple myeloma</e1> in an epilepsy patient on diphenylhydantoin (<e2>DILANTIN</e2>) therapy for 20 years is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7742	"The development of an IgG lambda-type monoclonal gammopathy and subsequent <e1>multiple myeloma</e1> in an epilepsy patient on <e2>diphenylhydantoin</e2> (DILANTIN) therapy for 20 years is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7743	"We recommended periodic examination of the serum proteins in patients receiving <e1>diphenylhydantoin</e1> in order to detect development of <e2>monoclonal gammopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7744	"CONCLUSION: <e1>Atovaquone</e1> should be added to the list of agents causing <e2>vortex keratopathy</e2> involving the corneal epithelium."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7745	"PURPOSE: We studied a case of <e1>vortex keratopathy</e1> that was associated with the use of <e2>atovaquone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7746	"RESULTS: Similar to previous findings of drug-induced <e1>vortex keratopathy</e1>, <e2>atovaquone</e2> <e1>vortex keratopathy</e1> is presumably caused by its lipophilic properties."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7747	"RESULTS: Similar to previous findings of drug-induced <e1>vortex keratopathy</e1>, <e2>atovaquone</e2> <e1>vortex keratopathy</e1> is presumably caused by its lipophilic properties."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7748	"<e1>Vortex keratopathy</e1> associated with <e2>atovaquone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7749	"Used injudiciously, <e1>naloxone</e1> can lead to withdrawal syndrome, return of <e2>severe pain</e2>, and other adverse effects."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7750	"Used injudiciously, <e1>naloxone</e1> can lead to <e2>withdrawal syndrome</e2>, return of severe pain, and other adverse effects."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7751	"However, there remain questions concerning whether these drugs, especially <e1>methimazole</e1> (MMI), may be associated with aplasia cutis congenita (<e2>ACC</e2>) and how best to avoid impairment of fetal thyroid function during their use."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7752	"However, there remain questions concerning whether these drugs, especially methimazole (<e1>MMI</e1>), may be associated with aplasia cutis congenita (<e2>ACC</e2>) and how best to avoid impairment of fetal thyroid function during their use."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7753	"However, there remain questions concerning whether these drugs, especially <e1>methimazole</e1> (MMI), may be associated with <e2>aplasia cutis congenita</e2> (ACC) and how best to avoid impairment of fetal thyroid function during their use."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7754	"However, there remain questions concerning whether these drugs, especially methimazole (<e1>MMI</e1>), may be associated with <e2>aplasia cutis congenita</e2> (ACC) and how best to avoid impairment of fetal thyroid function during their use."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7755	"A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an <e1>acute reversible encephalopathy</e1> within 15 days of initiation of <e2>flecainide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7756	"<e1>Acute reversible ataxo-myoclonic encephalopathy</e1> with <e2>flecainide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7757	"A 64 year old man with recurrent metastatic squamous cell carcinoma of the head and neck developed severe skin rash and <e1>bone marrow aplasia</e1> 4 and 7 days, respectively, following a single dose of 40 mg/m2 <e2>methotrexate</e2> (MTX)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7758	"A 64 year old man with recurrent metastatic squamous cell carcinoma of the head and neck developed severe skin rash and <e1>bone marrow aplasia</e1> 4 and 7 days, respectively, following a single dose of 40 mg/m2 methotrexate (<e2>MTX</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7759	"A 64 year old man with recurrent metastatic squamous cell carcinoma of the head and neck developed <e1>severe skin rash</e1> and bone marrow aplasia 4 and 7 days, respectively, following a single dose of 40 mg/m2 <e2>methotrexate</e2> (MTX)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7760	"A 64 year old man with recurrent metastatic squamous cell carcinoma of the head and neck developed <e1>severe skin rash</e1> and bone marrow aplasia 4 and 7 days, respectively, following a single dose of 40 mg/m2 methotrexate (<e2>MTX</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7761	"<e1>Bone marrow aplasia</e1> and severe skin rash after a single low dose of <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7762	"Bone marrow aplasia and <e1>severe skin rash</e1> after a single low dose of <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7763	"Development of an <e1>extensive skin rash</e1> following a single dose of <e2>MTX</e2> may be an early warning sign for life-threatening bone marrow aplasia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7764	"In the absence of mucositis or diarrhea, severe dermatologic toxicity following a single low dose of the drug suggests an 'allergic' or <e1>acute hypersensitivity reaction</e1> to <e2>MTX</e2> in this patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7765	"In the absence of mucositis or diarrhea, <e1>severe dermatologic toxicity</e1> following a single low dose of the drug suggests an 'allergic' or acute hypersensitivity reaction to <e2>MTX</e2> in this patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7766	"<e1>Chlormadinone acetate</e1> <e2>withdrawal syndrome</e2> under combined androgen blockade for advanced prostate cancer."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7767	"The second had acute cystitis and was treated by sulphonamide and the third developed <e1>myopia</e1> coincident with <e2>metronidazole</e2> treatment for trichomonas vaginalis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7768	"The second had acute cystitis and was treated by <e1>sulphonamide</e1> and the third developed <e2>myopia</e2> coincident with metronidazole treatment for trichomonas vaginalis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7769	"<e1>Nephrotic syndrome</e1> related to systemic lupus erythematosus after <e2>griseofulvin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7770	"Nephrotic syndrome related to <e1>systemic lupus erythematosus</e1> after <e2>griseofulvin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7771	"To our knowledge, this is the first case of <e1>griseofulvin</e1> -exacerbated <e2>lupus</e2> in which nephrotic syndrome has been observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7772	"To our knowledge, this is the first case of <e1>griseofulvin</e1> -exacerbated lupus in which <e2>nephrotic syndrome</e2> has been observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7773	"We report a 16-year-old male who developed <e1>nephrotic syndrome</e1> related to membranous glomerulopathy with clinical and serological evidence of systemic lupus erythematosus after treatment with <e2>griseofulvin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7774	"We report a 16-year-old male who developed nephrotic syndrome related to membranous glomerulopathy with clinical and serological evidence of <e1>systemic lupus erythematosus</e1> after treatment with <e2>griseofulvin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7775	"<e1>Neurological side effects</e1> in two patients receiving <e2>gold</e2> injections for rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7776	"The first patient developed <e1>mild nitritoid symptoms</e1> and pain in a band-like distribution, corresponding to T10-T12 dermatomes, shortly after <e2>gold sodium thiomalate</e2> (GSTM) injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7777	"The first patient developed <e1>mild nitritoid symptoms</e1> and pain in a band-like distribution, corresponding to T10-T12 dermatomes, shortly after gold sodium thiomalate (<e2>GSTM</e2>) injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7778	"The first patient developed mild nitritoid symptoms and <e1>pain</e1> in a band-like distribution, corresponding to T10-T12 dermatomes, shortly after <e2>gold sodium thiomalate</e2> (GSTM) injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7779	"The first patient developed mild nitritoid symptoms and <e1>pain</e1> in a band-like distribution, corresponding to T10-T12 dermatomes, shortly after gold sodium thiomalate (<e2>GSTM</e2>) injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7780	"The first patient developed mild nitritoid symptoms and pain in a band-like distribution, corresponding to <e1>T10-T12 dermatomes</e1>, shortly after <e2>gold sodium thiomalate</e2> (GSTM) injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7781	"The first patient developed mild nitritoid symptoms and pain in a band-like distribution, corresponding to <e1>T10-T12 dermatomes</e1>, shortly after gold sodium thiomalate (<e2>GSTM</e2>) injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7782	"The second patient experienced <e1>mild nitritoid symptoms</e1> following several <e2>GSTM</e2> injections prior experiencing a cerebrovascular accident within several hours of her next injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7783	"<e1>Acute sensorineural hearing loss</e1> following intravenous <e2>ketoralac</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7784	"Both PAN and <e1>methotrexate</e1> have been independently demonstrated to cause <e2>sensorineural hearing loss</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7785	"Both <e1>PAN</e1> and methotrexate have been independently demonstrated to cause <e2>sensorineural hearing loss</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7786	"We recommend the cautious use of <e1>ketorolac</e1> in patients with underlying illnesses where NSAID-induced <e2>ototoxicity</e2> could result in adverse otologic consequences."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7787	"We report the case of a 20-year-old female with polyarteritis nodosa (PAN) who developed <e1>bilateral sensorineural hearing loss</e1> 25 minutes after receiving 30 mg of intravenous <e2>ketoralac</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7788	"<e1>Anaphylactoid reactions</e1> with intraperitoneal <e2>cisplatin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7789	"CASE SUMMARIES: While conducting a protocol evaluating the efficacy of intraperitoneal <e1>cisplatin</e1> and hyperthermia in the treatment of recurrent ovarian cancer, 3 patients were noted to exhibit <e2>anaphylactoid reactions</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7790	"CONCLUSIONS: We conclude that a high dose combined with a short infusion time increases the risk of <e1>anaphylactoid reactions</e1> with the administration of intraperitoneal <e2>cisplatin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7791	"DISCUSSION: <e1>Anaphylactoid reactions</e1> have been described previously with <e2>cisplatin</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7792	"During her third cycle, she again received <e1>cisplatin</e1> <e2>100 mg/m2</e2> over 30 minutes and developed palmar pruritus, urticaria, and edema."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7793	"During her third cycle, she again received <e1>cisplatin</e1> 100 mg/m2 over 30 minutes and developed palmar pruritus, urticaria, and <e2>edema</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7794	"During her third cycle, she again received <e1>cisplatin</e1> 100 mg/m2 over 30 minutes and developed <e2>palmar pruritus</e2>, urticaria, and edema."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7795	"During her third cycle, she again received <e1>cisplatin</e1> 100 mg/m2 over 30 minutes and developed palmar pruritus, <e2>urticaria</e2>, and edema."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7796	"OBJECTIVE: To report the occurrence of <e1>anaphylactoid reactions</e1> to intraperitoneal <e2>cisplatin</e2> in 3 patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7797	"We observed 5 reactions in 3 patients that appear to be related to a high dose-infusion time ratio, indicating that dose and rate of infusion may be important factors in precipitating <e1>anaphylactoid reactions</e1> with <e2>cisplatin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7798	"<e1>Etoposide</e1> -related <e2>myocardial infarction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7799	"The occurrence of a <e1>myocardial infarction</e1> is reported after chemotherapy containing <e2>etoposide</e2>, in a man with no risk factors for coronary heart disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7800	"A 9-year-old boy developed <e1>acute renal failure</e1> following intravenous <e2>acyclovir</e2> (30 mg/kg per day) administered for 6 days to treat herpetic encephalitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7801	"<e1>Acute renal failure</e1> in a child associated with <e2>acyclovir</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7802	"<e1>Anterior ischemic optic neuropathy</e1> secondary to <e2>interferon alfa</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7803	"CONCLUSION: <e1>Anterior ischemic optic neuropathy</e1> may complicate treatment with <e2>interferon alfa</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7804	"OBJECTIVE: To report the occurrence of <e1>anterior ischemic optic neuropathy</e1> as a complication of treatment with <e2>interferon alfa</e2> and to consider the possible underlying mechanisms for this association."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7805	"PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with <e1>interferon alfa</e1> for malignant neoplasms experienced <e2>sudden bilateral, sequential visual loss</e2> with disc-related field defects and segmental optic disc edema."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7806	"The interval between initiating treatment with <e1>interferon alfa</e1> and onset of <e2>anterior ischemic optic neuropathy</e2> was similar to that of interferon-associated vascular retinopathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7807	"The interval between initiating treatment with <e1>interferon</e1> alfa and onset of anterior ischemic optic neuropathy was similar to that of <e1>interferon</e1> -associated <e2>vascular retinopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7808	"The authors describe a case of <e1>neuroleptic malignant syndrome</e1> that occurred in a patient on <e2>amitriptyline</e2> and lithium carbonate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7809	"The authors describe a case of <e1>neuroleptic malignant syndrome</e1> that occurred in a patient on amitriptyline and <e2>lithium carbonate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7810	"CASE SUMMARIES: Two patients with stable hypothyroidism experienced symptoms of hypothyroidism with <e1>increased serum thyroid-stimulating hormone</e1> (TSH) concentrations after switching from 1 <e2>levothyroxine</e2> product to another."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7811	"Evidence is shown in this report that <e1>adenosine</e1> was associated with dangerous worsening of <e2>arrhythmia</e2> in patients with atrial flutter."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7812	"Life-threatening <e1>alterations in heart rate</e1> after the use of <e2>adenosine</e2> in atrial flutter."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7813	"Comparable adverse effects, such as <e1>disorientation</e1> and temporary amnesia, have been reported in patients in the analogous agent, <e2>propranolol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7814	"Comparable adverse effects, such as disorientation and <e1>temporary amnesia</e1>, have been reported in patients in the analogous agent, <e2>propranolol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7815	"OBJECTIVE: To describe a probable case of <e1>transient global amnesia</e1> caused by <e2>propafenone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7816	"Probable <e1>propafenone</e1> -induced <e2>transient global amnesia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7817	"A case of <e1>acute subdural haematoma</e1> originating spontaneously from an angiomatous meningioma in a patient receiving prophylactic <e2>aspirin</e2> therapy is presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7818	"<e1>Intracranial haemorrhage</e1> from a meningioma in a patient receiving <e2>aspirin</e2> prophylaxis: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7819	"Beneficial effect of low-dose mianserin on <e1>fluvoxamine</e1> -induced <e2>akathisia</e2> in an obsessive-compulsive patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7820	"<e1>Extrapyramidal side effects</e1> induced by some selective serotonin reuptake inhibitors (SSRIs), i.e. <e2>fluoxetine</e2> and sertraline, have been previously reported in patients with depression and obsessive-compulsive disorder (OCD)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7821	"<e1>Extrapyramidal side effects</e1> induced by some selective serotonin reuptake inhibitors (SSRIs), i.e. fluoxetine and <e2>sertraline</e2>, have been previously reported in patients with depression and obsessive-compulsive disorder (OCD)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7822	"However, the occurrence and management of <e1>akathisia</e1> induced by <e2>fluvoxamine</e2> have not been described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7823	"In the presented case <e1>fluvoxamine</e1> -induced <e2>akathisia</e2> in an OCD patient was partially resistant to the anticholinergic agent biperiden, and was successfully treated with the 5-HT2A/5-HT2C antagonist mianserin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7824	"A 42 year old man, treated for testicular carcinoma with combination chemotherapy that included <e1>bleomycin</e1>, developed life threatening <e2>interstitial pneumonitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7825	"Severe <e1>bleomycin</e1> <e2>lung toxicity</e2>: reversal with high dose corticosteroids."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7826	"This report suggests that <e1>bleomycin</e1> <e2>lung toxicity</e2> may be reversible if treated aggressively."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7827	"Reversal of <e1>gold</e1> -induced <e2>neutropenia</e2> with granulocyte colony-stimulating factor (G-CSF)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7828	"We have successfully overcome <e1>severe neutropenia</e1> in an RA patient treated with <e2>gold</e2> salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7829	"<e1>Arrhythmias</e1> and cardiac arrest have been reported during <e2>amphotericin B</e2> administration but no effective technique has been described to prevent them."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7830	"Arrhythmias and <e1>cardiac arrest</e1> have been reported during <e2>amphotericin B</e2> administration but no effective technique has been described to prevent them."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7831	"Correction of serum electrolyte imbalance prevents <e1>cardiac arrhythmia</e1> during <e2>amphotericin B</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7832	"I saw two patients with kala-azar resistant to sodium stibogluconate who developed <e1>cardiac arrest</e1> after <e2>amphotericin</e2> infusion (in spite of tolerating a test dose)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7833	"We describe two cases that illustrate the use of <e1>lithium</e1> in the treatment of veterans with PTSD who complained of serious problems with irritability or <e2>angry outbursts</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7834	"We describe two cases that illustrate the use of <e1>lithium</e1> in the treatment of veterans with PTSD who complained of serious problems with <e2>irritability</e2> or angry outbursts."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7835	"<e1>Graves' hyperthyroidism</e1> following transient thyrotoxicosis during <e2>interferon</e2> therapy for chronic hepatitis type C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7836	"Graves' hyperthyroidism following <e1>transient thyrotoxicosis</e1> during <e2>interferon</e2> therapy for chronic hepatitis type C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7837	"This case showed sequential manifestation from transient thyrotoxicosis to the appearance of TSH-receptor autoantibodies, and then the occurrence of <e1>Graves' hyperthyroidism</e1> during <e2>IFN</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7838	"We report a case of <e1>Graves' hyperthyroidism</e1> induced by long-term interferon (<e2>IFN</e2>) therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7839	"We report a case of <e1>Graves' hyperthyroidism</e1> induced by long-term <e2>interferon</e2> (IFN) therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7840	"Acute <e1>INH</e1> <e2>neurotoxicity</e2> was not suspected on the first admission; however, when readmitted 4 weeks later with another seizure, the diagnosis of acute <e1>INH</e1> <e2>neurotoxicity</e2> was made."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7841	"Acute <e1>INH</e1> <e2>neurotoxicity</e2> was not suspected on the first admission; however, when readmitted 4 weeks later with another seizure, the diagnosis of acute <e1>INH</e1> <e2>neurotoxicity</e2> was made."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7842	"Acute <e1>isoniazid</e1> <e2>neurotoxicity</e2> in an urban hospital."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7843	"CONCLUSIONS: We have seen an increased incidence of acute <e1>INH</e1> <e2>neurotoxicity</e2> because of the resurgence of TB in New York City."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7844	"In patients with a known access to <e1>INH</e1>, <e2>seizures</e2> should be considered to be caused by <e1>INH</e1> toxicity unless proved otherwise."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7845	"OBJECTIVES: To describe the presentation and treatment of acute isoniazid (<e1>INH</e1>) <e2>neurotoxicity</e2> appearing at an inner-city municipal hospital."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7846	"OBJECTIVES: To describe the presentation and treatment of acute <e1>isoniazid</e1> (INH) <e2>neurotoxicity</e2> appearing at an inner-city municipal hospital."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7847	"Parenteral pyridoxine, the specific antidote for <e1>INH</e1> -induced <e2>refractory seizures</e2>, should be readily available in every emergency department in the areas similarly experiencing increasing trends of TB."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7848	"RESULTS: At our institution, no children appeared with acute <e1>INH</e1> <e2>neurotoxicity</e2> in the period 1985 through 1990, whereas seven patients were treated from 1991 through 1993."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7849	"<e1>Arterial hypertension</e1> associated with topical ocular use of <e2>phenylephrine</e2> in dogs."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7850	"CONCLUSION: <e1>Squamous metaplasia</e1> in these cases appears to be a consequence of <e2>progestin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7851	"OBJECTIVE: To report the finding of <e1>squamous metaplasia within endometrial glands</e1> occurring as a result of <e2>progestin</e2> therapy of hyperplasia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7852	"RESULTS: Extensive <e1>squamous metaplasia</e1> was found in endometrial glands following <e2>progestin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7853	"<e1>Fever</e1> caused by the use of <e2>furosemide</e2> was proved; the fever resolved after discontinuation of this medication and recurred after its reintroduction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7854	"<e1>Furosemide</e1> -associated <e2>fever</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7855	"The dose-limiting toxicity of <e1>KW-2149</e1> is <e2>pulmonary toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7856	"<e1>Musculoskeletal complaints</e1> were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of <e2>cyclophosphamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7857	"<e1>Musculoskeletal complaints</e1> were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with <e2>ifosfamide</e2>, a derivative of cyclophosphamide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7858	"Recognition of a potential drug-induced <e1>Fanconi syndrome</e1> is important when managing pediatric oncology patients previously treated with <e2>ifosfamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7859	"Our cases constitute the most severe cases of <e1>benzarone</e1> hepatotoxicity reported so far, and comprise the first cases of (sub)fulminant hepatitis and <e2>cirrhosis</e2> related to <e1>benzarone</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7860	"Our cases constitute the most severe cases of <e1>benzarone</e1> hepatotoxicity reported so far, and comprise the first cases of (sub)fulminant hepatitis and <e2>cirrhosis</e2> related to <e1>benzarone</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7861	"Our cases constitute the most severe cases of <e1>benzarone</e1> <e2>hepatotoxicity</e2> reported so far, and comprise the first cases of (sub)fulminant hepatitis and cirrhosis related to <e1>benzarone</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7862	"Our cases constitute the most severe cases of <e1>benzarone</e1> hepatotoxicity reported so far, and comprise the first cases of <e2>(sub)fulminant hepatitis</e2> and cirrhosis related to <e1>benzarone</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7863	"Our cases constitute the most severe cases of <e1>benzarone</e1> hepatotoxicity reported so far, and comprise the first cases of <e2>(sub)fulminant hepatitis</e2> and cirrhosis related to <e1>benzarone</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7864	"<e1>Severe hepatotoxicity</e1> related to <e2>benzarone</e2>: a report of three cases with two fatalities."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7865	"We report three cases of <e1>severe hepatotoxicity</e1> related to <e2>benzarone</e2>, a benzofuran derivative."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7866	"We stress the potential of <e1>benzarone</e1> to cause <e2>hepatotoxicity</e2>, which usually resembles severe chronic active hepatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7867	"We stress the potential of <e1>benzarone</e1> to cause hepatotoxicity, which usually resembles <e2>severe chronic active hepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7868	"Case study: a modified topical treatment regimen for sodium <e1>warfarin</e1> -induced <e2>necrotizing fasciitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7869	"This case study describes an atypical case of refractory, <e1>sodium warfarin</e1> -induced necrotizing fasciitis and <e2>myonecrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7870	"This case study describes an atypical case of refractory, <e1>sodium warfarin</e1> -induced <e2>necrotizing fasciitis</e2> and myonecrosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7871	"Clinicians who manage cachectic patients, particularly those with protracted diarrhoea and/or receiving anti-malarial drugs including <e1>mefloquine</e1>, should be aware of the risk of <e2>severe hypoglycaemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7872	"Mechanisms and triggering factors of <e1>hypoglycaemia</e1> induced by <e2>mefloquine</e2> and some other anti-malarial quinine analogues are discussed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7873	"<e1>Mefloquine</e1> -associated <e2>hypoglycaemia</e2> in a cachectic AIDS patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7874	"Quinine and its isomer <e1>quinidine</e1> are well-known causes of <e2>iatrogenic hypoglycaemia</e2>, due to excessive insulin secretion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7875	"<e1>Quinine</e1> and its isomer quinidine are well-known causes of <e2>iatrogenic hypoglycaemia</e2>, due to excessive insulin secretion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7876	"We report a case of <e1>hypoglycaemia</e1> after <e2>mefloquine</e2> therapy (1,500 mg over two days) for severe gastrointestinal cryptosporidiasis in a cachectic AIDS patient with protracted diarrhoea."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7877	"Because <e1>sumatriptan</e1> can cause <e2>coronary artery vasospasm</e2>, patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of <e1>sumatriptan</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7878	"<e1>Cardiac arrest</e1> following use of <e2>sumatriptan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7879	"I report a 35-year-old woman with occult coronary artery disease who experienced <e1>cardiac arrest</e1> within minutes after receiving a first-time dose of subcutaneous <e2>sumatriptan</e2> for migraine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7880	"<e1>Sotalol</e1> -induced <e2>bradycardia</e2> reversed by glucagon."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7881	"We present a case of <e1>sotalol</e1> -induced <e2>bradycardia</e2> reversed by glucagon."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7882	"<e1>Secretory endometrial adenocarcinoma</e1> in a patient on <e2>tamoxifen</e2> for breast cancer: a report of a case."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7883	"This unusual pattern of <e1>low-grade endometrial carcinoma</e1> adds to the spectrum of uterine neoplasia associated with <e2>tamoxifen</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7884	"This unusual pattern of low-grade endometrial carcinoma adds to the spectrum of <e1>uterine neoplasia</e1> associated with <e2>tamoxifen</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7885	"We believe that this is the first report of <e1>secretory carcinoma of the endometrium</e1> associated with <e2>tamoxifen</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7886	"Well-differentiated <e1>endometrial adenocarcinoma of the secretory type</e1> (FIGO Grade 1) with minimal myometrial invasion occurred in a postmenopausal patient on <e2>tamoxifen</e2> therapy 5 years after mastectomy for breast carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7887	"<e1>Esophageal candidiasis</e1> following <e2>omeprazole</e2> therapy: a report of two cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7888	"<e1>Esophageal candidiasis</e1> was diagnosed at endoscopy in two patients receiving <e2>omeprazole</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7889	"<e1>High-grade atrioventricular block</e1> during <e2>dipyridamole</e2> stress testing."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7890	"We present a case in which <e1>dipyridamole</e1> induced <e2>high-grade atrioventricular (AV) block</e2> that responded promptly to intravenous aminophylline but not to atropine."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7891	"Aggressive management of <e1>doxorubicin</e1> -induced <e2>cardiomyopathy</e2> associated with 'low' doses of <e1>doxorubicin</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7892	"Aggressive management of <e1>doxorubicin</e1> -induced <e2>cardiomyopathy</e2> associated with 'low' doses of <e1>doxorubicin</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7893	"There is a dose-effect relationship between <e1>doxorubicin</e1> and the incidence of <e2>symptomatic cardiac failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7894	"Ovarian endometrioid carcinoma and <e1>endometriosis</e1> developing in a postmenopausal breast cancer patient during <e2>tamoxifen</e2> therapy: a case report and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7895	"<e1>Ovarian endometrioid carcinoma</e1> and endometriosis developing in a postmenopausal breast cancer patient during <e2>tamoxifen</e2> therapy: a case report and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7896	"The association with prolonged unopposed estrogen-like stimulation with <e1>tamoxifen</e1> as a possible factor in the development of <e2>ovarian endometrioid carcinoma</e2> is discussed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7897	"We present the first case of ovarian endometrioid carcinoma and <e1>endometriosis</e1> in a postmenopausal patient who was treated with <e2>tamoxifen</e2> for breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7898	"We present the first case of <e1>ovarian endometrioid carcinoma</e1> and endometriosis in a postmenopausal patient who was treated with <e2>tamoxifen</e2> for breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7899	"<e1>Cerebral demyelinating disease</e1> developed in a patient during adjuvant therapy with <e2>levamisole</e2> for malignant melanoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7900	"<e1>Multifocal inflammatory leukoencephalopathy</e1> associated with <e2>levamisole</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7901	"Observations in our patient suggest that the <e1>leukoencephalopathy</e1> that developed in previously reported patients who received <e2>5-fluorouracil</e2> and levamisole may have been caused at least partly by levamisole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7902	"Observations in our patient suggest that the <e1>leukoencephalopathy</e1> that developed in previously reported patients who received 5-fluorouracil and <e2>levamisole</e2> may have been caused at least partly by <e2>levamisole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7903	"Observations in our patient suggest that the <e1>leukoencephalopathy</e1> that developed in previously reported patients who received 5-fluorouracil and <e2>levamisole</e2> may have been caused at least partly by <e2>levamisole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7904	"A case of <e1>noncardiogenic pulmonary edema</e1> by <e2>ethanolamine oleate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7905	"However, <e1>EO</e1> -induced <e2>noncardiogenic pulmonary edema</e2> has not been reported in human."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7906	"We report a case of <e1>noncardiogenic pulmonary edema</e1> developed after therapeutic trial of <e2>EO</e2> as sclerosing agent for esophageal varix."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7907	"Five patients are described in whom only <e1>gentamicin sulfate</e1> appeared responsible for <e2>acute renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7908	"<e1>Gentamicin</e1> -associated <e2>acute renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7909	"<e1>Renal failure</e1> appeared 8 to 17 days after beginning <e2>gentamicin</e2> therapy and was characterized by creatinine clearances 4 to 10 ml/min, urine to plasma creatinine ratios less than 20, urinary sodium concentrations 16 to 60 mEq/liter, proteinuria, and cylindruria."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7910	"A 15-year follow-up of <e1>phenytoin</e1> -induced <e2>unilateral gingival hyperplasia</e2>: a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7911	"INTRODUCTION-The aim of this case report is to present a 15-year follow-up of a patient with <e1>phenytoin</e1> (PHT) intoxication with <e2>unilateral gingival hyperplasia</e2> (GH)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7912	"INTRODUCTION-The aim of this case report is to present a 15-year follow-up of a patient with phenytoin (<e1>PHT</e1>) intoxication with <e2>unilateral gingival hyperplasia</e2> (GH)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7913	"We report a case of <e1>generalized cutaneous sclerosis</e1> associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil, diuron and <e2>aminotriazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7914	"We report a case of <e1>generalized cutaneous sclerosis</e1> associated with muscle and oesophageal involvement in a patient exposed to herbicides containing <e2>bromocil</e2>, diuron and aminotriazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7915	"We report a case of <e1>generalized cutaneous sclerosis</e1> associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil, <e2>diuron</e2> and aminotriazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7916	"<e1>Albuterol</e1> -induced hypokalemia and its potential <e2>cardiac toxicity</e2> are discussed briefly."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7917	"<e1>Albuterol</e1> -induced <e2>hypokalemia</e2> and its potential cardiac toxicity are discussed briefly."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7918	"<e1>Hypokalemia</e1> after normal doses of neubulized <e2>albuterol</e2> (salbutamol)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7919	"<e1>Hypokalemia</e1> after normal doses of neubulized albuterol (<e2>salbutamol</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7920	"The cases of two asthmatic patients who became <e1>hypokalemic</e1> after inhalation of normal doses of <e2>albuterol</e2> are presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7921	"<e1>Propoxyphene</e1> -induced <e2>wide complex dysrhythmia</e2> responsive to sodium bicarbonate therapy has not been previously reported in the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7922	"<e1>Propoxyphene</e1> -induced <e2>wide QRS complex dysrhythmia</e2> responsive to sodium bicarbonate--a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7923	"Case report: <e1>mannitol</e1> <e2>nephrotoxicity syndrome</e2>: role of hemodialysis and postulate of mechanisms."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7924	"Hemodialysis should be performed for rapid reversal of <e1>mannitol</e1> -induced <e2>ARF</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7925	"High-dose intravenous <e1>mannitol</e1> infusion in various clinical settings may result in <e2>acute renal failure</e2> (ARF)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7926	"High-dose intravenous <e1>mannitol</e1> infusion in various clinical settings may result in acute renal failure (<e2>ARF</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7927	"<e1>Mannitol</e1> -induced <e2>ARF</e2> responds promptly to hemodialysis with rapid resolution of anuria and recovery of renal failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7928	"The literature is also reviewed for <e1>ARF</e1> associated with <e2>mannitol</e2> infusion in patients who received dialysis and those who did not receive dialysis; and the possible mechanism(s) of <e2>mannitol</e2> nephrotoxicity are discussed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7929	"The literature is also reviewed for ARF associated with <e1>mannitol</e1> infusion in patients who received dialysis and those who did not receive dialysis; and the possible mechanism(s) of <e1>mannitol</e1> <e2>nephrotoxicity</e2> are discussed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7930	"This is a report of a case of <e1>anuric ARF</e1> after high-dose <e2>mannitol</e2> infusion for treatment of narrow-angle glaucoma that readily responded to acute hemodialysis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7931	"Two patients with <e1>extrapyramidal side effects</e1> after the use of <e2>fluphenazine decanoate</e2> were evaluated by means of IBZM-SPECT."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7932	"Flumazenil reversal of <e1>benzodiazepine</e1> -induced <e2>sedation</e2> for a patient with severe pre-ECT anxiety."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7933	"CASE SUMMARY: A 68-year-old woman developed a dry, <e1>irritating cough</e1> within one month of starting <e2>quinapril</e2> therapy for the treatment of essential hypertension."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7934	"<e1>Cough</e1> induced by <e2>quinapril</e2> with resolution after changing to fosinopril."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7935	"OBJECTIVE: To report a case of chronic, nonproductive <e1>cough</e1> secondary to the angiotensin-converting enzyme (ACE) inhibitor <e2>quinapril</e2>, with complete resolution after switching to another ACE inhibitor, fosinopril."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7936	"The <e1>cough</e1> continued for the duration of therapy with <e2>quinapril</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7937	"We report a case of <e1>cough</e1> following the administration of <e2>quinapril</e2>, with complete resolution after changing to the alternative ACE inhibitor fosinopril in a patient with essential hypertension."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7938	"<e1>Fracture of the femoral neck</e1> occurred in one patient during <e2>PSL</e2> therapy, although the relationship between the fracture and <e2>PSL</e2> therapy was uncertain."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7939	"<e1>Cefuroxime</e1> -induced <e2>acute renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7940	"In our patient, <e1>DIAN</e1> possibly was related to <e2>cefuroxime</e2>, but the patient did not experience associated allergic symptoms."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7941	"The diagnosis was supported by the temporal course of <e1>renal deterioration</e1> during exposure to <e2>cefuroxime</e2> and improvement on its discontinuation; the pattern repeated with rechallenge."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7942	"This is the first reported case of suspected <e1>DIAN</e1> due to <e2>cefuroxime</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7943	"A case of <e1>basilar invagination</e1> which is thought to have arisen from the patient's intrauterine exposure to <e2>phenytoin</e2> is presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7944	"<e1>Basilar invagination</e1> and mid-line skeletal abnormalities due to in utero exposure to <e2>phenytoin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7945	"Basilar invagination and <e1>mid-line skeletal abnormalities</e1> due to in utero exposure to <e2>phenytoin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7946	"His symptoms of brain stem compression were alleviated and the role of <e1>phenytoin</e1> in the production of his <e2>craniocervical abnormality</e2> is discussed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7947	"<e1>Temporary neurologic abnormalities</e1> were observed in one out of 23 patients undergoing chemotherapy with high-dose <e2>methotrexate</e2> (HD-MTX) for osteogenic sarcoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7948	"This patient developed sequential symptoms including alternative hemiparesis, dysarthria and <e1>altered consciousness</e1> 5 days after the second course of <e2>HD-MTX</e2> (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7949	"This patient developed sequential symptoms including alternative hemiparesis, <e1>dysarthria</e1> and altered consciousness 5 days after the second course of <e2>HD-MTX</e2> (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7950	"This patient developed sequential symptoms including alternative <e1>hemiparesis</e1>, dysarthria and altered consciousness 5 days after the second course of <e2>HD-MTX</e2> (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7951	"<e1>Transient neurological disturbances</e1> induced by the chemotherapy of high-dose <e2>methotrexate</e2> for osteogenic sarcoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7952	"We report a 5-year-old boy with CF who had a <e1>stricture of the hepatic flexure region with associated narrowing</e1> due to submucosal fibrosis of the transverse colon, secondary to <e2>high-lipase pancreatin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7953	"We report a 5-year-old boy with CF who had a stricture of the hepatic flexure region with associated narrowing due to <e1>submucosal fibrosis of the transverse colon</e1>, secondary to <e2>high-lipase pancreatin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7954	"<e1>Acute pancreatitis</e1> associated with <e2>danazol</e2> treatment for endometriosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7955	"Additionally, <e1>danazol</e1> produces <e2>hepatocellular damage</e2> in approximately 10% of women."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7956	"<e1>Hypo-oestrogenic and anabolic/androgenic side-effects</e1> of <e2>danazol</e2> are well known by the gynaecologist and some of them are present in > 50% of patients being treated for endometriosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7957	"The present report describes the first case of <e1>acute pancreatitis</e1> associated with <e2>danazol</e2> treatment of endometriosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7958	"<e1>Acyclovir</e1> <e2>neurotoxicity</e2>: clinical experience and review of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7959	"<e1>Acyclovir</e1> produces <e2>neurologic symptoms</e2> that resemble extension of viral infection into the central nervous system."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7960	"Systemic disease, most commonly renal dysfunction, preceded all 30 reported cases of <e1>acyclovir</e1> <e2>neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7961	"We discuss our observations in the cases of two patients with <e1>acyclovir</e1> <e2>neurotoxicity</e2> and review the findings of all previous reports in the English language literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7962	"Response of a <e1>promethazine</e1> -induced <e2>coma</e2> to flumazenil."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7963	"We report the first case of a patient in a <e1>promethazine</e1> -induced <e2>coma</e2> responding to treatment with flumazenil."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7964	"<e1>Amebic abscess of the spleen</e1> complicated by <e2>metronidazole</e2> -induced neurotoxicity: case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7965	"Amebic abscess of the spleen complicated by <e1>metronidazole</e1> -induced <e2>neurotoxicity</e2>: case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7966	"We describe a patient with a liver abscess due to Entamoeba histolytica, in whom <e1>metronidazole</e1> therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and <e2>ataxia</e2> and who relapsed 5 months later with a splenic abscess."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7967	"We describe a patient with a <e1>liver abscess</e1> due to Entamoeba histolytica, in whom <e2>metronidazole</e2> therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7968	"We describe a patient with a liver abscess due to Entamoeba histolytica, in whom <e1>metronidazole</e1> therapy (total dose, 21 g over 14 days) was complicated by <e2>reversible deafness</e2>, tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7969	"We describe a patient with a liver abscess due to Entamoeba histolytica, in whom <e1>metronidazole</e1> therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a <e2>splenic abscess</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7970	"We describe a patient with a liver abscess due to Entamoeba histolytica, in whom <e1>metronidazole</e1> therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, <e2>tinnitus</e2>, and ataxia and who relapsed 5 months later with a splenic abscess."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7971	"<e1>Actinomycin D</e1> associated <e2>hepatic veno-occlusive disease</e2> --a report of 2 cases."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7972	"There are now reports of <e1>liver failure</e1> following treatment of childhood cancers with <e2>AMD</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7973	"<e1>Phenylpropanolamine</e1> -induced <e2>psychosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7974	"We report a cae of <e1>paranoid psychosis</e1> following use of a decongestant containing <e2>PPA</e2> and summarize the case report literature of psychiatric adverse effects to <e2>PPA</e2> in which doses were known and stated to be within recommended guidelines."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7975	"We report a cae of paranoid psychosis following use of a decongestant containing <e1>PPA</e1> and summarize the case report literature of <e2>psychiatric adverse effects</e2> to <e1>PPA</e1> in which doses were known and stated to be within recommended guidelines."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7976	"CONCLUSIONS: Although <e1>budesonide</e1> may be beneficial because of its anti-inflammatory effects, clinicians should be alert to its potential for causing <e2>contact dermatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7977	"<e1>Contact dermatitis</e1> due to <e2>budesonide</e2>: report of five cases and review of the Japanese literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7978	"METHODS: Five cases of <e1>contact dermatitis</e1> due to <e2>budesonide</e2>, a nonhalogenated steroid, are described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7979	"RESULTS: <e1>Budesonide</e1> use can cause <e2>contact dermatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7980	"Although other nitrites induce <e1>methemoglobinemia</e1>, exposure to <e2>methyl nitrite</e2> during phenylpropanolamine production appears to be a new cause of occupational <e1>methemoglobinemia</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7981	"Although other nitrites induce <e1>methemoglobinemia</e1>, exposure to <e2>methyl nitrite</e2> during phenylpropanolamine production appears to be a new cause of occupational <e1>methemoglobinemia</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7982	"<e1>Methemoglobinemia</e1>: an occupational hazard of <e2>phenylpropanolamine</e2> production."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7983	"During and after <e1>IFN</e1> therapy we should consider the possibility of occurrence of <e2>IDDM</e2> as well as other autoimmune diseases and observe the clinical course carefully."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7984	"Four years after the beginning of <e1>IFN</e1> therapy, he acutely developed <e2>moderate hyperglycemia</e2> and severe ketonuria with positive islet cell antibody, and then 28 units/day of insulin injection was started."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7985	"Four years after the beginning of <e1>IFN</e1> therapy, he acutely developed moderate hyperglycemia and <e2>severe ketonuria</e2> with positive islet cell antibody, and then 28 units/day of insulin injection was started."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7986	"Occurrence of <e1>IDDM</e1> during <e2>interferon</e2> therapy for chronic viral hepatitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7987	"We report a case of <e1>IDDM</e1> which occurred during <e2>interferon</e2> therapy for chronic hepatitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7988	"Four patients who manifested symptoms of the antiepileptic drug (AED) <e1>hypersensitivity syndrome</e1> during therapy with <e2>carbamazepine</e2> are reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7989	"<e1>Recurrent hypotension</e1> immediately after seizures in <e2>nortriptyline</e2> overdose."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7990	"Recurrent hypotension immediately after <e1>seizures</e1> in <e2>nortriptyline</e2> overdose."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7991	"The use of <e1>methotrexate</e1> (MTX) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to potentiate opportunistic infections and <e2>accelerate HIV disease</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7992	"The use of methotrexate (<e1>MTX</e1>) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which <e1>MTX</e1> appeared to potentiate opportunistic infections and <e2>accelerate HIV disease</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7993	"The use of methotrexate (<e1>MTX</e1>) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which <e1>MTX</e1> appeared to potentiate opportunistic infections and <e2>accelerate HIV disease</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7994	"CONCLUSIONS: This case describes the clinically significant <e1>increase of INR</e1> in an elderly patient after adding a chemotherapy regimen of levamisole and <e2>5-FU</e2> to a previous regimen of warfarin alone."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7995	"CONCLUSIONS: This case describes the clinically significant <e1>increase of INR</e1> in an elderly patient after adding a chemotherapy regimen of <e2>levamisole</e2> and 5-FU to a previous regimen of warfarin alone."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7996	"CONCLUSIONS: This case describes the clinically significant <e1>increase of INR</e1> in an elderly patient after adding a chemotherapy regimen of levamisole and 5-FU to a previous regimen of <e2>warfarin</e2> alone."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7997	"However, prolongation of <e1>5-FU</e1> half-life and an <e2>increase in INR</e2> have been reported with the concurrent use of <e1>5-FU</e1> and warfarin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7998	"However, prolongation of 5-FU half-life and an <e1>increase in INR</e1> have been reported with the concurrent use of 5-FU and <e2>warfarin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7999	"<e1>Cholestatic liver disease</e1> with ductopenia (vanishing bile duct syndrome) after administration of <e2>clindamycin</e2> and trimethoprim-sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8000	"<e1>Cholestatic liver disease</e1> with ductopenia (vanishing bile duct syndrome) after administration of clindamycin and <e2>trimethoprim-sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8001	"Cholestatic liver disease with <e1>ductopenia</e1> (vanishing bile duct syndrome) after administration of <e2>clindamycin</e2> and trimethoprim-sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8002	"Cholestatic liver disease with <e1>ductopenia</e1> (vanishing bile duct syndrome) after administration of clindamycin and <e2>trimethoprim-sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8003	"Cholestatic liver disease with ductopenia (<e1>vanishing bile duct syndrome</e1>) after administration of <e2>clindamycin</e2> and trimethoprim-sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8004	"Cholestatic liver disease with ductopenia (<e1>vanishing bile duct syndrome</e1>) after administration of clindamycin and <e2>trimethoprim-sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8005	"One patient who received <e1>clindamycin</e1> had liver biopsy findings of marked cholestasis, portal inflammation, <e2>bile duct injury</e2> and bile duct paucity (ductopenia)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8006	"One patient who received <e1>clindamycin</e1> had liver biopsy findings of marked cholestasis, portal inflammation, bile duct injury and <e2>bile duct paucity</e2> (ductopenia)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8007	"One patient who received <e1>clindamycin</e1> had liver biopsy findings of marked cholestasis, portal inflammation, bile duct injury and bile duct paucity (<e2>ductopenia</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8008	"One patient who received <e1>clindamycin</e1> had liver biopsy findings of <e2>marked cholestasis</e2>, portal inflammation, bile duct injury and bile duct paucity (ductopenia)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8009	"One patient who received <e1>clindamycin</e1> had liver biopsy findings of marked cholestasis, <e2>portal inflammation</e2>, bile duct injury and bile duct paucity (ductopenia)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8010	"The second patient, who developed <e1>cholestasis</e1> after receiving <e2>trimethoprim-sulfamethoxazole</e2>, had marked duct paucity in the liver biopsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8011	"The second patient, who developed cholestasis after receiving <e1>trimethoprim-sulfamethoxazole</e1>, had marked <e2>duct paucity</e2> in the liver biopsy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8012	"This is the first description, to our knowledge, of <e1>ductopenia</e1> apparently caused by <e2>clindamycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8013	"Three years later, treatment with <e1>ampicillin</e1> caused another episode of cholestatic hepatitis with <e2>cholestasis</e2> and duct paucity on rebiopsy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8014	"Three years later, treatment with <e1>ampicillin</e1> caused another episode of <e2>cholestatic hepatitis</e2> with cholestasis and duct paucity on rebiopsy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8015	"Three years later, treatment with <e1>ampicillin</e1> caused another episode of cholestatic hepatitis with cholestasis and <e2>duct paucity</e2> on rebiopsy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8016	"METHODS: A patient who developed dramatic, permanent <e1>vision loss</e1> after a 9-month course of treatment with <e2>ethambutol</e2> and isoniazid for pulmonary tuberculosis is presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8017	"METHODS: A patient who developed dramatic, permanent <e1>vision loss</e1> after a 9-month course of treatment with ethambutol and <e2>isoniazid</e2> for pulmonary tuberculosis is presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8018	"RESULTS: <e1>Ethambutol</e1>, and to a lesser extent isoniazid, are both implicated in the <e2>development of visually related side effects</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8019	"RESULTS: Ethambutol, and to a lesser extent <e1>isoniazid</e1>, are both implicated in the <e2>development of visually related side effects</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8020	"There is documentation of <e1>ocular toxicity</e1> with <e2>ethambutol</e2> when administered at dosages generally pronounced as being safe."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8021	"<e1>Toxic optic neuropathy</e1> associated with <e2>ethambutol</e2>: implications for current therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8022	"Currently the use of <e1>zidovudine</e1> is one of the few specific measures available, and as a potentially teratogenic and fetotoxic agent, any decision for its use requires evaluation of the potential for <e2>fetal damage</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8023	"Currently the use of <e1>zidovudine</e1> is one of the few specific measures available, and as a potentially teratogenic and <e2>fetotoxic</e2> agent, any decision for its use requires evaluation of the potential for fetal damage."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8024	"Currently the use of <e1>zidovudine</e1> is one of the few specific measures available, and as a potentially <e2>teratogenic</e2> and fetotoxic agent, any decision for its use requires evaluation of the potential for fetal damage."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8025	"In a series of 104 cases of intentional or inadvertent use of <e1>zidovudine</e1> at differing gestations in pregnancy, there were eight spontaneous first trimester abortions, eight therapeutic terminations, and eight cases of <e2>fetal abnormality</e2> occurring among a total of 88 cases where the pregnancy progressed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8026	"In a series of 104 cases of intentional or inadvertent use of <e1>zidovudine</e1> at differing gestations in pregnancy, there were eight spontaneous <e2>first trimester abortions</e2>, eight therapeutic terminations, and eight cases of fetal abnormality occurring among a total of 88 cases where the pregnancy progressed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8027	"<e1>Zidovudine</e1> use in pregnancy: a report on 104 cases and the occurrence of <e2>birth defects</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8028	"<e1>Celiprolol</e1> <e2>pneumonitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8029	"Inadvertent subsequent rechallenge with <e1>celiprolol</e1> led to recurrence of the <e2>pneumonitis</e2>, 10 weeks after drug readministration."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8030	"We report on a patient who developed <e1>hypersensitivity pneumonitis</e1> during treatment with the beta-blocker, <e2>celiprolol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8031	"<e1>Ibopamine</e1> -induced reversible <e2>leukopenia</e2> during treatment for congestive heart failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8032	"<e1>Reversible leukopenia</e1> was documented in an 81-year-old woman treated with adjunctive <e2>ibopamine</e2> 100 mg t.i.d. for chronic congestive heart failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8033	"<e1>Diphenylhydantoin</e1> apparently adversely affected both the clinical and biochemical parameters of the <e2>acute intermittent porphyria</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8034	"Significant clinical improvement of the <e1>porphyria</e1> followed withdrawal of the <e2>diphenylhydantoin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8035	"A 53-year-old male, without any prior history of psychosis, developed <e1>schizophrenia</e1> 4 days after starting low-dose <e2>bromocriptine</e2> therapy for a macroprolactinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8036	"<e1>Bromocriptine</e1> -induced <e2>schizophrenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8037	"<e1>Concurrent acute megaloblastic anaemia</e1> and pneumonitis: a severe side-effect of low-dose <e2>methotrexate</e2> therapy during rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8038	"Concurrent acute megaloblastic anaemia and <e1>pneumonitis</e1>: a severe side-effect of low-dose <e2>methotrexate</e2> therapy during rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8039	"In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose <e1>methotrexate</e1>: an <e2>acute megaloblastic anaemia</e2> and a pneumonitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8040	"In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose <e1>methotrexate</e1>: an acute megaloblastic anaemia and a <e2>pneumonitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8041	"An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (<e1>Levemepromazine</e1>) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from <e2>respiratory distress syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8042	"An 11-year-old boy who was treated with a relatively high dose of <e1>methotrimeprazine meleate</e1> (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from <e2>respiratory distress syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8043	"The association of <e1>phenothiazine</e1> overdose and <e2>respiratory distress syndrome</e2> merits consideration."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8044	"In two patients, <e1>apomorphine</e1> remained effective in the morning, but increased the intensity of the <e2>dyskinesias</e2> in the afternoon."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8045	"We report on three observations of parkinsonian patients with <e1>levo-dopa</e1> -induced <e2>diphasic dyskinesias</e2>, who received subcutaneous apomorphine to reduce the duration of abnormal movements."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8046	"<e1>Fulminant hepatitis</e1> with severe lactate acidosis in HIV-infected patients on <e2>didanosine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8047	"Fulminant hepatitis with <e1>severe lactate acidosis</e1> in HIV-infected patients on <e2>didanosine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8048	"This prompted us to suspect that <e1>ddI</e1> might be responsible for <e2>fulminant hepatitis</e2> in all three AIDS patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8049	"We report two cases of <e1>fulminant hepatic failure</e1> in HIV-1-infected patients treated with didanosine (<e2>ddI</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8050	"We report two cases of <e1>fulminant hepatic failure</e1> in HIV-1-infected patients treated with <e2>didanosine</e2> (ddI)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8051	"<e1>Generalized argyria</e1> after habitual use of <e2>AgNO3</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8052	"A case of <e1>fluoxetine</e1> induced <e2>seizures</e2>, in a person with Down syndrome, is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8053	"<e1>Seizures</e1> associated with <e2>fluoxetine</e2> therapy are uncommon."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8054	"<e1>Seizures</e1> associated with <e2>fluoxetine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8055	"Although <e1>fluoxetine</e1> -induced <e2>headache</e2> occurred in one patient, the other five reported no side effects at the doses used."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8056	"Sodium valproate and <e1>carbamazepine</e1>, antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions, should be added to the growing list of drugs that produce <e2>psoriasiform eruptions</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8057	"<e1>Sodium valproate</e1> and carbamazepine, antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions, should be added to the growing list of drugs that produce <e2>psoriasiform eruptions</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8058	"We present findings from three patients who experienced a <e1>psoriasiform eruption</e1> apparently due to the antiepileptic agents sodium valproate and <e2>carbamazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8059	"We present findings from three patients who experienced a <e1>psoriasiform eruption</e1> apparently due to the antiepileptic agents <e2>sodium valproate</e2> and carbamazepine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8060	"<e1>Severe diffuse interstitial pneumonitis</e1> induced by carmustine (<e2>BCNU</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8061	"<e1>Severe diffuse interstitial pneumonitis</e1> induced by <e2>carmustine</e2> (BCNU)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8062	"We report a <e1>fatal case of acute interstitial pneumonitis</e1> in a patient treated with carmustine (<e2>BCNU</e2>) for a brain tumor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8063	"We report a <e1>fatal case of acute interstitial pneumonitis</e1> in a patient treated with <e2>carmustine</e2> (BCNU) for a brain tumor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8064	"A 78-year-old man with a transvenous cardioverter defibrillator system developed frequent <e1>shocks</e1> during oral <e2>procainamide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8065	"<e1>Electrical proarrhythmia</e1> with <e2>procainamide</e2>: a new ICD-drug interaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8066	"The failure of therapy with disopyramide and mexiletine to reproduce this observation suggests either a previously unreported <e1>electrophysiologic effect</e1> of, or idiosyncratic response to, <e2>procainamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8067	"Based on our experience and on previously published data, serum ammonia levels appear to be indicated in all ED patients on <e1>valproic acid</e1> therapy who present with <e2>altered mental status</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8068	"<e1>Hyperammonemia</e1> has been described as a complication of <e2>valproic acid</e2> therapy but may often be overlooked as a cause of lethargy in the postictal patient who presents to the emergency department."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8069	"Hyperammonemia has been described as a complication of <e1>valproic acid</e1> therapy but may often be overlooked as a cause of <e2>lethargy</e2> in the postictal patient who presents to the emergency department."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8070	"<e1>Hyperammonemia</e1> secondary to <e2>valproic acid</e2> as a cause of lethargy in a postictal patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8071	"Hyperammonemia secondary to <e1>valproic acid</e1> as a cause of <e2>lethargy</e2> in a postictal patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8072	"We present the case of a postictal patient with lethargy, <e1>hyperammonemia</e1>, otherwise normal liver function tests, and a therapeutic <e2>valproic acid</e2> level."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8073	"We present the case of a postictal patient with <e1>lethargy</e1>, hyperammonemia, otherwise normal liver function tests, and a therapeutic <e2>valproic acid</e2> level."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8074	"<e1>Central nervous system toxicity</e1> associated with <e2>meperidine</e2> use in hepatic disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8075	"In patients with cirrhosis, the metabolism of <e1>meperidine</e1> is decreased, leading to <e2>accumulation of the parent drug</e2> and possible CNS depressive effects similar to hepatic encephalopathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8076	"In patients with cirrhosis, the metabolism of <e1>meperidine</e1> is decreased, leading to accumulation of the parent drug and possible <e2>CNS depressive effects</e2> similar to hepatic encephalopathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8077	"<e1>Meperidine</e1> -associated central nervous system (CNS) excitatory toxicities are believed to be caused by <e2>accumulation of the active metabolite normeperidine</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8078	"<e1>Meperidine</e1> -associated <e2>central nervous system (CNS) excitatory toxicities</e2> are believed to be caused by accumulation of the active metabolite normeperidine."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8079	"She received an accidental 450-mg bolus injection of <e1>morphine</e1> intrathecally and developed <e2>hypertension</e2>, status epilepticus, intracerebral hemorrhage, and respiratory failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8080	"She received an accidental 450-mg bolus injection of <e1>morphine</e1> intrathecally and developed hypertension, status epilepticus, <e2>intracerebral hemorrhage</e2>, and respiratory failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8081	"She received an accidental 450-mg bolus injection of <e1>morphine</e1> intrathecally and developed hypertension, status epilepticus, intracerebral hemorrhage, and <e2>respiratory failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8082	"She received an accidental 450-mg bolus injection of <e1>morphine</e1> intrathecally and developed hypertension, <e2>status epilepticus</e2>, intracerebral hemorrhage, and respiratory failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8083	"<e1>Mitomycin C</e1> (MMC) is an alkylating agent that has been recently associated with the <e2>hemolytic-uremic syndrome</e2> (HUS)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8084	"Mitomycin C (<e1>MMC</e1>) is an alkylating agent that has been recently associated with the <e2>hemolytic-uremic syndrome</e2> (HUS)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8085	"<e1>Mitomycin C</e1> (MMC) is an alkylating agent that has been recently associated with the hemolytic-uremic syndrome (<e2>HUS</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8086	"Mitomycin C (<e1>MMC</e1>) is an alkylating agent that has been recently associated with the hemolytic-uremic syndrome (<e2>HUS</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8087	"Pulmonary hemorrhage as a clinical manifestation of <e1>hemolytic-uremic syndrome</e1> associated with <e2>mitomycin C</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8088	"<e1>Pulmonary hemorrhage</e1> as a clinical manifestation of hemolytic-uremic syndrome associated with <e2>mitomycin C</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8089	"Pulmonary hemorrhage is an uncommon feature in the <e1>HUS</e1>, and seems to appear especially in the <e1>HUS</e1> associated with <e2>MMC</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8090	"Pulmonary hemorrhage is an uncommon feature in the <e1>HUS</e1>, and seems to appear especially in the <e1>HUS</e1> associated with <e2>MMC</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8091	"<e1>Pulmonary hemorrhage</e1> is an uncommon feature in the HUS, and seems to appear especially in the HUS associated with <e2>MMC</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8092	"We describe two women who developed <e1>HUS</e1> after <e2>MMC</e2> therapy and presented massive pulmonary bleeding."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8093	"We describe two women who developed HUS after <e1>MMC</e1> therapy and presented <e2>massive pulmonary bleeding</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8094	"<e1>Clonidine</e1> -induced <e2>bradycardia</e2> in patients with spinal cord injury."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8095	"Possible mechanisms by which <e1>clonidine</e1> decreases spasticity are described, probable mechanisms of induced <e2>bradycardia</e2> are reviewed, and specific treatment recommendations for the use of <e1>clonidine</e1> in spinal cord injured patients are presented."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8096	"Possible mechanisms by which <e1>clonidine</e1> decreases spasticity are described, probable mechanisms of induced <e2>bradycardia</e2> are reviewed, and specific treatment recommendations for the use of <e1>clonidine</e1> in spinal cord injured patients are presented."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8097	"Though hypotension, dry mouth, and constipation are well-documented possible adverse effects, the possibility of <e1>clonidine</e1> -induced <e2>bradycardia</e2> is less well recognized and is rare."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8098	"Though hypotension, dry mouth, and <e1>constipation</e1> are well-documented possible adverse effects, the possibility of <e2>clonidine</e2> -induced bradycardia is less well recognized and is rare."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8099	"Though hypotension, <e1>dry mouth</e1>, and constipation are well-documented possible adverse effects, the possibility of <e2>clonidine</e2> -induced bradycardia is less well recognized and is rare."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8100	"Though <e1>hypotension</e1>, dry mouth, and constipation are well-documented possible adverse effects, the possibility of <e2>clonidine</e2> -induced bradycardia is less well recognized and is rare."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8101	"A high dose of <e1>cotrimoxazole</e1> induced hyperkalaemia with the <e2>elevation of serum creatinine and blood urea</e2>, and increased urinary N-acetyl glucosaminase after several days of the drug administration in these patients; one patient became unconscious."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8102	"A high dose of <e1>cotrimoxazole</e1> induced <e2>hyperkalaemia</e2> with the elevation of serum creatinine and blood urea, and increased urinary N-acetyl glucosaminase after several days of the drug administration in these patients; one patient became unconscious."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8103	"A high dose of <e1>cotrimoxazole</e1> induced hyperkalaemia with the elevation of serum creatinine and blood urea, and <e2>increased urinary N-acetyl glucosaminase</e2> after several days of the drug administration in these patients; one patient became unconscious."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8104	"A high dose of <e1>cotrimoxazole</e1> induced hyperkalaemia with the elevation of serum creatinine and blood urea, and increased urinary N-acetyl glucosaminase after several days of the drug administration in these patients; <e2>one patient became unconscious</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8105	"<e1>Hyperkalaemia</e1> with renal tubular dysfunction by oral therapy of sulfamethoxazole-trimethoprim (<e2>co-trimoxazole</e2>) is described in 2 elderly Japanese patients with lymphoid malignancy, who developed Pneumocystis carinii pneumonia and improved."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8106	"<e1>Hyperkalaemia</e1> with renal tubular dysfunction by oral therapy of <e2>sulfamethoxazole-trimethoprim</e2> (co-trimoxazole) is described in 2 elderly Japanese patients with lymphoid malignancy, who developed Pneumocystis carinii pneumonia and improved."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8107	"Hyperkalaemia with <e1>renal tubular dysfunction</e1> by oral therapy of sulfamethoxazole-trimethoprim (<e2>co-trimoxazole</e2>) is described in 2 elderly Japanese patients with lymphoid malignancy, who developed Pneumocystis carinii pneumonia and improved."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8108	"Hyperkalaemia with <e1>renal tubular dysfunction</e1> by oral therapy of <e2>sulfamethoxazole-trimethoprim</e2> (co-trimoxazole) is described in 2 elderly Japanese patients with lymphoid malignancy, who developed Pneumocystis carinii pneumonia and improved."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8109	"<e1>Hyperkalaemia</e1> with renal tubular dysfunction by <e2>sulfamethoxazole-trimethoprim</e2> for Pneumocystis carinii pneumonia in patients with lymphoid malignancy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8110	"Hyperkalaemia with <e1>renal tubular dysfunction</e1> by <e2>sulfamethoxazole-trimethoprim</e2> for Pneumocystis carinii pneumonia in patients with lymphoid malignancy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8111	"Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed <e1>subacute combined degeneration of the spinal cord</e1> following <e2>nitrous oxide</e2> anesthesia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8112	"<e1>Neurologic degeneration</e1> associated with <e2>nitrous oxide</e2> anesthesia in patients with vitamin B12 deficiency."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8113	"Patients with vitamin B12 deficiency are exceedingly sensitive to <e1>neurologic deterioration</e1> following <e2>nitrous oxide</e2> anesthesia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8114	"BACKGROUND: <e1>Fluoxetine</e1>, a highly specific serotonin reuptake inhibitor, has been reported to cause <e2>sexual dysfunction</e2> in a minority of patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8115	"<e1>Captopril</e1> -induced <e2>bone marrow suppression</e2> in two cardiac patients with trisomy 21."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8116	"<e1>Neutropenia</e1> is an infrequent complication following administration of the angiotensin-converting enzyme (ACE) inhibitor, <e2>captopril</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8117	"We report two cases of <e1>neutropenia</e1> following <e2>captopril</e2> use in cardiac patients with trisomy 21."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8118	"Can <e1>magnesium sulfate</e1> therapy impact <e2>lactogenesis</e2>?"
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8119	"No explanation for this delay was found, other than the possibility that <e1>magnesium sulfate</e1> treatment <e2>impeded lactogenesis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8120	"Four days after the initial injection of 3.6 mg of <e1>goserelin acetate</e1>, severe dyspnea developed due to worsening pleuritis carcinomatosa, which was considered as a <e2>flare-up</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8121	"Four days after the initial injection of 3.6 mg of <e1>goserelin acetate</e1>, <e2>severe dyspnea</e2> developed due to worsening pleuritis carcinomatosa, which was considered as a flare-up."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8122	"Four days after the initial injection of 3.6 mg of <e1>goserelin acetate</e1>, severe dyspnea developed due to <e2>worsening pleuritis carcinomatosa</e2>, which was considered as a flare-up."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8123	"<e2>Imidazoline</e2> intoxication due to overdose or accidental ingestion but also after normal therapeutic usage is frequent in children."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8124	"<e2>Imidazoline</e2> intoxication in children."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8125	"Cerebrovascular complications of <e1>L-asparaginase</e1> therapy in children with leukemia: <e2>aphasia</e2> and other neuropsychological deficits."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8126	"<e1>Cerebrovascular complications</e1> of <e2>L-asparaginase</e2> therapy in children with leukemia: aphasia and other neuropsychological deficits."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8127	"Cerebrovascular complications of <e1>L-asparaginase</e1> therapy in children with leukemia: aphasia and other <e2>neuropsychological deficits</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8128	"Children with acute lymphoblastic leukemia (ALL), treated with <e1>L-asparaginase</e1> are at risk for <e2>cerebral thrombosis</e2> or hemorrhage because of coagulation protein deficiencies."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8129	"Children with acute lymphoblastic leukemia (ALL), treated with <e1>L-asparaginase</e1> are at risk for cerebral thrombosis or hemorrhage because of <e2>coagulation protein deficiencies</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8130	"Children with acute lymphoblastic leukemia (ALL), treated with <e1>L-asparaginase</e1> are at risk for cerebral thrombosis or <e2>hemorrhage</e2> because of coagulation protein deficiencies."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8131	"<e1>Myoclonus</e1> and seizures disappeared after discontinuation of <e2>L-dopa</e2> and the introduction of valproate sodium (VPA)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8132	"Myoclonus and <e1>seizures</e1> disappeared after discontinuation of <e2>L-dopa</e2> and the introduction of valproate sodium (VPA)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8133	"<e1>Myoclonus</e1> and seizures in a patient with parkinsonism: induction by <e2>levodopa</e2> and its confirmation on SEPs."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8134	"Myoclonus and <e1>seizures</e1> in a patient with parkinsonism: induction by <e2>levodopa</e2> and its confirmation on SEPs."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8135	"Myoclonus was induced and enhanced by <e1>L-dopa</e1>, developing into <e2>generalized seizures</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8136	"<e1>Myoclonus</e1> was induced and enhanced by <e2>L-dopa</e2>, developing into generalized seizures."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8137	"We described the occurrence of <e1>L-dopa</e1> -induced <e2>myoclonus</e2> and seizures in a case of parkinsonism with its SEPs findings."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8138	"We described the occurrence of <e1>L-dopa</e1> -induced myoclonus and <e2>seizures</e2> in a case of parkinsonism with its SEPs findings."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8139	"Unintended exposure to <e1>acyclovir</e1> early in pregnancy, which is not uncommon, may cause <e2>excessive maternal and physician anxiety</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8140	"A severe form of <e1>exophthalmos</e1> resulting from <e2>lithium</e2> therapy has not been described in the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8141	"<e1>Lithium</e1> therapy was discontinued because of poor compliance to the medication and intolerable <e2>polyuria</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8142	"Regression of <e1>thyrotoxic ophthalmopathy</e1> following <e2>lithium</e2> withdrawal."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8143	"The case of a bipolar patient who developed thyrotoxicosis with <e1>severe exophthalmos</e1> while on <e2>lithium</e2> therapy is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8144	"The case of a bipolar patient who developed <e1>thyrotoxicosis</e1> with severe exophthalmos while on <e2>lithium</e2> therapy is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8145	"The <e1>exophthalmos</e1> improved dramatically within 72 hours of the withdrawal of <e2>lithium</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8146	"Severe <e1>abdominal pain</e1> in low dosage <e2>clofazimine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8147	"We describe a 41 yr old leprosy patient treated for 10 yrs with <e1>clofazimine</e1> who underwent laparotomy for severe <e2>abdominal pain</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8148	"<e1>Amphotericin B</e1> overdose in pediatric patients with associated <e2>cardiac arrest</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8149	"CONCLUSIONS: <e1>Amphotericin B</e1> overdose can be <e2>fatal</e2> in children and infants."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8150	"Hydrocortisone may decrease the incidence of mortality associated with <e1>cardiac arrhythmias</e1> in children receiving <e2>amphotericin B</e2> overdoses."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8151	"Hydrocortisone may decrease the incidence of <e1>mortality</e1> associated with cardiac arrhythmias in children receiving <e2>amphotericin B</e2> overdoses."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8152	"INTERVENTIONS AND RESULTS: <e1>Cardiac complications</e1> were observed in five pediatric patients who received between 4.6 and 40.8 mg/kg/d of <e2>amphotericin B</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8153	"OBJECTIVE: To report the first five cases of <e1>amphotericin B</e1> overdose with secondary <e2>cardiac complications</e2> in a pediatric population."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8154	"<e1>Hypertension</e1> develops in most patients after transplantation when immunosuppression is based on <e2>cyclosporine</e2> and prednisone."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8155	"<e1>Hypertension</e1> develops in most patients after transplantation when immunosuppression is based on cyclosporine and <e2>prednisone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8156	"<e1>Sudden death</e1> in an infant from methemoglobinemia after administration of "<e2>sweet spirits of nitre</e2>"."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8157	"The administration of "sweet spirits of nitre" (<e1>4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol</e1>) was followed by <e2>acute methemoglobinemia</e2> and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of hypoxemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8158	"The administration of "<e1>sweet spirits of nitre</e1>" (4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol) was followed by <e2>acute methemoglobinemia</e2> and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of hypoxemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8159	"The administration of "sweet spirits of nitre" (<e1>4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol</e1>) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin <e2>died</e2> from the consequences of hypoxemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8160	"The administration of "<e1>sweet spirits of nitre</e1>" (4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin <e2>died</e2> from the consequences of hypoxemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8161	"The administration of "sweet spirits of nitre" (<e1>4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol</e1>) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of <e2>hypoxemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8162	"The administration of "<e1>sweet spirits of nitre</e1>" (4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of <e2>hypoxemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8163	"The administration of "sweet spirits of nitre" (<e1>4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol</e1>) was followed by acute methemoglobinemia and <e2>severe anoxic metabolic acidosis</e2> in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of hypoxemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8164	"The administration of "<e1>sweet spirits of nitre</e1>" (4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol) was followed by acute methemoglobinemia and <e2>severe anoxic metabolic acidosis</e2> in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of hypoxemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8165	"<e1>Hepatotoxic effects</e1> in a child receiving valproate and <e2>carnitine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8166	"<e1>Hepatotoxic effects</e1> in a child receiving <e2>valproate</e2> and carnitine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8167	"L-Carnitine supplementation has been recommended to prevent the <e1>fatal hepatotoxic effects</e1> associated with <e2>valproic acid</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8168	"We report on a child with <e1>fatal</e1> <e2>valproate</e2> -related hepatotoxic effects despite this supplementation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8169	"We report on a child with fatal <e1>valproate</e1> -related <e2>hepatotoxic effects</e2> despite this supplementation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8170	"A case is reported of a 40 year old woman treated with intraventricular <e1>IL-2</e1> for leptomeningeal disease who developed progressive <e2>cognitive dysfunction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8171	"Delayed <e1>neurotoxicity</e1> of intraventricular <e2>interleukin-2</e2>: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8172	"The potential for progressive <e1>brain injury</e1> and subsequent disability related to intraventricular <e2>IL-2</e2> therapy is discussed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8173	"The potential for progressive brain injury and subsequent <e1>disability</e1> related to intraventricular <e2>IL-2</e2> therapy is discussed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8174	"Albeit rare among Western patients, such <e1>lithium</e1> -associated <e2>thyroid dysfunctions</e2> appeared to be more likely to occur in Hong Kong Chinese."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8175	"Four Chinese female patients who suffered from manic-depressive disorder and underlying autoimmune thyroiditis developed transient episodes of <e1>thyrotoxicosis</e1> during maintenance <e2>lithium</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8176	"<e1>Lithium</e1> -associated <e2>transient thyrotoxicosis</e2> in 4 Chinese women with autoimmune thyroiditis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8177	"They seemed to involve multiple aetiological factors, such as autoimmune thyroid disease, the <e1>toxic and immunomodulatory roles</e1> of <e2>lithium</e2> and perhaps genetic and dietary factors."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8178	"Although <e1>retinoic acid</e1> is well tolerated by the majority of patients with this disease, a potentially <e2>fatal complication</e2> of this kind of treatment has been reported: "the <e1>retinoic acid</e1> syndrome"."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8179	"Although <e1>retinoic acid</e1> is well tolerated by the majority of patients with this disease, a potentially fatal complication of this kind of treatment has been reported: "the <e1>retinoic acid</e1> syndrome"."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8180	"CONCLUSIONS: It is probable that <e1>foscarnet</e1> contributed to the <e2>electrolyte disorders</e2> and symptomatology in this patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8181	"DISCUSSION: <e1>Electrolyte disorders</e1> associated with <e2>foscarnet</e2> are reviewed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8182	"<e1>Foscarnet</e1> -induced severe hypomagnesemia and other <e2>electrolyte disorders</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8183	"<e1>Foscarnet</e1> -induced <e2>severe hypomagnesemia</e2> and other electrolyte disorders."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8184	"OBJECTIVE: To report a case of possible <e1>foscarnet</e1> -induced severe hypomagnesemia and other <e2>electrolyte disorders</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8185	"OBJECTIVE: To report a case of possible <e1>foscarnet</e1> -induced <e2>severe hypomagnesemia</e2> and other electrolyte disorders."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8186	"The patient experienced muscle twitches, tremulousness, and <e1>anxiety</e1> on day 17 of <e2>foscarnet</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8187	"The patient experienced <e1>muscle twitches</e1>, tremulousness, and anxiety on day 17 of <e2>foscarnet</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8188	"The patient experienced muscle twitches, <e1>tremulousness</e1>, and anxiety on day 17 of <e2>foscarnet</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8189	"<e1>Interference with the cortisol axis</e1> by the microtubule antagonist, <e2>CPH82</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8190	"The results clearly demonstrate that <e1>CPH82</e1> was associated with suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical <e2>hypercortisolism</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8191	"The results clearly demonstrate that <e1>CPH82</e1> was associated with <e2>suppression of the endogeneous production of ACTH and cortisol</e2> with a concomitant paradoxical picture of clinical hypercortisolism."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8192	"A variety of <e1>movement disorders</e1> are known to occur in association with <e2>carbamazepine</e2> (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other <e1>movement disorders</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8193	"A variety of <e1>movement disorders</e1> are known to occur in association with carbamazepine (<e2>CBZ</e2>) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other <e1>movement disorders</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8194	"A variety of movement disorders are known to occur in association with <e1>carbamazepine</e1> (CBZ) therapy in adults and children, but development of <e2>tics</e2> has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8195	"A variety of movement disorders are known to occur in association with carbamazepine (<e1>CBZ</e1>) therapy in adults and children, but development of <e2>tics</e2> has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8196	"<e1>Carbamazepine</e1> -induced <e2>tics</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8197	"In the third child, the <e1>tics</e1> ceased after <e2>CBZ</e2> discontinuation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8198	"These cases demonstrate that <e1>CBZ</e1> can induce simple <e2>motor tics</e2> in children."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8199	"We report 3 children with epilepsy who developed <e1>facial motor tics</e1> after initiation of <e2>CBZ</e2> for complex partial seizures."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8200	"<e1>Acyclovir</e1> -induced <e2>neurotoxicity</e2>: concentration-side effect relationship in acyclovir overdose."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8201	"CONCLUSIONS: The observation that <e1>neurotoxicity</e1> developed with a delay of 24 to 48 hours after <e2>acyclovir</e2> peak serum concentrations could explain the wide range of <e2>acyclovir</e2> levels reported in similar cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8202	"CONCLUSIONS: The observation that <e1>neurotoxicity</e1> developed with a delay of 24 to 48 hours after <e2>acyclovir</e2> peak serum concentrations could explain the wide range of <e2>acyclovir</e2> levels reported in similar cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8203	"METHODS: Repeated blood samples were drawn in a patient with severe <e1>acyclovir</e1> overdose who developed <e2>coma</e2> and nonoliguric renal failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8204	"METHODS: Repeated blood samples were drawn in a patient with severe <e1>acyclovir</e1> overdose who developed coma and <e2>nonoliguric renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8205	"PURPOSE: To investigate the concentration-side effect relationship in a patient with severe <e1>acyclovir</e1> -induced neurotoxicity and to summarize the information available in the literature about <e2>central nervous system side effects</e2> due to <e1>acyclovir</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8206	"PURPOSE: To investigate the concentration-side effect relationship in a patient with severe <e1>acyclovir</e1> -induced <e2>neurotoxicity</e2> and to summarize the information available in the literature about central nervous system side effects due to <e1>acyclovir</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8207	"A 16-year-old white male with acute biphenotypic leukemia developed evidence of the <e1>eosinophilia myalgia syndrome</e1> associated with total parenteral nutritional support with solutions containing <e2>tryptophan</e2>, which were given during his initial induction chemotherapy and also after autologous marrow transplantation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8208	"<e1>Fatal eosinophilia myalgia syndrome</e1> in a marrow transplant patient attributed to total parenteral nutrition with a solution containing <e2>tryptophan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8209	"Thus, the <e1>eosinophilia myalgia syndrome</e1> can be associated with parenteral <e2>tryptophan</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8210	"A patient with acute esophageal variceal bleeding developed <e1>fatal rhabdomyolysis</e1> during treatment with a continuous intravenous infusion of <e2>vasopressin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8211	"Idiosyncratic factors involving <e1>vasopressin</e1> receptor affinity and distribution, <e1>vasopressin</e1> -associated vasodilation in some vascular beds, and the effect of <e1>vasopressin</e1> on the renin-angiotensin system may further contribute to <e2>impaired tissue perfusion</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8212	"Idiosyncratic factors involving <e1>vasopressin</e1> receptor affinity and distribution, <e1>vasopressin</e1> -associated <e2>vasodilation</e2> in some vascular beds, and the effect of <e1>vasopressin</e1> on the renin-angiotensin system may further contribute to impaired tissue perfusion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8213	"<e1>Rhabdomyolysis</e1> associated with the use of intravenous <e2>vasopressin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8214	"These multiple overlapping factors probably lead to <e1>rhabdomyolysis</e1> in a minority of patients receiving <e2>vasopressin</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8215	"In one case, <e1>disulfiram</e1> was the only potential <e2>teratogen</e2> exposed to the fetus."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8216	"Nonspecific but <e1>significant abnormalities</e1> have been described in the infants of women treated with <e2>disulfiram</e2> in the first trimester of their pregnancies."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8217	"Although the essential cause of <e1>PV</e1> is unclear, its onset has occasionally been associated with drug therapy, in particular <e2>penicillamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8218	"<e1>Pemphigus vulgaris</e1> precipitated by <e2>glibenclamide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8219	"The patient described in this paper was a 78-year-old diabetic man who developed <e1>oral lesions of PV</e1> following institution of <e2>glibenclamide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8220	"<e1>Piritrexim</e1> -induced <e2>pulmonary toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8221	"The <e1>pulmonary toxicity</e1> is probably induced by <e2>piritrexim</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8222	"We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an <e1>abnormal chest x-ray with diffuse interstitial opacities</e1> while on chemotherapy with <e2>piritrexim</e2>, a methotrexate analog."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8223	"We describe a patient with transitional cell carcinoma of the renal pelvis who developed <e1>respiratory dysfunction</e1> and an abnormal chest x-ray with diffuse interstitial opacities while on chemotherapy with <e2>piritrexim</e2>, a methotrexate analog."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8224	"A 12 year old patient with atrial flutter is presented, in whom intravenous <e1>adenosine</e1> was followed by <e2>acceleration of the heart rate</e2> to a potentially dangerous arrhythmia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8225	"A 12 year old patient with atrial flutter is presented, in whom intravenous <e1>adenosine</e1> was followed by acceleration of the heart rate to a potentially dangerous <e2>arrhythmia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8226	"<e1>Acceleration of ventricular response</e1> to atrial flutter after intravenous <e2>adenosine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8227	"<e1>Lymphoma</e1> developing in a patient with rheumatoid arthritis taking <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8228	"The mild immunosuppression that occurs with <e1>methotrexate</e1> therapy probably places patients with rheumatoid arthritis at added risk of developing <e2>lymphoproliferative diseases</e2>, but coincidence cannot be excluded."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8229	"We report one case of <e1>non-Hodgkin lymphoma</e1> in a patient, with a 30-year history of rheumatoid arthritis, taking low dose <e2>methotrexate</e2> weekly over a 10-month period."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8230	"<e1>Hepatotoxicity</e1> of <e2>paracetamol</e2> enhanced by ingestion of alcohol: report of two cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8231	"The biochemistry of <e1>paracetamol</e1> hepatotoxicity is outlined and the increased susceptibility of alcoholic patients to the <e2>hepatotoxic effects</e2> of <e1>paracetamol</e1> is remarked upon."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8232	"The biochemistry of <e1>paracetamol</e1> <e2>hepatotoxicity</e2> is outlined and the increased susceptibility of alcoholic patients to the hepatotoxic effects of <e1>paracetamol</e1> is remarked upon."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8233	"Two <e1>fatal</e1> cases of poisoning by <e2>paracetamol</e2> are described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8234	"We report a case of drug-induced <e1>Kaposi's sarcoma</e1> (KS) on the sole of the right foot in a 71-year-old man, treated for 6 months with corticosteroid therapy (<e2>prednisolone</e2> 25 mg/day) for pericardial effusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8235	"<e1>Acute dystonic reaction</e1> with low-dose <e2>pimozide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8236	"This paper reports on a 6.9-year-old autistic male who developed repeated episodes of <e1>acute dystonic reactions</e1> associated with <e2>pimozide</e2> administration at the doses of 0.096 mg/kg/day and 0.032 mg/kg/day and 32 hours following <e2>pimozide</e2> withdrawal, as well as during subsequent thioridazine administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8237	"This paper reports on a 6.9-year-old autistic male who developed repeated episodes of <e1>acute dystonic reactions</e1> associated with <e2>pimozide</e2> administration at the doses of 0.096 mg/kg/day and 0.032 mg/kg/day and 32 hours following <e2>pimozide</e2> withdrawal, as well as during subsequent thioridazine administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8238	"This paper reports on a 6.9-year-old autistic male who developed repeated episodes of <e1>acute dystonic reactions</e1> associated with pimozide administration at the doses of 0.096 mg/kg/day and 0.032 mg/kg/day and 32 hours following pimozide withdrawal, as well as during subsequent <e2>thioridazine</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8239	"Although there is one case report of cholesterol crystal embolization following <e1>t-PA</e1> therapy with only extrarenal manifestations (N Engl J Med 321:1270, 1989), this is the first reported case of <e2>atheroembolic acute renal failure</e2> following <e1>t-PA</e1> therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8240	"Although there is one case report of <e1>cholesterol crystal embolization</e1> following <e2>t-PA</e2> therapy with only extrarenal manifestations (N Engl J Med 321:1270, 1989), this is the first reported case of atheroembolic acute renal failure following <e2>t-PA</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8241	"Although there is one case report of cholesterol crystal embolization following <e1>t-PA</e1> therapy with only <e2>extrarenal manifestations</e2> (N Engl J Med 321:1270, 1989), this is the first reported case of atheroembolic acute renal failure following <e1>t-PA</e1> therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8242	"<e1>Cholesterol crystal embolization</e1> -associated renal failure after therapy with recombinant <e2>tissue-type plasminogen activator</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8243	"Cholesterol crystal embolization-associated <e1>renal failure</e1> after therapy with recombinant <e2>tissue-type plasminogen activator</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8244	"We report the occurrence of renal failure due to <e1>cholesterol crystal embolization</e1> following thrombolytic therapy with intravenous <e2>recombinant tissue-type plasminogen activator</e2> (t-PA)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8245	"We report the occurrence of renal failure due to <e1>cholesterol crystal embolization</e1> following thrombolytic therapy with intravenous recombinant tissue-type plasminogen activator (<e2>t-PA</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8246	"We report the occurrence of <e1>renal failure</e1> due to cholesterol crystal embolization following thrombolytic therapy with intravenous <e2>recombinant tissue-type plasminogen activator</e2> (t-PA)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8247	"We report the occurrence of <e1>renal failure</e1> due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue-type plasminogen activator (<e2>t-PA</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8248	"Intravenous <e1>haloperidol</e1> is generally well tolerated, but <e2>multiform ventricular tachycardia</e2> has been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8249	"All developed <e1>mucocutaneous side effects</e1> within 20 weeks of beginning im <e2>gold</e2> therapy, at a time when RA had improved markedly compared to pretreatment status."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8250	"How low can you go? Use of very low dosage of <e1>gold</e1> in patients with <e2>mucocutaneous reactions</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8251	"<e1>Anterior spinal artery syndrome</e1> --a complication of cervical intrathecal <e2>phenol</e2> injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8252	"We have seen a case of terminal malignant melanoma in which clinical manifestations, indicative of <e1>anterior spinal artery syndrome</e1>, developed following the injection of 0.3 ml of 10% <e2>phenol-glycerine</e2> into the cervical subarachnoid space at the C4--C5 level for the control of severe right arm pain."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8253	"One patient required nursing home placement and a <e1>feeding gastrostomy</e1> as a result of the worsening parkinsonism during <e2>risperidone</e2> treatment, but was able to return home and have the gastrostomy removed after switching from <e2>risperidone</e2> to clozapine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8254	"One patient required nursing home placement and a <e1>feeding gastrostomy</e1> as a result of the worsening parkinsonism during <e2>risperidone</e2> treatment, but was able to return home and have the gastrostomy removed after switching from <e2>risperidone</e2> to clozapine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8255	"One patient required nursing home placement and a feeding gastrostomy as a result of the <e1>worsening parkinsonism</e1> during <e2>risperidone</e2> treatment, but was able to return home and have the gastrostomy removed after switching from <e2>risperidone</e2> to clozapine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8256	"One patient required nursing home placement and a feeding gastrostomy as a result of the <e1>worsening parkinsonism</e1> during <e2>risperidone</e2> treatment, but was able to return home and have the gastrostomy removed after switching from <e2>risperidone</e2> to clozapine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8257	"Two of the five patients who worsened motorically also developed <e1>encephalopathy</e1> during <e2>risperidone</e2> treatment; the <e1>encephalopathy</e1> resolved when the patients were switched to clozapine treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8258	"Two of the five patients who <e1>worsened motorically</e1> also developed encephalopathy during <e2>risperidone</e2> treatment; the encephalopathy resolved when the patients were switched to clozapine treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8259	"<e1>Azathioprine</e1> can cause severe <e2>myelosuppression</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8260	"<e1>Azathioprine</e1> -induced <e2>myelosuppression</e2> due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8261	"The <e1>azathioprine</e1> dose was low (1 mg/kg) and <e2>pancytopenia</e2> occurred after 56 days therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8262	"Thiopurine methyltransferase deficiency occurs at a frequency of one in 300 and is associated with profound <e1>myelosuppression</e1> after a short course of <e2>azathioprine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8263	"We describe the first documented case of <e1>azathioprine</e1> -induced severe <e2>myelosuppression</e2> due to thiopurine methyltransferase deficiency in autoimmune liver disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8264	"<e1>Nabumetone</e1> -associated <e2>interstitial nephritis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8265	"She had been taking <e1>nabumetone</e1> for 6 months, but had discontinued the agent 2 weeks before admission due to progressive <e2>edema</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8266	"<e1>Acute myeloid leukemia</e1> evolving from essential thrombocythemia in two patients treated with <e2>hydroxyurea</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8267	"In this report, two cases of ET which evolved into <e1>AL</e1> without prior exposure to radiation or alkylating agents, and which were treated with long-term <e2>hydroxyurea</e2> therapy, are described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8268	"Prolonged used of <e1>hydroxyurea</e1> in patients with ET may lead to therapy-associated <e2>acute leukemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8269	"However, in 1993, a clinical study involving 400 patients on the Thai-Burmese border revealed <e1>cardiac effects</e1> of antimalarial treatment with <e2>halofantrine</e2>, including one sudden death after the treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8270	"However, in 1993, a clinical study involving 400 patients on the Thai-Burmese border revealed cardiac effects of antimalarial treatment with <e1>halofantrine</e1>, including one <e2>sudden death</e2> after the treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8271	"In the present paper, we discuss the first Japanese vivax malaria patient whose <e1>QT interval was prolonged</e1> after treatment with <e2>halofantrine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8272	"<e1>Prolongation of the QT interval</e1> observed in a Japanese patient with vivax malaria following treatment with <e2>halofantrine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8273	"The pharmaceutical company producing <e1>Halfan</e1> has reported 8 <e2>cardiac arrests</e2>, leading to 6 deaths, when a higher dose than recommended was used, there was recent or concomitant treatment with mefloquine, there was pre-existing prolongation of the QT interval or the patient had a thiamine deficiency."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8274	"The pharmaceutical company producing Halfan has reported 8 <e1>cardiac arrests</e1>, leading to 6 deaths, when a higher dose than recommended was used, there was recent or concomitant treatment with <e2>mefloquine</e2>, there was pre-existing prolongation of the QT interval or the patient had a thiamine deficiency."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8275	"The pharmaceutical company producing <e1>Halfan</e1> has reported 8 cardiac arrests, leading to 6 <e2>deaths</e2>, when a higher dose than recommended was used, there was recent or concomitant treatment with mefloquine, there was pre-existing prolongation of the QT interval or the patient had a thiamine deficiency."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8276	"The pharmaceutical company producing Halfan has reported 8 cardiac arrests, leading to 6 <e1>deaths</e1>, when a higher dose than recommended was used, there was recent or concomitant treatment with <e2>mefloquine</e2>, there was pre-existing prolongation of the QT interval or the patient had a thiamine deficiency."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8277	"<e1>Supravenous hyperpigmentation</e1> in association with <e2>CHOP</e2> chemotherapy of a CD30 (Ki-1)-positive anaplastic large-cell lymphoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8278	"We report an unusual pattern of <e1>supravenous hyperpigmentation</e1> occurring after <e2>CHOP</e2> chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8279	"<e2>Phenytoin</e2> toxicity due to concomitant antituberculosis therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8280	"Seventy-four per cent of patients with epileptogenic disorders seen at the Emergency Unit at Groote Schuur Hospital were on <e1>phenytoin</e1> and 11.6% of these had <e2>blood levels in the toxic range</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8281	"Slow acetylators, who comprise roughly 50% of the South African population, are likely to develop clinical and biochemical features of <e2>phenytoin</e2> toxicity when this drug is given together with antituberculosis therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8282	"The wide use of <e1>phenytoin</e1> during the recent tuberculosis epidemic makes it imperative to suspect this drug interaction in patients exhibiting clinical features that might be related to <e1>phenytoin</e1> toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8283	"The wide use of <e1>phenytoin</e1> during the recent tuberculosis epidemic makes it imperative to suspect this drug interaction in patients exhibiting clinical features that might be related to <e1>phenytoin</e1> toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8284	"<e1>Nephrogenic diabetes insipidus</e1> and renal tubular acidosis secondary to <e2>foscarnet</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8285	"Nephrogenic diabetes insipidus and <e1>renal tubular acidosis</e1> secondary to <e2>foscarnet</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8286	"No cases of renal acidosis, and only one case of <e1>nephrogenic diabetes insipidus</e1>, has been previously reported as a complication of <e2>foscarnet</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8287	"Our patient developed both <e1>nephrogenic diabetes insipidus</e1> and renal tubular acidosis with a temporal pattern that demonstrated a link between <e2>foscarnet</e2> therapy and these abnormalities."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8288	"Our patient developed both nephrogenic diabetes insipidus and <e1>renal tubular acidosis</e1> with a temporal pattern that demonstrated a link between <e2>foscarnet</e2> therapy and these abnormalities."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8289	"We present a patient with human immunodeficiency virus infection under treatment with <e1>foscarnet</e1> for CMV retinitis who complained of thirst and <e2>polyuria</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8290	"We present a patient with human immunodeficiency virus infection under treatment with <e1>foscarnet</e1> for CMV retinitis who complained of <e2>thirst</e2> and polyuria."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8291	"<e1>Choroidal hemorrhage</e1> associated with systemic <e2>tissue plasminogen activator</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8292	"CONCLUSION: The administration of <e1>tissue plasminogen activator</e1> was responsible for the large extent of <e2>hemorrhage</e2> and should be considered in the differential diagnosis of hemorrhagic choroidal detachment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8293	"CONCLUSION: The administration of <e1>tissue plasminogen activator</e1> was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of <e2>hemorrhagic choroidal detachment</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8294	"PURPOSE: To determine the cause of <e1>spontaneous choroidal hemorrhage</e1> in a 67-year-old man after a myocardial infarction and administration of <e2>tissue plasminogen activator</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8295	"<e1>Accelerated nodulosis</e1> during <e2>methotrexate</e2> therapy for juvenile rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8296	"Although they had only a few <e1>nodules</e1> at diagnosis, the <e1>nodules</e1> increased in number and size 3 to 4 months after the start of <e2>methotrexate</e2> therapy in both patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8297	"Although they had only a few <e1>nodules</e1> at diagnosis, the <e1>nodules</e1> increased in number and size 3 to 4 months after the start of <e2>methotrexate</e2> therapy in both patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8298	"Physicians treating patients with <e1>methotrexate</e1> for juvenile rheumatoid arthritis must be aware of this <e2>extraarticular side effect</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8299	"The <e1>nodules</e1> regressed after withdrawal of <e2>methotrexate</e2> therapy in one patient and were arrested with the addition of hydroxychloroquine in the other."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8300	"We describe two patients with rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis in whom <e1>accelerated nodulosis</e1> developed during <e2>methotrexate</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8301	"A <e1>macrophage activation syndrome</e1>, possibly related to <e2>methotrexate</e2> toxicity, developed in a boy with systemic juvenile rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8302	"A macrophage activation syndrome, possibly related to <e2>methotrexate</e2> toxicity, developed in a boy with systemic juvenile rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8303	"<e1>Jaundice</e1> induced by <e2>streptokinase</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8304	"Only a few reports of overt <e1>jaundice</e1> are associated with <e2>streptokinase</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8305	"Although both patients recovered from the <e1>colitis</e1> after the administration of vancomycin, the first case demonstrated a relapse of the <e1>colitis</e1> after receiving a subsequent course of the same chemotherapy with <e2>cisplatin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8306	"Based on our findings, it is thus concluded that <e1>cisplatin</e1> may cause <e2>C. difficile colitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8307	"Both patients were then treated with a carboplatin alternative to <e1>cisplatin</e1> in the following courses, which resulted in neither a relapse of the <e2>colitis</e2> nor a recurrence of the malignancies up to this time."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8308	"<e1>Clostridium difficile colitis</e1> associated with <e2>cisplatin</e2> -based chemotherapy in ovarian cancer patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8309	"Severe <e1>C. difficile colitis</e1> occurred in 2 patients (6.1%) after receiving <e2>cisplatin</e2> -based combination chemotherapy for ovarian malignancies."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8310	"The purpose of this study was to examine the incidence and cause of <e1>Clostridium difficile colitis</e1> occurring after <e2>cisplatin</e2> -based combination chemotherapy in ovarian cancer patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

